<SEC-DOCUMENT>0001104659-21-033855.txt : 20210309
<SEC-HEADER>0001104659-21-033855.hdr.sgml : 20210309
<ACCEPTANCE-DATETIME>20210309164728
ACCESSION NUMBER:		0001104659-21-033855
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210309
DATE AS OF CHANGE:		20210309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Marker Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880277072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37939
		FILM NUMBER:		21726581

	BUSINESS ADDRESS:	
		STREET 1:		3200 SOUTHWEST FREEWAY
		STREET 2:		SUITE 2500
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
		BUSINESS PHONE:		(713) 400-6400

	MAIL ADDRESS:	
		STREET 1:		3200 SOUTHWEST FREEWAY
		STREET 2:		SUITE 2500
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC.
		DATE OF NAME CHANGE:	20170629

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC
		DATE OF NAME CHANGE:	20070628

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrkr-20201231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/9/2021 9:14:34 PM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: 4954f5fe-ad7c-43f7-b2f1-ddee11d9c9d8 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:mrkr="http://www.tapimmune.com/20201231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" name="us-gaap:DerivativeLiabilitiesCurrent" id="Hidden_hx2PinEYJUicAfLbSG_JWQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" xs:nil="true" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_psCQLqgm_U2YsvD07atjGA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" xs:nil="true" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_nE1w-i3HQEG-I60w3MD2ZQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" xs:nil="true" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" name="us-gaap:PreferredStockValue" id="Hidden_ZDFFjDW-yk69ppnYMlgkRg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" xs:nil="true" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" name="us-gaap:PreferredStockValue" id="Hidden_yg6a4xpMhkmloeK5PD1Nzw"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA" name="mrkr:FairValuesAssumptionsExpectedTerm" id="Hidden_p0q6djlt6UyBX7Cf1G6waA">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityCentralIndexKey" id="Tc_peBzxWU1gUq69MvxZYMv2w_2_1">0001094038</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:CurrentFiscalYearEndDate" id="Tc_FLigOv2nrEGIfq-kF_Ypow_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:DocumentFiscalYearFocus" id="Tc_AEv6SdCxSEODCY7YpnEmQw_4_1">2020</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:DocumentFiscalPeriodFocus" id="Tc_bkqI6QnjsUWV8vN1RWEY1g_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:AmendmentFlag" id="Tc_GQgvwjIDmEWsHF19fdV5-g_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-6" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_t8DVxv_EskeM_tkLTNiM-w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-6" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_pFeIENHd9EegMJrIVhyh9Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-5" name="us-gaap:CommonStockSharesIssued" id="Hidden_P_BpZ_byDU6Kv-H_E7IxWQ">45700000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_5yfXCU_Y60y5FpmLzFWqUg">50700000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mrkr-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O3dyd2IkiEOKoM1hwWKeZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tgvmmST_Hke5xeVNJK8Seg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pZiFWHEB4UO4INGI471GYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dANtDkv1f0qA4nDLM7h0Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SYa5-5t2RkuK9-fz8jtoFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WRGLryikz0KaY92hGWffvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_P9Qbbx0CNUGy-vJOvqifnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPytHBodskGfOc2ipJ9aIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_82up_zfWNUmUUgXpcdgRMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qZ9NHzo7YUC9v4IRoJS31Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_vMApe0EcyUGKDZi6FGn-GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_LhNNdP3e2Eqw1UGKZWWoVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wi8B3dNGskeO0KIAZp0PNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nia-K5yaQkK6PrPyNBtXQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_pXkrJdElCEK5luXf8RD1jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Z1owGgssVkun98tvJFc-ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_hm-aT4_utkG7keclj27JkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_9yHzLxI9J0KiGOFm8vPRig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_GrantMember_KRQJasOkrUe2D02MbHcHKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_cQNwlMiI7kK08D7_DtU4Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_mJazqkPfFkmc-QMBbBM7hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:PurchasesFromBioTechneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_MrqVXYEw1Uid9u_ZLvUPNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_2YaAsQK__kGBYij0npbG_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:PurchasesFromBioTechneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ConsultingAgreementWithDr.JuanVeraMember_eeZVsRCRzUeJu-ihCRWw2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ConsultingAgreementWithDr.JuanVeraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_vsg7AnMxjECUv2UMBZE8Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_B-vZs3Ppc06PCUnjXPTuOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_XdhD9gTpeU6hnY0-z8DASw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_zke-f8FZTkO88cP2_ZhOwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_olqT_Fwx7U-Odxkj912Fyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_A2_KcOuc7UCSujKL_kVBbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_v-vM_Z57j0W6NbhuDyp_Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lIiAzvSsBkSWpBXL8lYO6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_Y6NXa2tNyEWBTjwC2KHiAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_92qxNSp0JkO7pwogTgs1Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_PUj_K1bfHkGFM2Y4jHt9Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_ACdngx63MEKIMb7z31QBtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_FZSrIrNxmUyDqyxkQZDk4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_o2aish9KUkmT-1TlNuBhUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_UnPt_Wy98US1VFSStqyNsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_vLnol8OkUk2BmiKlJVI3qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_y0AGgi3VjEide44SDAm8EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ResearchFacilityInHoustonTexasMember_AUKUMDHj8UmZXAD59Q-Ixw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ResearchFacilityInHoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_OfficeSpaceMember_AzY5PjhRa0KWIVTuRWZcsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_5T8qVStqZEGO5cyYBUn0KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ManufacturingFacilityInHoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_CorporateHeadquartersMember_yvnuelJz_UW9l4GGuzdD-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CorporateHeadquartersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_lXNY-SqcckufSQP1_3M_NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_MlrJM6J87kKV_E3Gg6OHjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_fB-XBxEMVEuZ0AXnJJPCYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_H6133jjRH0CvkLeY903Lgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_ZI-qkKDgJE-mZLjhRnPZhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_g6VPuQbHC0y4V1O1fXaO1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_zThIObKJTkGFAkdmLkZJyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_7MInXfUOC0WNFuWoIBCLMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_5Gr7NCUwa0aVADJ5Uz_xrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_x8rh7aiZp06pdQPYS17Hvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:ExerciseOfStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_ZhSFY76i_kCH9MG-xjOj-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_otSldnsXxkWsBDD0krxySA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_ConsultingArrangementsMember_2YOLfsHrJUiQ-nXn-u702g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ConsultingArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_e3jl9ISh90CJS6uJdshXmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_95mnbsS_AUasMsjLjipGSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_mgveA6v0wUaCVTftpwttxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_3B73NaasBEmFQYB4WCOXUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2020_2wu45mhpe0Wt7jhL5XOOSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_C8Sjke4d3Uu2bMNfPrnSIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrkr:SharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrkr:SharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember__pIPPDpQCU-WKKP23kwqnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrkr:SharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_J3vACPWMbkmTs8PjTPKwqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrkr:SharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_-Qd7LU2lBUa_mee1OprAuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_j4K7-6m1s0mROj8Tc9Lrag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mrkr_CommonStockWarrantsLiabilityTreatmentMember__mhH4edEXEqL7o8fnQckTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mrkr:CommonStockWarrantsLiabilityTreatmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GPlgMEopskaT3rrayUflxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_OqczUH54BUevB2a6-k75Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mrkr_CommonStockWarrantsLiabilityTreatmentMember_aWBuEQRV-kK1UZ4Oeqku7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mrkr:CommonStockWarrantsLiabilityTreatmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_5QP_WyrpuE6d2eZgC1tMCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:AspireCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2021_dgrzcG53v0qHBae8oSbc7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_iR2ThMvN30malanztgioBw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Options_XwIwXkVLKk6WPb72jTZEwQ"><xbrli:measure>mrkr:Options</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 15pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:47.24pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b092b596_663d_41cd_a226_3e166c690712"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:15pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:15pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:DocumentType" id="Narr_976tp-VzHkuhriCCbTbAPw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ac7c0859_eda2_4f03_8547_effe1ab84986"></a><a id="Tc_6by1nzRs1ESue7xqnFA7Dg_0_1"></a><a id="Tc_0ciw7WQgC0-92B8tCpv2Xw_2_0"></a><a id="Tc_LeoUyoTJt0mmOVzZriYxlA_4_1"></a><a id="Tc_TE4uSklf8USjKALyAL2MXQ_6_1"></a><a id="Tc_Oq2eR8YJfUiHh41Oe9NoTQ_8_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:DocumentAnnualReport" id="Tc_m8iv75Rqm0SKMlz0USjuZA_0_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the Fiscal Year Ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:DocumentPeriodEndDate" id="Narr_D8TNsqtaEUKQ__FD_Pesxw"><b style="font-size:8pt;font-weight:bold;">December 31, 2020</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:DocumentTransitionReport" id="Tc_ASOkQA0iAk-T5_Q7qcirnw_6_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">For the transition period from _______________ to ______________.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityFileNumber" id="Narr_9Fo0HlBfJk6bhd8TIfObWw"><b style="font-size:8pt;font-weight:bold;">001-37939</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="mrkr-20201231x10k001.jpg" alt="Graphic" style="display:inline-block;height:47.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:209.97pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityRegistrantName" id="Narr_GvrmRc_9OUSvyFxvhmIE-w"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MARKER THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_11ec842d_d288_4c27_b8c1_6be4f6168352"></a><a id="Tc_KqIDTpgh5kuXPwa_V0Drig_1_0"></a><a id="Tc_c4kNJ51xZUGBM_ATZAHzrA_1_2"></a><a id="Tc_fLQWAcNuJE6iK9NsIw_o1A_3_0"></a><a id="Tc_-nAHSavBZE2RQ0gVpx2lCg_4_0"></a><a id="Tc_w1c-Bbr10EWSZRsscJDPPA_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityIncorporationStateCountryCode" id="Tc_objVe4sMwEeSYQ8w6GT2HQ_0_0"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityTaxIdentificationNumber" id="Tc_d2Qb591zhUGrsYDoyf_3Eg_0_2"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">45-4497941</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br />incorporation)</p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityAddressAddressLine1" id="Narr_7gcC2wFApkKglcFhKL7afw"><b style="font-size:8pt;font-weight:bold;">3200 Southwest Freeway</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityAddressAddressLine2" id="Narr_w8dKFXpAP0erznflFzrp_Q"><b style="font-size:8pt;font-weight:bold;">Suite&#160;2500</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityAddressCityOrTown" id="Narr_zq6ZuYRnb0C8oJyUgS2SeA"><b style="font-size:8pt;font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityAddressStateOrProvince" id="Narr_MDnFdvproEKfclZ7vQzE6w"><b style="font-size:8pt;font-weight:bold;">Texas</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityAddressPostalZipCode" id="Tc_Pl_xyWJ2a0Grqo-1l7WUJw_3_2"><b style="font-size:8pt;font-weight:bold;">77027</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">(</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:CityAreaCode" id="Narr_4HkdgzbyuE6t7zJbjzGFHg"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">713</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">) </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:LocalPhoneNumber" id="Narr_5ERWtwBvpEGscJOFZ3tS3Q"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">400-6400</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Telephone Number)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_30fd9b93_e51f_4292_9f56_eefebf830d65"></a><a id="Tc_wpy1Wx490UOBHyWtJp_V9g_1_0"></a><a id="Tc_JRFmfFZ1HUiSzVt6v2ko_Q_1_2"></a><a id="Tc_WLF_OHyXjEyXMe6IfxPO9g_1_4"></a><a id="Tc_hUBqm_XaBEuq4oG097yu0w_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:27.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:2.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:27.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:32.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:bottom;width:35.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:Security12bTitle" id="Tc_U-2hSQLftUKc_nhzLMiSLg_2_0"><span style="font-size:8pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:TradingSymbol" id="Tc_Cq3NjURBTUi6F2hfiqJXEQ_2_2"><span style="font-size:8pt;">MRKR</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:SecurityExchangeName" id="Narr_73M1_brLvUKYRVFlodmsaQ"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: <b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_bYozR2NUgU6zENfZkCQOXg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 of Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityVoluntaryFilers" id="Narr_gxeomVopVkKM1-kdibTJUw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityCurrentReportingStatus" id="Narr_ixGzoO8HKE6AybOGWvmmug"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;No </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityInteractiveDataCurrent" id="Narr_hH7aN1YoqEuIVK6Cwzle2w"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8328f2dc_9b0a_4e2e_92e1_9eeb50d1cfd8"></a><a id="Tc_LIGfWy1t60CS7e6z1JojWQ_1_0"></a><a id="Tc_Bu_wZtXOlkqiVsvNNlTZdg_1_1"></a><a id="Tc_w74ykCo_hkue-4bUXBnybg_1_2"></a><a id="Tc_AdsXwKLuNky4BwLpDvYRmA_1_3"></a><a id="Tc_W1o-As4zGkCBrVuCFnJ5ig_2_1"></a><a id="Tc_Xh5gdcjBsUGhyzHE2IM4BA_2_2"></a><a id="Tc_p1EORXLLD0eh1UfCs8xAew_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityFilerCategory" id="Tc_s8TH3HHjYkCPld6r7K3b-g_2_0"><span style="font-size:8pt;">Non-accelerated filer </span></ix:nonNumeric></p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntitySmallBusiness" id="Tc_UkFMNLpJdUG8aMdesk86JA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityEmergingGrowthCompany" id="Tc_ZBLJAovr0EWupdTwfU6hwQ_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:IcfrAuditorAttestationFlag" id="Narr_WnBsmWcIC0erkG70DHi9eg"><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by checkmark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="dei:EntityShellCompany" id="Narr_QVEydVdzHUOmWwEprkFBvw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June&#160;30, 2020 (the last day of the registrant&#8217;s most recently completed second fiscal quarter) based on the closing sale price of $2.07 as reported on the Nasdaq Capital Market as of that date was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg" decimals="0" name="dei:EntityPublicFloat" id="Narr_butnfVj6nkWbHt_4Em-lsA">64,600,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">The registrant had <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_1_2021_dgrzcG53v0qHBae8oSbc7g" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_zW1uGJdz7UaFxmX85GXXnA">50,731,072</ix:nonFraction> shares of common stock outstanding as of March 1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Documents Incorporated By Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Portions of the registrant&#8217;s proxy statement relating to registrant&#8217;s 2021 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120&#160;days after the close of the registrant&#8217;s fiscal&#160;year, are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K. Except with respect to information specifically incorporated by reference in this Annual Report on Form&#160;10-K, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_cbe30739_0920_41f3_aa0d_58fc0566f173"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#FORWARDLOOKINGSTATEMENTS_197689"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">FORWARD&#160;LOOKING&#160;STATEMENTS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">ii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTI_513007"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Part I</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1BUSINESS_525596"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUSINESS_525596"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Business&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_686864"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1a.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_686864"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1b.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM2PROPERTIES_338462"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 2.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2PROPERTIES_338462"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Properties&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_282506"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 3.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_282506"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURE_456568"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 4.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURE_456568"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosure&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTII_862782"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Part II</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 5.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Market For Registrant&#8217;s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_944586"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 6.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_944586"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Selected Financial Data&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 7.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion And Analysis Of Financial Condition And Results Of Operations&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 7a.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative And Qualitative Disclosures About Market Risk&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTS_684464"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 8.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTS_684464"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 9.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Changes In And Disagreements With Accountants On Accounting And Financial Disclosure&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_136839"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 9a.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_136839"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls And Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_833436"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 9b.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_833436"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIII_534190"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Part III</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 10.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Directors, Executive Officers And Corporate Governance&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_899018"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 11.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_899018"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Compensation&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 12.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 13.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certain Relationships And Related Transactions, And Director Independence&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 14.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Principal Accounting Fees And Services&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIV_855523"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Part IV</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 15.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits, Financial Statement Schedules&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_680075"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 16.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_680075"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form 10-K Summary&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a362b09b_fb42_405b_892a_30a4bb32d6b2"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="FORWARDLOOKINGSTATEMENTS_197689"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FORWARD LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This annual report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part&#160;I, Item&#160;1:&#160;&quot;Business,&quot; Part&#160;I, Item&#160;1A: &quot;Risk Factors,&quot; and Part&#160;2, Item&#160;7: &quot;Management&#39;s Discussion and Analysis of Financial Condition and Results of Operations,&quot; but are also contained elsewhere in this annual report. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;intend&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221; or &#8220;continue&#8221;, the negative of such terms or other comparable terminology. These statements speak only as of the date of this Annual Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.&#160;We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations.&#160; Forward-looking statements in this annual report include statements as to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the timing, progress and results of clinical trials of MultiTAA-specific T cell therapies and our other product candidates, including statements regarding the timing of initiation and completion of preclinical studies or clinical trials or related preparatory work, the period during which the results of the trials will become available and our research and development programs;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the timing of any submission of filings for regulatory approval of product candidates and our ability to obtain and maintain regulatory approvals for product candidates for any indication;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our ability to successfully commercialize product candidates;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our expectations regarding the potential benefits, activity, effectiveness and safety of our product candidates;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our expectations regarding the size of the patient populations, market acceptance and opportunity for and clinical utility of product candidates, if approved for commercial use;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our manufacturing capabilities and strategy, including the ease, scalability and commercial viability of our manufacturing methods and processes;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our expectations regarding the scope of any approved indications for product candidates;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the potential benefits of and our ability to maintain our relationships and collaborations with the Baylor College of Medicine and other potential collaboration or strategic relationships;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our ability to use the MultiTAA-specific T cell platform to develop future product candidates;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional funding;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our ability to identify, recruit and retain key personnel;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our ability to protect and enforce our intellectual property position for our product candidates, and the scope of such protection;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our financial performance;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our competitive position and the development of and projections relating to our competitors or our industry; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the impact of laws and regulations.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should refer to &quot;Item&#160;1A. Risk Factors&quot; in this annual report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its potential impact on our business and the global economy. As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this annual report represent our views as of the date of this annual report. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should read this annual report and the documents that we reference in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this report all references to (i) &#8220;Marker&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221; mean Marker Therapeutics, Inc. and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals, Inc., which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) &#8220;SEC&#8221; refers to the Securities and Exchange Commission; (iii) &#8220;Securities Act&#8221; refers to the United States <i style="font-style:italic;">Securities Act of 1933</i>, as amended; (iv) &#8220;Exchange Act&#8221; refers to the United States <i style="font-style:italic;">Securities Exchange Act of 1934</i>, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_61314dbf_e869_406b_831b_beae502c3950"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_513007"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PART I</b></p><a id="ITEM1BUSINESS_525596"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1. BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. We are advancing two pipelines of product candidates as part of our MultiTAA-specific T cell program: the autologous T cells for the treatment of lymphoma, multiple myeloma, or MM, and selected solid tumors and the allogeneic T cells for the treatment of acute myeloid leukemia, or AML, and acute lymphoblastic leukemia, or ALL. Because we do not genetically engineer the MultiTAA-specific T cell therapies, we believe that our product candidates are easier and less expensive to manufacture, have lower toxicities than current engineered chimeric antigen receptor, or CAR-T, and T cell receptor-based therapies and may provide patients with meaningful clinical benefit. We are also developing innovative peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are pursuing post-transplant AML as the lead indication for our first company-sponsored MultiTAA-specific T cell program. In April 2020, the FDA granted orphan drug designation to MT-401 for the treatment of AML after receiving an allogeneic stem cell transplant. The MultiTAA-specific T cell therapy has been well tolerated in an ongoing Phase 1 clinical trial in AML and myelodysplastic syndrome, or MDS, conducted by our strategic partner Baylor College of Medicine, or BCM. As reported in a recent publication by Lulla et al., 11 of the 17 patients in the adjuvant disease setting dosed with the MultiTAA-specific T cell therapy after receiving an allogeneic hematopoietic stem cell transplant, or HSCT, never relapsed [median leukemia-free survival, or LFS, not reached at a median follow-up of 1.9 years], with 11 of 15 patients remaining alive (estimated two-year overall survival of 77%) at a median follow-up of 1.9 years post-infusion which compares favorably with HSCT outcomes for risk-matched AML/MDS patients post-HSCT [median LFS of nine to 15 months and two-year survival probability of 42%]. &#160;Additionally, eight patients were treated for active disease that was resistant to salvage therapy post-HSCT with a median of five prior lines of therapy (range: four to 10). &#160;One of the eight patients crossed over from the adjuvant group while two patients enrolled twice, but all three patients had active AML that failed another line of salvage therapy after their first MultiTAA-specific T cell infusion. &#160;Two of the eight patients achieved objective responses with one complete response and one partial response, with six patients continuing with stable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We submitted an investigational new drug, or IND, application to the United States Food and Drug Administration, or the FDA, to initiate a Phase 2 clinical trial of MultiTAA-specific T cell therapy, which we refer to as MT-401 (zedenoleucel), in post-allogeneic HSCT patients with AML in both the adjuvant and active disease setting. The dose administered in this multicenter trial is the approximate flat dose equivalent of the current maximum tolerated dose from the ongoing Phase 1 trial. In the adjuvant setting, patients will be randomized to either MultiTAA-specific T cell therapy at approximately 90 days post-transplant versus standard of care observation, while the active disease patients will receive MT-401 following relapse post-transplant as part of a single-arm group. We expect to complete the safety lead-in portion of the trial in the first half of 2021. We anticipate that we will initiate the remainder of the Phase 2 trial in the third quarter of 2021 and complete enrollment of 20 patients in that phase of the trial in the fourth quarter of 2021 in order to report results from the active disease arm of the trial in the first quarter of 2022. We expect to begin manufacturing MT-401 for the Phase 2 trial at our cGMP manufacturing facility in the third quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We reported interim data for an ongoing Phase 1/2 clinical trial of the MultiTAA-specific T cell therapy for the treatment of pancreatic adenocarcinoma being conducted by BCM. In this trial, we have observed a clinical benefit correlated with the post-infusion detection of tumor-reactive T cells in patient peripheral blood and within tumor biopsy samples in patients in the tumor-resection arm of the trial. These T cells exhibited activity against both targeted antigens and non-targeted TAAs, indicating induction of antigen spreading. To date, we have not observed any cytokine release syndrome or neurotoxicity in this trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:154.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also evaluating the MultiTAA-specific T cell therapies in a Phase 2 clinical trial for the treatment of breast cancer and in Phase 1 clinical trials for the treatment of ALL, lymphoma, MM and sarcoma, all of which are being conducted by BCM. As of December 2020, the MultiTAA-specific T cell therapies have been generally well tolerated by all of the patients enrolled in clinical trials in hematological and solid tumor indications with no incidents of cytokine release syndrome or neurotoxicity, which are frequently associated with CAR-T therapies. Our ongoing clinical trials may be also affected by the COVID-19 pandemic. Based on our observations in clinical trials in AML, pancreatic cancer, lymphoma, ALL and MM, we believe that the MultiTAA-specific T cell therapies have the potential to mediate a meaningful anti-tumor effect, as well as significant&#160;in vivo&#160;expansion of T cells. We may initiate additional Phase 2 clinical trials investigating other indications in addition to our planned Phase 2 trial in post-transplant AML patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our clinical-stage pipeline, including clinical trials being conducted by BCM and other partners, is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20201231x10k002.jpg" alt="Graphic" style="display:inline-block;height:154.48pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:375.7pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Program Updates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initiation of Phase 2 Clinical Trial of MT-401 (zedenoleucel) for the Treatment of Post-Transplant AML</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2021, we announced that the FDA lifted the partial clinical hold on the Phase 2 clinical trial investigating the safety and efficacy of MT-401 for the treatment of patients with AML post-transplant, permitting us to initiate the trial with the safety lead-in portion that is expected to enroll approximately six patients. &#160;Three patients will be dosed with MT-401 manufactured with the legacy reagent used in the Phase 1 trial, and three patients will be dosed with MT-401 manufactured using a new reagent from an alternative supplier. We anticipate using this supplier for clinical and commercial manufacturing of MT-401. We expect to complete the safety lead-in portion of the trial in the first half of 2021, and we continue to work to identify clinical trial sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2021, the United States Adopted Names, orUSAN, Council and the World Health Organization International Nonproprietary Name, or WHO INN, Expert Committee adopted &#8220;zedenoleucel&#8221; as the non-proprietary name for MT-401. The USAN Council previously accepted &#8220;zelenoleucel&#8221; as the non-proprietary name for MT-401. The USAN Council forwarded the name to the WHO INN Expert Committee for additional review and clearance. &#160;The WHO INN Expert Committee revised the name to zedenoleucel to avoid a conflict with the existing INN selenomethothionine (75Se) and could evoke that the substance is selenium-labelled. &#160;The USAN Council agreed with the WHO INN Expert Committee&#8217;s revision of the name from &#8220;zelenoleucel&#8221; to &#8220;zedenoleucel.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our goal is to be the leader in the development and commercialization of transformative immunotherapies for the treatment of hematological malignancies and solid tumors. We are developing a portfolio of highly differentiated T cell therapies utilizing the MultiTAA-specific T cell platform that we believe have the potential to significantly disrupt the current cell therapy landscape, while substantially improving survival and quality of life for patients with cancers.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The key elements of our strategy include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Symbol';">&#183;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-style:italic;font-weight:bold;">Expedite clinical development, regulatory approval, and commercialization of our lead product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the results of the Phase 1 clinical trials of the MultiTAA-specific T cell therapies conducted at BCM, we plan to advance our lead product candidates into Phase 2 clinical trials and facilitate the initiation of company-sponsored clinical trials. We are pursuing post-transplant AML as the lead indication for the MultiTAA-specific T cell program. We expect to complete the safety lead-in portion of our Phase 2 trial in post-transplant AML in the first half of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to initiate in the future additional clinical trials in other tumor types based on emerging data. We expect our current Good Manufacturing Practices, or cGMP, manufacturing facility in Houston, Texas will be fully operational to support our clinical manufacturing in the first half of 2021. Until that time, we anticipate that clinical product manufacturing will be conducted at BCM&#8217;s Good Manufacturing Practices, or GMP, cell manufacturing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Symbol';">&#183;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-style:italic;font-weight:bold;">Continue to collaborate with our partners and increase our internal research and development activities to improve and develop adoptive cell therapy technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are party to a strategic alliance with BCM, pursuant to which we will sponsor selected research at BCM in support of our technology. In conjunction with this strategic alliance, BCM will conduct selected Phase 1 and Phase 2 clinical trials of our product candidates. If data from these early clinical trials are positive, we will consider the therapeutic and commercial potential for such therapies to be advanced as new product candidates for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we plan to use BCM facilities and our company laboratories to enable the process development required to support the Phase 2 clinical trials of our product candidates. We plan to invest in our own research and development and chemistry, manufacturing and controls, or CMC, capabilities to enhance our ability to conduct process development to optimize our manufacturing process, product quality and commercial scalability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Symbol';">&#183;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-style:italic;font-weight:bold;">Invest in our platform to maximize the beneficial outcomes for cancer patients.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to explore new product opportunities by increasing and/or customizing the antigens we target to expand the indications in which the MultiTAA-specific T cell products will be efficacious, including solid tumors or other hematologic malignancies. Additionally, our research and development efforts may include the exploration of different doses and/or frequency of dosing and the relationship of these factors with potential therapeutic benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Symbol';">&#183;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-family:'Symbol';">&#160;</span><span style="font-style:italic;font-weight:bold;">Leverage our relationships with our founding institutions, scientific founders and other scientific advisors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our world-renowned scientific founders and scientific advisors have made seminal contributions to major discoveries in the field of immuno-oncology, and have significant experience in oncology, immunology and cell therapy. We intend to significantly leverage the knowledge, experience and advice of our scientific founders and advisors, as well as the institutional expertise of BCM, the Mayo Foundation and our other major institutional partners, to advance our therapies through the clinic and into commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are in the process of evaluating the peptide vaccine therapeutic products and programs to determine the future strategy and the proper allocation of our resources to best maximize stockholder value. In conjunction with this evaluation process we may de-emphasize or terminate certain vaccine therapeutic products or programs. Such strategic review and evaluations are a priority and an important part of our ongoing operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Background and History of Cancer Immunotherapies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite advances in options for treatment, cancer continues to be one of the main causes of death in developed countries. Historically, cancer therapy has been constrained to surgery, radiation, and chemotherapy. More recently, advances in the understanding of the immune system&#8217;s role in cancer surveillance have led to immunotherapy becoming an important treatment approach. Cancer immunotherapy began with treatments that nonspecifically activated the immune system and had limited efficacy and/or significant toxicity. In contrast, newer immunotherapy treatments activate specific, potent immune cells, leading to improved safety and efficacy. Within the immunotherapy category, treatments have included vaccines, cytokine therapies, antibody therapies, and adoptive cell therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 1996, Dr. Dana Leach, Dr. Matthew Krummel and Dr. James Allison reported that monoclonal antibodies, or mAbs, blocking CTLA-4 could treat tumors in animal models. Subsequently, mAbs that targeted CTLA-4 and PD-1 became known as immune checkpoint inhibitors, or ICIs. Immune checkpoints are a means by which cancer cells inhibit or turn down the body&#8217;s immune response to cancer. By interfering with these cloaking mechanisms, ICIs have shown an ability to activate T cells, shrink tumors, and improve patient survival. Recent clinical data from checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab have confirmed both the validity of this approach and the importance of T cells as promising tools for the treatment of cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite these many advances, there persists a significant unmet need in cancer therapeutics. We believe that the use of human cells as a therapeutic modality to re-engage the immune system will be the next significant advancement in the treatment of cancer. These cellular therapies may avoid the long-term side effects associated with current treatments and have the potential to be effective regardless of the type of previous treatments patients have experienced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">T Cell Therapy Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The field of adoptive cell transfer is currently comprised primarily of CAR and TCR engineered T cells and has emerged from principles of basic immunology to become a paradigm-shifting clinical immunotherapy. T cell therapy has evolved as one of the most promising branches of immunotherapy. T cell immunotherapy involves the infusion of T cells into a patient. Immune cells used for immunotherapy treatments can either be collected from the patient (autologous) or harvested from a donor (allogeneic). The cells are retrieved and either genetically modified to express tumor-specific CARs or TCRs or mixed with specific antigens. The cells are then cultured to proliferate, and the proliferated cells are infused into the patient. Upon infusion, the cells can target and eliminate cancerous cells. Unlike chemotherapy, which is unable to distinguish between healthy and malignant cells, T cells produced for immunotherapy can selectively attack cancer cells that express the target antigen(s). This leads to a more effective treatment platform with fewer side effects. Some of these infused T cells may remain in the body for long periods, providing immunological memory, thus leading to longer and more durable responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">TCRs and CARs have distinct signaling properties and antigen sensitivities. TCRs recognize peptide fragments from proteins expressed either inside the cell or on the cell surface, which are presented to T cells via major histocompatibility complex molecules. CARs are programmed to recognize a specific cell surface protein. Because CARs are specific for a single antigen, or more precisely a single epitope within the single antigen, they are very narrowly focused and have limitations. When a CAR-T cell product is applied to a specific antigen of a heterogeneous disease, CAR-T cells may leave behind tumor cells that do not express the target antigen, which can lead to tumor relapse due to immune escape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our approach is to avoid genetic engineering by relying upon the native T cell receptor, which has evolved over millions of years to provide T cells with an exquisite capacity to recognize and kill cancer cells. Use of the native T cell receptor is the bedrock of our versatile immunotherapy, which is intended to provide a cost-effective and non-toxic strategy to target multiple tumor antigens and lead to durable responses. The process entails expanding tumor-specific T cells from patients (autologous), or a patient&#8217;s hematopoietic stem cell donor (allogeneic). This is achieved by&#160;<i style="font-style:italic;">in vitro</i>&#160;manipulation consisting of co-culturing a patient&#8217;s or donor&#8217;s antigen presenting cells with patient (or donor) peripheral blood mononuclear cells, or PBMCs, respectively. As a source of antigen, we use overlapping peptide libraries spanning each of several immunogenic target antigens that are typically associated with certain types of cancer. These peptides are at least 15 amino acids in length, overlapping by 11 amino acids and span the entire length of each of the target antigens. This typical footprint of peptides allows us to induce both CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>&#160;(helper) and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>&#160;(cytotoxic) T cells. Following manufacture, these cells are frozen and stored for later infusion. Once infused, the natural characteristics of T cells take over and the T cells multiply in quantity, forming an army of T cells that kill the targeted cancer cells.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:128.23pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have observed evidence of &#8220;epitope spreading&#8221; in our clinical trials, suggesting that the MultiTAA-specific T cell therapy is inducing an enhanced response by the patient&#8217;s own T cells (specific for an expanded set of tumor-associated antigens beyond those targeted by the infused product). Correlative analyses show expansion of endogenous T cells, other than those present in the infused product, in the months following infusion. This phenomenon, also known as &#8220;antigen spreading,&#8221; is potentially important in generating a deep and durable response for a patient because it enables the killing of tumors that do not express any of the antigens initially targeted by our therapy and could be due to the lack of lymphodepletion that allows recruitment of the endogenous immune system for anti-tumor activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The MultiTAA-Specific T Cell Therapies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In collaboration with BCM, we are advancing two MultiTAA-specific T cell therapies through clinical development:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Autologous MultiTAA-specific T cell therapies</i> target the NY-ESO-1, PRAME, MAGE-A4, Survivin and SSX2 antigens. We recently reported updated clinical data from BCM&#8217;s Phase 1/2 clinical trial of the autologous MultiTAA therapy for the treatment of patients with pancreatic cancer, and we are currently evaluating these therapies for the treatment of patients with lymphoma, MM and other selected solid tumors in Phase 1 trials.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Allogeneic MultiTAA-specific T cell therapies </i>target the WT1, NY-ESO-1, PRAME, and Survivin antigens. The stem cell transplant donor is used as the source of the cells manufactured for our allogeneic therapies. We are pursuing post-transplant AML as the lead indication for the MultiTAA-specific T cell program using our allogeneic therapies.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the blood source and the antigens for stimulation differ between the autologous and allogeneic therapies, the manufacturing process for each product is identical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cancers are heterogeneous in their expression of antigens. Tumors generally consist of individual cancer cells expressing different antigens, and each of those antigens can be present at a different level that can change over time. Therapies targeting only a single antigen are vulnerable to evolutionary escape mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20201231x10k003.jpg" alt="Graphic" style="display:inline-block;height:128.23pt;width:210.72pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While single-antigen specific therapy can eliminate all the tumor cells expressing the targeted antigen, the residual tumor cells that do not express that antigen may survive and expand. In addition, tumor cells may also downregulate or mutate the targeted antigen, thus becoming invisible to the T cell therapy. Both phenomena create a transformed tumor that is impervious to that therapy. This process is referred to as antigen-negative tumor escape.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:131.23pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our solution to the problem of tumor heterogeneity is the development of T cell products that simultaneously attack multiple tumor-expressed antigens and thereby enable more complete initial tumor targeting, thus minimizing the subsequent opportunity for the cancer to engage escape mechanisms. Of note, data suggest that this strategy may be responsible for recruitment and activation of unique cancer-killing cells from the patient&#8217;s own immune repertoire to participate in cancer eradication, further minimizing the possibility for tumor cell escape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20201231x10k004.jpg" alt="Graphic" style="display:inline-block;height:131.23pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:200.97pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe our proprietary MultiTAA-specific T cell platform may have meaningful advantages over current CAR and TCR-engineered cell therapy approaches. Compared to current gene-modified T cell therapies, the MultiTAA-specific T cell product candidates are characterized by the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Clinical benefits observed in early-stage clinical trials in multiple cancer indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on our observations in clinical trials in AML, pancreatic cancer, lymphoma, ALL and MM, we believe that the MultiTAA-specific T cell therapies have the potential to mediate a meaningful anti-tumor effect, as well as significant&#160;in vivo&#160;expansion of T cells. For example, in BCM&#8217;s Phase 1 clinical trial in lymphoma, there were complete responses, or CRs, in six of the fifteen evaluable patients with active disease. Significantly, no patient with a CR has subsequently relapsed with disease, whereas typically 30% or more of patients with CR in reported CAR-T studies relapse within one year. In patient results to date in this trial, observed therapeutic responses appear to be highly durable, with some patients being relapse-free beyond five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Non-gene modified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unlike CAR and TCR-based approaches, our MultiTAA-specific T cell therapy does not require genetic modification of T cells, a costly and complex process that significantly complicates the manufacturing of a patient product. We believe our MultiTAA-specific T cell therapy can be manufactured at a fraction of the cost of a gene-modified T cell product, with substantially reduced complexity of manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;No need for lymphodepletion before infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unlike CAR-T therapies, which require lymphodepletion of a patient&#8217;s existing T cells so that they will not compete with the infused therapy, the MultiTAA-specific T cell therapies work with the natural capabilities of T cells to target cancer and do not require lymphodepletion prior to infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Low incidence rate of adverse events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 2020, the MultiTAA-specific T cell therapy has been generally well tolerated by all of the patients enrolled in clinical trials in hematological and solid tumor indications with no incidences of cytokine release syndrome or neurotoxicity. In these trials, there has been only one Grade 3 adverse reaction considered possibly related to the therapy. This appears to compare favorably with published CD19 CAR-T studies that have been associated with substantial tolerability concerns, including one Phase 1 trial in which 95% of patients had Grade 3 or higher adverse events during treatment.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Appears to drive endogenous immune responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In our clinical trials, we have observed evidence of &#8220;epitope spreading&#8221; in the treated patients, meaning that the MultiTAA-specific T cell therapy is potentially inducing an enhanced response by the patient&#8217;s own T cells (specific for an expanded set of tumor-associated antigens beyond those targeted by the infused product). Correlative analyses show expansion of endogenous T cells, other than those present in the infused product, in the months following infusion. This phenomenon, also known as &#8220;antigen spreading,&#8221; is potentially important in generating a deep and durable response for a patient, because it enables the killing of tumors that do not express any of the antigens initially targeted by our therapy and could be due to the lack of lymphodepletion that allows recruitment of the endogenous immune system for anti-tumor activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Capable of addressing a broad repertoire of cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While CAR-T and TCR therapies generally target a single epitope, our manufacturing process selects for T cells that are specific for multiple peptides derived from several targeted antigens. Deep gene sequencing of our products shows that a typical patient dose usually consists of approximately 4,000 unique T cell clonotypes, some of which target up to five different tumor-associated antigens. The five antigen targets can be recognized by a very wide range of T cells, which we believe facilitates robust killing of targeted cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MT-401 for the Treatment of Post-Transplant AML</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have submitted an IND to the FDA to initiate a Phase 2 clinical trial in post-allogeneic HSCT patients with AML in both the adjuvant and active disease setting, which may become pivotal pending the results of the interim analysis. The dose administered in this multicenter trial is the current maximum tolerated dose from the Phase 1/2 trial. In the adjuvant setting, patients will be randomized to either MT-401 at approximately 90 days post-transplant versus standard of care observation, while the active disease patients will receive MT-401 following relapse post-transplant as part of a single-arm group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have initiated the Phase 2 trial, beginning with a safety lead-in portion that is expected to enroll approximately six patients. &#160;Three patients will be dosed with MT-401 manufactured using the legacy reagent used in the Phase 1 trial, and three patients will be dosed with MT-401 manufactured using a reagent from an alternative supplier. We anticipate using this supplier for clinical and commercial supply of MT-401. We expect to complete the safety lead-in portion of the trial in the first half of 2021. The safety lead-in will be followed by the 160-patient portion of the trial at approximately 20 transplant centers. Group 1 will comprise 120 adjuvant (disease-free) patients, with the primary endpoint of relapse-free survival of patients randomized to receive MT-401 versus a control group. Group 2 will comprise 40 active disease patients in a single arm, with primary endpoints of complete remission and duration of complete remission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development of Our MultiTAA-Specific T Cell Therapies by BCM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following clinical trials are being conducted by BCM pursuant to our strategic alliance. If data from these early clinical trials are positive, we will consider the therapeutic and commercial potential for such therapies to be advanced as new product candidates for us. In each trial, correlative studies showed significant expansion of MultiTAA-specific T cells, as well as significant evidence of epitope spreading with expansion of endogenous T cells specific for tumor-associated antigens that were not targeted by the MultiTAA-specific T cell therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acute Myeloid Leukemia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are pursuing post-transplant AML as the lead indication for the MultiTAA-specific T cell program. Currently, available treatments for post-transplant AML patients are limited and include donor lymphocyte infusion, which has an approximately 15% overall response rate but a 30% to 50% risk of severe and debilitating graft-versus-host disease. The five-year mortality rate for patients who receive an allogeneic HSCT exceeds 50%, and patients who relapse after a transplant have a survival expectation of approximately 4.5 months.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:283.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">BCM recently completed a Phase 1 AML/MDS clinical trial of the MultiTAA-specific T cell therapy for the treatment of patients with post-transplant AML. In this trial, we treated patients in remission and with active disease post-transplant. As reported in a recent publication by Lulla et al. and illustrated below, 11 of the 17 patients in the adjuvant disease setting dosed with the MultiTAA-specific T cell therapy after receiving an allogeneic HSCT never relapsed [median LFS not reached at a median follow-up of 1.9 years], with 11 of 15 patients remaining alive (estimated two-year overall survival of 77%) at a median follow-up of 1.9 years post-infusion which compares favorably with HSCT outcomes for risk-matched AML/MDS patients post-HSCT [median LFS of nine to 15 months and two-year survival probability of 42%].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20201231x10k005.jpg" alt="Graphic" style="display:inline-block;height:283.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:462.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:283.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additionally, eight patients were treated for active disease that was resistant to salvage therapy post-HSCT with a median of five prior lines of therapy (range: four to ten). &#160;One of the eight patients crossed over from the adjuvant group while two patients enrolled twice, but all three patients had active AML that failed another line of salvage therapy after their first MultiTAA-specific T cell infusion. &#160;As shown below, two of the eight patients achieved objective responses with one complete response and one partial response, with six patients continuing with stable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20201231x10k006.jpg" alt="Graphic" style="display:inline-block;height:283.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:501.57pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this trial, the MultiTAA-specific T cell therapy was well tolerated, with no drug-related serious adverse events and no instances of greater than Grade 2 graft-versus-host disease. The maximum grade treatment-related adverse event was seen in one patient in the adjuvant disease group who had a possibly drug-related Grade 3 elevation of liver enzymes but was treated with prednisone with complete resolution. After discontinuing treatment and receiving decitabine, the patient relapsed and later re-enrolled in the trial in the active disease group and entered CR for 13 months and survived for 2.5 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pancreatic Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2020, we reported interim data from an ongoing Phase 1/2 clinical trial of the MultiTAA-specific T cell therapy for the treatment of pancreatic adenocarcinoma being conducted by BCM. In this trial, BCM plans to enroll approximately 45 patients with advanced or borderline resectable pancreatic adenocarcinoma in three arms: Arm A, which includes patients with unresectable/metastatic disease who are responding to standard first-line chemotherapy; Arm B, which includes patients with progressive disease or therapy intolerance; and Arm C, which includes patients with surgically resectable disease. A total of 31 patients were administered the MultiTAA-specific T cell therapy: 13 patients in Arm A, 10 patients in Arm B and eight patients in Arm C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overall, we have observed a clinical benefit correlated with the detection of tumor-reactive T cells in patient peripheral blood (Arms A, B and C) and within tumor biopsy samples (Arm C) post-infusion. T cells exhibited activity against both targeted antigens as well as non-targeted TAAs, including MAGE-A2B and AFP, indicating induction of antigen/epitope spreading. No cytokine release syndrome or neurotoxicity has been observed in any arm of the trial to date.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Arm A</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Arm A is designed to evaluate the safety and potential efficacy of using MultiTAA-specific T cell therapy as part of first-line treatment for patients with pancreatic cancer. These patients in the chemo-responsive arm have completed or will complete at least three months of standard-of-care chemotherapy (gemcitabine/nab-paclitaxel or FOLFIRINOX), which is the period during which a response to chemotherapy would typically occur, before receiving up to six administrations of MultiTAA-specific T cell therapy in conjunction with chemotherapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For 12 of the 13 patients, sufficient cells for all six planned doses were generated; two doses were available for the remaining patient.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Out of the 13 evaluable patients (best overall response):</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">4 patients experienced objective responses after administration of MultiTAA cells;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1 patient experienced a radiographic complete response occurring at month 9 after starting chemotherapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">3 patients experienced partial responses per RECIST occurring at 6-9 months after starting chemotherapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">6 patients experienced stable disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1 patient experienced a mixed response (some lesions increased in size and others decreased for a net zero change in size of tumor lesions);</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Patients had durable cancer control with 9 of the 13 patients exceeding historical control of overall survival;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">5 patients enrolled in the study were not administered MultiTAA-specific T cells, either because of disease progression (4 patients) which made them ineligible for treatment, or because insufficient starting material from the patient was available for manufacturing (1 patient);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Evidence of epitope-spreading was observed in all responders, suggesting that the MultiTAA T cell therapy triggered the recruitment of a broader endogenous immune system response for improved anti-tumor activity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">No infusion-related reactions, cytokine release syndrome or neurotoxicity was observed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In patients responding to therapy, significant expansion of the infused MultiTAA-specific T cell therapy was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor specific antigens.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In patients responding to therapy, significant expansion of the infused MultiTAA-specific T cell therapy was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor specific antigens.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:172.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Arm B</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Arm B is designed to evaluate the use of MultiTAA-specific T cell therapy as a second-line therapy for patients who have failed first-line chemotherapy. The patients in this chemo-refractory arm are either ineligible for chemotherapy or have progressed on chemotherapy and have received or are receiving up to six doses of MultiTAA-specific T cell therapy as a monotherapy. The following graphic depicts the best clinical assessment of the 10 evaluable patients in Arm B:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20201231x10k007.jpg" alt="Graphic" style="display:inline-block;height:172.47pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:199.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Among the patients who saw clinical disease stabilization, significant expansion of the infused MultiTAA-specific T cell therapy was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor-specific antigens.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:225.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Arm C</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Arm C is designed to assess T cell infiltration and expansion. These patients with borderline surgically resectable disease received or will receive a dose of MultiTAA-specific T cell therapy following chemotherapy, radiotherapy or combination and prior to surgical resection and up to five additional doses of T cells after surgery. In the patients evaluable in Arm C, MultiTAA-specific T cells were measurable in meaningful numbers as detected by correlative analysis of resected tumor, and significant expansion of the infused MultiTAA-specific T cells was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor specific antigens. All eight patients in the adjuvant setting have received at least the pre-surgery dose of MultiTAA-specific T cells. Only two of the eight treated patients had all of the per-protocol MultiTAA-specific T cell infusions. One patient has not yet received any post-operative MultiTAA-specific T cells despite remaining in the trial on an observational basis. Five patients are still in the trial, while three patients had recurrence of disease. Two patients have not yet undergone surgery. As illustrated below with respect to the six patients treated in Arm C (excluding the two patients who have not yet undergone surgery), three of the patients in Arm C remain in the trial, while three patients had recurrence of disease:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20201231x10k008.jpg" alt="Graphic" style="display:inline-block;height:225.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:467.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Lymphoma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM is currently evaluating the MultiTAA-specific T cell therapy in a Phase 1 clinical trial for the treatment of patients with lymphoma. A total of 32 patients received two protocol-specified infusions of MultiTAA-specific T cells, 14 with Hodgkin lymphoma, or HL, and 18 with aggressive non-Hodgkin lymphoma, or NHL, [diffuse large B-cell lymphoma, or DLBCL, (n=12), mantle cell lymphoma, or MCL, (n=2), T-cell lymphoma (n=3) and composite lymphoma (HL and DLBCL, n=1)].</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:287.21pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As reported in a recent publication by Vasileiou et al., BCM had treated 15 patients with active disease, which we refer to as the active lymphoma group, all of whom had completed a follow-up period beyond three months post-infusion. These patients were heavily pre-treated and, on average, had failed a median of five prior lines of therapy (range four to eight) for the HL patients and a median of three prior lines of therapy (range three to four) for the NHL patients. As illustrated below, in the active lymphoma group, six patients entered CR and nine patients had experienced stable disease. None of the patients in CR had relapsed, and the range for the duration of CR in these patients were between two and over five years after being infused with the MultiTAA-specific T cell therapy with the exception of one CR patient who died of an unrelated pneumonia. Responses in all six patients who entered CR were associated with an expansion of infused T cells, as well as induction of antigen spreading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20201231x10k009.jpg" alt="Graphic" style="display:inline-block;height:287.21pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:503.93pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:296.21pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We also treated 17 patients, including one patient who was treated a second time after a relapse, in remission, which we refer to as the adjuvant lymphoma group. Like the active lymphoma group, these patients were heavily pre-treated with seven patients with HL treated with a median of 4 prior lines of therapy (range three to five) and 10 patients with NHL with a median of three prior lines of therapy (range one to five). As illustrated below, in the adjuvant lymphoma group, all 17 patients had entered CR, with 14 patients in continued complete remission, or CCR, without relapsing. The duration of response ranged from approximately nine months to over five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20201231x10k010.jpg" alt="Graphic" style="display:inline-block;height:296.21pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:503.93pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In both treatment groups, the MultiTAA-specific T cell therapy was well tolerated, with no drug-related serious adverse events, suggesting that the MultiTAA-specific T cell therapy might serve as a standard-of-care maintenance therapy for lymphoma patients in remission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, data from this trial show &#8220;epitope spreading,&#8221; or expansion of patients&#8217; endogenous T cells (specific for an expanded set of tumor-associated antigens beyond those targeted by the infused therapy) in the months following infusion. Significantly, we have observed this effect even though some patients in this trial received doses that had not yet been antigen-escalated to the full antigen dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acute Lymphoblastic Leukemia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM is currently evaluating the MultiTAA-specific T cell therapy in a Phase 1 clinical trial for the treatment of patients with ALL. Leukemic relapse is one of the primary causes of treatment failure in HSCT recipients. Like post-transplant AML patients, post-transplant ALL patients have limited treatment options, with donor lymphocyte infusions similarly associated with the risk of life-threatening graft-versus-host disease. While CAR-T therapies have shown potent anti-leukemia activity in post-transplant ALL patients, CD19-CAR-T cell therapies target a single antigen, carrying the inherent risk of immune escape, and are most effective in malignancies of B-cell lineage. In contrast, the MultiTAA-specific T cell therapy targets multiple antigens expressed in both B- and T-cell ALL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this trial, as reported in February 2019 we had treated 18 patients. Of the seven evaluable patients:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">All evaluable patients were up to 28 months in CCR;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">One patient experienced relapse displayed mixed donor/recipient chimerism after transplant, but remained in CCR for 6 months; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Patients who remained in CCR had been durable for between four to 28 months, with a median of 16 months.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Multiple Myeloma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM is currently evaluating the MultiTAA-specific T cell therapy in a Phase 1b/2a clinical trial for the treatment of patients with MM. In this trial, we are treating both active and adjuvant post-autologous stem cell transplant MM patients both within 90 days and more than 90 days post-transplant. We have not seen a meaningful difference in response rates or durability between the two arms and intend to standardize future trials based upon a protocol wherein patients will receive MultiTAA-specific T cell therapy immediately post-transplant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As reported in a recent publication by Lulla et al., of the 12 patients that had been treated in the active MM group with a median of 3.5 prior lines:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">One patient had a CR;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Two patients achieved partial responses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Nine patients had stable disease following initial MultiTAA-specific T cell infusion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Of the nine patients that had been treated in the adjuvant MM group, all nine patients had remained in CCR, with a median follow-up of 21 months. Only two patients had relapsed at months seven and 13 after infusion while the remaining patients remain in CCR at a median follow-up of 27.5 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Process Development and Manufacturing of The MultiTAA-Specific T Cell Therapies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the manufacturing process, blood is drawn from either the individual patient (in the case of the autologous T cells) or from the allogeneic stem cell transplant donor (in the case of the allogeneic T cells). Although the T cells that are selected and expanded by our process exist in a patient&#8217;s circulating blood, these T cells are often present at very low frequencies. Researchers at BCM believe that these T cells are adversely affected by the suppressive tumor microenvironment. It is a well-accepted concept that cancers not only evade immune detection but often actively suppress the function of the human immune system. Our manufacturing and culturing process is intended to (1)&#160;identify the T cells specific for the antigens that we intend to target, (2) restore these T cells to functionality with respect to their anti-tumor capability and (3) expand the population of those T cells specific for our targets to achieve the required patient dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After blood is drawn, PBMCs are isolated and used to manufacture a patient-specific product. These cells are placed inside a G-Rex manufacturing device and combined with an experimentally optimized mix of GMP-grade cytokines that is used to restore and enhance the functional capability of the cultured T cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, libraries of overlapping peptides, which we refer to as peptide pools, spanning the target antigens are combined with antigen presenting cells and added to the cell culture. Each peptide within a peptide pool represents a small segment of a target antigen, which a T cell might recognize. Each library represents the entire protein sequence of a target antigen, with each peptide overlapping significantly with the peptides adjacent to it within the antigen&#8217;s protein sequence. This overlapping structure allows us to isolate, activate and expand any T cell that is specific for any segment of the antigens that we target in the unique genetic background of every patient.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:230.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The G-Rex is a cell culture device manufactured by Wilson Wolf used by many cell therapy developers, both in commercial and academic settings. The device allows a user to introduce cells, medium and other reagents into a cell culture chamber, which has a gas-permeable membrane at its bottom. The cells settle on this gas-permeable membrane through which oxygen and carbon dioxide are exchanged (i.e.&#160;the cells can breathe at the base of the device), while nutrients required for cell expansion are obtained from the medium above the cells. This system allows for the highly robust growth of cells in culture, by providing them with superior access to oxygen and nutrients. Cells manufactured in the device grow efficiently without need for agitation by a technician, scientist or automated system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inside the G-Rex, PBMCs are co-cultured with antigen-presenting cells that have been exposed to the stimulating peptide pools. This results in the selective expansion of T cells that specifically recognize the target antigens. At the end of the manufacturing process, the resulting product is a mix of helper (CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>) and cytotoxic (CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>) T cells that recognize the targeted antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once cell manufacturing is complete, the product is tested for identity, sterility, phenotype and functionality before it is released for infusion into a patient. Sampling of product indicates that, on average, approximately 4,000 different T cell clonotypes are present in a typical 5-antigen-specific patient product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon release of the final patient product, the cells are frozen and transported to the site where the cells&#160;will be administered. The standard dose for patients with lymphoma, AML or myeloma ranges from 5&#8201;to&#8201;20 million cells per meter squared (corresponding to typical doses of 10&#8201;to 40 million cells per adult patient). These cell doses represent a significantly smaller dose of cells, when compared to CAR-T or TCR therapies. As a result, our therapy requires only a very small infusion volume that can be administered to patients within minutes at an outpatient center. Due to the low incidence of adverse events with our therapies, patients do not need to be hospitalized and monitored overnight. Instead, the patients are evaluated for any immediate infusion-related reactions and can then usually be discharged within two hours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our manufacturing process is illustrated below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20201231x10k011.jpg" alt="Graphic" style="display:inline-block;height:230.22pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:503.93pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Peptide-Based Immunotherapeutic Vaccines: TPIV200 and TPIV100/110</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to our MultiTAA-specific T cell therapies, we are developing peptide-based immunotherapeutic vaccines that are designed to precisely target breast and ovarian cancer cells, in contrast to standard therapies for the treatment of cancer that target both cancer cells and normal cells. Our peptide vaccines are derived from naturally processed T cell-targeted antigens. We believe that our peptide vaccines are potentially effective standalone therapies but may also enhance the efficacy of other immunotherapy approaches, including our own MultiTAA-specific T cell therapies. Our multipeptide approach is fundamentally different from traditional vaccine therapies that have generally targeted a major histocompatibility complex, or MHC, class I-restricted epitope and have historically performed poorly as stand-alone treatments. We are currently evaluating TPIV200 for the treatment of breast cancers that overexpress FRa in multiple Phase 2 clinical trials and TPIV100 for the treatment of breast cancers that overexpress HER2/neu in Phase 1b and Phase 2 clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are in the process of evaluating the peptide vaccine therapeutic products and programs to determine the future strategy and the proper allocation of our resources to best maximize stockholder value. In conjunction with this evaluation process we may de-emphasize or terminate certain vaccine therapeutic products or programs. Such strategic review and evaluations are a priority and an important part of our ongoing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">TPIV200 for the Treatment of FRa-Overexpressed Breast and Ovarian Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FRa is overexpressed in over 80% of breast cancers and over 90% of ovarian cancers. The only treatment options for these cancers are surgery, radiation therapy and chemotherapy, creating a very important and urgent clinical need for a new therapeutic strategy. Time to recurrence is relatively short for ovarian cancer and survival prognosis is extremely poor after recurrence. In the United States alone, every year there are 22,350 new ovarian cancer diagnoses and 268,600 new breast cancer diagnoses, of which 10% are diagnoses of triple-negative breast cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">TPIV200 is composed of a mixture of five FRa-derived immunogenic peptides adjuvanted with low-dose granulocyte-macrophage colony-stimulating factor, or GM-CSF, and is designed to activate both the CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> T cell compartments in order to activate a patient&#8217;s T cells against the targets. Recent developments in immunology suggest that both CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> activation support a robust immune response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Phase 1 Clinical Trial in Advanced Breast and Ovarian Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this Phase 1 clinical trial, completed by Mayo Clinic in 2015, 21 patients with advanced breast or ovarian cancer who had undergone standard surgery and adjuvant treatment were treated with one cycle of cyclophosphamide, followed by intradermal vaccination of TPIV200 on day one of a 28-day cycle for a maximum of six vaccination cycles. In the trial, 20 of 21 patients generated T cell responses. These responses developed slowly over the course of the vaccination cycles, with a median time to maximal immunity of five months. Over 90% of patients developed robust and durable antigen-specific immune responses against FRa without regard for HLA type, which aligns with the intended mechanism of action of the vaccine, and 89% of the patients responded to multiple epitopes included in the TPIV200 vaccine, with most patients demonstrating T cell immunity to three or more epitopes. Further, all 16 patients in the observation stage generated T cell responses that lasted over six months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">TPIV200 was well-tolerated, with only one Grade 3 drug-related adverse event. In a two-year patient follow-up analysis, the 10 enrolled ovarian cancer patients had longer median progression-free survival time of 528 days than the 313 days historically reported for the standard-of-care chemotherapy treatment. All patients were alive at the final follow-up. None of the 7 breast cancer patients had experienced a recurrence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Phase 2 Clinical Trials in Triple-Negative Breast Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Triple-negative breast cancer is one of the most difficult cancers to treat and represents a clear unmet medical need. With the support of a $13.3 million grant from the Department of Defense, the Mayo Foundation is conducting a 280-patient Phase 2 clinical trial of TPIV200 in patients with triple-negative breast cancer, which began enrolling patients in late 2017 and is still recruiting patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 21, 2016, we announced the initiation of a randomized four-arm Phase 2 trial of TPIV200 for the treatment of patients with Stage 1 to Stage 3 triple-negative breast cancer who have completed initial surgery and chemo/radiation therapy. This open-label, 80-patient clinical trial is designed to evaluate dosing regimens, pre-treatment, efficacy and immune responses. In the trial, we are evaluating a high dose and a low dose of TPIV200, each of which will be tested both with and without cyclophosphamide prior to vaccination. To date, there have been no drug-related serious adverse events reported. Based on a preliminary analysis of 34 patients enrolled in the triple negative breast cancer trial as of September 30, 2019, 31 patients showed meaningful immune response to vaccine treatment. These data are subject to final review by independent biostatistical analysis. As of December 31, 2020, 16 of the &#160;patients treated have shown disease progression following treatment with TPIV200.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Phase 2 Clinical Trial in Combination With Durvalumab for Patients with Ovarian Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 21, 2016, we announced our participation in an ovarian cancer trial sponsored by Memorial Sloan Kettering Cancer Center, or MSKCC, in collaboration with AstraZeneca Pharmaceuticals in ovarian cancer patients who are not responsive to platinum, a commonly used chemotherapy for ovarian cancer. This open-label Phase 2 trial of TPIV200 in 40 patients is designed to evaluate the effects of combination therapy with AstraZeneca&#8217;s checkpoint inhibitor durvalumab (anti-PD-L1). Interim results from the first 27 patients were presented at the AACR-Rivkin Symposium in September 2018; safety of the combination was shown in these heavily pretreated patients and a subset of patients exhibited durable disease stabilization. Objective response rate and progression-free survival with combination treatment was not superior from the expected efficacy of durvalumab as a monotherapy. However, post-immunotherapy follow-up was suggestive of improved clinical benefit from standard therapies, as the majority of patients&#8217; post-progression went on to receive subsequent standard therapy with durable clinical benefit, creating a rationale for exploration of these agents in combination with chemotherapy. Although we have no business relationship with AstraZeneca, we paid for half of the costs of this trial, in addition to providing TPIV200.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">TPIV 100/110 for the Treatment of HER2/neu-Overexpressed Breast Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">HER2/neu amplification/overexpression results in an effective therapeutic target in breast and gastric cancer. Over-expressed HER2 is detected predominantly in malignancies of epithelial origin, such as breast, gastric, esophageal, colorectal, salivary gland, pancreatic, epithelial ovarian, endometrial, and bladder carcinomas, as well as gallbladder and extrahepatic cholangiocarcinomas. HER2 is over-expressed in approximately 25% of breast cancers and its expression is associated with unfavorable pathologic features and aggressive disease if not treated with targeted therapies, relative to other forms of breast cancer. While the outcome of patients with HER2 positive breast cancer has significantly improved in the past few decades with an advent of anti-HER2 therapies, a substantial number of resected patients with all types of breast cancer subsequently develop metastatic disease. The continued prevalence of these cancers represents a high unmet medical need, justifying the targeted development of immunotherapeutic strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have added a MHC class I-restricted peptide, which we licensed from the Mayo Foundation on April 16, 2012, to the four MHC class II-restricted peptides present in TPIV100, resulting in TPIV 110 after the five peptides are mixed with GM-CSF. We have amended the existing IND to incorporate the fifth peptide and will use TPIV110 in future trials with the goal of producing an even more robust vaccine activating both CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> (helper) and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> (killer) T cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 7, 2016, we announced that we had exercised our option agreement with Mayo Foundation and signed a worldwide license agreement to TPIV100. The license gives us the right to develop and commercialize the technology in any cancer indication in which the HER2/neu antigen is overexpressed. As part of this agreement, the IND for the HER2/neu Phase 1 trial was transferred from Mayo Foundation to us for Phase 2 clinical trials of TPIV100. See &#8220;&#8212;Mayo Foundation for Medical Education and Research Relationships&#8212;Mayo HER2/neu License.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Phase 1 Clinical Trials in HER2/neu</span><sup style="font-size:7.5pt;line-height:100%;text-decoration:underline;text-decoration-color:#000000;top:0pt;vertical-align:top;">+</sup><span style="text-decoration:underline;text-decoration-color:#000000;"> Breast Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the Phase 1 trial of 20 patients conducted at the Mayo Clinic, TPIV100 was well tolerated. Nineteen of the twenty evaluable patients showed robust T-cell immune responses to the antigens in the vaccine. An additional secondary endpoint incorporated into this trial was a two-year follow-on recording the time to disease recurrence in the participating breast cancer patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 14, 2017, we announced that our partners at the Mayo Clinic received a $3.8 million grant from the Department of Defense to conduct a Phase 1b trial of TPIV100 in ductal carcinoma in situ, or DCIS, an early form of breast cancer. We are working closely with the Mayo Foundation on this clinical trial by providing clinical and manufacturing expertise, as well as providing GMP vaccine formulations under contract. The trial is expected to enroll 40 &#8211; 45 women with DCIS and commenced such enrollment during the first quarter of 2019. If the trial is successful and subject to receiving marketing approval from the FDA, we believe that TPIV100 may eventually augment or even replace standard surgery and chemotherapy, and potentially could become part of a routine immunization schedule for preventing breast cancer in healthy women.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Phase 2 Clinical Trials in HER2/neu</span><sup style="font-size:7.5pt;line-height:100%;text-decoration:underline;text-decoration-color:#000000;top:0pt;vertical-align:top;">+</sup><span style="text-decoration:underline;text-decoration-color:#000000;"> Breast Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2018, we announced that the Mayo Clinic had been awarded a grant of $11 million from the Department of Defense intended to cover the costs of a large randomized, double-blind Phase 2 trial of TPIV100. We are working closely with the Mayo Foundation on this clinical trial by providing clinical and manufacturing expertise, as well as providing GMP vaccine formulations under contract. In this trial, 190 patients will be randomized, in a 2:1 fashion, to receive TPIV100 plus maintenance ado-trastuzumab emtansine, or T-DM1, or maintenance T-DM1with placebo plus GM-CSF. The trial will evaluate whether the administration of vaccine during T-DM1 maintenance therapy in patients with residual disease post-neoadjuvant chemotherapy effectively blocks disease recurrence and the development of metastatic breast cancer. By prevention of recurrence and metastasis, the expectation is that mortality associated with breast cancer will be decreased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2021, we announced that we had completed the construction and qualification of our cGMP manufacturing facility in Houston, Texas. Our facility will allow for production of MultiTAA-specific T cell products according to FDA guidelines and is designed to be scalable using modular processes. We have initiated the technology transfer process and expect the facility to be fully operational in the first half of 2021. Until that time, we will continue to rely on BCM to manufacture our MultiTAA-specific T cell therapies, as well as the raw materials, our active pharmaceutical ingredients, or APIs, and finished solid dose products for our peptide vaccines for clinical uses, including our Phase 2 trial in AML. We anticipate using our manufacturing facility to produce commercial supply of any approved product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our supply chain for manufacturing raw materials, API, peptide vaccines and MultiTAA-specific T cell therapies ready for distribution and commercialization is a multi-step process. Establishing and managing the supply chain requires a significant financial commitment and the creation and maintenance of numerous third-party contractual relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third-party manufacturers supply us with raw materials for the peptide vaccines, and other third-party manufacturers convert these raw materials into API or convert the API into final dosage form. For most of our peptide vaccine candidates, once our raw materials are produced, we rely on different third parties to manufacture the API, to make finished drug product and to lyophilize, package and label the finished product. While we currently have focused on single vendors for manufacturing of peptide, formulation development, and lyophilization and vialing, we have access to numerous other vendors, if required.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our drug discovery, development and ultimate commercialization activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. We face significant competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals which are competitive with our drug candidates. Our product candidates may compete with product candidates from a number of companies, which are developing various types of similar in vivo T-cell immunotherapies and therapeutic cancer vaccines to treat cancer, including: Advaxis Inc., Merck/Immune Design, Celldex, BN Immunotherapeutics, Immunocellular, SELLAS Life Sciences Group, Inc. (formerly) Galena BioPharma, NuGenerex Immuno-Oncology (formerly) Antigen Express, Transgene S.A., and Bavarian Nordic. In addition, other adoptive T-cell therapies, monoclonal antibodies and checkpoint inhibitors also provide competition in the oncology space. In these areas, competitors include Iovance, Immatics, NexImmune, Repertoire Immune Medicines, Tessa Therapeutics, Adaptimmune, Mana Therapeutics, Bluebird Bio, Cellectis, Kuur Therapeutics, Juno Therapeutics/Celgene/Bristol Myers Squibb, Kite Pharma/Gilead, Novartis, Roche Pharmaceuticals, Merck &amp; Co, AstraZeneca plc and Medimmune, LLC. We believe that our non-engineered T cells therapy and our in vivo T-cell therapy approaches will be synergistic and may improve therapies being developed by these competitors. Many companies and institutions, either alone or together with their collaborative partners, have substantially greater financial, technical and human resources, and significantly greater experience than we do in the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">drug discovery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">developing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">undertaking preclinical testing and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtaining FDA and other regulatory approvals of products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">manufacturing, marketing, distributing and selling products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA and other regulatory approval or commercializing products that compete with our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, any drug candidate that we successfully develop may compete with existing therapies that have long histories of safe and effective use. Competition may also arise from:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">other drug development technologies and methods of preventing or reducing the incidence of disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">new small molecules; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">other classes of therapeutic agents.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face, and will continue to face, intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for establishing relationships with academic and research institutions and for licenses to drug candidates or proprietary technology. These competitors, either alone or with their collaborative partners, may succeed in developing products that are more effective than ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete successfully will depend, in part, on our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">develop proprietary products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">develop and maintain products that reach the market first, are technologically superior to and/or are of lower cost than other products in the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">attract and retain scientific, product development and sales and marketing personnel;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtain patent or other proprietary protection for our products and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtain required regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">manufacture, market, distribute and sell any products that we develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In a number of countries, including in particular, developing countries, government officials and other groups have suggested that pharmaceutical companies should make drugs available at a low cost. In some cases, governmental authorities have indicated that where pharmaceutical companies do not do so, their patents might not be enforceable to prevent generic competition. Some major pharmaceutical companies have greatly reduced prices for their drugs in certain developing countries. If certain countries do not permit enforcement of any of our patents, sales of our products in those countries, and in other countries could be reduced by generic competition or by parallel importation of our product. Alternatively, governments in those countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products in those countries, thereby reducing our product sales, or we could respond to governmental concerns by reducing prices for our products. In all these situations, our results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BCM Exclusive License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 16, 2018, we entered into an exclusive license agreement, or the BCM License Agreement, with BCM, under which we received a worldwide, exclusive license to BCM&#8217;s rights in and to certain intellectual property rights, including European patent EP 2470644 (estimated expiration date August 24, 2030), to develop and commercialize MultiTAA-specific T cell product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exclusive License to BCM&#8217;s Subject Technology:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1. &#8220;Generation of CTL Lines with Specificity Against Multiple Tumor Antigens or Multiple Viruses&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2. &#8220;Pepmixes to Generate Multiviral CTLs with Broad Specificity&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">3. &#8220;Immunogenic Antigen Identification from a Pathogen and Correlation to Clinical Efficacy&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">4. &quot;T cell performance assay as a prognostic factor for clinical outcome&quot;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In partial consideration for the exclusive rights granted under the BCM License Agreement, Marker Cell Therapy, Inc., an entity that is now our wholly owned subsidiary, issued shares of its common stock to BCM valued at approximately $5.0 million at the time of issuance. Such initial equity issuance was exchanged into merger consideration of 1,490,813 shares of our common stock and warrants to acquire 540,643 shares of our common stock in connection with the merger we completed in October 2018. Additional consideration includes a royalty paid on net sales by us to BCM according to the royalty schedule in the BCM License Agreement. The royalty fee schedule is based on aggregate net sales in four different ranges: (1) less than $500 million, (2) $500 million to $1.0 billion, (3) $1.0 billion and over, and (4) $2.0 billion and over. The corresponding royalty percentages range from 0.65% to 5.0%&#8201;-&#8201;increasing in proportion to the aggregate net sales. The royalty fee may be reduced in the event that we must pay additional royalties with respect to third-party owned patent rights or technology necessary for the use, manufacture or sale of a licensed product. We also agreed to pay BCM up to an aggregate of $64.85&#160;million in milestone payments upon the occurrence of nine particular milestones relating to completion of the first dosing in clinical trials for a first and second distinct product, receipt of approval from the FDA and the achievement of certain net sales goals. We are also responsible for sublicensing fees. In addition, under the BCM License Agreement, we are responsible for reimbursing BCM for patent-related expenses. BCM is responsible for filing, prosecuting and maintaining all patent applications and patents included in the licensed patent rights, and we have agreed to reimburse BCM for all such related legal costs incurred after the date of the BCM License Agreement, except such legal costs shall be reduced on a pro-rata basis on a patent or patent application basis should BCM license such patent or patent application in additional fields of use to any third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, upon a liquidity event (as defined in the BCM License Agreement) of the Company, BCM will receive a liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM License Agreement).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have agreed to indemnify BCM and certain persons affiliated with BCM against claims and liabilities directly or indirectly related to or arising out of the design, process, manufacture or use by any third party of the licensed products, even though such claims and liabilities result in whole or in part from the negligence of the BCM indemnified parties or are based upon doctrines of strict liability or product liability, but not claims or liabilities arising from the gross negligence or intentional misconduct of any such BCM indemnified parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless terminated sooner, the license will expire on a licensed product-by-product basis and country-by-country basis, on the later of&#8201;(1)&#160;the date of expiration of the last valid claim of patent rights to expire that covers the sale of such licensed product in such country, or (2)&#160;the first date following the tenth anniversary of the first commercial sale of first licensed product by us in such country. After such expiration, but not termination, the licenses granted to us shall survive and become a perpetual, paid-in-full license in such country with respect to such licensed product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have the right in our sole discretion to terminate the BCM License Agreement upon 60 days&#8217; written notice to BCM. BCM has the right to terminate the agreement upon material default or failure of us of our overall obligation to perform any of the terms, covenants or provisions of the license agreement, including failure to make timely payment, taken as a whole, and which default or failure remains uncured thirty days after written notice from BCM of such material default or failure to correct such default or failure. Notwithstanding the foregoing, if a material default or failure is not susceptible to cure within the 30-day cure period, BCM&#8217;s right to terminate shall be suspended if, and for so long as, (1)&#160;we have provided BCM with a written plan that is reasonably calculated to effect a cure, (2)&#160;such plan is reasonably acceptable to BCM, in its sole but reasonable discretion, and (3)&#160;we commit to and do carry out such plan; provided, however, that, unless mutually agreed to by the parties in such plan, such suspension of BCM&#8217;s right to terminate shall not extend beyond 60&#160;days after the original cure period. In addition, either party&#8217;s right to terminate the license agreement shall be tolled for so long as dispute resolution procedures are being pursued by the allegedly breaching party in good faith, and if it is finally and conclusively determined that the allegedly breaching party is in material breach, then the breaching party shall have the right to cure within 30 days after such determination. BCM also has the right to terminate the agreement if we shall (1)&#160;become involved in insolvency, dissolution, bankruptcy or receivership proceedings affecting the operation of our business, (2)&#160;make an assignment of all or substantially all of our assets for the benefit of creditors, or (3)&#160;if a receiver or trustee is appointed for us and we, after the expiration of 30 days following any of the enumerated events, are unable to secure a dismissal, stay or other suspension of such proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of termination of the BCM License Agreement, but not expiration, all rights to the subject technology and patent rights thereunder shall revert to BCM, except to the extent necessary to exercise any surviving right or license thereunder. We may sell any licensed products actually in our possession at the effective date of termination, provided that we continue to pay to BCM royalties on all such sales in accordance with the license agreement, otherwise comply with the terms of the license agreement and sell all such licensed products within six months after the effective date of the termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In furtherance of the BCM License Agreement and as contemplated by the terms thereof, we entered into a Sponsored Research Agreement, or the SRA, with BCM, which provides for the conduct of research for us by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have entered into additional agreements with BCM with respect to a strategic alliance to advance pre-clinical research, early-stage clinical trials, and Phase 2 clinical trials with respect to our product candidates, as well as continued access to our clinical data, and product manufacturing and support, including personnel and space at the institution for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Mayo Foundation for Medical Education and Research Relationships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have exclusively licensed the intellectual property for our TPIV100/110 HER2/neu breast cancer vaccine and TPIV200 folate receptor alpha vaccine product candidates from the Mayo Foundation for Medical Education and Research, or the Mayo Foundation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of our business strategy, we establish business relationships, including collaborative arrangements, with other companies and medical research institutions to assist in the clinical development of certain of our drugs and drug candidates and to provide support for our research programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Below is a brief description of our significant business relationships and collaborations and related license agreements with Mayo Foundation that expand our pipeline and provide us with certain rights to existing and potential new products and technologies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following approval of the IND by the FDA in July 2011, we executed a Sponsored Research Agreement with the Mayo Foundation for the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Mayo Patent &amp; Know-How License</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 25, 2012, we entered into a Patent &amp; Know-How License Agreement with the Mayo Foundation pursuant to which we licensed certain intellectual property rights from the Mayo Foundation for the development and commercialization of certain products, methods and processes property relating to a proprietary HER2/neu technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Mayo Foundation granted us a license (with a right to sublicense) on a worldwide basis to make, sell and use products for prophylactic and therapeutic use. This license is an exclusive license for products that are based on the licensed intellectual property and non-exclusive for products that are based on Mayo Foundation know&#8211;how and materials. The intellectual property licensed includes U.S. patents 9,814,767 (estimated expiration date February 15, 2033) and 10,117,919 (estimated expiration date February 15, 2033) and European patent 2814836 (estimated expiration date February 15, 2033).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under this agreement, and subject to certain exceptions, we are responsible for, among other things, developing the technology under the Patent Rights to bring Licensed Products (as defined in the agreement) to market and costs of filing, prosecution and maintenance of the Patent Rights. Mayo Foundation controls the prosecution and maintenance of the Patent Rights in consultation with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Mayo Foundation granted this license in exchange for an upfront payment of $250,000 that we paid in three installments. In addition to the upfront payment, we are to pay an annual license maintenance fee, milestone fees, royalty fees (which will be subject to a minimum annual royalty fee once royalty fees are due), a percentage of sublicense income (if applicable), and a $2,000,000 diligence fee if we fail to initiate a Phase 2 clinical trial for a Licensed Product prior to the eighth anniversary of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have agreed to indemnify and hold Mayo Foundation harmless from any damages caused as a result of (1) the practice or exercise of any rights and assignments granted pursuant to the agreement by or on behalf of us, any affiliate, or any sub-licensee; (2) research, development, design, manufacture, distribution, use, sale, importation, exportation or other disposition of Licensed Products; (3) our, any affiliates, or any sub-licensee&#8217;s act or omission; and (4) third party suits for patent infringement involving a Licensed Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The term of this agreement runs from March 25, 2012 until the date of the last to expire of the Valid Claims (as defined in the agreement), provided that Mayo Foundation may terminate the agreement if, among other matters, (1) 45 days after providing us with notice of a material breach of this agreement, we fail to cure such breach, (2) we fail to initiate a Phase 3 clinical trial for a Licensed Product prior to the tenth anniversary of the agreement, and (3) we cease to conduct business in the normal event of operations or become insolvent or bankrupt. We may voluntarily terminate the agreement at any time upon written notice to Mayo Foundation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Mayo HER2/neu License</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2016, we entered into a License and Assignment Agreement with Mayo Foundation, or the Mayo Foundation HER2/neu License, pursuant to which we licensed certain intellectual property rights from the Mayo Foundation for the development and commercialization of certain products, methods and processes property relating to any cancer indication in which the HER2/neu antigen is overexpressed. The Mayo Foundation HER2/neu License resulted from our exercise of an option that was issued pursuant to a Technology Option Agreement that we entered into with the Mayo Foundation on May 25, 2010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Mayo Foundation granted us a license (with a right to sublicense) on a worldwide basis to make, sell and use products for therapeutic use against breast, ovarian, lung and any other cancers that overexpress HER2/neu antigens. This license is an exclusive license for products that are based on the licensed intellectual property and non-exclusive for products that are based on Mayo Foundation know&#8211;how and materials. The intellectual property licensed includes European patent 2215111 (estimated expiration date October 30, 2028).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Mayo Foundation HER2/neu License, and subject to certain exceptions, we are responsible for, among other things, developing the technology under the Patent Rights to bring Licensed Products (both as defined in the Mayo Foundation HER2/neu License) to market and costs of filing, prosecution and maintenance of the Patent Rights. Mayo Foundation has sole control over the protection, defense, enforcement, maintenance abandonment and other handling of the Know-How (as defined in the Mayo Foundation HER2/neu License) and Materials (as defined in the Mayo Foundation HER2/neu License).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Mayo Foundation granted this license in exchange for an initial payment of $300,000. The Mayo Foundation assigned to us IND #14749, and we assumed all responsibility and liability for this investigational new drug application. In addition to the initial payment, we are to pay an annual license maintenance fee, milestone fees, royalty fees (which will be subject to a minimum annual royalty fee once royalty fees are due) and, if applicable, a percentage of sublicense income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have agreed to indemnify and hold Mayo Foundation harmless from any damages caused as a result of (1) the practice or exercise of any rights and assignments granted pursuant to the agreement by or on behalf of us or any sub-licensee; (2) research, development, design, manufacture, distribution, use, sale, importation, exportation or other disposition of Licensed Products; (3) our or any sub-licensee&#8217;s act or omission, including negligence or willful misconduct; and (4) third party suits for patent infringement involving a Licensed Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The term of this agreement runs from May 4, 2016 until the date of our last obligation to make payments under the agreement, provided that Mayo Foundation may terminate the agreement if, among other matters, (1) 30 days after providing us with notice of a material breach of this agreement, we fail to cure such breach, (2) 90 days after providing us with written notice, we fail to meet either of the following diligence events (a) initiate a Phase 2 clinical trial for a Licensed Product prior to the second anniversary of the agreement and, once initiated, keep current on all of our Phase 2 funding obligations and (b) initiate a Phase 2b or 3 clinical trial for a Licensed Product prior to the fifth anniversary of the agreement, (3) we fail to make a sale of a Licensed Product by May 4, 2026, and (4) we cease to conduct business in the normal event of operations or become insolvent or bankrupt. We may voluntarily terminate the agreement at any time upon written notice to Mayo Foundation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Mayo Folate Receptor Alpha License</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 21, 2015, we entered into a License and Assignment Agreement with Mayo Foundation, or the Mayo Foundation FRa License, pursuant to which we licensed certain intellectual property rights from the Mayo Foundation for the development and commercialization of certain products, methods and processes property relating to a Folate Receptor Alpha immunotherapeutic vaccine comprised of a set of unique peptide epitopes targeting breast, lung and ovarian cancer. The Mayo Foundation FRa License resulted from our exercise of an option that we acquired from Ayer Special Situations Fund I, LP, or Ayer, that was issued pursuant to a Technology Option Agreement that Ayer entered into with the Mayo Foundation on March 19, 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Mayo Foundation granted us a license (with a right to sublicense) on a worldwide basis to make, sell and use products for therapeutic use against breast, ovarian, lung and other cancers that overexpress Folate Receptor Alpha. This license is an exclusive license for products that are based on the licensed intellectual property and non-exclusive for products that are based on Mayo Foundation know&#8211;how and materials. The intellectual property that is licensed includes US patents 8,486,412 (estimated expiration date April 3, 2029), 8,858,952 (estimated expiration date March 10, 2031), 9,243,033 (July 10, 2027) and 9,915,646 (estimated expiration date June 1, 2027).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Mayo Foundation FRa License, and subject to certain exceptions, we are responsible for, among other things, developing the technology under the Patent Rights to bring Licensed Products (both as defined in the Mayo Foundation FRa License) to market and costs of filing, prosecution and maintenance of the Patent Rights. Mayo Foundation has sole control over the protection, defense, enforcement, maintenance abandonment and other handling of the Know-How (as defined in the Mayo Foundation FRa License) and Materials (as defined in the Mayo Foundation FRa License).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Mayo Foundation granted this license in exchange for an initial upfront payment of $350,000. The Mayo Foundation assigned to us IND # 14546, and we assumed all responsibility and liability for this investigational new drug application. In addition to the initial upfront payment, we are to pay additional upfront payments, an annual license maintenance fee, milestone fees, royalty fees (which will be subject to a minimum annual royalty fee once royalty fees are due), and, if applicable, a percentage of sublicense income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have agreed to indemnify and hold Mayo Foundation harmless from any damages caused as a result of (1) the practice or exercise of any rights and assignments granted by the Mayo Foundation FRa License by or on behalf of us or any sub-licensee; (2) research, development, design, manufacture, distribution, use, sale, importation, exportation or other disposition of Licensed Products; (3) our or any sub-licensee&#8217;s act or omission, including negligence or willful misconduct; and (4) third party suits for patent infringement involving a Licensed Product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The term of this agreement runs from July 21, 2015 until the date of our last obligation to make payments under this agreement, provided that the Mayo Foundation may terminate this agreement if, among other matters, (1) 30 days after providing us with notice of a material breach of this agreement, we fail to cure such breach, (2) 90 days after providing us with written notice, we fail to meet either of the following diligence events (a) initiate a Phase 2 clinical trial for a Licensed Product prior to the 2nd anniversary of the Mayo Foundation FRa License and, once initiated, keep current on all of our Phase 2 funding obligations and (b) initiate a Phase 2b or 3 clinical trial for a Licensed Product prior to the 5th anniversary of the Mayo Foundation FRa License, (3) we fail to make a sale of a Licensed Product by July 21, 2025 and (4) we cease to conduct business in the normal event of operations or become insolvent or bankrupt. We may voluntarily terminate the Mayo Foundation FRa License at any time upon written notice to Mayo Foundation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, improvements, and know-how related to the business; to defend and enforce proprietary rights, including any patents that we may own in the future; to preserve the confidentiality of our trade secrets and other intellectual property; to obtain and maintain licenses to use intellectual property owned by third parties; and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities&#8201;&#8212;&#8201;in other words, the rights obtained under exclusive license arrangements such as those pursuant to our BCM License Agreement and our Mayo Foundation licenses. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed in the future, nor can we be sure that any of our existing patents or any patents that may be granted in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To achieve this objective, a strategic focus for us has been to identify and license key patents and patent applications that serve to enhance our intellectual property and technology position. Currently, all of our MultiTAA-specific T cell intellectual property rights are licensed from BCM. Our intellectual property portfolio currently includes patent applications having: (1) claims directed to methods of generating multi-antigen specific T cell products; and (2) claims directed to therapeutic uses of such multi-antigen specific T cell products. We believe our patent portfolio, together with our efforts to develop and patent next-generation technologies, provides us with a substantial intellectual property position. However, the area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents and other proprietary rights are vital to our business operations. We protect our technology through various United States and foreign patent filings and maintain trade secrets that we own. Our policy is to seek appropriate patent protection both in the United States and abroad for our proprietary technologies and product candidates. An enforceable patent with appropriate claim coverage can provide an advantage over competitors who may seek to employ similar approaches to develop therapeutics, and so the future commercial success of products, and therefore our future success, will be in part dependent on our intellectual property strategy. We reassess the value of each patent at the time maintenance fees are due, and in cases where maintaining the patent is judged to be of no significant strategic value, we decline to pay the maintenance fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that our patents, and any patents that may be issued or licensed to us in the future, will afford protection against competitors with similar technology. In addition, no assurances can be given that the patents issued or licensed to us will not be infringed upon or designed around by others or that others will not obtain patents that we would need to license or design around. If the courts uphold existing or future patents containing broad claims over technology used by us, the holders of such patents could require us to obtain licenses to use such technology. Patent coverage may also vary from country to country based on the scope of available patent protection. There are also opportunities to obtain an extension of patent coverage for a product in certain countries, which adds further complexity to the determination of patent life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have a number of issued and pending patents covering composition of matter of our PolyStart technology and methods of using our PolyStart technology, including: U.S. 9,364,523 (estimated expiration date March 17, 2035); U.S. 9,655,956 (estimated expiration date March 17, 2035); U.S. 9,988,643 (estimated expiration date March 27, 2035); and U.S. 10,030,252 (estimated expiration date March 17, 2035)</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of the issued United States patents is that they provide us with patent protection for the claims covered by the patents. While the expiration of a product patent normally results in a loss of market exclusivity for the covered product or product candidate, commercial benefits may continue to be derived from , for example: (1)&#160;later- expiring patents on processes and intermediates related to more economical methods of manufacture of the active ingredient of such product; (2) patents relating to the use of such product; (3)&#160;patents relating to novel compositions and formulations; and (4) in the United States and certain other countries, other types of market exclusivity that may be available under relevant law. The effect of patent expiration on our product candidates also depends upon many other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient of the product and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our pending patent applications cover a range of technologies, including specific embodiments and applications for treatment of various medical indications, improved application methods and adjunctive utilization with other therapeutic modalities. The coverage claimed in a patent application can be significantly reduced before the patent is issued. Accordingly, we do not know whether any of the applications we will acquire, or license will result in the issuance of patents, or, if any patents are issued, whether they will provide significant proprietary protection or will be challenged, circumvented or invalidated. Because unissued U.S. patent applications are maintained in secrecy for a period of eighteen months and U.S. patent applications filed prior to November 29, 2000 are not disclosed until such patents are issued, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in opposition proceedings in a foreign patent office, or for United States patent applications filed before March 16, 2013, in interference proceedings declared by the United States Patent and Trademark Office, or the USPTO, to determine priority of invention, or in United States&#160;<i style="font-style:italic;">inter partes</i>&#160;review or post-grant review procedures, any of which could result in substantial cost to us, even if the eventual outcome is favorable to us. There can be no assurance that the patents, if issued, would be held valid by a court of competent jurisdiction. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease using such technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have patents and patent applications in other countries, as well as in the European Patent Office that we believe provide equivalent or comparable protection for our product candidates in jurisdictions internationally that we consider to be key markets. Because of the differences in patent laws and laws concerning proprietary rights, the extent of protection provided by U.S. patents or proprietary rights owned by us may differ from that of their foreign counterparts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Secrets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of immuno-oncology. However, trade secrets can be difficult to protect. We also plan to rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity and patent term extensions when available, as well as contractual agreements with our academic and commercial partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We require each of our employees, consultants and advisors to execute a confidentiality agreement upon the commencement of any employment, consulting or advisory relationship with us. Each agreement provides that all confidential information developed or made known to the individual during the course of the relationship will be kept confidential and not be disclosed to third parties except in specified circumstances. In the case of employees, the agreements provide that all inventions conceived by an employee shall be our exclusive property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have pending with the USPTO applications for registration of the trademarks POLYSTART and &#8220;Marker Therapeutics.&#8221; We currently have the trademark &#8220;TapImmune&#8221; registered with the USPTO. We also have rights to use other names essential to our business. Federally registered trademarks have a perpetual life if they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We regard our trademarks and other proprietary rights as valuable assets and believe they have significant value to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our patents, the protection of discoveries in connection with our development activities, our proprietary products, technologies, processes and know-how and all our intellectual property are important to our business. There can be no assurance that any of our patents, licenses or other intellectual property rights will afford us any protection from competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices, or GLP, regulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">preparation of and submission to the FDA of a biologics license application, or BLA, after completion of all pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Phase 1&#8212;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Phase 2&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Phase 3&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so- called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BLA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once a BLA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast-track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast-track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast-track product has opportunities for frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast-track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast-track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast-track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The regenerative medicine advanced therapy, or RMAT, designation is intended to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fines, warning letters or holds on post-approval clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biosimilars and Reference Product Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program; federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent; HIPAA, which created additional federal criminal statutes which prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters, and which, as amended by HITECH, also imposes certain requirements on HIPAA covered entities and their business associates and covered subcontractors relating to the privacy, security and transmission of individually identifiable health information; the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the federal government, information related to payments or other transfers of value made to covered health care professionals and teaching hospitals, as well as ownership and investment interests held by health care professionals and their immediate family members; and U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. In addition, certain states require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and certain states and local jurisdictions require the registration of pharmaceutical sales representatives. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#39;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#39;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. No regulatory authority has granted approval for a personalized cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions of particular importance to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. There remain judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the Tax Cuts and Jobs Act was enacted, which, among other things, removed penalties for not complying with ACA&#8217;s individual mandate to carry health insurance. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress as part of the Tax Cuts and Jobs Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. Although the Supreme Court has yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is also unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year through 2030, except for a temporary suspension from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken, and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump Administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#39;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#39;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product Liability and Insurance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. We have not experienced any product liability claims to date. We currently carry products and clinical trial liability insurance policies. There can be no assurance that liability claims will not exceed such insurance coverage limits, which could have a materially adverse effect on our business, financial condition or results of operations or that such insurance will continue to be available on commercially reasonable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had 44 full-time employees. There were 32 in research, development, quality, CMC and clinical and 12 were in finance, legal, human resources or administrative support. None of our employees is subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consultants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have consulting agreements with a number of leading academic scientists, clinicians and regulatory experts. They serve as important contacts for us throughout the broader scientific and clinical communities. They are distinguished individuals with expertise in numerous fields, including cellular biology, molecular biology, oncology, clinical, manufacturing and regulatory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We retain each consultant according to the terms of a consulting agreement. Under such agreements, we pay them a consulting fee and reimburse them for out-of-pocket expenses incurred in performing their services for us. In addition, some consultants hold options to purchase our common stock, subject to the vesting requirements contained in separate award agreements. Our consultants may be employed by other entities and therefore may have commitments to their employer or may have other consulting or advisory agreements that may limit their availability to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Human Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation awards. We strive to create a diverse environment, and our commitment to diversity, equity and inclusion begins with our leadership team of diverse backgrounds and experiences. Approximately 80% of our executive officers are women or self-identify as a member of an underrepresented minority group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We were incorporated under the laws of the State of Nevada in 1991 under the name &quot;TapImmune, Inc.&quot; and reincorporated in Delaware in October 2018 under the name &quot;Marker Therapeutics, Inc.&quot; On October 17, 2018, we completed a business combination with a Delaware corporation that was then known as &quot;Marker Therapeutics, Inc.,&quot; or Private Marker, in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of May 15, 2018, or the Merger Agreement, by and among us, Private Marker and Timberwolf Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of TapImmune, or Merger Sub, pursuant to which, among other matters, Merger Sub merged with and into Private Marker, with Private Marker continuing as a wholly owned subsidiary of TapImmune and the surviving corporation of the merger. In connection with the merger, we changed our name from &quot;TapImmune, Inc.&quot; to &quot;Marker Therapeutics, Inc.&quot; and Private Marker changed its name to &quot;Marker Cell Therapy, Inc.&quot; and became our wholly owned subsidiary. Our principal executive offices are located at 3200 Southwest Freeway, Suite 2500, Houston, Texas 77027, and our telephone number is (713) 400-6400. Our common stock is listed for trading on the Nasdaq Capital Market under the symbol &quot;MRKR&quot;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our website is located at <i style="font-style:italic;">www.markertherapeutics.com</i>. We make available free of charge on our website our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission. Our website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form&#160;10-K.</p><a id="_b996291c_bb5e_4e2e_ba93_9b0493a39bdd"></a><a id="ITEM1ARISKFACTORS_686864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1A. RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below before making an investment decision in our securities. These risk factors are effective as of the date of this Form 10-K and shall be deemed to be modified or superseded to the extent that a statement contained in our future filings modifies or replaces such statement. All of these risks may impair our business operations. The forward-looking statements in this Form 10-K involve risks and uncertainties and actual results may differ materially from the results we discuss in the forward-looking statements. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected. In that case, the trading price of our stock could decline, and you may lose all or part of your investment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Risks Associated with Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in this &#8220;Risk Factors&#8221; section and include, among others:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We are a development stage company with a history of operating losses, and we expect losses to continue for the indefinite future. These factors raise substantial doubt regarding our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our business and operations are likely to be adversely affected by the evolving and ongoing COVID-19 global pandemic.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">All of our product candidates are in clinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our product candidates, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may not be successful in establishing our own manufacturing infrastructure for supply of our requirements of product candidates for use in clinical trials and for commercial sale. Until our new manufacturing facility is fully operational, we will be dependent on third-party vendors to design, build, maintain and support our manufacturing and cell processing facilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our strategic relationship with BCM is dependent, in part, upon our ongoing relationship with key medical and scientific personnel and advisors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">If we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We are subject to extensive regulation, which can be costly, time consuming and can subject us to unanticipated delays. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The price of our stock may be volatile.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to our Financial Position and Capital Needs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a development stage company with a history of operating losses, and we expect losses to continue for the indefinite future. These factors raise substantial doubt regarding our ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immunotherapy company with a history of losses, and we may always operate at a loss. We expect that we will continue to operate at a loss throughout our development stage, and as a result, we may exhaust our financial resources and be unable to complete the development of our product candidates. We anticipate that our ongoing operational costs will increase significantly, and our deficit will continue to grow, as we continue conducting our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no approved products or product candidates pending approval. As a result, we have not derived any revenue from the sales of products and have not yet demonstrated ability to obtain regulatory approval, formulate and manufacture commercial-scale products, or conduct sales and marketing activities necessary for successful product commercialization. We have no sources of significant revenue to provide incoming cash flows to sustain our future operations. Our ability to pursue our planned business activities depends upon our successful efforts to raise additional financing, which may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the indefinite future due to the substantial investment in research and development. We expect that our cash and cash equivalents as of December 31, 2020 will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2021. We expect to spend substantial additional sums on the continued administration and research and development of licensed and proprietary product candidates and technologies with no certainty that our approach and associated technologies will become commercially viable or profitable as a result of these expenditures. If we fail to raise a significant amount of capital, we may need to significantly curtail operations, allocate limited financial resources among our product candidates, or cease operations in the near future. If any of our product candidates fail in clinical trials or do not gain regulatory approval, we may never generate revenue. Even if we generate revenue in the future, we may not be able to become profitable or sustain profitability in subsequent periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These and other factors raise substantial doubt regarding our ability to continue as a going concern, which may create negative reactions to the price of our common stock. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. Further, the perception that we may be unable to continue as a going concern may impede our ability to pursue strategic opportunities or operate our business due to concerns regarding our ability to discharge our contractual obligations. In addition, if there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Development of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations could be adversely affected by the evolving and ongoing COVID-19 global pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business and operations could be adversely affected by the effects of the recent and evolving COVID-19 virus, which was declared by the World Health Organization as a global pandemic. The COVID-19 pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease, including state and local orders across the United States that, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings and events and order cessation of non-essential travel. In response to public health directives and orders, we have implemented work-from-home policies for many of our employees, including at our headquarters in Houston, Texas, which is currently subject to an order that requires all non-essential businesses to cease in-person operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Remote work policies, quarantines, shelter-in-place and similar government orders, shutdowns or other restrictions on the conduct of business operations related to the COVID-19 pandemic may negatively impact productivity and, to date, have disrupted our ongoing research and development activities and delayed certain of our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In addition, although our employees are accustomed to working remotely, changes in internal controls due to remote work arrangements may result in control deficiencies in the preparation of our financial reports, which could be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such orders may also impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic may also affect the conduct of our clinical trials. Although we have begun enrolling patients in the safety lead-in portion of our Phase 2 trial of MT-401 (zedenoleucel) for post-transplant AML, we previously experienced temporary delays in enrollment due to the COVID-19 pandemic and in satisfying certain U.S. Food and Drug Administration, or the FDA, requirements to move forward with the trial, which together have resulted in a delay in our timelines for this trial. Our ongoing and future clinical trials may be also affected by the COVID-19 pandemic. Patient enrollment and clinical site initiation may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, we may be unable to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, which would adversely impact clinical trial operations. The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The global pandemic of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic impacts our business and operations, including our clinical development and regulatory efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence at the time of this Form 10-K, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">All of our product candidates are in clinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our product candidates, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are early in our development efforts and all of our product candidates are still in clinical development. Each of our programs and product candidates will require additional preclinical and/or clinical development, regulatory approval, obtaining manufacturing supply, capacity and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from our product candidates, which we do not expect will occur for several years, if ever, will depend heavily on the successful development, regulatory approval and eventual commercialization of our product candidates. The success of our MultiTAA product candidates or any other product candidates that we develop or otherwise may acquire will depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable, and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">effective investigational new drug applications, or INDs, from the FDA or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">successful enrollment and completion of clinical trials, including under the FDA&#8217;s current Good Clinical Practices, or GCPs, and current Good Laboratory Practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">successful development of, or making arrangements with third-party manufacturers for, our commercial manufacturing processes for any of our product candidates that receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">receipt of timely marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">launching commercial sales of products, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">acceptance of the benefits and use of our products, including method of administration, if approved, by patients, the medical community and third-party payors, for their approved indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the prevalence and severity of adverse events experienced our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the availability, perceived advantages, cost, safety and efficacy of alternative therapies for any product candidate, and any indications for such product candidate, that we develop;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to produce any product candidates we develop on a commercial scale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product candidates and otherwise protecting our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">maintaining compliance with regulatory requirements, including the FDA&#8217;s current Good Manufacturing Practices, or cGMPs, and complying effectively with other procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtaining and maintaining third-party coverage and adequate reimbursement and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">maintaining a continued acceptable safety, tolerability and efficacy profile of the products following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications for these product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any immunotherapies that we may develop are not likely to be commercially available for at least five years. Any delay in obtaining FDA and/or other necessary regulatory approvals in the United States and in countries outside the United States for any investigational new drug and failure to receive such approvals would have an adverse effect on the investigational new drug&#8217;s potential commercial success and on our business, prospects, financial condition and results of operations. The time required to obtain approval by the FDA and non-U.S. regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not previously submitted a biologics license application, or BLA, to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of cell therapies for cancer. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained, and the FDA or non-U.S. regulatory authorities may disagree with the design or implementation of our clinical trials or study endpoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the availability of financial resources to commence and complete the planned trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtaining approval by an independent institutional review board, or IRB, at each clinical trial site;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">recruiting suitable patients to participate in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">having patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">adding new clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a subject by subject basis for use in clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, the performance of our CROs may also be interrupted by the ongoing COVID-19 pandemic, including due to travel or quarantine policies, heightened exposure of CRO staff who are healthcare providers to COVID-19 or prioritization of resources toward the pandemic. We could also encounter delays if physicians face unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRB for the institutions in which such trials are being conducted, the Data and Safety Monitoring Board or Committee for such trial, or by the FDA or other regulatory authorities due to a number of factors. Those factors could include failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our product candidates are in clinical development and their risk of failure is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product candidates are based on new technologies and manufactured on a patient-by-patient basis for our MultiTAA-specific T cell product candidates we expect that they will require extensive research and development and have substantial manufacturing costs. In addition, the initial estimates of the clinical cost of development may prove to be inadequate, particularly if clinical trial timing or outcome is different than predicted or regulatory agencies require further testing before approval. For example, we anticipate that the COVID-19 pandemic will delay our planned timelines for our Phase 2 trial of MT-401 for the treatment of post-transplant AML, which may impact our cost estimates for this trial. &#160;Because our product candidates are based on new technologies and manufactured on a patient-by-patient basis for our MultiTAA-specific T cell product candidates we expect that they will require extensive research and development and have substantial manufacturing costs. In addition, costs to treat patients with relapsed/refractory cancer and to treat potential side effects that may result from our product candidates can be significant. Some clinical trial sites may not bill, or obtain coverage from, Medicare, Medicaid, or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and we may be required by those trial sites to pay such costs. Accordingly, our clinical trial costs may be significantly higher per patient than those of more conventional therapeutic technologies or drug products. In addition, our proposed personalized product candidates involve several complex manufacturing and processing steps, the costs of which will be borne by us. Depending on the number of patients we ultimately enroll in our trials, and the number of trials we may need to conduct, our overall clinical trial costs may be higher than for more conventional treatments. Further, delays and interruptions to ongoing trials related to the COVID-19 pandemic may also increase the duration and costs of such trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We outsource some of the management of our clinical trials to third parties. Agreements with clinical investigators and medical institutions for clinical testing and with other third parties for data management services, place substantial responsibilities on these parties that, if unmet, could result in delays in, or termination of, our clinical trials. If any of our clinical trial sites fail to comply with FDA-approved good clinical practices, we may be unable to use the data gathered at those sites. If these clinical investigators, medical institutions or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approval for, or successfully commercialize, agents. We cannot be certain that we will successfully recruit enough patients to complete our clinical trials nor that we will reach our primary endpoints. Delays in recruitment, lack of clinical benefit or unacceptable side effects would delay our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic is also likely to cause disruptions to our clinical programs. For example, we expect that we will be delayed in initiating our Phase 2 trial of MT-401 for post-transplant AML per previously communicated timelines. The COVID-19 pandemic may also result in difficulties in initiating clinical sites and enrolling patients, the diversion of healthcare resources away from clinical trials and other challenges related to travel or quarantine policies that may impede patient movement or interrupt healthcare services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We, or our regulators, may suspend or terminate our clinical trials for a variety of reasons. For example, in the fourth quarter of 2019 the FDA placed a clinical hold on our IND of MT-401 for the treatment of patients with post-transplant AML and requested certain information regarding quality and technical specifications for two reagents supplied by third party vendors that are used in our manufacturing process but not present in the final product infused to patients. In January 2021, the FDA lifted the clinical hold, permitting us to initiate a Phase 2 clinical trial with a safety lead-in portion. We may voluntarily suspend or terminate our clinical trials at any time if we believe they present an unacceptable risk to the patients enrolled in our clinical trials or do not demonstrate clinical benefit. For example, in November 2019 we elected to suspend our Phase 2 clinical trial of TPIV200 for the treatment of platinum-sensitive advanced ovarian cancer based on an unblinded review of interim results conducted by an independent Data and Safety Monitoring Board, or DSMB. Although the DSMB did not express any safety concerns with respect to TPIV200, we elected to suspend the trial because it did not meet the threshold for probability of clinical benefit based upon our pre-specified criteria. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the patients enrolled in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our clinical trial operations are subject to regulatory inspections at any time. If regulatory inspectors conclude that we or our clinical trial sites are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports of observations or warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory agencies deem our responses to be inadequate, or are dissatisfied with the corrective actions we or our clinical trial sites have implemented, our clinical trials may be temporarily or permanently discontinued, and we may be fined, we or our investigators may be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve our marketing applications or allow us to manufacture or market our products, and we may be criminally prosecuted. The lengthy approval process, as well as the unpredictability of future clinical trial results, may result in us failing to obtain regulatory approval for our product candidates, which would materially harm our business, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure can occur at any time during the clinical trial process. The results of preclinical testing and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage controlled clinical trials. Product candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. Our clinical trials to date have been conducted on a small number of patients in a single academic clinical site for a limited number of indications. We will have to conduct larger, well-controlled trials in our proposed indications at multiple sites to verify the results obtained to date and to support any regulatory submissions for further clinical development of our product candidates. Our assumptions related to our product candidates, such as with respect to lack of toxicity and manufacturing cost estimates, are based on early limited clinical trials and current manufacturing processes at Baylor College of Medicine, or BCM, and may prove to be incorrect. Several companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings, including IND submissions. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control, including with respect to challenges related to enrollment, manufacturing and our reliance on third parties to conduct, supervise or monitor some or all aspects of our clinical trials. We may experience numerous unforeseen events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For example, we have been delayed in initiating our planned Phase 2 trial of MT-401 for post-transplant AML due to the COVID-19 pandemic, including as a result of delays related to the partial clinical hold, which the FDA lifted in January 2021 and delays in our ability to enroll the first three patients in the safety lead-in portion of the trial required by the FDA. The pandemic may also impact our other clinical programs. We may experience difficulties in patient enrollment in our future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Accordingly, we cannot guarantee that our clinical trials will progress as planned or as scheduled. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure and effective for use in each target indication, and failures can occur at any stage of testing. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy of the product candidate studied for the target indication. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. If any such adverse events occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA, EMA or foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from personalized cell therapy, as with our MultiTAA-specific T cell therapy products, are not normally encountered in the general patient population and by medical personnel. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved. Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">regulatory authorities may require additional warnings on the labels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients or other requirements subject to a REMS;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">we may not be able to achieve or maintain third-party payor coverage and adequate reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our reputation and physician or patient acceptance of our products may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or foreign regulatory agency in a timely manner or at all. Moreover, any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not obtain or maintain the benefits associated with orphan drug designation, including market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Generally, a product that has orphan drug designation and subsequently receives the first FDA approval for the disease for which it has such designation is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has granted orphan drug designation for MT-401 for the treatment of AML after receiving an allogeneic stem cell transplant. We may seek orphan drug designation for other indications or product candidates. Even if we were to obtain orphan drug designation for a product candidate, we may not obtain orphan exclusivity and that exclusivity may not effectively protect the drug from the competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA or European Medicines Agency, or the EMA, later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any product candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in establishing our own manufacturing infrastructure for supply of our requirements of product candidates for use in clinical trials and for commercial sale. Until our new manufacturing facility is fully operational, we will be dependent on third-party vendors to design, build, maintain and support our manufacturing and cell processing facilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently do not operate our own facility that may be used as our clinical-scale manufacturing and processing facility. We currently rely on third-party contract manufacturing organizations, or CMOs, for manufacture of our product candidates. For early 2021, we anticipate that we will initially rely partially on the cGMP manufacturing facility within BCM for the manufacturing of our MultiTAA-specific T cell therapy-based product candidates. BCM has continued to restrict access to its facilities due to the COVID-19 pandemic, and manufacturing activities for MT-401 are ongoing albeit at a slower pace. If the cGMP manufacturing facility of BCM, which does manufacture for itself and other parties, experiences capacity constraints, other disruptions, or delays in manufacturing our MultiTAA-specific T cell therapy-based product candidates, our planned clinical trials and necessary manufacturing capabilities will be disrupted or delayed. &#160;Third-party manufacturers may not be able to meet our needs concerning timing, quantity, or quality. If we are unable to contract for a sufficient supply of needed materials on acceptable terms, or if we should encounter delays or difficulties in our relationships with manufacturers, our clinical trials may be delayed, thereby delaying the submission of product candidates for regulatory approval or the market introduction and subsequent sales of any approved products. Any such delay may lower our revenues and potential profitability. If any third party breaches or terminates its agreement with us or fails to conduct its activities in a timely manner, the commercialization of our product candidates could be slowed down or blocked completely. It is possible that third parties relied upon by us will change their strategic focus, pursue alternative technologies, or develop alternative product candidates, either on their own or in collaboration with others, as a means for developing treatments for the diseases targeted by our collaborative programs, or for other reasons. The effectiveness of these third parties in marketing their own products may also affect our revenues and earnings. We intend to continue to enter into additional third-party agreements in the future. However, we may not be able to negotiate any additional agreements successfully. Even if established, these relationships may not be scientifically or commercially successful.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to further develop our business as currently planned and to conduct our planned clinical studies, including our Phase 2 trial of MT-401, we expect that our cGMP manufacturing capacity will be fully operational in the first half of 2021 following the completion of the technology transfer process. We have completed qualification of our manufacturing facility and believe it is capable of supporting our manufacturing needs with respect to our clinical trials, particularly with pivotal studies. We expect that the establishment of our own manufacturing facility will provide us with enhanced control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes, and allow for better long-term margins. In order to transfer our MultiTAA-specific T cell manufacturing from or expand our manufacturing capabilities beyond BCM pursuant to our development plans, we will need access to the standard operating procedures and the specific batch production records that are used to manufacture the product candidates. If BCM does not support the transfer of our manufacturing processes or impedes our ability to transfer the manufacturing processes of its product candidates to us, our planned clinical trials and additional necessary manufacturing capabilities will be delayed, which will adversely affect our ability to conduct and further develop our business as currently planned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Establishment of our own manufacturing facility is subject to many risks. We have limited prior experience in establishing a manufacturing facility and, although we have made significant progress towards initiating clinical production in our cGMP manufacturing facility, we may encounter challenges given the complexity of manufacturing cell therapies. We will also compete for the small number of individuals with expertise in cell therapy manufacturing. Even with an operational facility, our manufacturing capabilities could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures, transportation difficulties and numerous other factors that could prevent us from fully realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our clinical development and/or commercialization plans. In addition, the manufacturing process for any product candidates that we may develop is subject to the FDA and foreign regulatory authority approval process, and we will need to contract with manufacturers who can meet all applicable FDA and foreign regulatory authority requirements on an ongoing basis. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA, or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize any approved products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Further, we may be required to establish multiple manufacturing facilities to expand our commercial footprint for any approved products, which may lead to regulatory delays or prove costly. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our clinical development and/or commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our manufacturing process is reliant upon the specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. For some of this equipment and materials, we rely or may rely on sole-source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will depend on a limited number of vendors for supply of certain materials and equipment used in the manufacture of our MultiTAA-specific T cell therapy-based product candidates. For example, we will purchase equipment and reagents critical for the manufacture of our product candidates from Wilson Wolf (a company controlled by our director John Wilson), Almac, JPT Peptide Technologies and other suppliers. Some of our suppliers may not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also may not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may not be able to obtain key materials and equipment to support clinical or commercial manufacturing. Further, the FDA may determine that our manufacturing process, or the materials required for the manufacture of our product candidates, are not acceptable, which would require us to find alternative suppliers or processes, which may not be available on favorable terms, if at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For some of this equipment and materials, we may rely, and may now and/or in the future rely, on sole-source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, which could be due to regulatory actions or requirements affecting the supplier, adverse financial, or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As we continue to develop and scale our manufacturing process, we may need to obtain rights to and supplies of specific materials and equipment to be used as part of that process. For example, our MultiTAA-specific T cell manufacturing process is based, in part, upon the G-Rex&#174; cell culture device manufactured by Wilson Wolf, which is used by many cell therapy developers, both in commercial and academic settings. Although we do hold the license to patents from BCM that could be used to prevent third parties from developing similar and competing processes, we do not own any exclusive rights to the G-Rex&#174;. We may not be able to obtain rights to such materials and equipment on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development or scaling up of our manufacturing capabilities. If we, or any of our third-party suppliers encounter such difficulties, our ability to supply our product candidates for clinical trials, or our product candidates for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates are biologics, and the process of manufacturing our product candidates is complex, highly regulated and subject to multiple risks. For example, the manufacture of our MultiTAA-specific T cell therapy-based product candidates involves complex processes, including drawing blood from patients/donors, manufacturing the clinical product, and ultimately infusing the product into a patient. As a result of the complexities, the cost to manufacture biologics is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. Our manufacturing processes will be susceptible to product loss or failure due to any of the following: logistical issues associated with the collection of blood cells, or starting material, from the patient or a donor, shipping such material to the manufacturing site, shipping the final product back to the patient, and infusing the patient with the product; manufacturing issues associated with the variability in patients&#8217; or donor&#8217;s starting cells; interruptions in the manufacturing process; contamination; equipment failure; improper installation or operation of equipment, vendor or operator error; inconsistency in cell growth; and variability in product characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If for any reason we lose a patient&#8217;s or a donor&#8217;s cells, or later-developed product at any point in the process, the manufacturing process for that patient will need to be restarted and the resulting delay may adversely affect that patient&#8217;s outcome and/or the results of clinical trials. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because our MultiTAA-specific T cell therapy-based product candidates are manufactured for each particular patient, we will be required to maintain a chain of identity with respect to the patient&#8217;s/donor&#8217;s blood cells as it moves from the patient to the manufacturing facility, through the manufacturing process, and back to the patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in adverse patient outcomes, loss of product, or regulatory action including withdrawal of our product candidates from the market. Further, as product candidates are developed through preclinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in order to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Currently, our product candidates are manufactured using processes developed by BCM, our third-party research institution collaborator. Although we are working to develop our own commercially viable processes, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale up, process reproducibility, stability issues, lot consistency, and timely availability of raw materials. As a result of these challenges, we may experience delays in our clinical development and/or commercialization plans. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No assurance can be given that we will be able to develop a new, FDA-compliant, more efficient, lower cost manufacturing process upon which our business plan to commercialize MultiTAA-based product candidates is dependent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In cooperation with our current contract manufacturers and suppliers, we are developing improved methods for generating and selecting T cells, and to develop methods for large-scale production of our current product candidates that are in accordance with current cGMP procedures. Developing a new, scaled-up, pharmaceutical manufacturing process that can more efficiently and cost effectively, and in a more automated manner produce, measure and control the physical and/or chemical attributes of our product candidates in a cGMP facility is subject to many uncertainties and difficulties. We have never manufactured our adoptive T cell therapy product candidate on a commercial scale. As a result, we cannot give any assurance that we will be able to establish a manufacturing process that can produce our product candidates at a cost or in quantities necessary to make them commercially viable. Moreover, we and our third-party manufacturers will have to continually adhere to current cGMP regulations enforced by the FDA through its facilities inspection program. If these facilities (including our new in-house facility) cannot pass a pre-approval plant inspection, the FDA premarket approval of our product candidates will not be granted. In complying with cGMP and foreign regulatory requirements, we and any of our third-party manufacturers will be obligated to expend time, money and effort in production, record-keeping and quality control to assure that our product candidates meet applicable specifications and other requirements. If we or any of our third-party manufacturers fail to comply with these requirements, we may be subject to regulatory action. No assurance can be given that we will be able to develop such manufacturing process, or that our partners will thereafter be able to establish and operate such a production facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may have difficulty demonstrating that the product candidates produced from our new processes are identical to the existing products. The FDA may require additional clinical testing before permitting a larger clinical trial with the new processes, and such drug product may not be as efficacious in the new clinical trials. Cellular products are not considered to be well characterized products because there are hundreds of markers present on T cells, and even small changes in manufacturing processes could alter the cell subtypes. It is unclear at this time which of those markers are critical for success of T cells to combat cancer, so our ability to predict the outcomes with newer manufacturing processes is limited. The changes that we may make to the existing manufacturing process may require additional testing, which may increase costs and timelines associated with these developments. In addition to developing a multi-antigen T cell-based therapy on existing adoptive T cell therapy technology, we are currently evaluating the desirability of conducting clinical trials of our product candidates in combination with other existing drugs. These combination therapies will require additional testing, and clinical trials will require additional FDA regulatory approval and will increase our future cost of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Catastrophic events may disrupt our business.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters and cGMP manufacturing facility are located in Houston, Texas. In the event of a major hurricane or other serious weather event or catastrophic event such as fire, power loss, cyberattack, war, terrorist attack or epidemic or pandemic, such as the COVID-19 pandemic, that impacts our corporate headquarters or other facilities, we may be unable to continue our operations and may experience delays in our manufacturing process and shipment of clinical supply to trial sites or interruptions in our clinical trials and research activities, all of which could delay our development plans and materially harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to our Reliance on Third Parties, Including BCM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our strategic relationship with BCM is dependent, in part, upon our ongoing relationship with key medical and scientific personnel and advisors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our MultiTAA-specific T cell therapy has been developed through our collaboration with the Center for Cell and Gene Therapy at BCM, founded by Malcolm K. Brenner, M.D., Ph.D., a recognized pioneer in immuno-oncology. Our strategic relationship with BCM is dependent, in part, on our relationship with certain key employees and advisors, some of whom serve on our Scientific Advisory board, and in particular Dr. Vera, our founder and Chief Development Officer. If Dr. Vera discontinues his employment with us, our relationship with BCM may deteriorate, and our business could be harmed. We may also be dependent on BCM facilities and personnel to conduct research and development and manufacturing activities in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we have an exclusive license agreement with BCM under which we received a worldwide, exclusive license to BCM&#8217;s rights in and to three patent families to develop and commercialize the MultiTAA-specific T cell product candidates, we will need to enter into additional agreements with BCM with respect to (i) a strategic alliance to advance preclinical research, early stage clinical trials, and Phase 2 clinical trials with respect to our product candidates, as well as continued access to our clinical data, and (ii) product manufacturing and support, including personnel and space at the institution for the foreseeable future. Any delays in entering into new strategic agreements with BCM related to our product candidates could delay the development, manufacture, and clinical trials of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An important element of our intellectual property portfolio is to license additional rights and technologies from BCM. Our inability to license the rights and technologies that we have identified, or newly developed MultiTAA-specific T cell technology that we may in the future identify, could have a material adverse impact on our ability to complete the development of our product candidates or to develop additional product candidates. No assurance can be given that we will be successful in licensing any additional rights or technologies from BCM and others. Failure to obtain additional rights and licenses may detrimentally affect our planned development of additional product candidates and could increase the cost, and extend the timelines associated with our development of such other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to establish or maintain the third-party relationships, including strategic collaborations, that are necessary to develop, commercialize and/or market some or all of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to depend on collaborators, partners, licensees, clinical research organizations and other third parties to support our discovery efforts, to formulate product candidates, to manufacture our product candidates, and to conduct clinical trials for some or all of our product candidates. We cannot guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully negotiate such agreements will depend on, among other things, potential partners&#8217; evaluation of the superiority of our technology over competing technologies and the quality of the preclinical and clinical data that it has generated, and the perceived risks specific to developing our product candidates. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates. Management of any third-party relationships will require significant time and effort from our management team, coordination of our research and development programs with the research and development priorities of our collaborators and effective allocation of our resources to multiple projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we continue to enter into research and development collaborations at the early phases of drug development, our success will in part depend on the performance of our corporate collaborators. We will not directly control the amount or timing of resources devoted by our corporate collaborators to activities related to our immunotherapies. Our corporate collaborators may not commit sufficient resources to their research and development programs or the commercialization, marketing or distribution of their immunotherapies. If any corporate collaborator fails to commit sufficient resources, our preclinical or clinical development programs related to this collaboration could be delayed or terminated. Also, our collaborators may pursue existing or other development-stage products or alternative technologies in preference to those being developed in collaboration with us. Finally, if we fail to make required milestones or royalty payments to our collaborators or to observe other obligations in our agreements with them, our collaborators may have the right to terminate those agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our strategy includes eventual substantial reliance upon strategic collaborations for marketing and commercialization of our product candidates, and we may rely even more on strategic collaborations for research, development, marketing and commercialization of our other immunotherapies. If we are unsuccessful in securing such strategic collaborations, we may be unable to commercialize any approved products as we have not yet licensed, marketed or sold any of our immunotherapies or entered into successful collaborations for these services in order to ultimately commercialize our immunotherapies. Establishing strategic collaborations is difficult and time-consuming. Our discussions with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all. Potential collaborators may reject collaborations based upon their assessment of our financial, clinical, regulatory or intellectual property position. If we successfully establish new collaborations, these relationships may never result in the successful development or commercialization of our immunotherapies or the generation of sales revenue. To the extent that we enter into co-promotion or other collaborative arrangements, our product revenues are likely to be lower than if we directly marketed and sold any products that we may develop.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or in asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to develop our business. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Commercialization of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for our product candidates, they may not gain market acceptance among physicians, healthcare payors, patients or the medical community. Market acceptance of our product candidates, if we receive approval, depends on a number of factors, including the:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">efficacy and safety of our product candidates as demonstrated in clinical trials and post-marketing experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">clinical indications for which our product candidates may be approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">acceptance by physicians and patients of our product candidates as safe and effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">potential and perceived advantages of our product candidates over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">safety of our product candidates seen in a broader patient group, including our use outside the approved indications should physicians choose to prescribe for such uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">product labeling, or product insert requirements of the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">timing of market introduction of our product candidates as well as competitive products;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">cost in relation to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">pricing and the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">relative convenience and ease of administration; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">effectiveness of any sales and marketing efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors and the medical community, we may not be able to generate significant revenues, which would compromise our ability to become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market for any products that we successfully develop will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it will cost to commercially manufacture our current product candidates, and the actual cost to manufacture these products could materially and adversely affect the commercial viability of these products. Our goal is to reduce the cost of manufacturing our therapies. However, unless we are able to reduce those costs to an acceptable amount, we may never be able to develop a commercially viable product. If we do not successfully develop and commercialize products based upon our approach or find suitable and economical sources for materials used in the production of our products, we will not become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we are successful in getting market approval, commercial success of any of our product candidates will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations, which may be affected by existing and future health care reform measures designed to reduce the cost of health care. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other health care payors were not to provide adequate coverage and reimbursement levels for any of our products if approved, market acceptance and commercial success would be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our MultiTAA-specific T cell therapy may be provided to patients in combination with other agents provided by third parties. The cost of such combination therapy may increase the overall cost of MultiTAA-specific T cell therapy and may result in issues regarding the allocation of reimbursements between our therapy and the other agents, all of which may adversely affect our ability to obtain reimbursement coverage for the combination therapy from third-party medical insurers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. In the United States, for example, principal decisions about reimbursement for new products are typically made by the CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. No regulatory authority has granted approval for a personalized cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success is highly dependent upon our key personnel, and our ability to attract, retain, and motivate additional qualified personnel. We will also be required to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any approved products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, scientific, and medical personnel and consultants, including Peter Hoang, our President and Chief Executive Officer, Juan Vera, M.D., our Chief Development and Scientific Officer, and Mythili Koneru, M.D., Ph.D. our Chief Medical Officer as well as others. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm to our business. We have a priority to quickly train additional qualified scientific and medical personnel to ensure the ability to maintain business continuity. Any delays in training such personnel could delay the development, manufacture, and clinical trials of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to attract and retain highly skilled personnel is critical to our operations and expansion. We face competition for these types of personnel from other biotechnology companies and more established organizations, many of which have significantly larger operations and greater financial, technical, human and other resources than us. We may not be successful in attracting and retaining qualified personnel on a timely basis, on competitive terms, or at all. If we are not successful in attracting and retaining these personnel, or integrating them into our operations, our business, prospects, financial condition and results of operations will be materially adversely affected. In such circumstances, we may be unable to conduct certain research and development programs, unable to adequately manage our clinical trials and development of our product candidates, and unable to adequately address our management needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not currently have an organization for the sale, marketing and distribution of any approved products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products approved by the FDA or comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. As a result, our actual or proposed immunotherapies could become obsolete before we recoup any portion of our related research and development and commercialization expenses. Competition in the biopharmaceutical industry is based significantly on scientific and technological factors. These factors include the availability of patent and other protection for technology and products, the ability to commercialize technological developments and the ability to obtain governmental approval for testing, manufacturing and marketing. We compete with specialized biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations. Many biopharmaceutical companies have focused their development efforts in the human therapeutics area, including cancer. Many major pharmaceutical companies have developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies. These companies, as well as academic institutions, governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing availability of capital to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Potential competitors in the market for treating hematological malignancies are companies such as Juno Therapeutics/Celgene/Bristol-Myers Squibb, Roche/Genentech, Merck, Novartis, Kite Pharma/Gilead, Amgen, Pfizer, and GlaxoSmithKline, which already have products on the market or in development. Other companies, such as Cellectis, Bluebird Bio, and Adaptimmune, which are focused on genetically engineered T cell technologies to treat cancer, may also be competitors. Furthermore, companies such as Iovance, Immatics, NexImmune, WindMIL Therapeutics, Mana Therapeutics, Tessa Therapeutics and Repertoire Immune Medicines are developing non-genetically modified T cell therapies such as tumor infiltrating lymphocytes and marrow infiltrating lymphocytes therapies that may compete with our product candidates. All these companies, and most of our other current and potential competitors have substantially greater research and development capabilities and financial, scientific, regulatory, manufacturing, marketing, sales, human resources, and experience than we do. Many of our competitors have several therapeutic products that have already been developed, approved and successfully commercialized, or are in the process of obtaining regulatory approval for their therapeutic products in the United States and internationally. Universities and public and private research institutions in the U.S. and around the world are also potential competitors. While these universities and public and private research institutions primarily have educational objectives, they may develop proprietary technologies that lead to other FDA approved therapies or that secure patent protection that we may need for the development of our technologies and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our lead product candidate is a therapy to treat post-allogeneic HSCT patients with AML. Currently, there are numerous companies that are developing various alternate treatments for AML. Accordingly, we face significant competition in the AML treatment space from multiple companies. Even if we obtain regulatory approval for our lead product candidate, the availability and price of competitors&#8217; products could limit the demand and the price we will be able to charge for our therapy. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from other methods of treatment to our product, or if physicians switch to other new therapies, drugs or biologic products or choose to reserve our product candidates for use in limited circumstances. We are aware of certain investigational new drugs under development or approved products by competitors that are used for the prevention, diagnosis, or treatment of certain diseases we have targeted for drug development. Various companies are developing biopharmaceutical products that have the potential to directly compete with our immunotherapies even though their approach may be different. The competition comes from both biotechnology firms and from major pharmaceutical companies. Many of these companies have substantially greater financial, marketing, and human resources than us. We also experience competition in the development of our immunotherapies from universities, other research institutions and others in acquiring technology from such universities and institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, certain of our immunotherapies may be subject to competition from investigational new drugs and/or products developed using other technologies, some of which have completed numerous clinical trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA often approves new oncology therapies initially only for use in patients with relapsed or refractory metastatic disease. We expect to initially seek approval of our product candidates in this setting. Subsequently, for those product candidates that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment and potentially as a first line therapy. There is no guarantee, however, that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive second or third-line therapy, and who have the potential to benefit from treatment with our product candidates, are based on our research and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research by third parties, and may prove to be incorrect. We do not have verifiable internal marketing data regarding the potential size of the commercial market for our product candidates, nor have we obtained independent marketing surveys to verify the potential size of the commercial markets for our current product candidates or any future product candidates. &#160;Further, new studies may change the estimated incidence or prevalence of these cancers. The number of treatable patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates and may also be limited by the cost of our treatments and the reimbursement of those treatment costs by third-party payors. For instance, we expect our lead product candidate to initially target a small patient population that suffers from AML. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, and we may spend large amounts of money trying to obtain approval for product candidates that have an uncertain commercial market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New regulatory pathways for biosimilar competition could reduce the duration of market exclusivity for our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the federal ACA enacted in 2010, there is an abbreviated path in the United States for regulatory approval of products that are demonstrated to be &#8220;biosimilar&#8221; or &#8220;interchangeable&#8221; with an FDA-approved biological product. The ACA provides a regulatory mechanism that allows for FDA approval of biologic drugs that are similar to (but not generic copies of) innovative drugs on the basis of less extensive data than is required by a full BLA. Under this regulation, an application for approval of a biosimilar may be filed four years after approval of the innovator product. However, qualified innovative biological products will receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. However, the term of regulatory exclusivity may not remain at 12 years in the United States and could be shortened. A number of jurisdictions outside of the United States have also established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier versions of biological products. For example, the European Union has had an established regulatory pathway for biosimilars since 2005.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to this risk, and uncertainties regarding patent protection, if one of our late-stage product candidates or other clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues from product sales of that product and thus our financial results and condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent to the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection laws. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">decreased demand for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">exhaustion of any available insurance and our capital resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inability to commercialize any product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could inhibit or prevent the commercialization of products we develop, alone or with collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no insurance coverage. While we obtained clinical trial insurance for our Phase II clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The multiple roles of certain of Dr. Vera, our Chief Development and Scientific Officer, and John Wilson, our director, could limit their time and availability to us, and create, or appear to create, conflicts of interest.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr. Vera is a co-founder and member of Allovir Inc., or Allovir. Allovir has technology which is being developed under a license agreement with BCM by the same research group at BCM. Allovir is a clinical-stage biopharmaceutical company that is investigating and developing virus-specific T cell therapy technology for the prevention and/or treatment of viral infections. Accordingly, Dr. Vera may have other commitments that would, at times, limit his availability to us. Other research being conducted by Dr. Vera may, at times, receive higher priority than research on our programs, which may, in turn, delay the development or commercialization of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, John Wilson is a co-founder, member and director of Allovir and is a director of our company. Both of these individuals have certain fiduciary or other obligations to us and certain fiduciary or other obligations to Allovir and, in the case of Dr. Vera to BCM. Such multiple obligations may in the future result in a conflict of interest with respect to presenting other potential business opportunities to us or to Allovir. A conflict of interest also may arise concerning the timing and scope of the parties&#8217; planned and ongoing clinical trials, investigational new drug application filings and the parties&#8217; opportunities for marketing their respective product candidates, as well as our intellectual property rights with those of Allovir. In addition, they may be faced with decisions that could have different implications for us than for Allovir. Consequently, there is no assurance that these members of our board and management will always act in our best interests in all situations should a conflict arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success is dependent in part on our ability to obtain, maintain, and enforce the patents and other proprietary rights that we have licensed and may develop, and on our ability to avoid infringing the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims are directed to the technology. There can be no assurance that our patent applications or those of our licensor will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with relevant employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of the premises and physical and electronic security of the information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, trade secrets may otherwise become known or be independently discovered by competitors. To the extent that the consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we have patents and patent applications in other countries, we cannot be certain that the claims in other pending U.S. or European patent applications, international patent applications, and patent applications in certain other foreign territories directed to methods of generating multi-antigen specific T cell product candidates, or our other product candidates, will be considered patentable by the USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued European patent will not be found invalid or unenforceable if challenged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Most of our intellectual property rights are currently licensed from BCM and the Mayo Foundation, so that the preparation and prosecution of these patents and patent applications was not performed by us or under our control. Furthermore, patent law relating to the scope of claims in the biotechnology field in which we operate is still evolving and, consequently, patent positions in our industry may not be as strong as in other more well-established fields. The patent positions of biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">patent applications may not result in any patents being issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our competitors, many of whom have substantially greater resources than us, and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of one of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensor have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and it is uncertain how much protection, if any, will be given to the patents we have licensed from a licensor if either the licensor or we attempt to enforce the patents and/or if they are challenged in court or in other proceedings, such as oppositions, which may be brought in foreign jurisdictions to challenge the validity of a patent. A third party may challenge our patents, if issued, or the patent rights that we license from others in the courts or patent offices in the United States and abroad. It is possible that a competitor may successfully challenge our patents or that a challenge will result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our products and product candidates. Moreover, the cost of litigation to uphold the validity of patents and to prevent infringement can be substantial. If the outcome of litigation is adverse to us, third parties may be able to use our patented invention without payment to us. Moreover, it is possible that competitors may infringe our patents or successfully avoid them through design innovation. To stop violation of our patent rights, we may need to file a lawsuit. These lawsuits are expensive and would consume time and other resources, even if we were successful in stopping the violation of our patent rights. In addition, there is a risk that a court would decide that our patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of our patents were upheld, a court would refuse to stop the other party on the ground that its activities are not covered by, that is, do not infringe, our patents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should third parties file patent applications, or be issued patents claiming technology also used or claimed by our licensor(s) or by us in any future patent application, we may be required to participate in interference proceedings in the USPTO to determine priority of invention for those patents or patent applications that are subject to the first-to-invent law in the United States, or may be required to participate in derivation proceedings in the USPTO for those patents or patent applications that are subject to the &#8220;first-inventor-to-file&#8221; law in the United States. We may be required to participate in such interference or derivation proceedings involving our issued patents and pending applications. We may be required to cease using the technology or to license rights from prevailing third parties as a result of an unfavorable outcome in an interference proceeding or derivation proceeding. A prevailing party in that case may not offer us a license on commercially acceptable terms or on any terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we, our licensing partners, or any potential future collaborator initiates legal proceedings against a third party to enforce a patent directed to one of our product candidates, the defendant could counterclaim that the patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, non-obviousness or enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they are no longer directed to our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid or could prevent a patent from issuing from one or more of our pending patent applications. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Furthermore, even if our patents are unchallenged, they may not adequately protect our intellectual property, provide exclusivity for our product candidates, prevent others from designing around our claims or provide us with a competitive advantage. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection could have a material adverse impact on our business development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The use of our technologies could potentially conflict with the rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential competitors or other entities may have or acquire patent or proprietary rights that they could enforce against our licensors. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations,&#160;<i style="font-style:italic;">inter partes&#160;</i>review proceedings and post-grant review, or PGR, proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. If they do so, then they could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position by requiring us to alter our product candidates, pay licensing fees or cease activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that later issue as patents that our product candidates may infringe. If our product candidates conflict with patent rights of others, third parties could bring legal actions against us or our collaborators, licensees, suppliers or customers, claiming damages and seeking to enjoin manufacturing and marketing of the affected product candidates. If these legal actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture or market the affected product candidates. We may not prevail in any legal action and a required license under the patent may not be available on acceptable terms or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO and may become involved in post-grant proceedings including post grant review, derivation, reexamination,&#160;<i style="font-style:italic;">inter-partes&#160;</i>review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. In addition, recent U.S. Supreme Court rulings on several patent cases have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. While we do not believe that any of the patents owned or licensed by us will be found invalid based on these decisions, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing its inventions in all countries outside the United States, or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. We have received confidential and proprietary information from third parties. We employ individuals or engage consultants who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to comply with any obligations under our existing license agreements or any future license agreements, or disputes arise with respect to those agreements, it could have a negative impact on our business and our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a party to license agreements with BCM and the Mayo Foundation that impose, and we may enter into additional licensing arrangements with third parties that may impose, diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Our rights to use the licensed intellectual property are subject to the continuation of and our compliance with the terms of these agreements. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the sublicensing of patent and other rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the scope and duration of our payment obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our rights upon termination of such agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the scope and duration of exclusivity obligations of each party to the agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future licensing agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under our license agreement with BCM for our MultiTAA-specific T cell therapy technologies, we are currently required to pay both substantial milestone payments and royalties to BCM based on our revenues from sales of any approved products utilizing the licensed technologies, and these payments could adversely affect the overall profitability for us of any products that we may seek to commercialize. In order to maintain our license rights under the BCM license agreement, we will need to meet certain specified milestones, subject to certain cure provisions, in the development of our product candidates. Similarly, we are also required to pay both substantial milestone payments and royalties to the Mayo Foundation based on our revenues from sales of our products utilizing those licensed technologies. There is no assurance that we will be successful in meeting all of the milestones in our licenses in the future on a timely basis or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, upon a liquidity event (as defined in our BCM license agreement with BCM) of the licensee under the BCM license agreement (which, the licensee shall be the Company), BCM will receive a liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM license agreement) received by such licensee or its stockholders in the liquidity event, thereby diluting the amount of proceeds available to the licensee or its stockholders in a liquidity event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be subject to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide sufficient rights to exclude others from commercializing products similar or identical to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our technologies are in-licensed from third parties, and the protection of those technologies is not entirely within our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have world-wide exclusive licenses from the Mayo Foundation on (i) a novel set of Class II HER2/neu peptide antigens, (ii) a novel Class I HER2/neu antigen, and (iii) a novel set of Class II Folate Receptor Alpha peptide antigens. We have a world-wide exclusive license from BCM of the rights in and to three patent families to develop and commercialize MultiTAA-specific T cell product candidates in the field of oncology. As a result of these in-licenses, we could lose the right to develop each of the technologies if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the owners of the patent rights underlying the technologies that we license do not properly maintain or enforce the patents and intellectual property underlying those properties,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Mayo Foundation or BCM seeks to terminate our license in contravention of the license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">we fail to make all payments due and owing under any of the licenses; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">we fail to obtain on commercially reasonable terms, if at all, in-licenses from the Mayo Foundation or BCM or others for other rights that are necessary to develop the technology that we have already in-licensed.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of the above occurs, we could lose the right to use the in-licensed intellectual property, which would adversely affect our ability to commercialize our technologies, products or services. The loss of any current or future licenses from Mayo Foundation or BCM, or the exclusivity rights provided by such license agreements, could materially harm our financial condition and operating results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely upon patents and licensed technologies to protect our technology. We may be unable to protect our intellectual property rights, and we may be liable for infringing the intellectual property rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete effectively depends on our ability to maintain the proprietary nature of our technologies and the proprietary technology of others with whom we have entered into collaboration and licensing agreements. We own or hold licenses to a number of issued patents and U.S. pending patent applications, as well as foreign patents and foreign counterparts. Our success depends in part on our ability to obtain patent protection both in the United States and abroad for our product candidates, as well as the methods for treating patients in the product indications using these product candidates. Such patent protection is costly to obtain and maintain, and sufficient funds might not be available. Our ability to protect our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Even if our product candidates, as well as methods for treating patients for prescribed indications using these product candidates are covered by valid and enforceable patents and have claims with sufficient scope, disclosure and support in the specification, the patents will provide protection only for a limited amount of time. Accordingly, rights under any issued patents may not provide us with sufficient protection for our product candidates or provide sufficient protection to afford us a commercial advantage against competitive products or processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we cannot guarantee that any patents will be issued from any pending or future patent applications owned by or licensed to us. Even if patents have been issued or will be issued, we cannot guarantee that the claims of these patents are or will be valid or enforceable or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. Furthermore, different countries have different procedures for obtaining patents, and patents issued in different countries offer different degrees of protection against use of the patented invention by others. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent positions of biotechnology and pharmaceutical companies, including our patent positions, involve complex legal and factual questions, and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be challenged, deemed unenforceable, invalidated, or circumvented. Our patents can be challenged by our competitors who can argue that our patents are invalid, unenforceable, lack sufficient written description or enablement, or that the claims of the issued patents should be limited or narrowly construed. Patents also will not protect our product candidates if competitors devise ways of making or using these product candidates without infringing our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our technologies, methods of treatment, product candidates, and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets and we have the funds to enforce our rights, if necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The expiration of our owned or licensed patents before completing the research and development of our product candidates and receiving all required approvals in order to sell and distribute the products on a commercial scale can adversely affect our business and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may face legal claims involving stockholders, consumers, competitors, entities from whom we license technology, entities with whom we collaborate, persons claiming that we are infringing on their intellectual property and others. The biotechnology and pharmaceutical industries have been characterized by extensive litigation regarding patents and other intellectual property rights, and companies have employed intellectual property litigation to gain a competitive advantage. Competitors may infringe our intellectual property rights or those of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that one or more of the patents which we own or in-license is not valid or is unenforceable, and/or is not infringed. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In addition, litigation may be necessary to enforce our issued patents, to protect our trade secrets and know-how, or to determine the enforceability, scope, and validity of the proprietary rights of others. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patent and/or pending patent applications will be due to the USPTO and foreign patent agencies in several stages over the lifetime of our patents and/or applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. Should third parties file patent applications or be issued patents claiming technology also used or claimed by us, we may be required to participate in interference or derivation proceedings in the USPTO to determine priority of invention. We may be required to participate in interference or derivation proceedings involving our issued patents and pending applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially acceptable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The costs of litigation or any proceeding relating to our intellectual property or contractual rights could be substantial even if resolved in our favor. Some of our competitors or financial funding sources have far greater resources than we do and may be better able to afford the costs of complex legal procedures. Also, in a lawsuit for infringement or contractual breaches, even if frivolous, we will require considerable time commitments on the part of management, our attorneys and consultants. Defending these types of proceedings or legal actions involve considerable expense and could negatively affect our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain licenses needed for the development of our product candidates, or if we breach any of the agreements under which we license rights to patents or other intellectual property from third parties, we could lose license rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to maintain and/or obtain licenses needed for the development of our product candidates in the future, we may have to develop alternatives to avoid infringing on the patents of others, potentially causing increased costs and delays in drug development and introduction or precluding the development, manufacture, or sale of planned product candidates. Some of our licenses provide for limited periods of exclusivity that require minimum license fees and payments and/or may be extended only with the consent of the licensor. We might not meet these minimum license fees in the future, or these third parties might not grant extensions on any or all such licenses. This same restriction may be contained in licenses obtained in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the patents underlying the licenses might not be valid and enforceable. To the extent any product candidates developed by us are based on licensed technology, royalty payments on the licenses will reduce our gross profit from such product sales and may render the sales of such product candidates uneconomical. In addition, the loss of any current or future licenses or the exclusivity rights provided therein could materially harm our business financial condition and our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to extensive regulation, which can be costly, time consuming and can subject us to unanticipated delays. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our current and future product candidates, cell processing and manufacturing activities, are subject to comprehensive regulation by the FDA in the United States and by comparable authorities in other countries. The process of obtaining FDA and other required regulatory approvals, including foreign approvals, is expensive and often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. In addition, regulatory agencies may lack experience with our technologies and product candidates, which may lengthen the regulatory review process, increase our development costs and delay or prevent their commercialization. No adoptive T cell therapy using MultiTAA-specific T cells has been approved for marketing in the U.S. by the FDA. Consequently, there is no precedent for the successful commercialization of products based on our technologies. In addition, we have had only limited experience in filing and pursuing applications necessary to gain regulatory approvals, which may impede our ability to obtain timely FDA approvals, if at all. We have not yet sought FDA approval for any adoptive T cell therapy product. We will not be able to commercialize any of our potential product candidates until we obtain FDA approval, and so any delay in obtaining, or inability to obtain, FDA approval would harm our proposed business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we violate regulatory requirements at any stage, whether before or after marketing approval is obtained, we may be fined, forced to remove a product from the market and experience other adverse consequences including delay, which could materially harm our business development. Additionally, we may not be able to obtain the labeling claims necessary or desirable for the promotion of our products. We may also be required to undertake post-marketing trials. Prescription drugs may be promoted only for the approved indications in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatment but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products. In addition, if we or others identify side effects after any of our adoptive T cell therapy products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn, and reformulation of our products may be required.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fines, warning letters or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of any approved product candidates will be harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">analogous state, local, and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug takeback&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, any sales of our product once commercialized outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recently enacted and future legislation in the United States and other countries may affect the prices we may obtain for our product candidates and increase the difficulty and cost to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States and many other countries, rising healthcare costs have been a concern for governments, patients and the health insurance sector, which has resulted in a number of changes to laws and regulations, and may result in further legislative and regulatory action regarding the healthcare and health insurance systems that could affect our ability to profitably sell any product candidates for which we have obtained marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the ACA was enacted in the United States in March 2010, with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare, and includes measures to change health care delivery, increase the number of individuals with insurance, ensure access to certain basic health care services, and contain the rising cost of care. Since January 2017, President Trump signed executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act. Further, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. Although the Supreme Court has yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is also unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, other federal health reform measures have been proposed and adopted in the United States. For example, as a result of the Budget Control Act of 2011 and subsequent legislative amendments thereto, providers are subject to Medicare payment reductions of 2% per fiscal year through 2030, except for a temporary suspension from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and also introduced a quality payment program, or the Quality Payment Program, under which certain individual Medicare providers will be subject to certain incentives or penalties based on new program quality standards. This Quality Payment Program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. It is still unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement under the Medicare program. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump Administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The combination of healthcare cost containment measures, increased health insurance costs, reduction of the number of people with health insurance coverage, as well as future legislation and regulations focused on reducing healthcare costs by reducing the cost of, or reimbursement and access to, pharmaceutical products, may limit or delay our ability to commercialize our products, generate revenue or attain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">It is possible that additional governmental action is taken in response to the COVID-19 pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described above, the ACA and potential regulations thereunder easing the entry of competing follow-on biologics into the marketplace, other new legislation or implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of previously enacted and possible future changes in laws that could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that additional state and federal healthcare reform measures will continue to be adopted in the future. While it is not possible to predict whether and when any such changes will occur, particularly in light of the recent presidential election, changes in the laws, regulations, and policies governing the development and approval of our product candidates and the commercialization, importation, and reimbursement of our product candidates could adversely affect our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Risks Related to our Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our stock may be volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The listing of our common stock on Nasdaq does not assure that a meaningful, consistent and liquid trading market currently exists or will exist in the future. The trading price of our common stock may fluctuate substantially. The price of our common stock that will prevail in the market may be higher or lower than the price at which our shares of common stock, depending on many factors, some of which are beyond our control and may not be related to our company or our operating performance. These fluctuations could cause you to lose part or all of your investment in our common stock. Those factors that could cause fluctuations include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">price and volume of fluctuations in the overall stock market from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fluctuations in stock market prices and trading volumes of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the thinly traded nature of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">actual or anticipated changes in our net loss or fluctuations in our operating results or in the expectations of securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">results of our preclinical studies and clinical trials or delays in anticipated timing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the issuance of new equity securities pursuant to a future offering, including issuances of preferred stock , or sales of large blocks of our stock and sales by insiders and our institutional investors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">announcements of new collaboration agreements with strategic partners or developments by our existing collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">announcements of acquisitions, mergers or business combinations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">competitive developments, including announcements by competitors of new products or services or significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">general economic conditions and trends, including changes in interest rates, and other national and global conditions, including the ongoing COVID-19 pandemic and related global economic uncertainty;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">major catastrophic events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">events affecting BCM, Mayo Clinic, Mayo Foundation for Medical Education and Research or any future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">announcements of new product candidates or technologies, commercial relationships or other events , including the results of clinical trials, or variations in our quarterly operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">regulatory developments in the United States and other countries , including changes in the structure of healthcare payment systems, or other positive and negative events relating to healthcare and the overall pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">failure of our common stock to maintain listing requirements on Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the outcome of any litigation to which we are a party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">changes in accounting principles; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">discussion of our company or our stock price by the financial and scientific press and in online investor communities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The stock market in general, and the Nasdaq Global Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Due to the potential volatility of our stock price, we may therefore be the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales of additional equity securities may adversely affect the market price of our common stock and your rights may be reduced. Our stockholders may experience dilution in the future and it may adversely affect the market price of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur drug development and sale, general and administrative costs. Until such time, if ever, as we can generate substantial product revenue, we expect to fund our cash requirements through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. We do not currently have a committed external source of funds. To the extent that we sell equity securities or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. The sale or the proposed sale of substantial amounts of our common stock or other equity securities in the public markets may adversely affect the market price of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had 50.7 million shares of our common stock issued and outstanding. Those outstanding shares represent a minority of our authorized shares, meaning that the ownership position of the current stockholders could be diluted significantly were we to issue a large number of additional shares. In addition, as of December 31, 2020, there were outstanding warrants to purchase up to approximately 20.8 million shares of our common stock at a weighted average exercise price of&#8201;$4.47 per share, and options exercisable for an aggregate of approximately 6.0 million shares of common stock at a weighted average exercise price of&#8201;$6.22 per share. We have registered the resale of the shares issuable upon exercise of our outstanding warrants, and as a result the shares issued upon exercise will be tradable by the exercising party. Upon such registration, the holders may sell these shares in the public markets from time to time, without limitations on the timing, amount, or method of sale. If our stock price rises, the holders may exercise their warrants and options and sell a large number of shares. This could cause the market price of our common stock to decline and cause existing stockholders to experience significant further dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not intend to pay cash dividends.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividends for the foreseeable future. Any future determination as to the payment of cash dividends on our common stock will be at our board of directors&#8217; discretion and depends on our financial condition, operating results, capital requirements and other factors that our board of directors considers to be relevant.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of cybersecurity/information systems risk.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cybersecurity incidents have increased in number and severity recently and it is expected that these trends will continue. Despite the implementation of security measures, our internal computer systems, and those of our manufacturers and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, successful breaches, employee malfeasance, or human or technological error, war and telecommunication and electrical failures. In addition, our systems safeguard important confidential personal data regarding our subjects. If a disruption event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should we be affected by such an incident, we may incur substantial costs and suffer other negative consequences, which may include investigation costs and costs to engage specialized consultants; remediation costs, such as liability for stolen assets or information, repairs of system damage, and incentives to customers or business partners in an effort to maintain relationships after an attack; and litigation and legal risks, including regulatory actions by state and federal regulators. We have cybersecurity insurance for a breach event covering expenses for notification, credit monitoring, investigation, crisis management, public relations and legal advice. We also maintain property and casualty insurance that may cover restoration of data, certain physical damage or third-party injuries caused by potential cybersecurity incidents. However, damage and claims arising from such incidents may not be covered or may exceed the amount of any insurance available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As a result of being a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. We are also required to disclose significant changes made in our internal control procedures on a quarterly basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To comply with Section 404, we have engaged in the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404. Our compliance with Section 404 requires that we incur substantial professional fees and expend significant management efforts, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the evaluation and testing process of our internal controls, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to limitation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our NOLs generated in tax years beginning on or prior to December 31, 2017 are permitted to be carried forward for only 20 years under applicable U.S. tax law. Our federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax years beginning after December 31, 2020 is subject to certain limitations. It is uncertain if and to what extent various states will conform to the Tax Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, or, the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage over a rolling three-year period. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our net operating loss carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax laws or regulations could materially adversely affect our company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us, which could adversely affect our business and financial condition. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or Tax Act, enacted many significant changes to the U.S. tax laws, including changes in corporate tax rates, the utilization of our NOLs and other deferred tax assets, the deductibility of expenses, and the taxation of foreign earnings. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. The impact of changes under the Tax Act, the CARES Act, or future reform legislation could increase our future U.S. tax expense and could have a material adverse impact on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounting treatment for certain of our warrants is complex and subject to judgments concerning the valuation of embedded derivative rights within the applicable securities. Fluctuations in the valuation of these rights could cause us to take charges to our statement of operations and make our financial results unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our outstanding warrants contain or contained prior to being amended, or may be deemed to contain from time to time, embedded derivative rights in accordance with U.S. Generally Accepted Accounting Principles , or GAAP. There is a risk that questions could arise from investors or regulatory authorities concerning the appropriate accounting treatment of these instruments, which could require us to restate previous financial statements, which in turn could adversely affect our reputation, as well as our results of operations. These derivative rights, or similar rights in securities we may issue in the future, need to be, or may need to be, separately valued as of the end of each accounting period in accordance with GAAP. We record these embedded derivatives as liabilities at issuance, valued using the Black Scholes Option Pricing Model and are subject to revaluation at each reporting date. Any change in fair value between reporting periods is reported on our statement of operations. At December 31, 2020, the fair value of the derivative liability-warrants was $0. Changes in the valuations of these rights, the valuation methodology or the assumptions on which the valuations are based could cause us to take charges to our earnings, which would adversely impact our results of operations. Moreover, the methodologies, assumptions and related interpretations of accounting or regulatory authorities associated with these embedded derivatives are complex and, in some cases uncertain, which could cause our accounting for these derivatives, and as a result, our financial results, to fluctuate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_50b8de4d_8031_4ace_b635_2f0824a0fccc"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1B. UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_4d9e9fff_5689_4860_8b8e_930d5accdabe"></a><a id="ITEM2PROPERTIES_338462"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 2. PROPERTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not own any real estate or other properties. We lease office space at 3200 Southwest Freeway, Suite 2500, Houston, Texas 77027 on a ten-year agreement set to expire in July 2030, which is our principal business office. We also lease office space at 5 West Forsyth Street, Suite 200, Jacksonville, Florida 32202 on a five-year agreement due to expire on June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April 2020, we entered into a lease for a research facility in Houston, Texas. The lease term is 71 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, we entered into a lease for a manufacturing facility in Houston, Texas. The lease term is ten years from rent commencement date, which was in November 2020.</p><a id="_1d5f153a_23db_4870_9b21_bcd7c889c30c"></a><a id="ITEM3LEGALPROCEEDINGS_282506"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 3. LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, we were not a party to any material legal proceedings.</p><a id="_56f56aa5_3b57_44b0_81cf_47a0b9d75b68"></a><a id="ITEM4MINESAFETYDISCLOSURE_456568"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 4. MINE SAFETY DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not Applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_66bcb019_9d3e_4c59_8795_34a7981c755b"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII_862782"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PART II</b></p><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is listed for trading on the Nasdaq Capital Market under the symbol &#8220;MRKR&#8221;. As of February 26, 2021, we had 412 stockholders of record whom are holding shares. The price of our common stock on February 26, 2021 was $2.42 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No dividends have been declared or paid on our common stock. We have incurred recurring losses and do not currently intend to pay any cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not record any issuances of unregistered securities during the fourth quarter of 2020.</p><a id="_773a234e_9fa6_4634_b797_108dd894a8e6"></a><a id="ITEM6SELECTEDFINANCIALDATA_944586"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 6. SELECTED FINANCIAL DATA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_295bdf37_bfbf_4659_8df6_58877e771128"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following discussion of our financial condition, changes in financial condition, plan of operations and results of operations should be read in conjunction with (i) our audited consolidated financial statements as at December 31, 2020 and December 31, 2019 and (ii) the section entitled &#8220;Business&#8221;, included in this annual report. The discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Company Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. We are advancing two pipelines of product candidates as part of our MultiTAA-specific T cell program: the autologous T cells for the treatment of lymphoma, multiple myeloma, or MM, and selected solid tumors and the allogeneic T cells for the treatment of acute myeloid leukemia, or AML, and acute lymphoblastic leukemia, or ALL. Because we do not genetically engineer the MultiTAA-specific T cell therapies, we believe that our product candidates are easier and less expensive to manufacture, have lower toxicities than current engineered chimeric antigen receptor, or CAR-T, and T cell receptor-based therapies and may provide patients with meaningful clinical benefit. We are also developing innovative peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are pursuing post-transplant AML as the lead indication for our first company-sponsored MultiTAA-specific T cell program. In April 2020, the FDA granted orphan drug designation to MT-401 for the treatment of AML after receiving an allogeneic stem cell transplant. The MultiTAA-specific T cell therapy has been well tolerated in an ongoing Phase 1 clinical trial in AML and myelodysplastic syndrome, or MDS, conducted by our strategic partner Baylor College of Medicine, or BCM. As reported in a recent publication by Lulla et al., 11 of the 17 patients in the adjuvant disease setting dosed with the MultiTAA-specific T cell therapy after receiving an allogeneic hematopoietic stem cell transplant, or HSCT, never relapsed [median leukemia-free survival, or LFS, not reached at a median follow-up of 1.9 years], with 11 of 15 patients remaining alive (estimated two-year overall survival of 77%) at a median follow-up of 1.9 years post-infusion, which compares favorably with HSCT outcomes for risk-matched AML/MDS patients post-HSCT [median LFS of nine to 15 months and two-year survival probability of 42%]. &#160;Additionally, eight patients were treated for active disease that was resistant to salvage therapy post-HSCT with a median of five prior lines of therapy (range: four to 10). &#160;One of the eight patients crossed over from the adjuvant group, while two patients enrolled twice, but all three patients had active AML that failed another line of salvage therapy after their first MultiTAA-specific T cell infusion. &#160;Two of the eight patients achieved objective responses, with one complete response and one partial response, with six patients continuing with stable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We submitted an investigational new drug, or IND, application to the United States Food and Drug Administration, or the FDA, to initiate a Phase 2 clinical trial of MultiTAA-specific T cell therapy, which we refer to as MT-401 (zedenoleucel), in post-allogeneic HSCT patients with AML in both the adjuvant and active disease setting. The dose administered in this multicenter trial is the approximate flat dose equivalent of the current maximum tolerated dose from the ongoing Phase 1 trial. In the adjuvant setting, patients will be randomized to either MultiTAA-specific T cell therapy at approximately 90 days post-transplant versus standard of care observation, while the active disease patients will receive MT-401 following relapse post-transplant as part of a single-arm group. We expect to complete the safety lead-in portion of the trial in the first half of 2021. We anticipate that we will initiate the remainder of the Phase 2 trial in the third quarter of 2021 and complete enrollment of 20 patients in that phase of the trial in the fourth quarter of 2021 in order to report results from the active disease arm of the trial in the first quarter of 2022. We expect to begin manufacturing MT-401 for the Phase 2 trial at our cGMP manufacturing facility in the third quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We reported interim data for an ongoing Phase 1/2 clinical trial of the MultiTAA-specific T cell therapy for the treatment of pancreatic adenocarcinoma being conducted by BCM. In this trial, we have observed a clinical benefit correlated with the post-infusion detection of tumor-reactive T cells in patient peripheral blood and within tumor biopsy samples in patients in the tumor-resection arm of the trial. These T cells exhibited activity against both targeted antigens and non-targeted TAAs, indicating induction of antigen spreading. To date, we have not observed any cytokine release syndrome or neurotoxicity in this trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also evaluating the MultiTAA-specific T cell therapies in a Phase 2 clinical trial for the treatment of breast cancer and in Phase 1 clinical trials for the treatment of ALL, lymphoma, MM and sarcoma, all of which are being conducted by BCM. As of December 2020, the MultiTAA-specific T cell therapies have been generally well tolerated by all of the patients enrolled in clinical trials in hematological and solid tumor indications with no incidents of cytokine release syndrome or neurotoxicity, which are frequently associated with CAR-T therapies. Our ongoing clinical trials may be also affected by the COVID-19 pandemic. Based on our observations in clinical trials in AML, pancreatic cancer, lymphoma, ALL and MM, we believe that the MultiTAA-specific T cell therapies have the potential to mediate a meaningful anti-tumor effect, as well as significant&#160;in vivo&#160;expansion of T cells. We may initiate additional Phase 2 clinical trials investigating other indications in addition to our planned Phase 2 trial in post-transplant AML patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and assumptions used are consistent with those described under Note 3 in the Notes to Consolidated Financial Statements in this Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, our research and development expenses have related primarily to the development of our clinical platform and the identification and development of our product candidates. Clinical and research and development expenses consist of expenses incurred in performing research and development activities, cost of our clinical trials, including compensation, share-based compensation expense and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of supplies, manufacturing expenses, fees paid to third parties and other outside expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical costs are expensed as incurred. Costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">per patient clinical trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the number of patients that participate in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the number of sites included in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the length of time required to enroll eligible patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the number of doses that patients receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the drop-out or discontinuation rates of patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">potential additional safety monitoring or other studies requested by regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the duration of patient follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the efficacy and safety profile of the product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the ability to successfully manufacture patient doses.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the potential for success of each product candidate will depend on numerous factors, including clinical trial outcomes, acceptance by regulatory authorities, competition, manufacturing capability and commercial viability. We determine which programs to pursue and how much to fund each program in response to ongoing scientific assessments, competitive developments, clinical trial results, as well as an assessment of each product candidate&#39;s commercial potential. We anticipate our research and development costs will continue to increase over the next several years due to increased spending on the clinical development and manufacturing of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in executive, finance, accounting, business development, legal and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, insurance costs and professional fees for consultancy, accounting, audit and investor relations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities, and the potential commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not recognize any income tax expense for the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists of interest income and change in fair value of warrant liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations For the Years Ended December 31, 2020 and 2019</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the results of our operations (rounded to the thousand except for per share amounts) for the years ended December 31, 2020 and 2019, together with the changes to those items:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 467,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 213,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 254,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 119</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 467,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 213,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 254,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 119</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,881,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,765,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,116,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 48</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,472,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,977,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 495,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,353,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,742,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,611,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,886,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22,529,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,357,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense):</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 149,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,083,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (934,000)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (86)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (28,706,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (21,428,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (7,278,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 34</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.61)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.47)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,040,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,588,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,452,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not generate any revenue during the years ended December 31, 2020 and 2019, respectively, from the sales or licensing of our product candidates. &#160;During the year ended December 31, 2020, we recognized $0.5 million of revenue associated with a grant awarded to Mayo Foundation from the US Department of Defense for the Phase 2 clinical trial of TPIV200 which Mayo paid to us for clinical supplies manufactured by us and provided for the clinical trial funded by the grant. &#160;We refer to this grant as the Mayo Grant. &#160;During the year ended December 31, 2019, we recognized $0.2 million of grant income from the Mayo Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating expenses incurred during the fiscal year ended December 31, 2020 were $29.4 million compared to $22.7 million in the prior year. Significant changes and expenditures in operating expenses are outlined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Research and Development Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by 48% to $18.9 million for the year ended December 31, 2020, compared to $12.8 million for the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The increase of $6.1 million in 2020 was primarily attributable to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increase of $2.9 million in headcount-related expenses as we increased the number of research and development personnel,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increase of $2.3 million in process development expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increase of $1.7 million in sponsored research and consulting expenses from BCM agreements,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increase of $0.6 million in rent expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">decrease of $1.3 million in our peptide vaccine clinical trial expenses due to the stages of ongoing clinical trials and the decreased number of active patients in such trials , and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">decrease of $0.1 million of other expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Included in research and development expenses, are expenses related to agreements with BCM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2018 and February 2020, we entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for us by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy. &#160;During the years ended December 31, 2020 and 2019, we incurred $0.3 million and $0.1 million of expenses related to these agreements, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, we entered in a Clinical Supply Agreement with BCM, which provided for BCM to provide to us multi tumor antigen specific products. &#160;During the year ended December 31, 2020, we incurred $0.6 million related to this agreement. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, we entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to us manpower costs of projects for manufacturing, quality control testing and validation run activities. &#160;During the year ended December 31, 2020, we incurred $0.6 million related to this agreement. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, we entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to us investigator-initiated research studies. &#160;During the year ended December 31, 2020, we incurred $0.3 million related to this agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by 5% to $10.5 million for the year ended December 31, 2020 from $10.0 million during the prior period. The increase in general and administrative expenses of $0.5 million was mainly comprised of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increase of $1.0 million in headcount-related expenses as we increased the number of administrative personnel,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increase of $0.2 million in rent expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increase of $0.4 million in insurance expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">decrease of $0.3 million in other general and administrative expenses, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">decrease of $0.8 million in legal and professional fees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Change in Fair Value of Warrant Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Change in fair value of warrant liabilities for the year ended December 31, 2020 was $31,000 as compared to $18,000 for the fiscal year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest income was $0.1 million and $1.1 million for the years ended December 31, 2020 and 2019, respectively, and was attributable to interest income relating to funds that are held in U.S. Treasury notes and U.S. government agency-backed securities. &#160;As part of the reaction to the COVID-19 pandemic, the Federal Reserve cut rates in mid-March 2020 to a range of 0.0%-0.25%. &#160;As such, we recorded lower interest income during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The increase in our net loss during the year ended December 31, 2020 compared to the year ended December 31, 2019 was due to the continued expansion of our research and development activities, increased expenses relating to future clinical trials, and the overall growth of our corporate infrastructure. We anticipate that we will continue to incur net losses in the future as we continue to invest in research and development activities, including clinical development of our MultiTAA T cell product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not generated any revenues from the sales or licensing of our product candidates since inception and only have limited revenue associated with grants. We have financed our operations primarily through public and private offerings of our stock and debt including warrants and the exercise thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth our cash and cash equivalents and working capital as of December 31, 2020 and 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,352,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,904,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,009,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,494,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our cash flows for the years ended December 31, 2020 and 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Cash provided by (used in):</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18,860,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18,284,000)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,428,000)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (375,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,736,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 816,000</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22,552,000)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,843,000)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities during the year ended December 31, 2020 was $18.9 million. The use of cash primarily related to our net loss of $28.7 million, in addition to the effect of changes in asset and liability accounts, including an increase in prepaid expenses and deposits of $0.5 million, an increase in accounts payable and accrued liabilities of $4.3 million and an increase in lease liabilities of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities during the year ended December 31, 2019 was $18.3 million. The use of cash primarily related to our net loss of $21.4 million, in addition to the effect of changes in asset and liability accounts, including an increase in prepaid expenses and deposits of $1.4 million, a decrease in accounts payable and accrued liabilities of $1.0 million, a decrease in interest receivable of $52,000 and a net increase in lease liabilities of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $10.4 million and $0.4 million for the purchase of property and equipment during the years ended December 31, 2020 and 2019, respectively. &#160;The increase relates to $6.8 million in construction in progress towards the new modular cleanrooms and the buildout of our manufacturing facility, an additional $2.2 million in laboratory equipment, $0.6 million in computers and equipment, $0.5 million in furniture and fixtures and $0.3 million in leasehold improvements at the new research facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $6.7 million during the year ended December 31, 2020, mainly due to the sale of 4,113,440 shares of stock under the Purchase Agreement with Aspire Capital that provided proceeds to the Company of approximately $6.2 million, along with $0.6 million of proceeds from the exercise of stock warrants. Net cash provided by financing activities was $0.8 million during the year ended December 31, 2019, due to the exercise of stock warrants and stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenues from the commercial sale of approved drug products, and we do not expect to generate substantial revenue for at least the next several years. If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be compromised. We do not know when, or if, we will generate any revenue from our product candidates, and we do not expect to generate significant revenue unless and until we obtain regulatory approval of, and commercialize, our product candidates. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of and seek marketing approval for our product candidates. In addition, if we obtain approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had working capital of $18.0 million, compared to working capital of $43.5 million as of December 31, 2019. Based on our revised clinical and research and development plans and our revised timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of December 31, 2020 will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2021. &#160;We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Furthermore, our operating plan may change, and we may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future funding requirements will depend on many factors, as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">initiate or continue clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">continue the research and development of our product candidates and seek to discover additional product candidates; seek regulatory approvals for our product candidates if they successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">establish sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">evaluate strategic transactions we may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates and, if a product candidate is approved, our commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because all of our product candidates are in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability. Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During fiscal 2020, we entered into agreements to buildout a manufacturing facility, to lease a research lab and to expand our corporate headquarters in Houston, Texas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to continue to fund our operations and capital funding needs through equity and/or debt financing. We may also consider new collaborations or selectively partner our technology. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our existing stockholders&#8217; common stock. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us. We may also be required to pay damages or have liabilities associated with litigation or other legal proceedings involving our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, based on our current assessment, we do not expect any material impact on our long-term liquidity due to the COVID-19 pandemic. However, we will continue to assess the effect of the pandemic on our operations. The extent to which the COVID-19 pandemic will impact our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Aspire Common Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February 2020, we entered into a common stock purchase agreement, or the Purchase Agreement, with Aspire Capital Fund, LLC, or Aspire Capital, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of shares of our common stock over the 30-month term of the Purchase Agreement. As of December 31, 2020, Aspire Capital had purchased 4,113,440 shares under the Purchase Agreement, providing aggregate proceeds to the Company of approximately $6.2 million. In consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 345,357 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchase Agreement provides that we and Aspire Capital shall not effect any sales under the Purchase Agreement on any purchase date where the closing sale price of our common stock is less than $0.25. There are no trading volume requirements or restrictions under the Purchase Agreement, and we will control the timing and amount of sales of our common stock to Aspire Capital. Aspire Capital has no right to require any sales by us but is obligated to make purchases from us as directed by us on future funding, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. The Purchase Agreement may be terminated by us at any time, at its discretion, without any cost to us. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of our common stock during any time prior to the termination of the Purchase Agreement. We expect to use any proceeds under the Purchase Agreement for working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchase Agreement provides that the number of shares that may be sold pursuant to the Purchase Agreement will be limited to 9,232,814 shares, including the Commitment Shares, or the Exchange Cap, which represents 19.99% of our outstanding shares of common stock as of the date of the Purchase Agreement, unless stockholder approval is obtained to issue more than 19.99%. This limitation will not apply if, at any time the Exchange Cap is reached and at all times thereafter, the average price paid for all shares issued under the Purchase Agreement is equal to or greater than $2.41, which was the closing price of our shares on The Nasdaq Global Market immediately preceding the execution of the Purchase Agreement. We are not required or permitted to issue any shares of common stock under the Purchase Agreement if such issuance would breach our obligations under the rules or regulations of The Nasdaq Global Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no sources of revenue to provide incoming cash flows to sustain our future operations. As outlined above, our ability to pursue our planned business activities is dependent upon our successful efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While these factors raise substantial doubt regarding our ability to continue as a going concern. Our consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Tax Loss and Credit Carryforwards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we have approximately $97.2 million of federal and $39.0 million of state net operating loss carryforwards that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $41.6 million, if not utilized, will expire between 2029 and 2037. The federal net operating loss carryforwards of $55.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $17.1 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. &#160;Any change in ownership greater than 50% under Section 382 of the Internal Revenue Code places significant annual limitations on the use of such net operating loss carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2020 and 2019, we recorded a 100% valuation allowance against our deferred tax assets of approximately $29.7 million and $24.6 million, respectively, as our management believes it is uncertain that they will be fully realized. If we determine in the future that we will be able to realize all or a portion of our net operating loss carryforwards, an adjustment to valuation allowance against our deferred tax assets would increase net income in the period in which we make such a determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inflation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inflation affects the cost of raw materials, goods and services that we use. In recent years, inflation has been modest. However, fluctuations in energy costs and commodity prices can affect the cost of all raw materials and components. The competitive environment somewhat limits our ability to recover higher costs resulting from inflation by raising prices. Although we cannot precisely determine the effects of inflation on our business, it is management&#8217;s belief that the effects on future revenues and operating results will not be significant. We do not believe that inflation has had a material impact on our results of operations for the periods presented, except with respect to payroll-related costs and other costs arising from or related to government-imposed regulations.</p><a id="_ca4d41cd_49a6_4c41_b3c6_25b6ac7ce3b2"></a><a id="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><a id="_047d94fc_73c9_4e2a_b198_8a878584a70f"></a><a id="ITEM8FINANCIALSTATEMENTS_684464"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 8. FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Financial Statements are incorporated herein by reference to pages F-1 to F-21 at the end of this report and the supplementary data is not applicable.</p><a id="_aa147ca0_6725_46c7_9fc7_8d4e708898ad"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have had no changes in, or disagreements with our principal independent accountants.</p><a id="_6b335771_8b5f_4c12_a1b5_10333811d82f"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM9ACONTROLSANDPROCEDURES_136839"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9A. CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2020 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Our management, with participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2020 to provide reasonable assurance that the information required to be disclosed by us in this Annual Report was (a) reported within the time periods specified by SEC rules and regulations and (b) communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding any required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control Over Financial Reporting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive, financial and accounting officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the framework in Internal Control&#8212;Integrated Framework 2013 issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cybersecurity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We utilize information technology for internal and external communications with vendors, clinical sites, banks, investors and shareholders. Loss, disruption or compromise of these systems could significantly impact operations and results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are not aware of any material cybersecurity violation or occurrence. We believe our efforts toward prevention of such violation or occurrence, including system design and controls, processes and procedures, training and monitoring of system access, limit, but may not prevent unauthorized access to our systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other than temporary disruption to operations that may be caused by a cybersecurity breach, we consider cash transactions to be the primary risk for potential loss. We and our financial institution take steps to minimize the risk by requiring multiple levels of authorization and other controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended December 31, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inherent Limitations on Effectiveness of Internal Controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In designing and evaluating the disclosure controls and procedures, management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.</p><a id="_8f34e729_9b0f_437a_b8eb_15ff56cd43f5"></a><a id="ITEM9BOTHERINFORMATION_833436"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9B. OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6a2fb558_ec0e_4a02_a582_ebb5f4b2c773"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIII_534190"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PART III</b></p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item and not set forth below will be set forth in the sections headed &#8220;Election of Directors,&#8221; &#8220;Management and Named Executive Officers&#8221; and &#8220;Section 16(a) Beneficial Ownership Reporting Compliance&#8221; in our definitive proxy statement for our 2020 Annual Meeting of Stockholders, or our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2020 and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial and accounting officer or controller, or persons performing similar functions, known as the Code of Ethics and Business Conduct. The Code of Ethics and Business Conduct is available on our website at www.markertherapeutics.com under the Corporate Governance section of our Investors page. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.</p><a id="_613e1674_2e40_4a46_b7e9_7f7800102dae"></a><a id="ITEM11EXECUTIVECOMPENSATION_899018"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 11. EXECUTIVE COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Executive Compensation-Compensation Discussion and Analysis&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_6b5f80c2_9dfe_401d_89ba_eb02eac151f0"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Equity Compensation Plan Information&#8221; and &#8220;Security Ownership of Management and Certain Beneficial Owners&#8221; in our Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by Item 201(d) of Regulation S-K will be set forth in the section headed &#8220;Executive Compensation-Compensation Discussion and Analysis&#8221; and &#8220;Board of Directors and Corporate Governance&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_fe33c51a_c8e3_454a_b330_d1f4905c4db9"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Certain Relationships and Related Transactions&#8221; and &#8220;Board of Directors and Corporate Governance&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_73e021ee_9986_41f4_a72e_c7d503489548"></a><a id="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Independent Auditors&#8217; Fees and Services&#8221; in our Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_748ad7cd_d7cf_4ebb_b1eb_fc9c81a966b5"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIV_855523"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PART IV</b></p><a id="ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;The documents filed as part of this report are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.25pt;text-align:justify;text-indent:-30.25pt;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The financial statements and accompanying report of independent registered public accounting firm are set forth immediately following the signature page of this report on pages F-1 through F-21.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.25pt;text-align:justify;text-indent:-30.25pt;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All financial statement schedules are omitted because they are inapplicable, not required or the information is included elsewhere in the financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.25pt;text-align:justify;text-indent:-30.25pt;margin:0pt 0pt 12pt 0pt;">3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">EXHIBIT INDEX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:42.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b> <br /><b style="font-weight:bold;">number</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b>&#160;<br /><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b>&#160;<br /><b style="font-weight:bold;">herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">3.1</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Incorporation</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">3.2</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bylaws of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.0</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054210/tv504949_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Common Stock Certificate of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-A/A</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.1</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488414000086/exhibit4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Common Stock Purchase Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/14/14</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.2</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000006/exhibit4-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series A</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/12/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.3</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000006/exhibit4-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series C</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/12/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.4</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000006/exhibit4-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series D</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/12/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.5</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000006/exhibit4-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series E</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/12/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.6</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000030/exhibit4-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series A-1</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/10/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.7</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000030/exhibit4-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series E-1</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/10/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.8</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex42.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Amended Series A Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.9</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex43.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Amended Series C Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.10</p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex44.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Amended Series D Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.11</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex45.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Amended Series E Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:42.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b> <br /><b style="font-weight:bold;">number</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b>&#160;<br /><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b>&#160;<br /><b style="font-weight:bold;">herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.12</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex46.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Amended Series A-1 Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.13</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex47.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Amended Series D-1 Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.14</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex49.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Series F Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.15</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex410.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Series F-1 Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.16</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of August 2016 Private Placement Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.17</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex411.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of 2016 Private Placement Agent Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.11</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.18</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417033502/v469341_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of June 2017 Private Placement Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">6/22/17</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.19</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417033502/v469341_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of 2017 Private Placement Agent Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">6/22/17</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.20</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex103.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Warrant Amendment Agreement August 2016 Private Placement</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.21</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417033502/v469341_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Warrant Exercise Agreement</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">6/22/17</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.22</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418033374/tv496182_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Private Placement Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">6/8/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.23</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418033374/tv496182_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Private Placement Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37393</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">6/8/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.24</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418028370/tv494002_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Marker Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">5/15/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">4.25</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920032463/tm205467d1_ex4-25.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Description of Common Stock of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4.25</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3/12/20</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.1</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000054/exhibit10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restructuring Agreement dated May 28, 2015</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">6/3/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.2</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000057/exhibit10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Restructuring Agreement, dated as of June 2, 2015</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">6/5/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.3</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418033374/tv496182_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Form of Securities Purchase Agreement (including registration rights)</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">6/8/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.4</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418028370/tv494002_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Registration Rights Agreement</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">5/15/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.5</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000124/exhibit10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">License and Assignment Agreement, dated July 21, 2015, with The Mayo Foundation for Medical Education and Research**</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/14/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.6</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516682054/d157003dex107.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">License and Assignment Agreement with Mayo Foundation for Medical Education and Research dated May 19, 2016**</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/15/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.7</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Exclusive License Agreement between Baylor College of Medicine and Marker Therapeutics, Inc. dated March 16, 2018***</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-22.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Sponsored Research Contract between Baylor College of Medicine and Marker Therapeutics, Inc. dated November 16, 2018***</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488410000008/forddef14-c.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2009 Stock Incentive Plan*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DEF14-C</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">B</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/29/10</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:42.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b> <br /><b style="font-weight:bold;">number</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b>&#160;<br /><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b>&#160;<br /><b style="font-weight:bold;">herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.10</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417046574/v474594_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2014 Omnibus Stock Ownership Plan, as amended through August 29, 2017*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9/5/17</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.11</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to 2014 Omnibus Stock Ownership Plan, as amended *</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.12</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054989/tv505356_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Award Agreement &#8211;Employee*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/23/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418056172/tv505663_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Award Agreement &#8211; Non-Employee Director*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-228056</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/30/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054989/tv505356_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Award Agreement &#8211; Consultant*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/23/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000168/exhibit10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Award Agreement &#8211; Consultant*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/16/15</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417049357/v475675_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement between TapImmune Inc. and Peter Hoang dated as of September 22, 2017*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9/25/17</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.17</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516690727/d230909dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement by and between TapImmune Inc. and Michael J. Loiacono dated as of August 25, 2016*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/25/16</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418062867/tv508378_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Employment Agreement between Marker Therapeutics, Inc. and Michael J. Loiacono dated as of November 27, 2018*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/3/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418062867/tv508378_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement between Marker Therapeutics, Inc. and Anthony Kim dated as of November 27, 2018*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/3/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.20</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054989/tv505356_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consulting Agreement between Dr. Juan Vera and Marker Therapeutics, Inc. dated October 19, 2018*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/23/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-39.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Director and Officer Indemnification Agreement*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.39</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-40.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Employment Agreement between Marker Therapeutics, Inc. and Peter Hoang, dated March 14, 2019*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.40</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419025316/tv520511_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement between Marker Therapeutics, Inc. and Mythili Koneru, dated February 6, 2019.*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/10/19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920072918/tm2022347d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Marker Therapeutics, Inc. 2020 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-239136</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/12/20</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:42.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b> <br /><b style="font-weight:bold;">number</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b>&#160;<br /><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b>&#160;<br /><b style="font-weight:bold;">herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920123055/mrkr-20200930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Grant Notice and Stock Option Agreement under the Marker Therapeutics, Inc. 2020 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/9/20</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">10.26</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920123055/mrkr-20200930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Marker Therapeutics, Inc. 2020 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/9/20</p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrkr-20201231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">List of Subsidiaries</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrkr-20201231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consent of Marcum LLP, an independent public accounting firm.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">24.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_412578"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Powers of Attorney (included on signature page).</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrkr-20201231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrkr-20201231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrkr-20201231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer pursuant to 18 U. S. C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.#</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mrkr-20201231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer pursuant to 18 U. S. C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.#</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;white-space:normal;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*&#160;&#160;&#160;&#160;&#160;Executive management contract or compensatory plan or arrangement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">**&#160;&#160;&#160;Confidential treatment has been granted as to certain portions of this exhibit pursuant to Rule 406 of the Securities Act of 1933, as amended, or Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">***&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for conditional treatment and this exhibit has been submitted separately with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">#&#160;&#160;&#160;&#160;&#160;These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p><a id="_47e8a7fc_13a7_43f1_b1b8_31bdca8bdce1"></a><a id="ITEM16FORM10KSUMMARY_680075"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 16. FORM 10-K SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_8cf2550b_5536_4fab_bacc_c3050d67d4d1"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_412578"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 and 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dated: March 9, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marker Therapeutics, Inc.</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter Hoang</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter Hoang</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (Principal Executive Officer)&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Anthony Kim</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anthony Kim</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of the undersigned officers and directors of Marker Therapeutics, Inc., hereby constitutes and appoints Peter Hoang and Anthony Kim, their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">S-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on March 9, 2021 on behalf of the registrant and in the capacities indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Peter Hoang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director (Principal Executive Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Peter Hoang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Frederick Wasserman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Frederick Wasserman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ David Laskow-Pooley</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Laskow-Pooley</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ John Wilson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">John Wilson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Juan Vera</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Juan Vera</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ N. David Eansor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">N. David Eansor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Steve Elms</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steve Elms</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Anthony Kim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Anthony Kim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_7b187b73_25bd_4fb4_a694_9e2225835eaf"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">S-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DECEMBER 31, 2020 AND DECEMBER 31, 2019</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Report of Independent Registered Public Accounting Firm</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_711572"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Consolidated Balance Sheets</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_85122"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Consolidated Statements of Operations</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Consolidated Statements of Stockholders&#8217; Equity </b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_67365"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Consolidated Statements of Cash Flows</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Notes to the Consolidated Financial Statements</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p><a id="_bf113b98_e2b1_46c8_9ad4_40269e0f5898"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the Shareholders and Board of Directors of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Marker Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We have audited the accompanying consolidated balance sheet of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, the related consolidated statements of operations, stockholders&#8217; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Explanatory Paragraph - Going Concern </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#39;s ability to continue as a going concern. Management&#39;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#39;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&quot;PCAOB&quot;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Audit Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Critical Audit Matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">/s/ Marcum LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Marcum LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have served as the Company&#8217;s auditor since 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">New York, NY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March 9, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_a65eef38_b7ce_498f_94f5_9a144e95cdcb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARKER THERAPEUTICS,&#160;INC.</b></p><a id="CONSOLIDATEDBALANCESHEETS_711572"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_85c3d5ca_44ab_45ce_957c_3ef7769313c5"></a><a id="Tc_OsLZwyquFEWKxmOT3xTQxw_1_2"></a><a id="Tc_9KsYy3qvJU2rbKN06F69aA_1_5"></a><a id="Tc_KQwWbFVHak6nRvZ4m1uGFQ_2_2"></a><a id="Tc_koxF1qIoSU6O3IB09VQr4w_2_5"></a><a id="Tc_chxnbO23F0-e_q9VuUp0Mw_3_0"></a><a id="Tc_O6PoYXsEi0ObyMKSIyB5lQ_4_0"></a><a id="Tc_vXSbPi1f9EqRNUYVkW80Kg_5_0"></a><a id="Tc_0CUhAhI2LUq_Ea3lrOAb7w_5_2"></a><a id="Tc_guY7ZEjLxkaF5HI6a40iHA_5_5"></a><a id="Tc_0tihFfQSF0OcjbGV2wEQIg_6_0"></a><a id="Tc_thC6E_nQAkivatMoSboZlg_7_0"></a><a id="Tc_MfAJfIILok6Dh5Lv8TcIzQ_8_0"></a><a id="Tc_9UZ2NqLbjk-gSea_ntIqWQ_9_0"></a><a id="Tc_hb0PCZdJDEKStLYeP1ievQ_10_0"></a><a id="Tc_wSI6u0Bo-Eyme5Up8yUG8Q_11_0"></a><a id="Tc_W9gtPJqkwUmu6h-NU7Sufw_12_0"></a><a id="Tc_0XJ1usXxuEKlSwEjjv7vew_13_0"></a><a id="Tc_RllM7Hk5yU-pWr_hAPhlew_14_0"></a><a id="Tc_b-GnxwYPm0Ou5Pxob8GQkA_16_0"></a><a id="Tc_b9g_QdvVpUO9HbzdKNVrnw_16_2"></a><a id="Tc_5VylF2X_1EKR8htTFtVfjg_16_5"></a><a id="Tc_xfBgP92SKEa8fI-zrP-kQA_18_0"></a><a id="Tc_hVDzEljo-UiDbThxErn95A_19_0"></a><a id="Tc_YriFb0F0gkGKuxeNrzTg3w_20_0"></a><a id="Tc_3JWvexOMRkaaDL293Wu26g_20_2"></a><a id="Tc_ymE-26GvFEur-cgay0oG0Q_20_5"></a><a id="Tc_wOfYHoZrwkqdqOOEUt_pCA_21_0"></a><a id="Tc_Ziq3iA_cn02wV445lWVfgQ_22_0"></a><a id="Tc_0br3R_fLgUm7_pKoXuawiQ_23_0"></a><a id="Tc_jSp7xNNFIU6x2Ppw6aCIEQ_24_0"></a><a id="Tc_FMJy8cXgLkW3FftnmApglw_25_0"></a><a id="Tc_O3KeP4vaJEq8E-YyCky3gw_26_0"></a><a id="Tc_KRubtZmPZUaWmXJnHK48Ug_28_0"></a><a id="Tc_OP-TKQWatUi2Ck6aAIlK_Q_30_0"></a><a id="Tc_vBtfB29DmEG68Xrdc3mFqQ_32_0"></a><a id="Tc_5o6E45CoW0y7xuGfIug9Jg_33_0"></a><a id="_8da35c11_e67c_4f30_aede_74a3983cce0d"></a><a id="_8da35c11_e67c_4f30_aede_74a3983cce0d_2"></a><a id="_8da35c11_e67c_4f30_aede_74a3983cce0d_3"></a><a id="Tc_gtdD0uTvA0WHdHRcT49-sA_34_0"></a><a id="Tc_sicxdrg_T0anb2PN4BpXtw_35_0"></a><a id="Tc_dREgLPC14UmWw_kywF618w_36_0"></a><a id="Tc_nlSHixIgREGB3mUFbuKgrg_37_0"></a><a id="Tc_Lg0Ev1tlzUC7pyYuOU75Fw_39_0"></a><a id="Tc_ovpHZ56XX0KTXoRPpno8ew_39_2"></a><a id="Tc_uio51xT9FE6zskk4iFMTsA_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_df4dPepje0iEL56jOxX1bw_5_3">21,352,382</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_mTGH5MtXD0Kn76fzv-M5Hw_5_6">43,903,949</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_-ozx6j2LuUWagQaMX3E2Nw_6_3">2,057,924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_tpzO6Tg4h0K4TeaR0doaBg_6_6">1,526,442</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="0" id="Tc_b0GQkrwKA0mD5uONUXyZYQ_7_3">559</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="0" id="Tc_nHheJquYtUqJpMov8FFJEQ_7_6">56,189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_oBphqmyu6k-bSqYjZwbcPw_8_3">1,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:zerodash" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc__iFMKXPX2EKimfVgH-HHNQ_8_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_Yvfcn6b1jU6GYBc-HFu4Rg_9_3">24,410,865</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_Cfk1QU0cakyEVh40IQuGtQ_9_6">45,486,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property, plant and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress" scale="0" id="Tc_a8Vvc53bq0aJaFGodyseOw_11_3">3,570,736</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress" scale="0" id="Tc_7axJIb_1jU2pXALN2VBHNQ_11_6">417,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="0" id="Tc_WSrMn8gT60yi4SRaycc2HA_12_3">6,789,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:zerodash" name="us-gaap:ConstructionInProgressGross" scale="0" id="Tc_2Pw_-hrNx0qakqYsRE16yg_12_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_v8Rd_k6Nc0WNDF1a8f2F4A_13_3">10,844,116</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_0pM0VSrT_U27N0CXOpWu8w_13_6">455,174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_E_pPBc75eESyPrLLgcUYmQ_14_3">21,203,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_O1YKPCcfiEKj1DwsFVBROw_14_6">872,702</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_QfIlnmUZzkKNlpJ2OFuH-w_16_3">45,614,815</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_oD9SPs_Zsk-8kHvzryEeWw_16_6">46,359,282</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#39; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_injjOyjEkkCqA4betPh7gw_20_3">6,013,010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_LxLBH9JEKkav_u5bRA3LFQ_20_6">1,757,680</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_OZuomakWkUeQ_wg7C1v1WA_21_3">388,792</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_3vranmkeC0CLCEZBpdd5Og_21_6">204,132</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_hx2PinEYJUicAfLbSG_JWQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;white-space:pre-wrap;">                              -</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" id="Tc_1c0Hv6lr-EeWLpiqZMvGjw_22_6">31,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_CP3G0r-z6kOqqMqzARaT7g_23_3">6,401,802</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_eVGFm9E7s06H0YqcoNknmA_23_6">1,992,812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability, net of current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_HCWAQ2sHYEqgM5fmmAh9Wg_25_3">11,868,440</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_8yvF14YtgE2vWN9ur9nhoA_25_6">280,247</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="Tc_AFjDo4lJZkCJ83DgDJ8SuA_26_3">11,868,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="Tc_47L6-vlaSkSPAd4gXdKECg_26_6">280,247</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_M7G16hawd0S2k4uam1NqyA_28_3">18,270,242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_UpIGgwCoTkSJDbuVdX-4ug_28_6">2,273,059</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (see Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_psCQLqgm_U2YsvD07atjGA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_nE1w-i3HQEG-I60w3MD2ZQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;">&#8212;</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#39; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Z3BymwsDUkeM9xXpunA3bA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_IjDknAQlRESjb5eiE6YB9A">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_wZ1712jHoUy2Zl_2q107LA"><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_gZsru9RefU2tLi_A_Xu_Kw">5</ix:nonFraction></ix:nonFraction> million shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="6" id="Narr_LbpgznvMWkeYInCxMNyjVQ"><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="6" id="Narr_lvyugOCC_0yn8_FZvP_zUA">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31,&#160;2020 and 2019, respectively</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ZDFFjDW-yk69ppnYMlgkRg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_yg6a4xpMhkmloeK5PD1Nzw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_F26agtgoZ0eWNOeKE5QrYA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_K8xqV99SUU6MYz6PNhvSmw">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_31M4uIvrIUCQWA_J-lNenQ"><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_i_uKtLzzl0KbV8eNaI5yuA">150</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="Narr_5ypHk58bGEC4HK5nve0Cew">50.7</ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="Narr_nkvvHRhIfUCfHVqvEy6OMw">45.7</ix:nonFraction> million shares <span style="-sec-ix-hidden:Hidden_P_BpZ_byDU6Kv-H_E7IxWQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_5yfXCU_Y60y5FpmLzFWqUg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span> as of December&#160;31,&#160;2020 and 2019, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_S32s3j9d_k6MR0gbDd2JLA_34_3">50,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_tNpyJWUpbEeoLziUY4hHzw_34_6">45,728</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_6BLu9YGPV0Kn3Q2cc0YrNA_35_3">383,533,326</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_cif-FgMlWk-3LqYkgDPGQg_35_6">371,573,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_swHgklR1n0e547NX2FpseA_36_3">356,239,484</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_l8QEyduP20SB8OT-Fnihbg_36_6">327,533,414</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#39; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_nBmEBBa-o0OzZgAEwdCDkg_37_3">27,344,573</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_a9PMDR7r5EqN5JnbV5HufQ_37_6">44,086,223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#39; equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_tppTEA8rqkWBaPLHG43Z4g_39_3">45,614,815</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_4rfQqGt-70iouuN5H7I6pQ_39_6">46,359,282</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_09bdf5ee_28a4_41c3_b83e_797e1d1d9fc3"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_85122"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46f8db94_14a3_4e2e_b350_f7c72443ecca"></a><a id="Tc_lg0WDpUufkS2qJrnSGILLQ_1_2"></a><a id="Tc_M7ToSmSBvEiOdYNpzxwjxA_2_2"></a><a id="Tc_3CsaAtAzkUyqUnMHdGM-5g_3_2"></a><a id="Tc_aUOh_iu0uUKlYGkX4U3BPw_3_5"></a><a id="Tc_M7MuJEy6dkyooclJ4FIO6Q_4_0"></a><a id="Tc_v5WiO3jZjkiX9ML567l5ZQ_5_0"></a><a id="Tc__8p_RUHw2kKfw8T_3ZsaKA_5_2"></a><a id="Tc_B_9AdJBhEUmCXzscFtZvZw_5_5"></a><a id="Tc_93pBATMhJUCy1SGCZqrSxA_6_0"></a><a id="Tc_gz5_4LLJYUSV2r3JHvu6ig_7_0"></a><a id="Tc_RHgC7Xdz3Em4mUIaCpxrNg_8_0"></a><a id="Tc_n7trsdbIe0CRd5TOEI5mMg_9_0"></a><a id="Tc_Mine3a8Xq0arLeRNYuR9NQ_10_0"></a><a id="Tc_Ojt8V-GrQ0yVTWJc06KkqA_11_0"></a><a id="Tc_1vwg5551lUeetyqadco0hg_12_0"></a><a id="Tc_ASWfBUUyz0uGIebror7yYQ_13_0"></a><a id="Tc_L86EqCCKsUWO_RmhuaglzA_14_0"></a><a id="Tc_a1QUikHnDkO13BYzV2blfw_15_0"></a><a id="Tc_vhn-3crqnEyTrBh7AGBXtw_15_2"></a><a id="Tc_sgsN-yot7UuEvFzOJssl3A_15_5"></a><a id="Tc_zjWFhaeBJUWcY5NMoa-kkw_17_0"></a><a id="Tc_YB80TCp6hE-NY9krrjKXYQ_17_2"></a><a id="Tc_hCnp66dyQ0SSe8XP5d4C3A_17_5"></a><a id="Tc_x78NeBXHAUG5Xy3sppGUAg_18_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_hm-aT4_utkG7keclj27JkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_qiF8q09Pd02sF52vrrIoZA_5_3">466,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_GrantMember_KRQJasOkrUe2D02MbHcHKg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_6dS2WJG9PE2XMtnkinZrqg_5_6">213,194</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_MVYHoCooYESSghHBAPMb7w_6_3">466,785</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_doHwU3RGfEqBdPZYWjkyTQ_6_6">213,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_lkhVCr15h0Gp50VGlxo0JA_8_3">18,880,751</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_1H4DXcSxkU6dsLwPihIsOA_8_6">12,764,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_ZmVhDON7N0uaQqvYoJp_WQ_9_3">10,471,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_8_-t7dO9FEaNyqxY2CgZgQ_9_6">9,977,196</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_OXVLGEP0D0WTYqMX1y949w_10_3">29,352,597</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_sohEyRh2kkmhAaTt3FnuZg_10_6">22,742,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_NpINiOtODUGRdzslFyvoog_11_3">28,885,812</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_217FAGCwJEKRa7FNn84gvg_11_6">22,528,806</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other income (expense):</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_J2N1zrzeh0SQKOsnmbNr6w_13_3">31,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_F7C1JNKba0CW78Zu97uDaQ_13_6">18,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_khue7h-ymU6JYPFBmZv4eg_14_3">148,742</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_ocMmWWBSsEWco3Nr8NRULA_14_6">1,082,842</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_r9j-_npAskWUlNjYZJR1KQ_15_3">28,706,070</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_tebdaXJO2EWIzqbVbbCzgQ_15_6">21,427,964</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_nAX-zTxMMkWyR6V7kxALqQ_17_3">0.61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_qk6aMAt_CE6fAJlMqfvtTA_17_6">0.47</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_9ICSUcvZvkeGls3IWDO6cQ_18_3">47,039,862</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_uFOoywFAb02o_ffeTc7-oA_18_6">45,587,734</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_db21b432_7407_4473_8336_791fb7c4faf7"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_133b3394_3b56_4c08_abef_35b282544f78"></a><a id="Tc_XOZJHQ0utUSDLYzsu1ie7Q_1_13"></a><a id="Tc_BvhAH_cvFEKFsLnsoyqcUw_2_2"></a><a id="Tc_rOaO1AUxAkO9cL6rdpqU9A_2_7"></a><a id="Tc_pXjiLvy0JEuDPFTJ_ya11w_2_10"></a><a id="Tc_WHpt0-HtDUWWqixHPeX3vw_2_13"></a><a id="Tc_73zUewqZOUeuzE_Pn2UbpQ_3_2"></a><a id="Tc_vFu7xYGZI0elG00qz96XFA_3_4"></a><a id="Tc_Bk-aCSIE1USKWzgW4-yv0w_3_7"></a><a id="Tc_swc2znssGkydLDR_wKVh3Q_3_10"></a><a id="Tc_hKkprMb4-EeVpPi5ucAQNw_3_13"></a><a id="Tc_DPCzvu9zPEyOVKrWH4fepQ_4_0"></a><a id="Tc_X3sH5IlvkE2EnCxYmKVX5g_4_4"></a><a id="Tc_xk8G9Oo2GkSn53Y3KDQj1A_4_7"></a><a id="Tc_G7vdbSMAGUW0XnQxWsQZ7Q_4_10"></a><a id="Tc_CAgKrvUOEEacKn93c_CNLw_4_13"></a><a id="Tc_-Wnpp4iC-0-BkscknqgDAw_5_0"></a><a id="Tc_-eAZY0qWNUeu3Rljndz-5A_6_0"></a><a id="Tc_4yq5AVEhYU6b6teurJ2avQ_7_0"></a><a id="Tc_GmMV7cS45UiCdKTu37JCGg_8_0"></a><a id="Tc_FQWHb5SKkkCjKD8njWoJiA_9_0"></a><a id="Tc_m24NZuoE_EeLrLywSO4-9Q_10_0"></a><a id="Tc__QN6tD6bUUyrSqXBN1cVww_11_0"></a><a id="Tc_VsxnKb-qOkuJayE4WsZQIQ_12_0"></a><a id="Tc_yhHjHK0ujE-3GdMpafkoVQ_13_0"></a><a id="Tc_qBBPIRB92kSUtRZpOFWa4A_14_0"></a><a id="Tc_Jliwcsgd6EWZtDV6gfbtJg_15_0"></a><a id="Tc_sVYHRRoHykWhqLh-pR4IHA_16_0"></a><a id="Tc_v8-iJdzYzEKN2DblndVarw_16_4"></a><a id="Tc_m5cdxviaBUGMzDiPwJ0isw_16_7"></a><a id="Tc_HICN2iGyzkK4F4BCsvlG6Q_16_10"></a><a id="Tc_-ho-sLW9W0KDckN0CFDxRQ_16_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional&#160;Paid-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Par&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in&#160;Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_82up_zfWNUmUUgXpcdgRMQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_XnnecHIIk0qNXRHevct0DQ_4_2">45,440,704</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_82up_zfWNUmUUgXpcdgRMQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_XU3ChTBuuUiWYTiSM5mpNA_4_5">45,440</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WRGLryikz0KaY92hGWffvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_eZlwXLxlyEOW-uL6vSMbUQ_4_8">365,400,748</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SYa5-5t2RkuK9-fz8jtoFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_pQGs00rTdUa7hZq9wJGi7w_4_11">306,105,450</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_8dxlycTMyUyM6WCcOxlfhQ_4_14">59,340,738</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Stock options exercised for cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_BicagGEhuEWHs-snnsRI_g_5_2">11,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_7Z8KwCYfpEe63n3Qi1Kv9g_5_5">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_7ZHWLkgkf063VpMMm9JJjw_5_8">57,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_QdUYvvjE-UinLoWPWc1R7Q_5_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_W-jmANQUSUyJeuMkI3_FwA_5_14">57,744</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Warrants exercised for cash </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:numdotdecimal" name="mrkr:ExerciseOfWarrantsShare" scale="0" id="Tc_hPK5qYy01E2lPFBE1VYDoQ_6_2">190,258</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:numdotdecimal" name="mrkr:ExerciseOfWarrantsAmount" scale="0" id="Tc_-HiFNJyX60CSBEbwYduywA_6_5">190</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q" decimals="0" format="ixt:numdotdecimal" name="mrkr:ExerciseOfWarrantsAmount" scale="0" id="Tc_AdV35mVfz0-uCVfHIjSOJg_6_8">758,543</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ" decimals="0" format="ixt:zerodash" name="mrkr:ExerciseOfWarrantsAmount" scale="0" id="Tc_22DOCa2slkSt2_JlVJOw-A_6_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:ExerciseOfWarrantsAmount" scale="0" id="Tc_xYr49eiGzESBgPrk8cxqAQ_6_14">758,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Stock warrants cashless exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:numdotdecimal" name="mrkr:WarrantOfCashLessExercisedSharesIssued" scale="0" id="Tc_BFxb52JN7ECYhIXPPoR_rg_7_2">9,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:numdotdecimal" name="mrkr:WarrantOfCashLessExercised" scale="0" id="Tc_sauHiyNCxUenKn-tJpjiIw_7_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q" decimals="0" format="ixt:numdotdecimal" name="mrkr:WarrantOfCashLessExercised" sign="-" scale="0" id="Tc_YMdR-qW_R02pidyattgpqA_7_8">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ" decimals="0" format="ixt:zerodash" name="mrkr:WarrantOfCashLessExercised" scale="0" id="Tc_qwvo8Q9uO0ue7TyjxWHHGA_7_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:zerodash" name="mrkr:WarrantOfCashLessExercised" scale="0" id="Tc_HNBUrvgOjU6tkYlbvp7GZQ_7_14">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Stock-based compensation </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_18lk_yxKf0unJDkSokoHmg_8_2">76,440</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_THYtetitp02jpEcv6znKXA_8_5">77</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_FjRcE7yobkeDVla3RjF5Tg_8_8">5,356,895</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_fXRROn5OZU6SF8UJNInQWg_8_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_TvRmYtuIfkGpwP9Qc-EO5A_8_14">5,356,972</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_3-iYqv6gOUqf2aqf7Mi1IQ_9_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_VBxZSKDaIk-1JFjdK9DAew_9_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_HIoCHDSSxECdigwzgv8Vsg_9_8">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_wI8SaRu1HUaDEvG6WOjqoA_9_11">21,427,964</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_hztdpa_wBUSkEekX91YM5w_9_14">21,427,964</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPytHBodskGfOc2ipJ9aIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_QyvVCUXpe0-3TFr5_Rzhmw_10_2">45,728,831</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPytHBodskGfOc2ipJ9aIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_QfgD5XhU10aG-ZtgKqZeog_10_5">45,728</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dANtDkv1f0qA4nDLM7h0Pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_9ax5lnW_ZU-uEMN4rDz9lg_10_8">371,573,909</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pZiFWHEB4UO4INGI471GYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ofJU4cJ4F0WYbmaXcvHv3A_10_11">327,533,414</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_QvC8Ru9XQECcZiKIIcCQjA_10_14">44,086,223</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Issuance common stock for cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_mwneln-KQESh3gEVHk0fKg_11_2">4,113,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_DJYAyB4jbUSrJgjU5jxzQw_11_5">4,114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_afBEu4fR-0C9ohE5KZS_Cw_11_8">6,181,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_Vg6sul_oXUO785EfUOoW_g_11_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_HUxJ9cpFfU-mmOyc21fCyA_11_14">6,186,011</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Warrants exercised for cash </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:numdotdecimal" name="mrkr:ExerciseOfWarrantsShare" scale="0" id="Tc_H1vVFn5bVEyoc1eILn-Cjg_12_2">458,334</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:numdotdecimal" name="mrkr:ExerciseOfWarrantsAmount" scale="0" id="Tc_2CbELbFXqEixRQk_A28P3w_12_5">459</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g" decimals="0" format="ixt:numdotdecimal" name="mrkr:ExerciseOfWarrantsAmount" scale="0" id="Tc_0EpSszRrtkOt-wEtqTWQhQ_12_8">549,541</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg" decimals="0" format="ixt:zerodash" name="mrkr:ExerciseOfWarrantsAmount" scale="0" id="Tc_DX6dLbAxFU-kabh7R6XV1w_12_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:ExerciseOfWarrantsAmount" scale="0" id="Tc_LWA-bEAq_UmOoe2rZ68OKw_12_14">550,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Issuance of common stock as commitment fee for future financing </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:numdotdecimal" name="mrkr:IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" scale="0" id="Tc_RMIOjMhwtE2PGxgceE4DuQ_13_2">345,357</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:numdotdecimal" name="mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" scale="0" id="Tc_kds7iRuSWE-mUurMzq0YTw_13_5">345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g" decimals="0" format="ixt:numdotdecimal" name="mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" sign="-" scale="0" id="Tc_VmdD-kNF2Euj45ESDJ9AXA_13_8">345</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg" decimals="0" format="ixt:zerodash" name="mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" scale="0" id="Tc_4W9U2t9ic06-koE8vXbOMg_13_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:zerodash" name="mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" scale="0" id="Tc__B7WYAZAo0KQM9SRgb3EDg_13_14">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Stock-based compensation </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_fHE5BNvgi0610tNktlxM4Q_14_2">85,110</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_e4QDU8p7Y0KPRiT2R8mRGw_14_5">85</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_wIh6U4UzmU20rZdEH9pvPg_14_8">5,228,324</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_VgatXvEws0qw88EA6AymBw_14_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_9awUjkN-_0qNrg_v_58MyQ_14_14">5,228,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_ivdAAlWREE69o6OyYtdBtg_15_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_QYUg7_CxW0CB6uIxIjAktA_15_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_xKcW9kcrw0iPbZo-_APONQ_15_8">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_efHsHddLak2R6OXUGjJ7bw_15_11">28,706,070</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_urT8nAw7X0uzpDxBJiZpEw_15_14">28,706,070</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_P9Qbbx0CNUGy-vJOvqifnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_3vPFLDDTQU2KorsjQ_pVyg_16_2">50,731,072</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_P9Qbbx0CNUGy-vJOvqifnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_GW7HF4yOfUmtEOdJXYNWSA_16_5">50,731</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tgvmmST_Hke5xeVNJK8Seg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Aa-dG1eYkEeDaakoQDKIKw_16_8">383,533,326</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O3dyd2IkiEOKoM1hwWKeZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Nki9fPv2IUCQ7DE6RUjKMw_16_11">356,239,484</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_qPODH5IsqkiWI_LXj8hlqg_16_14">27,344,573</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_78dc1cd2_a924_4937_a912_daa63397a6f2"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_67365"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0a2f81dd_7746_4e72_8b1e_c682bb5dcfcd"></a><a id="Tc_kCh1D7Otuk6BY1LIOiU8Pw_1_2"></a><a id="Tc_cRQda8zKJEyHdL4GiuGHfQ_2_2"></a><a id="Tc_5CvNegEew0if4ORtggUxBg_3_2"></a><a id="Tc_PEm7EIZK-kKhtKBp2AQH0g_3_5"></a><a id="Tc_P6OHHCOX5k2zZZ_aG-Cq1A_4_0"></a><a id="Tc_b9PDH_2sK0SCBhpkyoUdaA_5_0"></a><a id="Tc_sfs-tLst0EaABVPqvT6v_g_5_2"></a><a id="Tc_KwqYTwhLAUW6E3JYkDg_0Q_5_5"></a><a id="Tc_lN9rEeb8JEO5M278Qybf1Q_6_0"></a><a id="Tc_ipPKNPPsaE6XCUmid-KA1g_7_0"></a><a id="Tc_UAyKDXSUM0qeYuWJ04_cxQ_8_0"></a><a id="Tc_JtrWRaSm_UCHaYZeUKwPqw_9_0"></a><a id="Tc_XURuo-zBuUilSj5ZNAyPFw_10_0"></a><a id="Tc_B5VMBpHR-0CGM1iwUYIrzw_11_0"></a><a id="Tc_M7VSZFk06kiE1RewMZ6bwQ_12_0"></a><a id="Tc_idYMbZxOeUejSCQiSAXJSg_13_0"></a><a id="Tc_QEX2sSUBmE2xa9NkM3hxxQ_14_0"></a><a id="Tc_nwLQ7PdwpE-cgY4rFbA8Ow_15_0"></a><a id="Tc_kpFVTK0S_Uy2Jp6Y6F_Gkw_16_0"></a><a id="Tc_Xtz_Trds10mwQ6cWprGgYA_17_0"></a><a id="Tc_draLzy9lNEuu50baWQGukg_18_0"></a><a id="Tc_d71xmwqzA0aL1f8eDj-RHw_19_0"></a><a id="Tc_Xyo-P36NxkO3mUK5rAyCxA_20_0"></a><a id="Tc_5ma9im3vIEWkWcBJLcBAuQ_21_0"></a><a id="Tc_FBFpwRFTjU6RcUkTxVvOuA_22_0"></a><a id="Tc_KWckT9usSES-j6aUmRRg6w_23_0"></a><a id="Tc_3eUICohNf0iHW0xTw8LAXg_24_0"></a><a id="Tc_sTPfNJztiESAG6Br_Koi5Q_25_0"></a><a id="Tc_USlNLAeVbEa7W-kruVOkTw_26_0"></a><a id="Tc_SB6DdyWf9Em26l8oDzHWWA_28_0"></a><a id="Tc_yTdwRyfdDkONszctkMGwrA_29_0"></a><a id="Tc_TjCQwLQB2E6jD8hLHo3Y8Q_29_2"></a><a id="Tc_Mz4whbp72EuWtuETpgWoRg_29_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_USuBZb-BhEKY-9vCWOKvjg_5_3">28,706,070</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_7cq9lI_Sf06Pfu7yDJ4KlQ_5_6">21,427,964</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Reconciliation of net loss to net cash used in operating activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_AdfSiv9MJky5on22547AGA_7_3">485,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_lGlWq4wctUuT61ZvKiCuRw_7_6">105,123</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in fair value of warrant liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" sign="-" scale="0" id="Tc__bj_2Yod40eNjc34WQbXXw_8_3">31,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" sign="-" scale="0" id="Tc_ZLozQn_NqEGSpqYBqK5VqA_8_6">18,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_95BZfb6Or02VLFhZmQq0oA_9_3">5,228,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_3eAqO3LMIka6B9dKAvdFSA_9_6">5,356,972</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization on right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:AmortizationOfOperatingLeaseRightOfUseAssets" scale="0" id="Tc_Y6QD9ZV7pEKg1hpPcRCipw_10_3">590,039</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:AmortizationOfOperatingLeaseRightOfUseAssets" scale="0" id="Tc_iCyoYfJ5bUGljpRM98tg_g_10_6">181,459</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Changes in operating assets and liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_KG6qfgvSa0OTQvMzu10k7w_12_3">531,482</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_p_e2OFfvKkKIaUNXul-Esg_12_6">1,384,725</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" sign="-" scale="0" id="Tc_nL6Y3GoR6k-QFaE9c1Gqqw_13_3">55,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" sign="-" scale="0" id="Tc_CwquYUzTPUeMSEs_nB8YIg_13_6">51,988</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable and accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_TiNfqnHx00mXpJ0xTMQUXA_14_3">4,222,470</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_SBlrQuRShUaXAx8i-RzKBA_14_6">963,967</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="0" id="Tc_DJVUboeTTECjuO7Z5pONgA_15_3">173,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="0" id="Tc__ny_PJw4VUuGnGW7tTrqOw_15_6">185,179</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_bw21L00woka1KUICf2-AuA_16_3">18,859,631</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_D4NbbSezfU-Blpzpc5AfPA_16_6">18,284,293</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchase of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" scale="0" id="Tc_L7lh2gvEe0y9eLTobpFtsg_18_3">3,638,849</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" scale="0" id="Tc_d2u4wPGlwkCi9IDHg68nqQ_18_6">374,983</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchase of construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForConstructionInProcess" scale="0" id="Tc_ziiVfYtan0CyjiCI4vhsAw_19_3">6,789,098</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForConstructionInProcess" scale="0" id="Tc_G-yLVgCZG0C9yO9RebIDrQ_19_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash used in investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_AGdbd_2dLEOZK7Ykzl2PKw_20_3">10,427,947</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_afiKNaO1SUS5jPs2yAKkyA_20_6">374,983</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_f3xGWoeOPUeESvmbTUG8Cw_22_3">6,186,011</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_5QLcSlBDPkWvQqZP9np33w_22_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_eZZID9t3F0C3HDQWT2j22g_23_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_aSJNV7OKX0SwSISzzXR03Q_23_6">57,744</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_OXk7uZlH8kyJg7NQN-527Q_24_3">550,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_9jwHOx8tikmLweYvqaiUnQ_24_6">758,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_0kmw2njQIEKgFtsR46HtUA_25_3">6,736,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_RC1zW0ynm0uXTJ82JoZBFg_25_6">816,477</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_1eY1hecOsUegX_j7YraGLg_26_3">22,551,567</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_J-Znjq2ZNEWsvIysBb_lwg_26_6">17,842,799</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at beginning of the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Tc_a3E_r_UTzEKSabk4bxibuQ_28_3">43,903,949</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Tc_CLCbgkJbm0qhKumxdHMhVw_28_6">61,746,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Tc_69nLLHO7P0aNi6XsZVBNkQ_29_3">21,352,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Tc_8uyWdCEoLEu_Pr0c1CJl7g_29_6">43,903,949</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8c1e4292_077e_47a5_8031_913151b48145"></a><a id="Tc_N70kvO8tQkOK4LRitTDPNQ_1_2"></a><a id="Tc_7xWvZ94TyUmbnGaZUD7m6A_2_2"></a><a id="Tc_sKVFMg30IkSZE8FAErRZew_3_2"></a><a id="Tc_dEYHAdObSUer0gzPIUnbKg_3_5"></a><a id="Tc_73kdDBE-JEGLDb5TLX3T6Q_4_0"></a><a id="Tc_3MvyBliFhkq7BMpXYOhsZw_5_0"></a><a id="Tc_VJV8cuc9WUGtqW5vVQTiJw_5_2"></a><a id="Tc_PtdvyROm3EeYVCigRs8QHg_5_5"></a><a id="Tc_UAYvqjSAO0KaIQwwTEv2qw_6_0"></a><a id="Tc__5xDfY9nF0-ORssAziEqJQ_6_2"></a><a id="Tc_ZsjZBTS5PkOUFZvHugGTyg_6_5"></a><a id="Tc_-GWOxjAHdUG_qT--gGwNYg_7_0"></a><a id="Tc_oFD6CHqxMk2TLbH69cBLxw_7_2"></a><a id="Tc_ngkrc4W33UCjAHGtS-lXrg_7_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental schedule of non-cash financing activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Issuance of common stock as commitment fee for future financing </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" scale="0" id="Tc_P8ONNvnkUki9Lxm7-zulXQ_5_3">345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:zerodash" name="mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" scale="0" id="Tc_HnkM8bRE70af0wnBoxBqxQ_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Recognition of right-of-use assets and lease liability from new operating lease agreements </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="Tc_9eXH7CKLuk69kZ0ADfSzgw_6_3">11,114,300</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="Tc_S_6gVrnMXkyeu2GnS2sL5g_6_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Stock warrants cashless exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:zerodash" name="mrkr:NonCashExerciseOfWarrantsAmount" scale="0" id="Tc_CPETUUVdCUGKRia6baSiTQ_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:NonCashExerciseOfWarrantsAmount" scale="0" id="Tc_WT1s9ppEYkS7KlYmBW1IaA_7_6">9</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ad7f3f35_daa4_455f_bbcb_e31a03c535d1"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FOR THE FISCAL YEARS DECEMBER&#160;31, 2020 AND 2019</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:NatureOfOperations" id="Tb_vgE2PNFpn0iK5K57Yx0-Qg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Marker Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;we&#8221;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s MultiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock" id="Tb_1UiMEcfYlUiJFjYderfw0A" continuedAt="Tb_1UiMEcfYlUiJFjYderfw0A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2020, the Company had cash and cash equivalents of approximately </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_LgVplVIIqEeBfHdRSvzI4g">21.4</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million. The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical trials. Further, the Company&#8217;s product candidates will require regulatory approval prior to commercialization. These activities will span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from sales of its product candidates, if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Based on the Company&#8217;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of December 31, 2020 will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2021, as such these factors raise substantial doubt regarding the Company&#39;s ability to continue as a going concern. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#8217;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#8217;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#8217;s future funding requirements will depend on many factors, as it:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">initiates or continues clinical trials of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">continues the research and development of its product candidates and seeks to discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">maintains and enforces intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1UiMEcfYlUiJFjYderfw0A_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">evaluates strategic transactions the Company may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, based on the Company&#8217;s current assessment, the Company does not expect any material impact on its long-term liquidity due to the COVID-19 pandemic. However, the Company will continue to assess the effect of the pandemic on its operations, including its clinical programs. The extent to which the COVID-19 pandemic will impact the Company&#8217;s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing the Company&#8217;s ability to access capital, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company&#8217;s business and the value of its common stock.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_OlJ3BImfw0WeTxVLdqCd-g" continuedAt="Tb_OlJ3BImfw0WeTxVLdqCd-g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_BdAi-hTb6k2m3LlhqvHP-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_N7xy6yJ5CUWeq8TgaaSBLg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:UseOfEstimates" id="Tb_ywJ-JxOPBEGxD_tTSECFRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#8217;s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_DrGNUNpnlk-DphGsSRRQVA" continuedAt="Tb_DrGNUNpnlk-DphGsSRRQVA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31, 2020 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_wM5XTVszlUixcF8rf0gr7w">250,000</ix:nonFraction>. As of December&#160;31, 2020, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="6" id="Narr_ikBAOoZElEOUJyDif_c_Ew">2.7</ix:nonFraction> million in cash was uninsured based upon the FDIC insurance coverage limits.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OlJ3BImfw0WeTxVLdqCd-g_cont1" continuedAt="Tb_OlJ3BImfw0WeTxVLdqCd-g_cont2"><ix:continuation id="Tb_DrGNUNpnlk-DphGsSRRQVA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:RetainExistingPolicy" id="Tb_hfZWZN_cCkauCDZQs99zAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Narr_ohNrncNosUC98c_8ivx0Xg">the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:PropertyAndEquipmentConstructionInProgressPolicyTextBlock" id="Tb_0uoeLK4On02oBN6Lz6bbnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment - Construction in Progress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility&#39;s construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout will be recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_1PUkzCRTJE6peFDHToPqqQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows Accounting Standards Codification (&#8220;ASC&#8221;) 820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 1&#160;- Quoted prices (unadjusted) in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 2&#160;- Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 3&#160;- Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, financial instruments and concentration of credit risk.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_s_MpDlYBfkGAs8pqJjjhUQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents and Patent Application Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" id="Tb_uSGH8j3BKkuNGEr1fGoGdg" continuedAt="Tb_uSGH8j3BKkuNGEr1fGoGdg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i>&#160;&#8212; The expected life of stock options was estimated using the &quot;simplified method,&quot; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i>&#160;&#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OlJ3BImfw0WeTxVLdqCd-g_cont2" continuedAt="Tb_OlJ3BImfw0WeTxVLdqCd-g_cont3"><ix:continuation id="Tb_uSGH8j3BKkuNGEr1fGoGdg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#160;&#8212; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i>&#160;&#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_VDlB24xZDE2hcWFa0cCKOQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_8Wo-6aUMXkGXTX12g-Ub1g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2020 and 2019, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2020 and 2019.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:DerivativesPolicyTextBlock" id="Tb_vggzDajjx0qzsEUPyfqoiA" continuedAt="Tb_vggzDajjx0qzsEUPyfqoiA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrant Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amounts of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. If the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OlJ3BImfw0WeTxVLdqCd-g_cont3"><ix:continuation id="Tb_vggzDajjx0qzsEUPyfqoiA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12&#160;months of the balance sheet date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management must determine whether an instrument (or an embedded feature) is indexed to the Company&#8217;s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. This exercise affects the accounting for (i)&#160;certain freestanding warrants that contain exercise price adjustment features and (ii)&#160;convertible notes containing full-ratchet and anti-dilution protections (iii)&#160;certain free-standing warrants that contain contingently putable cash settlement.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:GrantIncomePolicyTextBlock" id="Tb_Rd5B0gUDvESCWh8VT9_wsw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company&#8217;s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable and are not dependent on the Company&#8217;s ongoing future performance. The Company has adopted a policy of recognizing these payments when received and as revenue in accordance with Accounting Standards Update No.&#160;2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; issued by the Financial Accounting Standards Board.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_C35Rll5Kmk6sd13fBp--ew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_X5nmZkSHEE-UIFYPuwtPqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Standards Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, the FASB issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company has adopted the new standard effective January 1, 2021 and is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:MinorityInterestDisclosureTextBlock" id="Tb_nWLLkv_RM0O_rSKRqRQdLQ" continuedAt="Tb_nWLLkv_RM0O_rSKRqRQdLQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share Applicable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_dlXkzFZwk0uDze18KYdQGw_1_2"></a><a id="Tc_pWHFs2KdaU6NGU42mB5rPg_2_2"></a><a id="Tc_yuiL69C4WkuQsFSOLjmU-w_3_2"></a><a id="Tc_sMUfwQwbb0CCjIiUv4ll3g_3_5"></a><a id="Tc_MMf55rL2Q0y6EaohlHlyiQ_4_0"></a><a id="Tc_e8X37oIsbUyPbD1bZlFWMw_5_0"></a><a id="Tc_IfW2UEfHGkaYPfgX0F8UyQ_5_2"></a><a id="Tc_fPyGkCd1A0urYBhf_WkTkA_5_5"></a><a id="Tc_oLbthHdfaE6r166Wcjgw2w_7_0"></a><a id="Tc_xg0jDjdFQ06l6vRViPbnDw_8_0"></a><a id="Tc_TYvQ9IH4_U-jTO_MkcZ9XQ_10_0"></a><a id="Tc_M4uHe6rwp0iqJzLC3SY9hg_11_0"></a><a id="Tc_gS_VgEEHd0SqP7PbfN1Tdg_11_2"></a><a id="Tc_SzDPsLDVXki-gTe-RIecTA_11_5"></a><a id="Tc_LiNQ4FBjdUawUE30JfFR0A_1_2"></a><a id="Tc_VE7CpmJVY0mS5LMOhQCO3w_2_2"></a><a id="Tc_1KqkirY2kkGCn5vL9HfP8w_3_2"></a><a id="Tc_tnOxKb0Cr0WZesk0BvgeWQ_3_4"></a><a id="Tc_K2S6FABhh0i4j6yrEMT0LA_4_0"></a><a id="Tc_vx69cUbakEWVa65coB3UcA_5_0"></a><a id="Tc_OR5qxy453EyXVVw1q6zbMA_6_0"></a><a id="Tc_b53fpxYg9k-FBajMb09qMg_7_0"></a><ix:continuation id="Tb_nWLLkv_RM0O_rSKRqRQdLQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth the computation of loss per share for the&#160;years ended December&#160;31, 2020 and 2019, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_MoNPCIiE5kKC-fOchIOIQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_iJXTXyzNyESihjYT7ldlXg_5_3">28,706,070</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_B7Tz7BtwL0aoHIxLPYzZbQ_5_6">21,427,964</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_xxckLMtYWkOwAPAytRSiAQ_8_3">47,039,862</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_aeLb_Uqu0UumXHGEGgJy8Q_8_6">45,587,734</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per share data:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_kkli5B46l0ipZ_9QISGJMg_11_3">0.61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_cbnjLS_3h0eLjgIqUYXM3g_11_6">0.47</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:NetLossPerShareTableTextBlockTableTextBlock" id="Tb_sXc-LdMpXkWexkTnwdzzlw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_j4K7-6m1s0mROj8Tc9Lrag" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_NYtU0NJlEEypWSo2l_iXSA_4_2">6,002,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_OqczUH54BUevB2a6-k75Bg" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_f_70H_gROUC1liVuMqUcww_4_4">4,983,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_-Qd7LU2lBUa_mee1OprAuA" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_zUVSph3ShU-p79p5LZESxA_5_2">20,830,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GPlgMEopskaT3rrayUflxg" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_puwduVPP4kS2Fbr3vzr0CA_5_4">22,605,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants - liability treatment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mrkr_CommonStockWarrantsLiabilityTreatmentMember__mhH4edEXEqL7o8fnQckTw" decimals="0" format="ixt:zerodash" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_EWV3yUUsLkS8po_VjWGUTQ_6_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mrkr_CommonStockWarrantsLiabilityTreatmentMember_aWBuEQRV-kK1UZ4Oeqku7w" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_opVffWN5vU2Y5YoJMimodg_6_4">59,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_aUnrVOP1qUOsPpbpQCUPdA_7_2">26,832,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ou67-rQz2EWTm0jByWkWUg_7_4">27,647,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_aoFswfAljkSdwWwzHj9wFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company&#8217;s lease agreement for its manufacturing facility, the Company incurred and paid for the construction invoices directly for both the structural improvements of the facility and the building of the manufacturing modular cleanroom (i.e. leasehold improvements and manufacturing equipment). &#160; At the time the construction invoices are received by the Company, a fixed asset is recorded in construction-in-progress. In accordance with the agreement, upon completion of the facility&#8217;s construction, the Company is owed up to $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="6" id="Narr_otehMWT0JkCzKHyBX4UqjA">1.0</ix:nonFraction> million as reimbursement, and as such a landlord receivable is recorded, which provides for a legal right to receive construction reimbursements from the landlord for tenant improvement allowances.    The construction of the facility was completed during December 2020, and a certificate was occupancy was delivered to the Company in January 2021.  During the fiscal year ended 2020, the Company recorded a $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="Narr_LXplb2IufUSiDgXMUWwYpg">1.0</ix:nonFraction> million receivable in its consolidated financial statements. &#160;The Company expects to receive the $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_6_30_2021_UnPt_Wy98US1VFSStqyNsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="Narr_xSFqrTeP6UKN25K9vRepHg">1.0</ix:nonFraction> million in the first half of 2021.</p></ix:nonNumeric><a id="Tc_aiNjxHTg40yMBN7YOm13wQ_1_4"></a><a id="Tc_O84cbBX9Kk6IHGDP46adkA_1_7"></a><a id="Tc_nFgz-u4Ev0OIGjupiN0DsA_2_2"></a><a id="Tc_wC9tIOoMrUq2JakNpAO_CQ_2_4"></a><a id="Tc_JOYPJcNdkU6NVZF5_mBUUg_2_7"></a><a id="Tc_aN2bECfrfkS63kO3vKitpg_4_0"></a><a id="Tc_kQSNQGT-K0SCKQ85To7Xeg_4_4"></a><a id="Tc_m3jJTfh74EmNTl56Y59XkA_4_7"></a><a id="Tc_Pdi92PugsUuYN0zKDJVEGw_5_0"></a><a id="Tc_Pm_S8GqVSE-6m0jIQL9hCw_5_2"></a><a id="Tc_UWX_vmSl-Eemr_E2rPnLTA_6_0"></a><a id="Tc_ErqUuENldkmVCSkat1V3_w_7_0"></a><a id="Tc_MJG2GZXoukaERjYGBtiH1w_7_2"></a><a id="Tc_mjJ-Inzzk0CtsPU4ccCU3g_8_0"></a><a id="Tc_OjwSx7SfPEygQE0Z1SXILQ_9_0"></a><a id="Tc_FXAcacnSuUaMWuo7aRh33A_10_0"></a><a id="Tc_4bD5eV6kyEy-lh5UVBVcWg_11_0"></a><a id="Tc_BpYK1YRJZEu62suy9XFCnw_11_4"></a><a id="Tc_YHjx8klPIk6GASstB1mR3Q_11_7"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_wSS0WAvFR0ODKRaa4bPHew" continuedAt="Tb_wSS0WAvFR0ODKRaa4bPHew_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;6:&#160;&#160;&#160;&#160;PROPERTY AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment consist of the following as of December&#160;31, 2020 and 2019, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_yLd38UB6qESD7CB_UQxlmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_olqT_Fwx7U-Odxkj912Fyg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_thyNNc9eW02mK_1L15Gp3Q_4_2">5 Years</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lIiAzvSsBkSWpBXL8lYO6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_95JQg-EIAk2rotxhRAcuaQ_4_5">2,360,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_ACdngx63MEKIMb7z31QBtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_T_EJTslx_EG6ms96TU_WyQ_4_8">111,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_B-vZs3Ppc06PCUnjXPTuOg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_kS_bxe-a7kqcg-GOGKjQkw">3</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_XdhD9gTpeU6hnY0-z8DASw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_KgH3g3oBfkWa-tYJdJniWg">5</ix:nonNumeric> Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_Y6NXa2tNyEWBTjwC2KHiAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_YILucaB2HEiM2wlBAUhtLg_5_5">835,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_FZSrIrNxmUyDqyxkQZDk4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_k6yfUWUm7UWLXU83EDeghA_5_8">211,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_zke-f8FZTkO88cP2_ZhOwQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_y3eLDl3ePUmy2Zq7_U-e1Q_6_2">5 Years</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_A2_KcOuc7UCSujKL_kVBbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_xrsNFIDojUuR7r2RUnQP0w_6_5">678,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_92qxNSp0JkO7pwogTgs1Tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_6FawPjiq7E6U3lghNBZLIA_6_8">178,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or estimated useful life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_v-vM_Z57j0W6NbhuDyp_Og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_okqi_HR0-EKUd4WwxWvaYg_7_5">289,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_PUj_K1bfHkGFM2Y4jHt9Qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_D8cOdr8TLUyedr0RI111yQ_7_8">23,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Total   </span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_3BAHYk52IE2YiRR6q5r_zg_8_5">4,162,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Y5gT0PJw8Um3AxjPXuiOIA_8_8">523,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc__z7SPIHFAk-Tl1yV0NHXfg_9_5">591,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_p8yxp1qkaEa1RVvGf3stXw_9_8">105,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="0" id="Tc_p9_ys8w0gUu7V7i8pzkCUw_10_5">6,789,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:zerodash" name="us-gaap:ConstructionInProgressGross" scale="0" id="Tc_ilj-uzGHrUaLbcVglJnu9w_10_8">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fixed assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_KHAv9cIzlEm5fW1PERDsjA_11_5">10,360,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_ADCrc0F_SUecXbjDYWh_KQ_11_8">418,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the years ended December 31, 2020 and 2019 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_q1k8ECYpnUKbhYBVxvS2NQ">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_T1Y5-5Z020awooaz-HVScg">0.1</ix:nonFraction> million, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_wSS0WAvFR0ODKRaa4bPHew_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and eventually install modular cleanrooms in a manufacturing facility. &#160;$<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="Narr_pw0mXgFP20erRoC0ZZn7IA">6.8</ix:nonFraction> million is recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2020.  The completion of the facility&#8217;s construction occurred during December 2020 and the Company received its certificate of occupancy in January 2021, and as such was placed into service in January 2021.  During January 2021, all costs associated with the buildout will be recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the research facility that the Company opened during the second quarter of 2020, the Company incurred approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_o2aish9KUkmT-1TlNuBhUA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="6" id="Narr_NNuc_jNRcUy_dBQAHSRZ7Q">2.2</ix:nonFraction> million of costs acquiring necessary lab equipment to carry out its experiments. The $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_o2aish9KUkmT-1TlNuBhUA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="6" id="Narr_tlaZaLr-jUegc4m8Tg3pVw">2.2</ix:nonFraction> million is included in Lab equipment within fixed assets and is being depreciated over <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_olqT_Fwx7U-Odxkj912Fyg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_DU5pFkskNUKPJ32CGP2rSw">five years</ix:nonNumeric>. &#160;Additionally, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="6" id="Narr_5kw0WDZnCkGYFIBN3o8zkQ">0.3</ix:nonFraction> million in leasehold improvements relating to the research facility.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_lLYTXHMWd0WAgK4yMC1kug" continuedAt="Tb_lLYTXHMWd0WAgK4yMC1kug_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 7: LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into a new agreement for its corporate headquarters in Houston, Texas, which commenced in August of 2020. &#160; The initial lease term is <ix:nonNumeric contextRef="As_Of_8_31_2021_lXNY-SqcckufSQP1_3M_NA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_LRcrThtfOky4bBJ2cWqUQw">ten years</ix:nonNumeric> with <ix:nonFraction unitRef="Unit_Standard_Options_XwIwXkVLKk6WPb72jTZEwQ" contextRef="Duration_8_1_2020_To_8_31_2020_95mnbsS_AUasMsjLjipGSQ" decimals="0" format="ixt-sec:numwordsen" name="mrkr:NumberOfRenewalOptions" scale="0" id="Narr_yYjJQySuVUib0PEznx7sMw">two</ix:nonFraction> <ix:nonNumeric contextRef="As_Of_8_31_2020_2wu45mhpe0Wt7jhL5XOOSA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_xKl1TTG1REusRYmJXGXEjw">five-year</ix:nonNumeric> renewal options. Fixed rent payments under the initial term are approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_8_31_2020_2wu45mhpe0Wt7jhL5XOOSA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FixedLeaseRentPayment" scale="6" id="Narr_6l5fFOIo6kSZZxBfFcbglA">5.6</ix:nonFraction> million. &#160;Additionally, the Company is also responsible for its share of operating expenses. &#160; &#160;As of December 31, 2020, the Company had remaining $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_CorporateHeadquartersMember_yvnuelJz_UW9l4GGuzdD-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_MI76bj-8-kOJpgCBD7s99g">4.1</ix:nonFraction> million from the lease liability and $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_CorporateHeadquartersMember_yvnuelJz_UW9l4GGuzdD-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_QDWp3pObr0mAwGNRFzT11Q">4.0</ix:nonFraction> million of the related right-of-use asset resulting from the lease of its corporate headquarters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April 2020, the Company entered into a lease for a research facility in Houston, Texas. &#160; The lease term is <ix:nonNumeric contextRef="As_Of_4_30_2020_C8Sjke4d3Uu2bMNfPrnSIQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_f2VWtg45jE6sUTX7XbYnBw">71 months</ix:nonNumeric>. Fixed rent payments under the initial term are approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_4_30_2020_C8Sjke4d3Uu2bMNfPrnSIQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FixedLeaseRentPayment" scale="6" id="Narr_IGJMgX5E4UqlZEHPOdGQPQ">1.1</ix:nonFraction> million. As of December 31, 2020, the Company had remaining $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ResearchFacilityInHoustonTexasMember_AUKUMDHj8UmZXAD59Q-Ixw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_-nJeotiCvEapl-aZjKiPeA">0.8</ix:nonFraction> million from the lease liability and $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ResearchFacilityInHoustonTexasMember_AUKUMDHj8UmZXAD59Q-Ixw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_0ihN4XOEzkCzd1ghZpU8qQ">0.8</ix:nonFraction> million of the related right-of-use asset resulting from the lease of its research facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. The initial lease term is <ix:nonNumeric contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_fI74nryWUEaPk8LkTUa-qA">ten years</ix:nonNumeric> from the rent commencement date in the fourth quarter of 2020 with <ix:nonFraction unitRef="Unit_Standard_Options_XwIwXkVLKk6WPb72jTZEwQ" contextRef="Duration_6_1_2020_To_6_30_2020_mgveA6v0wUaCVTftpwttxQ" decimals="0" format="ixt-sec:numwordsen" name="mrkr:NumberOfRenewalOptions" scale="0" id="Narr_fokZ7P7280yn5Ex-C9107g">two</ix:nonFraction> <ix:nonNumeric contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_qu2QL4gojkOSczKygzKC8w">five-year</ix:nonNumeric> renewal options. Fixed rent payments under the initial term are approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FixedLeaseRentPayment" scale="6" id="Narr_gdyMuOiIhUuLPoAW4Kvehw">9.8</ix:nonFraction> million. &#160;Additionally, the Company is also responsible for its share of operating expenses. In accordance with the agreement, upon completion of the facility&#8217;s construction, the Company is owed up to $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="Narr_yYL8RcexV0yTC8VUtLnUcA">1.0</ix:nonFraction> million as reimbursement, and as such a landlord receivable is recorded, which provides for a legal right to receive construction reimbursements from the landlord for tenant improvement allowances. As of December 31, 2020, the Company had remaining $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_5T8qVStqZEGO5cyYBUn0KA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_P4RyNCSeMEGAcEiLpWtlQg">7.2</ix:nonFraction> million from the lease liability and $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_5T8qVStqZEGO5cyYBUn0KA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_7xwIRdiKXUe49xMnYJUQ-Q">5.8</ix:nonFraction> million of the related right-of-use asset resulting from the lease of its manufacturing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also leases office space under agreements classified as operating leases that expire in 2022. As of December 31, 2020, the Company had remaining $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_OfficeSpaceMember_AzY5PjhRa0KWIVTuRWZcsQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_87rcN9llfkicrkDMR2d2vQ">0.2</ix:nonFraction> million from the lease liability and $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_OfficeSpaceMember_AzY5PjhRa0KWIVTuRWZcsQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_g1OQhFZyrEa79LbN8vQH_Q">0.2</ix:nonFraction> million of the related right-of-use asset resulting from the lease of its Jacksonville, Florida office space, which expires in 2022. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. &#160;Certain of the Company&#8217;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. &#160;Variable expenses generally represent the Company&#8217;s share of the landlord&#8217;s operating expenses. &#160;The Company does not act as a lessor or have any leases classified as financing leases. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2020, the Company had operating lease liabilities of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_3AaysiWsgEiAjnRw01UnAw">12.3</ix:nonFraction> million and right-of-use assets of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_aiQrY0VjJU2eZD5iTE6oPA">10.8</ix:nonFraction> million, which were included in the consolidated balance sheet.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_eL4FWkPsAkOcWU04OTfU3Q_1_2"></a><a id="Tc_zXBiKd7T8E6IwEuLlUI5jg_2_2"></a><a id="Tc_-OC1HUpcVUKK0slUoREDLg_3_2"></a><a id="Tc_iC5SivxUQkqRs7EcZe1puQ_3_5"></a><a id="Tc_GJIHPQcxhUKImfGoLzwZ8g_4_0"></a><a id="Tc_RiATRHg7RkCcMK7R_luuow_5_0"></a><a id="Tc_eBXX5NsWnkeWyFjldchhcw_5_2"></a><a id="Tc_qJdxuX49dk6Qj0jKnxzs9A_5_5"></a><a id="Tc_-2e8wEkqOk-iUvuGmYlXwg_6_0"></a><a id="Tc_hU2Znu1PvEmEyc5XHQqDzw_7_0"></a><a id="Tc_K5ed178kt0CoxeIKSDoVvA_8_0"></a><a id="Tc_m4Zehi3FY0OJOWJkEMEuqg_8_2"></a><a id="Tc_y7TNvdzrTUGqobVQO9kVsg_8_5"></a><a id="Tc_7UaLr1KMd0mQY88nH5wniQ_10_0"></a><a id="Tc_ebot80mYi0qV6_kyqahFkg_11_0"></a><a id="Tc_1OZo-k1GoE-wt6aNZmMIjg_11_2"></a><a id="Tc_-_oRpUCUUkmX3oIwcVz96g_11_5"></a><a id="Tc_D5x5mVaGNUyboRtIEv_B2w_12_0"></a><a id="Tc_7oxE1vPHJkexdQ2CN5gbOQ_13_0"></a><a id="Tc_Dhkzwm6wj062nIxq47VIXA_13_4"></a><a id="Tc_Y98I-cXMREKs-J_HzCa5Bg_13_7"></a><a id="Tc_2f3H5giHkUyEDUV08EPXzw_1_0"></a><a id="Tc_SHhcVvJ_bE2lj5zwnK8vIA_1_2"></a><a id="Tc_x2jYnvDNIke4uR3ITlNDbQ_2_0"></a><a id="Tc_wOury9w9oEW_4oxweM6Z9g_3_0"></a><a id="Tc_-5CklYVxFU2RSyII7FRJ2g_4_0"></a><a id="Tc_zML9TbsyP0OW-3W1cjKXIA_5_0"></a><a id="Tc_p0Qmr4FFhECE2QRWpyv0JQ_6_0"></a><a id="Tc_Ex0RHYXv4ki3ea8JCfox_A_7_0"></a><a id="Tc_Zt6wrlUBY0KGuD5w2ogiew_8_0"></a><a id="Tc_p-mGY7apL06BZRQUuyVrBg_9_0"></a><a id="Tc_dEJboOzngEWM8Rvw_itYcQ_9_2"></a><ix:continuation id="Tb_lLYTXHMWd0WAgK4yMC1kug_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company&#8217;s operating leases:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" id="Tb_zcYHvau8KkOQj2GoHM2hSw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense summary:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc_n38CwCiJpEu4BEgpiGO_Sw_5_3">960,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc__lCfL4jHvku53rfgBTnDUA_5_6">220,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="0" id="Tc_w3iq_P9_fkGMJPwiCiczzg_6_3">22,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="0" id="Tc_zfv3j6InCECY2Kcgw4lBIA_6_6">100,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="0" id="Tc_m1XG75ilrE6HxlDE7axR7w_7_3">167,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="0" id="Tc_6uR-M3n6c0Sebe8q4TVhHg_7_6">90,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="Tc_h8doxLJ_8ka9VnP5uposXw_8_3">1,149,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="Tc_H9-DWublK0arfrGiOXw3lQ_8_6">410,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_wsXec7lkakqWMMBN3Mv0cQ_11_3">544,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_x5WyFZ1iG02p8JGNQ1hCqA_11_6">225,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term &#8211; operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_xAVIn2kLu0mJNmCKdTQq7Q_12_3"> 9.3</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_faQAJ_C_k0OH-dsQDLtFRw_12_6">1.6</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate as of adoption date &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Z0svEu-TjUaXqzVcUx8kiw_13_3">5.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_ijsptgEYO0SyR73OSgQCAg_13_6">6.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of the Company&#8217;s operating leases, excluding short-term leases, are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_qLjXeJm0X0GpSwnb2_ephA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_kMzmYnlAh0euAeFmYGTe2w_1_3">1,077,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="Tc_4PKZhBoZAEK4xco_bR_zLA_2_3">1,278,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="Tc_bo2JkGJm_EqphX2-b_vnxA_3_3">1,542,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="Tc_Oryhzt8LMEa5310bOSxHow_4_3">1,826,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" id="Tc_6_5GFzd-VUiyRb4eB9lw_Q_5_3">1,874,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="Tc_w4L0s3-bh0O_dIYNLGqKCg_6_3">8,772,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_vX5jt4L1W0CoxKb2H6sG2w_7_3">16,369,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_vmjnstd5ZkWA_AaYw3AiPg_8_3">4,112,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_5NNBC89MUUqntyDfifAfTQ_9_3">12,257,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc__BaiQjOjTkSLRmPvwWYD-Q_1_2"></a><a id="Tc_NhAvQx2fiEqRnzydAWBZhw_1_5"></a><a id="Tc_OPby7p9uMkOr-nnIiWmMkg_2_2"></a><a id="Tc_ArhN1coMckS3wk_0PokHVg_2_5"></a><a id="Tc_F0wLOlQcEUu6Qai6TGk4mg_3_0"></a><a id="Tc_8lzonaS0NUSWUTz5m-ZXqQ_3_2"></a><a id="Tc_T-5eXDl96U2WV7PJV0p3zw_3_5"></a><a id="Tc_5wGRwgdGJUmfZ9v2tTpXhg_4_0"></a><a id="Tc_vC8SSeq7J0OmHuEims_-Yw_5_0"></a><a id="Tc_0aRqudkuVUWhRueRud4OQg_6_0"></a><a id="Tc_-qHyd7lkxkixS5UaSBpRFA_7_0"></a><a id="Tc_4f1oKGnoCUyCA1hG3YlytA_8_0"></a><a id="Tc_WxGpfhFFpEG9S_VCo9YNWA_8_2"></a><a id="Tc_ghNpPUCuB0yCA7ul3ltF_A_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_XtahVbTE30i2I-HYS4rMhA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8: &#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued liabilities consist of the following as of December&#160;31, 2020 and 2019, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_mP0VWMAu9kqNhSbbcItwaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_iieK3TpzPkKSMxro5SArLg_3_3">2,935,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_JrDCwL1mLUap7vfB0YyNoQ_3_6">993,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_Akqss7hljkCy9IXIphk7mA_4_3">1,694,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_II_PKAjn6UaSHHVbfN2Uqg_4_6">323,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_RVc08c2XjUC3oXDQSyyY6g_5_3">875,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_Dwe6e7v7Vk6J7Dk-u3lNDw_5_6">94,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology license fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="mrkr:AccruedTechnologyLicenseFees" scale="0" id="Tc_mmb1kUMjkUuDWn-GSkC7wQ_6_3">105,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="mrkr:AccruedTechnologyLicenseFees" scale="0" id="Tc_rlDRzJfidE6BdtaJEN5dpA_6_6">105,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_nu97se9n50WYwMm8gYd9Gw_7_3">404,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_8KTfuPjucEy5aK56KDTIig_7_6">243,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_dfqOgA16h0CUR-efONMglw_8_3">6,013,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_05qUh1mUiUGIU5gdofPUZQ_8_6">1,758,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-VNoP5yA2EiwIlYKdEJXOQ_1_2"></a><a id="Tc_ppZEt2YZ2k2IK1cjbf_aHA_2_2"></a><a id="Tc_KlFkkKpTS0qPIejomkvAmg_3_2"></a><a id="Tc_R4f_-zHPLUyTqt_FPkijSw_4_2"></a><a id="Tc_Va6YalgizkSa8XbTqnYunQ_4_5"></a><a id="Tc_VJ1dB4o7_0i_RBIUo5chyw_5_0"></a><a id="Tc_SOjuK2Y0HEufdq-n6QP1Sg_5_2"></a><a id="Tc_MwKNfX-F1U616cRLCc-Drg_5_5"></a><a id="Tc_SmYrnktjNE61Ckj2Vbqm2Q_6_0"></a><a id="Tc_fC8I6RkvMkCBJ348xAFIwg_7_0"></a><a id="Tc_UISEJHgsGU6Dev139VvaCw_7_7"></a><a id="Tc_orYa1UreCkKOwTm-xu_rOg_8_0"></a><a id="Tc_SQ7pKlriLUqXqHK8KVdXhQ_8_7"></a><a id="Tc_jeo-ORyg5UeyARC2aQw6Zw_9_0"></a><a id="Tc_7_BXOMWQ5kqTEiY41c0ATw_9_7"></a><a id="Tc_Kb9SUBy4SUqhPHgSkyhDRw_1_2"></a><a id="Tc_IDN4ACJxkkCjizFLeQFuEw_2_2"></a><a id="Tc_-9sCE3sMfUOwi7PpdDtOWQ_3_0"></a><a id="Tc_tRwT4uYPEEKiTBoL2GWW0Q_4_0"></a><a id="Tc_D8h9sqzbp06cLGoIx_pKPQ_5_0"></a><a id="Tc_ruD0qixoPk-FD0iW3SYrtw_6_0"></a><a id="Tc_Wp88je8L6UukTdyY-GK92g_7_0"></a><a id="Tc_-f3JT-eWx0-ExmI1X-V6aA_7_2"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:WarrantLiabilityTextBlock" id="Tb_NIJ6IlfjikqjDMpS2jdD3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;9:&#160;&#160;&#160;&#160;WARRANT LIABILITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&#8217;s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the&#160;years ended 2020 and 2019, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_3B73NaasBEmFQYB4WCOXUQ" name="mrkr:ValuationMethodology" id="Tb_WiW7Kuw4tkCt2_BncUpFCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember__pIPPDpQCU-WKKP23kwqnw" decimals="2" format="ixt:zerodash" name="mrkr:FairValuesAssumptionsExercisePrice" scale="0" id="Tc_Q4mLAzTrGUa1Sa9Exq9EiQ_5_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_J3vACPWMbkmTs8PjTPKwqQ" decimals="2" format="ixt:numdotdecimal" name="mrkr:FairValuesAssumptionsExercisePrice" scale="0" id="Tc_XgzQJEtSyUeyUMlTy4zovw_5_6">6.92</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_p0q6djlt6UyBX7Cf1G6waA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw" format="ixt-sec:duryear" name="mrkr:FairValuesAssumptionsExpectedTerm" id="Tc_1kNb3ttQXka4Ao0cQP9aIQ_6_6"> 0.05</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility (annual)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA" decimals="2" format="ixt:zerodash" name="mrkr:FairValuesAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_MQT8oIwYZUujk30S7LhJ4g_7_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw" decimals="2" format="ixt:numdotdecimal" name="mrkr:FairValuesAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_HVZpfHiyc0iguPn3N_llfw_7_6">83</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA" decimals="2" format="ixt:zerodash" name="mrkr:FairValuesAssumptionsRiskFreeInterestRate" scale="-2" id="Tc__u0J8jr1sEmLcvFWWLexow_8_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw" decimals="2" format="ixt:numdotdecimal" name="mrkr:FairValuesAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_DSHeQ7xrdkKvN8rJntD1xQ_8_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield (per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA" decimals="4" format="ixt:zerodash" name="mrkr:FairValuesAssumptionsExpectedDividendRate" scale="-4" id="Tc_otooC_qOYU2KSlPtbMOihg_9_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw" decimals="4" format="ixt:numdotdecimal" name="mrkr:FairValuesAssumptionsExpectedDividendRate" scale="-4" id="Tc_Yo1PF0AgkECmcOapTiA1Ag_9_6">0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The foregoing assumptions are recalculated every reporting period and are subject to change based primarily on management&#8217;s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents changes in Level 3 warrant liabilities, reflected in accrued expenses measured at fair value for the&#160;years ended December&#160;31, 2020 and 2019, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_3B73NaasBEmFQYB4WCOXUQ" name="mrkr:MeasuredAtFairValue" id="Tb_Hl_k1BhkDkSAjoIHfpp-9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_es92KzL1UECJKLykT2cn4A_3_3">49,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" sign="-" scale="0" id="Tc_4XqO8WPO6Eqs8dQJI5mw2A_4_3">18,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance &#8211; December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_LUR97Py-SUuMYlhVmpL2cQ_5_3">31,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" sign="-" scale="0" id="Tc_exHmIAggTkGtqHeYvN8Z8g_6_3">31,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance &#8211; December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_KxH6ev21VUmtlrH4-i7IRg_7_3">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c3eb0bd6_baa5_4cfd_8906_891a7e6a5b37"></a><a id="Tc_ndDUCOk1vUqh9pfVi53Cjw_1_2"></a><a id="Tc__GKiEoitUkOXWdYLXUNlvA_2_2"></a><a id="Tc_V3smuKmJm0CCxr2mkoBOiA_2_5"></a><a id="Tc_ENFB-BUbe0ikg_TB4_wKVQ_2_8"></a><a id="Tc_qWVrcn59P0ywYj2VlJZC5g_3_2"></a><a id="Tc_fdw2BQ1t1UWMqCuHRZ9mWA_3_5"></a><a id="Tc_wlrlPKs4aUWYHCIgGS8H9A_3_8"></a><a id="Tc_-jC7HOrRlEam4EPJX7QXKg_3_11"></a><a id="Tc_ulx4jWhkCkKMH0CvnjUClg_4_2"></a><a id="Tc_xdMadAlO7kCJUOPRLuf0nA_4_5"></a><a id="Tc_RtKuVjdHCkCqiwuoHGxQ1A_4_8"></a><a id="Tc_dSr6YfO5F0ujnd6FhrGAMg_4_11"></a><a id="Tc_COV_shsRWk-N8LD3WgTqdA_5_0"></a><a id="Tc_kMu-lAzsHkuZv46lQfrI6A_5_2"></a><a id="Tc_lp1c9tj2iUKCILHW_CWKfQ_5_5"></a><a id="Tc_teLk0nZz7kKO9aM613-tNA_5_8"></a><a id="Tc_Anvlz319bkCucrdIgKrRZQ_5_11"></a><a id="_1a793802_f211_4a6c_a2f4_c20adf27ef82"></a><a id="Tc_YO3ByCWsjkiUyZOxq6FsHQ_1_2"></a><a id="Tc_yZ69VTVfWUG3rGMx2RY7cQ_2_2"></a><a id="Tc_0THT7je-GEm166GrcmP0mQ_2_5"></a><a id="Tc_ve1H5932YU6uwPmtIwItHg_2_8"></a><a id="Tc_r-t-wFuNZ0ixRHkjc2QRuA_3_2"></a><a id="Tc_iI_hRTYkgkm0rYrsZDuHsw_3_5"></a><a id="Tc_msvhWIywBE6i3ad4NOHi1A_3_8"></a><a id="Tc_Fa6TKndYVEujIDiJ77lSIg_3_11"></a><a id="Tc_LsFK32KRJE-jluqHu4XUJA_4_2"></a><a id="Tc_IPmWbwI3-kaNYf0_5SnDOg_4_5"></a><a id="Tc_RCW_iDyFGkGZmI9ldu1x3g_4_8"></a><a id="Tc_xpEFpGlaD0KMWjqnhRcunA_4_11"></a><a id="Tc_j0g8Ylm8Gk6DXKCKEWNlCw_5_0"></a><a id="Tc_3aYbtMg9QEq9vW0bTVeiOw_5_2"></a><a id="Tc_p4ip7VLhXk-UbTFVYzp0Hw_5_5"></a><a id="Tc_05bJI4lCL0SvAT0FD1j87A_5_8"></a><a id="Tc_X-aiI8HF2EiiwXank429yQ_5_11"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="Tb_7Sq77lYWdkSpEHrNAXApHQ" continuedAt="Tb_7Sq77lYWdkSpEHrNAXApHQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;10:&#160;&#160;&#160;&#160;FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock" id="Tb_83odUJWInEKsElegGQGrvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in&#160;active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value at</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_H6133jjRH0CvkLeY903Lgw" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="Tc_65oA9yBi1EaBuSmp7aEfVw_5_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_fB-XBxEMVEuZ0AXnJJPCYQ" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="Tc_Wnx1Z0I58EuxoEwu424E4Q_5_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_MlrJM6J87kKV_E3Gg6OHjA" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="Tc_7NmlUZgYBUWb2h3aAn7H8A_5_9">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_ZI-qkKDgJE-mZLjhRnPZhQ" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="Tc_pQ0Iaoh_t0KM_6GYppF62w_5_12">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in&#160;active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable&#160;inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable&#160;inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_7MInXfUOC0WNFuWoIBCLMA" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="Tc_2D8nTMucb0ugUfCN6zgUZA_5_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_zThIObKJTkGFAkdmLkZJyA" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="Tc_KdNYl63jK0KzYaWdKy-e6A_5_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_g6VPuQbHC0y4V1O1fXaO1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="Tc_-Y0fgujUvUaTlvu93OKUBw_5_9">31,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_5Gr7NCUwa0aVADJ5Uz_xrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="Tc_67Fuv3ZBckO-LWt-Ac6sdg_5_12">31,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt-sec:numwordsen" name="mrkr:FairValueTransfersAmount" scale="0" id="Narr_aiOktO_aMUi1ytRhdWKckw"><ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt-sec:numwordsen" name="mrkr:FairValueTransfersAmount" scale="0" id="Narr_A4DtH4l3G06Td9Z3_h_e0w">no</ix:nonFraction></ix:nonFraction> transfers between Level 1, 2 or 3 during the&#160;years ended December&#160;31, 2020 and 2019, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_7Sq77lYWdkSpEHrNAXApHQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U. S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The net cash settlement value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following inputs at that time: the consideration value per share of the Company&#8217;s common stock, the volatility of the Company&#8217;s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U. S. Treasury security yields, and the Company&#8217;s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_AcAIOY6g7k2wwY1gf1FR3w" continuedAt="Tb_AcAIOY6g7k2wwY1gf1FR3w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;11:&#160;&#160;&#160;&#160;STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_qtSbivKTlkmpIPDdU1ujwA"><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_gHCrKWwWHEee7m2fDtz4fQ">5,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_ebtooEYsWkK5Hj0UYFDZhA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_0--amOwhlEOdGcDV-zcoow">0.001</ix:nonFraction></ix:nonFraction> par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_4nRfwP92RkOhUmAIZ1U-LQ"><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_tF9xebyRJ0S_sK0UTAn5XA">150,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Ax8fYxqNF0uKOH0q8wepWw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_OccHLbfJXUqVgIAjbEJ9Og">0.001</ix:nonFraction></ix:nonFraction> par value per share, for issuance. Significant 2020 and 2019 common stock transactions were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">2020 Common Stock Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Exercise of Stock Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the year ended December 31, 2020, certain outstanding warrants were exercised for </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_x8rh7aiZp06pdQPYS17Hvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="Narr_5avrHfHGeUSEK7eH1aGbug">0.5</ix:nonFraction></span><span style="font-weight:normal;"> million shares of common stock providing aggregate proceeds to the Company of approximately </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="Narr_ONxwGcXfjEOSJ6zDPXmLvA">0.6</ix:nonFraction></span><span style="font-weight:normal;"> million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Board Compensation </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_ZhSFY76i_kCH9MG-xjOj-w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="Narr_eEflCxeeBESFviOpTh0sGA">0.1</ix:nonFraction><b style="font-weight:bold;"> </b>million shares of common stock to its non-employee directors. The fair value of the common stock of approximately <b style="font-weight:bold;"> </b>$<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_vMApe0EcyUGKDZi6FGn-GQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_vX9q4vTYiEiPhfkMgAbsNg">0.2</ix:nonFraction><b style="font-weight:bold;"> </b>million was recognized as a component of stock-based compensation expense in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Aspire Capital</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 28, 2020, the Company entered into a common stock purchase agreement (the &#8220;Purchase Agreement&#8221;) with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:MaximumCommonStockCommittedToPurchase" scale="6" id="Narr_pziZOh691Ea3cAmvGyTE8A">30.0</ix:nonFraction> million of shares of the Company&#8217;s common stock over the <ix:nonNumeric contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ" format="ixt-sec:durwordsen" name="mrkr:AgreementTerm" id="Narr_w0jEg9CcUkSbP5PO1VPfQg">30-month</ix:nonNumeric> term of the purchase agreement. In consideration for entering into the purchase agreement, the Company issued to Aspire Capital <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="6" id="Narr_ZsojiUA8ek6tmQIFLn3AOw">0.3</ix:nonFraction> million shares of the Company&#8217;s common stock as a commitment fee. &#160;The Company recorded the commitment fee to additional paid in capital. &#160;As of December 31, 2020, Aspire Capital had purchased <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_XkW-YKfQ_kG8B05tKDo4kw">4.1</ix:nonFraction> million shares under the Purchase Agreement, providing aggregate proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_DuhTVk7JdUK1GsCDzQjYYQ">6.2</ix:nonFraction> million.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_AcAIOY6g7k2wwY1gf1FR3w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">2019 Common Stock Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Consulting Arrangements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_ConsultingArrangementsMember_2YOLfsHrJUiQ-nXn-u702g" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_MniMKlp7FEKr7W8N2CBi0A">0.05</ix:nonFraction> million shares of common stock in connection with consulting agreements. The fair value of the common stock of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_ConsultingArrangementsMember_2YOLfsHrJUiQ-nXn-u702g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_12xl7c0_kUmuHWHFhE3dbQ">0.3</ix:nonFraction> million was recognized as stock-based compensation expense in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Board Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_otSldnsXxkWsBDD0krxySA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="Narr_4dImpRshQEy80dkVeT8Slw">0.03</ix:nonFraction> million shares of common stock to its non-employee directors. The fair value of the common stock of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_LhNNdP3e2Eqw1UGKZWWoVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_-NR8PfEQ006O-WF6xKjnlA">0.2</ix:nonFraction> million was recognized as stock-based compensation expense in general and administrative expenses.</p></ix:continuation><a id="Tc_UqX0JAOpPkmNQiep0xnu0Q_1_7"></a><a id="Tc_mB-R2G1bg0WdQ4PsNUmGPQ_2_2"></a><a id="Tc_6guoGp-9dkOtxIhi5bilNA_2_4"></a><a id="Tc_GNn4bNcDJ0y2WKo03san0w_2_7"></a><a id="Tc_gKpokWvUOkSMjYVtTc7Nqw_2_9"></a><a id="Tc_f5Iamy5zf02-qG8OWueSWw_3_2"></a><a id="Tc_scqBzOj2B06WsgOOkQutOw_3_4"></a><a id="Tc_lMhuxZrukUWWaKWQxJp_AA_3_7"></a><a id="Tc_thugus7Rc0eTI_BtmaKs0A_3_9"></a><a id="Tc_Dk__aW-jYk-AR2pfCr6WaQ_4_0"></a><a id="Tc_xpiaVONeW0-pIeSV0i2gVw_4_9"></a><a id="Tc_8AJykswKIE6Tx_dAy5Z6Ow_5_0"></a><a id="Tc_46ZBtwQRe0a1zB4XgrFc_A_5_7"></a><a id="Tc_b8ufjGzNykeb4r5GR_HncQ_5_10"></a><a id="Tc_MNQfu9EArEKZaz1FA80SYA_6_0"></a><a id="Tc_u11Jq8dBIE2VAMKLvrOMig_6_7"></a><a id="Tc_n9XeqVxHaEKi5uzwOd_vhw_6_10"></a><a id="Tc_d9kbFnh7UEuSEILflGTeOA_7_0"></a><a id="Tc_eGvtYx9d7UW7pF2uAwz15Q_7_7"></a><a id="Tc_rgy9SXekzUCC-iTu0t5OzA_7_10"></a><a id="Tc_-WiUEgipE0yMGkcqrxD0jw_8_0"></a><a id="Tc_cVdwO0j6Q02lqwU2aP-Hfg_8_7"></a><a id="Tc_GBKDNYnnBkuwZz7KIAPWwA_8_10"></a><a id="Tc_UblFTH3WwkS6fN9A6lxsfA_9_0"></a><a id="Tc_86Ilfv9kUEuZj_l4YAl0EA_10_0"></a><a id="Tc_XmzTuZEjdE-Qrp-IXocixw_10_7"></a><a id="Tc_Tb3a7BAdSEeonQMcBVKA1w_10_10"></a><a id="Tc_PXS4ifzI5kS-SsyQb06p1w_11_0"></a><a id="Tc_sBl9VDkJ1U-GwAIfOLIBqg_11_7"></a><a id="Tc_9lW1i8ZsYk-DHGD8TFv2Cw_11_10"></a><a id="Tc_4KxUDvMvcUSHUI_eRYtk2Q_12_0"></a><a id="Tc_9807uwZas0KOOYYnwDk63Q_12_4"></a><a id="Tc_GiUSehi87EKys-nV7PuQ8g_12_9"></a><a id="Tc_B2zbq9S6KE2fl6_ECbfSxg_12_10"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:WarrantsDisclosureTextBlock" id="Tb_GwRbcPrXBE6LgaanF8jhEw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;12:&#160;&#160;&#160;&#160;WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share Purchase Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s share purchase warrants as of December&#160;31, 2020 and 2019, respectively, and changes during the period is presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_e3jl9ISh90CJS6uJdshXmA" name="mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock" id="Tb__k73oPHOhkK2OkqnFfHd2g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_iOxASZMEN0SCelhM434_iw_4_2">23,016,000</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_PzhyZ8zsF02XP3BQ01bsrQ_4_5">4.78</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_5QP_WyrpuE6d2eZgC1tMCA" format="ixt-sec:duryear" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" id="Tc_-8e22u0efUO4wvYMC0N85g_4_7"><b style="font-weight:bold;"> 4.29</b></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw" decimals="0" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightOutstandingIntrinsicValue" scale="0" id="Tc_8fereMMW-kaljE_cI1G72w_4_10">26,066,000</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:NumberOfWarrantsGranted" scale="0" id="Tc_AMCSiKWmb0C_RElE5ico5w_5_2">45,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice" scale="0" id="Tc_3c3572AlB0ynQCHsCDlBnA_5_5">4.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:NumberOfWarrantExercisedForCash" scale="0" id="Tc_kx97DdlcH0uMaNBHDSQgag_6_2">190,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" scale="0" id="Tc_UgTYcjLxtkSSk9TGrw0-Dg_6_5">3.99</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cashless exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:NumberOfWarrantCashlessExercised" scale="0" id="Tc_y9bHCvoRj06-tROkcEs4XA_7_2">17,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised" scale="0" id="Tc_DAeT0qsy2Uqj0ICfOaHzRw_7_5">2.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:NumberOfWarrantExpiredOrCancelled" scale="0" id="Tc_CovtGbNDakWAwGcUO0hIiA_8_2">190,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" scale="0" id="Tc_4U97mILv2kemL4Zo9_GNdg_8_5">13.63</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_wYYDUIttokKNxQk5vJNfQQ_9_2">22,664,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8bNkt6U_8kiH1RN-Jb0uGg_9_5">4.71</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" format="ixt-sec:duryear" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" id="Tc_EvYT6_ropUiBq0XZvS597Q_9_7"><b style="font-weight:bold;">3.33</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightOutstandingIntrinsicValue" scale="0" id="Tc_hgPa_hzMJkaC8SwEizIJrA_9_10">954,000</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:NumberOfWarrantExercisedForCash" scale="0" id="Tc_TbU34GchDUiYIheLfeaNew_10_2">458,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" scale="0" id="Tc_x3OLF-_CTE6zeHRq_rhd9A_10_5">1.20</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:NumberOfWarrantExpiredOrCancelled" scale="0" id="Tc_jC4lsUlPxUqQUTOaqJZR8g_11_2">1,376,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" scale="0" id="Tc_Prbh0pF-dUWFyh-Yus7cUQ_11_5">9.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_yiBGN3gNzE2Cv4IJjJIsiA_12_2">20,830,000</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_InRdRPu-UU2Z58MgqUbbyA_12_5">4.47</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" format="ixt-sec:duryear" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" id="Tc_pl4pjiBIaUe2qMk8NWPnow_12_7"><b style="font-weight:bold;"> 2.60</b></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2020 Warrant Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Exercise of Stock Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, certain outstanding warrants were exercised for <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="6" id="Narr_TWWGeEixo0CWCN9rksCqGw">0.5</ix:nonFraction> million shares of common stock providing aggregate proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="Narr_jD_lVPx6ykO7Wgrt65GN-A">0.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2019 Warrant Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Exercise of Stock Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, certain outstanding warrants were exercised for <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="6" id="Narr_PjuPENYScES6eobBlaH6kg">0.2</ix:nonFraction> million shares of common stock providing aggregate proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="Narr_TVkRHnl0LEeMjLvrHRgaLA">0.8</ix:nonFraction> million.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_716020f1_fc06_4f75_82d9_fc4877315a6b"></a><a id="Tc__tzcTZFFdUerwAeD1byGSA_1_10"></a><a id="Tc_4lCVFCl-l0GWxjhZ-Z3qAQ_2_10"></a><a id="Tc_YwZkJ5if3kuS-vdhbQebGQ_3_4"></a><a id="Tc_8R25DvteKUG6PC4yFlgqRg_3_7"></a><a id="Tc_xmwqGpmi7kmbAcAhNbdqsQ_3_10"></a><a id="Tc_-3phGxnXnk6Dz5fxtCi0QQ_4_2"></a><a id="Tc_YeTAg-Oxn0O_lDC65R3uaQ_4_4"></a><a id="Tc_zIDJgJciFEWL6hur1qNl2g_4_7"></a><a id="Tc_2wVTzgOF80aspwt80_yePw_4_10"></a><a id="Tc_4dMD0qG3vki9sYAHzS2JQg_5_0"></a><a id="Tc_9YgftXgSzkOPrAn-BbiagQ_5_4"></a><a id="Tc_MEd-HzZPQUi3kU2M56xpPw_5_7"></a><a id="Tc_HqIKmGr7rE2vzLSbODfTUA_6_0"></a><a id="Tc_AWHqfstp2E2Q87-miZdOBQ_6_8"></a><a id="Tc_-1eT6fBeOUmnK1Rhv4QpJw_7_0"></a><a id="Tc_jr8aQKTYVEiIZaCfwfj9qA_7_5"></a><a id="Tc_Xp2n_bASZE2hJ0CpqxX80g_7_8"></a><a id="Tc_lMbLoLtd6UGaomYgtT5Eiw_7_10"></a><a id="Tc_Wi2o2aF96k-ObsbVqCXiPA_8_0"></a><a id="Tc_42SjcxRIm06zxEMn7RQBPQ_8_4"></a><a id="Tc_7iVsf_8IcE2f-0Hwq3iP4A_8_7"></a><a id="Tc_HiEyC9BML0WMxWKDH5x_mg_8_8"></a><a id="Tc_nKkRJNWh2E2LgbF_PLEVDQ_9_0"></a><a id="Tc_LmDCPvAQS0O8zEYqAegquQ_9_4"></a><a id="Tc_o26p_7lqh0yfAA_jbeOFMQ_9_7"></a><a id="Tc_lgfhyc81Ik6NRZklplqVmA_9_8"></a><a id="_15bf4721_92c9_4a19_9c4a_1f7d9780974f"></a><a id="Tc_28stm5LGTUGWRZBVE5jGBA_1_2"></a><a id="Tc_KmaXedILDEOR9UyPuhnJag_2_2"></a><a id="Tc_SK2kBF34S0-NWQBXgekULA_3_2"></a><a id="Tc_wrDcC1jnWkev94rG2JV3tA_3_5"></a><a id="Tc_1k_QjuZumUC3GhkyqjzrFA_4_0"></a><a id="Tc_GtvJB-W4PkiW7BDWO6nZqA_4_2"></a><a id="Tc_Bw1pFpGkqUmtRMDHL2ojPA_4_5"></a><a id="Tc_1VYwJm2MnE21Ue3Xth9_fQ_5_0"></a><a id="Tc_tZ03lJwdbk6UEV8Z9WzvhQ_6_0"></a><a id="Tc_r3WSwYIKr0CmuwGGomkPbA_6_4"></a><a id="Tc_dVFm_8CYakuOQTEa24wnIQ_6_7"></a><a id="Tc_DvmgqUaXJES_XpnEtptfGg_7_0"></a><a id="Tc_WCc76mtvwU2ZIiXat2VRKQ_7_4"></a><a id="Tc_iw6-19a7-UaWq9_Hay5QjQ_7_7"></a><a id="Tc_d-PJg02FJEakLkohj0o7gA_8_0"></a><a id="Tc_EwVAnkPsUk-X0FhOvsMlLQ_8_4"></a><a id="Tc_d0Sh4q-1gUe6wHwP5WR44g_8_7"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_-uZYsIslYkG4CsLNKbTH6A" continuedAt="Tb_-uZYsIslYkG4CsLNKbTH6A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;13:&#160;&#160;&#160;&#160;STOCK OPTION PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Options to Purchase Shares of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">2020 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May&#160;19, 2020, the Board adopted the 2020 Equity Incentive Plan (&quot;2020 Plan&quot;) which replaced the 2014 Omnibus Stock Option Plan (&#8220;2014 Plan&#8221;). The 2020 Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Plan may be at prices and for terms as determined by the Board of Directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#8217;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules&#160;and regulations of the New York Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Options granted under the 2020 Plan have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_mGgOht7j1kClyGZAl_vbQw">ten years</ix:nonNumeric> from the date of grant. Options granted in 2020 and 2019 generally vest over <ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_bcCzmPs2CkCTQUiZtifYjg"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_TeBClg-42E2xw3vW27HiwA">four years</ix:nonNumeric></ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, approximately <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued" scale="6" id="Narr_ZeW1i3Aci0qOtE4sUsyrXg">4.7</ix:nonFraction> million options are available to be issued from the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">2014 Omnibus Stock Ownership Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2014 Plan, which the Board adopted on May 19, 2020 and subsequently amended from time to time, allowed for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. The terms of the 2014 plan are substantially identical to the terms of the 2020 Plan described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg" name="us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" id="Tb_PUokIuS9s0-iIE1Rvyu-Hw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s stock option activity is as follows for stock options:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ew5YbkX_jUCVRq2JAJsmBA_5_2">4,983,314</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_fPHlsCWmZUWSyUPbotgU4g_5_5">7.79</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_LkQ4cHQLDEGFZAuHVnCrlA_5_8">18,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qZ9NHzo7YUC9v4IRoJS31Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_M0MStYgEHkWjWDU5im3AvQ_5_10"> 8.9</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_urNr4Sf3MUWFcL5WNvQ-8g_6_2">1,531,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_DEyG_-HAw0SVtkyJshBXeA_6_5">2.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg" format="ixt-sec:duryear" name="mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" id="Tc_VwVRu_SxE0-3dWINA2E3rQ_6_10"> 9.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_gBYbXm2JG0amSExNHq3Z7A_7_2">512,500</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_wMrhCJkkaUaQXNF6sGITkQ_8_2">6,001,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_titK_JUm2Eiu06PovGLXeQ_8_5">6.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_k4vC3VXl20aRMKpjgSGH9g_8_10"> 8.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_JkpQ1sLT_0G4SizelvEgUQ_9_2">2,598,981</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_vMLEKXgw50iasXB2QfsqGw_9_5">7.29</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_9uS6G2wydUu8iwJw9W1loA_9_10"> 8.0</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_aaGc9gKOl0y7WW64DylDww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the&#160;years ended December&#160;31, 2020 and 2019, respectively, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_flCW-ZCtoUiUq23EHzokag_4_3">2.08</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_9c-9kTlgg0GF_ZnZN1iIxg_4_6">4.70</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_I6NoWzfXPky90cCntRTDmw_5_3"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_qPULqtWu_UujcMaPWCzIuA_5_6"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ktHLQZARukGJVyVz_RRYAA_6_3">108</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_vrYS8QYYPkSCqulwc8RrhA_6_6">126</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_EOJ0ndhnakOkVIGK530tYg_7_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_wDl7BNGBnUGAT9uQn8NdSg_7_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_cCSGstrhkU-Q4auFsyvZwQ_8_3">0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_VFZ2MMDGmk-K5s8A6SbpUw_8_6">0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_31925e33_82f7_45c4_ab3a_177ef81d48c0"></a><a id="Tc_TGNEpqAU_UiexU_jlx2e2w_1_2"></a><a id="Tc_1770EHJLk02Y8mufcTCuEw_2_2"></a><a id="Tc_OtrzDj44IUGgPGBsGiVqbA_3_2"></a><a id="Tc_7gjTN8C51kmntRAjfryD3Q_3_5"></a><a id="Tc__oKLXQpPK0yIvEZhhK8c_Q_4_0"></a><a id="Tc_28dHk-yDtkyjatjwRBv_zg_5_0"></a><a id="Tc_A8DC0Fwwak-41SHs5D44FQ_5_2"></a><a id="Tc_9aoMtUkNBkuaUwGJIV-gEA_5_5"></a><a id="Tc_KKolTrD10E60ub32lB-BQw_6_0"></a><a id="Tc_K_QfQL-gCEai4651uFnaaw_7_0"></a><a id="Tc_TGIbTZ3gPEKngW6kKR6qAw_7_2"></a><a id="Tc_xR35Sm95dkact63EZLgp0g_7_5"></a><ix:continuation id="Tb_-uZYsIslYkG4CsLNKbTH6A_cont1"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:StockBasedCompensationExpensesTableTextBlock" id="Tb_XnET9VkGNU-8XAReILEtYw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wi8B3dNGskeO0KIAZp0PNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_J2N03tbx1UGdB5qnlx7H2A_5_3">2,588,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_pXkrJdElCEK5luXf8RD1jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_WJIB2-kh9k2ij6VNUwZgDQ_5_6">2,574,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nia-K5yaQkK6PrPyNBtXQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_kENX8aWoAE6gD4kwUXfuBA_6_3">2,640,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Z1owGgssVkun98tvJFc-ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_OGLXJISBt0-Et1W3gJINYw_6_6">2,783,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_elpZ6S5NJ0CQRG5ttNZ34g_7_3">5,228,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_IRlRbSvQMUKZ7k9an7khbg_7_6">5,357,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At December&#160;31, 2020, the total stock-based compensation cost related to unvested awards not yet recognized was $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_wYpguwVqsE6ryC4fHMkfsQ">10.6</ix:nonFraction> million. The expected weighted average period compensation costs to be recognized was <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_RwPe2Jr0N0iXbm62Y_-lRA">2.2</ix:nonNumeric>&#160;years. Future option grants will impact the compensation expense recognized.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:GrantIncomeTextBlock" id="Tb_kaOWEn2a5UWWGrG4t3gjTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;14:&#160;&#160;&#160;&#160;GRANT INCOME</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the&#160;years ended December&#160;31, 2020 and 2019, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_RcUisMl_I02V-BgJEBZ0cg">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_9avLlBSBUUySQlQLxHDlQg">0.2</ix:nonFraction> million, respectively, of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study. In accordance with Accounting Standards Update No.&#160;2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; issued by the Financial Accounting Standards Board, the Company recorded the $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_9yHzLxI9J0KiGOFm8vPRig" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_RsAe21I7TUOqq54o-cMgXQ">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_cQNwlMiI7kK08D7_DtU4Cw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_Sc_3nwjzdEetVPe0OdBecQ">0.2</ix:nonFraction> million, respectively, of grant income as revenue.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_sTqt-mB2RkeEQjjyspfeEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;15:&#160;&#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An arbitration proceeding was brought against the Company before the Financial Industry Regulatory Authority, Inc. by a broker seeking to be paid approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="Narr_o76GRGlW3E-AbShFslO5eQ">1.0</ix:nonFraction> million as compensation for <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt-sec:numwordsen" name="mrkr:LossContingencyDamagesSoughtNumberOfTransactions" scale="0" id="Narr_2t0vP7DnoEaof1qkilzyuQ">two</ix:nonFraction> financing transactions that occurred in 2018, a warrant conversion and a private placement brokered by another broker. The broker&#8217;s claims are based on a placement agent agreement for a private placement it brokered in 2017, under which it alleges it is entitled to compensation for the 2018 transactions. The Company believes it has defenses to all of the allegations and intends to vigorously defend itself in this matter.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="Tb_KtudkS3WHEaHdKTQD6BO2g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;16:&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#8217;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#8217;s interest.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4244cdad_f2d1_45ef_8a0b_cb72d6147e9a"></a><a id="Tc_J0HhAtE57EOIWBu04BOH_w_1_2"></a><a id="Tc_ztm3zj7k2EahaaLihoN1dQ_2_2"></a><a id="Tc_XRVBPORTGkSNEqJwY6c2NQ_3_2"></a><a id="Tc_aVu7VpHvOEC2WmIo-jjl5g_3_5"></a><a id="Tc_rdRiWw6WiEWZmyURx4yL6Q_4_0"></a><a id="Tc_ytYCn-BQ2E2AujKfoERkUQ_4_2"></a><a id="Tc_uf0D0YSQSkqso133n6cuWg_4_5"></a><a id="Tc_-U2LZf_WHECe4cAMfE178A_5_0"></a><a id="Tc_olthXy65akS-dUO6pwfSDg_6_0"></a><a id="Tc_jOKVWdK1uEStPDWqNJCcsQ_6_2"></a><a id="Tc_zZdvcgzLEUitBvV1RsTFdg_6_3"></a><a id="Tc_OMdSkhz0-UaaRzvX8QL8yA_6_5"></a><a id="Tc_0Z8ivbu1wU6Or2TKcR99tQ_7_0"></a><a id="Tc_HGyum8uxhkqTEFF9DlwWsQ_7_2"></a><a id="Tc_vtBZF9jWU0Cri2Ht5FMuXQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_FaWlPnJuRk2rT-Io3PzKow" continuedAt="Tb_FaWlPnJuRk2rT-Io3PzKow_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;17:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_ax8NzrOrqEylyUy9-4AFDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth related party transaction expenses recorded for the years ended December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baylor College of Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_MrqVXYEw1Uid9u_ZLvUPNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_G3Oq1xu6UEOwktdt7WIjLg_4_3">1,818,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_vsg7AnMxjECUv2UMBZE8Og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_MzFVccKKy0-Qqm6B6MIyWg_4_6">69,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bio-Techne Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_mJazqkPfFkmc-QMBbBM7hA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_th9QB0C05ked1AZ74HE5OA_5_3">152,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_2YaAsQK__kGBYij0npbG_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_PyuCvoThMEqn0HSwPuR0zQ_5_6">51,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dr Juan Vera</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ConsultingAgreementWithDr.JuanVeraMember_eeZVsRCRzUeJu-ihCRWw2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_d1iSOMjCYUmBi45d_DQ4vQ_6_6">233,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_21drmnkmUUu6BLIOlL0lIQ_7_3">1,970,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_GjgIgxDU4UGaapSX5SAnVQ_7_6">353,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Agreements with The Baylor College of Medicine (&#8220;BCM&#8221;)</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160; 2018 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FaWlPnJuRk2rT-Io3PzKow_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, the Company entered in a Clinical Supply Agreement with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Purchases from Bio-Techne Corporation</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is currently utilizing Bio-Techne Corporation and two of its brands for the purchases of reagents, primarily cytokines. Mr. David Eansor is a member of the Company&#39;s board of directors and is serving as the President of the Protein Sciences Segment of Bio-Techne Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Consulting Agreement with Dr.&#160;Juan Vera</i><i style="font-style:italic;">.</i> On October&#160;19, 2018, after the closing of the Company&#8217;s merger, the Company entered into a consulting agreement with Dr.&#160;Juan Vera, a member of the Company&#8217;s board of directors, to serve as the Company&#8217;s Chief Development Officer. On September 1, 2019, Dr. Vera became an employee of the Company and his consulting agreement was terminated.</p></ix:continuation><a id="Tc_otwPy4hu7kq8Mafb1ReULA_1_2"></a><a id="Tc_wk_vCGX79EqHjKsFNYL2uQ_2_2"></a><a id="Tc_GpSgf2ZbF0S0fjs5CobT8Q_3_2"></a><a id="Tc_PLnnpfQ3AEy6Q2lRxq-cPg_3_4"></a><a id="Tc_Fv5Dvn_FWk2Cy3GifCDYzA_4_0"></a><a id="Tc_3JFCfabtUU-_KoiSmuzzNA_5_0"></a><a id="Tc_ggBUPAfDXUmp-hyaCFs5QA_6_0"></a><a id="Tc_4SvPGnkaN0mLrX_R5Tzxdg_7_0"></a><a id="Tc_VJuWjXv-LE6PW6BgiDpgJQ_8_0"></a><a id="Tc_8SgFVz63VEanUOtEAYZ1BA_9_0"></a><a id="Tc_lGF0PhOT0UC8m35siuUHwg_10_0"></a><a id="Tc_petvlgPBBkq0W9qTWxKCXg_12_0"></a><a id="Tc_2-cZBieFWk-tgB7nbRbVlg_13_0"></a><a id="Tc_u7OZEB6rx0aO7Jqv9g9dDg_15_0"></a><a id="Tc_m7ca_Vpls02cu_XoWXO7Mw_16_0"></a><a id="Tc_3U3VNtskJkOLwS3HgixbKQ_16_2"></a><a id="Tc_kJIxuhVndkmvZrCzqWy2cw_17_0"></a><a id="Tc_f_G4G1PxlUWaZ4n659OShA_17_4"></a><a id="Tc_i-4dmY2vMUSE_5pPIA2Z4w_19_0"></a><a id="Tc_E3ArCkStbUiKzInoWGGU7g_21_0"></a><a id="Tc_gipP7oYq8kGIwzcc_2WD1w_21_2"></a><a id="Tc_xxeHluklak--a4N1FMvEsQ_21_4"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_39mllzXd0EiY_DDXHdN2JA" continuedAt="Tb_39mllzXd0EiY_DDXHdN2JA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;18:&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has no income tax expense due to operating losses incurred for the&#160;years ended December&#160;31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December&#160;31, 2020 and 2019 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_4b3lOtXySUKKHjYrKPdIyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_MfhFr-Q4h0St8e66apMzDQ_5_2">21,783,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_AgCHBFXf8kWbnnDoWlwTZg_5_4">17,166,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="mrkr:Deferredtaxstockbasedcompensation" scale="0" id="Tc_8ZtSAx2odUGmwqtn6clWuA_6_2">6,775,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="mrkr:Deferredtaxstockbasedcompensation" scale="0" id="Tc_Zy6ISmkhOEaI1cnMiJzdTw_6_4">6,538,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">License Agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="mrkr:Deferredtaxassetslicenseagreement" scale="0" id="Tc_x_5utFvUxECrHxMhy_rlLg_7_2">144,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="mrkr:Deferredtaxassetslicenseagreement" scale="0" id="Tc_y-z4xAETxk6DxG0loEN_QA_7_4">177,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_Qwq9KHjIyUSgmyLvdyjvyQ_8_2">733,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_Z-SYuUybh02okxoh4hQ-5g_8_4">733,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Charitable Contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="0" id="Tc_wSKTWsqx4kObLeP4MdJZMw_9_2">8,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="0" id="Tc_caMr_-SA-06574m3mDIfvg_9_4">9,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating Lease Liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxAssetsOperatingLeaseLiability" scale="0" id="Tc_x50-F9ye1kyhEuoOoGa0Uw_10_2">2,626,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxAssetsOperatingLeaseLiability" scale="0" id="Tc_98Kx7p0jGUeM6QnbJNuvQQ_10_4">115,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_c5DcZs-cDkiyN4GrAnk-jQ_11_2">32,069,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_lVW73f9c3EGutXt1sOjGOQ_11_4">24,738,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_IwRBh0B1R0ivC5j7eA2J-A_12_2">29,689,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_pe36x3H3H0qjQRYHqzF4OA_12_4">24,632,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_ttayjP63rUOCa5i3kWPZAQ_13_2">2,380,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_-R96YOAU5ESPeS5ivzfBoQ_13_4">106,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed Assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxLiabilitiesFixedAssets" scale="0" id="Tc_f6fZjRVU6ECN6ucfuYzN8g_16_4">106,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-Use Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxLiabilitiesRightOfUseAssets" scale="0" id="Tc_2aQE_S90DkCWFqNJzk2jBQ_17_2">2,380,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_CCVgPfeXTUyt6XAJJf2KGQ_19_2">2,380,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_UhLpxqZwxE67prnGgyqvuQ_19_4">106,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_6EDnzGLwKka5V1Mc4KxGww_1_2"></a><a id="Tc_cLS1Z1hdpEmT2PM3bEuRuw_2_2"></a><a id="Tc_oUAfQyXes0KNumzsT5n9TQ_2_6"></a><a id="Tc_dz_otSNdMEOFsECgSDZELA_3_4"></a><a id="Tc_R5PSbVTbjkqubJ6abNV1UA_3_8"></a><a id="Tc_jjX20f_jXkKbjue5jqf0aQ_4_2"></a><a id="Tc_9jci-9kHiECT4depxodjUQ_4_4"></a><a id="Tc_XPiKER1fn0euPnfh3P1blw_4_6"></a><a id="Tc_yjwfPnHC4Eub0cdLRc5FwA_4_8"></a><a id="Tc_6sslB9VH_0ymMlnTaGzquQ_5_0"></a><a id="Tc_MniDlAGM_EWTZmkhWyfo4w_5_5"></a><a id="Tc_KSwhZ5tw3U-JWnXJyQU2Jg_5_9"></a><a id="Tc_kyGyw63DBk6QiYOSQfW2mA_6_0"></a><a id="Tc_3wKiFlKyXUuPjMs_6eLcXQ_6_5"></a><a id="Tc_5vh_LFvXKEimjw-Wr2nD8Q_6_9"></a><a id="Tc_5dH9ll49v0euMzOJvbRrTA_7_0"></a><a id="Tc_P9JgK1M9-EeSccnfsnF9uw_7_5"></a><a id="Tc_6whLaG8jNUW7oGfUwDd_tg_7_9"></a><a id="Tc_JiPfgzAUkkm74eS4qRBhtg_8_0"></a><a id="Tc_NY-ooJ_DPkaNhIi_eRcp8Q_9_0"></a><a id="Tc_aH9yrZiONUeAZeZMIdY9pg_9_5"></a><a id="Tc_s08dwkkrIECfpGOgmvSflQ_9_9"></a><a id="Tc_0mrl7us9O0qA9XqsK_9pPw_10_0"></a><a id="Tc_N5DhPzG0_E6NA1nGkBlxWA_10_5"></a><a id="Tc__m64JF4lSUeI1uAdLJW-RA_10_9"></a><a id="Tc_m9iYrbMLVEWAvLkFfgXFhA_11_0"></a><a id="Tc_c04lkAzCYESBZya5hlITtg_11_5"></a><a id="Tc_Co5Hyq3nt0-JA4tXHKosrg_11_9"></a><a id="Tc_yIX0avJanE2WZHxHEREdAA_12_0"></a><a id="Tc_7MmkNh975keC1NHkCgSXYg_12_5"></a><a id="Tc_pk0lZC8jF0-WBw5Sj7c4gw_12_9"></a><a id="Tc_TKIs73XpiUah1luAvBHnhg_13_0"></a><a id="Tc_BPYJCEE9EEypQS-xlMUfsg_13_2"></a><a id="Tc_yZJCisVpKEOCKOgRUaMbQQ_13_5"></a><a id="Tc_Vg1XeNrmskCtJ5C5QGpipw_13_6"></a><a id="Tc_4oarglmoPUiNP4dkmmk1Fg_13_9"></a><ix:continuation id="Tb_39mllzXd0EiY_DDXHdN2JA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the&#160;years ended December&#160;31, 2020 and 2019. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="-5" format="ixt:numdotdecimal" name="mrkr:DecreasedDeferredTaxAssets" scale="6" id="Narr_9uhoOT9HF0mk8OAJHctd3Q">5.1</ix:nonFraction> million as of December&#160;31, 2020. The Company has research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="Narr_hwaJIl9W_06dMmkawQkeOA">0.7</ix:nonFraction> million available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr_Ko2XuH5mNUy2lAwA-C_qHg">97.2</ix:nonFraction> million of federal and $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_f-1h1bj240uy7oRLJpGyFQ">39.0</ix:nonFraction> million of state Net Operating Losses (&#8220;NOL&#8221;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr_n5VtgECcLkWN2Ch_jo_sKg">41.6</ix:nonFraction> million, if not utilized, will expire between <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:Taxcreditcarryforwardexpirationyearrangestart" id="Narr_vtO96NYlAkaP5tpA0VZ8Tw">2029</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:Taxcreditcarryforwardexpirationyearrangeend" id="Narr_W491ulF250-mW71WDjZ43w">2037</ix:nonNumeric>. The federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_y0AGgi3VjEide44SDAm8EA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_a5KbL7KOiEOJrWfB92FOMA">55.6</ix:nonFraction> million generated in 2018 and thereafter are subject to an <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="mrkr:OperatingLossCarryforwardsLimitationPercentage" scale="-2" id="Narr_m3opfQk0iEKmDGP-KiSHLQ">80</ix:nonFraction>% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_0drBtrFr20eAhx0_kKaR-A">21.9</ix:nonFraction> million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_vLnol8OkUk2BmiKlJVI3qg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_Nf27gisMSEqKUlgy8gLZKw">17.1</ix:nonFraction> million generated in 2018 and thereafter are subject to an <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="2" format="ixt:numdotdecimal" name="mrkr:OperatingLossCarryforwardsLimitationPercentage" scale="-2" id="Narr_k-OlotiCxUaKF25hifjkxQ">80</ix:nonFraction>% limitation on taxable income, do not expire and will carry forward indefinitely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#8217;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s income tax returns for 2016 to 2019 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;years ended December&#160;31, 2020 and 2019, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" name="mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" id="Tb_jYHIvCZ9-kWwlHjdSSCoSQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre-Tax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre-Tax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_inTBx0Up_0usbjFAKTa8gg_5_2">6,028,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_quZv1tFES0GV58aWqY2HZw_5_4">21.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_wWkK4mjpkU6JYuXazNXMnQ_5_6">4,500,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_dVgQD-sCPEynKZdgFkOrFA_5_8">21.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="0" id="Tc_B6CASvsxxk6WuT2wikDIBg_6_2">118,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_-rIODiGDDUaEIErFOXffUA_6_4">0.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="0" id="Tc_HSdB6Z3eu0uOJLIuJr2pJQ_6_6">600,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_P2n22qfqGkGkYTHogkEucw_6_8">2.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax rate change</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="Tc_hyL2j8OJG0eXedxX-aVglg_7_2">677,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_nxhteO8iaE-l87sX1fSUJw_7_4">2.36</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="Tc_6pwQeDMvmU6Iv_VSQy7agg_7_6">665,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_MjKyRFUS40-099aTDXuFVg_7_8">3.10</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent Differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Change in fair value of derivative liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:Incometaxreconciliationchangeinfairvalueofderivativeliability" sign="-" scale="0" id="Tc_K7UDD-U1n0eNf0wpGrq9uA_9_2">7,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="4" format="ixt:numdotdecimal" name="mrkr:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" scale="-2" id="Tc_dOhNhtA4S0ywrPdKJ0DGXg_9_4">0.02</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:Incometaxreconciliationchangeinfairvalueofderivativeliability" sign="-" scale="0" id="Tc_QL2VNCXr8U6FxYz7UfEFkg_9_6">4,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="4" format="ixt:numdotdecimal" name="mrkr:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" scale="-2" id="Tc_4MpYOh83rUioLb2zmwBWCw_9_8">0.02</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:Permanentdifferencesotherpermanentdifferences" sign="-" scale="0" id="Tc_DHfCdsdO5USCeNOUm2pBQg_10_2">182,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="4" format="ixt:numdotdecimal" name="mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" sign="-" scale="-2" id="Tc_hjFMvoRPCUmXcCTg-0POHw_10_4">0.63</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:Permanentdifferencesotherpermanentdifferences" sign="-" scale="0" id="Tc_e81AValCT0qDyIhImnR3VA_10_6">32,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="4" format="ixt:numdotdecimal" name="mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" sign="-" scale="-2" id="Tc_8_h2duooZkK7oWDEYZh3rg_10_8">0.15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="0" id="Tc_fJl--T6iaEqrVMDoaKDXUA_11_2">5,057,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_nUqLPAMEQEqjo2fDvayUOw_11_4">17.62</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="0" id="Tc_RDHsJtLuSEy4485ZjEW-kA_11_6">4,681,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_GFPcw3Nah0SJdhTZ32kK3Q_11_8">21.85</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" id="Tc_lp4q_b9bDUaLvYpV-OWbbw_12_2">237,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_FUi6o8NxPEuR89zydb002Q_12_4">0.83</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" sign="-" scale="0" id="Tc_aZJMUcKEpEOi-YXnqW2dew_12_6">274,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_2el_UtbZAUytdfGNqawCgw_12_8">1.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_RxfzjEEBK0-cOzdR05k27Q_13_4">0.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw" contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_Q79j6gjrAUW0GONwtFyjxg_13_8">0.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December&#160;31, 2020, and 2019, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December&#160;31, 2020 and 2019. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 27, 2020, the CARES Act was enabled in response to COVID-19 pandemic. Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. The CARES Act made various tax law changes including among other things (i) increasing the limitation under Section 163(j) of the Internal Revenue Code of 1986, as amended (the &#8220;IRC&#8221;) for 2019 and 2020 to permit additional expensing of interest, (ii) enacting a technical correction so that qualified improvement property can be immediately expensed under IRC Section 168(k),(iii) making modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019 and 2020 to be carried back to the five preceding taxable years in order to generate a refund of previously paid income taxes and (iv) enhancing the recoverability of alternative minimum tax credits. Given the Company&#8217;s full valuation allowance position, the CARES Act did not have an impact on the financial statements.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>mrkr-20201231xex21d1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/9/2021 09:14:06 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SUBSIDIARIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marker Cell Therapy, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GeneMax Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GeneMax Pharmaceuticals Canada, Inc.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>mrkr-20201231xex23d1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/9/2021 09:14:10 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#8217;S CONSENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We consent to the incorporation by reference in the Registration Statement of Marker Therapeutics, Inc., on Form S-3 File No. 333-215258, No. 333-220538, No. 333-228059 and No. 333-232122 and on Form S-8 File No. 333-223900, No. 333-228056 and 333-239136 of our report dated March 9, 2021, which includes an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Marker Therapeutics, Inc. as of December 31, 2020 and 2019 and for each of the two years in the period ended December 31, 2020, which report is included in this Annual Report on Form 10-K of Marker Therapeutics, Inc. for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Marcum LLP</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marcum LLP</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>mrkr-20201231xex31d1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/9/2021 09:14:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Peter L. Hoang, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1.</font></font>I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a.</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">b.</font></font>Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">c.</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">d.</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a.</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">b.</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Peter L. Hoang</i></p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Peter L Hoang</b></p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>mrkr-20201231xex31d2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/9/2021 09:14:16 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Anthony Kim, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1.</font></font>I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a.</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">b.</font></font>Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">c.</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">d.</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a.</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">b.</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">/s/ Anthony Kim</i></p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Anthony Kim</b></p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>mrkr-20201231xex32d1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/9/2021 09:14:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">18 U.S.C. Section 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Peter L. Hoang, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><i style="font-style:italic;">/s/ Peter L. Hoang</i></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Peter L. Hoang</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>mrkr-20201231xex32d2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/9/2021 09:14:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">18 U.S.C. Section 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Anthony Kim, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9</p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;">March 9, 2021</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><i style="font-style:italic;">/s/ Anthony Kim</i></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Anthony Kim</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mrkr-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2021 9:14:48 PM-->
<!--Modified on: 3/9/2021 9:14:48 PM-->
<schema xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:mrkr="http://www.tapimmune.com/20201231" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.tapimmune.com/20201231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" id="DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails">
        <link:definition>40701 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" id="DisclosureLeasesMaturitiesOfOperatingLeasesDetails">
        <link:definition>40702 - Disclosure - LEASES - Maturities of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" id="DisclosureAccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails">
        <link:definition>41801 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails">
        <link:definition>41802 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit" id="StatementConsolidatedStatementOfStockholdersEquityDeficit">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables" id="DisclosureWarrantLiabilityTables">
        <link:definition>30901 - Disclosure - WARRANT LIABILITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>31201 - Disclosure - WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansTables" id="DisclosureStockOptionPlansTables">
        <link:definition>31301 - Disclosure - STOCK OPTION PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>31701 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails" id="DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails">
        <link:definition>40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails">
        <link:definition>40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>40703 - Disclosure - LEASES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails" id="DisclosureWarrantLiabilityValuationMethodologyDetails">
        <link:definition>40901 - Disclosure - WARRANT LIABILITY - Valuation Methodology (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails" id="DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails">
        <link:definition>40902 - Disclosure - WARRANT LIABILITY - Changes in Level 3 Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>41001 - Disclosure - FAIR VALUE MEASUREMENTS - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>41101 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails" id="DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails">
        <link:definition>41201 - Disclosure - WARRANTS - Summary of Share Purchase Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails" id="DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>41202 - Disclosure - WARRANTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" id="DisclosureStockOptionPlansStockOptionActivityDetails">
        <link:definition>41301 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails" id="DisclosureStockOptionPlansWeightedAverageAssumptionsDetails">
        <link:definition>41302 - Disclosure - STOCK OPTION PLANS - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" id="DisclosureStockOptionPlansStockBasedCompensationExpensesDetails">
        <link:definition>41303 - Disclosure - STOCK OPTION PLANS- Stock-based compensation expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails" id="DisclosureStockOptionPlansAdditionalInformationDetails">
        <link:definition>41304 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails" id="DisclosureGrantIncomeAdditionalInformationDetails">
        <link:definition>41401 - Disclosure - GRANT INCOME - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41701 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>41803 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" id="DisclosureFinancialConditionGoingConcernAndManagementPlans">
        <link:definition>10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" id="DisclosureNetLossPerShareApplicableToCommonShareholders">
        <link:definition>10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivable" id="DisclosureOtherReceivable">
        <link:definition>10501 - Disclosure - OTHER RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10601 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10701 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities" id="DisclosureAccountsPayableAndAccruedLiabilities">
        <link:definition>10801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiability" id="DisclosureWarrantLiability">
        <link:definition>10901 - Disclosure - WARRANT LIABILITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>11001 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11101 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>11201 - Disclosure - WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlans" id="DisclosureStockOptionPlans">
        <link:definition>11301 - Disclosure - STOCK OPTION PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncome" id="DisclosureGrantIncome">
        <link:definition>11401 - Disclosure - GRANT INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11501 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedings" id="DisclosureLegalProceedings">
        <link:definition>11601 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11701 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11801 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" id="DisclosureNetLossPerShareApplicableToCommonShareholdersTables">
        <link:definition>30401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30601 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30701 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" id="DisclosureAccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>30801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>31001 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31801 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" id="DisclosureFinancialConditionGoingConcernAndManagementPlansDetails">
        <link:definition>40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" id="DisclosureOtherReceivableDetails">
        <link:definition>40501 - Disclosure - OTHER RECEIVABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <element id="mrkr_ExerciseOfWarrantsAmount" name="ExerciseOfWarrantsAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="mrkr_ExerciseOfWarrantsShare" name="ExerciseOfWarrantsShare" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="AmortizationOfOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="RelatedPartyDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_RelatedPartyDisclosureAbstract" substitutionGroup="xbrli:item" />
  <element name="NetLossPerShareTableTextBlockTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_NetLossPerShareTableTextBlockTableTextBlock" substitutionGroup="xbrli:item" />
  <element name="ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" substitutionGroup="xbrli:item" />
  <element id="mrkr_ValuationMethodology" name="ValuationMethodology" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock" name="FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_StockBasedCompensationExpensesTableTextBlock" name="StockBasedCompensationExpensesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="CommonStockWarrantsEquityTreatment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_CommonStockWarrantsEquityTreatment" substitutionGroup="xbrli:item" />
  <element name="CommonStockWarrantsLiabilityTreatmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_CommonStockWarrantsLiabilityTreatmentMember" substitutionGroup="xbrli:item" />
  <element name="OperatingLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_OperatingLeaseExpenseAbstract" substitutionGroup="xbrli:item" />
  <element id="mrkr_OtherLeaseInformationAbstract" name="OtherLeaseInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="AccruedTechnologyLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="mrkr_AccruedTechnologyLicenseFees" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="SharePurchaseWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_SharePurchaseWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="FairValuesAssumptionsExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="mrkr_FairValuesAssumptionsExercisePrice" substitutionGroup="xbrli:item" />
  <element name="FairValuesAssumptionsExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_FairValuesAssumptionsExpectedTerm" substitutionGroup="xbrli:item" />
  <element name="FairValuesAssumptionsExpectedVolatilityRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_FairValuesAssumptionsExpectedVolatilityRate" substitutionGroup="xbrli:item" />
  <element name="FairValuesAssumptionsRiskFreeInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_FairValuesAssumptionsRiskFreeInterestRate" substitutionGroup="xbrli:item" />
  <element name="FairValuesAssumptionsExpectedDividendRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_FairValuesAssumptionsExpectedDividendRate" substitutionGroup="xbrli:item" />
  <element id="mrkr_NumberOfWarrantExercisedForCash" name="NumberOfWarrantExercisedForCash" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_NumberOfWarrantExpiredOrCancelled" name="NumberOfWarrantExpiredOrCancelled" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
  <element name="ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" substitutionGroup="xbrli:item" />
  <element name="ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
  <element name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" substitutionGroup="xbrli:item" />
  <element id="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue" name="ClassOfWarrantOrRightOutstandingIntrinsicValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="CommonStockCapitalSharesReservedForFutureIssuanceTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="ExerciseOfStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_ExerciseOfStockWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="CommonStockCapitalSharesReservedForFutureIssuanceLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" substitutionGroup="xbrli:item" />
  <element id="mrkr_FairValueTransfersAmount" name="FairValueTransfersAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="mrkr_WarrantOfCashLessExercised" name="WarrantOfCashLessExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="mrkr_WarrantOfCashLessExercisedSharesIssued" name="WarrantOfCashLessExercisedSharesIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_BoardCompensationMember" name="BoardCompensationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="mrkr_NonCashExerciseOfWarrantsAmount" name="NonCashExerciseOfWarrantsAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="mrkr_LossContingencyDamagesSoughtNumberOfTransactions" name="LossContingencyDamagesSoughtNumberOfTransactions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_WarrantLiabilityAbstract" name="WarrantLiabilityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_WarrantLiabilityTextBlock" name="WarrantLiabilityTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_WarrantsDisclosureAbstract" name="WarrantsDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_GrantIncomeAbstract" name="GrantIncomeAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_GrantIncomeTextBlock" name="GrantIncomeTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" name="SharePurchaseWarrantsTableTextBlockTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_NumberOfWarrantCashlessExercised" name="NumberOfWarrantCashlessExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised" name="ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_Deferredtaxstockbasedcompensation" name="Deferredtaxstockbasedcompensation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="mrkr_Deferredtaxassetslicenseagreement" name="Deferredtaxassetslicenseagreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability" name="Incometaxreconciliationchangeinfairvalueofderivativeliability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="mrkr_Permanentdifferencesotherpermanentdifferences" name="Permanentdifferencesotherpermanentdifferences" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_IncomeTaxLineItems" name="IncomeTaxLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_Taxcreditcarryforwardexpirationyearrangestart" name="Taxcreditcarryforwardexpirationyearrangestart" nillable="true" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_Taxcreditcarryforwardexpirationyearrangeend" name="Taxcreditcarryforwardexpirationyearrangeend" nillable="true" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_OperatingLossCarryforwardsLimitationPercentage" name="OperatingLossCarryforwardsLimitationPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_DecreasedDeferredTaxAssets" name="DecreasedDeferredTaxAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="mrkr_ConsultingArrangementsMember" name="ConsultingArrangementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_NumberOfWarrantsGranted" name="NumberOfWarrantsGranted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice" name="ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="mrkr_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="mrkr_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="mrkr_ConsultingAgreementWithDr.JuanVeraMember" name="ConsultingAgreementWithDr.JuanVeraMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" name="IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" name="IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" name="NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="mrkr_FixedLeaseRentPayment" name="FixedLeaseRentPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="mrkr_NumberOfRenewalOptions" name="NumberOfRenewalOptions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_AspireCapitalMember" name="AspireCapitalMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_AgreementTerm" name="AgreementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_MaximumCommonStockCommittedToPurchase" name="MaximumCommonStockCommittedToPurchase" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_PurchasesFromBioTechneCorporationMember" name="PurchasesFromBioTechneCorporationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" name="PropertyPlantAndEquipmentOtherThanConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" name="PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" name="ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" name="LiquidityFinancialConditionAndGoingConcernAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" name="LiquidityFinancialConditionAndGoingConcernTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_MeasuredAtFairValue" name="MeasuredAtFairValue" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_RetainExistingPolicy" name="RetainExistingPolicy" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock" name="PropertyAndEquipmentConstructionInProgressPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" name="SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="mrkr_CorporateHeadquartersMember" name="CorporateHeadquartersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_OfficeSpaceMember" name="OfficeSpaceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="mrkr_ManufacturingFacilityInHoustonTexasMember" name="ManufacturingFacilityInHoustonTexasMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_ResearchFacilityInHoustonTexasMember" name="ResearchFacilityInHoustonTexasMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="mrkr_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>mrkr-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2021 9:14:48 PM-->
<!--Modified on: 3/9/2021 9:14:48 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLeasesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" />
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637509212870008963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637509212870008963" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637509212870008963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637509212870008963" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637509212870008963" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637509212870008963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637509212870008963" xlink:to="us-gaap_PrepaidExpenseCurrent_637509212870008963" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_637509212870008963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637509212870008963" xlink:to="us-gaap_InterestReceivable_637509212870008963" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637509212870008963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637509212870008963" xlink:to="us-gaap_OtherReceivablesNetCurrent_637509212870008963" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_637509212870018967" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637509212870018967" xlink:to="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_637509212870018967" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637509212870018967" xlink:to="us-gaap_ConstructionInProgressGross_637509212870018967" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637509212870018967" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637509212870018967" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637509212870018967" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637509212870018967" xlink:to="us-gaap_LiabilitiesCurrent_637509212870018967" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637509212870018967" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637509212870018967" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637509212870018967" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637509212870018967" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_637509212870018967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637509212870018967" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_637509212870018967" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637509212870028962" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637509212870018967" xlink:to="us-gaap_LiabilitiesNoncurrent_637509212870028962" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637509212870028962" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637509212870028962" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637509212870028962" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637509212870028962" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637509212870028962" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637509212870028962" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637509212870028962" xlink:to="us-gaap_PreferredStockValue_637509212870028962" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637509212870028962" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637509212870028962" xlink:to="us-gaap_CommonStockValue_637509212870028962" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637509212870028962" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637509212870028962" xlink:to="us-gaap_AdditionalPaidInCapital_637509212870028962" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637509212870028962" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637509212870028962" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637509212870028962" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637509212870038965" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest_637509212870038965" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637509212870038965" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637509212870038965" xlink:to="us-gaap_OperatingExpenses_637509212870038965" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637509212870038965" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637509212870038965" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637509212870038965" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637509212870038965" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637509212870038965" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637509212870038965" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637509212870038965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="us-gaap_ProfitLoss_637509212870038965" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637509212870048964" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_637509212870048964" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="us-gaap_ShareBasedCompensation_637509212870048964" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_637509212870048964" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_637509212870048964" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637509212870048964" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:label="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets_637509212870048964" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="mrkr_IncreaseDecreaseInOperatingLeaseLiability_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870038965" xlink:to="mrkr_IncreaseDecreaseInOperatingLeaseLiability_637509212870048964" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637509212870048964" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_637509212870048964" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637509212870048964" xlink:to="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_637509212870048964" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="us-gaap_PaymentsForConstructionInProcess_637509212870058965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637509212870048964" xlink:to="us-gaap_PaymentsForConstructionInProcess_637509212870058965" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637509212870058965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637509212870058965" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637509212870058965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637509212870058965" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637509212870058965" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637509212870058965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637509212870058965" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637509212870058965" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637509212870058965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637509212870058965" xlink:to="us-gaap_ProceedsFromWarrantExercises_637509212870058965" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_637509212870058965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_ConstructionInProgressGross_637509212870058965" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637509212870058965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637509212870058965" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637509212870058965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637509212870058965" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_637509212870068965" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_637509212870068965" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_637509212870068965" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - LEASES - Maturities of Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637509212870068965" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637509212870068965" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637509212870068965" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637509212870068965" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637509212870068965" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637509212870068965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637509212870068965" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637509212870078966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_637509212870078966" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637509212870078966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637509212870078966" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637509212870078966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637509212870078966" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AccruedTechnologyLicenseFees" xlink:label="mrkr_AccruedTechnologyLicenseFees_637509212870078966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="mrkr_AccruedTechnologyLicenseFees_637509212870078966" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637509212870078966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637509212870078966" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637509212870078966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637509212870078966" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_637509212870078966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637509212870078966" xlink:to="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_637509212870078966" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_637509212870078966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637509212870078966" xlink:to="mrkr_DeferredTaxLiabilitiesFixedAssets_637509212870078966" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_637509212870088966" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637509212870088966" xlink:to="us-gaap_DeferredTaxAssetsGross_637509212870088966" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637509212870088966" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637509212870088966" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Deferredtaxstockbasedcompensation" xlink:label="mrkr_Deferredtaxstockbasedcompensation_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637509212870088966" xlink:to="mrkr_Deferredtaxstockbasedcompensation_637509212870088966" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Deferredtaxassetslicenseagreement" xlink:label="mrkr_Deferredtaxassetslicenseagreement_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637509212870088966" xlink:to="mrkr_Deferredtaxassetslicenseagreement_637509212870088966" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637509212870088966" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637509212870088966" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637509212870088966" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_637509212870088966" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637509212870088966" xlink:to="mrkr_DeferredTaxAssetsOperatingLeaseLiability_637509212870088966" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637509212870088966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637509212870088966" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637509212870088966" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41802 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637509212870098969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637509212870098969" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637509212870098969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637509212870098969" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_637509212870098969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_637509212870098969" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability" xlink:label="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability_637509212870098969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability_637509212870098969" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Permanentdifferencesotherpermanentdifferences" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_637509212870098969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="mrkr_Permanentdifferencesotherpermanentdifferences_637509212870098969" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637509212870098969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637509212870098969" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_637509212870098969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_637509212870098969" order="7" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>mrkr-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2021 9:14:48 PM-->
<!--Modified on: 3/9/2021 9:14:48 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantLiabilityTables" roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantsTables" roleURI="http://www.tapimmune.com/role/DisclosureWarrantsTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlansTables" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantLiabilityValuationMethodologyDetails" roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlansStockOptionActivityDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureGrantIncomeAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637509212870108984" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637509212870108984" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637509212870128976" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637509212870128976" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfWarrantsAmount" xlink:label="mrkr_ExerciseOfWarrantsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_ExerciseOfWarrantsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfWarrantsShare" xlink:label="mrkr_ExerciseOfWarrantsShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_ExerciseOfWarrantsShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantOfCashLessExercised" xlink:label="mrkr_WarrantOfCashLessExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_WarrantOfCashLessExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantOfCashLessExercisedSharesIssued" xlink:label="mrkr_WarrantOfCashLessExercisedSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_WarrantOfCashLessExercisedSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables" xlink:type="extended" xlink:title="30901 - Disclosure - WARRANT LIABILITY (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212870158978" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212870158978" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ValuationMethodology" xlink:label="mrkr_ValuationMethodology" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_ValuationMethodology" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_MeasuredAtFairValue" xlink:label="mrkr_MeasuredAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_MeasuredAtFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="31201 - Disclosure - WARRANTS (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansTables" xlink:type="extended" xlink:title="31301 - Disclosure - STOCK OPTION PLANS (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637509212870168976" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637509212870168976" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637509212870178975" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637509212870178975" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockWarrantsLiabilityTreatmentMember" xlink:label="mrkr_CommonStockWarrantsLiabilityTreatmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mrkr_CommonStockWarrantsLiabilityTreatmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockWarrantsEquityTreatment" xlink:label="mrkr_CommonStockWarrantsEquityTreatment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_CommonStockWarrantsEquityTreatment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870188977" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870188977" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ComputerEquipmentAndSoftwareMember" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrkr_ComputerEquipmentAndSoftwareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637509212870188977" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637509212870188977" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - LEASES - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637509212870218976" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637509212870218976" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CorporateHeadquartersMember" xlink:label="mrkr_CorporateHeadquartersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrkr_CorporateHeadquartersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OfficeSpaceMember" xlink:label="mrkr_OfficeSpaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrkr_OfficeSpaceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_637509212870218976" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember_637509212870218976" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ResearchFacilityInHoustonTexasMember" xlink:label="mrkr_ResearchFacilityInHoustonTexasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProjectMember" xlink:to="mrkr_ResearchFacilityInHoustonTexasMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProjectMember" xlink:to="mrkr_ManufacturingFacilityInHoustonTexasMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfRenewalOptions" xlink:label="mrkr_NumberOfRenewalOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_NumberOfRenewalOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FixedLeaseRentPayment" xlink:label="mrkr_FixedLeaseRentPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_FixedLeaseRentPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails" xlink:type="extended" xlink:title="40901 - Disclosure - WARRANT LIABILITY - Valuation Methodology (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharePurchaseWarrantsMember" xlink:label="mrkr_SharePurchaseWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mrkr_SharePurchaseWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExercisePrice" xlink:label="mrkr_FairValuesAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="mrkr_FairValuesAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedTerm" xlink:label="mrkr_FairValuesAssumptionsExpectedTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="mrkr_FairValuesAssumptionsExpectedTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedVolatilityRate" xlink:label="mrkr_FairValuesAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="mrkr_FairValuesAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsRiskFreeInterestRate" xlink:label="mrkr_FairValuesAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="mrkr_FairValuesAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedDividendRate" xlink:label="mrkr_FairValuesAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="mrkr_FairValuesAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="41001 - Disclosure - FAIR VALUE MEASUREMENTS - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="us-gaap_HedgingRelationshipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="us-gaap_HedgingRelationshipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="us-gaap_HedgingRelationshipDomain_637509212870248976" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="us-gaap_HedgingRelationshipDomain_637509212870248976" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="us-gaap_FairValueHedgingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_HedgingRelationshipDomain" xlink:to="us-gaap_FairValueHedgingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValueTransfersAmount" xlink:label="mrkr_FairValueTransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_FairValueTransfersAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41101 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637509212870368989" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637509212870368989" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_ExerciseOfStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637509212870368989" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637509212870368989" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ConsultingArrangementsMember" xlink:label="mrkr_ConsultingArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_ConsultingArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AspireCapitalMember" xlink:label="mrkr_AspireCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_AspireCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_BoardCompensationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_MaximumCommonStockCommittedToPurchase" xlink:label="mrkr_MaximumCommonStockCommittedToPurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_MaximumCommonStockCommittedToPurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AgreementTerm" xlink:label="mrkr_AgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_AgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41301 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="41303 - Disclosure - STOCK OPTION PLANS- Stock-based compensation expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637509212870418994" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637509212870418994" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="41401 - Disclosure - GRANT INCOME - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637509212870428986" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_637509212870428986" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637509212870439002" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_637509212870439002" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PurchasesFromBioTechneCorporationMember" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_PurchasesFromBioTechneCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ConsultingAgreementWithDr.JuanVeraMember" xlink:label="mrkr_ConsultingAgreementWithDr.JuanVeraMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_ConsultingAgreementWithDr.JuanVeraMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="41803 - Disclosure - INCOME TAXES - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637509212870538989" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637509212870538989" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IncomeTaxLineItems" xlink:label="mrkr_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangestart" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangestart" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangeend" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangeend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DecreasedDeferredTaxAssets" xlink:label="mrkr_DecreasedDeferredTaxAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_DecreasedDeferredTaxAssets" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>mrkr-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2021 9:14:48 PM-->
<!--Modified on: 3/9/2021 9:14:48 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">WARRANTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Receivables of reimbursement for out of pocket buildout costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" xlink:to="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_lbl" xml:lang="en-US">Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Excludes construction in progress.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_lbl" xml:lang="en-US">Property, Plant and Equipment Other Than Construction in Progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Construction in Progress, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (see Note 15)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at December 31, 2020 and 2019, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 150 million shares authorized, 50.7 million and 45.7 million shares issued and outstanding as of December 31, 2020 and 2019, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock shares par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Grant income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Grant received recorded as revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Beginning Balance, Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance common stock for cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance common stock for cash, Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised for cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised for cash, Shares</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfWarrantsAmount" xlink:label="mrkr_ExerciseOfWarrantsAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ExerciseOfWarrantsAmount" xlink:to="mrkr_ExerciseOfWarrantsAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ExerciseOfWarrantsAmount_lbl" xml:lang="en-US">Exercise of warrants amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ExerciseOfWarrantsAmount_lbl" xml:lang="en-US">Exercise Of Warrants Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ExerciseOfWarrantsAmount_lbl" xml:lang="en-US">Warrants exercised for cash</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfWarrantsShare" xlink:label="mrkr_ExerciseOfWarrantsShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ExerciseOfWarrantsShare" xlink:to="mrkr_ExerciseOfWarrantsShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ExerciseOfWarrantsShare_lbl" xml:lang="en-US">Exercise of warrants share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ExerciseOfWarrantsShare_lbl" xml:lang="en-US">Exercise Of Warrants share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ExerciseOfWarrantsShare_lbl" xml:lang="en-US">Warrants exercised for cash, shares</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xlink:to="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">It represents value of common stock as commitment fee for future financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">Issuance Of Common Stock , Value, As Commitment Fee For Future Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">Issuance of common stock as commitment fee for future financing</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xlink:to="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">It represents number of common stock issued as commitment fee for future financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">Issuance Of Common Stock, Shares, As Commitment Fee For Future Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">Issuance of common stock as commitment fee for future financing (Shares)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantOfCashLessExercised" xlink:label="mrkr_WarrantOfCashLessExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WarrantOfCashLessExercised" xlink:to="mrkr_WarrantOfCashLessExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_WarrantOfCashLessExercised_lbl" xml:lang="en-US">Warrant Of Cash Less Exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WarrantOfCashLessExercised_lbl" xml:lang="en-US">Warrant Of Cash Less Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_WarrantOfCashLessExercised_lbl" xml:lang="en-US">Stock warrants cashless exercised</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantOfCashLessExercisedSharesIssued" xlink:label="mrkr_WarrantOfCashLessExercisedSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WarrantOfCashLessExercisedSharesIssued" xlink:to="mrkr_WarrantOfCashLessExercisedSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_WarrantOfCashLessExercisedSharesIssued_lbl" xml:lang="en-US">The warrant exercised of non cash transaction shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WarrantOfCashLessExercisedSharesIssued_lbl" xml:lang="en-US">Warrant Of Cash Less Exercised Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_WarrantOfCashLessExercisedSharesIssued_lbl" xml:lang="en-US">Stock warrants cashless exercised, Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Reconciliation of net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Changes in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Total stock compensation expenses</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:label="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:to="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">The expense charged against earnings for the periodic recognition of operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization Of Operating Lease Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization on right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Interest receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="mrkr_IncreaseDecreaseInOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="mrkr_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">The increase (decrease) during the period in operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" xlink:to="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_lbl" xml:lang="en-US">The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; excluding cash outflows to pay for construction of self-constructed assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment Excluding Construction In Progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="us-gaap_PaymentsForConstructionInProcess" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForConstructionInProcess" xlink:to="us-gaap_PaymentsForConstructionInProcess_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForConstructionInProcess_lbl" xml:lang="en-US">Payments for Construction in Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForConstructionInProcess_lbl" xml:lang="en-US">Purchase of construction in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental schedule of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" xlink:to="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">The value of Issuance of common stock as commitment fee for future financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">Non Cash Issuance Of Common Stock As Commitment Fee For Future Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_lbl" xml:lang="en-US">Issuance of common stock as commitment fee for future financing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Recognition of right-of-use assets and lease liability from new operating lease agreements</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NonCashExerciseOfWarrantsAmount" xlink:label="mrkr_NonCashExerciseOfWarrantsAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NonCashExerciseOfWarrantsAmount" xlink:to="mrkr_NonCashExerciseOfWarrantsAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NonCashExerciseOfWarrantsAmount_lbl" xml:lang="en-US">The value of warrant exercised of non cash amount transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NonCashExerciseOfWarrantsAmount_lbl" xml:lang="en-US">Non Cash Exercise Of Warrants Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NonCashExerciseOfWarrantsAmount_lbl" xml:lang="en-US">Stock warrants cashless exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xml:lang="en-US">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity Financial Condition And Going Concern Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity Financial Condition And Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">LEASES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantLiabilityAbstract" xlink:label="mrkr_WarrantLiabilityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WarrantLiabilityAbstract" xlink:to="mrkr_WarrantLiabilityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WarrantLiabilityAbstract_lbl" xml:lang="en-US">WARRANT LIABILITY</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantLiabilityTextBlock" xlink:label="mrkr_WarrantLiabilityTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WarrantLiabilityTextBlock" xlink:to="mrkr_WarrantLiabilityTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_WarrantLiabilityTextBlock_lbl" xml:lang="en-US">The entire disclosure for warrant liability, including all tables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WarrantLiabilityTextBlock_lbl" xml:lang="en-US">Warrant Liability [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_WarrantLiabilityTextBlock_lbl" xml:lang="en-US">WARRANT LIABILITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_WarrantsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WarrantsDisclosureAbstract_lbl" xml:lang="en-US">WARRANTS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantsDisclosureTextBlock" xlink:label="mrkr_WarrantsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WarrantsDisclosureTextBlock" xlink:to="mrkr_WarrantsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for information about warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Warrants Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">WARRANTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK OPTION PLANS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK OPTION PLANS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_GrantIncomeAbstract" xlink:label="mrkr_GrantIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomeAbstract" xlink:to="mrkr_GrantIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomeAbstract_lbl" xml:lang="en-US">Represents the Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomeAbstract_lbl" xml:lang="en-US">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_GrantIncomeTextBlock" xlink:label="mrkr_GrantIncomeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomeTextBlock" xlink:to="mrkr_GrantIncomeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomeTextBlock_lbl" xml:lang="en-US">Represents the Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomeTextBlock_lbl" xml:lang="en-US">Grant Income [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantIncomeTextBlock_lbl" xml:lang="en-US">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">LEGAL PROCEEDINGS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US">LEGAL PROCEEDINGS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_RelatedPartyDisclosureAbstract" xlink:label="mrkr_RelatedPartyDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RelatedPartyDisclosureAbstract" xlink:to="mrkr_RelatedPartyDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RelatedPartyDisclosureAbstract_lbl" xml:lang="en-US">Related Party Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RelatedPartyDisclosureAbstract_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents and Credit Risk</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_RetainExistingPolicy" xlink:label="mrkr_RetainExistingPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RetainExistingPolicy" xlink:to="mrkr_RetainExistingPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RetainExistingPolicy_lbl" xml:lang="en-US">No Defined.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RetainExistingPolicy_lbl" xml:lang="en-US">Property and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RetainExistingPolicy_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock" xlink:to="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for property and equipment, construction in progress.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment - Construction in Progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment - Construction in Progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patents and Patent Application Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans, Director Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_GrantIncomePolicyTextBlock" xlink:label="mrkr_GrantIncomePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomePolicyTextBlock" xlink:to="mrkr_GrantIncomePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of loss per share</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NetLossPerShareTableTextBlockTableTextBlock" xlink:label="mrkr_NetLossPerShareTableTextBlockTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NetLossPerShareTableTextBlockTableTextBlock" xlink:to="mrkr_NetLossPerShareTableTextBlockTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NetLossPerShareTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NetLossPerShareTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Net Loss Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NetLossPerShareTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of lease cost and other information related to operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule Of Lease Cost And Other Information Related to Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of quantitative information about operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ValuationMethodology" xlink:label="mrkr_ValuationMethodology" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ValuationMethodology" xlink:to="mrkr_ValuationMethodology_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ValuationMethodology_lbl" xml:lang="en-US">Valuation methodology.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ValuationMethodology_lbl" xml:lang="en-US">Schedule of valuation methodology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ValuationMethodology_lbl" xml:lang="en-US">Schedule of valuation methodology</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_MeasuredAtFairValue" xlink:label="mrkr_MeasuredAtFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_MeasuredAtFairValue" xlink:to="mrkr_MeasuredAtFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_MeasuredAtFairValue_lbl" xml:lang="en-US">Measured at fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_MeasuredAtFairValue_lbl" xml:lang="en-US">Measured At Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_MeasuredAtFairValue_lbl" xml:lang="en-US">Schedule of Changes in Level 3 Liabilities Measured at Fair Value</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock" xlink:label="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock" xlink:to="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Financial assets and liabilities measured at fair value on recurring basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Financial Assets And Liabilities Measured At Fair Value On Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of financial liabilities measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" xlink:to="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of share purchase warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Share Purchase Warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule or Description of Weighted Average Discount Rate [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule or Description of Weighted Average Discount Rate</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of stock based compensation expenses recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US">Stock based Compensation Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of related party transaction expenses recorded during the respective periods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" xlink:to="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of expected tax expense benefit based on federal statutory rate is reconciled with actual tax provision benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_lbl" xml:lang="en-US">Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rate is Reconciled With Actual Tax Provision Benefit [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_lbl" xml:lang="en-US">Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net loss per share data:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Common stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Common stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockWarrantsLiabilityTreatmentMember" xlink:label="mrkr_CommonStockWarrantsLiabilityTreatmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockWarrantsLiabilityTreatmentMember" xlink:to="mrkr_CommonStockWarrantsLiabilityTreatmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockWarrantsLiabilityTreatmentMember_lbl" xml:lang="en-US">Common Stock Warrants Liability Treatment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockWarrantsLiabilityTreatmentMember_lbl" xml:lang="en-US">Common Stock Warrants Liability Treatment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommonStockWarrantsLiabilityTreatmentMember_lbl" xml:lang="en-US">Common stock warrants - liability treatment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockWarrantsEquityTreatment" xlink:label="mrkr_CommonStockWarrantsEquityTreatment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockWarrantsEquityTreatment" xlink:to="mrkr_CommonStockWarrantsEquityTreatment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockWarrantsEquityTreatment_lbl" xml:lang="en-US">Common stock warrants - equity treatment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockWarrantsEquityTreatment_lbl" xml:lang="en-US">Common Stock Warrants Equity Treatment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_CommonStockWarrantsEquityTreatment_lbl" xml:lang="en-US">Common stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Reimbursements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab equipment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ComputerEquipmentAndSoftwareMember" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ComputerEquipmentAndSoftwareMember" xlink:to="mrkr_ComputerEquipmentAndSoftwareMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Computer Equipment And Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Computers, equipment and software</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US">Cost to acquire necessary lab equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Lease hold improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Lease hold improvements</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OperatingLeaseExpenseAbstract" xlink:label="mrkr_OperatingLeaseExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OperatingLeaseExpenseAbstract" xlink:to="mrkr_OperatingLeaseExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OperatingLeaseExpenseAbstract_lbl" xml:lang="en-US">Operating lease expense summary:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OtherLeaseInformationAbstract" xlink:label="mrkr_OtherLeaseInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OtherLeaseInformationAbstract" xlink:to="mrkr_OtherLeaseInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OtherLeaseInformationAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OtherLeaseInformationAbstract_lbl" xml:lang="en-US">Other information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OtherLeaseInformationAbstract_lbl" xml:lang="en-US">Other information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows - operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate as of adoption date - operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Year ended December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Year ended December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Year ended December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Year ended December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Year ended December 31, 2025</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less present value discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease, liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease, liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Initial lease term</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfRenewalOptions" xlink:label="mrkr_NumberOfRenewalOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfRenewalOptions" xlink:to="mrkr_NumberOfRenewalOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfRenewalOptions_lbl" xml:lang="en-US">It represents number of renewal options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfRenewalOptions_lbl" xml:lang="en-US">Number of Renewal Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NumberOfRenewalOptions_lbl" xml:lang="en-US">Number of renewal options</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FixedLeaseRentPayment" xlink:label="mrkr_FixedLeaseRentPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FixedLeaseRentPayment" xlink:to="mrkr_FixedLeaseRentPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FixedLeaseRentPayment_lbl" xml:lang="en-US">It represents amount of fixed lease rent payments under the initial term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FixedLeaseRentPayment_lbl" xml:lang="en-US">Fixed Lease Rent Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_FixedLeaseRentPayment_lbl" xml:lang="en-US">Fixed lease rent payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Renewal term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AccruedTechnologyLicenseFees" xlink:label="mrkr_AccruedTechnologyLicenseFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccruedTechnologyLicenseFees" xlink:to="mrkr_AccruedTechnologyLicenseFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccruedTechnologyLicenseFees_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of Consulting agreements payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccruedTechnologyLicenseFees_lbl" xml:lang="en-US">Accrued Technology License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AccruedTechnologyLicenseFees_lbl" xml:lang="en-US">Technology license fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharePurchaseWarrantsMember" xlink:label="mrkr_SharePurchaseWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SharePurchaseWarrantsMember" xlink:to="mrkr_SharePurchaseWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SharePurchaseWarrantsMember_lbl" xml:lang="en-US">Share Purchase Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SharePurchaseWarrantsMember_lbl" xml:lang="en-US">Share Purchase Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SharePurchaseWarrantsMember_lbl" xml:lang="en-US">Share Purchase Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExercisePrice" xlink:label="mrkr_FairValuesAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FairValuesAssumptionsExercisePrice" xlink:to="mrkr_FairValuesAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FairValuesAssumptionsExercisePrice_lbl" xml:lang="en-US">Agreed upon price for the exchange of the underlying asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FairValuesAssumptionsExercisePrice_lbl" xml:lang="en-US">Fair Values Assumptions Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FairValuesAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedTerm" xlink:label="mrkr_FairValuesAssumptionsExpectedTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FairValuesAssumptionsExpectedTerm" xlink:to="mrkr_FairValuesAssumptionsExpectedTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FairValuesAssumptionsExpectedTerm_lbl" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FairValuesAssumptionsExpectedTerm_lbl" xml:lang="en-US">Fair Values Assumptions Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FairValuesAssumptionsExpectedTerm_lbl" xml:lang="en-US">Contractual term (years)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedVolatilityRate" xlink:label="mrkr_FairValuesAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FairValuesAssumptionsExpectedVolatilityRate" xlink:to="mrkr_FairValuesAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FairValuesAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FairValuesAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Fair Values Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FairValuesAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility (annual)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsRiskFreeInterestRate" xlink:label="mrkr_FairValuesAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FairValuesAssumptionsRiskFreeInterestRate" xlink:to="mrkr_FairValuesAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FairValuesAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FairValuesAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Fair Values Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FairValuesAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedDividendRate" xlink:label="mrkr_FairValuesAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FairValuesAssumptionsExpectedDividendRate" xlink:to="mrkr_FairValuesAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FairValuesAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FairValuesAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Fair Values Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FairValuesAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_lbl" xml:lang="en-US">Hedging Relationship [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="us-gaap_HedgingRelationshipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingRelationshipDomain" xlink:to="us-gaap_HedgingRelationshipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HedgingRelationshipDomain_lbl" xml:lang="en-US">Hedging Relationship [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_HedgingRelationshipDomain_lbl" xml:lang="en-US">Hedging Relationship [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="us-gaap_FairValueHedgingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueHedgingMember" xlink:to="us-gaap_FairValueHedgingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueHedgingMember_lbl" xml:lang="en-US">Fair Value Hedging [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueHedgingMember_lbl" xml:lang="en-US">Fair value hedging</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValueTransfersAmount" xlink:label="mrkr_FairValueTransfersAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FairValueTransfersAmount" xlink:to="mrkr_FairValueTransfersAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FairValueTransfersAmount_lbl" xml:lang="en-US">Amount of transfers between levels 1, 2 or 3 of the fair value hierarchy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FairValueTransfersAmount_lbl" xml:lang="en-US">Fair Value Transfers Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FairValueTransfersAmount_lbl" xml:lang="en-US">Transfers between levels 1, 2 or 3 of the fair value hierarchy</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of common stock</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_MaximumCommonStockCommittedToPurchase" xlink:label="mrkr_MaximumCommonStockCommittedToPurchase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_MaximumCommonStockCommittedToPurchase" xlink:to="mrkr_MaximumCommonStockCommittedToPurchase_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_MaximumCommonStockCommittedToPurchase_lbl" xml:lang="en-US">Represents maximum number of common stock to be purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_MaximumCommonStockCommittedToPurchase_lbl" xml:lang="en-US">Maximum Common Stock Committed to Purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_MaximumCommonStockCommittedToPurchase_lbl" xml:lang="en-US">Aggregate shares of common stock</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AgreementTerm" xlink:label="mrkr_AgreementTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AgreementTerm" xlink:to="mrkr_AgreementTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AgreementTerm_lbl" xml:lang="en-US">Term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AgreementTerm_lbl" xml:lang="en-US">Agreement Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfWarrantsGranted" xlink:label="mrkr_NumberOfWarrantsGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfWarrantsGranted" xlink:to="mrkr_NumberOfWarrantsGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfWarrantsGranted_lbl" xml:lang="en-US">Number Of Warrants, Granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfWarrantsGranted_lbl" xml:lang="en-US">Number Of Warrants, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NumberOfWarrantsGranted_lbl" xml:lang="en-US">Number Of Warrants, Warrants granted</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfWarrantExercisedForCash" xlink:label="mrkr_NumberOfWarrantExercisedForCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfWarrantExercisedForCash" xlink:to="mrkr_NumberOfWarrantExercisedForCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfWarrantExercisedForCash_lbl" xml:lang="en-US">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfWarrantExercisedForCash_lbl" xml:lang="en-US">Number Of Warrant Exercised For Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_NumberOfWarrantExercisedForCash_lbl" xml:lang="en-US">Number of Warrants, Exercised for cash</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfWarrantCashlessExercised" xlink:label="mrkr_NumberOfWarrantCashlessExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfWarrantCashlessExercised" xlink:to="mrkr_NumberOfWarrantCashlessExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfWarrantCashlessExercised_lbl" xml:lang="en-US">Number of warrants cashless exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfWarrantCashlessExercised_lbl" xml:lang="en-US">Number Of Warrant Cashless Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_NumberOfWarrantCashlessExercised_lbl" xml:lang="en-US">Number of Warrants, Cashless exercised</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfWarrantExpiredOrCancelled" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfWarrantExpiredOrCancelled" xlink:to="mrkr_NumberOfWarrantExpiredOrCancelled_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled_lbl" xml:lang="en-US">Number of warrants expired or cancelled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled_lbl" xml:lang="en-US">Number of Warrants, Expired or cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled_lbl" xml:lang="en-US">Number of Warrants, Expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Warrants Granted Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants granted</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_lbl" xml:lang="en-US">Class of warrant or rights outstanding exercised weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercised For Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised for cash</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercise Price Cashless Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercise Price Cashless Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cashless exercised</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Class of warrant or right outstanding issued weighted average remaining life.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue" xlink:label="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue" xlink:to="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of outstanding class of warrant or right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue_lbl" xml:lang="en-US">Class Of Warrant Or Right, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue_lbl" xml:lang="en-US">Total Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, grants in period, gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Total Intrinsic Value Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options granted in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock price volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate of interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Award vesting period</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued_lbl" xml:lang="en-US">Share based compensation arrangement number of share options available for issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Options Available for Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued_lbl" xml:lang="en-US">Number of shares options available to be issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Compensation cost not yet recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Compensation cost not yet recognized, period for recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_LossContingencyDamagesSoughtNumberOfTransactions" xlink:label="mrkr_LossContingencyDamagesSoughtNumberOfTransactions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LossContingencyDamagesSoughtNumberOfTransactions" xlink:to="mrkr_LossContingencyDamagesSoughtNumberOfTransactions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LossContingencyDamagesSoughtNumberOfTransactions_lbl" xml:lang="en-US">The number of transactions of the award the plaintiff seeks in the legal matter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LossContingencyDamagesSoughtNumberOfTransactions_lbl" xml:lang="en-US">Loss Contingency, Damages Sought, Number of Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related party transaction expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US">Deferred Income Taxes and Other Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US">Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net Operating Loss Carryforward</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Deferredtaxstockbasedcompensation" xlink:label="mrkr_Deferredtaxstockbasedcompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Deferredtaxstockbasedcompensation" xlink:to="mrkr_Deferredtaxstockbasedcompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Deferredtaxstockbasedcompensation_lbl" xml:lang="en-US">Deferred tax stock based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Deferredtaxstockbasedcompensation_lbl" xml:lang="en-US">Deferred tax stock based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Deferredtaxstockbasedcompensation_lbl" xml:lang="en-US">Stock Compensation</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Deferredtaxassetslicenseagreement" xlink:label="mrkr_Deferredtaxassetslicenseagreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Deferredtaxassetslicenseagreement" xlink:to="mrkr_Deferredtaxassetslicenseagreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Deferredtaxassetslicenseagreement_lbl" xml:lang="en-US">Deferred tax assets license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Deferredtaxassetslicenseagreement_lbl" xml:lang="en-US">Deferred tax assets license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Deferredtaxassetslicenseagreement_lbl" xml:lang="en-US">License Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Charitable Contributions</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="mrkr_DeferredTaxAssetsOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">The amount of Deferred tax assets, operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:to="mrkr_DeferredTaxLiabilitiesFixedAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_lbl" xml:lang="en-US">The amount of deferred tax liability, Fixed Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_lbl" xml:lang="en-US">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">The amount of deferred tax liability, Right-of-Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities Right of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Right-of-Use Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total Deferred Tax Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net Deferred Tax Assets/(Liabilities)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U. S. federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Tax rate change</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U. S. federal statutory rate, Percent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit, Percent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Tax rate change, Percent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Permanent Differences</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability" xlink:label="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability" xlink:to="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability_lbl" xml:lang="en-US">Income tax reconciliation change in fair value of derivative liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability_lbl" xml:lang="en-US">Income tax reconciliation change in fair value of derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability_lbl" xml:lang="en-US">Permanent differences- Change in fair value of derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Permanentdifferencesotherpermanentdifferences" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Permanentdifferencesotherpermanentdifferences" xlink:to="mrkr_Permanentdifferencesotherpermanentdifferences_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_lbl" xml:lang="en-US">Permanent differences other permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_lbl" xml:lang="en-US">Permanent differences other permanent differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_lbl" xml:lang="en-US">Permanent differences- Other permanent differences</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Deferred true-up</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision/ (benefit)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" xlink:to="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Represents the effective tax rate reconciliation due to change in fair value of derivative liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change in Fair Value Of Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Permanent differences- Change in fair value of derivative liabilities, Percent</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:to="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xml:lang="en-US">Represents the effective tax rate reconciliation due to other permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Other Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xml:lang="en-US">Permanent differences- Other permanent differences, Percent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance, Percent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Deferred true-up, Percent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax provision (benefit), Percent</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IncomeTaxLineItems" xlink:label="mrkr_IncomeTaxLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_IncomeTaxLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IncomeTaxLineItems_lbl" xml:lang="en-US">Income Tax [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IncomeTaxLineItems_lbl" xml:lang="en-US">Income Tax [Line Items]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangestart" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Taxcreditcarryforwardexpirationyearrangestart" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangestart_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart_lbl" xml:lang="en-US">Tax credit carryforward expiration year range start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart_lbl" xml:lang="en-US">Tax credit carry forward expiration year range start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart_lbl" xml:lang="en-US">Tax credit carryforwards expiration period</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangeend" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Taxcreditcarryforwardexpirationyearrangeend" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangeend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend_lbl" xml:lang="en-US">Tax credit carryforward expiration year range end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend_lbl" xml:lang="en-US">Tax credit carry forward expiration year range end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend_lbl" xml:lang="en-US">Tax credit carryforwards expiration year end</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" xml:lang="en-US">The percentage of limitation for operating loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" xml:lang="en-US">Operating Loss Carryforwards Limitation Percentage</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DecreasedDeferredTaxAssets" xlink:label="mrkr_DecreasedDeferredTaxAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DecreasedDeferredTaxAssets" xlink:to="mrkr_DecreasedDeferredTaxAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DecreasedDeferredTaxAssets_lbl" xml:lang="en-US">It represents the amount of decreased deferred tax assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DecreasedDeferredTaxAssets_lbl" xml:lang="en-US">Decreased Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid- in Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed To Issuers Equity Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CorporateHeadquartersMember" xlink:label="mrkr_CorporateHeadquartersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CorporateHeadquartersMember" xlink:to="mrkr_CorporateHeadquartersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CorporateHeadquartersMember_lbl" xml:lang="en-US">The expense/Income in Corporate headquarters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CorporateHeadquartersMember_lbl" xml:lang="en-US">Corporate Headquarters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CorporateHeadquartersMember_lbl" xml:lang="en-US">Corporate headquarters (Member)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OfficeSpaceMember" xlink:label="mrkr_OfficeSpaceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OfficeSpaceMember" xlink:to="mrkr_OfficeSpaceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OfficeSpaceMember_lbl" xml:lang="en-US">The expense/income at Office Space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OfficeSpaceMember_lbl" xml:lang="en-US">Office Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OfficeSpaceMember_lbl" xml:lang="en-US">Office space (Member)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US">Project [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US">Project [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US">Project [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ResearchFacilityInHoustonTexasMember" xlink:label="mrkr_ResearchFacilityInHoustonTexasMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ResearchFacilityInHoustonTexasMember" xlink:to="mrkr_ResearchFacilityInHoustonTexasMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ResearchFacilityInHoustonTexasMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ResearchFacilityInHoustonTexasMember_lbl" xml:lang="en-US">Research Facility In Houston Texas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ResearchFacilityInHoustonTexasMember_lbl" xml:lang="en-US">Research Facility in Houston, Texas [Member]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:to="mrkr_ManufacturingFacilityInHoustonTexasMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_lbl" xml:lang="en-US">Manufacturing Facility In Houston Texas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_lbl" xml:lang="en-US">Manufacturing Facility in Houston, Texas [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ExerciseOfStockWarrantsMember" xlink:to="mrkr_ExerciseOfStockWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ExerciseOfStockWarrantsMember_lbl" xml:lang="en-US">Exercise Of Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ExerciseOfStockWarrantsMember_lbl" xml:lang="en-US">Exercise of Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ConsultingArrangementsMember" xlink:label="mrkr_ConsultingArrangementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ConsultingArrangementsMember" xlink:to="mrkr_ConsultingArrangementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ConsultingArrangementsMember_lbl" xml:lang="en-US">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ConsultingArrangementsMember_lbl" xml:lang="en-US">Consulting Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ConsultingArrangementsMember_lbl" xml:lang="en-US">Consulting Arrangement</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AspireCapitalMember" xlink:label="mrkr_AspireCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AspireCapitalMember" xlink:to="mrkr_AspireCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AspireCapitalMember_lbl" xml:lang="en-US">Aspire Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AspireCapitalMember_lbl" xml:lang="en-US">Aspire Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AspireCapitalMember_lbl" xml:lang="en-US">Aspire Capital</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_BoardCompensationMember" xlink:to="mrkr_BoardCompensationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_BoardCompensationMember_lbl" xml:lang="en-US">Board Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_BoardCompensationMember_lbl" xml:lang="en-US">Board Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_BoardCompensationMember_lbl" xml:lang="en-US">Board Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type Of Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type of Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xml:lang="en-US">Accounting Standards Update201409 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US">Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US">Clinical Trial Agreement With Baylor College Of Medicine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US">Baylor College of Medicine</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PurchasesFromBioTechneCorporationMember" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PurchasesFromBioTechneCorporationMember" xlink:to="mrkr_PurchasesFromBioTechneCorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember_lbl" xml:lang="en-US">Represents information about the purchases from bio techne corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember_lbl" xml:lang="en-US">Purchases From Bio Techne Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember_lbl" xml:lang="en-US">Bio-Techne Corporation</label>
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ConsultingAgreementWithDr.JuanVeraMember" xlink:label="mrkr_ConsultingAgreementWithDr.JuanVeraMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ConsultingAgreementWithDr.JuanVeraMember" xlink:to="mrkr_ConsultingAgreementWithDr.JuanVeraMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ConsultingAgreementWithDr.JuanVeraMember_lbl" xml:lang="en-US">This member stands for Consulting Agreement with Dr. Juan Vera.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ConsultingAgreementWithDr.JuanVeraMember_lbl" xml:lang="en-US">Consulting Agreement With Dr. Juan Vera [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ConsultingAgreementWithDr.JuanVeraMember_lbl" xml:lang="en-US">Dr Juan Vera</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State And Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>mrkr-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2021 9:14:48 PM-->
<!--Modified on: 3/9/2021 9:14:48 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureNatureOfOperations" roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperations" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureFinancialConditionGoingConcernAndManagementPlans" roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholders" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureOtherReceivable" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivable" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipment" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLeases" roleURI="http://www.tapimmune.com/role/DisclosureLeases" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureAccountsPayableAndAccruedLiabilities" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantLiability" roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiability" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.tapimmune.com/role/DisclosureFairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockholdersEquity" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrants" roleURI="http://www.tapimmune.com/role/DisclosureWarrants" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlans" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlans" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureGrantIncome" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncome" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLegalProceedings" roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedings" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureIncomeTaxes" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersTables" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLeasesTables" roleURI="http://www.tapimmune.com/role/DisclosureLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesTables" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantLiabilityTables" roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.tapimmune.com/role/DisclosureFairValueMeasurementsTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantsTables" roleURI="http://www.tapimmune.com/role/DisclosureWarrantsTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlansTables" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureOtherReceivableDetails" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLeasesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantLiabilityValuationMethodologyDetails" roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.tapimmune.com/role/DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails" roleURI="http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureWarrantsAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlansStockOptionActivityDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlansWeightedAverageAssumptionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureStockOptionPlansAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureGrantIncomeAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20201231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <presentationLink xlink:role="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637509212870569006" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637509212870569006" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637509212870569006" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637509212870569006" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637509212870569006" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637509212870569006" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637509212870569006" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637509212870569006" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637509212870569006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637509212870569006" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637509212870579009" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637509212870579009" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637509212870579009" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637509212870579009" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637509212870579009" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637509212870579009" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637509212870579009" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637509212870579009" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637509212870579009" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637509212870579009" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637509212870579009" order="20" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637509212870579009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637509212870579009" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637509212870589011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637509212870589011" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637509212870589011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637509212870589011" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637509212870589011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637509212870589011" order="24" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637509212870589011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637509212870589011" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637509212870589011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637509212870589011" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637509212870589011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637509212870589011" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637509212870589011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637509212870589011" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637509212870589011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637509212870589011" order="29" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637509212870599006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637509212870599006" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637509212870599006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637509212870599006" order="31" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637509212870599006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637509212870599006" order="32" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637509212870599006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637509212870599006" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637509212870599006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637509212870599006" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_32" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637509212870599006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32" xlink:to="us-gaap_AssetsAbstract_637509212870599006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637509212870599006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637509212870599006" xlink:to="us-gaap_AssetsCurrentAbstract_637509212870599006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637509212870599006" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637509212870609023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637509212870599006" xlink:to="us-gaap_PrepaidExpenseCurrent_637509212870609023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637509212870599006" xlink:to="us-gaap_InterestReceivable_637509212870609023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637509212870599006" xlink:to="us-gaap_OtherReceivablesNetCurrent_637509212870609023" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637509212870599006" xlink:to="us-gaap_AssetsCurrent_637509212870609023" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637509212870599006" xlink:to="us-gaap_AssetsNoncurrentAbstract_637509212870609023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637509212870609023" xlink:to="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_637509212870609023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637509212870609023" xlink:to="us-gaap_ConstructionInProgressGross_637509212870609023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637509212870609023" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637509212870609023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637509212870609023" xlink:to="us-gaap_AssetsNoncurrent_637509212870609023" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637509212870599006" xlink:to="us-gaap_Assets_637509212870609023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637509212870609023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637509212870609023" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637509212870609023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637509212870609023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637509212870609023" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637509212870609023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637509212870619011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637509212870609023" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637509212870619011" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_637509212870619011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637509212870609023" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_637509212870619011" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637509212870619011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637509212870609023" xlink:to="us-gaap_LiabilitiesCurrent_637509212870619011" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637509212870628998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637509212870609023" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637509212870628998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637509212870628998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637509212870628998" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637509212870628998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637509212870628998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637509212870628998" xlink:to="us-gaap_LiabilitiesNoncurrent_637509212870628998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637509212870628998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637509212870609023" xlink:to="us-gaap_Liabilities_637509212870628998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637509212870628998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637509212870609023" xlink:to="us-gaap_CommitmentsAndContingencies_637509212870628998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637509212870628998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637509212870609023" xlink:to="us-gaap_StockholdersEquityAbstract_637509212870628998" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637509212870628998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637509212870628998" xlink:to="us-gaap_PreferredStockValue_637509212870628998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637509212870628998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637509212870628998" xlink:to="us-gaap_CommonStockValue_637509212870628998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637509212870638998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637509212870628998" xlink:to="us-gaap_AdditionalPaidInCapital_637509212870638998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637509212870638998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637509212870628998" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637509212870638998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637509212870638998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637509212870628998" xlink:to="us-gaap_StockholdersEquity_637509212870638998" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637509212870638998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637509212870638998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_119" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637509212870638998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637509212870638998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637509212870638998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_PreferredStockSharesAuthorized_637509212870638998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637509212870638998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_PreferredStockSharesIssued_637509212870638998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637509212870638998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_PreferredStockSharesOutstanding_637509212870638998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637509212870648997" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_CommonStockSharesAuthorized_637509212870648997" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_CommonStockSharesIssued_637509212870648997" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_CommonStockSharesOutstanding_637509212870648997" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_234" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234" xlink:to="us-gaap_StatementTable_637509212870648997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870648997" xlink:to="srt_ProductOrServiceAxis_637509212870648997" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637509212870648997" xlink:to="srt_ProductsAndServicesDomain_637509212870648997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637509212870648997" xlink:to="us-gaap_GrantMember_637509212870648997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870648997" xlink:to="us-gaap_StatementLineItems_637509212870648997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870648997" xlink:to="us-gaap_RevenuesAbstract_637509212870648997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637509212870648997" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637509212870648997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870648997" xlink:to="us-gaap_CostsAndExpensesAbstract_637509212870648997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637509212870648997" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637509212870648997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637509212870648997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637509212870648997" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637509212870648997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637509212870648997" xlink:to="us-gaap_OperatingExpenses_637509212870658999" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637509212870648997" xlink:to="us-gaap_OperatingIncomeLoss_637509212870658999" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870648997" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637509212870658999" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637509212870658999" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637509212870658999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637509212870658999" xlink:to="us-gaap_InvestmentIncomeInterest_637509212870658999" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870648997" xlink:to="us-gaap_NetIncomeLoss_637509212870658999" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870648997" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637509212870658999" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870648997" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637509212870658999" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_493" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_493" xlink:to="us-gaap_StatementTable_637509212870658999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637509212870658999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870658999" xlink:to="us-gaap_StatementEquityComponentsAxis_637509212870658999" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637509212870658999" xlink:to="us-gaap_CommonStockMember_637509212870668999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637509212870658999" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637509212870668999" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637509212870658999" xlink:to="us-gaap_RetainedEarningsMember_637509212870668999" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637509212870658999" xlink:to="us-gaap_EquityComponentDomain_637509212870668999" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870658999" xlink:to="us-gaap_StatementLineItems_637509212870668999" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_StockholdersEquity_637509212870668999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_SharesIssued_637509212870668999" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637509212870668999" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637509212870668999" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637509212870668999" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637509212870668999" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfWarrantsAmount" xlink:label="mrkr_ExerciseOfWarrantsAmount_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="mrkr_ExerciseOfWarrantsAmount_637509212870668999" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfWarrantsShare" xlink:label="mrkr_ExerciseOfWarrantsShare_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="mrkr_ExerciseOfWarrantsShare_637509212870668999" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_637509212870668999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing_637509212870668999" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_637509212870679000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing_637509212870679000" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantOfCashLessExercised" xlink:label="mrkr_WarrantOfCashLessExercised_637509212870679000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="mrkr_WarrantOfCashLessExercised_637509212870679000" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantOfCashLessExercisedSharesIssued" xlink:label="mrkr_WarrantOfCashLessExercisedSharesIssued_637509212870679000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="mrkr_WarrantOfCashLessExercisedSharesIssued_637509212870679000" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637509212870679000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637509212870679000" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_637509212870679000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_637509212870679000" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637509212870679000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_NetIncomeLoss_637509212870679000" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637509212870679000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_StockholdersEquity_637509212870679000" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637509212870679000" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870668999" xlink:to="us-gaap_SharesIssued_637509212870679000" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_655" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" xlink:to="us-gaap_ProfitLoss_637509212870689002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637509212870689002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_637509212870689002" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" xlink:to="us-gaap_ShareBasedCompensation_637509212870689002" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:label="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" xlink:to="mrkr_AmortizationOfOperatingLeaseRightOfUseAssets_637509212870689002" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637509212870689002" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637509212870689002" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_637509212870689002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637509212870689002" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_637509212870689002" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637509212870689002" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637509212870689002" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="mrkr_IncreaseDecreaseInOperatingLeaseLiability_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637509212870689002" xlink:to="mrkr_IncreaseDecreaseInOperatingLeaseLiability_637509212870689002" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870689002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637509212870689002" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637509212870689002" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637509212870699002" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637509212870699002" xlink:to="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_637509212870699002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="us-gaap_PaymentsForConstructionInProcess_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637509212870699002" xlink:to="us-gaap_PaymentsForConstructionInProcess_637509212870699002" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637509212870699002" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637509212870699002" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637509212870699002" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637509212870699002" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637509212870699002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637509212870699002" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637509212870699002" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637509212870699002" xlink:to="us-gaap_ProceedsFromWarrantExercises_637509212870699002" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637509212870699002" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637509212870699002" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637509212870699002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637509212870699002" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_637509212870709019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_Cash_637509212870709019" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_6375092128707090191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_Cash_6375092128707090191" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637509212870709019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637509212870709019" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing" xlink:label="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_637509212870709019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637509212870709019" xlink:to="mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing_637509212870709019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637509212870709019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637509212870709019" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637509212870709019" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NonCashExerciseOfWarrantsAmount" xlink:label="mrkr_NonCashExerciseOfWarrantsAmount_637509212870709019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637509212870709019" xlink:to="mrkr_NonCashExerciseOfWarrantsAmount_637509212870709019" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_728" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637509212870719011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_728" xlink:to="us-gaap_NatureOfOperations_637509212870719011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" xlink:type="extended" xlink:title="10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_637509212870719011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_637509212870719011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_731" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637509212870719011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_731" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637509212870719011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" xlink:type="extended" xlink:title="10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_734" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_637509212870719011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_734" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_637509212870719011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivable" xlink:type="extended" xlink:title="10501 - Disclosure - OTHER RECEIVABLE">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_637509212870729003" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_637509212870729003" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10601 - Disclosure - PROPERTY AND EQUIPMENT">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327057" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637509212870729003" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327057" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637509212870729003" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10701 - Disclosure - LEASES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_416650" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637509212870729003" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416650" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637509212870729003" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities" xlink:type="extended" xlink:title="10801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637509212870729003" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637509212870729003" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantLiability" xlink:type="extended" xlink:title="10901 - Disclosure - WARRANT LIABILITY">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantLiabilityAbstract" xlink:label="mrkr_WarrantLiabilityAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantLiabilityTextBlock" xlink:label="mrkr_WarrantLiabilityTextBlock_637509212870739001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantLiabilityAbstract_637040620889325859" xlink:to="mrkr_WarrantLiabilityTextBlock_637509212870739001" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="11001 - Disclosure - FAIR VALUE MEASUREMENTS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_637509212870739001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637040620889325859" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_637509212870739001" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11101 - Disclosure - STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_14" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637509212870739001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_14" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637509212870739001" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="11201 - Disclosure - WARRANTS">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantsDisclosureTextBlock" xlink:label="mrkr_WarrantsDisclosureTextBlock_637509212870739001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract_637040620889325859" xlink:to="mrkr_WarrantsDisclosureTextBlock_637509212870739001" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlans" xlink:type="extended" xlink:title="11301 - Disclosure - STOCK OPTION PLANS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_414378" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637509212870749002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_414378" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637509212870749002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncome" xlink:type="extended" xlink:title="11401 - Disclosure - GRANT INCOME">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_GrantIncomeAbstract" xlink:label="mrkr_GrantIncomeAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_GrantIncomeTextBlock" xlink:label="mrkr_GrantIncomeTextBlock_637509212870749002" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeAbstract_637040620889325859" xlink:to="mrkr_GrantIncomeTextBlock_637509212870749002" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11501 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637509212870762094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637509212870762094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLegalProceedings" xlink:type="extended" xlink:title="11601 - Disclosure - LEGAL PROCEEDINGS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_637509212870762094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_637040620889325859" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_637509212870762094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11701 - Disclosure - RELATED PARTY TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_RelatedPartyDisclosureAbstract" xlink:label="loc_mrkr_RelatedPartyDisclosureAbstract_327033" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637509212870769028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrkr_RelatedPartyDisclosureAbstract_327033" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637509212870769028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11801 - Disclosure - INCOME TAXES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637509212870769028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620889325859" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637509212870769028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637509212870769028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637509212870769028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637509212870779017" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637509212870779017" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637509212870779017" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_RetainExistingPolicy" xlink:label="mrkr_RetainExistingPolicy_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrkr_RetainExistingPolicy_637509212870779017" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock_637509212870779017" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637509212870779017" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_637509212870779017" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_637509212870779017" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637509212870779017" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637509212870779017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637509212870779017" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_637509212870789009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock_637509212870789009" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_GrantIncomePolicyTextBlock" xlink:label="mrkr_GrantIncomePolicyTextBlock_637509212870789009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrkr_GrantIncomePolicyTextBlock_637509212870789009" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637509212870789009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637509212870789009" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637509212870789009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637509212870789009" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" xlink:type="extended" xlink:title="30401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_81" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637509212870799022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_81" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637509212870799022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NetLossPerShareTableTextBlockTableTextBlock" xlink:label="mrkr_NetLossPerShareTableTextBlockTableTextBlock_637509212870799022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_81" xlink:to="mrkr_NetLossPerShareTableTextBlockTableTextBlock_637509212870799022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30601 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327063" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637509212870809007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327063" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637509212870809007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30701 - Disclosure - LEASES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_416654" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_637509212870819023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416654" xlink:to="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_637509212870819023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637509212870819023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416654" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637509212870819023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" xlink:title="30801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_85" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637509212870819023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_85" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637509212870819023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables" xlink:type="extended" xlink:title="30901 - Disclosure - WARRANT LIABILITY (Tables)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantLiabilityAbstract" xlink:label="mrkr_WarrantLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212870819023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantLiabilityAbstract" xlink:to="us-gaap_StatementTable_637509212870819023" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637509212870819023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870819023" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637509212870819023" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212870819023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637509212870819023" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212870819023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637509212870819023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212870819023" xlink:to="us-gaap_FairValueInputsLevel3Member_637509212870819023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212870829010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870819023" xlink:to="us-gaap_StatementLineItems_637509212870829010" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ValuationMethodology" xlink:label="mrkr_ValuationMethodology_637509212870829010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870829010" xlink:to="mrkr_ValuationMethodology_637509212870829010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_MeasuredAtFairValue" xlink:label="mrkr_MeasuredAtFairValue_637509212870829010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870829010" xlink:to="mrkr_MeasuredAtFairValue_637509212870829010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="31001 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock" xlink:label="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock_637509212870829010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637040620889325859" xlink:to="mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock_637509212870829010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="31201 - Disclosure - WARRANTS (Tables)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212870829010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract_637040620889325859" xlink:to="us-gaap_StatementTable_637509212870829010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637509212870829010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870829010" xlink:to="us-gaap_StatementEquityComponentsAxis_637509212870829010" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637509212870829010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637509212870829010" xlink:to="us-gaap_EquityComponentDomain_637509212870829010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637509212870829010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637509212870829010" xlink:to="us-gaap_WarrantMember_637509212870829010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870829010" xlink:to="us-gaap_StatementLineItems_637509212870839008" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870839008" xlink:to="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_637509212870839008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansTables" xlink:type="extended" xlink:title="31301 - Disclosure - STOCK OPTION PLANS (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620889325859" xlink:to="us-gaap_StatementTable_637509212870839008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870839008" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637509212870839008" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637509212870839008" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637509212870839008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637509212870839008" xlink:to="us-gaap_EmployeeStockOptionMember_637509212870839008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870839008" xlink:to="us-gaap_StatementLineItems_637509212870839008" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870839008" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_637509212870839008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870839008" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637509212870839008" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_637509212870839008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870839008" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock_637509212870839008" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="31701 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_RelatedPartyDisclosureAbstract" xlink:label="mrkr_RelatedPartyDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_637509212870849007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_RelatedPartyDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_637509212870849007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31801 - Disclosure - INCOME TAXES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637509212870849007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637509212870849007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_637509212870849007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_637509212870849007" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" xlink:type="extended" xlink:title="40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637509212870859048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637509212870859048" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_149" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_637509212870859048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_149" xlink:to="us-gaap_CashFDICInsuredAmount_637509212870859048" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_637509212870859048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_149" xlink:to="us-gaap_CashUninsuredAmount_637509212870859048" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_149" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_637509212870869007" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract_636948102906705552" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_636948102906705552" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_637509212870869007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_637509212870869007" xlink:to="us-gaap_NetIncomeLoss_637509212870869007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_636948102906705552" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637509212870869007" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637509212870869007" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637509212870869007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_636948102906705552" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637509212870869007" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637509212870869007" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637509212870869007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract_636948103393835552" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_636948103393835552" xlink:to="us-gaap_StatementTable_637509212870869007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870869007" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637509212870869007" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637509212870869007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637509212870869007" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637509212870869007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637509212870879008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637509212870869007" xlink:to="us-gaap_EmployeeStockOptionMember_637509212870879008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637509212870879008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637509212870869007" xlink:to="us-gaap_WarrantMember_637509212870879008" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockWarrantsLiabilityTreatmentMember" xlink:label="mrkr_CommonStockWarrantsLiabilityTreatmentMember_637509212870879008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637509212870869007" xlink:to="mrkr_CommonStockWarrantsLiabilityTreatmentMember_637509212870879008" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212870879008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870869007" xlink:to="us-gaap_StatementLineItems_637509212870879008" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockWarrantsEquityTreatment" xlink:label="mrkr_CommonStockWarrantsEquityTreatment_637509212870879008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870879008" xlink:to="mrkr_CommonStockWarrantsEquityTreatment_637509212870879008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637509212870879008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870879008" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637509212870879008" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER RECEIVABLE (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements_637509212870879008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_TenantImprovements_637509212870879008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637509212870879008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_637509212870879008" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327071" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327071" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637509212870889006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637509212870889006" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637509212870889006" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637509212870889006" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870889006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870889006" xlink:to="us-gaap_EquipmentMember_637509212870889006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ComputerEquipmentAndSoftwareMember" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870889006" xlink:to="mrkr_ComputerEquipmentAndSoftwareMember_637509212870889006" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870889006" xlink:to="us-gaap_OfficeEquipmentMember_637509212870889006" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870889006" xlink:to="us-gaap_LeaseholdImprovementsMember_637509212870889006" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637509212870889006" xlink:to="srt_RangeAxis_637509212870889006" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637509212870889006" xlink:to="srt_RangeMember_637509212870889006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637509212870889006" xlink:to="srt_MinimumMember_637509212870889006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637509212870889006" xlink:to="srt_MaximumMember_637509212870889006" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637509212870889006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637509212870889006" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637509212870889006" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637509212870899006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637509212870889006" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637509212870899006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637509212870899006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637509212870889006" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637509212870899006" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_637509212870899006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637509212870889006" xlink:to="us-gaap_ConstructionInProgressGross_637509212870899006" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637509212870899006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637509212870889006" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637509212870899006" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637509212870899006" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637509212870889006" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637509212870899006" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_416638" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212870909012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_416638" xlink:to="us-gaap_StatementTable_637509212870909012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637509212870909012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870909012" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637509212870909012" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870909012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637509212870909012" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870909012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637509212870909012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637509212870909012" xlink:to="us-gaap_EquipmentMember_637509212870909012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212870922831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870909012" xlink:to="us-gaap_StatementLineItems_637509212870922831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870922831" xlink:to="us-gaap_Depreciation_637509212870929040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870922831" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_637509212870929040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870922831" xlink:to="us-gaap_LeaseholdImprovementsGross_637509212870929040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870922831" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637509212870929040" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_636947436315711245" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OperatingLeaseExpenseAbstract" xlink:label="mrkr_OperatingLeaseExpenseAbstract_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636947436315711245" xlink:to="mrkr_OperatingLeaseExpenseAbstract_637509212870929040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OperatingLeaseExpenseAbstract_637509212870929040" xlink:to="us-gaap_OperatingLeaseCost_637509212870929040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OperatingLeaseExpenseAbstract_637509212870929040" xlink:to="us-gaap_ShortTermLeaseCost_637509212870929040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OperatingLeaseExpenseAbstract_637509212870929040" xlink:to="us-gaap_VariableLeaseCost_637509212870929040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OperatingLeaseExpenseAbstract_637509212870929040" xlink:to="us-gaap_LeaseCost_637509212870929040" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OtherLeaseInformationAbstract" xlink:label="mrkr_OtherLeaseInformationAbstract_637509212870929040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636947436315711245" xlink:to="mrkr_OtherLeaseInformationAbstract_637509212870929040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OtherLeaseInformationAbstract_637509212870929040" xlink:to="us-gaap_OperatingLeasePayments_637509212870939032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OtherLeaseInformationAbstract_637509212870929040" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637509212870939032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OtherLeaseInformationAbstract_637509212870929040" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637509212870939032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - LEASES - Maturities of Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_416700" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637509212870939032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637509212870939032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637509212870939032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637509212870939032" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637509212870939032" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637509212870939032" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637509212870939032" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637509212870939032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637509212870939032" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637509212870949017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_OperatingLeaseLiability_637509212870949017" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - LEASES - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_416659" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212870949017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416659" xlink:to="us-gaap_StatementTable_637509212870949017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637509212870949017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870949017" xlink:to="srt_CounterpartyNameAxis_637509212870949017" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637509212870949017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637509212870949017" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637509212870949017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CorporateHeadquartersMember" xlink:label="mrkr_CorporateHeadquartersMember_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637509212870949017" xlink:to="mrkr_CorporateHeadquartersMember_637509212870959013" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OfficeSpaceMember" xlink:label="mrkr_OfficeSpaceMember_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637509212870949017" xlink:to="mrkr_OfficeSpaceMember_637509212870959013" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870949017" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_637509212870959013" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_637509212870959013" xlink:to="us-gaap_ProjectMember_637509212870959013" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ResearchFacilityInHoustonTexasMember" xlink:label="mrkr_ResearchFacilityInHoustonTexasMember_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_637509212870959013" xlink:to="mrkr_ResearchFacilityInHoustonTexasMember_637509212870959013" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_637509212870959013" xlink:to="mrkr_ManufacturingFacilityInHoustonTexasMember_637509212870959013" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212870949017" xlink:to="us-gaap_StatementLineItems_637509212870959013" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870959013" xlink:to="us-gaap_OperatingLeaseLiability_637509212870959013" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637509212870959013" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870959013" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637509212870959013" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870959013" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_637509212870969033" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfRenewalOptions" xlink:label="mrkr_NumberOfRenewalOptions_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870959013" xlink:to="mrkr_NumberOfRenewalOptions_637509212870969033" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FixedLeaseRentPayment" xlink:label="mrkr_FixedLeaseRentPayment_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870959013" xlink:to="mrkr_FixedLeaseRentPayment_637509212870969033" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870959013" xlink:to="us-gaap_OtherReceivablesNetCurrent_637509212870969033" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212870959013" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637509212870969033" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_184" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_184" xlink:to="us-gaap_AccountsPayableCurrent_637509212870969033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_184" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637509212870969033" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_184" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637509212870969033" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AccruedTechnologyLicenseFees" xlink:label="mrkr_AccruedTechnologyLicenseFees_637509212870969033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_184" xlink:to="mrkr_AccruedTechnologyLicenseFees_637509212870969033" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_184" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637509212870979015" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_184" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637509212870979015" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails" xlink:type="extended" xlink:title="40901 - Disclosure - WARRANT LIABILITY - Valuation Methodology (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantLiabilityAbstract" xlink:label="mrkr_WarrantLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantLiabilityAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637509212870979015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637509212870979015" xlink:to="us-gaap_StatementEquityComponentsAxis_637509212870979015" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637509212870979015" xlink:to="us-gaap_EquityComponentDomain_637509212870979015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharePurchaseWarrantsMember" xlink:label="mrkr_SharePurchaseWarrantsMember_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637509212870979015" xlink:to="mrkr_SharePurchaseWarrantsMember_637509212870979015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637509212870979015" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637509212870979015" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExercisePrice" xlink:label="mrkr_FairValuesAssumptionsExercisePrice_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637509212870979015" xlink:to="mrkr_FairValuesAssumptionsExercisePrice_637509212870979015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedTerm" xlink:label="mrkr_FairValuesAssumptionsExpectedTerm_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637509212870979015" xlink:to="mrkr_FairValuesAssumptionsExpectedTerm_637509212870979015" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedVolatilityRate" xlink:label="mrkr_FairValuesAssumptionsExpectedVolatilityRate_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637509212870979015" xlink:to="mrkr_FairValuesAssumptionsExpectedVolatilityRate_637509212870979015" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsRiskFreeInterestRate" xlink:label="mrkr_FairValuesAssumptionsRiskFreeInterestRate_637509212870979015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637509212870979015" xlink:to="mrkr_FairValuesAssumptionsRiskFreeInterestRate_637509212870979015" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValuesAssumptionsExpectedDividendRate" xlink:label="mrkr_FairValuesAssumptionsExpectedDividendRate_637509212871109026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637509212870979015" xlink:to="mrkr_FairValuesAssumptionsExpectedDividendRate_637509212871109026" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" xlink:title="40902 - Disclosure - WARRANT LIABILITY - Changes in Level 3 Liabilities Measured at Fair Value (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantLiabilityAbstract" xlink:label="mrkr_WarrantLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantLiabilityAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637509212871119021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantLiabilityAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_637509212871119021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6375092128711190211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantLiabilityAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6375092128711190211" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="41001 - Disclosure - FAIR VALUE MEASUREMENTS - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable_637509212871119021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871119021" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637509212871119021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637509212871119021" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212871119021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212871119021" xlink:to="us-gaap_FairValueInputsLevel1Member_637509212871119021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212871119021" xlink:to="us-gaap_FairValueInputsLevel2Member_637509212871119021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637509212871119021" xlink:to="us-gaap_FairValueInputsLevel3Member_637509212871119021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871119021" xlink:to="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_637509212871119021" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="us-gaap_HedgingRelationshipDomain_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_637509212871119021" xlink:to="us-gaap_HedgingRelationshipDomain_637509212871119021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="us-gaap_FairValueHedgingMember_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingRelationshipDomain_637509212871119021" xlink:to="us-gaap_FairValueHedgingMember_637509212871119021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212871119021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871119021" xlink:to="us-gaap_StatementLineItems_637509212871119021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871119021" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_637509212871129032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_FairValueTransfersAmount" xlink:label="mrkr_FairValueTransfersAmount_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871119021" xlink:to="mrkr_FairValueTransfersAmount_637509212871129032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41101 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_637509212871129032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_637509212871129032" xlink:to="us-gaap_StatementEquityComponentsAxis_637509212871129032" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637509212871129032" xlink:to="us-gaap_EquityComponentDomain_637509212871129032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637509212871129032" xlink:to="us-gaap_CommonStockMember_637509212871129032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_637509212871129032" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637509212871129032" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637509212871129032" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637509212871129032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637509212871129032" xlink:to="mrkr_ExerciseOfStockWarrantsMember_637509212871129032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637509212871129032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_637509212871129032" xlink:to="us-gaap_TypeOfArrangementAxis_637509212871129032" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637509212871129032" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637509212871139018" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ConsultingArrangementsMember" xlink:label="mrkr_ConsultingArrangementsMember_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637509212871139018" xlink:to="mrkr_ConsultingArrangementsMember_637509212871139018" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AspireCapitalMember" xlink:label="mrkr_AspireCapitalMember_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637509212871139018" xlink:to="mrkr_AspireCapitalMember_637509212871139018" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637509212871139018" xlink:to="mrkr_BoardCompensationMember_637509212871139018" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_637509212871129032" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_PreferredStockSharesAuthorized_637509212871139018" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637509212871139018" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_CommonStockSharesAuthorized_637509212871139018" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637509212871139018" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637509212871139018" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637509212871139018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637509212871139018" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637509212871149032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637509212871149032" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_MaximumCommonStockCommittedToPurchase" xlink:label="mrkr_MaximumCommonStockCommittedToPurchase_637509212871149032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="mrkr_MaximumCommonStockCommittedToPurchase_637509212871149032" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_AgreementTerm" xlink:label="mrkr_AgreementTerm_637509212871149032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="mrkr_AgreementTerm_637509212871149032" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637509212871149032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637509212871149032" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637509212871149032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637509212871149032" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637509212871149032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637509212871149032" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637509212871149032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_637509212871139018" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637509212871149032" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - WARRANTS - Summary of Share Purchase Warrants (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637509212871159036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfWarrantsGranted" xlink:label="mrkr_NumberOfWarrantsGranted_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_NumberOfWarrantsGranted_637509212871159036" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfWarrantExercisedForCash" xlink:label="mrkr_NumberOfWarrantExercisedForCash_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_NumberOfWarrantExercisedForCash_637509212871159036" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfWarrantCashlessExercised" xlink:label="mrkr_NumberOfWarrantCashlessExercised_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_NumberOfWarrantCashlessExercised_637509212871159036" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_NumberOfWarrantExpiredOrCancelled" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_NumberOfWarrantExpiredOrCancelled_637509212871159036" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6375092128711590361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6375092128711590361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_637509212871159036" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice_637509212871159036" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_637509212871159036" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised_637509212871159036" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_637509212871159036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_637509212871159036" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_637509212871169024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_637509212871169024" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_637509212871169024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_637509212871169024" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue" xlink:label="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue_637509212871169024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue_637509212871169024" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - WARRANTS - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract_637040620891023944" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637509212871169024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract_637040620891023944" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637509212871169024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637509212871169024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract_637040620891023944" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637509212871169024" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41301 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212871169024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_StatementTable_637509212871169024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637509212871169024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871169024" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637509212871169024" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637509212871169024" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637509212871179024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637509212871179024" xlink:to="us-gaap_EmployeeStockOptionMember_637509212871179024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871169024" xlink:to="us-gaap_StatementLineItems_637509212871179024" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637509212871179024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637509212871179024" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637509212871179024" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375092128711790241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375092128711790241" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637509212871179024" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637509212871179024" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637509212871179024" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6375092128711790241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6375092128711790241" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637509212871179024" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637509212871179024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637509212871179024" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637509212871189046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637509212871189046" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_637509212871189046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_637509212871189046" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637509212871189046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871179024" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637509212871189046" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="41302 - Disclosure - STOCK OPTION PLANS - Weighted Average Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637509212871189046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637509212871189046" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637509212871189046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637509212871189046" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637509212871189046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637509212871189046" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637509212871189046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637509212871189046" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637509212871189046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637509212871189046" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="41303 - Disclosure - STOCK OPTION PLANS- Stock-based compensation expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_637509212871199029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871199029" xlink:to="us-gaap_IncomeStatementLocationAxis_637509212871199029" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637509212871199029" xlink:to="us-gaap_IncomeStatementLocationDomain_637509212871199029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637509212871199029" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637509212871199029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637509212871199029" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637509212871199029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871199029" xlink:to="us-gaap_StatementLineItems_637509212871199029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871199029" xlink:to="us-gaap_ShareBasedCompensation_637509212871199029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails" xlink:type="extended" xlink:title="41304 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637509212871199029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637509212871199029" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued_637509212871199029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637509212871199029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637509212871199029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637509212871199029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="41401 - Disclosure - GRANT INCOME - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_GrantIncomeAbstract" xlink:label="mrkr_GrantIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212871209032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeAbstract" xlink:to="us-gaap_StatementTable_637509212871209032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637509212871209032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871209032" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637509212871209032" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637509212871209032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637509212871209032" xlink:to="us-gaap_TypeOfAdoptionMember_637509212871209032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_637509212871209032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637509212871209032" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_637509212871209032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637509212871209032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871209032" xlink:to="us-gaap_StatementLineItems_637509212871209032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637509212871209032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637509212871209032" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637509212871209032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_637509212871209032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_637509212871209032" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_LossContingencyDamagesSoughtNumberOfTransactions" xlink:label="mrkr_LossContingencyDamagesSoughtNumberOfTransactions_637509212871209032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="mrkr_LossContingencyDamagesSoughtNumberOfTransactions_637509212871209032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_RelatedPartyDisclosureAbstract" xlink:label="mrkr_RelatedPartyDisclosureAbstract_637040620891492737" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637509212871219031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_RelatedPartyDisclosureAbstract_637040620891492737" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637509212871219031" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637509212871219031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637509212871219031" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637509212871219031" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637509212871219031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637509212871219031" xlink:to="us-gaap_RelatedPartyDomain_637509212871219031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_637509212871219031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637509212871219031" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_637509212871219031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_PurchasesFromBioTechneCorporationMember" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember_637509212871219031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637509212871219031" xlink:to="mrkr_PurchasesFromBioTechneCorporationMember_637509212871219031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_ConsultingAgreementWithDr.JuanVeraMember" xlink:label="mrkr_ConsultingAgreementWithDr.JuanVeraMember_637509212871219031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637509212871219031" xlink:to="mrkr_ConsultingAgreementWithDr.JuanVeraMember_637509212871219031" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637509212871232266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637509212871219031" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637509212871232266" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637509212871232266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637509212871232266" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637509212871232266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637509212871239045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Deferredtaxstockbasedcompensation" xlink:label="mrkr_Deferredtaxstockbasedcompensation_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="mrkr_Deferredtaxstockbasedcompensation_637509212871239045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Deferredtaxassetslicenseagreement" xlink:label="mrkr_Deferredtaxassetslicenseagreement_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="mrkr_Deferredtaxassetslicenseagreement_637509212871239045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637509212871239045" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_637509212871239045" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="mrkr_DeferredTaxAssetsOperatingLeaseLiability_637509212871239045" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="us-gaap_DeferredTaxAssetsGross_637509212871239045" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637509212871239045" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_637509212871239045" xlink:to="us-gaap_DeferredTaxAssetsNet_637509212871239045" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_637509212871239045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_637509212871239045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637509212871239045" xlink:to="mrkr_DeferredTaxLiabilitiesFixedAssets_637509212871239045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637509212871239045" xlink:to="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_637509212871249032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637509212871239045" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637509212871249032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637509212871249032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41802 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637509212871249032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637509212871249032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_637509212871249032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637509212871249032" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637509212871249032" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_637509212871249032" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability" xlink:label="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability_637509212871249032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability_637509212871249032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Permanentdifferencesotherpermanentdifferences" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="mrkr_Permanentdifferencesotherpermanentdifferences_637509212871259031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637509212871259031" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_637509212871259031" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637509212871259031" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability_637509212871259031" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_637509212871259031" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637509212871259031" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637509212871259031" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637509212871259031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_637509212871249032" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637509212871259031" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="41803 - Disclosure - INCOME TAXES - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_StatementTable_637509212871269034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871269034" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637509212871269034" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637509212871269034" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637509212871269034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637509212871269034" xlink:to="us-gaap_ForeignCountryMember_637509212871269034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637509212871269034" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637509212871269034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_IncomeTaxLineItems" xlink:label="mrkr_IncomeTaxLineItems_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637509212871269034" xlink:to="mrkr_IncomeTaxLineItems_637509212871269034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangestart" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_637509212871269034" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangestart_637509212871269034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_637509212871269034" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637509212871269034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangeend" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_637509212871269034" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangeend_637509212871269034" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_637509212871269034" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_637509212871269034" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_637509212871269034" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_637509212871269034" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_637509212871269034" xlink:to="us-gaap_OperatingLossCarryforwards_637509212871269034" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_637509212871269034" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage_637509212871269034" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20201231.xsd#mrkr_DecreasedDeferredTaxAssets" xlink:label="mrkr_DecreasedDeferredTaxAssets_637509212871269034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_637509212871269034" xlink:to="mrkr_DecreasedDeferredTaxAssets_637509212871269034" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>mrkr-20201231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? :0# 2(  A$! Q$!_\0
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MW;?F!Y'(KU?QY?#4/AOHMQNSDJN?H"/Z4JL?WD)#@_=:/*:V_!__ "-^E_\
M7=?YBL/(]:W/!Q'_  E^E\_\MU_F*VG\+(CNCU7XS:1]HT6VU)1\UNVUO]TY
M->'U]3^*M,&K^&+VS(RSQ';]:^674QR-&W#*2"*YL'.\+=C6LK2N=_\ "/5_
ML'BDV;MB.Z3'XCI_.M_XW]=,_'^9KRW1]0.F:S:7JG!BE5C],UZ5\8KE;NRT
M6X4@B2,-GZTYPM7C+N*+_=M'E%=-\/P&\;:?D _-_45S&1ZUT_P](_X3?3^?
MXOZBMZGP,SC\2/5?C#I/VSPRMXBYDMGR3_L\UX)7UCKEBNIZ)>6; $2QE:^4
MKF%K:ZE@<8:-BI!KFP4[P<>QK75G<TO#.IG1_$=E>@X"2 -]">:]^\>RB?X?
MWTR]'@##\<&OFK/H>:]K36?[8^"]R[-F6&$QO^!X_2GB8>]&7F*E+1H\5I02
MK CJ#D4W(]:,CUKK,CL(?B9XG@A2&.\PB*%48'0?A3_^%I>*O^?W]!_A7&9'
MK1D>M9^RA_*5SR[GL'@;QEK7B&?4;?4;CS(UMF(&.^#7DMS_ ,?EQ_UU;^9K
MNOA4?^)CJ?\ UZM_(UPER1]LN.?^6K?S-33BHU))+L.3;BKD1Z&OH3P?8KJ7
MPL6T89\V)E'UQ7SV2,&OI/X9_P#(C6/T/]*RQCM!/S+H[GSE=0-;7D\#C#1R
M,N/H:=97+6=_;W*'#1R*WZUU'Q+TG^RO&-QA<13_ +Q?R&?UKC\C'6NF#YXI
M]S)JSL?6ND7RZCI%K=JP(EC5OS%%>9> /&UM8^$X+:ZD'F1NRC)[=J*\B=&2
MDTD=D9IH]:J*YMX[JVD@D&4=2I%2T5B6>->*=,U;PY(UYHMS-&\)RT18LK+]
M*T?!OQ7MM3D2QUI5MKH\+(/NN?Z5Z)JFF1ZA"<@>8!QGO[5XAXR^'\\$TE[I
MT;<'+Q#JI]16]/DDN66C(E=:H]X$@(!!!!Y!H\P5Y'\-?&LTH_L'57/GQC]R
M[]2/2O3?M(]:RG!Q=F4G=71?WUPOQ0\.)K7AYKR)/]*M!N! Y*]_Y5U7VD>M
M(\D<T;1/@HX*L#Z&G"3A)20I1NK'RM]>M%:OB33CIGB*\M0IP)"5'L>:W/"7
M@2\UN9+BZ1H+('.YARWL*]F56,8\S.-1;=D6?AYX9DU"_749HSY$1^0$?>:O
M?K"U%K:J@Z]35#1=&@TZVC2.(1H@PB@?J:V*\BM5=27,SKA'E5@HHHK(L#R,
M5AS>#]!N)GFETZ!I'.68H.36Y7-ZA%XDC>XFM[FU$"@LJMG. /I50OT=A,D_
MX0GPZ?\ F%V__? _PK:MK6&TMUMX$"1(,*H' KD-&NO%.KZ>MVEQ:(I8KM.>
MWX5V,(D$2"4@R8&XCIFJGS+1NXHVZ(QY_"&A7-P\\NG0-(YRQ*#DU9TW0-,T
MF1I+&TCA9A@E% S5:^UB:V\3:?IRHIBN VYNXP"?Z5N4FY6U8)(IZCIEGJMN
M(+V!)HP<[6&>:R_^$)\._P#0+M_^^!_A5BQU2:YU_4+%E41V^W:1U.0#_6KF
MJ73V6F7%Q& 7C0L ?6A.4=$PT>I0MO"6AV=PEQ!I\*2H<JP09!J2^\,:/J-T
MUS=V,4LS=69036/I[>*M0T^"\6YLU69 X4YXR/I6IIT&OQW8-_<6SP8Y"9S_
M "JGS)WYA*W8B_X0GP]_T#(/^^!_A6KI^F6>EV_D64"0Q9SM48&:M$X!-<;9
M7_B+69[Q[2:UBAAG:)0V<\''I27--:L>BZ'8LBNA5AE3P16$?!7AYF+'3(,G
MD_(/\*I75_XAT. W=ZEO=6J<R^63N4>HZ5T]O.EU;QSQG*.N0:7O1U3#1F)_
MPA/AW_H%V_\ WP/\*MR^'-)FL([*2SB:VC.4C*C -:M<EK7BFYL-:2&W@62S
M@Q]LD_N9Z4XN<G9,'9%W_A"?#O\ T"[?_O@?X5+;^$="M;A)X=.A21#E6"#(
M-;,<BR1JZG*L,@TZIYY=Q\J$(!&".#Q6%)X-\/R2-(^FP%F.2=@K+M-0\0ZQ
M>WPLY;:*&WE\L!\Y/'TJ:?5==T+RY=2B@N+-F"O)"3N3)P#SCBK491T3U)NG
MNBY_PA/AT_\ ,+@_[X'^%6[OPYI5]!##<V<4D<(PBLH.T5IQNLL:NARK#(/J
M*Y:\U#6KOQ)<:?ITD$<<* DR9R>GM[THN4GOL-I+H6_^$)\._P#0+M_^^!_A
M4UKX4T2QN4N+;3X8Y4^ZRH 15/[+XK_Y^[/]?\*Z&W$JV\8G(,H4;BO0FB4I
M+J"2[$G7K6)/X0T&XG>:738&D<Y9B@Y-+J&KS6OB/3]/1%,=PI+$]1S6W4^]
M'5#T9S__  A/A[_H&0?]\"KD'A[2[>PELHK.-;:7[\848-1+JLI\4OIFU?*6
M$/N[YQ6N^XH=N-V.,TW*75B21@_\(3X=_P"@7;_]\#_"C_A"?#O_ $"[?_O@
M?X5GZK)XHTVQFNS<VC(G.WG_  J;3/\ A)KN"UNY+FT$4JJ[*,YP?PJ_?M?F
M%IM8M?\ "$^'?^@7;_\ ? _PH_X0GP[_ - NW_[X'^%;XS@9Z]ZQ9]8FB\5P
M:6$7RI(=Y;OGG_"I4IO9C:2);'PWI.FN[VEE%$SKM8JH&158^"_#S,6.F09)
MR3L'^%;]8.K:_);WJ:=IL NKYADK_#&/5J47-O1@TD-_X0GP[_T#(/\ O@5L
M6=E;V%JMO:Q+'$O15& *PG7Q5$IF#64A'/E9;GVZ5J:/J%QJ%IONK1[69259
M&]?4>U.7-;5W!6[#=2T#2]7D22^LXIG08!90<52_X0GP]_T#(/\ O@?X5IZM
MJ4>DZ9/>R@E8ESM'>L6%_%%Y"MTOV2 ,-RPL6S^/%$7*V]D#M?8LKX-T!1@:
M="![***6TU35O)Q>:6PF#$'R^5(]1DT47GW#W3=HHHK,H*K75E%=#YAANS"K
M-% ' :YX&AFOHM0@A"7,3;O-BXS]:N_:F0!7)# 8.:[*N+\1V\XU0M$J[6'K
MBG=O<0[[9[T?;/>L?R+S^ZO_ 'U2_9[W^ZO_ 'U0,O6_A32]7U-M4FMA-<#
M^;[H_"NPMK".!5X'RC@ <#Z5D^%4GCMYA, /F&,'-=#0VWN))!1112&%%%%
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<WBV[.KS216QE "QCYOE'3FBM.2CU9/-/HC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mrkr-20201231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U O # 2(  A$! Q$!_\0
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M6.Q86##:,<BH'T"(W4]Q'<R1O,ZLVWV.<54_X1_4_P#H-3_Y_"C_ (1_4_\
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M!G@?G5^[T.WO+NUN'=E:W0HH'3H1_6J'_"/ZG_T&I_\ /X4O_"/ZG_T&I_\
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M)G96&"YZ]<U'9:)!8WQNDD8OY8CP?09_QJA_PC^I_P#0:G_S^%'_  C^I_\
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MI_\ /X4?\(_J?_0:G_S^%'+'N'/+^4Z.BN<_X1_4_P#H-3_Y_"C_ (1_4_\
MH-3_ .?PHY8]PYY?RG1T5SG_  C^I_\ 0:G_ ,_A5BPT>^M;M99M3EF0=4;H
M:'%=QJ4NQMT445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%1W#,EO(R?>"DB@#$\2>+-.\.)$MU*!/,=L:#
MK]:CEUZXTV%+F^AWV[D#?$,[<]S7-ZWX!M?%\SW-Q>2QWZCY.>%_"J-AXQE\
M(M_PCOBV(LB+MBN0N1(OO6RIJ45RZOJB')IZGIDEVC:<]U P=?++J?7BO*M
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M@VVP8")U[CWJ6X\;P.DL=M"XE3'+#@'/?\*YN[\8^";JV%O^]2/<K';'UP,
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MN+6/]BF_N-^5'V*;^XWY4 ;'_"0G^XM'_"0G^XM8_P!BF_N-^5'V*;^XWY4
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M?VO:?WF_*C^U[3^\WY4 7Z*H?VO:?WF_*I8+^WN&VH_/H>* +5%%% !1110
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MC+I5M*@7;C'3%/33;9?X,D]35NB@"".TACW;5Y88)]:B73+96)V'GMZ5<HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 444R6011,Y["@#G6N[]=3N9%9O(BSG(XQ2)XANY(PZP#
M"@L<]P#44^L3-(V. >H%0C59@, X% %\:W>2*C1Q)N=RNPYRH SS3!X@N1%/
M))!L5#A?K50:K,#D$Y]:0ZI,<Y/7K0!8;5[R7>[C"8!5!UZ5>34KF;29KA54
M2#H@ZK]:R?[5FSG)XZ4HU:=<X8C/7WH N/J[65O;^7*;AY"-V12'7[M?O0*
M^=IY^7'K5/\ M244'59B,$G% %]M=NQ/+&MN&$8QN]?>MFPEFFLHI9P!(XR0
M.U<O_:LV<Y.:<-9N0,"1@* .OHKD?[9NO^>C4?VS=?\ /1J .NHKD?[9NO\
MGHU']LW7_/1J .NHKD?[9NO^>C4?VS=?\]&H ZZBN1_MFZ_YZ-1_;-U_ST:@
M#KJ*Y ZS==I&I?[9NO\ GHU '745R/\ ;-U_ST:C^V;K_GHU '745R/]LW7_
M #T:C^V;K_GHU '745R/]LW7_/1JM6&LS&X5)"64^M '244 Y -% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DC$L3(W0C%/HH
MYF?0IO-.P KZYJ/^PKG^Z/SKIQ-&9#&'&\=13\CUH Y7^PKG^Z/SH_L*Y_NC
M\ZZK(]:,CUH Y7^PKG^Z/SH_L*Y_NC\ZZJB@#E?["N?[H_.C^PKG^Z/SKJJ*
M .5_L*Y_NC\Z/["N?[H_.NJHH Y7^PKG^Z/SH_L*Y_NC\ZZJB@#E?["N?[H_
M.C^PKG^Z/SKJJ* .5_L*Y_NC\Z/["N?[H_.NJHH Y7^PKG^Z/SH_L*Y_NC\Z
MZJB@#E#H5SV4?G2_V%<_W1^==510!RO]A7/]T?G1_85S_='YUU5% '*_V%<_
MW1^=']A7/]T?G7544 <K_85S_='YU:L=$D28/+@ 'UKH** $' Q2T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_GJ__?5 ':45Q?\ :5S_ ,]7_P"^J/[2N?\ GJ__ 'U0!VE%<7_:5S_SU?\
M[ZH_M*Y_YZO_ -]4 =I17%_VE<_\]7_[ZH_M*Y_YZO\ ]]4 =I17%_VE<_\
M/5_^^J/[2N?^>K_]]4 =I17%_P!I7/\ SU?_ +ZH_M*Y_P">K_\ ?5 ':45Q
M?]I7/_/5_P#OJC^TKG_GJ_\ WU0!VE%<4=1N?^>S_P#?5']I7/\ SU?_ +ZH
M [6BN+_M*Y_YZO\ ]]4?VE<_\]7_ .^J .THKB_[2N?^>K_]]4?VE<_\]7_[
MZH [2BN+_M*Y_P">K_\ ?57-/U6<7"J[%@>N3F@#J**0'(!I: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;(@DC9&Z$444 <=J5L
MMM<LBDD52HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K7T2T2>?<Q/RT44 =3C HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mrkr-20201231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $! :8# 2(  A$! Q$!_\0
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M=&@V@YS7E3Q'6+UZGE^UY?WD6^=[LF5=JA?08I:**Y#F"BBB@ HHHH ****
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MR-/!'(4.5+*#BK  4  8 Z"IK8_GI\D8V[E4,O\ 9U.><N;L<AXI\'-JD_\
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MI9>0.BDTXNVMRYJ?AR#[;+-=:BB*[;BO?^5/T[PQHFHS,5\V3RL9;. 36#J
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MF(K9>%EEX!^E<QXKGN_$&F?9F: E&W*037EJG4JUO:3[GN*K2HT/94WLCG/
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M249.2W84445D:A17+>-M5O=+LK4V) DDEP>.PY-37NOF/PJM_$<RR (O^\:
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MH ***R]5URVTO:C9DG?[L2<DU48N3LB9245>1J8SUKRGXL:DL<MK81\8&]U
MZ_YS72W6NZJH#R-!; _=0G+?C@UQWB*TFUS4;>[FEB;R^& &"PKOPE!QJJ<M
MCS\7B8SI.$=V9>GW-XGAZXU2XED+2$6\63T'!X_6NCOGCLO!YCMW'R*N<>G>
MF^(XK&X\"Q1Z0I M) \J'[P[?UK-MG2_TL '*2)@UZ%%*K>6UF>1C9NAR+=-
M;F6EVMW$K(V5  QZ4X-Y9W XQSFL"YT_4M(N7-N"T1.>.E5Y[S4IU"2*8D8[
M22,5Z*Q"BN5K4Y/8<[YHR5CJ5NDU&PN?+./GX([$GFHM.\[1+PV%ZI190'C8
M]"#S_6IK2Q2RT^WL(6#S3R+G'7J,UZCJ?A"QUK1X+>Z7$\<8"2CJIQ7G5\0J
M$HM]=SLP^&^N0G%=-CSC4=(M=33,@^;LPK'7P5")-SW)9/[HKK9/!/B73V9+
M6:.XA'3<<'^=2VOA/Q).5^T&*WC/+-G) _.J>*P\E=R1A' XZG[D5H8T=K';
M0IIVGQYFE^4 =?J:]8T#3%TG2(+4?> RWUKQ:#69/#7B6YDB?[0R;HU)[GU_
M2O8_"[7LFAPS7[[YI!N/MS7'F,I."M\)Z>54E3E+FUEU-FBBHY[B&VB,DTBH
M@&26.*\BUSW+V)*9+-%"A:6144=237 Z]\3+:U=K?3(S/+G&[' KE/(\7>+I
M-S^:L3#O\J_K7=3P$VN:H^5>9P5<?!/EIKF?D>CZGXZT3325:Y61\?=2N3OO
MBSG<EE9G/8M1IWPGRJO?W7S=U6NGM/A[H%J0WV;S&'=^:V_V*EWDS'_;JO:*
M//)_B1K]SE8T"9Z;150^)/%<[;DDGY]%KV:'0-*MP!'8PKC_ &:N):P1_<B1
M?H*/KU"/P4D+ZA7E\=5GA@U'QCNR'N<_[HJ6>\\836TD=Q'</$R_,"!TKW/:
MO]T?E3)HA)!(F!\RD?I1_:,;_P -#_LV27\1G@OASQKJ/AZ81LS2P \QL>E>
MQZ!XELO$5J7MFQ(!\R'J*Y&T^%T4FHRW%]-F-G+"-?3-=UINBV&DQ!+.W2/C
M!(')I8ZKAJFL%[P\!1Q-/2;]T\MNE>V\4:E;RD[S(6!/<5R6I1WNEZG).D;2
MPR'/%>P>+_"3:N4OK!A'?1_DX]#7%.E_ 3#>Z=-N'!*KD'\J[<+B83II7LT>
M5C<)6HUY5(QYHR.4AOKV_E2*UMGC8GESVKTWP';2F_GE)RD:!"?4_P"369IV
MA:CJ9V6]J;:(GYG<8X^E>BZ1I4&D6*6T(SC[S'JQK+'XJ+@X7NV=&6X:HZBJ
M./+%?B7Z***\0^A"BBB@ HHHH **** "F2Q)-&8Y%#*>H/>GT4 </;Z99?\
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M^+J<U*4I::'5@TOK$(4W?JST>BBBOF3ZT**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH P_%NC#6_#]Q; 9E W1_6O)](O613878,=S%
M\I5J]TKE?$G@>QUV3[2A^SWG_/5>_P!:[\%BU1;C+9GFYC@/K44X_$CS>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mrkr-20201231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $' 9(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *K7U_;:=;M/=2K&@]:GDD6*-I&.%49->2ZEJ<OB+5)9I&)M(6*QQ]
MCCO75A<,Z\[=$<6.QBPM/G>KZ'9#QB;EO]"TZ:6/_GH2 #^=6K?Q0GF!+VTE
MM<]'8[@?RZ5YO-XH:VD73K-P''WFQFK]GK4\A\MY1(I^]'(,AJ]"67IIN*T/
M-IYG-V<GN>KHZ2('1@RGD$&G5YY#XMC\/0E'1Y(9/]4O]UO2G6WC;5K+5%77
M++R;*;F*1!D#ZFO/EA*B>G_#GJQQ=-K\_([\R(K!2ZACT!/)IU<;XGAN9Y['
M5=,D\R1/F$6_ =>*JQ?$&:&<1W^F/$,X)#9(_#%2L.Y13B5]82DU)'>45GZ9
MK5CJT0>TG#'NIX8?A6A6#BXNS-U)25T%17$ZVT)D?H*9=7<=J!YK! >C'UKA
MO$%WJPD9Q)OM3T:,Y'XUE)RFG&E\16D;.6QW"W]L8U<RHH(S@FJ<&LPO),KO
M&H3[ISUKRUKB9_O2L?QIF]_[[?G3>%KRY7S)6W\R?;05]#UFRU6&YC)>1%8'
M&,U.U_"LZ1!@S/TP:\?$DJ_=D8?C6KH%W>/J:()&8 ]S7/7AB,/A^;F3:W\S
M2G.G4J6M:YZK134SY:YZXYIU=2=U<@****8!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%0W-W#:1
M^9.X1?4TTFW9";25V345E'Q'I('-XGZTV/Q-I,L@1+L,Q.  IK3V%7^5_<9?
M6*7\R^\L:UN_L6\VYSY3=/I7D.C,'LGVGG>V?KDU[4Z+/"R,,JXP?I7B^JV$
M_A'6YHYHR=/G<M'(!PN?6N_+:D8R<'U/+SJA*I24XZV.2AD\CQ'.)N"QX)KH
M(\^:FWKD8HU/1K/6-L\4RI+V8'K5>WTNXTZ16N=25XA_"G4U[=.HX7BT>%*4
M*J3O9K2QOG3%\026^GB4HQ;(8=C6C?\ ARYTW3"VMWYNHXALMXAQD^I_.M;P
MC81P,-3N]L"L-L"2'!QZU5\4WWV[6S$#F"U7/!R"U>/5K-U;1>B/?HT4J-Y+
MWF,NC+:>#[ B0B5&QD'D=.*SX]1AO (M10$=!*!R*LW<K2>%8@PP?.X_.H=$
MTU;R;S)E+1*?N_WJY-[MG>ERI)$Y\+:A;.EYID_RGE7!Q^==C9ZTEK8VPU*X
MC,SG877[NZJ>KS6HMX]+CN4MW*\(#S]*YR6QDCTBXM+C)6-MX:IE=Q7/L"LF
M^3<VO%]V6V1HWRA=W'>N1M=3N;5OE?<AZHW(JR91+8A%=F"C W5E=#7-A7S4
MI2M9MO?<UJW4DCJ;33]/U.,2B,1RM_#G@T3>'%.Y%@='Q\I'.:@T8^:L,:GY
M@P%=+K.J&UC\E' *I\Q[U\?A\9B*SE.I.2<9):=;]+'JSHTXQ5DG=7]#B?[)
M>-R+F9(0#R&/-=3X>LM.MIUDBF,A(SEA7%,SW5QEF+%F[UUR:M8>'=*02()K
MEQ\L:]?QKZC&JI5G3H0U>[]$>?ATDI3^1V%K?VMZ'-M.DH0[6VGH:L5Y=X+O
M=1MM8G58H_LMRY=E[I74:!K6HZUK-TQ1(["$[%&?F)]:[IT>5NST13BMT]#J
M:***P("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ)9OIBLL,@!+ =3Z5-*C*I/V<7N.I5C3CSRZ%3Q;H-O::_\ VG?:D8XW8,J
M9;@_6NKL[O3/$FD,EFX=PFP[N#TKB_%>DZSJ]C87[0M)(4^>->H_"IO!MG=^
M&8+C4[Z)HU<;4B;C-=]:$9852E/WHZ)'%2G*.(:C'W67KR.PTZ%+)&WW&3O8
M=![5B7-NR.2!P:U+Y+'5)6N+*0QSMRT;]S[5F_;!83^5J *+ZD5XLN>C><$Y
M7W2WOY'I7C))2=O/H7/#MQ';ZM&\S!54$\]ZJZE>27M_/)DE6;CZ5T&F:/9:
MU:&ZLYMZ#C&.<U'J-I::/I_FS+_I+G$<9ZGWKB3I0K<D*#YGKM;7N;1A*<+\
MZL8=M;S(IF6-F;'R@#-+;Z+J-Y.6\ES*W4OQ4UE=W-R',D@BCC7=(X'05=TG
M7[741*^GZDZK;?-()E ##US^%=>$H5^:=6LES/3R2Z%.*G%0I_"OS+$EN?#<
M5LA;_297RY'8>E1&Y;P]XE^U1$BUN2!,G8$]Z9JFL:9XGDC2QN5-U".4)^]]
M*TM9TN2[TJ&X5<_N\..X-=:O%VGUW,DI4Y6>QVR.LD:NARK#(-.KS[PCJOB"
M^DAMQ%&+*V)CD<GYFQQZ5Z#6%2FX.S-)1LPHHHK,D**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ.I6VF6S37#@ =!W-1
M:OK%OI%J99F^;'RKW-><,VI>+=3P-Q0'\%%=^$P;J^_-V@NIP8S&JC^[IJ\W
MT)-6U^_\0W7V>V5Q$3A47O\ 6N@\/^"HX MSJ&'DZA.PK;T3P[:Z/"-JAIB/
MF<BMFM<1CTH^RPZM'\S'#Y>W+VV)=Y?@AJ(L:A44*HZ 4ZBBO+/5"BBD)P":
M ,C7-;CTV,1*-UQ(/E7TKS66.*&\FN#\TTIRP'2M_68[V2_N;F6!S_#'A3P*
MYITD#$NC ^XKKIKE5D9SFUHAWF/+(J*.I P!6]XC@:&WL;>.-CMCRQ ]A4GA
M:RCN[@;$4O$<N7&?RK,\2ZWXCC\8BUMK5C:(RCA#M*^YJU!RE9>I4*$I+<FA
MB.L:,;-DWSP-F,'J?\YI+'PB='F-[?WRV]NP^:'O6Y<6K:;J=I>Q!5\T#..F
M<5SNOK>W=U<"Z+O&IP#V%3&<MD]&9R@H[HL/JFG>=)#IUN%D7_EJPSG\>E-M
M=7O;>\C><B2+=R",C%1>#+S2[&&[T_55CV9+AGQR.:Z>/P[IFK6WVK2[EUC;
M[HSE?RJZBA&5EMW(4*JC>2,_Q)=7=G>Q7EK*RQ3+D =!6=K6H7%W9VB3ON.W
M)_2NEU'1+D>'O*N9XG>%@ROMP N1GO\ 6N?O+33)[FSDN+Y_L\V$01KCGZU%
M.'-L3.IR[G-R3^4K,@9F49PHSBO0O!MJU]HRW%\8KA7YC!&2H]*T[/P_H]E;
M/'#$@,B89R1N(^M+IT6E>'=*>."X7[/'EF)<$BE.I%P:BG<<*<^=.6QH16]O
MI]LXMX511D[5XR:\]U/3;W4;^2[OKB*+G"(6SM'X5>U/Q=I^NS?V;87$BR,N
MY)!QDCM7*RF42,LK,6!P<T1A..LMV;3DH^XCL](\,6XMY//NDD6YCV87H:Q=
M3^'HT;PS?1Z;,TDLAS@D#(YXJ[I,SW>A[(VQ<6C;H^>OUK/\9W?B'5-)@N-.
M66/RSB5(LYSZC'45=)SYDE(Z:+;2LSAO"NAZG)XBMF6"2)8'W2,PP !7H]_X
MCN)]55;?Y8(_E*_WA[U3^VZC'H]M#<2G[4Z?O#GH/>JNF+!)JZ6%PSPF3GS'
M7 ?V!K2M)U97:V(K2E5E9=#LO"D]D5NGMR07D)9<=#FNHJK::?:V4:I!$J[1
MC(')JU7!.2E*Z$PHHHJ!!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 51U;5(-)LGN)F P/E7U-6IYTMH'ED8*JC))KS6\FN_%NN"
M&'(@4X![ >M=F#PWMI<T](K<XL9BG1BHPUD]D0QQW_B_5MS9$0/)[**]&TS2
M[;2[588$ P.6QR:72],@TNT6"% ,#YCZFKM5B\7[7W(:06R)P>#]C[\]9O=A
M1117"=X4444 %07EPEM;.[R*A"G!/K4]8^O^'X-?MD@GEDC"G.4.,U4;7][8
M:M?4X^7Q1J,]HS&1#AR/NBJ UZ\+ E(6/H8Q_A4UMX;NH;JZTZ&)C$K91STQ
M4TJ6.@_+\MU>?^.I74U%.R,:B:D^Q=N/&EAX;L[>2ZM@MS<?>5% X]:YCXB>
M)Y[I+&33W,=K/'N\Q>">!QFMNWTFU\:%$U-&62$Y611C(]*WM8T;2(]-@TZ>
MQ1X8UPA8]*NG.E"46U=]3JI3@DGU.$^'FK37?VB+5)7EM(L,KN<E3]:[V]U3
M1[M9K.3,3R#[S =>U8"#2M+M_*2.((IW"*+.&/OFL2\NFO+IYV&"QX [4JO+
M4GS+0SQ%2+?NCM8\(WYV/%#]H"G</+YW"O3-$:&UT2WS!]D 4 HPQ@US?A;4
MEN$:"X&98%+1L3VKE_$OBB_N;6:V9LP^80"O!%2E*JU39E[3EIV1ZQ?7$$%C
M)-/AH0/F&,Y%>>:Z;C5HXHK:UC2P# QM$.<_7M52#4K_ /X1E$NIW<S\*#V6
MG:'<74%UF%SL7DIZT1BZ3?*[M&#:JI<RT9I7\PT&SCLXGDDN)4!D=W)P/:N?
M:X$D;1N&*MU&X\UU&N7&F7]Q!YUU##=$8,;Y)_2L'6=3MM"U*+3X[".?=C?(
M<\Y...:VHTJM1V2U>IG4J4H*[>B*-AI%K+J<$EHKI.K J%KJ?$'AR4R1W,+Q
M+E1YH8XP:?//9^';99+:/-W<*&7=_ #7/1W]Q/=$S2L_F=0364ISF[OH:J$8
MK3J6_#%W!;:]+;37=N873;D/U-3WVIR^%M?$;2^9;R\@$\8-<C%9K'?W*@GY
M6S4LMA]KNH7DF=F1A@DU-=24GRQZ=_Q.G"/#M1=63\]#U.S\/V5Q*M\[-()
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MFO1:*F4(S^)$3IPFK35SB=,^'-K:R*]]>R7>TY QM'\Z[.&&.WB6*) B*,
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=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mrkr-20201231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (W YX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***2@!:*2B@!:*2E% !1110 4444 %%%%*X!1124P%HI**+@+1244
M +1244 +1244 +1110 444E "T4E% "T4VB@!U%)10 M%)11J M%)10 M%-S
M2T +124M !124M*X!1124P%HI** %HI** %HI** %HI*6E< HI*3(-,!U%)1
M0 M%%':@ HI**+@+12447 6BDHHN M%)10 M%)1Q0 M%)Q2T %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK184=(]+M$60;7"Q ;A[U(^@:3)'%&^G6K)#_JU,0PGTJG65K(2IV=RU:?\
M'M'G^Z*BU3_D&W'^X:MJ@48'%#QK(A5AD'J*QO[US2VAY5\(?N:KCG]ZW]*;
MX)4?\+,UXD<B5_ZUZ79:58Z=O^R6D,&\Y;RT"Y^N*6#2K&UN9+F"TACGD.7D
M5 &8^YK1U5=D\NQYAXP./BAHI Y##^8K&U/6SJ7B'4;'7M4N;*P'"0Q(07Z<
M=#7L\VD6%S=QW4UG#)<1_<D9 67Z'M4=SH&DW<XGN-.MI9A_&\8)_.JC66F@
MG \7\#"**?7XXM^S[.^SS1AB,-UKL_A$1_8-X>WG?U-=NNC::DSS+8P"21=K
MN(QEAZ&I;33K/3XS'9VT4"DY(C0+D_A2G54DT$86.6^(FA7.M>'R;4;IK<^8
MJ]SBL;PW\2](MM%@M=6=[2Z@384>-OFQWZ<5Z6169<^'-&O)VGN=,M)I6ZN\
M0)-1&<;<LD-Q=[GFNCFY\9_$&/6XK9XM/M#^[=Q][&/YXJE9:M;^%_B9J<VJ
MEH(I3\K%2<C YKV2VM(+2%8;:)(8EZ(@P!5:]T/2]1E66]T^WN)%& TL88C\
MZM55?R$X-GD-CJL.M_%;[;;;O)9"J%E(+#GGGMS4F@:E::)\1]0%^YB\S>JD
MJ>23Q7K46B:7!.D\6GVZ3(NU76, @>@I)]"TNYNQ=3Z?;2W Z2-&"WYTW66U
MM!>S9Y7HNK6W@_QSJDVL!XH;H?NY=I((X.?TKHV\40>,+34['2["7RQ$^VZ8
M85S@]NM=I>:-IVHA1>64$^SA?,C#8^E26>G6FGP^59VT4"9SMC0*/TJ74C>]
MM1J+VZ'DG@KQ=I?AG0[K3-5WV]U&YPC1G,G7IQ6996=R_ACQ%JKQ/';W(Q&K
M#&?F4YKV:Y\/Z1?3F>ZTVUFE/\;Q G\ZLOI]I):?9)+>)K?&/**C;CZ57M4M
M1<CV/*< ?!Q< =?\*0J!\%3QS\W]:]4_LG3_ +%]C^QP?9O^>6P;?RH_LG3_
M +#]B^QP_9O^>.P;?RI>V'R'@&J:>6T;0;RZ6460C*221_P_,?RK4TO3/"MQ
MXBMH-);5K]U8-YH<!5^N17M9TG3S8_8C9P?9<8\G8-OY4RRT73=.8M96-O;L
M1@F*,+G\JJ5>Z%[/6YY%XDC\,R^)9UU1;_2;E%PLZD%),=#@ FM7X:ZSJU[K
M5W;R7;WUC&N$F*X Z8KTF]T;3=296OK&WN&3A3+&&Q^=26>FV>G1F.SMHK="
M<E8U"C/X5#J)QLRE#4L@YI: ,45CT+%HHHI@%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -H-.HH 9SP<=Z=2T
M4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )1WI:*0"44M%.P"44M% "4
M4M%*P#:!3J*+ )12TE !111F@ HHHIB"C%%+2&)24ZB@!**6BF E+110 444
M4 )12T4 )12T4 )12T4 )24ZB@!**6B@!**6B@!**6B@!!0:6B@!**6B@!**
M6B@!**6BE8!**6BF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )FC-%9T>KVTVJ2:>C?OHP&8?Y^
ME '(^-/BG9^#-1CM+FQFEWKNWKG _2NLT#68M>T2UU.%"B7"[@I[5P?QNM(#
MX'GN#$GG!P ^T9 P:N?#_P 06MKX%TF)P=RPX/YFHG4C#XA.26YZ&**P1XGM
M!V-+_P )1:>C5C]:I]R>>)N49XK#_P"$HL_1JKWGC&PLK5[B0-M09/%-8JF]
M$QQDI-);G2 TZN=\->*[+Q/%+)9[L1G!S71#I6Z=U<TG"4)<LEJ%%%%,D***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5H]KB>P<U0T?^$L'_/&C_A+!_P \:SO^$=OO[JT?\([??W5H]KB>P<U0T?\
MA+!_SQH_X2P?\\:SO^$=OO[JT?\ ".WW]U:/:XGL'-4-'_A+!_SQH_X2P?\
M/&L[_A';[^ZM'_".WW]U:/:XGL'-4-'_ (2P?\\:/^$L'_/&LW_A';_^ZM'_
M  CM]_=6CVN)[!S5#2_X2P?\\JW[*Y^UVJ38QN%<?_PCM]_=6NKTN"2WL8HI
M.&4<UU8:=63]\UIN7VB\*6DI:] U"BBBF 4444 %%%% !1110 4444 %%%%
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M:,T6 3%&*7-&:+ )BC%+FC-%@$Q1BES1FBP"8HVT4M !1110 4444P"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[==?\_#_ )T?;KK_ )^'_.C^TEV#VZ/1MZ^M&]?6O.OMUU_SW?\ .C[==?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)X6#QN,JP[U+C-<]X*5X_"E@KJ581\@_6NB%>K'5#J149.(8IU)2TR0HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:/04O KIP^%C1=TRX4^4*6DS25U(T'44W/-+3 6BBB@ HHHH **** "BBB@
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M%=?1^5<_U&CL9^QB<A_PBMS_ ,]11_PBMS_SU%=?FC-'U"B/V,3D/^$5N?\
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M'\XR,[QQ^!H\!>'([KP/I4YD(+PYQ^)KEQ4:DH^X9S4NA?\ ^$@O_P"^*/\
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ME_=/YUK>?%_ST7\Z/M$7_/1?SI^QH=@Y8F1_PC5E_=/YT?\ "-67]T_G6O\
M:(?^>B_G2?:(O^>B_G2]C0[!RQ,G_A&K'^Z?SH_X1JR_NG\ZV<@C([TZJ^K4
MGT#D78Q/^$:LO[I_.C_A&;+^Z?SK<HQ1]6I=@Y$8G_"-67]T_G2?\(U9?W3^
M=;F*,4?5J78.1&)_PC5E_=/YTG_"-67]T_G6YBC%'U:EV#D1B?\ "-67]T_G
M1_PC5E_=/YUMT9H^K4NP<B*=E8Q6,>R+H>:MBEHK:,5%61:T$I:**H HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 TCFD[XJ">]M[>2..654>0X52>IJK%K=I/J#6,;%I$.& [&@#ROXY^
M*K*'1VT%E?[3(0X('&,?_7KMOAO;0O\ #_1V:-2?(ZD>YKG_ (WV%HW@J:Z:
M!#<*P D(Y P>*U?AYK%G;^ M(CDDPRPX/YFHG**7O";2W.U%I!_SR3\J7[)!
M_P \D_*J/]O6/_/7]*/[>L?^>M8^TH^1/-$O?9(/^>2?E1]D@_YY)^54?[?L
M?^>OZ4?V]8_\]?TI>UH=T/FB7OLD'_/)/RH^R0?\\D_*JL&L6ES*(HY<N>G%
M:-:05.>L1JS(/L<'_/)/RH^QP?\ /)/RJ>BK]G'L%D0?9(/^>2?E1]D@_P">
M2?E4]%'LX]@LB#[)!_SR3\J/LL'_ #R3\JGHHY(]@LBN;6#'^J3\JB&G6:S>
M:+>,/U#;1FKM%-02V*3:V$'%+115""BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .=\0:8]W?:=/%%N
M:&8LQ]!@UEQZ=<0^)3+:6[QNTI>61C\K*3_^NNS_  H [XH \X^-O_)/Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*Y/^>(H^O41^UB=7BE%<G_PE<G_/&C_A*Y/^>-'UZCW#VL3K*,UR?_"5R?\
M/&MW2[XW]MYK+M.:UI8FG4=HCC-2V-"BFBE[5T%BT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH^P?%7_G_MO^^1_\33 ]:HKR7[!\5?\ G_MO^^1_\31]@^*O_/\ VW_?(_\
MB: /6J*\E^P?%7_G_MO^^1_\31]@^*O_ #_VW_?(_P#B: /6J*\E^P?%7_G_
M +;_ +Y'_P 31]@^*O\ S_VW_?(_^)H ]:HKR7[!\5?^?^V_[Y'_ ,31]@^*
MO_00M?\ OD?_ !- 'K.:,UX9XCU7XE^&[2.YNKVW9))!& %[D@?W?>M:"U^*
M<]O%*M_; 2*&P5'&1G^[0!Z]FBO)?L'Q5_Y_[;_OD?\ Q-'V#XJ_\_\ ;?\
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M_8/BK_S_ -M_WR/_ (FC[!\5?^?^V_[Y'_Q- 'K5%>2_8/BK_P _]M_WR/\
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M,?E[D'R^G%9FM:+<:C<0217)18SG8>0:V;='C@C1R"R@ D"@":BBB@ HHHH
M**** "BBB@ HHHH :?:N6\53FW:.=K&&:*+G=(,X^E=4>:P]7T.34Y!MN&2-
MAM=.Q%(#5M)!-9Q28V[E!P*GJ*W@%O;I"IR$&.:EI@+1110 4444 %%%% !1
M110 4&BB@#F-;U2PM=7LHGMXY;B1\!B1E.M=(O(SZU@ZGX2L=2OX[QMRRHV[
M(/6MY%"J .PH ?1110 4444 %%%% !1110 4444 ,-<;/?H_BLH]I%&$P!.Z
M')/IFNS(K"O- :\OQ(\Y\D,&V =Z -P8QQ]>*?35   '0"G4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )CO
M12T4 %%%% !1110 4444 %%%% !1110 48HHH ,8HHHH **** "BBB@ HHHH
M **** "BBB@!"*.E!Z5C>(OM,.G-=6KXD@.\*.C =J -G-&:\\E\1:C8V4%T
MRL\MZVX+G 0#/'Z?K0?'%[YD$IA 1P R'JI- 'H=%<$_B?58TBE<1A'=N<]
M#]:T=:UN]@N;6*T>) Z;V9^,_2@#K,TN:X./Q=?31BZ546-0%,3=23W%0_\
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MFC% '*V^E72[XFM2&)7;.6!VX[U>TZWN;.*X#0LB[3M9F!;-;FVD*@@@\YH
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M3-*"A5B7'!S6YCG-&* .)N=)U?\ M:>>&*0!GRA5P!UZD5I"+6B%#&8CD/\
M.O/N*Z3;[\T8H S=/2XCTU8I86$B@_>8'//M60NG7;$R-9$,V?D#C ]*ZG%&
M* .9FL+R:4DVF-L04,&')QWJR+*X&FSIY!W.01'N'M6YM]Z7% ',S6>J),7L
M(S;HXP4W#@^M:%BM\JL+L2.VWKN&#6MCCBC% &3I-K+;23[XF17;*EF!/Z5K
M#K1B@#% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mrkr-20201231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (W ^P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 44E% "T4E%(!:*2BF M%
M)10 M%)10 M%)10 M%)10 M%)2YH **** "BBCO2N 444E,!:*2C- "T4E%
M"T4E%(!:*2BF M%)^-% "T4E% "T4E% "T4E% "T4E% "T4E&: %HI,T9H 6
MBC-% !1244 +1124 +129HH 6BBDH 6BBBD 44E%.X"T44E%P%HI**+@+124
M4 +124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+HU\BE%<KHWC_P /:Y>?9;.Z;S>PDC*9_.NJ7I0U8$[BT444AA1110 4444
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M'W1U%=O?> DO->TW4_MS*;)5 CV9#XQWSQTJ2V\$);>,9O$ O&9I<?N=F ,
M#KGVK1U(\MB>5W.)\8Z;::7\1M'%C D D3<RQC:,Y([4S2BP^*&M$<-C@_\
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M )12T4 )12T4 )24N*,4( HI:3% !11BEQ3 *2EHQ2 2@TN*3% !12XI,<T
M%%+BC%%@"D-+13 3-%&*,4NH!12XI,4 %%&*,46 **,48H **7%% "44M&*
M$HI:,4 )2BDQ2TP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHI,CCWH 6BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0USWBO6;G1K 36X!8GO70FN-^(1_XE X[T <
M]_PL'5<#Y(\_2NCT3Q7+<Z7<7M\JA8AG"CK7EXXSUKMO"Y0>'[PR6YG7',8Z
MD<4 ;=MXON65)[K2WBLY!F.990V?P'(K0L?%FF7L,\IE")"VTECUKAC*EN8?
M[&GGEW\-:3 L$_PILIA@L[FW6SB61I?F9HLJO3DBAA;4[?4?%EA96*7<;B6)
MF"DJWW:DG\4V*V8GMW$V" 55AD5Y>56*UN(YT$\8D4GRHBJD9'05H:@EO=3>
M;HUNT<(4!]D9 )JK: STF/7M/+11-/&DL@!"EA5Z:YBMH3-*X2,<EB:\8BL+
MUY_*GNHHYB5V@VI9QSV.:]!\0PS+X;MT;?(B*@EP#E@,9XJ1(F/C.RDU#[+;
M 384MO#@ 5HCQ!IZB-9KB-)).B[@:\WD&GW&KJVEVA11;D/MCV@G'TJ.:**W
MGCEC"F;'^JF@+$_[I[4#ZGJ,VMZ=;SI%)=1J[= 6HNM<TZS=5FND5G^Z-W6O
M)I[6\FNY#<RPV[.!L22V+MT['M5G5(Y3#'!*L8D2/[\L&YF^GI3%U/4+C6].
MM-GG7,:[_N_,#FEGUO3[94,EU&H?[N6ZUY=.L!MK.7<//1"-L\!8-SVSTJO=
MPWL]T)+AH;6)DPBRVYDS]/2BPV>S1R)/&KHP93R"#4@K!\)6\MMH4,<LID)Y
M#%2OZ=JWJ0"T444 %%%% !1110 4444 %%%% !1110 444G>@!:3.**J:E=I
M8V$US(<+&I.:3 F2YBDE:-)$9UZJ#DBF/=VXD\AID$C?PE@#7E'A76(K;Q/]
MJ^T3.^H,PD5R=JG.!C\!1#J-G=WU]=7_ -M21;@+'<*K;(QCOVJD!Z#IGA:P
MTO5KG4H/,-Q<'+9;([?X5Y'\;76/Q;H3N<!9!D_B:]UMV#0QD-N!4$'UKP/X
M]?\ (PZ/]1_6D![)'XLTA8D'VI>%%._X2W2/^?I:\: &T<#I1@>@H ]E_P"$
MMTC_ )^EH_X2W2/^?I:\:P/048'H* /9?^$MTC_GZ6C_ (2W2/\ GZ6O&L#T
M%&!Z"@#V4^+-(/2Z6A/$^FO($6X7)KQQ0-PX%7K-1]LAX_B%>;B\8Z,E%=3T
M\'@HUX.5]CVY&#J&'((R*?4%I_QZP_[@_E4XZ5Z,7=7/-:L[!1113$%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !10:2@!#56]M;2ZBV72*R^C59[UB^("1;##$?2N;%XCZO2=0N
MG#GERB_V)HG_ #[P_D*NV=G96L9%M&BH?O8Q7&[Y,??;\ZL74\L/AJ\=960A
M?O \BO'P.<_6:O):QU5<)[./-<ZN*QL893)#! LAZLJ#)J1K&U?=NMHB&^]E
M1S7DNG71%O8W&E7M[<W[\RQNS,OY9KJ9O&UY:Z@L5Q:0B MMW"7YL_[N*^A6
MJ.):ZG7C3[,+M%K"%QC 04Z*SM(5V16\2*>=JJ!7#ZMXIURX2]CTZQBV0=9'
MEV]_I3--\0ZA%% \\ >Y, ; DRIX_2FDQI'=&RM?.$QMXO-7HY49_.I719%(
M90RGL1P:X(>+KS4+.YMYXHH+A!N!AEW_ *CI6Y/K,^F>%H+T)Y\VQ>&.,Y%*
MS%8VX["TA_U5M$F>N$%#6%I)(LCVL3.OW6* D5R%WXTOK:*!&M+=;J51)Y;S
MA1MQGKBDD\?2RVL9L[6)IBV'WR;5!^N* .Q>RM)I5DDMXG=>C,@)'XT2V-K*
MZO);12,. 64$BN1NO%VKA[:"STN.2XEZ@RX4?CB@^-+V4BSM[&-]4W;3"TF%
M'XXH%<ZQM.LY /,M8F"_=W(#BG265K.$\VWB?9]W<@./I7(S>-;U+0HM@K7R
MML:+?QGZXIK^-;^UM9A>6"1WB<A%?*_BV* 1VZ@(N%P!V '2G9KB#XVN(-,\
MZZMH%G8X0+,"A_X%BM+PUXF.LS36UQ'&ES$,D1R;UQ]:+#.G%% HH **** "
MBBB@ HHHH **** "BBB@ HHHH 2L[6=*&L:>]FTIC1^&(&>*TJ#0!@7_ (6L
MKRUMX8U2!H""LD<8!) K.F\"K+)*BZ@Z6<S!I;<1C#'&.N:["BBX$4,*P1)&
MGW5&!7@GQUC:7Q+HR+]YF 'YFO>;NZ@L[=KBXD6.).69C@"O /BWJECJ7B[0
MFLKF.8+(,E&SW- '3KX+U<HI$0Z#O2_\(5K'_/(?G7K4(_<1_P"Z/Y5)B@#R
M'_A"M8_YY#\Z/^$*UC_GD/SKU[%&* /(?^$*UC_GD/SH_P"$+UC_ )Y"O7:*
M3 \B'@O5P1^Y'YU;M?"6II<QNT8P&&>:]1-(17-6PL*LDV==#&5*,6HC;=#'
M!&IZJH!J44"BNE*RL<K=W<****8@HHHH **** "BBB@ HHHH **** "BBB@
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M5T@(Q4TZL:BO%E5*4Z;M-"T445H9A1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "@T44  HHHH **** "BBB@ HHHH
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M*2O8?^$-TC_GW'YFD_X0W2/^>'ZT7L!X_P#G4T1^0UZU_P (;I _Y8?K2_\
M"(:6!@0UQ8N@Z\.5'=@L2J%3F9G^!,_V9)_O5UXJG8:=!IT1C@7:IYQ5RM</
M3=."B^AAB:JJU'-=1:***Z# **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M #J.BCZQB.[#V<"3[1-_SV?\Z/M$W_/9_P ZCHH^L8CNP]G3)?M$_P#SV?\
M.C[1/_SV>HOPH_"CZQB.[#V=,D^T3?\ /9_SH^T3_P#/9_SJ.BCZQB.[#V<"
M7[1/_P ]GH^T3_\ /9ZBHH^L8CNP]G E^T3_ //9_P Z/M$__/9ZBHH^L8CN
MP]G E^T3_P#/9_SH^T3_ //9_P ZBHH^L8CNP]G E^T3_P#/9_SH^T3_ //9
M_P ZBX]*./2CZQB.[%R4R7[1/_SV?\Z/M$__ #V?\ZBX]**/K&([L?LZ9+]H
MG_Y[/^='VB?_ )[/45%'UC$=V'LX$OVB?_GL_P"='VB?_GL]144?6,1W8>S@
M2_:)_P#GL]'VB?\ Y[/^=144?6,1W8>S@2_:)_\ GL]'VB?_ )[/^=144?6,
M1W8>S@2_:)_^>S_G1]HG_P">S_G47'I1QZ4?6,1W8O9TR7[1/_SV?\Z/M$__
M #V?\ZBX]*./2CZQB.[#DIDOVB?_ )[/^='VB?\ Y[/^=1<>E''I1]8Q'=AR
M4R7[1/\ \]G_ #H^T3_\]G_.HN/2BCZQB.['[.!+]HG_ .>ST?:)_P#GL]14
M4?6,1W8>S@2_:)_^>S_G1]HG_P">SU%11]8Q'=A[.!+]HG_Y[/\ G1]HG_Y[
M/^=14<>E'UC$=V'LZ9+]HG_Y[/\ G1]HG_Y[/^=1<>E''I1]8Q'=BY*9+]HG
M_P">S_G1]HG_ .>S_G45%'UC$=V/V<"7[1/_ ,]G_.C[1/\ \]GJ*BCZQB.[
M#V<"7[1/_P ]G_.C[1/_ ,]GJ*BCZQB.[#V<"7[1/_SV?\ZXWQSJ%] D'DWD
ML9)YP:ZWBN)\>Y$< YZU[W#U6I/%I3O8RJP@H[%KX::C?7'B/9<7DLJE2=K&
MO;%ZUX5\+0#XF]]AKW5>M??8M14]#QJUN8=1117,8A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]]BO"_-E_P">TG_?1H\V7_GK)_WT:.@'NGV^T_Y^8O\ OL4U=0M6;:)XR?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'I1BKW]D7_\ S[O1_9%__P ^[_E1]7J]@Y)=BCBBKW]D7_\ S[O^5']D7_\
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M48]JO?V1?_\ /N_Y4?V1?_\ /N_Y4?5ZO8.278HXHJ]_9%__ ,^[T?V1?_\
M/N]'U>KV#DEV*-%7O[(O_P#GW>C^R+__ )]WH^KU>P<DNQ1HJ]_9%_\ \^[_
M )4?V1?_ //N]'U>KV#DEV*-%7O[(O\ _GW>C^R+_P#Y]WH^KU>P<DNQ1HJ]
M_9%__P ^[T?V1?\ _/N_Y4?5ZO8.278HT5>_LB__ .?=_P J/[(O_P#GW?\
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MM;\:[^O>IIJ"N<V,DI5Y-"T4459RA1110 4444 %%%% !1110 4444 %%%%
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M4ZBE%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML?\ GWD_.O-<48H ]*_X6/8_\^\GYT?\+'L?^?>3\Z\UQ1B@#TK_ (6/8_\
M/O)^8H_X6/8_\^TGYBO-<48H ]*_X6/8_P#/M)^8H_X6/8_\^TGYBO-<48H
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M444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
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M[_A?G@K_ )^+G_P';_"C_A?G@K_GXN?_  ';_"@#U&BO+O\ A?G@K_GXN?\
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MU&BO+O\ A?G@K_GXN?\ P';_  H_X7YX*_Y^+G_P';_"@#U&BO+O^%^>"O\
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M]FO5Z* /*/\ A0?A?UF_[[-'_"@_"_K-_P!]FO5Z* /*/^%!^%_6;_OLT?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HJ-I0AP2!]>]*9 " 3C- #J,4W=2[O6@!:6FYH+<XXH =130U&[(XI
M+12;NOM2!P3@$4 .I*3>-V,C)Z4;N,\8H\P'44U9 PRI!'3BG;J8!133( <$
MC/I2A\C(H =130U.'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )BC
M%+10 FWFC;[TM% #=N<48IU% #=HZ\4;:=10 W;ZFC;3J0T )MZ4N**6@!-M
M)M]Z=10 W'7]* #ZTZB@!,4N*** "BCO10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449H **,T4 %%%%
M!1110 4449H **,YHH **,TF: %HHS10 44F12YH **3(I<B@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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,G$B'!VQY%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mrkr-20201231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %9 8\# 2(  A$! Q$!_\0
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M_>V=PVZW=_F=2!CC/-6O!VK65QX$31XM<&C7\-WYTDV=N],YZY&<>GO7E5%
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M-_PJ'P=_T#V_[^-_C5+5/AWX;T"S^W:?:-'.&"AMY/!Z]Z]&K#\6_P#(#/\
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M+_8TEC]H(D\\SQR@?=8DGI^-4-3\/3O!<:CJ$S75YA%C\A,>6%;(( ZUT_\
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M[WIU%:UO/%=6\=Q X>*0;E8=Q2LT--,DHHHH&%9]O_R.2?\ 7LW\JT*S[?\
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MV;W,%NDZM+/'YD2C^)>N?UJW7#?#^RG>2[O[M@XMV^QVKCH8TR,CZC%=S4L
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M_P#?T?X4?VWKG_/C;_\ ?T?X444#^KP#^V]<_P"?&W_[^C_"C^V]<_Y\;?\
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MKQYR5,!YJ3^UH^UI>?\ ?@TK,I2BGN:%%9_]K1_\^E[_ -^#1_:T?_/I>_\
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MM$TMM$B,?[P!S6K_ &]"!CR+S_OR:#KL!ZV]Y_WX-%P44G>YQ\=G,8M,T_\
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M_P!''YFL9OE=CHI47.-[FM]OLO\ G\M_^_@H^WV7_/Y;_P#?P5D'2[ #)MU
M'?)IB66E2-MC2-CZ!ZGG-/JS[FU]OLO^?RW_ ._@K.L[;2K.2Y N[9X)I?-6
M)F!"-QT_*HO[*L?^?<?F:/[*L?\ GW'YFCG#ZL^YIO<Z;)*DKW%JTB?=<L"5
M^AJ&%=%M[AIX38QS-]YU*@G\:I?V58_\^X_,T?V58_\ /N/S-'.'U9]R\O\
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M@H:6T(5=HRPX'I]*CF71KC9YWV*3R_N;BIV_2M<Z/IBXW6T8SP,FG?V+IO\
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MF;8[B)VWCA7!-=)_8NF_\^B5C>)],LK?1S)%;JC[P,BJC53DD14ORLO>&_\
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MW;V+O]GW/_05N/\ OD4?V?<_]!6X_P"^16!>>*I9Y]/%G;316TUWY7GL1M<
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M .N _F:T;RVCO;*>TE_U<\;1M]",5R7AR_UI/#6G+';6A00C:6=LXR?:M/\
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M: :C>Q)! .%@&#*<8YQVJJGA.=;>&/[0F8[;R2<=\DY_6NH_LW7_ /GG9?\
M?;?X4?V;K_\ SSLO^^V_PIB]I3[G/WGAN:ZALT$ZCR+)[8\=2R@9_2F)H.J:
M?.TNEW,2M-$L<V\?=( &X?@*Z/\ LW7_ /GG9?\ ?;?X4?V;K_\ SSLO^^V_
MPH#VE/N<??>$=2NY;D/=1SB;!$LHR8\'. #6QH^A/IYNA/('6XA2(X_V00?Y
MUL?V;K__ #SLO^^V_P */[-U_P#YYV7_ 'VW^% *I23O<Y9/#>JA+.R:ZA.G
MVMP9E^7YF!SQ^M00^"IH6%K_ **;(,3YAC!<@CI_]>NP_LW7_P#GG9?]]M_A
M1_9NO_\ /.R_[[;_  HN+VE+N<W%H6L163:8E[&FG@.$('S,#T!YJ.7PE/);
MR1"X0;[4P#CN6!S^E=1_9NO_ //.R_[[;_"C^S=?_P">=E_WVW^%%Q^TI=S
MU3PR=4F4R3 1BV$.,?Q D@TS0_#MSI]_'<7*VJB&/RU\I!EN.I/:NB_LW7_^
M>=E_WVW^%']FZ_\ \\[+_OMO\* ]K2O>X^BF?V;K_P#SSLO^^V_PH_LW7_\
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M7LM$L[9PP:.,*0S;B/QJ)126A<9-O4OT445)85GV_P#R.2?]>S?RK0K/M_\
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M\.7L5[9VMQ;W1N(+PRM( 0F P.[?WSZ4K(#U2BBBD 4444 %<]XT_P"1?/\
MUT6NAKGO&G_(OG_KHM-;@8_A[5EC\.:>GV*[;$0&548/)]ZTO[83_GQO/^^!
M_C6CX5/_ !2>F=/]2.WN:UF8*I9B H&23V%=:DR;',?VRO\ SXWG_? _QH_M
MA/\ GQO/^^!_C5^Q\4Z5J-]]CMYB93D(6C(#X.#@D<ULY^GY4<S"QP6HZP@U
MC3'-G=@+OZJ.>GO6L?$$.?\ CSN_^^!_C5C7?^0OI/3J_P#2KQZ]J\_$OW]3
MNPZ]S0R/^$@A_P"?.[_[X'^-'_"00_\ /G=_]\#_ !K7_*C\JY[HWL^YD?\
M"00_\^=W_P!\#_&E_P"$AB_Y\[S_ +X'^-:WY5@S^,=(M[MH&>1@C['E6)BB
MMZ9QBFM=D)Z;LL?\)#%_SYWG_? _QH_X2&+_ )\[S_O@?XU>AOK6>X>WBF1Y
M44.RCL#T-%Y?6]C9RW<[J(8AER.<?E2^0:]RC_PD,7_/G>?]\#_&C_A(8O\
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M@\7Z3/:2W'FM'Y)"R))&59<]."*U;>\BN7F5.#$VUMPQSU_K0!G_ /"1P?\
M/G>_]\#_ !H_X2.#_GSO?^^!_C6A<7D5J(B_(E<(I49Y/TJ?(SC*[O3C- &1
M_P )'!_SYWO_ 'P/\:BN=:L[NVDMY[&^:*0;6 4#(^H-;;2(BNQ9?D4LPR,@
M"LZSU_3[Z>&&"7+S*S("N,A>O\Z *EKK%C96R6]MIUW'"@PJA!Q^M3?\)'!_
MSYWO_? _QK7S]*"ZC.67@9(XR!0!D?\ "1P?\^=[_P!\#_&C_A(X/^?.]_[X
M'^-:%K>VU[ 9[>9'B#%2PQC(ZTRZU.UL[FU@FD4/=-LB]"?K^% %+_A(X/\
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MZ=K1(T*^(//DM_*N#TK3IK_2])%AH\EI<*8G>]+;<J,9[<Y^M9HUD[.UCO\
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MN9)7_O,: ,OQ9_Q_:5_O/_2N2\87TMFNGHEX;2.:X"22CLN#76^+/^/[2O\
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;QJCJVBZWJ]D;662R12P;*HV>/QKK:*?*@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mrkr-20201231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '$ Z@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH :\B1H7D=44=2QP!4,=_9RR"..
M[@>0]%60$_EFHM6TNWUG39K"Z,@AE&&,;[6_ UY%:^%;#PM\9-)M-.DNC%);
MM(PFF+G(8#O0![51110 4444 %%%% !1110 4444 %%%% !113)"0!CU% #Z
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BFQDE3GUIU !1110 4444 %
M%%% !1110 4444 %%%% !13 3YQ';;3Z "BBB@ HHHH **** "BBB@ HHHH
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ME<[M.G7/5#6'\-O^0]<?[G]:[2[\.>9:O&) "PQFJ?A?P=)H&H27+W D#KC
MKDKKFJ1<3T\+4C##U(2>K.OHHHIG(%%%% !1110 4444 %%%% !1110 4R'_
M %?XFGTR'_5_B: 'T444 %%%% !1110 4444 %%%% !1110 5&/]<?I4E1C_
M %Q^E $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT[/H/HHHK4\\**** "BBB@ HHHH **** "BBB@",?Z\_[M25&/\ 7G_=J2@
MHHHH **** "BBB@ HHHH **** "BBB@!DOW1]:?VIDOW1]:?VH **** "BBB
M@ HHHH **** "BBB@ HHHH *9#_J_P 33Z9#_J_Q- #Z*** "BBB@ HHHH *
M*** "BBB@ HHHH *C'^N/TJ2HQ_KC]* )**** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS'6O\
MDN&B_P#7F_\ Z$*].KR;Q9>_V?\ &71I]N[%H_'_  (4TKNR$W;4]9HKE_\
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MXSZ/<:9,\D:VS1DLA7DL#0![-Y<?]Q?RH\N/^XOY4ZB@!OEQ_P!Q?RH\N/\
MN+^5.HH ;Y<?]Q?RH\N/^XOY4ZB@!OEQ_P!Q?RH\N/\ N+^5.HH ;Y<?]Q?R
MH\N/^XOY4ZB@!OEQ_P!Q?RH\N/\ N+^5.HH ;Y<?]Q?RJ.6--J_(OWAVJ:F2
M_=7_ 'A0 OEQ_P!Q?RH\N/\ N+^5.HH ;Y<?]Q?RH\N/^XOY4ZB@!OEQ_P!Q
M?RH\N/\ N+^5.HH ;Y<?]Q?RH\N/^XOY4ZB@!OEQ_P!Q?RH\N/\ N+^5.HH
M;Y<?]Q?RH\N/^XOY4ZB@!OEQ_P!Q?RI/+CQ]Q?RI]':@"**--I^1>OI3_+C_
M +B_E21?=/U-/H ;Y<?]Q?RH\N/^XOY4ZB@!OEQ_W%_*CRX_[B_E3J* &^7'
M_<7\J-B#HJ_E3J* $V+_ '1^5&Q?[H_*EHH 38O]T?E1L7^Z/RI:* $V+_='
MY4;%_NC\J6B@"(*OGGY1]WTJ38O]T?E3!_KS_NU)0 FQ?[H_*C8O]T?E2T4
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M@!U%-WKZT;U]: $E^Z/K3^U5[JXBA@:61PJ)RQ]!5:PUW3-3E:*SNTED49(
M/%%R'4@FHMZLT:***"PHHHH **** "BBB@ HHHH **** "F0_P"K_$T^F0_Z
MO\30 ^BBB@ HHHH **** "BBB@ HHHH **** "HQ_KC]*DJ,?ZX_2@"2BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#C/'FO:GI%SHEKIVHV.G_;IY(Y;F]CW(@5-P[CO[UCKXTU;2-/U>:]U"
MQUH6UOYL4^G0X1&P3AL,WYUTWB3PZVN:WX?N'AMYK2QGEDN(YP&!#1E1@$8/
M-6-9\.V\_A?5=,TNTM;62[MGB'EQB,$D$#.![T 6]!U9-;T*TU)4DC$T08K(
MA0@XYX/:N>/B^ZN?&UIIEG"ITUG>*2X8??<*3A?;ISTK?T&WO8O#UI:ZG%%'
M<QPB)UA<LN , @X'85R*_"W3K'Q#IE]ISWBP02,\RR7TAZ@XV@GUH ]"KRGQ
M,_E_&G1F_P"G-_\ T(5ZM7D/C)BOQAT8C_GT?_T(545=BEL>A_:_>C[7[UB>
M>]'GO73[,PYS;^U^]'VOWK$\]Z//>CV8<YM_:_>C[7[UB>>]'GO1[,.<V_M?
MO1]K]ZQ//>CSWH]F'.;?VOWH^U^]8GGO1Y[T>S#G-O[7[T?:_>L3SWH\]Z/9
MASFW]K]Z/M?O6)Y[T>>]'LPYS;^U^]'VOWK$\]Z//>CV8<YM_:_>C[7[UB>>
M]'GO1[,.<V_M?O1]K]ZQ//>CSWH]F'.;?VOWH^U^]8GGO1Y[T>S#G-O[7[T?
M:_>L3SWH\]Z/9ASFW]K]Z/M?O6)Y[T>>]'LPYS;^U^]'VOWK$\]Z//>CV8<Y
MM_:_>C[7[UB>>]'GO1[,.<V_M?O1]K]ZQ//>CSWH]F'.;?VOWH^U^]8GGO1Y
M[T>S#G-O[7[T?:_>L3SWH\]Z/9ASFW]K]Z/M?O6)Y[T>>]'LPYS;^U^]'VOW
MK$\]Z//>CV8<YM_:_>C[7[UB>>]'GO1[,.<V_M?O1]K]ZQ//>CSWH]F'.;?V
MOWH^U^]8GGO1Y[T>S#G-O[7[T?:_>L3SWH\]Z/9ASFW]K]Z/M?O6)Y[T>>]'
MLPYS;^U^]'VOWK$\]Z//>CV8<YM_:_>C[7[UB>>]'GO1[,.<V_M?O1]K]ZQ/
M/>CSWH]F'.7=8N=VD72YZH:Y#X;?\AZX_P!S^M;.H3,=/G!_N&L;X;?\AZX_
MW/ZUQ8B-JD3R<4[XZB>L44451[P4444 %%%% !1110 4444 %%%% !3(?]7^
M)I],A_U?XF@!]%%% !1110 4444 %%%% !1110 4444 %1C_ %Q^E25&/]<?
MI0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7EOB"%)_C9HJ.,K]C?\ ]"%>HLRH,L0 .Y->
M8:O+')\;]%*.K#[&_0Y_B% 'H?\ 95K_ '*/[*M?[E7:*KFEW%RHI?V5:_W*
M/[*M?[E7:*.:7<.5%+^RK7^Y1_95K_<J[11S2[ARHI?V5:_W*/[*M?[E7:*.
M:7<.5%+^RK7^Y1_95K_<J[11S2[ARHI?V5:_W*/[*M?[E7:*.:7<.5%+^RK7
M^Y3)-+ME PG<"M"F2_=7_>%'-+N'*BK_ &5:_P!RC^RK7^Y5VBCFEW#E12_L
MJU_N4?V5:_W*NT4<TNX<J*7]E6O]RC^RK7^Y5VBCFEW#E12_LJU_N4?V5:_W
M*NT4<TNX<J*7]E6O]RC^RK7^Y5VBCFEW#E12_LJU_N4?V5:_W*NT4<TNX<J*
M7]E6O]RD_LJU_N5>H[4<TNX<J,]-+M2IRG>G_P!E6O\ <JU%]T_4T^CFEW#E
M12_LJU_N4?V5:_W*NT4<TNX<J*7]E6O]RC^RK7^Y5VBCFEW#E12_LJU_N4?V
M5:_W*NT4<TNX<J*7]E6O]RC^RK7^Y5VBCFEW#E12_LJU_N4?V5:_W*NT4<TN
MX<J*7]E6O]RC^RK7^Y5VBCFEW#E1GC2[;S2NSC&:?_95K_<JR/\ 7G_=J2CF
MEW#E12_LJU_N4?V5:_W*NT4<TNX<J*7]E6O]RC^RK7^Y5VBCFEW#E12_LJU_
MN4?V5:_W*NT4<TNX<J*7]E6O]RC^RK7^Y5VBCFEW#E12_LJU_N4?V5:_W*NT
M4<TNX<J*7]E6O]RC^RK7^Y5VBCFEW#E1F7.CVDD+1M'\K<&H=*\,Z=H]PT]I
M%M=A@FM:7[H^M/[5+U=V0Z--R4FM4%%%%!H%%%% !1110 4444 %%%% !111
M0 4R'_5_B:?3(?\ 5_B: 'T444 %%%% !1110 4444 %%%% !1110 5&/]<?
MI4E1C_7'Z4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD>M "T4F1ZT9'K0 M%)D>M&1ZT +1VI,CUHR/6@!L7W3]33ZCC(VGZT_(]:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\G\562ZA\9M&@9RH-H_(_WA7K%>8ZU_R7#1?^O-_P#T(4T[.Z$U?0ZK_A$(
M/^?F3\A1_P (A!_S\R?D*Z2BM/;3[D^SAV.;_P"$0@_Y^9/R%'_"(0?\_,GY
M"NDHH]M/N'LX=CF_^$0@_P"?F3\A1_PB$'_/S)^0KI**/;3[A[.'8YO_ (1"
M#_GYD_(4?\(A!_S\R?D*Z2BCVT^X>SAV.;_X1"#_ )^9/R%'_"(0?\_,GY"N
MDHH]M/N'LX=CF_\ A$(/^?F3\A1_PB$'_/S)^0KI**/;3[A[.'8YO_A$(/\
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M]>?]VI* "BBB@ HHHH **** "BBB@ HHHH **** &2_='UI_:F2_='UI_:@
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M%%% !1110 4444 %%%% !48_UQ^E25&/]<?I0!)1110 4444 %%%% !1110
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M%% !1110 4444 ,E^Z/K3^U,E^Z/K3^U !1110 4444 %%%% !1110 4444
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M3OQ]_P!"$/\ P);_ .(H_P"$[\??]"$/_ EO_B*]/HH \P_X3OQ]_P!"$/\
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M;A@>1]VM'_A._'W_ $(0_P# EO\ XBNT\-^&;3PU!<Q6LCN+B9IF+^K'-;=
M'F'_  G?C[_H0A_X$M_\11_PG?C[_H0A_P"!+?\ Q%>GT4 >8?\ "=^/O^A"
M'_@2W_Q%'_"=^/O^A"'_ ($M_P#$5Z?10!YA_P )WX^_Z$(?^!+?_$4?\)WX
M^_Z$(?\ @2W_ ,17I]% 'F'_  G?C[_H0A_X$M_\11_PG?C[_H0A_P"!+?\
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M?\)WX^_Z$(?^!+?_ !%'_"=^/O\ H0A_X$M_\17I]% 'D&L?%#QCHUB;N_\
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MZJ6E6U[:V"0ZA>K>7"]95A$0/I\HZ5=H **** "BBB@ HHHH **** "BBB@
MJCK&JVVBZ7/?W3A(HAU)P"3P!^=7J@N[.VO[9K:\MXKB!_O1RH&4_4&@#B?
M>OWNKZUJRWVHP3Y6.6"&*0,(E;)V\$Y(XR:[VL#1_".FZ)K5[J-E;V\/VA44
M1Q0JFS&<XQZYK?H **** "BBB@ HHHH **** "BBB@ ILC;(G8=@33J1@&4J
M>A&#0!Y GB#7I;RWUQGU&&QDN C.;@&V7)QCRL;CUZY[U[!7&MX(N&N!;_VN
M?[%$HE%AY SD'(&_.<9 /2NRH **** "BBB@ HHHH **** "BBB@ HHHH X#
MQUJ4]KK=I')J5_9Z<;=BQTXEI3-N^4%0"=N,Y.,>]=-X3N;R[\+V$VH2(]XT
M?[UD8,,Y/<>V*IZUX9O+W5TU32]46PNO),+LUN)0R$Y(P2,=*TM T:/0='@T
M^)S((QRY&-Q]<=J -.BBB@ HHHH **** "BBB@ HHHH **** ./U^\URW\3Z
M<L4\<.F/(%9 /G<Y'?/3\*R]0DU74Y]=U&#6+NT&G.JVT$38C;@9\P?Q<YZ8
MKLM3T@:E<6DIF*?9Y ^,9W<C_"L/4_!MU=WU\]GK#6EGJ!4W=OY(8O@ ?*V?
MDZ=J .DTVY:\TVWN&&&= 35JH[>!+:WCAC&$1<"I* "BBB@ HHHH **** "B
MBB@ HHHH Q/%,FK1Z).VCR0Q3B-V,LJ[@@ ST!'/I6+%#?ZQX0T6YGUZ;3X#
M:K)=3QOLE=BH(PQX'?/%=?>6_P!KLKBV+;1-&T>['3(QFN2U7P3>WNBZ3IEG
MK7V:.PC".'MA(LV  ,J3CMT]Z +O@F:\FTF7S[BXNK=92MO<7.?-D7)R6SCO
MTXZ5TU9NBV6H6-EY.HZA'>R#A72W$(4>F :TJ "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mrkr-20201231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (_ _ # 2(  A$! Q$!_\0
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M/2L_^T7_ +@H_M%_[@I<K#F1H8'I1@>E9_\ :+_W!1_:+_W!3Y6',C0P/2C
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M'I1@>E9_]HO_ '!1_:+_ -P4^5AS(T,#THP/2L_^T7_N"C^T7_N"CE8<R-#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"^Q2LPNNY;Q1BJG]J6'_/W#_WV*/[4L/\ G[A_[[%%F',BWBC%5/[4L/\
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MGU(***6K)"E12[J@ZL<#-)2QA#*@D8A"1N(Z@4GL-;E^^T:[T^UCNI2CPR'
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M^%4Q_P#01?\ [Y%'UBGW#ZM4['FM%>E?\*IC_P"@B_\ WR*/^%4Q_P#01?\
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M3L>:45Z7_P *I3_H(O\ ]\BC_A5,?_01?_OD4?6*?</JU3L>:45Z5_PJF/\
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MO2_^%4Q_]!%_^^11_P *H3_H(O\ ]\BE]8I]P^K5.QYI17I?_"J8_P#H(O\
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MX53'_P!!%_\ OD4?\*IC_P"@B_\ WR*/K%/N'U:IV/-:*]*_X53'_P!!%_\
MOD4?\*IC_P"@B_\ WR*/K%/N'U:IV/-:*]*_X53'_P!!%_\ OD4?\*IC_P"@
MB_\ WR*/K%/N'U:IV/-:*]*_X53'_P!!%_\ OD4?\*IC_P"@B_\ WR*/K%/N
M'U:IV/-:2O2_^%4Q_P#01?\ [Y%'_"J8_P#H(O\ ]\BCZQ3[A]6J=CS6BO2O
M^%4Q_P#01?\ [Y%'_"J(_P#H(O\ ]\BCZQ3[A]6J=CS7V_2BO2_^%4Q_]!%_
M^^11_P *IC_Z"+_]\BCZS3[A]6J=CS2BO2_^%41_]!%_^^12?\*HC_Z"+_\
M?(H^L4^X?5JG8\THKTO_ (53'_T$7_[Y%'_"J8_^@B__ 'R*/K%/N'U:IV/-
M*6O2O^%4Q_\ 01?_ +Y%'_"J8_\ H(O_ -\BCZQ3[A]6J=CS6C)/4D_6O2O^
M%4Q_]!%_^^11_P *IC_Z"+_]\BE]8I]P^K5.QYK1DXQDX]*]*_X53'_T$7_[
MY%'_  JF/_H(O_WR*/K%/N'U:IV/-:*]*_X53'_T$7_[Y%'_  JF/_H(O_WR
M*?UBGW#ZM4['FM%>E?\ "J8_^@B__?(H_P"%4Q_]!%_^^11]8I]P^K5.QYK1
M7I7_  JF/_H(O_WR*/\ A5,?_01?_OD4?6*?</JU3L>ET445YIZ@4444 9]W
MK%C97T%G/-MGG.(TP>:HQ^*=/E\1MH:LWVM5W$8X_P \U4\26LTVJZ=-!9>:
MT4H9Y!P0,BMF/2; 7W]H"U1;IAS)CF@#0HHHH *I7^HPZ=#YLV[;[#.*NUB^
M($FEL&ABBE?S 5S&V"./Y4 2-XATQ#:*;D9N\>2,'YO\YINJ:]:Z7=1PSY^9
M"[,/X5!QDUS<NDWT-AHL36*R3V\JLS)QM4$4ZXL;C7H=:N4A82.H@@#<8'&?
MU% '76%_%J$'FQ*P7MN&,U<K/TFR>QL(X7EDD8#DNV<5H4 %%%% !1110!DW
MGB#3K*[%M--A^-V 3MR<#-:JD,H93D'D&N,\1^'WO+V3[%'*LMT5\U]V%P&S
M_2NNM8O(M8H<Y\M0N?7% $U%%% !1110 QAN4CID8KRSQ?;>(=#N6N;;4+B2
MR<YXQ\GZ5ZH>!FN \=>,+:TMI-+M2DL\@PY/(4?XUK1OS62N8UK<NKL<KI'B
MZ]=)-/U&]E\J?A9Q]Z,^M86MW_B?1+PPRZI.\+<Q3*1M<4W3--FU6Y\J+:J#
MF25ONH/<T>*==M9K2'1;!A):VIYF;DL?;VK#-(TXQNG9GN\*.M5KN$H*4.K?
M0[KP%\0!?*FF:M+BX'^KF;^.O30P(!!R*^??!'@ZZ\17\=RX:*RB8$R="Q'I
M7O\ !"L$*1+DJBA1FN?"SG*'OFF?8?#4<3;#OU71$HZ4M%%=1X@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_N;?6-2GA8[[6VQ$OH25YJE_:\QDMM+\Z6(O(?M%QYNX8QQANW- 'HX8&D#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?[2P1-G<D9_I3;S0'O;9K>6_D,+Y#KM^\#VJ6YT&VN(K*(LRI:,&C ]AC^M
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M>>G/6HI;F&&14DE1&?[H8XS0!/134D2091U8>JG-.H **** "BBB@!,#THP
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M&[(]V0RG!!0C%64\7:/+8->QW.Z%#AMJDD?A7E>L6-OK.@+X@$2VEP/ED0C
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M"#;%$IX45[01[T8XH^HT^7E0?V;14>57/-?!OP]:QG^W:N@:53\D78>]>DJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHJEJ&IVNF0K)=2;0QVJ!U8^@JI<>)=/MI%CD,H=EW[=O*CU- &Q16=<:Q:0:
M2VHB0/ %R"O.:B_M^SCEAAGWQ/-PI9<#/IF@#6HK.U#6K'2Y(8[N<1O,X2->
MY)JV]Q%$F^1PB^K'% $U%5TN[>5ML<R.V,X![56O=7MK.SDN=XD2,@/LYVT
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M>?C=Y>><>N*L5YSX?AOKSQ5:ZU=6\L3W,9!1O^6:C.!^=>C"@ HHHH ****
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MM-?,<JLTU9_([?5?&_B;1[QK:Y2$=T?:,./4<5IZ;XUO]:TUH[5HH]5CY$;
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M9S@9]:7-&?K0 M%%% !2$9I:;N]J (I[6&Y0I-&KJ>H(ZU((U4 #@ 8 IQ;
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M15%A1110 4444 %%%% !1110 UD#=0*-M+FC- %9K&W>]6[:,&=%VAO:K&P
M8P,>E*6 &2<"D#AAD'(/<4 )L'<"E"@#   I30#D4 -V4I0'L.*=36=4&6(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,#Q6FH/I@.GR!75MSKG!=>X%<O!J']JZA&B
MW<]O ENQVL>5<#]:[V\L8+Z+RKB,.GH:IR>'=*D\O=9Q_NQA>.U '.76J7D_
M@02R,1*[F(OT)4,0#^E3R-<V?C'38A>M]EDB(\CC P"<^M=#J.DP7^E/8$>7
M&5PNW^&H_P"P;)YH;BXB$MS$NT2GK0!S/CO7)H($M;.X: *1(\RC/ _A_&M7
M5-8NK33M*^R;6>Z*(6?ME<Y_2MDZ79&V:W:W0Q,VXJ1WI\EA;3"(21*PB(*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "DP/2EJH^HVD=S]G>X038SL[T 6\ C!H  &!5&WU:PNIO*@NHWDZ;0:2
MYU6UM;M;:64*Y7><]AZT 7\"BJUK?6]['YEO*LB>HZ5/O7^\/SH =BD(!ZC-
M!91U(_.JEI?P7SRK ^3$Y1QZ$4 7**** "BBB@ HHHH **** "BBB@ HHHH
M**** .-\4.;S5K72UMW6,NLLMR$)P <@"HHR-0\7P?Z/)!!8X",4/[UL=<^E
M=M@>E&!Z4 *.E%%% !7GE]%JEKXCU"6!9&EFD!B7'RLG&1GMWKT.DP/2@#RJ
MT2\TK5I-0EBD,:><1"5/[HGI@]\_TJ;4_#US*FERQ0L9T#7(D'9RQ(S^!KTN
M6&.="DJ*Z]PPS4@  V@8 X H \\\/V-_/XGM=;O;9XYKF,[P?X!S@5Z)110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )_Q_P!\C_"E^RZIG_C_ !_WR/\ "BWF!K45D_9=4_Y_A_WR/\*3[)JG_/\
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M_A1]DU7_ )_A_P!\C_"BWF!K45D_9-5_Y_A_WR/\*/LFJ_\ /\/^^1_A1;S
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MX46\P-:BLG[)JO\ S_#_ +Y'^%'V35?^?X?]\C_"BWF!K45D_9-5_P"?X?\
M?(_PH^R:K_S_  _[Y'^%%O,#6HK)^R:K_P _P_[Y'^%'V35?^?X?]\C_  HM
MY@:U!JM]N@]6_*C[=!ZM^5(!TUM%/$\;H"&&#Q7GTS:]X-UO>OF7NB3-@KU:
M'/I[5W_VZ#U;\J:]U;2(5<%E/4%::=A,JC4H)HP<AHW'?N#7AVN>!;^]\:SV
MFF0$VTS;_,Q\JYZ_SKURXTL23LT5R4C/10O2M'2UCT^)DDE,C,<YVUI2K.FV
MXDR@I;D/A7PW;^&M(CLX@"^,NV.IK>JO]N@]6_*C[=!ZM^59MN3NRDK#KJ!K
MBVDB5RC,,!AU%8<Z7UJ(((FDE%N-SO\ WJVOMT'JWY4GVV#W_*D,QWO-1= X
M&Q6;(PIR!4(U2\AG6$#[QSEAUK>^VP>_Y5$\EE)*)'3<Z]"5H S4O]2D5<1!
M22<Y!X]JDN9+B2XLV;<JE,N,<9XK3%[;CU_*@WMN>N?RH RDU"[,NQD( /WM
MIP?:J_V^]FN S1.%C)(P.O%;OVRW]_RH^VP>_P"5 &"+W49FWL&5>0% /-3G
M4-0.%2+YCP05/RUK_;;?W_*C[;![_E0!G3SW3V41D#+\^)"@YQ5>YN[K8\,"
M,4(PN0<D>M;/VV#U/Y4?;;?W_*@#'%[?P1K$R9P!A]IY]J>+G49#%))^Z0R;
M2H!Z8K5^VP>_Y4?;8#Z_E0!87IQ3JK"]@'0G\J/MT'JWY4 6:*K?;H/5ORH^
MW0>K?E0!9HJM]N@]6_*C[=!ZM^5 %D]*Q[VVNVNS);9 (Y)/\JO_ &Z#U;\J
M/MT'J?RH S5AU1@$:3&/XL]:+>#4?M(,LC>7W7/YUH_;8/?\J/ML'J?RH S)
M;/45=O*D_B^4Y[5&UGJK'>)<-ZYYK8^W0>I_*D^VP>K?E0!EK;ZK&1B7..>O
M6GW-OJ,\<864ID?. :T?ML'J?RH^VP>I_*@#.FMM09X1&V$11N&>IJR]K*]V
MMPN%(3'/8U8^VP>I_*E^W0>I_*@#):SO]FV-MCELNX/WA4G]FW#V/ER-F0-D
M'-:/VV#W_*E^W0>I_*@#)^Q:FDBHDY$7UILD.JB8@2,4/0@]*U_ML'O^5'VV
M#U/Y4 9GV:_N;$;Y&$H;(]Q4L-O?F&4S2$G'R+FK_P!N@]3^5'VZ#U/Y4 98
MBU&>5@':-%P ,]:8]MJ<DI3S&"@_>SUK6^VP>I_*C[;!ZG\J ,L6VJEBK3D#
M/7/;M4D5MJ*W($DN8=N"<]:T?ML'J?RH^W0>I_*@#):UU$XV';V(S^M$B:C;
MRP#S'=2PW8[5K?;H/4_E2?;8/4_E0!ES6&H+/YD,IVL<D9Z?2@VNK>7D3D,3
MTST%:OVZ#U/Y4?;H/4_E0!C7$6IPE,2NX8X(':GR6FJ[ 4G(/<5K?;H/4_E1
M]M@]3^5 &2MIJQ5\W)W=J=!::@Q<7$C'*%0<UI_;8/4_E2_;8/4_E0!E+::G
M$WF"3<<;<9[5']@U./<8Y26/.2>E;/VV#U;\J3[;!ZM^5 &4UEJ3;"TY9@.>
M>,U%%'J\SG$K1H#CD]:VOML'J?RI?MT'JWY4 4GL[J6U,<K[L$$$]:JO#J:+
M*YD;8OW54]JU_MT'J?RI/ML'8G\J ,9+759E$CS,#U5<_P ZFM[74?/C-Q*7
M09SS6I]M@]3^5)]M@]3^5 % V$J0;5&[]X6*YZC-0?8=2>0NTA"@_*H/ %:W
MVV#W_*E^W0>I_*@#/-O?F"+#GS5///6FW5M?&4O;\,R@%B>GTK2^VP#N?RI/
MML'J?RH R[2SOX)P7F9D(R03U-"VVK>4Q,QWYX7/:M3[;![_ )4OVZ#U/Y4
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2"S15;[=!ZM^5'VZ#U;\J /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>mrkr-20201231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )1 _ # 2(  A$! Q$!_\0
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MM'DQ_P!P54_M%?[AH_M%?[AH]FNP>VEW+?DQ?W%H\F+^X*J?VDG]PT?VDO\
M<-'LUV#VTNY;\F+^XM'DQ_\ /,54_M%/[AH_M%?[AH]FNP>VEW+?DQ?W!1Y,
M7]P55_M%?[AH_M%?[AH]G'L'M9=RUY,?_/,4>3%_<6JG]HK_ '#1_:*?W#1[
M./8/;2[EOR8O[BT>3%_<6JG]HK_<-']HI_<-'LUV#VTNY;\F/_GF*/)C_P">
M8JI_:*_W#1_:*_W#1[-=@]M+N6_)B_N+1Y,7]P54_M)?[AI?[27^X:/9KL'M
MI=S/V/\ W&_*C8_]QORKZ)_LNQ_Y]8O^^:/[+L?^?6+\JY_K?D;_ %/S/G;8
M_P#<;\J-C_W&_*OHG^R['_GUB_[YH_LNQ_Y]8ORH^M^0?4_,^=MC_P!QORHV
M/_<;\J^B?[+L?^?6+\J/[+L?^?6+_OFCZWY!]3\SYVV/_<;\J-C_ -QORKZ)
M_LNQ_P"?6+\J/[+L?^?6+\J/K?D'U/S/G;8_]QORHV/_ '&_*OHG^R['_GUB
M_P"^:/[+L?\ GUB_*CZWY!]3\SYVV/\ W&_*C8_]QORKZ)_LNQ_Y]8ORH_LN
MQ_Y]8O\ OFCZWY!]3\SYVV/_ '&_*C8_]QORKZ)_LNQ_Y]8ORH_LNQ_Y]8OR
MH^M^0?4_,^=MC_W&_*C8_P#<;\J^B?[+L?\ GUB_[YH_LNQ_Y]8ORH^M^0?4
M_,^=MC_W&_*C8_\ <;\J^B?[+L?^?6+\J/[+L?\ GUB_[YH^M^0?4_,^=MC_
M -QORHV/_<;\J^B?[+L?^?6+\J/[+L?^?6+\J/K?D'U/S/G;8_\ <;\J-C_W
M&_*OHG^R['_GUB_*C^R['_GUB_*CZWY!]3\SYVV/_<;\J-C_ -QORKZ)_LNQ
M_P"?6+\J/[+L?^?6+_OFCZWY!]3\SYVV/_<;\J-C_P!QORKZ)_LNQ_Y]8ORH
M_LNQ_P"?6+\J/K?D'U/S/G;8_P#<;\J-C_W&_*OHG^R['_GUB_[YH_LNQ_Y]
M8ORH^M^0?4_,^=MC_P!QORHV/_<;\J^B?[+L?^?6+\J/[+L?^?6+_OFCZWY!
M]3\SYVV/_<;\J-C_ -QORKZ)_LNQ_P"?6+\J/[+L?^?6+\J/K?D'U/S/G;8_
M]QORHV/_ '&_*OHG^R['_GUB_P"^:/[+L?\ GUB_*CZWY!]3\SYVV/\ W&_*
MC8_]QORKZ)_LNQ_Y]8ORH_LNQ_Y]8O\ OFCZWY!]3\SYVV/_ '&_*C8_]QOR
MKZ)_LNQ_Y]8ORH_LNQ_Y]8ORH^M^0?4_,^=MC_W&_*C8_P#<;\J^B?[+L?\
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M_P#?-'U[R#V'F?)NR3_GF_Y4;)/^>;_E7UE_8NF_\^,/_?-']BZ;_P ^4/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIJ6GVK7"*H!"#)!!)KM_ E]K%[H8&L69MI8CL12,945E5E>E&Q4%:;)O'_\
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M]3_Y\X?U_P :CZM4[%?6:9ZU@>@HQ7DO_"T]3_Y\X?U_QH_X6GJ?_/G#^O\
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MV%>2_P#"T]3_ .?.']?\:7_A:>I_\^</Z_XT?5J@?6:9ZS1UKR;_ (6GJ?\
MSYP_K_C1_P +3U/_ )\X?U_QI_5JG8/K-,]9Q17DW_"T]3_Y\X?U_P :/^%I
MZG_SYP_K_C1]6J!]:IGJQAB)R8T)]2HIV!Z5Y/\ \+3U/_GSA_7_ !H_X6GJ
M?_/G#^O^-'U>IV#ZS3/6,>PI<#VKR;_A:>I_\^</Z_XT?\+3U/\ Y\X?U_QH
M^KU ^LTSUC'L*,?2O)_^%IZG_P ^</Z_XT?\+3U/_GSA_7_&E]7J!]9IGK./
M848KR;_A:>I_\^</Z_XTG_"T]3_Y\X?U_P :/JU3L'UFF>M45Y+_ ,+3U/\
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MT]3_ .?.']?\:7U:IV#ZS3/6<>PHQ["O)_\ A:>I_P#/G#^O^-'_  M/4_\
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MO_"T]3_Y\X?U_P :/^%IZG_SYP_K_C1]6J!]:IGK6:,UY+_PM/4_^?.']?\
M&C_A:>I_\^</Z_XT?5J@?6J9ZU1116!T!1110 4444 5K[_CPN/^N;?RKYVG
M_P"/F7_?-?1-]_QXW'_7-OY5\[S?\?,O^^:[,)U.'&=".BBBNTX0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV\N^0F-D RBY/M7(9QT)'T-&XXQN./K63IWE>YHJEE:P444E:F8OX4GX444
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MC_A5,W_00'_?/_UZ]0I*/K%3N'U:GV/,/^%4S?\ 00'_ 'S_ /7I/^%53?\
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MK)B0<12G^+V-52S64Y\DM&71Q-&<_9SC9B?\*JF_Z" _[Y_^O1_PJF;_ *"
M_P"^?_KUZ:#D9%.KM^L5.YZ/U>GV/+_^%4S?]! ?]\__ %Z7_A5,W_00'_?/
M_P!>O3Z*/K%3N'U:GV/+_P#A5,W_ $$!_P!\_P#UZ7_A5,W_ $$!_P!\_P#U
MZ]0I*/K%3N'U:GV/,/\ A5,W_00'_?/_ ->C_A5,W_00'_?/_P!>O4**/K%3
MN'U>GV/+_P#A54O_ $$!_P!\_P#UZ/\ A54O_00'_?/_ ->N]U'6(=/GBMPC
MS7,OW(D&21ZU6D\0HMPELEM-)=%=SQ*.4'O1[>IW#ZO3['%?\*IF_P"@@/\
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M$DJQ1&!XAP", 9K=T30&TS4[RY*H$E"A .JX4#^E #9_%]I!K!L#&YVR>6S
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MJ*Q]!\0W&C3L'+26LORS1,Q/'J*IX[EE:2T?44LQY))26CZGO8U?3CTOK?\
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M^'S<*+=[/S?X=K+FB6#32@I60IY?%I04K(\GVIX/M-J(9=8F7E@IQ"#_ %K
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MS=SXH6'Q/;Z/% 9%D!\R8=$/85TA&017)R^#$&MV^HP7DJA)6D=#CYB3GTH
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MTTG[7W/^ -*7MOW?S[%#Q%H$NB7"2QRM)93?-!,&/(K5TC5+;Q!9KHFL2$2
M8MKG/(/8']*R-<U/4-=O0S6\J0+\L,(0X45NZ?ID7A73UU74+9IM0D7-O;A2
M=ON?TJH7]HW'X2J:?M6X?#UN<SJ6G7FAZB;:5G29#E'#'D=C6SB#QG9B&9_)
MUF%/D<' F ['WZUBW3ZGK&H&6:&:2>5L ;3Q[5LW-M=>&K,VUG9RS:G,O[R<
M+Q$/0?Y[U-)/G=E[IZG#T<5]?7U5V76^UCDX+B\TC4?,BD>*Y@;!^8]1VKW;
MP/XRA\36/ER#;>1#$B^OO7BVF>&M7UC44MUM)E:0_-(XX'J:]Z\+^&;/PWIJ
MV\*@S$9DD[L:[<'&HI-]#]&XDJX.5*,='4\C?QTHQ0!BEKTCXH3 ]*  *6B@
M P*,444@#%)^%+13 ,48%%% "8%&*6B@ Q2?A2T4 )^%+BBBD 8HQ113 3 H
MX]*6B@ Q1BBB@ P*,444 &*,444 &*3 I:* "C%%% "8%&*6B@ Q1BBB@ Q2
M8I:*0!@48HHI@&!28%+10 8%&!110 F!2XHHI &*2EHI@&*,444 &!1BBB@
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M1#(T4M]$CJ<,K, 14UMKFFWD<CV]W'((QEMK X%>1-;Q>,]-DN8D$.K6R9D
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M6G+!TVTG+0)X"E)I<VBZ'D6IVFH:?:'2=)T^?;_RWN .9#Z#VJCHG@[4]3O
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M(8<O[42C-UE[,J4)O$+V*U/8=(U2'5].BO;<YC<9^E7Z@M;2*SMT@@0)&@P
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MM'-$-[1L[K@*PZBK%YX=AN=.L[)',<=JP9<=\54D\'PR!@T[;6N&G(QZG.*
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M/J!3AC.>+M'5="H9ASQ?+'5=#V"*XT[R&GAE@,0X9E88_&H/M^A 9^TV?/\
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M8N<R()#F(^G6A8Y.-T@CF2E#FC'5;H]R-Q;[-WFQ;/7>,4P75K_S\0?]]BO
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M_P />&9+Q7U'44DAL(.2"O+GT%0^(-6O=7F6*"TE@L(N(H0IQCU-"4O9>_\
M($I*A:I\OZ[":-K,(MCI6K$R6$AP&)^:(^HJEK6B3Z+>*I<M _S0R@_>%:VD
MZ(MC9C6=4MG9%/[FWV\R'WK,U*XU/6+XS36\Q+'$<87A1Z"I:E[-<V_04U/V
M:4]^AK:?>6_B.U32=2?;=J,6UQW)[*?TK G@O-%U,QN6BN86X(-=+!8'PI9K
M=2V[SZK,O[M-N1$#W^M<^EEJ>K:CM,$TEQ,W+,M%12LD_B"HI\L4_B-LQ0>,
M+5IH0(]8A7,B#@2@=ZPM-U*\T341<6[%9$.'C)X/J#707A/ANT;3=-ADDO7&
M+BZ"GCV%9&B^';[6K\0+%)''UDE<?='>G-2YER_$.I&;E'E^(V-4TJV\0Z:^
MN:.N)$_X^H!V/J*R= \0RZ/,T<B^;92_++"W(QZBM;7-1-I9_P!BZ+;2I:IQ
M-*%.93WJIX>\,2Z@7O;]'AL(/F8E>7]A5S4G57)OU[%S4G67L]^O83Q#X>BM
M8$U;2R9=+N#D9_@/I4.BZW%% VF:KF33I3C)Y,9]14GB#5KO576WMK2:#3X>
M(H@IY]S4NCZ$+2T_MG5K>0PH?W5OMYD-2T_:WA\Q6?MKT]NO8S=;T671KI0&
M+VTOS02@_>%=KX$\=&&2+2=3<LI.V&4]?H:XK5;K4M8O?.EMY0.D<07A!Z"O
M1? G@06@CU34TS.PS'&?X?>M,.I^W_=[&F$51XB]+1'I"L" 1WIU)@ #%+7M
MGT04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDTZ=X8WM[JVQ*48?>0__ *Q76V\HFMHY1_$H- $M%%% !1110 4444 %%%%
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M:YW5=0NY-?MM'M91#YB>8\F,G'/ _*JZ7.HWFO2Z2EV(UM8U9Y-@RY/3C\*
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M8X&15B^\5:3ILBI=7.PL,J<'!_&CVD-[C5:F];HVZ*P+;QGH=W.L$5ZID;@
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MV\T5ST'C70;B=8H[U2[' SQ6^KJP!4Y!&0:<9QELRHSC/X7<?1115%A1110
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M<@#LQKDI(I+"\=4D FA? =#W%=_J.BZIH^G_ -DZ-I\CNP_?W0 RWL*Y_3_
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MOKNILMK9Z5-!IT/RQQJ -WN>:])@\::5=:;)?0,TB1_?11\P]\5G?\+.\/\
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M;RV9I%B^^@!W#WQ1]7H2G?FO;H'U;#RG?GO;H>;^(;?7+\BRL=)F@TZ'A$7
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M""AS_*A8>A&-^?<(X7#PC=3WZGG.A^!M4U&\Q>6TEO;1_,Y;JWL*N^((-:O
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M+80M--$=-E1+@@D;W) Q[\$5ZR.@JM_9]K\W^CQ_,VYOEZGUJR!@4 +1110
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MQI-.-[]#D=+U*XTN]66#YMW#1'D./3%:?B?2[:RD@N8,1-<KO>V/6,UT^D>
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M* /3BP'4@?6G#I7E%YK=]J@L(5GEA;3Y46Z*DC<Y(&#^8KU93\H/K0 M%%%
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MST,#BGB(>]NBR!CG%&/:G45V'<-Q013J*0#<4;<TZBF W%&*=10 W;1BG44
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MT%>I8I-M)8*FG=;BCE]*+<NIXF/AEKTDX,C1X8_,Q))K:U#P3J\%@NFZ2$2
M@>;*2=TA_P *]2VBC ]*%@J:V%'+Z,4[=3QFP^%^J27:"\=$MP<L5)R:NZSX
M+U^_9;:W2*&QBXCC!//N:]9VB@J#0L%24;(%EU%1Y4>2Z%\,[N&[-QJ>QDC&
M4B4_?/O4>L^"_$VLW?FR^2L*\1Q*3A1^5>O8%&*?U.GR\O0?]GTN3D6QY=X>
M^'MSIB27UVD<UVH_<Q?P@^IK,U+P'XGU2\>ZN'C9VZ#)PH]!Q7LF* H%#P=-
MQY>@/ 4G%0Z'F^G^"K[0-(9K)(Y=4F&#(_2,>U<Y)\-O$4\YDE>-G<Y9R237
MM94&@#%$L'3DDGL.> I22B]D>8S^"=5T[25L=($8DE'[^X/WC[#]:P[7X7:Q
M)<H+EXTA)^=@3G%>UX%)M%$L%2DU<4LOHR:OT/*]9\&:U/ NGZ:D<-A'TY.7
M/J:J:-\,+];SS-1*>0@SL4_?/I7K^T4;10\'3;YF#R^BY<S/(=8\%>)-6N0S
M+"EO'\L42DX4?E5SP_\ #NYT\RWM\D<UR@_<Q?PY]37J6 *-H-'U.GS<SU8U
M@*2GS[L\<U/P-XGU:]>ZN3$6/1<G"CT'%;>F>"KW0=)>6T2.;59> [=(Q[5Z
M1M!HVBFL)34N;J$<#24G/J>*2?#CQ'<S/+,\;R.<LS$UNOX)U73-)6STD1^?
M*/W]PW7Z#]:].P*,4E@J:]11R^E&[6[/%8/AAK,ER@N'C6,GYVR<XK8UCP9K
M4MNNFZ6D<-@G4Y(:0^IKU+:*, 41P5-*R".7T8II'CVE?##4/MJOJ)06Z<[5
M/WCZ5-K/@KQ'JTP $,5M'Q%"I. /RKUO:*-HI?4J2CRH%E]%1Y4>6^'OAU<6
M#O>Z@J2RQC]S#V)]36?JO@CQ1K%XUU<F(Y^X@)PH]!Q7L6!1@4_J=/EY.@/
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M:!0?,R"2!0!H45GG5[,?\M1C'7M0NK6C8(DZ]J -"BJMM?V]V6$,@8KU%6J
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MN:]%9']LR?\ /A/_ -\FE_MB7_GPG_[Y-%F%S6HK(_MB3_GPG_[Y-']L2?\
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MFM+,XKE;^P +TNK@1$8([U?.D6QG\T AL8J'^V)/^?"?_ODT?VQ+_P ^$_\
MWR:+,+C_ .Q+;: 2V <]:&T2S;?E3E@!],4S^V)/^?"?_ODT?VQ)_P ^$_\
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M\)_^^319A<UJ*R?[8E_Y\)_^^32?VQ)_SX3_ /?)HLPN:]%9/]L2_P#/A/\
M]\FD_MB3_GPG_P"^319A<UZ*R/[9D_Y\)_\ ODT?VS)_SX3_ /?)HLPN:]%9
M']LR?\^$_P#WR:/[9D_Y\)_^^319A<UZ*R/[9D_Y\)_^^31_;,G_ #X3_P#?
M)HLPN:]%%%(9G7>DP7ERL\F=ZC Q7+:CXFF\)ZK'#J=J6TZ4[4N4_@^M=U5/
M4--M=3M7M[N%98V&"&%-6OJ)A%=P7,"31.LD4BY5AR"*\+^*OAJ+2M634K1
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M12 ****8"4M%% !1112 ****8!1110 4&BB@ HHHH **** $[TM%% !1112
M*!113 *.]%%( HHHI@'>BBB@ HHHI %%%% !1110 4444P"BBBD 4444 %%%
M% !1WHHH ****8!1112 **** "BBBF 4444 %%%% !1112 2EHHH *3O110
<4M%%, H[T44 %%%%( HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>mrkr-20201231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20201231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '- _ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHI,T +129H!S0 M-<X4GT%.I",@@T <!!XSOCJ4BND4D*2LIC3[R@
M#.:U!XUCD@22&QF=GRP7'.T=3UK:M]"L+6.=(X0/.)+GOS52X\*Z?/;PPC?&
M(@55D.#@]10!DZEXW'V:0Z=;/*R)N=^R?6KB>,+5( 9E;<K;6(]<9J6?P;I<
MS*0'0!=K*IX?ZTK>#M+>\-R5?)YV9^7- %&[\7SKISWEOI[F,.%C9NC@U=M?
M%"SZM'IS6SI(R!B3ZD _UIP\)V"P30>9+Y4ASMR,+]*DB\+V,>H0WI:1Y8@
MNX\4 ;>:6DHS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)FC</44
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M11L&2#@>E<RL.N:AJ=UY9E1U<<ER%7ID8[T^'P]KUM.TD$Q1GD8M\_&,]<4
M=#-X7L)IIW,CCSSF501@U-!H&GVQN#%\HG7:V".!7.1:/XA$4^;B3SF4C/F<
M'FK%[HVL_9+)8)G^5?WX$G)/^<4 :,/A'2X/,Y9O-38VXCD4D'A31HY&:$8;
M9L)!Z5F7&DZV&MGCED=E !!DXJ)M$UWRYB9'#,X*A).V.](#L8+6*SL%MX1^
M[1<"O-/BIG^Q[3'7S/\ "O0M*BNXM)1+P?O@.><UY[\5<_V/: =?,_J*SK?
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MMT_2AQ87/2**CAE2>)9(V#(PR".XJ2I&%%%% !1110 "B@44 %%%% !1110
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MUU^W>YA@9+<':C,?O'O^M;58^B:#;Z$)(K1W\ER"(VY"FMBD,**** "BBB@
MHHHH **** "BB@\B@#G+[_D,R_[G^%,J74(+E=4>5(&D1EP"#4&+K_GS?\Z
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M4[H?+FMC(Q/ VN/K'A^/[3Q=VY\J8=]PKJ*\Z\+M_9OQ"U>P'$=R@F4>^?\
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M/X9KOX/"FDP::]@ML#"[;WSU8^IJ>3P[IDVHVU_):HUS;)LBD/5106<=\,[
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M2'I0.+Y7<^5X= U67Q$MI]BG$@G&<H<8SZUT7Q(T&_MM;AF%K))$T*KE%)Y
M]J^@1;P!_,$,>_\ O;1G\Z5X(I>)(D<?[2@US?58V:/;>>5/:QJ<NRL<1\*+
M"YL/"86ZB:-G?<JL,''-=X*8J*BX4  =@*>*WC%15D>17K.M5E4?46BBBJ,A
M*6BB@ HHHH **** "BBB@ HHHH ***1C@9H 1FVBLN[N))I?LEN?WK?>;^Z*
MDOKQH@(XQNFDX4>GO7/>(]=A\)Z4V&#W\PX!ZY]:J,7)V1+DDKLI>+_%<'AB
MP^P6)#7T@Y(YV^YKQN>66YG>:9R\CG+,>IJ:[N9KVZDN;AR\DAR234.*]2C2
M5->9YU2JYLB*\UL>'?#5[XCOA#;(5B!^>4C@"I_#7AFY\1Z@(HU*VZG]Y)V
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M;Z5[/'&L,21)PJ# %9XF>G*:X6G=\S).E12$LPC'U-/9L*2>U1PCJYZFN(]
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MJ_X<_P"0]+_US%53^(PQO\)G8T445U'AA1110 4444 %%%%  **!10 4444
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M&QMQQBM+-,9HPP5F4,W0$\FH1O)"12B5<J,8J2FHBHN%&!3J"D9.L^'--UR
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M%%% !1110 4444 %%%% !1110 4444 !I*4TE "T49HH ,4F*6B@!*!2FD%
M"FN?O[V[M=8+(=UND9+IC]:WZC,$;.7*@DC!)]* .:34KP6=O=0MYR7'R_[I
M]:LZC=7$&FM%B42*R@R8QN^E;2VD"QK&L:A%.0!VITUO'<1F.50R'L: .<D^
MTC3XS'(_+ NI8[B/:ECN_MSQ6_VEXH0F=QX+&MK^R[3RO+\H;.N,FG/IMH\2
MQ-"NU>@]* ,VQO9C"\++),H<HLJCH/4U;T:21[,^8Y=E<C)^IJ[%!'#&(XU"
MJ.PIR1)&,(H Z\4 /HHHH **** "BBB@ I&.%)I:BG;;"QH P]1.Y%3^^^*Y
M7Q[-_P >MN.@&2*Z>X^>]MD]\UQ7C.7S-:*YSL7%=%!>\<^)=H',[:GL8/M%
M]!$/XG%,Q6MX9A$NOVXQP#FNR;M%L\^"O)(]0C3RXD0=% %/)P*:3S2-T->:
MW<]9;6"/H3ZT^F#@4N:0Q2>*S;^3"D5H.WRUC7K;I0,T 5-M*1@9I^*,9('O
M5"+EI'LB![FK2BHDX %2K2 D%2+48J51Q0QD@IPIHIPI /%/%,%/% QPIU)2
MB@!13J;3J0!1110 4444 (:2EQ24 )24M(:8#33#TIYIAZ4"&M3#S3VIAXH
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M'[&JI_$<V/?)1;9[_134;=&K>H!IU=)XX4444 %%%% !1110 "B@44 %%%%
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M >CO<0Q[=\JKN^[D]:DS7D%EO\BY76#-O$(^P[LYZ\8Q_6NLO[_4M/\ "NF
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M45U]"*8;*W,8C,*% <A<<"IZ* (7M8)"I>)6*_=R.E/>))4*2*&4]0>]/HH
MB2VA10J1J% Q@"G")%((4 C@4^B@ Q1110 5!>1M-9S1K]YT(%3T4 <UX)TB
MZT30OLMX )?-=N#G@L2/YUTM&** "BBB@ HHHH ****  44"B@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,B[EQ6/=PO#()HSAU.0:0'5[:S[^U(/FIU':IM,ODOK8-G]XO#"KI0,,$9%
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M 4444 %%%% !1110 4444 %%%%  **!10 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT\T.M3M[R.UFBVXD0YC;I[5%FGPSF,E2,H>HITT("^9&=T9_2OH3G(3S56>
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M+QO]-LF\J7/4X[_K77CI7WL)*45)=3@M8****H HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ %% HH **** "BBB@
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M*K7E[!8VSW$[A8T&6/M3K>ZAN($ECD!2097)ZT 3T4F]?[P_.DWH3C<,^F:
M'45EWFNZ?8:A!8W$VRXG_P!6N.M%KK^G7>J3Z?#.&N(?OKCI^- &I152_P!0
MM]/MC/<2!8P0,CGK44NKV4,)D,P( !(7DC/3@4 :%%8-[XNTC3[G[/<R2K)V
M B8Y^G%6(?$&G37D-HDQ$TR;T1E(.* -:BL^^UBRTV>"&ZF$<D[;4'K5BZNH
M[2U:XE)\M1D[1D_D* +%%8.G^+-)U.[%M:RRM*?6)@!]>*FU'Q)IFE3B&ZG(
MD/)"*6Q]<=* -BBH8+F&X@2:.16C<95L]:S[GQ!IUK/+#-,5>(J&&#QGI0!K
M44Q)8W52''S $<T^@ HHHH **** "BBB@ %% HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K(\36AOO#E_; 9+Q$ 5KTQUW*0>01@T >
M$>'O!B:EI,%]I-\]E>#*RIU0GZ9KHH_!OB@I_I&J6RQC^-5&:2Q#>&?&M]I,
MI*VUTWG6Y/3W'Z5?\5:LT$MEND9K/=F5$/.>*:IRG=1W,ZE54X\S$LO#UA9+
M+'<@WDK#YI)>?R!Z5"GA/29E\Q!*@/\ "LA IFA+)/+<WL4K-;2'Y(W/S"M9
M%:.3,4FP'JIK\_QM;&X/$2A&JT_F=D(4J\%*44>?:UX'']NPVUEJ$OE$^;,K
M$DH!SP<_6M"\\F$K"7DF90!ESFM"PD:?Q=K%C,X%S)"#"3WX/2L#4I&M+MUN
MHI(W'!!'6OK<!SSP\)5GS2MN9.,8.T%9!'/'->):R@PE_P#52Q';@^X%174.
MI+J3S"+S9H1B4*.77UIFG6T^I:E'-Y;);Q'.X]Z[+1K234/$[F)@JI'B0GIS
M5XJC!QYDM3LP.,GAZE[Z''S2Z;JD02:15<?WCAEJK'ING12 ),\[Y^6-3G->
MQ7'A;1(XFDN;1)9,9)''\JRK;3=/MF,T-JD?IQG%>74M36K/HJ6<\Z<8)G(G
M0M;MH8=9TPD7L7_+J> R>GU_"L77M=?Q!J>FV-SIC6E[YH:0-'@X&>]>F0WC
MRR-Y>$B7JU<*)I-?\5W&JE,VUK^YB<#J>Y_,&N[*J[K2Y4M#Y[,[W=26[.C5
MRFW:<$5I6NI=$F/_  *L7?[TN^OI)14CYV%1Q=SJU8, 0<@]Z6N=M[Z2W/!R
MOH:U[:^BN ,'#>AKFG3<3LA54C1CNF0;6 =/0T_RHIN86VM_<:JF:-WH<5%C
M4EDC>(X=2*;FI([MU&UL.OHU/ MINA,3>AZ4 09I",U,]K*HR@#KZBH#E3@@
M@T@&-$#V%1-:J>PJQFEI@46LE/:H6TY3VK4I:+ 8YTQ?05#_ &<OVC;@=/2M
MW STJO@?;?\ @-%@,]=,7^Z/RJ1=-4'H*U, TX8Q2 SUL%':IULU7L*LT<4
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M8B&E^=O>MB.WCB&$4 5+12 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8]<'@TVTTU+>=/WIN;@G"HO('N:]&O? F@64>1Y^_IA9#C-)9Z3I^D1F2*(
M]V/)_.N"HU3W>Q[RS?VE.U.YR<5_J/@^>2+5+5KW2[KYMR*3L/H1^=:'P[6R
MU/QW?ZAI\(2WBB"\#'.?_KUT-UJJ6^EW%S<1I]FC4DAQD&I?AEI!LM$EU&2%
M89;^0R[%& !Q_A7J8#$>UCML?*XR%IN3W9W0 I:04M>@<@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  **!10 4444
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:** "BBB@ %% HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>mrkr-20201231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrkr="http://www.tapimmune.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrkr-20201231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O3dyd2IkiEOKoM1hwWKeZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tgvmmST_Hke5xeVNJK8Seg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pZiFWHEB4UO4INGI471GYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dANtDkv1f0qA4nDLM7h0Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SYa5-5t2RkuK9-fz8jtoFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WRGLryikz0KaY92hGWffvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_P9Qbbx0CNUGy-vJOvqifnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPytHBodskGfOc2ipJ9aIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_82up_zfWNUmUUgXpcdgRMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qZ9NHzo7YUC9v4IRoJS31Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_vMApe0EcyUGKDZi6FGn-GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_LhNNdP3e2Eqw1UGKZWWoVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wi8B3dNGskeO0KIAZp0PNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nia-K5yaQkK6PrPyNBtXQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_pXkrJdElCEK5luXf8RD1jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Z1owGgssVkun98tvJFc-ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_hm-aT4_utkG7keclj27JkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_9yHzLxI9J0KiGOFm8vPRig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_GrantMember_KRQJasOkrUe2D02MbHcHKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_cQNwlMiI7kK08D7_DtU4Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_mJazqkPfFkmc-QMBbBM7hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:PurchasesFromBioTechneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_MrqVXYEw1Uid9u_ZLvUPNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_2YaAsQK__kGBYij0npbG_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:PurchasesFromBioTechneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ConsultingAgreementWithDr.JuanVeraMember_eeZVsRCRzUeJu-ihCRWw2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ConsultingAgreementWithDr.JuanVeraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_vsg7AnMxjECUv2UMBZE8Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_B-vZs3Ppc06PCUnjXPTuOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_XdhD9gTpeU6hnY0-z8DASw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_zke-f8FZTkO88cP2_ZhOwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_olqT_Fwx7U-Odxkj912Fyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_A2_KcOuc7UCSujKL_kVBbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_v-vM_Z57j0W6NbhuDyp_Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lIiAzvSsBkSWpBXL8lYO6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_Y6NXa2tNyEWBTjwC2KHiAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_92qxNSp0JkO7pwogTgs1Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_PUj_K1bfHkGFM2Y4jHt9Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_ACdngx63MEKIMb7z31QBtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_FZSrIrNxmUyDqyxkQZDk4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_o2aish9KUkmT-1TlNuBhUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_UnPt_Wy98US1VFSStqyNsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_vLnol8OkUk2BmiKlJVI3qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_y0AGgi3VjEide44SDAm8EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ResearchFacilityInHoustonTexasMember_AUKUMDHj8UmZXAD59Q-Ixw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ResearchFacilityInHoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_OfficeSpaceMember_AzY5PjhRa0KWIVTuRWZcsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_5T8qVStqZEGO5cyYBUn0KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ManufacturingFacilityInHoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_CorporateHeadquartersMember_yvnuelJz_UW9l4GGuzdD-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CorporateHeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_lXNY-SqcckufSQP1_3M_NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_MlrJM6J87kKV_E3Gg6OHjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_fB-XBxEMVEuZ0AXnJJPCYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_H6133jjRH0CvkLeY903Lgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_ZI-qkKDgJE-mZLjhRnPZhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_g6VPuQbHC0y4V1O1fXaO1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_zThIObKJTkGFAkdmLkZJyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_7MInXfUOC0WNFuWoIBCLMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_5Gr7NCUwa0aVADJ5Uz_xrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_x8rh7aiZp06pdQPYS17Hvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:ExerciseOfStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_ZhSFY76i_kCH9MG-xjOj-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_otSldnsXxkWsBDD0krxySA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_ConsultingArrangementsMember_2YOLfsHrJUiQ-nXn-u702g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ConsultingArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_e3jl9ISh90CJS6uJdshXmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_95mnbsS_AUasMsjLjipGSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_mgveA6v0wUaCVTftpwttxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_3B73NaasBEmFQYB4WCOXUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2020_2wu45mhpe0Wt7jhL5XOOSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2020_C8Sjke4d3Uu2bMNfPrnSIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrkr:SharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrkr:SharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember__pIPPDpQCU-WKKP23kwqnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrkr:SharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_J3vACPWMbkmTs8PjTPKwqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrkr:SharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_-Qd7LU2lBUa_mee1OprAuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_j4K7-6m1s0mROj8Tc9Lrag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mrkr_CommonStockWarrantsLiabilityTreatmentMember__mhH4edEXEqL7o8fnQckTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mrkr:CommonStockWarrantsLiabilityTreatmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GPlgMEopskaT3rrayUflxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_OqczUH54BUevB2a6-k75Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mrkr_CommonStockWarrantsLiabilityTreatmentMember_aWBuEQRV-kK1UZ4Oeqku7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mrkr:CommonStockWarrantsLiabilityTreatmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_5QP_WyrpuE6d2eZgC1tMCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:AspireCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2021_dgrzcG53v0qHBae8oSbc7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_iR2ThMvN30malanztgioBw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Options_XwIwXkVLKk6WPb72jTZEwQ">
        <measure>mrkr:Options</measure>
    </unit>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Hidden_hx2PinEYJUicAfLbSG_JWQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      id="Hidden_psCQLqgm_U2YsvD07atjGA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      id="Hidden_nE1w-i3HQEG-I60w3MD2ZQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      id="Hidden_ZDFFjDW-yk69ppnYMlgkRg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      id="Hidden_yg6a4xpMhkmloeK5PD1Nzw"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg"
      xsi:nil="true"/>
    <mrkr:FairValuesAssumptionsExpectedTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA"
      id="Hidden_p0q6djlt6UyBX7Cf1G6waA">P0Y</mrkr:FairValuesAssumptionsExpectedTerm>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_peBzxWU1gUq69MvxZYMv2w_2_1">0001094038</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_FLigOv2nrEGIfq-kF_Ypow_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_AEv6SdCxSEODCY7YpnEmQw_4_1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_bkqI6QnjsUWV8vN1RWEY1g_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_GQgvwjIDmEWsHF19fdV5-g_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-6"
      id="Hidden_t8DVxv_EskeM_tkLTNiM-w"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-6"
      id="Hidden_pFeIENHd9EegMJrIVhyh9Q"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-5"
      id="Hidden_P_BpZ_byDU6Kv-H_E7IxWQ"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">45700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Hidden_5yfXCU_Y60y5FpmLzFWqUg"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">50700000</us-gaap:CommonStockSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_976tp-VzHkuhriCCbTbAPw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_m8iv75Rqm0SKMlz0USjuZA_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_D8TNsqtaEUKQ__FD_Pesxw">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_ASOkQA0iAk-T5_Q7qcirnw_6_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_9Fo0HlBfJk6bhd8TIfObWw">001-37939</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_GvrmRc_9OUSvyFxvhmIE-w">MARKER THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_objVe4sMwEeSYQ8w6GT2HQ_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_d2Qb591zhUGrsYDoyf_3Eg_0_2">45-4497941</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_7gcC2wFApkKglcFhKL7afw">3200 Southwest Freeway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_w8dKFXpAP0erznflFzrp_Q">Suite&#160;2500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_zq6ZuYRnb0C8oJyUgS2SeA">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_MDnFdvproEKfclZ7vQzE6w">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_Pl_xyWJ2a0Grqo-1l7WUJw_3_2">77027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_4HkdgzbyuE6t7zJbjzGFHg">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_5ERWtwBvpEGscJOFZ3tS3Q">400-6400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_U-2hSQLftUKc_nhzLMiSLg_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_Cq3NjURBTUi6F2hfiqJXEQ_2_2">MRKR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_73M1_brLvUKYRVFlodmsaQ">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_bYozR2NUgU6zENfZkCQOXg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_gxeomVopVkKM1-kdibTJUw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_ixGzoO8HKE6AybOGWvmmug">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_hH7aN1YoqEuIVK6Cwzle2w">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_s8TH3HHjYkCPld6r7K3b-g_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_UkFMNLpJdUG8aMdesk86JA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_ZBLJAovr0EWupdTwfU6hwQ_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_WnBsmWcIC0erkG70DHi9eg">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_QVEydVdzHUOmWwEprkFBvw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg"
      decimals="0"
      id="Narr_butnfVj6nkWbHt_4Em-lsA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">64600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_1_2021_dgrzcG53v0qHBae8oSbc7g"
      decimals="INF"
      id="Narr_zW1uGJdz7UaFxmX85GXXnA"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">50731072</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_df4dPepje0iEL56jOxX1bw_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">21352382</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_mTGH5MtXD0Kn76fzv-M5Hw_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">43903949</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_-ozx6j2LuUWagQaMX3E2Nw_6_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2057924</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_tpzO6Tg4h0K4TeaR0doaBg_6_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1526442</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InterestReceivable
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_b0GQkrwKA0mD5uONUXyZYQ_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">559</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_nHheJquYtUqJpMov8FFJEQ_7_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">56189</us-gaap:InterestReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_oBphqmyu6k-bSqYjZwbcPw_8_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1000000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc__iFMKXPX2EKimfVgH-HHNQ_8_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_Yvfcn6b1jU6GYBc-HFu4Rg_9_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">24410865</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_Cfk1QU0cakyEVh40IQuGtQ_9_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">45486580</us-gaap:AssetsCurrent>
    <mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_a8Vvc53bq0aJaFGodyseOw_11_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">3570736</mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress>
    <mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_7axJIb_1jU2pXALN2VBHNQ_11_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">417528</mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_WSrMn8gT60yi4SRaycc2HA_12_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6789098</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_2Pw_-hrNx0qakqYsRE16yg_12_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:ConstructionInProgressGross>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_v8Rd_k6Nc0WNDF1a8f2F4A_13_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">10844116</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_0pM0VSrT_U27N0CXOpWu8w_13_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">455174</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_E_pPBc75eESyPrLLgcUYmQ_14_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">21203950</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_O1YKPCcfiEKj1DwsFVBROw_14_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">872702</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_QfIlnmUZzkKNlpJ2OFuH-w_16_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">45614815</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_oD9SPs_Zsk-8kHvzryEeWw_16_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">46359282</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_injjOyjEkkCqA4betPh7gw_20_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6013010</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_LxLBH9JEKkav_u5bRA3LFQ_20_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1757680</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_OZuomakWkUeQ_wg7C1v1WA_21_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">388792</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_3vranmkeC0CLCEZBpdd5Og_21_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">204132</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_1c0Hv6lr-EeWLpiqZMvGjw_22_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">31000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_CP3G0r-z6kOqqMqzARaT7g_23_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6401802</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_eVGFm9E7s06H0YqcoNknmA_23_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1992812</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_HCWAQ2sHYEqgM5fmmAh9Wg_25_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">11868440</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_8yvF14YtgE2vWN9ur9nhoA_25_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">280247</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_AFjDo4lJZkCJ83DgDJ8SuA_26_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">11868440</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_47L6-vlaSkSPAd4gXdKECg_26_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">280247</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_M7G16hawd0S2k4uam1NqyA_28_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">18270242</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_UpIGgwCoTkSJDbuVdX-4ug_28_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2273059</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="3"
      id="Narr_Z3BymwsDUkeM9xXpunA3bA"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="3"
      id="Narr_IjDknAQlRESjb5eiE6YB9A"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-6"
      id="Narr_wZ1712jHoUy2Zl_2q107LA"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-6"
      id="Narr_gZsru9RefU2tLi_A_Xu_Kw"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-6"
      id="Narr_LbpgznvMWkeYInCxMNyjVQ"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-6"
      id="Narr_lvyugOCC_0yn8_FZvP_zUA"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="3"
      id="Narr_F26agtgoZ0eWNOeKE5QrYA"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="3"
      id="Narr_K8xqV99SUU6MYz6PNhvSmw"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-6"
      id="Narr_31M4uIvrIUCQWA_J-lNenQ"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-6"
      id="Narr_i_uKtLzzl0KbV8eNaI5yuA"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_5ypHk58bGEC4HK5nve0Cew"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">50700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-5"
      id="Narr_nkvvHRhIfUCfHVqvEy6OMw"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">45700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_S32s3j9d_k6MR0gbDd2JLA_34_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">50731</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_tNpyJWUpbEeoLziUY4hHzw_34_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">45728</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_6BLu9YGPV0Kn3Q2cc0YrNA_35_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">383533326</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_cif-FgMlWk-3LqYkgDPGQg_35_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">371573909</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_swHgklR1n0e547NX2FpseA_36_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-356239484</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_l8QEyduP20SB8OT-Fnihbg_36_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-327533414</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_nBmEBBa-o0OzZgAEwdCDkg_37_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">27344573</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_a9PMDR7r5EqN5JnbV5HufQ_37_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">44086223</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_tppTEA8rqkWBaPLHG43Z4g_39_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">45614815</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_4rfQqGt-70iouuN5H7I6pQ_39_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">46359282</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_hm-aT4_utkG7keclj27JkA"
      decimals="0"
      id="Tc_qiF8q09Pd02sF52vrrIoZA_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">466785</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_GrantMember_KRQJasOkrUe2D02MbHcHKg"
      decimals="0"
      id="Tc_6dS2WJG9PE2XMtnkinZrqg_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">213194</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_MVYHoCooYESSghHBAPMb7w_6_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">466785</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_doHwU3RGfEqBdPZYWjkyTQ_6_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">213194</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_lkhVCr15h0Gp50VGlxo0JA_8_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">18880751</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_1H4DXcSxkU6dsLwPihIsOA_8_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">12764804</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_ZmVhDON7N0uaQqvYoJp_WQ_9_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">10471846</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_8_-t7dO9FEaNyqxY2CgZgQ_9_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">9977196</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_OXVLGEP0D0WTYqMX1y949w_10_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">29352597</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_sohEyRh2kkmhAaTt3FnuZg_10_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">22742000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_NpINiOtODUGRdzslFyvoog_11_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-28885812</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_217FAGCwJEKRa7FNn84gvg_11_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-22528806</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_J2N1zrzeh0SQKOsnmbNr6w_13_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">31000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_F7C1JNKba0CW78Zu97uDaQ_13_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">18000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_khue7h-ymU6JYPFBmZv4eg_14_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">148742</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_ocMmWWBSsEWco3Nr8NRULA_14_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1082842</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_r9j-_npAskWUlNjYZJR1KQ_15_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-28706070</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_tebdaXJO2EWIzqbVbbCzgQ_15_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-21427964</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Tc_nAX-zTxMMkWyR6V7kxALqQ_17_3"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">-0.61</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_qk6aMAt_CE6fAJlMqfvtTA_17_6"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_9ICSUcvZvkeGls3IWDO6cQ_18_3"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">47039862</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_uFOoywFAb02o_ffeTc7-oA_18_6"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">45587734</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_82up_zfWNUmUUgXpcdgRMQ"
      decimals="0"
      id="Tc_XnnecHIIk0qNXRHevct0DQ_4_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">45440704</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_82up_zfWNUmUUgXpcdgRMQ"
      decimals="0"
      id="Tc_XU3ChTBuuUiWYTiSM5mpNA_4_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">45440</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WRGLryikz0KaY92hGWffvA"
      decimals="0"
      id="Tc_eZlwXLxlyEOW-uL6vSMbUQ_4_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">365400748</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SYa5-5t2RkuK9-fz8jtoFw"
      decimals="0"
      id="Tc_pQGs00rTdUa7hZq9wJGi7w_4_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-306105450</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw"
      decimals="0"
      id="Tc_8dxlycTMyUyM6WCcOxlfhQ_4_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">59340738</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_BicagGEhuEWHs-snnsRI_g_5_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">11980</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_7Z8KwCYfpEe63n3Qi1Kv9g_5_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">12</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q"
      decimals="0"
      id="Tc_7ZHWLkgkf063VpMMm9JJjw_5_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">57732</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ"
      decimals="0"
      id="Tc_QdUYvvjE-UinLoWPWc1R7Q_5_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_W-jmANQUSUyJeuMkI3_FwA_5_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">57744</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <mrkr:ExerciseOfWarrantsShare
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_hPK5qYy01E2lPFBE1VYDoQ_6_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">190258</mrkr:ExerciseOfWarrantsShare>
    <mrkr:ExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_-HiFNJyX60CSBEbwYduywA_6_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">190</mrkr:ExerciseOfWarrantsAmount>
    <mrkr:ExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q"
      decimals="0"
      id="Tc_AdV35mVfz0-uCVfHIjSOJg_6_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">758543</mrkr:ExerciseOfWarrantsAmount>
    <mrkr:ExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ"
      decimals="0"
      id="Tc_22DOCa2slkSt2_JlVJOw-A_6_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:ExerciseOfWarrantsAmount>
    <mrkr:ExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_xYr49eiGzESBgPrk8cxqAQ_6_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">758733</mrkr:ExerciseOfWarrantsAmount>
    <mrkr:WarrantOfCashLessExercisedSharesIssued
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_BFxb52JN7ECYhIXPPoR_rg_7_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">9449</mrkr:WarrantOfCashLessExercisedSharesIssued>
    <mrkr:WarrantOfCashLessExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_sauHiyNCxUenKn-tJpjiIw_7_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">9</mrkr:WarrantOfCashLessExercised>
    <mrkr:WarrantOfCashLessExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q"
      decimals="0"
      id="Tc_YMdR-qW_R02pidyattgpqA_7_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-9</mrkr:WarrantOfCashLessExercised>
    <mrkr:WarrantOfCashLessExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ"
      decimals="0"
      id="Tc_qwvo8Q9uO0ue7TyjxWHHGA_7_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:WarrantOfCashLessExercised>
    <mrkr:WarrantOfCashLessExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_HNBUrvgOjU6tkYlbvp7GZQ_7_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:WarrantOfCashLessExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_18lk_yxKf0unJDkSokoHmg_8_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">76440</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_THYtetitp02jpEcv6znKXA_8_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">77</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q"
      decimals="0"
      id="Tc_FjRcE7yobkeDVla3RjF5Tg_8_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5356895</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ"
      decimals="0"
      id="Tc_fXRROn5OZU6SF8UJNInQWg_8_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_TvRmYtuIfkGpwP9Qc-EO5A_8_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5356972</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_3-iYqv6gOUqf2aqf7Mi1IQ_9_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_riTgAxX2vECZ7pNqrXkCyw"
      decimals="0"
      id="Tc_VBxZSKDaIk-1JFjdK9DAew_9_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pcX_0RTE_kGsKKDMrD6N9Q"
      decimals="0"
      id="Tc_HIoCHDSSxECdigwzgv8Vsg_9_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2EhJ_qzS1E21J15g2n8FlQ"
      decimals="0"
      id="Tc_wI8SaRu1HUaDEvG6WOjqoA_9_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-21427964</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_hztdpa_wBUSkEekX91YM5w_9_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-21427964</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPytHBodskGfOc2ipJ9aIA"
      decimals="0"
      id="Tc_QyvVCUXpe0-3TFr5_Rzhmw_10_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">45728831</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPytHBodskGfOc2ipJ9aIA"
      decimals="0"
      id="Tc_QfgD5XhU10aG-ZtgKqZeog_10_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">45728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dANtDkv1f0qA4nDLM7h0Pw"
      decimals="0"
      id="Tc_9ax5lnW_ZU-uEMN4rDz9lg_10_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">371573909</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pZiFWHEB4UO4INGI471GYw"
      decimals="0"
      id="Tc_ofJU4cJ4F0WYbmaXcvHv3A_10_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-327533414</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_QvC8Ru9XQECcZiKIIcCQjA_10_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">44086223</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_mwneln-KQESh3gEVHk0fKg_11_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">4113440</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_DJYAyB4jbUSrJgjU5jxzQw_11_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">4114</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g"
      decimals="0"
      id="Tc_afBEu4fR-0C9ohE5KZS_Cw_11_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6181897</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg"
      decimals="0"
      id="Tc_Vg6sul_oXUO785EfUOoW_g_11_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_HUxJ9cpFfU-mmOyc21fCyA_11_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6186011</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrkr:ExerciseOfWarrantsShare
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_H1vVFn5bVEyoc1eILn-Cjg_12_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">458334</mrkr:ExerciseOfWarrantsShare>
    <mrkr:ExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_2CbELbFXqEixRQk_A28P3w_12_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">459</mrkr:ExerciseOfWarrantsAmount>
    <mrkr:ExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g"
      decimals="0"
      id="Tc_0EpSszRrtkOt-wEtqTWQhQ_12_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">549541</mrkr:ExerciseOfWarrantsAmount>
    <mrkr:ExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg"
      decimals="0"
      id="Tc_DX6dLbAxFU-kabh7R6XV1w_12_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:ExerciseOfWarrantsAmount>
    <mrkr:ExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_LWA-bEAq_UmOoe2rZ68OKw_12_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">550000</mrkr:ExerciseOfWarrantsAmount>
    <mrkr:IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_RMIOjMhwtE2PGxgceE4DuQ_13_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">345357</mrkr:IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing>
    <mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_kds7iRuSWE-mUurMzq0YTw_13_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">345</mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing>
    <mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g"
      decimals="0"
      id="Tc_VmdD-kNF2Euj45ESDJ9AXA_13_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-345</mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing>
    <mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg"
      decimals="0"
      id="Tc_4W9U2t9ic06-koE8vXbOMg_13_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing>
    <mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc__B7WYAZAo0KQM9SRgb3EDg_13_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_fHE5BNvgi0610tNktlxM4Q_14_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">85110</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_e4QDU8p7Y0KPRiT2R8mRGw_14_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">85</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g"
      decimals="0"
      id="Tc_wIh6U4UzmU20rZdEH9pvPg_14_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5228324</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg"
      decimals="0"
      id="Tc_VgatXvEws0qw88EA6AymBw_14_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_9awUjkN-_0qNrg_v_58MyQ_14_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5228409</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_ivdAAlWREE69o6OyYtdBtg_15_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dBq95qKRCkSmoQkEE7rUSw"
      decimals="0"
      id="Tc_QYUg7_CxW0CB6uIxIjAktA_15_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wICCkvDCwUyl73mKsWwi5g"
      decimals="0"
      id="Tc_xKcW9kcrw0iPbZo-_APONQ_15_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7nI3D7CZPEiAmP2VL9ccpg"
      decimals="0"
      id="Tc_efHsHddLak2R6OXUGjJ7bw_15_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-28706070</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_urT8nAw7X0uzpDxBJiZpEw_15_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-28706070</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_P9Qbbx0CNUGy-vJOvqifnQ"
      decimals="0"
      id="Tc_3vPFLDDTQU2KorsjQ_pVyg_16_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">50731072</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_P9Qbbx0CNUGy-vJOvqifnQ"
      decimals="0"
      id="Tc_GW7HF4yOfUmtEOdJXYNWSA_16_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">50731</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tgvmmST_Hke5xeVNJK8Seg"
      decimals="0"
      id="Tc_Aa-dG1eYkEeDaakoQDKIKw_16_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">383533326</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O3dyd2IkiEOKoM1hwWKeZQ"
      decimals="0"
      id="Tc_Nki9fPv2IUCQ7DE6RUjKMw_16_11"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-356239484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_qPODH5IsqkiWI_LXj8hlqg_16_14"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">27344573</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_USuBZb-BhEKY-9vCWOKvjg_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-28706070</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_7cq9lI_Sf06Pfu7yDJ4KlQ_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-21427964</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_AdfSiv9MJky5on22547AGA_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">485641</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_lGlWq4wctUuT61ZvKiCuRw_7_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">105123</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc__bj_2Yod40eNjc34WQbXXw_8_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-31000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_ZLozQn_NqEGSpqYBqK5VqA_8_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-18000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_95BZfb6Or02VLFhZmQq0oA_9_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5228409</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_3eAqO3LMIka6B9dKAvdFSA_9_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5356972</us-gaap:ShareBasedCompensation>
    <mrkr:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_Y6QD9ZV7pEKg1hpPcRCipw_10_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">590039</mrkr:AmortizationOfOperatingLeaseRightOfUseAssets>
    <mrkr:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_iCyoYfJ5bUGljpRM98tg_g_10_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">181459</mrkr:AmortizationOfOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_KG6qfgvSa0OTQvMzu10k7w_12_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">531482</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_p_e2OFfvKkKIaUNXul-Esg_12_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1384725</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_nL6Y3GoR6k-QFaE9c1Gqqw_13_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-55630</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_CwquYUzTPUeMSEs_nB8YIg_13_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-51988</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_TiNfqnHx00mXpJ0xTMQUXA_14_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">4222470</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_SBlrQuRShUaXAx8i-RzKBA_14_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-963967</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <mrkr:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_DJVUboeTTECjuO7Z5pONgA_15_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-173268</mrkr:IncreaseDecreaseInOperatingLeaseLiability>
    <mrkr:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc__ny_PJw4VUuGnGW7tTrqOw_15_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-185179</mrkr:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_bw21L00woka1KUICf2-AuA_16_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-18859631</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_D4NbbSezfU-Blpzpc5AfPA_16_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-18284293</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_L7lh2gvEe0y9eLTobpFtsg_18_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">3638849</mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress>
    <mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_d2u4wPGlwkCi9IDHg68nqQ_18_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">374983</mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress>
    <us-gaap:PaymentsForConstructionInProcess
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_ziiVfYtan0CyjiCI4vhsAw_19_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6789098</us-gaap:PaymentsForConstructionInProcess>
    <us-gaap:PaymentsForConstructionInProcess
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_G-yLVgCZG0C9yO9RebIDrQ_19_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:PaymentsForConstructionInProcess>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_AGdbd_2dLEOZK7Ykzl2PKw_20_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-10427947</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_afiKNaO1SUS5jPs2yAKkyA_20_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-374983</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_f3xGWoeOPUeESvmbTUG8Cw_22_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6186011</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_5QLcSlBDPkWvQqZP9np33w_22_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_eZZID9t3F0C3HDQWT2j22g_23_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_aSJNV7OKX0SwSISzzXR03Q_23_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">57744</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_OXk7uZlH8kyJg7NQN-527Q_24_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">550000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_9jwHOx8tikmLweYvqaiUnQ_24_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">758733</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_0kmw2njQIEKgFtsR46HtUA_25_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6736011</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_RC1zW0ynm0uXTJ82JoZBFg_25_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">816477</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_1eY1hecOsUegX_j7YraGLg_26_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-22551567</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_J-Znjq2ZNEWsvIysBb_lwg_26_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-17842799</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_a3E_r_UTzEKSabk4bxibuQ_28_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">43903949</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw"
      decimals="0"
      id="Tc_CLCbgkJbm0qhKumxdHMhVw_28_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">61746748</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_69nLLHO7P0aNi6XsZVBNkQ_29_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">21352382</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_8uyWdCEoLEu_Pr0c1CJl7g_29_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">43903949</us-gaap:Cash>
    <mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_P8ONNvnkUki9Lxm7-zulXQ_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">345</mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing>
    <mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_HnkM8bRE70af0wnBoxBqxQ_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_9eXH7CKLuk69kZ0ADfSzgw_6_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">11114300</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_S_6gVrnMXkyeu2GnS2sL5g_6_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mrkr:NonCashExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_CPETUUVdCUGKRia6baSiTQ_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:NonCashExerciseOfWarrantsAmount>
    <mrkr:NonCashExerciseOfWarrantsAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_WT1s9ppEYkS7KlYmBW1IaA_7_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">9</mrkr:NonCashExerciseOfWarrantsAmount>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_vgE2PNFpn0iK5K57Yx0-Qg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Marker Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d; or &#x201c;we&#x201d;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company&#x2019;s MultiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_1UiMEcfYlUiJFjYderfw0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;As of December 31, 2020, the Company had cash and cash equivalents of approximately &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$21.4&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million. The Company&#x2019;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical trials. Further, the Company&#x2019;s product candidates will require regulatory approval prior to commercialization. These activities will span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from sales of its product candidates, if approved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Based on the Company&#x2019;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of December 31, 2020 will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2021, as such these factors raise substantial doubt regarding the Company's ability to continue as a going concern. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#x2019;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#x2019;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#x2019;s future funding requirements will depend on many factors, as it:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;initiates or continues clinical trials of its product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;continues the research and development of its product candidates and seeks to discover additional product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;seeks regulatory approvals for any product candidates that successfully complete clinical trials;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;maintains and enforces intellectual property rights;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;evaluates strategic transactions the Company may undertake; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition to the foregoing, based on the Company&#x2019;s current assessment, the Company does not expect any material impact on its long-term liquidity due to the COVID-19 pandemic. However, the Company will continue to assess the effect of the pandemic on its operations, including its clinical programs. The extent to which the COVID-19 pandemic will impact the Company&#x2019;s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing the Company&#x2019;s ability to access capital, which could in the future negatively affect the Company&#x2019;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company&#x2019;s business and the value of its common stock.&lt;/p&gt;</mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_LgVplVIIqEeBfHdRSvzI4g"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">21400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_OlJ3BImfw0WeTxVLdqCd-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#x2013; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#x2019;s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents and Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31, 2020 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $250,000. As of December&#160;31, 2020, approximately $2.7 million in cash was uninsured based upon the FDIC insurance coverage limits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment - Construction in Progress&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility's construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout will be recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; (&#x201c;ASC 820&#x201d;) for the Company&#x2019;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 1&#160;- Quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 2&#160;- Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 3&#160;- Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, financial instruments and concentration of credit risk.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patents and Patent Application Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#160;&#x2014; The expected life of stock options was estimated using the "simplified method," as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#160;&#x2014; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#160;&#x2014; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend&lt;/i&gt;&#160;&#x2014; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2020 and 2019, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#x2019;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Warrant Liability&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amounts of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. If the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12&#160;months of the balance sheet date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management must determine whether an instrument (or an embedded feature) is indexed to the Company&#x2019;s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#x2019;s contingent exercise and settlement provisions. This exercise affects the accounting for (i)&#160;certain freestanding warrants that contain exercise price adjustment features and (ii)&#160;convertible notes containing full-ratchet and anti-dilution protections (iii)&#160;certain free-standing warrants that contain contingently putable cash settlement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company&#x2019;s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable and are not dependent on the Company&#x2019;s ongoing future performance. The Company has adopted a policy of recognizing these payments when received and as revenue in accordance with Accounting Standards Update No.&#160;2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d; issued by the Financial Accounting Standards Board.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Loss per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New Accounting Standards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Standards Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#x201c;ASU 2019-12&#x201d;), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company has adopted the new standard effective January 1, 2021 and is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_BdAi-hTb6k2m3LlhqvHP-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_N7xy6yJ5CUWeq8TgaaSBLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#x2013; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_ywJ-JxOPBEGxD_tTSECFRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#x2019;s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_DrGNUNpnlk-DphGsSRRQVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents and Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31, 2020 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $250,000. As of December&#160;31, 2020, approximately $2.7 million in cash was uninsured based upon the FDIC insurance coverage limits.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Narr_wM5XTVszlUixcF8rf0gr7w"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_ikBAOoZElEOUJyDif_c_Ew"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2700000</us-gaap:CashUninsuredAmount>
    <mrkr:RetainExistingPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_hfZWZN_cCkauCDZQs99zAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&lt;/p&gt;</mrkr:RetainExistingPolicy>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_ohNrncNosUC98c_8ivx0Xg">the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <mrkr:PropertyAndEquipmentConstructionInProgressPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_0uoeLK4On02oBN6Lz6bbnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment - Construction in Progress&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility's construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout will be recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.&lt;/p&gt;</mrkr:PropertyAndEquipmentConstructionInProgressPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_1PUkzCRTJE6peFDHToPqqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; (&#x201c;ASC 820&#x201d;) for the Company&#x2019;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 1&#160;- Quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 2&#160;- Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Level 3&#160;- Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, financial instruments and concentration of credit risk.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_s_MpDlYBfkGAs8pqJjjhUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patents and Patent Application Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_uSGH8j3BKkuNGEr1fGoGdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#160;&#x2014; The expected life of stock options was estimated using the "simplified method," as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#160;&#x2014; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#160;&#x2014; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend&lt;/i&gt;&#160;&#x2014; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_VDlB24xZDE2hcWFa0cCKOQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_8Wo-6aUMXkGXTX12g-Ub1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2020 and 2019, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#x2019;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2020 and 2019.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_vggzDajjx0qzsEUPyfqoiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Warrant Liability&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amounts of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. If the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12&#160;months of the balance sheet date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management must determine whether an instrument (or an embedded feature) is indexed to the Company&#x2019;s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#x2019;s contingent exercise and settlement provisions. This exercise affects the accounting for (i)&#160;certain freestanding warrants that contain exercise price adjustment features and (ii)&#160;convertible notes containing full-ratchet and anti-dilution protections (iii)&#160;certain free-standing warrants that contain contingently putable cash settlement.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <mrkr:GrantIncomePolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_Rd5B0gUDvESCWh8VT9_wsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company&#x2019;s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable and are not dependent on the Company&#x2019;s ongoing future performance. The Company has adopted a policy of recognizing these payments when received and as revenue in accordance with Accounting Standards Update No.&#160;2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d; issued by the Financial Accounting Standards Board.&lt;/p&gt;</mrkr:GrantIncomePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_C35Rll5Kmk6sd13fBp--ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Loss per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_X5nmZkSHEE-UIFYPuwtPqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New Accounting Standards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Standards Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#x201c;ASU 2019-12&#x201d;), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company has adopted the new standard effective January 1, 2021 and is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_nWLLkv_RM0O_rSKRqRQdLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share Applicable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth the computation of loss per share for the&#160;years ended December&#160;31, 2020 and 2019, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,706,070)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,427,964)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,039,862&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,587,734&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share data:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.47)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,002,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,983,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock purchase warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,830,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,605,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants - liability treatment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Potentially dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,832,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,647,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_MoNPCIiE5kKC-fOchIOIQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,706,070)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,427,964)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,039,862&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,587,734&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share data:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.47)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_iJXTXyzNyESihjYT7ldlXg_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-28706070</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_B7Tz7BtwL0aoHIxLPYzZbQ_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-21427964</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_xxckLMtYWkOwAPAytRSiAQ_8_3"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">47039862</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_aeLb_Uqu0UumXHGEGgJy8Q_8_6"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">45587734</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Tc_kkli5B46l0ipZ_9QISGJMg_11_3"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">-0.61</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_cbnjLS_3h0eLjgIqUYXM3g_11_6"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <mrkr:NetLossPerShareTableTextBlockTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_sXc-LdMpXkWexkTnwdzzlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,002,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,983,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock purchase warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,830,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,605,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock warrants - liability treatment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Potentially dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,832,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,647,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:NetLossPerShareTableTextBlockTableTextBlock>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_j4K7-6m1s0mROj8Tc9Lrag"
      decimals="0"
      id="Tc_NYtU0NJlEEypWSo2l_iXSA_4_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">6002000</mrkr:CommonStockWarrantsEquityTreatment>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_OqczUH54BUevB2a6-k75Bg"
      decimals="0"
      id="Tc_f_70H_gROUC1liVuMqUcww_4_4"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">4983000</mrkr:CommonStockWarrantsEquityTreatment>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_-Qd7LU2lBUa_mee1OprAuA"
      decimals="0"
      id="Tc_zUVSph3ShU-p79p5LZESxA_5_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">20830000</mrkr:CommonStockWarrantsEquityTreatment>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GPlgMEopskaT3rrayUflxg"
      decimals="0"
      id="Tc_puwduVPP4kS2Fbr3vzr0CA_5_4"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">22605000</mrkr:CommonStockWarrantsEquityTreatment>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mrkr_CommonStockWarrantsLiabilityTreatmentMember__mhH4edEXEqL7o8fnQckTw"
      decimals="0"
      id="Tc_EWV3yUUsLkS8po_VjWGUTQ_6_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">0</mrkr:CommonStockWarrantsEquityTreatment>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mrkr_CommonStockWarrantsLiabilityTreatmentMember_aWBuEQRV-kK1UZ4Oeqku7w"
      decimals="0"
      id="Tc_opVffWN5vU2Y5YoJMimodg_6_4"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">59000</mrkr:CommonStockWarrantsEquityTreatment>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_aUnrVOP1qUOsPpbpQCUPdA_7_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">26832000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_ou67-rQz2EWTm0jByWkWUg_7_4"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">27647000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_aoFswfAljkSdwWwzHj9wFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Company&#x2019;s lease agreement for its manufacturing facility, the Company incurred and paid for the construction invoices directly for both the structural improvements of the facility and the building of the manufacturing modular cleanroom (i.e. leasehold improvements and manufacturing equipment). &#160; At the time the construction invoices are received by the Company, a fixed asset is recorded in construction-in-progress. In accordance with the agreement, upon completion of the facility&#x2019;s construction, the Company is owed up to $1.0 million as reimbursement, and as such a landlord receivable is recorded, which provides for a legal right to receive construction reimbursements from the landlord for tenant improvement allowances.    The construction of the facility was completed during December 2020, and a certificate was occupancy was delivered to the Company in January 2021.  During the fiscal year ended 2020, the Company recorded a $1.0 million receivable in its consolidated financial statements. &#160;The Company expects to receive the $1.0 million in the first half of 2021.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:TenantImprovements
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_otehMWT0JkCzKHyBX4UqjA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1000000.0</us-gaap:TenantImprovements>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_LXplb2IufUSiDgXMUWwYpg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1000000.0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_6_30_2021_UnPt_Wy98US1VFSStqyNsw"
      decimals="-5"
      id="Narr_xSFqrTeP6UKN25K9vRepHg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1000000.0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_wSS0WAvFR0ODKRaa4bPHew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;6:&#160;&#160;&#160;&#160;PROPERTY AND EQUIPMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Property and equipment consist of the following as of December&#160;31, 2020 and 2019, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,360,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 111,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3-5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 835,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 678,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 178,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease term or estimated useful life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 289,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Total   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,162,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 523,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (591,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (105,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,789,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total fixed assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,360,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 418,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense for the years ended December 31, 2020 and 2019 was approximately $0.5 million and $0.1 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and eventually install modular cleanrooms in a manufacturing facility. &#160;$6.8 million is recorded in fixed assets &#x2013; construction in progress on the balance sheet as of December 31, 2020.  The completion of the facility&#x2019;s construction occurred during December 2020 and the Company received its certificate of occupancy in January 2021, and as such was placed into service in January 2021.  During January 2021, all costs associated with the buildout will be recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the research facility that the Company opened during the second quarter of 2020, the Company incurred approximately $2.2 million of costs acquiring necessary lab equipment to carry out its experiments. The $2.2 million is included in Lab equipment within fixed assets and is being depreciated over five years. &#160;Additionally, the Company incurred $0.3 million in leasehold improvements relating to the research facility.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_yLd38UB6qESD7CB_UQxlmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,360,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 111,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3-5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 835,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 678,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 178,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease term or estimated useful life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 289,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Total   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,162,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 523,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (591,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (105,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,789,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total fixed assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,360,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 418,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_olqT_Fwx7U-Odxkj912Fyg"
      id="Tc_thyNNc9eW02mK_1L15Gp3Q_4_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lIiAzvSsBkSWpBXL8lYO6A"
      decimals="-3"
      id="Tc_95JQg-EIAk2rotxhRAcuaQ_4_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2360000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_ACdngx63MEKIMb7z31QBtA"
      decimals="-3"
      id="Tc_T_EJTslx_EG6ms96TU_WyQ_4_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_B-vZs3Ppc06PCUnjXPTuOg"
      id="Narr_kS_bxe-a7kqcg-GOGKjQkw">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_XdhD9gTpeU6hnY0-z8DASw"
      id="Narr_KgH3g3oBfkWa-tYJdJniWg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_Y6NXa2tNyEWBTjwC2KHiAg"
      decimals="-3"
      id="Tc_YILucaB2HEiM2wlBAUhtLg_5_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">835000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_FZSrIrNxmUyDqyxkQZDk4A"
      decimals="-3"
      id="Tc_k6yfUWUm7UWLXU83EDeghA_5_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_zke-f8FZTkO88cP2_ZhOwQ"
      id="Tc_y3eLDl3ePUmy2Zq7_U-e1Q_6_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_A2_KcOuc7UCSujKL_kVBbg"
      decimals="-3"
      id="Tc_xrsNFIDojUuR7r2RUnQP0w_6_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">678000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_92qxNSp0JkO7pwogTgs1Tw"
      decimals="-3"
      id="Tc_6FawPjiq7E6U3lghNBZLIA_6_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_v-vM_Z57j0W6NbhuDyp_Og"
      decimals="-3"
      id="Tc_okqi_HR0-EKUd4WwxWvaYg_7_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_PUj_K1bfHkGFM2Y4jHt9Qg"
      decimals="-3"
      id="Tc_D8cOdr8TLUyedr0RI111yQ_7_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">23000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_3BAHYk52IE2YiRR6q5r_zg_8_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">4162000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_Y5gT0PJw8Um3AxjPXuiOIA_8_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">523000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc__z7SPIHFAk-Tl1yV0NHXfg_9_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">591000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_p8yxp1qkaEa1RVvGf3stXw_9_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">105000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_p9_ys8w0gUu7V7i8pzkCUw_10_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6789000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_ilj-uzGHrUaLbcVglJnu9w_10_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_KHAv9cIzlEm5fW1PERDsjA_11_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">10360000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_ADCrc0F_SUecXbjDYWh_KQ_11_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">418000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="-5"
      id="Narr_q1k8ECYpnUKbhYBVxvS2NQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="-5"
      id="Narr_T1Y5-5Z020awooaz-HVScg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">100000</us-gaap:Depreciation>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_pw0mXgFP20erRoC0ZZn7IA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_o2aish9KUkmT-1TlNuBhUA"
      decimals="-5"
      id="Narr_NNuc_jNRcUy_dBQAHSRZ7Q"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2200000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_o2aish9KUkmT-1TlNuBhUA"
      decimals="-5"
      id="Narr_tlaZaLr-jUegc4m8Tg3pVw"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2200000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_olqT_Fwx7U-Odxkj912Fyg"
      id="Narr_DU5pFkskNUKPJ32CGP2rSw">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg"
      decimals="-5"
      id="Narr_5kw0WDZnCkGYFIBN3o8zkQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">300000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_lLYTXHMWd0WAgK4yMC1kug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE 7: LEASES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a new agreement for its corporate headquarters in Houston, Texas, which commenced in August of 2020. &#160; The initial lease term is ten years with two five-year renewal options. Fixed rent payments under the initial term are approximately $5.6 million. &#160;Additionally, the Company is also responsible for its share of operating expenses. &#160; &#160;As of December 31, 2020, the Company had remaining $4.1 million from the lease liability and $4.0 million of the related right-of-use asset resulting from the lease of its corporate headquarters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In April 2020, the Company entered into a lease for a research facility in Houston, Texas. &#160; The lease term is 71 months. Fixed rent payments under the initial term are approximately $1.1 million. As of December 31, 2020, the Company had remaining $0.8 million from the lease liability and $0.8 million of the related right-of-use asset resulting from the lease of its research facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. The initial lease term is ten years from the rent commencement date in the fourth quarter of 2020 with two five-year renewal options. Fixed rent payments under the initial term are approximately $9.8 million. &#160;Additionally, the Company is also responsible for its share of operating expenses. In accordance with the agreement, upon completion of the facility&#x2019;s construction, the Company is owed up to $1.0 million as reimbursement, and as such a landlord receivable is recorded, which provides for a legal right to receive construction reimbursements from the landlord for tenant improvement allowances. As of December 31, 2020, the Company had remaining $7.2 million from the lease liability and $5.8 million of the related right-of-use asset resulting from the lease of its manufacturing facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company also leases office space under agreements classified as operating leases that expire in 2022. As of December 31, 2020, the Company had remaining $0.2 million from the lease liability and $0.2 million of the related right-of-use asset resulting from the lease of its Jacksonville, Florida office space, which expires in 2022. &#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. &#160;Certain of the Company&#x2019;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. &#160;Variable expenses generally represent the Company&#x2019;s share of the landlord&#x2019;s operating expenses. &#160;The Company does not act as a lessor or have any leases classified as financing leases. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2020, the Company had operating lease liabilities of approximately $12.3 million and right-of-use assets of approximately $10.8 million, which were included in the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following summarizes quantitative information about the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense summary:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 960,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 167,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,149,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 410,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 544,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.6&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate as of adoption date &#x2013; operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Maturities of the Company&#x2019;s operating leases, excluding short-term leases, are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,077,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,278,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,826,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,874,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,772,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,369,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,112,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,257,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_8_31_2021_lXNY-SqcckufSQP1_3M_NA"
      id="Narr_LRcrThtfOky4bBJ2cWqUQw">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mrkr:NumberOfRenewalOptions
      contextRef="Duration_8_1_2020_To_8_31_2020_95mnbsS_AUasMsjLjipGSQ"
      decimals="0"
      id="Narr_yYjJQySuVUib0PEznx7sMw"
      unitRef="Unit_Standard_Options_XwIwXkVLKk6WPb72jTZEwQ">2</mrkr:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_8_31_2020_2wu45mhpe0Wt7jhL5XOOSA"
      id="Narr_xKl1TTG1REusRYmJXGXEjw">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrkr:FixedLeaseRentPayment
      contextRef="As_Of_8_31_2020_2wu45mhpe0Wt7jhL5XOOSA"
      decimals="-5"
      id="Narr_6l5fFOIo6kSZZxBfFcbglA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5600000</mrkr:FixedLeaseRentPayment>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_CorporateHeadquartersMember_yvnuelJz_UW9l4GGuzdD-g"
      decimals="-5"
      id="Narr_MI76bj-8-kOJpgCBD7s99g"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">4100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_CorporateHeadquartersMember_yvnuelJz_UW9l4GGuzdD-g"
      decimals="-5"
      id="Narr_QDWp3pObr0mAwGNRFzT11Q"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">4000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_4_30_2020_C8Sjke4d3Uu2bMNfPrnSIQ"
      id="Narr_f2VWtg45jE6sUTX7XbYnBw">P71M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mrkr:FixedLeaseRentPayment
      contextRef="As_Of_4_30_2020_C8Sjke4d3Uu2bMNfPrnSIQ"
      decimals="-5"
      id="Narr_IGJMgX5E4UqlZEHPOdGQPQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1100000</mrkr:FixedLeaseRentPayment>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ResearchFacilityInHoustonTexasMember_AUKUMDHj8UmZXAD59Q-Ixw"
      decimals="-5"
      id="Narr_-nJeotiCvEapl-aZjKiPeA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ResearchFacilityInHoustonTexasMember_AUKUMDHj8UmZXAD59Q-Ixw"
      decimals="-5"
      id="Narr_0ihN4XOEzkCzd1ghZpU8qQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg"
      id="Narr_fI74nryWUEaPk8LkTUa-qA">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mrkr:NumberOfRenewalOptions
      contextRef="Duration_6_1_2020_To_6_30_2020_mgveA6v0wUaCVTftpwttxQ"
      decimals="0"
      id="Narr_fokZ7P7280yn5Ex-C9107g"
      unitRef="Unit_Standard_Options_XwIwXkVLKk6WPb72jTZEwQ">2</mrkr:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg"
      id="Narr_qu2QL4gojkOSczKygzKC8w">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrkr:FixedLeaseRentPayment
      contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg"
      decimals="-5"
      id="Narr_gdyMuOiIhUuLPoAW4Kvehw"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">9800000</mrkr:FixedLeaseRentPayment>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg"
      decimals="-5"
      id="Narr_yYL8RcexV0yTC8VUtLnUcA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1000000.0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_5T8qVStqZEGO5cyYBUn0KA"
      decimals="-5"
      id="Narr_P4RyNCSeMEGAcEiLpWtlQg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">7200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_5T8qVStqZEGO5cyYBUn0KA"
      decimals="-5"
      id="Narr_7xwIRdiKXUe49xMnYJUQ-Q"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_OfficeSpaceMember_AzY5PjhRa0KWIVTuRWZcsQ"
      decimals="-5"
      id="Narr_87rcN9llfkicrkDMR2d2vQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_mrkr_OfficeSpaceMember_AzY5PjhRa0KWIVTuRWZcsQ"
      decimals="-5"
      id="Narr_g1OQhFZyrEa79LbN8vQH_Q"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_3AaysiWsgEiAjnRw01UnAw"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">12300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_aiQrY0VjJU2eZD5iTE6oPA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">10800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_zcYHvau8KkOQj2GoHM2hSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense summary:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 960,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 167,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,149,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 410,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 544,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.6&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate as of adoption date &#x2013; operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_n38CwCiJpEu4BEgpiGO_Sw_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">960000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc__lCfL4jHvku53rfgBTnDUA_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">220000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_w3iq_P9_fkGMJPwiCiczzg_6_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">22000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_zfv3j6InCECY2Kcgw4lBIA_6_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">100000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_m1XG75ilrE6HxlDE7axR7w_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">167000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_6uR-M3n6c0Sebe8q4TVhHg_7_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">90000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_h8doxLJ_8ka9VnP5uposXw_8_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1149000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_H9-DWublK0arfrGiOXw3lQ_8_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">410000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_wsXec7lkakqWMMBN3Mv0cQ_11_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">544000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_x5WyFZ1iG02p8JGNQ1hCqA_11_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">225000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      id="Tc_xAVIn2kLu0mJNmCKdTQq7Q_12_3">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      id="Tc_faQAJ_C_k0OH-dsQDLtFRw_12_6">P1Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="INF"
      id="Tc_Z0svEu-TjUaXqzVcUx8kiw_13_3"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="INF"
      id="Tc_ijsptgEYO0SyR73OSgQCAg_13_6"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_qLjXeJm0X0GpSwnb2_ephA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,077,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,278,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,826,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,874,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,772,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,369,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,112,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,257,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_kMzmYnlAh0euAeFmYGTe2w_1_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1077000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_4PKZhBoZAEK4xco_bR_zLA_2_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1278000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_bo2JkGJm_EqphX2-b_vnxA_3_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1542000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_Oryhzt8LMEa5310bOSxHow_4_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1826000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_6_5GFzd-VUiyRb4eB9lw_Q_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1874000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_w4L0s3-bh0O_dIYNLGqKCg_6_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">8772000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_vX5jt4L1W0CoxKb2H6sG2w_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">16369000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_vmjnstd5ZkWA_AaYw3AiPg_8_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">4112000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_5NNBC89MUUqntyDfifAfTQ_9_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">12257000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_XtahVbTE30i2I-HYS4rMhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;8: &#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accounts payable and accrued liabilities consist of the following as of December&#160;31, 2020 and 2019, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,935,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 993,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,694,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 323,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 875,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Technology license fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 404,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,013,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,758,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_mP0VWMAu9kqNhSbbcItwaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,935,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 993,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,694,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 323,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 875,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Technology license fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 404,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,013,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,758,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_iieK3TpzPkKSMxro5SArLg_3_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2935000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_JrDCwL1mLUap7vfB0YyNoQ_3_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">993000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_Akqss7hljkCy9IXIphk7mA_4_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1694000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_II_PKAjn6UaSHHVbfN2Uqg_4_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">323000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_RVc08c2XjUC3oXDQSyyY6g_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">875000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_Dwe6e7v7Vk6J7Dk-u3lNDw_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">94000</us-gaap:AccruedProfessionalFeesCurrent>
    <mrkr:AccruedTechnologyLicenseFees
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_mmb1kUMjkUuDWn-GSkC7wQ_6_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">105000</mrkr:AccruedTechnologyLicenseFees>
    <mrkr:AccruedTechnologyLicenseFees
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_rlDRzJfidE6BdtaJEN5dpA_6_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">105000</mrkr:AccruedTechnologyLicenseFees>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_nu97se9n50WYwMm8gYd9Gw_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">404000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_8KTfuPjucEy5aK56KDTIig_7_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">243000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-3"
      id="Tc_dfqOgA16h0CUR-efONMglw_8_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6013000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-3"
      id="Tc_05qUh1mUiUGIU5gdofPUZQ_8_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1758000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <mrkr:WarrantLiabilityTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_NIJ6IlfjikqjDMpS2jdD3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;9:&#160;&#160;&#160;&#160;WARRANT LIABILITY&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&#x2019;s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the&#160;years ended 2020 and 2019, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.92&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_p0q6djlt6UyBX7Cf1G6waA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility (annual)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield (per share)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The foregoing assumptions are recalculated every reporting period and are subject to change based primarily on management&#x2019;s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents changes in Level 3 warrant liabilities, reflected in accrued expenses measured at fair value for the&#160;years ended December&#160;31, 2020 and 2019, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - January 1, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance &#x2013; December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance &#x2013; December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrkr:WarrantLiabilityTextBlock>
    <mrkr:ValuationMethodology
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_3B73NaasBEmFQYB4WCOXUQ"
      id="Tb_WiW7Kuw4tkCt2_BncUpFCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&#160;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.92&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_p0q6djlt6UyBX7Cf1G6waA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility (annual)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield (per share)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:ValuationMethodology>
    <mrkr:FairValuesAssumptionsExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember__pIPPDpQCU-WKKP23kwqnw"
      decimals="2"
      id="Tc_Q4mLAzTrGUa1Sa9Exq9EiQ_5_3"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0</mrkr:FairValuesAssumptionsExercisePrice>
    <mrkr:FairValuesAssumptionsExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_J3vACPWMbkmTs8PjTPKwqQ"
      decimals="2"
      id="Tc_XgzQJEtSyUeyUMlTy4zovw_5_6"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">6.92</mrkr:FairValuesAssumptionsExercisePrice>
    <mrkr:FairValuesAssumptionsExpectedTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw"
      id="Tc_1kNb3ttQXka4Ao0cQP9aIQ_6_6">P0Y18D</mrkr:FairValuesAssumptionsExpectedTerm>
    <mrkr:FairValuesAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA"
      decimals="2"
      id="Tc_MQT8oIwYZUujk30S7LhJ4g_7_3"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0</mrkr:FairValuesAssumptionsExpectedVolatilityRate>
    <mrkr:FairValuesAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw"
      decimals="2"
      id="Tc_HVZpfHiyc0iguPn3N_llfw_7_6"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.83</mrkr:FairValuesAssumptionsExpectedVolatilityRate>
    <mrkr:FairValuesAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA"
      decimals="2"
      id="Tc__u0J8jr1sEmLcvFWWLexow_8_3"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0</mrkr:FairValuesAssumptionsRiskFreeInterestRate>
    <mrkr:FairValuesAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw"
      decimals="2"
      id="Tc_DSHeQ7xrdkKvN8rJntD1xQ_8_6"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.02</mrkr:FairValuesAssumptionsRiskFreeInterestRate>
    <mrkr:FairValuesAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_OFXvkOsY4EKyysTZdDgnoA"
      decimals="4"
      id="Tc_otooC_qOYU2KSlPtbMOihg_9_3"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0</mrkr:FairValuesAssumptionsExpectedDividendRate>
    <mrkr:FairValuesAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember_9-MA2wVm-kGLZjB2suPlYw"
      decimals="4"
      id="Tc_Yo1PF0AgkECmcOapTiA1Ag_9_6"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0</mrkr:FairValuesAssumptionsExpectedDividendRate>
    <mrkr:MeasuredAtFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_3B73NaasBEmFQYB4WCOXUQ"
      id="Tb_Hl_k1BhkDkSAjoIHfpp-9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - January 1, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance &#x2013; December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance &#x2013; December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:MeasuredAtFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw"
      decimals="0"
      id="Tc_es92KzL1UECJKLykT2cn4A_3_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">49000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_4XqO8WPO6Eqs8dQJI5mw2A_4_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-18000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_LUR97Py-SUuMYlhVmpL2cQ_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">31000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_exHmIAggTkGtqHeYvN8Z8g_6_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-31000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_KxH6ev21VUmtlrH4-i7IRg_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_7Sq77lYWdkSpEHrNAXApHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;10:&#160;&#160;&#160;&#160;FAIR VALUE MEASUREMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&#160;in&#160;active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&#160;in&#160;active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&#160;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&#160;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There were no transfers between Level 1, 2 or 3 during the&#160;years ended December&#160;31, 2020 and 2019, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U. S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The net cash settlement value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following inputs at that time: the consideration value per share of the Company&#x2019;s common stock, the volatility of the Company&#x2019;s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U. S. Treasury security yields, and the Company&#x2019;s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <mrkr:FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_83odUJWInEKsElegGQGrvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&#160;in&#160;active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;prices&#160;in&#160;active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&#160;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&#160;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_H6133jjRH0CvkLeY903Lgw"
      decimals="0"
      id="Tc_65oA9yBi1EaBuSmp7aEfVw_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_fB-XBxEMVEuZ0AXnJJPCYQ"
      decimals="0"
      id="Tc_Wnx1Z0I58EuxoEwu424E4Q_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_MlrJM6J87kKV_E3Gg6OHjA"
      decimals="0"
      id="Tc_7NmlUZgYBUWb2h3aAn7H8A_5_9"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_ZI-qkKDgJE-mZLjhRnPZhQ"
      decimals="0"
      id="Tc_pQ0Iaoh_t0KM_6GYppF62w_5_12"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_7MInXfUOC0WNFuWoIBCLMA"
      decimals="0"
      id="Tc_2D8nTMucb0ugUfCN6zgUZA_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_zThIObKJTkGFAkdmLkZJyA"
      decimals="0"
      id="Tc_KdNYl63jK0KzYaWdKy-e6A_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_g6VPuQbHC0y4V1O1fXaO1Q"
      decimals="0"
      id="Tc_-Y0fgujUvUaTlvu93OKUBw_5_9"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">31000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_5Gr7NCUwa0aVADJ5Uz_xrg"
      decimals="0"
      id="Tc_67Fuv3ZBckO-LWt-Ac6sdg_5_12"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">31000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <mrkr:FairValueTransfersAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Narr_aiOktO_aMUi1ytRhdWKckw"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:FairValueTransfersAmount>
    <mrkr:FairValueTransfersAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Narr_A4DtH4l3G06Td9Z3_h_e0w"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">0</mrkr:FairValueTransfersAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_AcAIOY6g7k2wwY1gf1FR3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;11:&#160;&#160;&#160;&#160;STOCKHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#x2019;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has authorized up to 150,000,000 shares of common stock, $0.001 par value per share, for issuance. Significant 2020 and 2019 common stock transactions were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;2020 Common Stock Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Exercise of Stock Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;During the year ended December 31, 2020, certain outstanding warrants were exercised for &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;0.5&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million shares of common stock providing aggregate proceeds to the Company of approximately &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$0.6&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Board Compensation &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2020, the Company issued an aggregate of 0.1&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;million shares of common stock to its non-employee directors. The fair value of the common stock of approximately &lt;b style="font-weight:bold;"&gt; &lt;/b&gt;$0.2&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;million was recognized as a component of stock-based compensation expense in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Aspire Capital&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 28, 2020, the Company entered into a common stock purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with Aspire Capital Fund, LLC (&#x201c;Aspire Capital&#x201d;) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of shares of the Company&#x2019;s common stock over the 30-month term of the purchase agreement. In consideration for entering into the purchase agreement, the Company issued to Aspire Capital 0.3 million shares of the Company&#x2019;s common stock as a commitment fee. &#160;The Company recorded the commitment fee to additional paid in capital. &#160;As of December 31, 2020, Aspire Capital had purchased 4.1 million shares under the Purchase Agreement, providing aggregate proceeds to the Company of approximately $6.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;2019 Common Stock Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Consulting Arrangements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2019, the Company issued 0.05 million shares of common stock in connection with consulting agreements. The fair value of the common stock of approximately $0.3 million was recognized as stock-based compensation expense in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Board Compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2019, the Company issued an aggregate of 0.03 million shares of common stock to its non-employee directors. The fair value of the common stock of approximately $0.2 million was recognized as stock-based compensation expense in general and administrative expenses.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="INF"
      id="Narr_qtSbivKTlkmpIPDdU1ujwA"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="INF"
      id="Narr_gHCrKWwWHEee7m2fDtz4fQ"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="3"
      id="Narr_ebtooEYsWkK5Hj0UYFDZhA"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="3"
      id="Narr_0--amOwhlEOdGcDV-zcoow"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="INF"
      id="Narr_4nRfwP92RkOhUmAIZ1U-LQ"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="INF"
      id="Narr_tF9xebyRJ0S_sK0UTAn5XA"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="3"
      id="Narr_Ax8fYxqNF0uKOH0q8wepWw"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="3"
      id="Narr_OccHLbfJXUqVgIAjbEJ9Og"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_x8rh7aiZp06pdQPYS17Hvw"
      decimals="-5"
      id="Narr_5avrHfHGeUSEK7eH1aGbug"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="-5"
      id="Narr_ONxwGcXfjEOSJ6zDPXmLvA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_ZhSFY76i_kCH9MG-xjOj-w"
      decimals="-5"
      id="Narr_eEflCxeeBESFviOpTh0sGA"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_vMApe0EcyUGKDZi6FGn-GQ"
      decimals="-5"
      id="Narr_vX9q4vTYiEiPhfkMgAbsNg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <mrkr:MaximumCommonStockCommittedToPurchase
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ"
      decimals="-5"
      id="Narr_pziZOh691Ea3cAmvGyTE8A"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">30000000.0</mrkr:MaximumCommonStockCommittedToPurchase>
    <mrkr:AgreementTerm
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ"
      id="Narr_w0jEg9CcUkSbP5PO1VPfQg">P30M</mrkr:AgreementTerm>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ"
      decimals="-5"
      id="Narr_ZsojiUA8ek6tmQIFLn3AOw"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ"
      decimals="-5"
      id="Narr_XkW-YKfQ_kG8B05tKDo4kw"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">4100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_TypeOfArrangementAxis_mrkr_AspireCapitalMember_2JjHc7vrFUOdCh4bLbShAQ"
      decimals="-5"
      id="Narr_DuhTVk7JdUK1GsCDzQjYYQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_ConsultingArrangementsMember_2YOLfsHrJUiQ-nXn-u702g"
      decimals="-4"
      id="Narr_MniMKlp7FEKr7W8N2CBi0A"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">50000.00</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_ConsultingArrangementsMember_2YOLfsHrJUiQ-nXn-u702g"
      decimals="-5"
      id="Narr_12xl7c0_kUmuHWHFhE3dbQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_otSldnsXxkWsBDD0krxySA"
      decimals="-4"
      id="Narr_4dImpRshQEy80dkVeT8Slw"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">30000.00</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_LhNNdP3e2Eqw1UGKZWWoVw"
      decimals="-5"
      id="Narr_-NR8PfEQ006O-WF6xKjnlA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <mrkr:WarrantsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_GwRbcPrXBE6LgaanF8jhEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;12:&#160;&#160;&#160;&#160;WARRANTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share Purchase Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of the Company&#x2019;s share purchase warrants as of December&#160;31, 2020 and 2019, respectively, and changes during the period is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&#160;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance - January 1, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 23,016,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.78&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.29&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,066,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised for cash&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (190,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.99&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cashless exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (190,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.63&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance - December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 22,664,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.71&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3.33&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 954,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised for cash&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (458,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,376,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance - December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 20,830,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.47&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2.60&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2020 Warrant Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Exercise of Stock Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2020, certain outstanding warrants were exercised for 0.5 million shares of common stock providing aggregate proceeds to the Company of approximately $0.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2019 Warrant Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Exercise of Stock Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2019, certain outstanding warrants were exercised for 0.2 million shares of common stock providing aggregate proceeds to the Company of approximately $0.8 million.&lt;/p&gt;</mrkr:WarrantsDisclosureTextBlock>
    <mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_e3jl9ISh90CJS6uJdshXmA"
      id="Tb__k73oPHOhkK2OkqnFfHd2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&#160;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance - January 1, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 23,016,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.78&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.29&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,066,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised for cash&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (190,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.99&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cashless exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (190,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.63&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance - December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 22,664,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.71&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3.33&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 954,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised for cash&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (458,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,376,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance - December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 20,830,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4.47&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2.60&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw"
      decimals="0"
      id="Tc_iOxASZMEN0SCelhM434_iw_4_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">23016000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw"
      decimals="2"
      id="Tc_PzhyZ8zsF02XP3BQ01bsrQ_4_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">4.78</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2018_To_12_31_2018_5QP_WyrpuE6d2eZgC1tMCA"
      id="Tc_-8e22u0efUO4wvYMC0N85g_4_7">P4Y3M14D</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife>
    <mrkr:ClassOfWarrantOrRightOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw"
      decimals="0"
      id="Tc_8fereMMW-kaljE_cI1G72w_4_10"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">26066000</mrkr:ClassOfWarrantOrRightOutstandingIntrinsicValue>
    <mrkr:NumberOfWarrantsGranted
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_AMCSiKWmb0C_RElE5ico5w_5_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">45000</mrkr:NumberOfWarrantsGranted>
    <mrkr:ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_3c3572AlB0ynQCHsCDlBnA_5_5"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">4.26</mrkr:ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice>
    <mrkr:NumberOfWarrantExercisedForCash
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_kx97DdlcH0uMaNBHDSQgag_6_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">190000</mrkr:NumberOfWarrantExercisedForCash>
    <mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_UgTYcjLxtkSSk9TGrw0-Dg_6_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">3.99</mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash>
    <mrkr:NumberOfWarrantCashlessExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_y9bHCvoRj06-tROkcEs4XA_7_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">17000</mrkr:NumberOfWarrantCashlessExercised>
    <mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_DAeT0qsy2Uqj0ICfOaHzRw_7_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">2.38</mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised>
    <mrkr:NumberOfWarrantExpiredOrCancelled
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_CovtGbNDakWAwGcUO0hIiA_8_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">190000</mrkr:NumberOfWarrantExpiredOrCancelled>
    <mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_4U97mILv2kemL4Zo9_GNdg_8_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">13.63</mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_wYYDUIttokKNxQk5vJNfQQ_9_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">22664000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="2"
      id="Tc_8bNkt6U_8kiH1RN-Jb0uGg_9_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">4.71</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      id="Tc_EvYT6_ropUiBq0XZvS597Q_9_7">P3Y3M29D</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife>
    <mrkr:ClassOfWarrantOrRightOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_hgPa_hzMJkaC8SwEizIJrA_9_10"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">954000</mrkr:ClassOfWarrantOrRightOutstandingIntrinsicValue>
    <mrkr:NumberOfWarrantExercisedForCash
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_TbU34GchDUiYIheLfeaNew_10_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">458000</mrkr:NumberOfWarrantExercisedForCash>
    <mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Tc_x3OLF-_CTE6zeHRq_rhd9A_10_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">1.20</mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash>
    <mrkr:NumberOfWarrantExpiredOrCancelled
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_jC4lsUlPxUqQUTOaqJZR8g_11_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">1376000</mrkr:NumberOfWarrantExpiredOrCancelled>
    <mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Tc_Prbh0pF-dUWFyh-Yus7cUQ_11_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">9.46</mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_yiBGN3gNzE2Cv4IJjJIsiA_12_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">20830000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="2"
      id="Tc_InRdRPu-UU2Z58MgqUbbyA_12_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">4.47</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_pl4pjiBIaUe2qMk8NWPnow_12_7">P2Y7M6D</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_TWWGeEixo0CWCN9rksCqGw"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="-5"
      id="Narr_jD_lVPx6ykO7Wgrt65GN-A"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-5"
      id="Narr_PjuPENYScES6eobBlaH6kg"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="-5"
      id="Narr_TVkRHnl0LEeMjLvrHRgaLA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_-uZYsIslYkG4CsLNKbTH6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;13:&#160;&#160;&#160;&#160;STOCK OPTION PLANS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Options to Purchase Shares of Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;"&gt;2020 Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May&#160;19, 2020, the Board adopted the 2020 Equity Incentive Plan ("2020 Plan") which replaced the 2014 Omnibus Stock Option Plan (&#x201c;2014 Plan&#x201d;). The 2020 Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Plan may be at prices and for terms as determined by the Board of Directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#x2019;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules&#160;and regulations of the New York Stock Exchange.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Options granted under the 2020 Plan have a maximum term of ten years from the date of grant. Options granted in 2020 and 2019 generally vest over four years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2020, approximately 4.7 million options are available to be issued from the 2020 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;2014 Omnibus Stock Ownership Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The 2014 Plan, which the Board adopted on May 19, 2020 and subsequently amended from time to time, allowed for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. The terms of the 2014 plan are substantially identical to the terms of the 2020 Plan described above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of the Company&#x2019;s stock option activity is as follows for stock options:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Intrinsic &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,983,314&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.79&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,531,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (512,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,001,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,598,981&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.29&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#x2019;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the&#160;years ended December&#160;31, 2020 and 2019, respectively, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.08&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.70&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth stock-based compensation expenses recorded during the respective periods:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Compensation expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,588,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,574,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,640,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,783,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,228,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,357,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At December&#160;31, 2020, the total stock-based compensation cost related to unvested awards not yet recognized was $10.6 million. The expected weighted average period compensation costs to be recognized was 2.2&#160;years. Future option grants will impact the compensation expense recognized.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_mGgOht7j1kClyGZAl_vbQw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      id="Narr_bcCzmPs2CkCTQUiZtifYjg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_TeBClg-42E2xw3vW27HiwA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_ZeW1i3Aci0qOtE4sUsyrXg"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">4700000</mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued>
    <us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg"
      id="Tb_PUokIuS9s0-iIE1Rvyu-Hw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of the Company&#x2019;s stock option activity is as follows for stock options:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Intrinsic &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,983,314&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.79&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,531,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (512,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,001,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,598,981&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.29&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg"
      decimals="0"
      id="Tc_ew5YbkX_jUCVRq2JAJsmBA_5_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">4983314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg"
      decimals="2"
      id="Tc_fPHlsCWmZUWSyUPbotgU4g_5_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">7.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg"
      decimals="0"
      id="Tc_LkQ4cHQLDEGFZAuHVnCrlA_5_8"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qZ9NHzo7YUC9v4IRoJS31Q"
      id="Tc_M0MStYgEHkWjWDU5im3AvQ_5_10">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg"
      decimals="0"
      id="Tc_urNr4Sf3MUWFcL5WNvQ-8g_6_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">1531000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg"
      decimals="2"
      id="Tc_DEyG_-HAw0SVtkyJshBXeA_6_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">2.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg"
      id="Tc_VwVRu_SxE0-3dWINA2E3rQ_6_10">P9Y2M12D</mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg"
      decimals="0"
      id="Tc_gBYbXm2JG0amSExNHq3Z7A_7_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">512500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ"
      decimals="0"
      id="Tc_wMrhCJkkaUaQXNF6sGITkQ_8_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">6001814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ"
      decimals="2"
      id="Tc_titK_JUm2Eiu06PovGLXeQ_8_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg"
      id="Tc_k4vC3VXl20aRMKpjgSGH9g_8_10">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ"
      decimals="0"
      id="Tc_JkpQ1sLT_0G4SizelvEgUQ_9_2"
      unitRef="Unit_Standard_shares_iR2ThMvN30malanztgioBw">2598981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_qe3-CzyXwkuJjhe1lD0oJQ"
      decimals="2"
      id="Tc_vMLEKXgw50iasXB2QfsqGw_9_5"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">7.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg"
      id="Tc_9uS6G2wydUu8iwJw9W1loA_9_10">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_aaGc9gKOl0y7WW64DylDww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#x2019;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the&#160;years ended December&#160;31, 2020 and 2019, respectively, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.08&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.70&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="2"
      id="Tc_flCW-ZCtoUiUq23EHzokag_4_3"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">2.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="2"
      id="Tc_9c-9kTlgg0GF_ZnZN1iIxg_4_6"
      unitRef="Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tc_I6NoWzfXPky90cCntRTDmw_5_3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      id="Tc_qPULqtWu_UujcMaPWCzIuA_5_6">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Tc_ktHLQZARukGJVyVz_RRYAA_6_3"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_vrYS8QYYPkSCqulwc8RrhA_6_6"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Tc_EOJ0ndhnakOkVIGK530tYg_7_3"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_wDl7BNGBnUGAT9uQn8NdSg_7_6"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Tc_cCSGstrhkU-Q4auFsyvZwQ_8_3"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="2"
      id="Tc_VFZ2MMDGmk-K5s8A6SbpUw_8_6"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <mrkr:StockBasedCompensationExpensesTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_XnET9VkGNU-8XAReILEtYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth stock-based compensation expenses recorded during the respective periods:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Compensation expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,588,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,574,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,640,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,783,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,228,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,357,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:StockBasedCompensationExpensesTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wi8B3dNGskeO0KIAZp0PNA"
      decimals="-3"
      id="Tc_J2N03tbx1UGdB5qnlx7H2A_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2588000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_pXkrJdElCEK5luXf8RD1jA"
      decimals="-3"
      id="Tc_WJIB2-kh9k2ij6VNUwZgDQ_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2574000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nia-K5yaQkK6PrPyNBtXQw"
      decimals="-3"
      id="Tc_kENX8aWoAE6gD4kwUXfuBA_6_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2640000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Z1owGgssVkun98tvJFc-ug"
      decimals="-3"
      id="Tc_OGLXJISBt0-Et1W3gJINYw_6_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2783000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="-3"
      id="Tc_elpZ6S5NJ0CQRG5ttNZ34g_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5228000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="-3"
      id="Tc_IRlRbSvQMUKZ7k9an7khbg_7_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5357000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_wYpguwVqsE6ryC4fHMkfsQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">10600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_RwPe2Jr0N0iXbm62Y_-lRA">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <mrkr:GrantIncomeTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_kaOWEn2a5UWWGrG4t3gjTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;14:&#160;&#160;&#160;&#160;GRANT INCOME&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the&#160;years ended December&#160;31, 2020 and 2019, the Company received $0.5 million and $0.2 million, respectively, of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study. In accordance with Accounting Standards Update No.&#160;2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d; issued by the Financial Accounting Standards Board, the Company recorded the $0.5 million and $0.2 million, respectively, of grant income as revenue.&lt;/p&gt;</mrkr:GrantIncomeTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="-5"
      id="Narr_RcUisMl_I02V-BgJEBZ0cg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="-5"
      id="Narr_9avLlBSBUUySQlQLxHDlQg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_9yHzLxI9J0KiGOFm8vPRig"
      decimals="-5"
      id="Narr_RsAe21I7TUOqq54o-cMgXQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_cQNwlMiI7kK08D7_DtU4Cw"
      decimals="-5"
      id="Narr_Sc_3nwjzdEetVPe0OdBecQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_sTqt-mB2RkeEQjjyspfeEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;15:&#160;&#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;An arbitration proceeding was brought against the Company before the Financial Industry Regulatory Authority, Inc. by a broker seeking to be paid approximately $1.0 million as compensation for two financing transactions that occurred in 2018, a warrant conversion and a private placement brokered by another broker. The broker&#x2019;s claims are based on a placement agent agreement for a private placement it brokered in 2017, under which it alleges it is entitled to compensation for the 2018 transactions. The Company believes it has defenses to all of the allegations and intends to vigorously defend itself in this matter.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="-5"
      id="Narr_o76GRGlW3E-AbShFslO5eQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1000000.0</us-gaap:LossContingencyDamagesSoughtValue>
    <mrkr:LossContingencyDamagesSoughtNumberOfTransactions
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Narr_2t0vP7DnoEaof1qkilzyuQ"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">2</mrkr:LossContingencyDamagesSoughtNumberOfTransactions>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_KtudkS3WHEaHdKTQD6BO2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;16:&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#x2019;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#x2019;s interest.&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_FaWlPnJuRk2rT-Io3PzKow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;17:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth related party transaction expenses recorded for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Baylor College of Medicine&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,818,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bio-Techne Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 152,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dr Juan Vera&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 233,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,970,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 353,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Agreements with The Baylor College of Medicine (&#x201c;BCM&#x201d;)&lt;/i&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160; 2018 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#x2019;s Center for Cell and Gene Therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2019, the Company entered in a Clinical Supply Agreement with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Purchases from Bio-Techne Corporation&lt;/i&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is currently utilizing Bio-Techne Corporation and two of its brands for the purchases of reagents, primarily cytokines. Mr. David Eansor is a member of the Company's board of directors and is serving as the President of the Protein Sciences Segment of Bio-Techne Corporation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Consulting Agreement with Dr.&#160;Juan Vera&lt;/i&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; On October&#160;19, 2018, after the closing of the Company&#x2019;s merger, the Company entered into a consulting agreement with Dr.&#160;Juan Vera, a member of the Company&#x2019;s board of directors, to serve as the Company&#x2019;s Chief Development Officer. On September 1, 2019, Dr. Vera became an employee of the Company and his consulting agreement was terminated.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_ax8NzrOrqEylyUy9-4AFDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth related party transaction expenses recorded for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Baylor College of Medicine&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,818,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bio-Techne Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 152,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dr Juan Vera&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 233,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,970,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 353,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_MrqVXYEw1Uid9u_ZLvUPNg"
      decimals="-3"
      id="Tc_G3Oq1xu6UEOwktdt7WIjLg_4_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1818000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_vsg7AnMxjECUv2UMBZE8Og"
      decimals="-3"
      id="Tc_MzFVccKKy0-Qqm6B6MIyWg_4_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">69000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_mJazqkPfFkmc-QMBbBM7hA"
      decimals="-3"
      id="Tc_th9QB0C05ked1AZ74HE5OA_5_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">152000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_2YaAsQK__kGBYij0npbG_w"
      decimals="-3"
      id="Tc_PyuCvoThMEqn0HSwPuR0zQ_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">51000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ConsultingAgreementWithDr.JuanVeraMember_eeZVsRCRzUeJu-ihCRWw2Q"
      decimals="-3"
      id="Tc_d1iSOMjCYUmBi45d_DQ4vQ_6_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">233000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="-3"
      id="Tc_21drmnkmUUu6BLIOlL0lIQ_7_3"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">1970000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="-3"
      id="Tc_GjgIgxDU4UGaapSX5SAnVQ_7_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">353000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_39mllzXd0EiY_DDXHdN2JA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;18:&#160;&#160;&#160;&#160;INCOME TAXES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has no income tax expense due to operating losses incurred for the&#160;years ended December&#160;31, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December&#160;31, 2020 and 2019 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net Operating Loss Carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,783,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,166,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,775,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,538,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;License Agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 144,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Charitable Contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating Lease Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,626,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,069,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,738,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29,689,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,632,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,380,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (106,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,380,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,380,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (106,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Deferred Tax Assets/(Liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the&#160;years ended December&#160;31, 2020 and 2019. The valuation allowance increased by $5.1 million as of December&#160;31, 2020. The Company has research and development tax credit carryforwards of $0.7 million available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has approximately $97.2 million of federal and $39.0 million of state Net Operating Losses (&#x201c;NOL&#x201d;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $41.6 million, if not utilized, will expire between 2029 and 2037. The federal net operating loss carryforwards of $55.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $17.1 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#x2019;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s income tax returns for 2016 to 2019 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the&#160;years ended December&#160;31, 2020 and 2019, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pre-Tax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pre-Tax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,028,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,500,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (118,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (600,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 677,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.36)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 665,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent Differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;- Change in fair value of derivative liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.02&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.02&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;- Other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 182,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.63)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,057,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17.62)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,681,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.85)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred true-up&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 237,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.83)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (274,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision/(benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December&#160;31, 2020, and 2019, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December&#160;31, 2020 and 2019. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next&#160;year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On March 27, 2020, the CARES Act was enabled in response to COVID-19 pandemic. Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. The CARES Act made various tax law changes including among other things (i) increasing the limitation under Section 163(j) of the Internal Revenue Code of 1986, as amended (the &#x201c;IRC&#x201d;) for 2019 and 2020 to permit additional expensing of interest, (ii) enacting a technical correction so that qualified improvement property can be immediately expensed under IRC Section 168(k),(iii) making modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019 and 2020 to be carried back to the five preceding taxable years in order to generate a refund of previously paid income taxes and (iv) enhancing the recoverability of alternative minimum tax credits. Given the Company&#x2019;s full valuation allowance position, the CARES Act did not have an impact on the financial statements.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_4b3lOtXySUKKHjYrKPdIyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net Operating Loss Carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,783,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,166,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,775,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,538,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;License Agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 144,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Charitable Contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating Lease Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,626,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,069,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,738,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29,689,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,632,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,380,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (106,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,380,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,380,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (106,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Deferred Tax Assets/(Liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_MfhFr-Q4h0St8e66apMzDQ_5_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">21783000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_AgCHBFXf8kWbnnDoWlwTZg_5_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">17166000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <mrkr:Deferredtaxstockbasedcompensation
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_8ZtSAx2odUGmwqtn6clWuA_6_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6775000</mrkr:Deferredtaxstockbasedcompensation>
    <mrkr:Deferredtaxstockbasedcompensation
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_Zy6ISmkhOEaI1cnMiJzdTw_6_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">6538000</mrkr:Deferredtaxstockbasedcompensation>
    <mrkr:Deferredtaxassetslicenseagreement
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_x_5utFvUxECrHxMhy_rlLg_7_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">144000</mrkr:Deferredtaxassetslicenseagreement>
    <mrkr:Deferredtaxassetslicenseagreement
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_y-z4xAETxk6DxG0loEN_QA_7_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">177000</mrkr:Deferredtaxassetslicenseagreement>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_Qwq9KHjIyUSgmyLvdyjvyQ_8_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">733000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_Z-SYuUybh02okxoh4hQ-5g_8_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">733000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_wSKTWsqx4kObLeP4MdJZMw_9_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">8000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_caMr_-SA-06574m3mDIfvg_9_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">9000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <mrkr:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_x50-F9ye1kyhEuoOoGa0Uw_10_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2626000</mrkr:DeferredTaxAssetsOperatingLeaseLiability>
    <mrkr:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_98Kx7p0jGUeM6QnbJNuvQQ_10_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">115000</mrkr:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_c5DcZs-cDkiyN4GrAnk-jQ_11_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">32069000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_lVW73f9c3EGutXt1sOjGOQ_11_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">24738000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_IwRBh0B1R0ivC5j7eA2J-A_12_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">29689000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_pe36x3H3H0qjQRYHqzF4OA_12_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">24632000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_ttayjP63rUOCa5i3kWPZAQ_13_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2380000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_-R96YOAU5ESPeS5ivzfBoQ_13_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">106000</us-gaap:DeferredTaxAssetsNet>
    <mrkr:DeferredTaxLiabilitiesFixedAssets
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_f6fZjRVU6ECN6ucfuYzN8g_16_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">106000</mrkr:DeferredTaxLiabilitiesFixedAssets>
    <mrkr:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_2aQE_S90DkCWFqNJzk2jBQ_17_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2380000</mrkr:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="0"
      id="Tc_CCVgPfeXTUyt6XAJJf2KGQ_19_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">2380000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="0"
      id="Tc_UhLpxqZwxE67prnGgyqvuQ_19_4"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">106000</us-gaap:DeferredIncomeTaxLiabilities>
    <mrkr:DecreasedDeferredTaxAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="-5"
      id="Narr_9uhoOT9HF0mk8OAJHctd3Q"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">5100000</mrkr:DecreasedDeferredTaxAssets>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_hwaJIl9W_06dMmkawQkeOA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_Ko2XuH5mNUy2lAwA-C_qHg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">97200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA"
      decimals="-5"
      id="Narr_f-1h1bj240uy7oRLJpGyFQ"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">39000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-5"
      id="Narr_n5VtgECcLkWN2Ch_jo_sKg"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">41600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <mrkr:Taxcreditcarryforwardexpirationyearrangestart
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_vtO96NYlAkaP5tpA0VZ8Tw">2029</mrkr:Taxcreditcarryforwardexpirationyearrangestart>
    <mrkr:Taxcreditcarryforwardexpirationyearrangeend
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Narr_W491ulF250-mW71WDjZ43w">2037</mrkr:Taxcreditcarryforwardexpirationyearrangeend>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_y0AGgi3VjEide44SDAm8EA"
      decimals="-5"
      id="Narr_a5KbL7KOiEOJrWfB92FOMA"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">55600000</us-gaap:OperatingLossCarryforwards>
    <mrkr:OperatingLossCarryforwardsLimitationPercentage
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Narr_m3opfQk0iEKmDGP-KiSHLQ"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.80</mrkr:OperatingLossCarryforwardsLimitationPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw"
      decimals="-5"
      id="Narr_0drBtrFr20eAhx0_kKaR-A"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">21900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_vLnol8OkUk2BmiKlJVI3qg"
      decimals="-5"
      id="Narr_Nf27gisMSEqKUlgy8gLZKw"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">17100000</us-gaap:OperatingLossCarryforwards>
    <mrkr:OperatingLossCarryforwardsLimitationPercentage
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="2"
      id="Narr_k-OlotiCxUaKF25hifjkxQ"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.80</mrkr:OperatingLossCarryforwardsLimitationPercentage>
    <mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      id="Tb_jYHIvCZ9-kWwlHjdSSCoSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pre-Tax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pre-Tax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,028,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,500,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (118,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (600,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 677,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.36)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 665,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent Differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;- Change in fair value of derivative liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.02&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.02&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;- Other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 182,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.63)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,057,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17.62)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,681,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.85)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred true-up&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 237,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.83)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (274,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision/(benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_inTBx0Up_0usbjFAKTa8gg_5_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-6028000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="4"
      id="Tc_quZv1tFES0GV58aWqY2HZw_5_4"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_wWkK4mjpkU6JYuXazNXMnQ_5_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-4500000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="4"
      id="Tc_dVgQD-sCPEynKZdgFkOrFA_5_8"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_B6CASvsxxk6WuT2wikDIBg_6_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-118000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="4"
      id="Tc_-rIODiGDDUaEIErFOXffUA_6_4"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.0041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_HSdB6Z3eu0uOJLIuJr2pJQ_6_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-600000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="4"
      id="Tc_P2n22qfqGkGkYTHogkEucw_6_8"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.0280</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_hyL2j8OJG0eXedxX-aVglg_7_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">677000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="4"
      id="Tc_nxhteO8iaE-l87sX1fSUJw_7_4"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">-0.0236</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_6pwQeDMvmU6Iv_VSQy7agg_7_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">665000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="4"
      id="Tc_MjKyRFUS40-099aTDXuFVg_7_8"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">-0.0310</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <mrkr:Incometaxreconciliationchangeinfairvalueofderivativeliability
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_K7UDD-U1n0eNf0wpGrq9uA_9_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-7000</mrkr:Incometaxreconciliationchangeinfairvalueofderivativeliability>
    <mrkr:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="4"
      id="Tc_dOhNhtA4S0ywrPdKJ0DGXg_9_4"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.0002</mrkr:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability>
    <mrkr:Incometaxreconciliationchangeinfairvalueofderivativeliability
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_QL2VNCXr8U6FxYz7UfEFkg_9_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-4000</mrkr:Incometaxreconciliationchangeinfairvalueofderivativeliability>
    <mrkr:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="4"
      id="Tc_4MpYOh83rUioLb2zmwBWCw_9_8"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.0002</mrkr:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability>
    <mrkr:Permanentdifferencesotherpermanentdifferences
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_DHfCdsdO5USCeNOUm2pBQg_10_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-182000</mrkr:Permanentdifferencesotherpermanentdifferences>
    <mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="4"
      id="Tc_hjFMvoRPCUmXcCTg-0POHw_10_4"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">-0.0063</mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <mrkr:Permanentdifferencesotherpermanentdifferences
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_e81AValCT0qDyIhImnR3VA_10_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-32000</mrkr:Permanentdifferencesotherpermanentdifferences>
    <mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="4"
      id="Tc_8_h2duooZkK7oWDEYZh3rg_10_8"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">-0.0015</mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_fJl--T6iaEqrVMDoaKDXUA_11_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-5057000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="4"
      id="Tc_nUqLPAMEQEqjo2fDvayUOw_11_4"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">-0.1762</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_RDHsJtLuSEy4485ZjEW-kA_11_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-4681000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="4"
      id="Tc_GFPcw3Nah0SJdhTZ32kK3Q_11_8"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">-0.2185</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="0"
      id="Tc_lp4q_b9bDUaLvYpV-OWbbw_12_2"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">237000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="4"
      id="Tc_FUi6o8NxPEuR89zydb002Q_12_4"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">-0.0083</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="0"
      id="Tc_aZJMUcKEpEOi-YXnqW2dew_12_6"
      unitRef="Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg">-274000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="4"
      id="Tc_2el_UtbZAUytdfGNqawCgw_12_8"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.0128</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw"
      decimals="4"
      id="Tc_RxfzjEEBK0-cOzdR05k27Q_13_4"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ"
      decimals="4"
      id="Tc_Q79j6gjrAUW0GONwtFyjxg_13_8"
      unitRef="Unit_Standard_pure_ydf-a8vauUuACbDXMFRCvw">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298454786616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MARKER THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4497941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3200 Southwest Freeway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;2500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-6400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRKR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,731,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001094038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298454772088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,352,382<span></span>
</td>
<td class="nump">$ 43,903,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">2,057,924<span></span>
</td>
<td class="nump">1,526,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">56,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">24,410,865<span></span>
</td>
<td class="nump">45,486,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,570,736<span></span>
</td>
<td class="nump">417,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">6,789,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">10,844,116<span></span>
</td>
<td class="nump">455,174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">21,203,950<span></span>
</td>
<td class="nump">872,702<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">45,614,815<span></span>
</td>
<td class="nump">46,359,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">6,013,010<span></span>
</td>
<td class="nump">1,757,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">388,792<span></span>
</td>
<td class="nump">204,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,401,802<span></span>
</td>
<td class="nump">1,992,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">11,868,440<span></span>
</td>
<td class="nump">280,247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">11,868,440<span></span>
</td>
<td class="nump">280,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,270,242<span></span>
</td>
<td class="nump">2,273,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 150 million shares authorized, 50.7 million and 45.7 million shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">50,731<span></span>
</td>
<td class="nump">45,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">383,533,326<span></span>
</td>
<td class="nump">371,573,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(356,239,484)<span></span>
</td>
<td class="num">(327,533,414)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">27,344,573<span></span>
</td>
<td class="nump">44,086,223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 45,614,815<span></span>
</td>
<td class="nump">$ 46,359,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Excludes construction in progress.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455060872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock shares par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">50,700,000<span></span>
</td>
<td class="nump">45,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">50,700,000<span></span>
</td>
<td class="nump">45,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298459483320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 466,785<span></span>
</td>
<td class="nump">$ 213,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,880,751<span></span>
</td>
<td class="nump">12,764,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,471,846<span></span>
</td>
<td class="nump">9,977,196<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">29,352,597<span></span>
</td>
<td class="nump">22,742,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(28,885,812)<span></span>
</td>
<td class="num">(22,528,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">148,742<span></span>
</td>
<td class="nump">1,082,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,706,070)<span></span>
</td>
<td class="num">$ (21,427,964)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">47,039,862<span></span>
</td>
<td class="nump">45,587,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 466,785<span></span>
</td>
<td class="nump">$ 213,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455398104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid- in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 45,440<span></span>
</td>
<td class="nump">$ 365,400,748<span></span>
</td>
<td class="num">$ (306,105,450)<span></span>
</td>
<td class="nump">$ 59,340,738<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, Shares at Dec. 31, 2018</a></td>
<td class="nump">45,440,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised for cash</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">57,732<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised for cash, Shares</a></td>
<td class="nump">11,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ExerciseOfWarrantsAmount', window );">Warrants exercised for cash</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">758,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">758,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ExerciseOfWarrantsShare', window );">Warrants exercised for cash, shares</a></td>
<td class="nump">190,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantOfCashLessExercised', window );">Stock warrants cashless exercised</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantOfCashLessExercisedSharesIssued', window );">Stock warrants cashless exercised, Shares</a></td>
<td class="nump">9,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">5,356,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,356,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">76,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,427,964)<span></span>
</td>
<td class="num">(21,427,964)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 45,728<span></span>
</td>
<td class="nump">371,573,909<span></span>
</td>
<td class="num">(327,533,414)<span></span>
</td>
<td class="nump">44,086,223<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">45,728,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance common stock for cash</a></td>
<td class="nump">$ 4,114<span></span>
</td>
<td class="nump">6,181,897<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,186,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance common stock for cash, Shares</a></td>
<td class="nump">4,113,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ExerciseOfWarrantsAmount', window );">Warrants exercised for cash</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">549,541<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ExerciseOfWarrantsShare', window );">Warrants exercised for cash, shares</a></td>
<td class="nump">458,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing', window );">Issuance of common stock as commitment fee for future financing</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing', window );">Issuance of common stock as commitment fee for future financing (Shares)</a></td>
<td class="nump">345,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">5,228,324<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,228,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">85,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,706,070)<span></span>
</td>
<td class="num">(28,706,070)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 50,731<span></span>
</td>
<td class="nump">$ 383,533,326<span></span>
</td>
<td class="num">$ (356,239,484)<span></span>
</td>
<td class="nump">$ 27,344,573<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">50,731,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ExerciseOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ExerciseOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ExerciseOfWarrantsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ExerciseOfWarrantsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of common stock issued as commitment fee for future financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of common stock as commitment fee for future financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantOfCashLessExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Of Cash Less Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantOfCashLessExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantOfCashLessExercisedSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The warrant exercised of non cash transaction shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantOfCashLessExercisedSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298452317016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (28,706,070)<span></span>
</td>
<td class="num">$ (21,427,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">485,641<span></span>
</td>
<td class="nump">105,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Changes in fair value of warrant liabilities</a></td>
<td class="num">(31,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,228,409<span></span>
</td>
<td class="nump">5,356,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_AmortizationOfOperatingLeaseRightOfUseAssets', window );">Amortization on right-of-use assets</a></td>
<td class="nump">590,039<span></span>
</td>
<td class="nump">181,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="num">(531,482)<span></span>
</td>
<td class="num">(1,384,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="nump">55,630<span></span>
</td>
<td class="nump">51,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">4,222,470<span></span>
</td>
<td class="num">(963,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(173,268)<span></span>
</td>
<td class="num">(185,179)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,859,631)<span></span>
</td>
<td class="num">(18,284,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress', window );">Purchase of property and equipment</a></td>
<td class="num">(3,638,849)<span></span>
</td>
<td class="num">(374,983)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForConstructionInProcess', window );">Purchase of construction in progress</a></td>
<td class="num">(6,789,098)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(10,427,947)<span></span>
</td>
<td class="num">(374,983)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">6,186,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">758,733<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,736,011<span></span>
</td>
<td class="nump">816,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="num">(22,551,567)<span></span>
</td>
<td class="num">(17,842,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">43,903,949<span></span>
</td>
<td class="nump">61,746,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">21,352,382<span></span>
</td>
<td class="nump">43,903,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing', window );">Issuance of common stock as commitment fee for future financing</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of right-of-use assets and lease liability from new operating lease agreements</a></td>
<td class="nump">11,114,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_NonCashExerciseOfWarrantsAmount', window );">Stock warrants cashless exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AmortizationOfOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AmortizationOfOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NonCashExerciseOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of warrant exercised of non cash amount transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NonCashExerciseOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of Issuance of common stock as commitment fee for future financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; excluding cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298454884088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Marker Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;we&#8221;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s MultiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298449936392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock', window );">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2020, the Company had cash and cash equivalents of approximately </span><span style="font-style:normal;font-weight:normal;">$21.4</span><span style="font-style:normal;font-weight:normal;"> million. The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical trials. Further, the Company&#8217;s product candidates will require regulatory approval prior to commercialization. These activities will span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from sales of its product candidates, if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Based on the Company&#8217;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of December 31, 2020 will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2021, as such these factors raise substantial doubt regarding the Company's ability to continue as a going concern. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#8217;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#8217;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#8217;s future funding requirements will depend on many factors, as it:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">initiates or continues clinical trials of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">continues the research and development of its product candidates and seeks to discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">maintains and enforces intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">evaluates strategic transactions the Company may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, based on the Company&#8217;s current assessment, the Company does not expect any material impact on its long-term liquidity due to the COVID-19 pandemic. However, the Company will continue to assess the effect of the pandemic on its operations, including its clinical programs. The extent to which the COVID-19 pandemic will impact the Company&#8217;s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing the Company&#8217;s ability to access capital, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company&#8217;s business and the value of its common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity Financial Condition And Going Concern Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455512040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#8217;s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31, 2020 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of December&#160;31, 2020, approximately $2.7 million in cash was uninsured based upon the FDIC insurance coverage limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment - Construction in Progress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility's construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout will be recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows Accounting Standards Codification (&#8220;ASC&#8221;) 820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 1&#160;- Quoted prices (unadjusted) in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 2&#160;- Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 3&#160;- Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, financial instruments and concentration of credit risk.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents and Patent Application Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i>&#160;&#8212; The expected life of stock options was estimated using the "simplified method," as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i>&#160;&#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#160;&#8212; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i>&#160;&#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2020 and 2019, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrant Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amounts of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. If the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12&#160;months of the balance sheet date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management must determine whether an instrument (or an embedded feature) is indexed to the Company&#8217;s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. This exercise affects the accounting for (i)&#160;certain freestanding warrants that contain exercise price adjustment features and (ii)&#160;convertible notes containing full-ratchet and anti-dilution protections (iii)&#160;certain free-standing warrants that contain contingently putable cash settlement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company&#8217;s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable and are not dependent on the Company&#8217;s ongoing future performance. The Company has adopted a policy of recognizing these payments when received and as revenue in accordance with Accounting Standards Update No.&#160;2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; issued by the Financial Accounting Standards Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Standards Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, the FASB issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company has adopted the new standard effective January 1, 2021 and is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298449971736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share Applicable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth the computation of loss per share for the&#160;years ended December&#160;31, 2020 and 2019, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,706,070)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,427,964)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,039,862</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,587,734</p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per share data:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.47)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,002,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,983,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,830,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,605,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants - liability treatment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,832,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,647,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298466505800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">OTHER RECEIVABLE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company&#8217;s lease agreement for its manufacturing facility, the Company incurred and paid for the construction invoices directly for both the structural improvements of the facility and the building of the manufacturing modular cleanroom (i.e. leasehold improvements and manufacturing equipment). &#160; At the time the construction invoices are received by the Company, a fixed asset is recorded in construction-in-progress. In accordance with the agreement, upon completion of the facility&#8217;s construction, the Company is owed up to $1.0 million as reimbursement, and as such a landlord receivable is recorded, which provides for a legal right to receive construction reimbursements from the landlord for tenant improvement allowances.    The construction of the facility was completed during December 2020, and a certificate was occupancy was delivered to the Company in January 2021.  During the fiscal year ended 2020, the Company recorded a $1.0 million receivable in its consolidated financial statements. &#160;The Company expects to receive the $1.0 million in the first half of 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298449936392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;6:&#160;&#160;&#160;&#160;PROPERTY AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment consist of the following as of December&#160;31, 2020 and 2019, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 Years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,360,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111,000</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3-5 Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 835,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 Years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 678,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 178,000</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or estimated useful life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 289,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Total   </span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,162,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,000</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (591,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,789,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fixed assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,360,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 418,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the years ended December 31, 2020 and 2019 was approximately $0.5 million and $0.1 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and eventually install modular cleanrooms in a manufacturing facility. &#160;$6.8 million is recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2020.  The completion of the facility&#8217;s construction occurred during December 2020 and the Company received its certificate of occupancy in January 2021, and as such was placed into service in January 2021.  During January 2021, all costs associated with the buildout will be recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the research facility that the Company opened during the second quarter of 2020, the Company incurred approximately $2.2 million of costs acquiring necessary lab equipment to carry out its experiments. The $2.2 million is included in Lab equipment within fixed assets and is being depreciated over five years. &#160;Additionally, the Company incurred $0.3 million in leasehold improvements relating to the research facility.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451591656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 7: LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into a new agreement for its corporate headquarters in Houston, Texas, which commenced in August of 2020. &#160; The initial lease term is ten years with two five-year renewal options. Fixed rent payments under the initial term are approximately $5.6 million. &#160;Additionally, the Company is also responsible for its share of operating expenses. &#160; &#160;As of December 31, 2020, the Company had remaining $4.1 million from the lease liability and $4.0 million of the related right-of-use asset resulting from the lease of its corporate headquarters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April 2020, the Company entered into a lease for a research facility in Houston, Texas. &#160; The lease term is 71 months. Fixed rent payments under the initial term are approximately $1.1 million. As of December 31, 2020, the Company had remaining $0.8 million from the lease liability and $0.8 million of the related right-of-use asset resulting from the lease of its research facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. The initial lease term is ten years from the rent commencement date in the fourth quarter of 2020 with two five-year renewal options. Fixed rent payments under the initial term are approximately $9.8 million. &#160;Additionally, the Company is also responsible for its share of operating expenses. In accordance with the agreement, upon completion of the facility&#8217;s construction, the Company is owed up to $1.0 million as reimbursement, and as such a landlord receivable is recorded, which provides for a legal right to receive construction reimbursements from the landlord for tenant improvement allowances. As of December 31, 2020, the Company had remaining $7.2 million from the lease liability and $5.8 million of the related right-of-use asset resulting from the lease of its manufacturing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also leases office space under agreements classified as operating leases that expire in 2022. As of December 31, 2020, the Company had remaining $0.2 million from the lease liability and $0.2 million of the related right-of-use asset resulting from the lease of its Jacksonville, Florida office space, which expires in 2022. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. &#160;Certain of the Company&#8217;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. &#160;Variable expenses generally represent the Company&#8217;s share of the landlord&#8217;s operating expenses. &#160;The Company does not act as a lessor or have any leases classified as financing leases. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2020, the Company had operating lease liabilities of approximately $12.3 million and right-of-use assets of approximately $10.8 million, which were included in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company&#8217;s operating leases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense summary:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 960,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 167,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,149,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 410,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 544,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term &#8211; operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate as of adoption date &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of the Company&#8217;s operating leases, excluding short-term leases, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,077,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,278,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,826,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,874,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,772,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,369,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,112,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,257,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451545896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8: &#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued liabilities consist of the following as of December&#160;31, 2020 and 2019, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,935,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 993,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,694,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 875,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology license fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 404,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,013,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,758,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451560632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantLiabilityAbstract', window );"><strong>WARRANT LIABILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantLiabilityTextBlock', window );">WARRANT LIABILITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;9:&#160;&#160;&#160;&#160;WARRANT LIABILITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company&#8217;s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the&#160;years ended 2020 and 2019, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.92</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_p0q6djlt6UyBX7Cf1G6waA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility (annual)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield (per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The foregoing assumptions are recalculated every reporting period and are subject to change based primarily on management&#8217;s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents changes in Level 3 warrant liabilities, reflected in accrued expenses measured at fair value for the&#160;years ended December&#160;31, 2020 and 2019, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance &#8211; December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance &#8211; December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrant liability, including all tables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450051256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;10:&#160;&#160;&#160;&#160;FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in&#160;active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value at</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in&#160;active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable&#160;inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable&#160;inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no transfers between Level 1, 2 or 3 during the&#160;years ended December&#160;31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U. S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The net cash settlement value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following inputs at that time: the consideration value per share of the Company&#8217;s common stock, the volatility of the Company&#8217;s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U. S. Treasury security yields, and the Company&#8217;s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450036696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;11:&#160;&#160;&#160;&#160;STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to 150,000,000 shares of common stock, $0.001 par value per share, for issuance. Significant 2020 and 2019 common stock transactions were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">2020 Common Stock Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Exercise of Stock Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the year ended December 31, 2020, certain outstanding warrants were exercised for </span><span style="font-weight:normal;">0.5</span><span style="font-weight:normal;"> million shares of common stock providing aggregate proceeds to the Company of approximately </span><span style="font-weight:normal;">$0.6</span><span style="font-weight:normal;"> million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Board Compensation </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company issued an aggregate of 0.1<b style="font-weight:bold;"> </b>million shares of common stock to its non-employee directors. The fair value of the common stock of approximately <b style="font-weight:bold;"> </b>$0.2<b style="font-weight:bold;"> </b>million was recognized as a component of stock-based compensation expense in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Aspire Capital</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 28, 2020, the Company entered into a common stock purchase agreement (the &#8220;Purchase Agreement&#8221;) with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of shares of the Company&#8217;s common stock over the 30-month term of the purchase agreement. In consideration for entering into the purchase agreement, the Company issued to Aspire Capital 0.3 million shares of the Company&#8217;s common stock as a commitment fee. &#160;The Company recorded the commitment fee to additional paid in capital. &#160;As of December 31, 2020, Aspire Capital had purchased 4.1 million shares under the Purchase Agreement, providing aggregate proceeds to the Company of approximately $6.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">2019 Common Stock Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Consulting Arrangements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company issued 0.05 million shares of common stock in connection with consulting agreements. The fair value of the common stock of approximately $0.3 million was recognized as stock-based compensation expense in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Board Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company issued an aggregate of 0.03 million shares of common stock to its non-employee directors. The fair value of the common stock of approximately $0.2 million was recognized as stock-based compensation expense in general and administrative expenses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298459662824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantsDisclosureAbstract', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantsDisclosureTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;12:&#160;&#160;&#160;&#160;WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share Purchase Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s share purchase warrants as of December&#160;31, 2020 and 2019, respectively, and changes during the period is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 23,016,000</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.78</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.29</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 26,066,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (190,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.99</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cashless exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (190,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.63</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 22,664,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.71</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">3.33</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 954,000</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (458,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,376,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 20,830,000</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.47</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2.60</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2020 Warrant Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Exercise of Stock Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, certain outstanding warrants were exercised for 0.5 million shares of common stock providing aggregate proceeds to the Company of approximately $0.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2019 Warrant Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Exercise of Stock Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, certain outstanding warrants were exercised for 0.2 million shares of common stock providing aggregate proceeds to the Company of approximately $0.8 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298484842760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTION PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTION PLANS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;13:&#160;&#160;&#160;&#160;STOCK OPTION PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Options to Purchase Shares of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;">2020 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May&#160;19, 2020, the Board adopted the 2020 Equity Incentive Plan ("2020 Plan") which replaced the 2014 Omnibus Stock Option Plan (&#8220;2014 Plan&#8221;). The 2020 Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Plan may be at prices and for terms as determined by the Board of Directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#8217;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules&#160;and regulations of the New York Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Options granted under the 2020 Plan have a maximum term of ten years from the date of grant. Options granted in 2020 and 2019 generally vest over four years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, approximately 4.7 million options are available to be issued from the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">2014 Omnibus Stock Ownership Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2014 Plan, which the Board adopted on May 19, 2020 and subsequently amended from time to time, allowed for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. The terms of the 2014 plan are substantially identical to the terms of the 2020 Plan described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s stock option activity is as follows for stock options:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,983,314</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.79</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,531,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (512,500)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,001,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,598,981</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.29</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the&#160;years ended December&#160;31, 2020 and 2019, respectively, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 126</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,588,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,574,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,640,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,783,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,228,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,357,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At December&#160;31, 2020, the total stock-based compensation cost related to unvested awards not yet recognized was $10.6 million. The expected weighted average period compensation costs to be recognized was 2.2&#160;years. Future option grants will impact the compensation expense recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451294152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_GrantIncomeAbstract', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_GrantIncomeTextBlock', window );">GRANT INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;14:&#160;&#160;&#160;&#160;GRANT INCOME</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the&#160;years ended December&#160;31, 2020 and 2019, the Company received $0.5 million and $0.2 million, respectively, of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study. In accordance with Accounting Standards Update No.&#160;2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; issued by the Financial Accounting Standards Board, the Company recorded the $0.5 million and $0.2 million, respectively, of grant income as revenue.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Grant Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Grant Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451525800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;15:&#160;&#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An arbitration proceeding was brought against the Company before the Financial Industry Regulatory Authority, Inc. by a broker seeking to be paid approximately $1.0 million as compensation for two financing transactions that occurred in 2018, a warrant conversion and a private placement brokered by another broker. The broker&#8217;s claims are based on a placement agent agreement for a private placement it brokered in 2017, under which it alleges it is entitled to compensation for the 2018 transactions. The Company believes it has defenses to all of the allegations and intends to vigorously defend itself in this matter.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298452395592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>LEGAL PROCEEDINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;16:&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, the Company may be party to ordinary, routine litigation incidental to their business. The Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#8217;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#8217;s interest.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451525800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_RelatedPartyDisclosureAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;17:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth related party transaction expenses recorded for the years ended December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baylor College of Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,818,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bio-Techne Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dr Juan Vera</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 233,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,970,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Agreements with The Baylor College of Medicine (&#8220;BCM&#8221;)</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160; 2018 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, the Company entered in a Clinical Supply Agreement with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Purchases from Bio-Techne Corporation</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is currently utilizing Bio-Techne Corporation and two of its brands for the purchases of reagents, primarily cytokines. Mr. David Eansor is a member of the Company's board of directors and is serving as the President of the Protein Sciences Segment of Bio-Techne Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Consulting Agreement with Dr.&#160;Juan Vera</i><i style="font-style:italic;">.</i> On October&#160;19, 2018, after the closing of the Company&#8217;s merger, the Company entered into a consulting agreement with Dr.&#160;Juan Vera, a member of the Company&#8217;s board of directors, to serve as the Company&#8217;s Chief Development Officer. On September 1, 2019, Dr. Vera became an employee of the Company and his consulting agreement was terminated.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451551832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;18:&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has no income tax expense due to operating losses incurred for the&#160;years ended December&#160;31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December&#160;31, 2020 and 2019 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,783,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,166,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,775,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,538,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">License Agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Charitable Contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating Lease Liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,626,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,069,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,738,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,689,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,632,000)</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,380,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed Assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (106,000)</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-Use Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,380,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,380,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (106,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the&#160;years ended December&#160;31, 2020 and 2019. The valuation allowance increased by $5.1 million as of December&#160;31, 2020. The Company has research and development tax credit carryforwards of $0.7 million available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has approximately $97.2 million of federal and $39.0 million of state Net Operating Losses (&#8220;NOL&#8221;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $41.6 million, if not utilized, will expire between 2029 and 2037. The federal net operating loss carryforwards of $55.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $17.1 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#8217;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s income tax returns for 2016 to 2019 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;years ended December&#160;31, 2020 and 2019, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre-Tax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre-Tax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,028,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,500,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (118,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (600,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax rate change</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 677,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.36)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 665,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent Differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Change in fair value of derivative liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.02</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.02</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.63)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,057,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17.62)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,681,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.85)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 237,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.83)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (274,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December&#160;31, 2020, and 2019, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December&#160;31, 2020 and 2019. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 27, 2020, the CARES Act was enabled in response to COVID-19 pandemic. Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. The CARES Act made various tax law changes including among other things (i) increasing the limitation under Section 163(j) of the Internal Revenue Code of 1986, as amended (the &#8220;IRC&#8221;) for 2019 and 2020 to permit additional expensing of interest, (ii) enacting a technical correction so that qualified improvement property can be immediately expensed under IRC Section 168(k),(iii) making modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019 and 2020 to be carried back to the five preceding taxable years in order to generate a refund of previously paid income taxes and (iv) enhancing the recoverability of alternative minimum tax credits. Given the Company&#8217;s full valuation allowance position, the CARES Act did not have an impact on the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455424104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#8217;s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31, 2020 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of December&#160;31, 2020, approximately $2.7 million in cash was uninsured based upon the FDIC insurance coverage limits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_RetainExistingPolicy', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock', window );">Property and equipment - Construction in Progress</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment - Construction in Progress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility's construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout will be recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows Accounting Standards Codification (&#8220;ASC&#8221;) 820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 1&#160;- Quoted prices (unadjusted) in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 2&#160;- Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Level 3&#160;- Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, financial instruments and concentration of credit risk.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents and Patent Application Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents and Patent Application Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i>&#160;&#8212; The expected life of stock options was estimated using the "simplified method," as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i>&#160;&#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#160;&#8212; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i>&#160;&#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2020 and 2019, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrant Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amounts of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. If the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12&#160;months of the balance sheet date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management must determine whether an instrument (or an embedded feature) is indexed to the Company&#8217;s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. This exercise affects the accounting for (i)&#160;certain freestanding warrants that contain exercise price adjustment features and (ii)&#160;convertible notes containing full-ratchet and anti-dilution protections (iii)&#160;certain free-standing warrants that contain contingently putable cash settlement.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company&#8217;s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable and are not dependent on the Company&#8217;s ongoing future performance. The Company has adopted a policy of recognizing these payments when received and as revenue in accordance with Accounting Standards Update No.&#160;2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; issued by the Financial Accounting Standards Board.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Standards Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, the FASB issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company has adopted the new standard effective January 1, 2021 and is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Income [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for property and equipment, construction in progress.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RetainExistingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No Defined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RetainExistingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450112328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,706,070)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,427,964)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,039,862</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,587,734</p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per share data:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.47)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_NetLossPerShareTableTextBlockTableTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,002,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,983,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,830,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,605,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants - liability treatment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,832,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,647,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NetLossPerShareTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Loss Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NetLossPerShareTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450215064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 Years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,360,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 111,000</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3-5 Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 835,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 Years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 678,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 178,000</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or estimated useful life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 289,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Total   </span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,162,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,000</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (591,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,789,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:41.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fixed assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,360,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 418,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451484232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of quantitative information about operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense summary:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 960,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 167,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,149,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 410,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 544,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term &#8211; operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate as of adoption date &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,077,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,278,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,826,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,874,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,772,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,369,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,112,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,257,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lease cost and other information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450160680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,935,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 993,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,694,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 323,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 875,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology license fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 404,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,013,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,758,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451945624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Tables) - Level 3<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ValuationMethodology', window );">Schedule of valuation methodology</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.92</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_p0q6djlt6UyBX7Cf1G6waA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility (annual)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield (per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_MeasuredAtFairValue', window );">Schedule of Changes in Level 3 Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance &#8211; December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance &#8211; December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_MeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_MeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ValuationMethodology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ValuationMethodology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451454232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock', window );">Schedule of financial liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in&#160;active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value at</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;measured&#160;at&#160;December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;prices&#160;in&#160;active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable&#160;inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable&#160;inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets and liabilities measured at fair value on recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451823544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock', window );">Schedule of share purchase warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 23,016,000</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.78</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.29</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 26,066,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (190,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.99</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cashless exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (190,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.63</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 22,664,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.71</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">3.33</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 954,000</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (458,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,376,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 20,830,000</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4.47</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2.60</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298452061832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule or Description of Weighted Average Discount Rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the&#160;years ended December&#160;31, 2020 and 2019, respectively, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 126</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_StockBasedCompensationExpensesTableTextBlock', window );">Schedule of stock-based compensation expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,588,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,574,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,640,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,783,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,228,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,357,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock', window );">Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s stock option activity is as follows for stock options:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,983,314</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.79</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,531,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (512,500)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,001,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,598,981</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.29</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of stock based compensation expenses recorded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock awards granted to nonemployee directors that were outstanding at the beginning and end of the year, and the number of awards that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451825832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_RelatedPartyDisclosureAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transaction expenses recorded during the respective periods</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth related party transaction expenses recorded for the years ended December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baylor College of Medicine</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,818,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bio-Techne Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dr Juan Vera</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 233,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,970,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 353,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450171144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,783,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,166,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,775,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,538,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">License Agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Charitable Contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating Lease Liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,626,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,069,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,738,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,689,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,632,000)</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,380,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed Assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (106,000)</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-Use Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,380,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,380,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (106,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock', window );">Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre-Tax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre-Tax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,028,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,500,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (118,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (600,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax rate change</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 677,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.36)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 665,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent Differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Change in fair value of derivative liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.02</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.02</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.63)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,057,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17.62)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,681,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.85)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 237,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.83)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (274,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected tax expense benefit based on federal statutory rate is reconciled with actual tax provision benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451591656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,352,382<span></span>
</td>
<td class="nump">$ 43,903,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455599336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC Insured Amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298449969832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,706,070)<span></span>
</td>
<td class="num">$ (21,427,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">47,039,862<span></span>
</td>
<td class="nump">45,587,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share data:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450159512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">26,832,000<span></span>
</td>
<td class="nump">27,647,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockWarrantsEquityTreatment', window );">Common stock purchase warrants</a></td>
<td class="nump">6,002,000<span></span>
</td>
<td class="nump">4,983,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockWarrantsEquityTreatment', window );">Common stock purchase warrants</a></td>
<td class="nump">20,830,000<span></span>
</td>
<td class="nump">22,605,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mrkr_CommonStockWarrantsLiabilityTreatmentMember', window );">Common stock warrants - liability treatment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockWarrantsEquityTreatment', window );">Common stock purchase warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommonStockWarrantsEquityTreatment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants - equity treatment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommonStockWarrantsEquityTreatment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mrkr_CommonStockWarrantsLiabilityTreatmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mrkr_CommonStockWarrantsLiabilityTreatmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298449965688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER RECEIVABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298460334728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 4,162,000<span></span>
</td>
<td class="nump">$ 523,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(591,000)<span></span>
</td>
<td class="num">(105,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">6,789,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,360,000<span></span>
</td>
<td class="nump">418,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 2,360,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember', window );">Computers, equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 835,000<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember', window );">Computers, equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember', window );">Computers, equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 678,000<span></span>
</td>
<td class="nump">178,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 289,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455129112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Lease hold improvements</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Cost to acquire necessary lab equipment</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298454783160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Quantitative Information About Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_OperatingLeaseExpenseAbstract', window );"><strong>Operating lease expense summary:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">167,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">1,149,000<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_OtherLeaseInformationAbstract', window );"><strong>Other information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows - operating leases</a></td>
<td class="nump">$ 544,000<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate as of adoption date - operating leases</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OperatingLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OperatingLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OtherLeaseInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OtherLeaseInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455862360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ended December 31, 2021</a></td>
<td class="nump">$ 1,077,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ended December 31, 2022</a></td>
<td class="nump">1,278,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ended December 31, 2023</a></td>
<td class="nump">1,542,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ended December 31, 2024</a></td>
<td class="nump">1,826,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ended December 31, 2025</a></td>
<td class="nump">1,874,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,772,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">16,369,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(4,112,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December 31, 2020</a></td>
<td class="nump">$ 12,257,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298452354440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>Options</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>Options</div>
</th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,844,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">71 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_NumberOfRenewalOptions', window );">Number of renewal options | Options</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_FixedLeaseRentPayment', window );">Fixed lease rent payment</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Receivables of reimbursement for out of pocket buildout costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ResearchFacilityInHoustonTexasMember', window );">Research Facility in Houston, Texas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember', window );">Manufacturing Facility in Houston, Texas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrkr_CorporateHeadquartersMember', window );">Corporate headquarters (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrkr_OfficeSpaceMember', window );">Office space (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FixedLeaseRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount of fixed lease rent payments under the initial term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FixedLeaseRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of renewal options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ResearchFacilityInHoustonTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ResearchFacilityInHoustonTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrkr_CorporateHeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrkr_CorporateHeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrkr_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrkr_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455314136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 2,935,000<span></span>
</td>
<td class="nump">$ 993,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">1,694,000<span></span>
</td>
<td class="nump">323,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">875,000<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_AccruedTechnologyLicenseFees', window );">Technology license fees</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">404,000<span></span>
</td>
<td class="nump">243,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 6,013,010<span></span>
</td>
<td class="nump">$ 1,757,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AccruedTechnologyLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Consulting agreements payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AccruedTechnologyLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298448354616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY - Valuation Methodology (Details) - Share Purchase Warrants - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_FairValuesAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_FairValuesAssumptionsExpectedTerm', window );">Contractual term (years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_FairValuesAssumptionsExpectedVolatilityRate', window );">Volatility (annual)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_FairValuesAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_FairValuesAssumptionsExpectedDividendRate', window );">Dividend yield (per share)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FairValuesAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upon price for the exchange of the underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FairValuesAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FairValuesAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FairValuesAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FairValuesAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FairValuesAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FairValuesAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FairValuesAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FairValuesAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FairValuesAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrkr_SharePurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrkr_SharePurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451502264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY - Changes in Level 3 Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantLiabilityAbstract', window );"><strong>WARRANT LIABILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value of warrant liability</a></td>
<td class="num">(31,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451669496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_FairValueTransfersAmount', window );">Transfers between levels 1, 2 or 3 of the fair value hierarchy</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair value hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair value hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair value hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FairValueTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers between levels 1, 2 or 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FairValueTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298459464776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,186,011<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_ConsultingArrangementsMember', window );">Consulting Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance common stock for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_AspireCapitalMember', window );">Aspire Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_MaximumCommonStockCommittedToPurchase', window );">Aggregate shares of common stock</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_AgreementTerm', window );">Agreement Term</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common shares issued</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance common stock for cash, Shares</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember', window );">Board Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">30,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember', window );">Exercise of Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance common stock for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,113,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_MaximumCommonStockCommittedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum number of common stock to be purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_MaximumCommonStockCommittedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_ConsultingArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_ConsultingArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_AspireCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_AspireCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298476818680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS - Summary of Share Purchase Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantsDisclosureAbstract', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Beginning balance</a></td>
<td class="nump">22,664,000<span></span>
</td>
<td class="nump">23,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_NumberOfWarrantsGranted', window );">Number Of Warrants, Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_NumberOfWarrantExercisedForCash', window );">Number of Warrants, Exercised for cash</a></td>
<td class="num">(458,000)<span></span>
</td>
<td class="num">(190,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_NumberOfWarrantCashlessExercised', window );">Number of Warrants, Cashless exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_NumberOfWarrantExpiredOrCancelled', window );">Number of Warrants, Expired or cancelled</a></td>
<td class="num">(1,376,000)<span></span>
</td>
<td class="num">(190,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Ending balance</a></td>
<td class="nump">20,830,000<span></span>
</td>
<td class="nump">22,664,000<span></span>
</td>
<td class="nump">23,016,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash', window );">Weighted Average Exercise Price, Exercised for cash</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised', window );">Weighted Average Exercise Price, Cashless exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired or cancelled</a></td>
<td class="nump">9.46<span></span>
</td>
<td class="nump">13.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife', window );">Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
<td class="text">4 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue', window );">Total Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 954,000<span></span>
</td>
<td class="nump">$ 26,066,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding class of warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercise Price Cashless Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights outstanding exercised weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right outstanding issued weighted average remaining life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfWarrantCashlessExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants cashless exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfWarrantCashlessExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfWarrantExercisedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfWarrantExercisedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfWarrantExpiredOrCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants expired or cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfWarrantExpiredOrCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants, Granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451488680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS - Additional Information (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_WarrantsDisclosureAbstract', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298459641288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS - Stock Option Activity (Details) - Common stock options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="nump">4,983,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">1,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled</a></td>
<td class="num">(512,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="nump">6,001,814<span></span>
</td>
<td class="nump">4,983,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options vested and exercisable</a></td>
<td class="nump">2,598,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Outstanding, Beginning Balance</a></td>
<td class="nump">$ 7.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
<td class="nump">2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Outstanding, Ending Balance</a></td>
<td class="nump">6.22<span></span>
</td>
<td class="nump">$ 7.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and exercisable</a></td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total Intrinsic Value Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life, Options granted</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options vested and exercisable</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450068136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS - Weighted Average Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTION PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">108.00%<span></span>
</td>
<td class="nump">126.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298475929992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS- Stock-based compensation expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock compensation expenses</a></td>
<td class="nump">$ 5,228,409<span></span>
</td>
<td class="nump">$ 5,356,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock compensation expenses</a></td>
<td class="nump">2,588,000<span></span>
</td>
<td class="nump">2,574,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock compensation expenses</a></td>
<td class="nump">$ 2,640,000<span></span>
</td>
<td class="nump">$ 2,783,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298450102040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS - Additional Information (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTION PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued', window );">Number of shares options available to be issued</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost not yet recognized, period for recognition</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement number of share options available for issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455421224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Grant received recorded as revenue</a></td>
<td class="nump">$ 466,785<span></span>
</td>
<td class="nump">$ 213,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Grant received recorded as revenue</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298451595384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_LossContingencyDamagesSoughtNumberOfTransactions', window );">Loss Contingency, Damages Sought, Number of Transactions</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LossContingencyDamagesSoughtNumberOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of transactions of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LossContingencyDamagesSoughtNumberOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298454948888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses</a></td>
<td class="nump">$ 1,970<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember', window );">Baylor College of Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_PurchasesFromBioTechneCorporationMember', window );">Bio-Techne Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ConsultingAgreementWithDr.JuanVeraMember', window );">Dr Juan Vera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_PurchasesFromBioTechneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_PurchasesFromBioTechneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ConsultingAgreementWithDr.JuanVeraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ConsultingAgreementWithDr.JuanVeraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298455871656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss Carryforward</a></td>
<td class="nump">$ 21,783,000<span></span>
</td>
<td class="nump">$ 17,166,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_Deferredtaxstockbasedcompensation', window );">Stock Compensation</a></td>
<td class="nump">6,775,000<span></span>
</td>
<td class="nump">6,538,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_Deferredtaxassetslicenseagreement', window );">License Agreements</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="nump">177,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and Development</a></td>
<td class="nump">733,000<span></span>
</td>
<td class="nump">733,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable Contributions</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating Lease Liability</a></td>
<td class="nump">2,626,000<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets</a></td>
<td class="nump">32,069,000<span></span>
</td>
<td class="nump">24,738,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation Allowance</a></td>
<td class="num">(29,689,000)<span></span>
</td>
<td class="num">(24,632,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Assets</a></td>
<td class="nump">2,380,000<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_DeferredTaxLiabilitiesFixedAssets', window );">Fixed Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-Use Assets</a></td>
<td class="num">(2,380,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">$ (2,380,000)<span></span>
</td>
<td class="num">$ (106,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Deferred tax assets, operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liability, Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liability, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Deferredtaxassetslicenseagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Deferredtaxassetslicenseagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Deferredtaxstockbasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Deferredtaxstockbasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298459758088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U. S. federal statutory rate</a></td>
<td class="num">$ (6,028,000)<span></span>
</td>
<td class="num">$ (4,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(118,000)<span></span>
</td>
<td class="num">(600,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax rate change</a></td>
<td class="nump">$ 677,000<span></span>
</td>
<td class="nump">$ 665,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U. S. federal statutory rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit, Percent</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change, Percent</a></td>
<td class="num">(2.36%)<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Permanent Differences</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability', window );">Permanent differences- Change in fair value of derivative liabilities</a></td>
<td class="num">$ (7,000)<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_Permanentdifferencesotherpermanentdifferences', window );">Permanent differences- Other permanent differences</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">5,057,000<span></span>
</td>
<td class="nump">4,681,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Deferred true-up</a></td>
<td class="nump">$ 237,000<span></span>
</td>
<td class="num">$ (274,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability', window );">Permanent differences- Change in fair value of derivative liabilities, Percent</a></td>
<td class="nump">0.02%<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences', window );">Permanent differences- Other permanent differences, Percent</a></td>
<td class="num">(0.63%)<span></span>
</td>
<td class="num">(0.15%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Percent</a></td>
<td class="num">(17.62%)<span></span>
</td>
<td class="num">(21.85%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Deferred true-up, Percent</a></td>
<td class="num">(0.83%)<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision (benefit), Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the effective tax rate reconciliation due to change in fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the effective tax rate reconciliation due to other permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation change in fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Permanentdifferencesotherpermanentdifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Permanent differences other permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Permanentdifferencesotherpermanentdifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140298459438056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_Taxcreditcarryforwardexpirationyearrangestart', window );">Tax credit carryforwards expiration period</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 733,000<span></span>
</td>
<td class="nump">$ 733,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_Taxcreditcarryforwardexpirationyearrangeend', window );">Tax credit carryforwards expiration year end</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</a></td>
<td class="nump">$ 97,200,000<span></span>
</td>
<td class="nump">41,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="nump">$ 39,000,000.0<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_OperatingLossCarryforwardsLimitationPercentage', window );">Operating Loss Carryforwards Limitation Percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_DecreasedDeferredTaxAssets', window );">Decreased Deferred Tax Assets</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrkr_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DecreasedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of decreased deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DecreasedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OperatingLossCarryforwardsLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of limitation for operating loss carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OperatingLossCarryforwardsLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Taxcreditcarryforwardexpirationyearrangeend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year range end.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Taxcreditcarryforwardexpirationyearrangeend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Taxcreditcarryforwardexpirationyearrangestart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year range start.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Taxcreditcarryforwardexpirationyearrangestart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MG:-)>R[\-U</>:51(5:@"C4,85";H];-C9%U>UIY+XV197NY%AR@6P%XOY)
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MBF!B9=6-5P]:[$Q#^RHTM,?F-H4O&"9+ _A_(X0^/90#--]$DW\!4$L#!!0
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MR>]Q)92.5HNP=V=7"]-0J33>67!-50G[<HZE:9?1/!HV[E5>D-^(5XM:Y/B
M]+6^LVS%(TNF*M1.&0T6]\MH/3\]/_;X /A38>L.UN SV1GSZ(WK;!DE7A"6
M*,DS"/Y[P@LL2T_$,K[UG-$8TCL>K@?V+R%WSF4G'%Z8\B^54;&,3B+(<"^:
MDNY-^P?V^7ST?-*4+OQ"VV%3CB@;1Z;JG=FNE.[^Q7-?AP.'D^0G#FGOD ;=
M7:"@\E*06"VL:<%Z-+/Y14@U>+,XI?VE/)#E4\5^M+I=;[_>7\'F"VSNKN[7
MV^O-[<,B)F;VY['L6<X[EO0G+/,4;HRFPL&5SC![31"SI%%7.N@Z3W_)>(ER
M!D?S":1)FOR"[VC,\RCP'?WG/%_1'H^TQX'V^'^6[U]8-MLKF)_"C]C@1MA'
MM+ MT(H:&U+23>!:R]D$!%QB*5IA$:2QM;$BO/3W5"#\]NXD39.S"U/50K\$
M:WX&Q@X'+?9['R:@'%-)5J6D**>.N!M!556CS=1H?F$F?^$ @0A<C5*)4GU7
M.@>EP<?*\(F[N^9>)1 Z\]@*;0?K))D]:,,@V(+D#ISZ1LKZ&!0R4^B"K](,
M%+Y5H<::5(8]^$E(R75SP),H1"4>0A1B,KN?5>25^A2X04J5:Z'EP.I,J3*@
MIF)?I3,&>5ENYLL*!S6:?SIS<,,=K;;K]33DNE>R5PV$LM!=.;ADG2S3E:"?
M,ZP:GYG,C4GK*>J<=:/%;-(I>,OKF$$0CSAI<JV^8Z]3.&>XAL1!A":5\R2<
M0%LH68"_\0Y$PN9(?."S?%1>9-CO>%F+1>?\55%A' [PD#>;0WS/EZ'CFG$P
M,@=2*E^+NGP3SF-J:[)&(NRL$5EX%F2;*DB=]@GX@BAZ>55E:(7C*QC>JW\%
M&F[Q263"K^:?/Z<A%XMO0>-;Y_5&DMEQ5Z3)_&3VHSZ.#T8BO\4\#'['+[/1
MU$W'<7?\MJR[D?H/O/LP<0/R!3HH<<^NR>S3QPAL-^P[@TP=!NS.$(_KL"SX
M^XC6 _A\;PP-A@\P?G%7?P-02P,$%     @ ZH5I4BWQOA=5"@  $AP  !@
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MY6@!GJ\M,)DN2$'W&?#L_U!+ P04    " #JA6E2% ,XRXX3  "M-@  &
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MYTK?F]WERJCXR;ADD_L5\_+8@F&N4.R(XA18JF;DRD<C-&.RJP'ZH,)([12
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M^V?WIGUM_C5OW^P/PNV4X9E4D.ML>GF1M-UR7 1;Q[>'9@>]9/&SI)\.Z-B
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M7@M\;0E+$_!_;HQ?#VB#]OOM[%]02P,$%     @ ZH5I4KPQ0&;Y!@  718
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M2YDTN&;L3G!87DJ[8':IV R#LD//,':(#2HJIQDR?78I;^% 4YPYOZ-X#2N
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M- G@_4PI6]^0@^9$^>1?4$L#!!0    ( .J%:5*J .EXQ@(   $'   9
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M:0)P/Q-"GPR3H'GUQK\ 4$L#!!0    ( .J%:5)=<6\G3 0  *,*   9
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MR?)3F+%K-'Q[. "JGT3UQ)DR/$.6QO&C)@QS?D4B>0/>SXQQ[<0'Z-ZELW\
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M-(J^<L*9P:_%<+:"R6Q\,[WJ!888K3^(]^A1C8[>0+<CF$IA,@U7(L'D.4%
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M9=-^[_(B 1M';!3(-&&L;0SQD S+BE\EM%Z!S[?&T(O@'1S?N<D/4$L#!!0
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M<<Z4?+E4"&U+$_!\88QK;VB#[MOGZ_\ 4$L#!!0    ( .J%:5+G]NJ<=A0
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MBWX+2:5!D_?$67#2>$D9"WYP2JA&0]@G>;5K:PH)PI!#%O T6\#3@TJ[!K6
M?-_[H%?HOD-J_SD*&*0@M+#>^ZHCV3Y[Y7_($.Z%)?1;B 9_M1JB(&1! [@!
M!V-L6,D;$%9F 64I/6"--8N2]";G<P #HE(N %X!2FOK*%JLV,QP4JU]U5C?
MP@IC<DA7@S\V8#V@E198A >0\7$';8/#YQB<<%&G*0;-G5W!<M87[(S%5:%]
M4"L$'=X'^GJWD2R>_1M)_G$KFY8E#*O:#05-^%)CK,2H'L F89X*X RU N[
MBG Q5,9<:D<$2&^ ,:J;8X0VM4";!,@5"</2Y</2-D<#A/ 7)&"-*IQV(YW#
M73=:SG2C@TZ;JBK7 M7B]T/F_"R;\[.#QG@A_7(D\%_Q'@0,S*FDV@N0BP[B
MJ_8W0T;^GZ!+*3F%*;1Q72L'61>P(9A&HV$F)II;T"];.:=;M)_6H9V3T)Q2
M8L7(R3H!X11#':;LUE5+5H6%)"XJY$9UW(R9/^1I]Y$ \P?TI%8SL-:$H)A#
MCRX ZU9Y+O@'9SL.Y#7XB=<8M> _,,S0)E.\G_S'XCR'L\[3>M,(@JB[2BD
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M(2;':.9=<MVQ,6OPS!(-#0;1(4=Q7HIZ@FH MGBCJ$*%$A<K8Q:?A\ EJ>E
MYP_J3M))-:9SC)C(0+RLD4]C8N52BL)WIA"3"A3R"\1979D3F<_-D853>.#*
M##V9H*2PI,Q\1NW*AI8@[EB]*.RQ."L<&K<>6TVM*?@*A<Q23RHJD;J+U%,V
MV]XX2&D2\DK6[VZ/BLQ!@2\G =>6Q+G"ZW=\,29RD#'1JNN5H;EPYVWO 1)-
M.9U,7XP0KO<WN7=W5"I$$-YY!O<+6&OY5HYLO*43\M;[:(NP9>^[-B!PE>HH
MG? R,@4I0C;L(F8G5GX;D-0:;YUM4>!T_P=E?H!>KFEWC!CS:'<BC;QU*Z>T
M-1:?;4<:04BFO%'ED5)LCW>Q1N&EM@,Z.)CHNOLYT\-W:OZ,Q^>_)64.9KN?
MI-&'2%R1Y4(2RSZ>X+O65P*-GL\I^#X!Q+AYC+3=<YB" JGK6&>7MP'Z(_\"
MA*/G6T&5JM.W=*4K]3 \7R%1?*L+ P$['=J+]F7V#1@,R$'RU1!R+K+.@2R7
MN2L7G<7N7'T<['%JBL4.<$QS@J_)4O#E(W;G]&Z[%VK>^6Y=788-,LGLF RQ
MNGQ13"K,+>:!DDP,,%=E OF]2R#=T4<T>%1*LO?K>(T(,I^GPES=0?C4GD:M
MRIY^2KB@[)C:.I$5;;U1!.OI.\5T$B8=?_9:X;$ B6MWP@P).Z;H<4]^,<XP
M450TGF[A29UV5;O"V(AY<$/@F)H"G1'FY6+M3P=F_'/0#"5*WG=BX4S/6U?Q
M82]S&D^;*1JR>PS85*_O&?6U9\WB:&+/RBSB@I,]ZS#0+MR%#0XA%K;:R1];
MLV<ZA^+[ 7VPE5M6\B!TD@*UZDMV_)(N2>V<RO4 $W'(ZARQ\(\1MGC/GD6:
M-'4NKW9/8\9T=X".<;MELSPU9E)JKA?FD]?C<;&XBIVFF&_Z,HB0J6>!77*-
M7-[OC!<:MLFX=RBC_8\AAPQHHR>F=+A9\!!-JA^<\$ 7"W03N+]OCM-7;GSB
MH6]4%CT/PJAP3/=*.H"4B^!!MG0!S?$4%OB8GN;K2O,!IGB3G[KK>JN6D&I*
M(HDC:<IU'A# ZCQKKO".E'J(#&A(O7?WSILS>L S,VH%XOUCO!* :HJVB%U0
M*<+&'ON@UGSA!@T+@TI,A"5#;"EX0>2F=U%QA]'O<4DW@!)7I>O$-5.H[\B6
M-R53H9\#-;6@.WU1H\*G5C0I* VD.L:7MVE3P?I /\SWL^9.*4*7Y,TI^9-[
MX/*2[D5%DMQ=Y;8%K1ZWS,70 XUDBS#'M[PC%5J[;9IC2%35,A;7> !V7.NF
MC5ULF!!;RT!LA\GC[W#9"0M\?ATKXQWS/HC+NENST\.77C\2HN(^PB D^_'I
M/32607H\'RC*7$FW4<FQ\O4'SLT^Z'7+>;.-G0<5ITL05+W?52K;Y"ZH3Z'L
MD]Q:\0$3!4>I?(YT/197&*ZPFY0BQ3NH. E77&)O'V)R"_SHP#U^W[\=$_MX
M/NLT-ZR*)?:M$-O">C5KG<^!*G<14P=W'*^:]WIA& F=FN..T"+2F04&0.X+
M%D'Z7C0Q"\N&2UV8V"M%-?0[>7CU1]:6WS](%0S50ZS1Z.,E:]0QR\W->#O&
M8=.L'=3XH3<,/MLQEAV/CR<O\J6+KY$42?<B V^B=4$O%^'MU ??[%I7XNGD
MZ<.NTO5MU_C\D3<4#GI5=WEW>OB6[6_64S<:A8HG;E=+4-.@>_T"'8%OT52B
M2<_\DC%"[*Q0)X1N+-.K7*B0>'LR'?_A>$\]_AB%1B1*O'V4[OIFT)3[1D"4
M@]NMZEU.?8<_XOW0/>S\'"<QDFZ'U^V=7W:W@A.=A$YE4V$4^<Z+!=/NJNCT
M\!W/SVHS:#&#"OTU4N(#!0Z]XEXW_!T!I-GT7P"RQF*+H L'/V_>@R_@=.5Q
M:LU0FL'I,ZBC4B&Z41P7T+DC0,(V*L,X[C2BDA@F71NZ[TUD-YIZF-QNJ?NA
MM+9 'N-7O%O0U;P:!E0A1A[.A'&_N8'4O^>RA43<L4%0DTY\97ZM(=,TA&0Z
M&)1Z+8)/[.C%B'XODYIOM'TT*_&56!H6]&?@Y?^ E[,81'M->L@NQ<U$['"1
MZD ;:7=G5]<I"+XXGI[F(-@C$V/=L\>3AR_%%6P+.Q )?9WU$5)_8O<"5UHA
MF4$Z)B?(%[@MA!<:(_6<%24USWUYT>#@(4*Q%%[OM67BQ&OJZ=46SNSQ+;CR
M?3<8E[?+ 0(K5J@A'-I>NN$(#"-BU'RVGWM]B%KY.F1^30#A1'?A)6+-\I6]
MSHIP-W.P7&"(NF6C>(D5[6D5:S>?Z@=N#/6'S]1"&P*,<HZMWJS\Z9-T69[2
M&(S&%E&=+D%@31'"[DEFF9M16!@BLL]V7*>+I]S*FS+/N:1JMO?@>G8U.NK)
M%*.??/\E)[XWR.90OGDT%'Y/BK=\(6\OZ%UF>@_)!'[A-_^:WY<^X[>$N^'\
MLO4GZ1;X*D2CYC!U,G[VY$@X?G^9OP2[IG>&9S8 2*"/>(:N' Z Y_C^9OJ"
M"^2WR-_^/U!+ P04    " #JA6E2%"_9*$L#  #5"   &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6RU5MMNVS@0_96!MEC4@!K)E*^I;<!V7*1 $AMV
M=HM]I"7:(D*)6I*JF[_OD))5!TW<;+=]D$0.YW+FQM'H(-6#3ADS\"43N1Y[
MJ3'%91#H.&49U1>R8#F>[*3*J,&MV@>Z4(PF3B@3 0G#7I!1GGN3D:.MU&0D
M2R-XSE8*=)EE5#W.F)"'L=?VCH0UWZ?&$H+)J*![MF'FKV*E<!<T6A*>L5QS
MF8-BN[$W;5_.NI;?,?S-V4&?K,%ZLI7RP6X^)F,OM("88+&Q&BA^/K,Y$\(J
M0AC_UCJ]QJ05/%T?M7]POJ,O6ZK97(I//#'IV!MXD+ =+859R\,UJ_UQ &,I
MM'O#H>+M$0_B4AN9U<*((.-Y]:5?ZCB<" S"%P1(+4 <[LJ00WE%#9V,E#R
MLMRHS2Z<JTX:P?'<)F5C%)YRE#.3N\4]W"PW&U@MUK"YGJX7,%VM;C[.I[.;
M!=PO8;Z\O5W>54?7RYNKQ7H#;^_I5C#=&@4&(5A%05R;FU7FR OFV@1N96Y2
M#8L\8<E3!0%B;QP@1P=FY*S&*Q9?0-3V@80D/*,O:@(2.7W1+PS(&;.=QFS'
MF>V\8':#W9:4@H'<02RSHC3452UNA=0:"H:=E%+%GHOY>=5__C$@8?0>_N\7
MNP!,RN ?1E6=O^8,L\"R+6*TF3@2;4;PU1["79DQ18U4E__9ZAU>3"X"1\(;
M>$L&?C_L^6$_;#TAM_T.Z?O#7J?UTTY>L5QBF[T.ZR?7\Q@&^AG=VS.;N0R3
MYA*E >] ;6B>\'S?B'3Z?A@-_4&/?"-U_>Z@[_>CSD^C;H+4E DD>!O\V(,9
MU3P&Q @)%Z4YR2C&,[SHM5M/"9U^ZTRQ=YMB[[ZZV&EN^#MG'&]GT"PN%3><
MZ>?J_+S6WUG?KZSS>9U_(^,'D(7M8 U8J"'!)X2./QQ$;O6$L2A5G.)D@0-5
M"N.A49D_B$+'28C?"[O?"S6\[T!PNN6"FT<P.)<-CDSCL+7)>^@.G>A*&J1R
M*L0C/!-L(#TT6('$#NK9*@V?O4V#DU&#/;UW U5CX9>YJ:9.0VUF]K0:5=_8
MJX%_2]6>8WP$VZ%H>-'']*IJB%8;(PLWN+;2X!ATRQ3_.YBR#'B^D^A5O;$&
MFC^9R5=02P,$%     @ ZH5I4D1 2=8+ P  Q0<  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&ULO55M3]LP$/XK5C9-('7DK2T%VDJ\=!H2+QV437QT
MDTMKX=C!=BC\^YV=-"U0.DV:]L7VG>\>/W>V[_H+J1[T',"0YYP+/?#FQA2'
MOJ^3.>14[\D"!.YD4N74H*AFOBX4T-0YY=R/@J#KYY0);]AWNK$:]F5I.!,P
M5D27>4[5RPEPN1AXH;=4W+#9W%B%/^P7= :W8.Z*L4+);U!2EH/03 JB(!MX
MQ^'A2=O:.X.?#!9Z;4UL)%,I'ZQPG@Z\P!("#HFQ"!2G)S@%SBT0TGBL,;WF
M2.NXOEZB?W.Q8RQ3JN%4\E\L-?.!U_-("ADMN;F1B^]0Q].Q>(GDVHUD4=G&
M'8\DI38RKYV10<Y$-=/G.@]K#KW@ X>H=H@<[^H@Q_*,&CKL*[D@REHCFEVX
M4)TWDF/"7LJM4;C+T,\,QS?7X]'-Y)X<7YV1T8^[\_'EZ&I"=B9TRD'O]GV#
MAUA3/ZD!3RK Z / ,"*74IBY)B.10OH:P$=V#<5H2?$DVHIX!LD>B<,6B8(H
MV((7-R''#B_^JY"W +<;X+8#;G\ ?(L_)BTY$)F10N&_4>:%4)$2>"Q9@2_9
M;$KG=LPOGWI1$!^1_S5CLB&?@G()WZH<:</P5T!*[C1D)2<7^+VTNR0<PH-_
M1NF"3E<9;+0=<@]4Z4;^3*)6W U:01"LZ<(P=)I3F1>E :5;:U#V:K3,S((J
M(/'7MXC+N1=W7J$NYZC&OLXRE@#)2B68*1'J+5!WO_<*(*SE"\!R,I<\)2S'
M]_($EM7*[0*TQISC8^+6D"#]G$A%H$E\626>LPS>L^L=;&8=._5$&LK?;;9;
M83?:Z-:I_2RI0ZRE29F7W)%( ;M!PJ@KLDOSG<Z!2\[N2A,&G4IS*H4VJJRJ
M,A/VJ\P4PO[Q(71;^Q\$9><P.JJCRM@S\J*8/8/W+<"L/XA@PRMIA^Y"-I4
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M;^%R.IY,+Z>W7Z%UR^8"S1$<PR6N4$!W$%K*Y.+#I&:=5*SQ'M9.#%=*VLS
M!YEB^I0@I!*;.N-MG9/X(.,%)FWH=MY ',71 ;YNTW?7\_7V\-V0NM-2(*@%
MK)@HF==(CC93J1)JN7FNZ<.4KU_TXZC['O[U>.^5A2F,5ZCIH,!4%J4U>^-)
MK6 SA*_(=+T!>V-I63&?H_9+^^-/M]3TZ9PUG@^/J!-N$ K-$VS<+_VL$[_?
M\9RVS^+&/"<Q:#J )1-@4>?0VKCBCIZDW,5'[>BD,>Z4H.T1W&Z@Q:0DDOW
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M,WJD4;L ^K]0RFX-EZ!Y]D?_ U!+ P04    " #JA6E2>T6>J*,"  "-"
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M(6&R-9LQK#86K:>AI?F+*R7T+M4X%3XF:93&2?2$XGDZ3IZ3>7J#IO,DG9I
M/%FF*$K':!:ET70RFZ3/:/$4I2MT-09%*)/7Z#MZ68W1U;?K "O=D*'%65/\
MH2[N72@^AJR#_.X-\ES/_00>?QG>'?X)QUJ&5@NOU<*S?/[_U>(?E?VVLF\K
M]RY4CHG,$2DW*#,&O!WHD3 HE?Q,TYIJ8*G,)3V&7M?O>_Z=%^#CN7I_)_;\
MH>L/>\,VL>X6GYT?<W=G1.QH*1&#K8:ZG=N^@T1]'VI'\;T]4FNN] &U9JZ?
M$! F0>]O.5<GQYS2]E$*?P-02P,$%     @ ZH5I4J'P^SR= @  $@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULG55M;]HP$/XKIVR:6HDU(;RT
MZ@ ) FTCM125LGUVDPNQZMC4=J#]][,=R)@&;!H?\)WO[GD>V]S1VPCYJG)$
M#>\%XZKOY5JOKGU?)3D61%V(%7(3R80LB#:N7/IJ)9&DKJA@?A@$7;\@E'N#
MGMN;R4%/E)I1CC,)JBP*(C]&R,2F[S6]W<837>;:;OB#WHHL<8YZL9I)X_DU
M2DH+Y(H*#A*SOC=L7H^Z-M\E?*>X47LVV).\"/%JG3CM>X$5A P3;1&(6=88
M(6,6R,AXVV)Z-:4MW+=WZ#?N[.8L+T1A)-@/FNJ\[UUYD&)&2J:?Q.8.M^?I
M6+Q$,.6^85/E=MH>)*72HM@6&P4%Y=5*WK?WL%=P%1PI"+<%H=-=$3F58Z+)
MH"?%!J3--FC6<$=UU48<Y?91YEJ:*#5U>C"/;Z?Q31P-I\\PC*+'Q?0YGM["
M[/$^CN+)',[&J EEZKSG:T-GB_QD"SVJH,,CT,T0'@37N8()3S']'< W.FNQ
MX4[L*#R).,;D EK-!H1!&"SF8SC[?'X"ME7?0<O!MO[O#DXPM&N&MF-H'V&(
MB,H;<#..(XBY*B6F,"Q$R?6A6ZV@N@[*]M1Z$'8"\^GYZP,2.K6$SC](6'#Z
M5_[.G_R7P7$!W5I ]Z2 F3231.J/!LP8X1H(3V'R5M*5:7'=@(G2U#294;90
MF)4,[DVWJD/Z3M/H'$%I26PW?K5!*%#G(@6Q1@DVBC5363$QRP0B<U&)S,6(
M4JA5 S8Y37*0A"\1,BF*+Y^:W>";SB7BUA35FAF4ROI (M6A7XV_UZ<%RJ6;
M1@H2^Q)5R]:[]< ;5GW^*[V:E@]$+LU3 L/,E 87E^;59#6!*D>+E>OZ%Z'-
M#'%F;H8V2IM@XID0>N=8@OIO8/ 34$L#!!0    ( .J%:5+Q2W$]U (  "\'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(U5VV[B,!#]E5&T#ZVT
M)5>2M (D;JM6@H)(NWUV$T.B)G;6=J#[]VL[(4L19/<%?)DY.>>,/1X<*/O@
M*<8"/HN<\*&1"E$^F":/4UP@WJ,E)G)G2UF!A)RRG<E+AE&BDXK<="S+-PN4
M$6,TT&MK-AK02N09P6L&O"H*Q'Y/<$X/0\,VC@N;;)<*M6".!B7:X0B+UW+-
MY,QL49*LP(1GE ##VZ$QMA^FH8K7 3\S?. G8U!*WBG]4).G9&A8BA#.<2P4
M I)_>SS%>:Z )(U?#:;1?E(EGHZ/Z#^T=JGE'7$\I?E;EHAT:(0&)'B+JEQL
MZ.$1-WKZ"B^F.=>_<&AB+0/BB@M:-,F209&1^A]]-CZ<)-C^E02G27#.$[PK
M"6Z3X&JA-3,M:X8$&@T8/0!3T1)-#;0W.ENJR8BJ8B28W,UDGA@]SU]@L8HB
M6,\W$#V.-W,8K]>+I^EXLIC#RPJFJ^5R]5QO/:X6L_DF@CN8TJ*L!-*5H%O(
M*>=08@91BAB&FQD6*,OYK8Q\C69P\^UV8 K)5GW3C!MFDYJ9<X69[<"2$I%R
MF),$)U\!3"FSU>H<M4Z<3L09CGO@VM_!L1SK J'I?Z?;]QUTW-9Z5^.YUZRO
M"LR0H.RA \QKP3P-YET#DQ=>5>&2SW6FKS/5K=Z/[IPPL'PKD"[L3PVX%&E[
M3G#O>VWD%WK]EEZ_4^L,$RI/[[_4^BV<WZGV3=].G #:2PMW&&):%/(H<G7\
M.,ANQ04B249VE_RHL?LG*KW <N]#WSFSXT)@OQ\&@7O%C:"E'W17OBF6OC*:
M,R3R\G8Y$[;08:<S$\2S&*1V2+*\$N?WIC:@A@A/RVSU?/M,_<4H+SB3;I[T
M'GF>=[HE<UF0BHCZ:K:K;=<?ZV9WMCZ1KT'=O/_"U$_)$K%=1CCD>"LAK5X@
M*\+J]EQ/!"UUAWNG0O9+/4SEBX:9"I#[6TK%<:(^T+Z1HS]02P,$%     @
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MNPYRDF47*B=:Y+:0;X3&MF"'"39ND"8 ][<"BTLU,0?4GP+#?U!+ P04
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M    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;)56VVZC,!#]%0OM2JVT#;<
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M8Q:05<:1R!\09H@L$ Y)KDI/*-<N5*<]KM/QC.\GI6CW<SN]8[\B<WVOY*9
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MV\A!N0-V?RVE.4Q<;VG_&LS^ 5!+ P04    " #JA6E2@M3"#&$$    $@
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M.@I'*(8%*1+YP-;74!OD:;Z():+\1>MJKN^,4%0(R=(:K!2D-*O^R4OMB V
M$^X .#7 &0HXJ@%'[P#8W0%P:X#[_@UX!\"K =Y0@%\#_*& H 8$0P%A#0C+
MZ%;A*&-Y3B29C#E;(ZYG*S9]42Z($JU"2#.]=A\E5T^IPLG)+Q=GCQ>/Z "=
MQ3'5JXDDZ":K<D*OK;USD(0FXMO8DNIU&F1%-?6THG9V4&-TRS*Y$N@BBR'>
MQEM*9J/5>=,Z=8R$9\7R$!WA?>38COW]\1SM_?3M+M<R18^ZF9GLYR)39/9
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MSW%"N\"DM.*A69OS>,BVDI(2YAR);5%@_C8!RG8CR[7>%Q[))I=ZP8Z'%=[
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MX\H3F@7_&R#Y )Y?&N/V'?^!YF]C_ -02P,$%     @ ZH5I4B*80@=^ @
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M;'YAXZ=K^5+!E/N%39,;>)!62HNR 1L%)>7UD[PT==@!A+T#@*@!1!\!G0.
MN '$SFBMS-F:$$V2OA0;D#;;L-F%JXU#&S>4VW_Q3DMS2@U.)T_#^7SX^QYF
MT^%H.IO>_X$S&!>$+U$!Y3##-3*(84;)@C*JJ0G?(%&5Q R(AFM")3P25B&<
M3% 3RM2I87BXF\#)M].^KXU$>Y&?-G)&M9SH@)PP@AO!=:'@)\\P>T_@&V^M
MP6AK<!0=99Q@>@YQ^!VB( KV"!I_&1Y>'I$3M_6.'5_\U7H?X>RTG!W'V3G
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M(BA,@+X?<Z[V [- ^6W3^P=02P,$%     @ ZH5I4N<@)=^4!   WQ,  !D
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MVTST,P:$"=#S2\[5KF,6*!]&@[]02P,$%     @ ZH5I4L%GV'"K P  (PP
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M&EO$<IAB%P_2".#[1 C]-C%]8O._8/X#4$L#!!0    ( .J%:5+:_C264@0
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M"?KY2@CU,C O:+Z/3/\%4$L#!!0    ( .J%:5*0TE<-=@,  -<+   9
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MT(WF>I(UL.1O$"=_8)G[Z;Y 4CD#%*],ZH7/-&I@)C"(31!X,RA'P >NYTV
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MI_.]^?KXR_+KY.R]7'!.MQ7E^2]02P,$%     @ ZH5I4O\GIW7C 0  ;"0
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M#P72AP;IHP#IXQRDCPN0/BY!^N 3E$901.4HI'(44SD*JAQ%58["*D=QE:/
MRE%D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+(*%%DEBJP215:)(JM$D56B
MR"I19)4HLDH4626*K!)%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5
MH\BJ4635*+)J%%DUBJP:15:-(JM&D56CR*I19"U09"U09"W^4]9G:Y=_'#\\
M\];4W2&?#7\RFKT!4$L! A0#%     @ ZH5I4@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #JA6E2
M594C->\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #JA6E2F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .J%:5+KUTDNY04
M -48   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " #JA6E2@-DPZ^,%  #\%@  &               @($I
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ZH5I4L.I
MP\6D @  )PD  !@              ("!0A0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( .J%:5(!N+JL% 0  !\-   8
M  " @1P7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #J
MA6E2800H1&<%  ""%P  &               @(%F&P  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ ZH5I4A[WCL4]!@  4!<  !@
M         ("! R$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( .J%:5)B,H2C=@,  'T'   8              " @78G  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #JA6E2+?&^%U4*   2'
M&               @($B*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ ZH5I4A0#.,N.$P  K38  !@              ("!K34  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .J%:5*Q+?[V6P0
M (\+   9              " @7%)  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ ZH5I4@&,3Q6] P  F @  !D              ("!
M TX  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #JA6E2
MG-3\64,%  #+#0  &0              @('W40  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( .J%:5*\,4!F^08  %T6   9
M      " @7%7  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ ZH5I4JH Z7C& @   0<  !D              ("!H5X  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #JA6E277%O)TP$  "C"@
M&0              @(&>80  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( .J%:5*1I_:*BP4  /\/   9              " @2%F  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ZH5I4H S7K%"
M!0  60X  !D              ("!XVL  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " #JA6E2;2^Q6=4#  "$"@  &0
M@(%<<0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .J%
M:5(QH^S@B <  . 4   9              " @6AU  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ ZH5I4K?J0O<. P  L08  !D
M         ("!)WT  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " #JA6E2@2,UJBT#  #S!@  &0              @(%L@   >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .J%:5*QN;TRU0(  %8&
M   9              " @="#  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ ZH5I4J 7ZJZC!   /0L  !D              ("!W(8
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #JA6E2+X7H
MV'8*   ''0  &0              @(&VBP  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( .J%:5+G]NJ<=A0  %$^   9
M  " @6.6  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MZH5I4A0OV2A+ P  U0@  !D              ("!$*L  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " #JA6E21$!)U@L#  #%!P  &0
M            @(&2K@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( .J%:5)'*N(2F ,  -,*   9              " @=2Q  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ZH5I4H>;ANZH @
M:P8  !D              ("!H[4  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " #JA6E2<0'G.!8#   ""   &0              @(&"
MN   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .J%:5)[
M19ZHHP(  (T(   9              " @<^[  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ ZH5I4DF02OL5 P  ^0<  !D
M     ("!J;X  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .J%:5*A\/L\G0(  !(&   9              "
M@6S1  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ZH5I
M4O%+<3W4 @  +P<  !D              ("!0-0  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " #JA6E2L\_F+<@"   6"   &0
M        @(%+UP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( .J%:5(;7O=('P(  .H%   9              " @4K:  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ ZH5I4@W4WWSS P  AQ
M !D              ("!H-P  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " #JA6E2RE)3D+0"  !8!P  &0              @('*X
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .J%:5*:5SCL
M+0,  "<*   9              " @;7C  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ ZH5I4B04K\^Z @  )@@  !D
M ("!&><  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #J
MA6E2@M3"#&$$    $@  &0              @($*Z@  >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( .J%:5)(-PE3LP(  ,$'   9
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M970U,"YX;6Q02P$"% ,4    " #JA6E2"WX 2P@$  " #P  &0
M    @(%9_P  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M .J%:5(!E_'=> (  /T%   9              " @9@# 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ ZH5I4F,YF &P P  *0T  !D
M             ("!1P8! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " #JA6E2!A _?K\"   Y"   &0              @($N"@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .J%:5*&@GN.E (
M .\&   9              " @20- 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ ZH5I4HJL;]'1 @  RP<  !D              ("!
M[P\! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #JA6E2
M.DE^LFL"  #@!0  &0              @('W$@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( .J%:5*FI$9D/ (   \%   9
M      " @9D5 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ ZH5I4IE@XT#3 @  ) D  !D              ("!#!@! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #JA6E2P6?8<*L#   C#
M&0              @($6&P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( .J%:5+:_C264@0  "L1   9              " @?@> 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ ZH5I4I#25PUV
M P  UPL  !D              ("!@2,! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " #JA6E2H2>O'E("  !<#   #0
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:+GAM;%!+!08     1@!& "$3  !>- $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>92</ContextCount>
  <ElementCount>348</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans</Role>
      <ShortName>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - OTHER RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivable</Role>
      <ShortName>OTHER RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - WARRANT LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantLiability</Role>
      <ShortName>WARRANT LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrants</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - STOCK OPTION PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlans</Role>
      <ShortName>STOCK OPTION PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - GRANT INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncome</Role>
      <ShortName>GRANT INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLegalProceedings</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11701 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11801 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30601 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30701 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30901 - Disclosure - WARRANT LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables</Role>
      <ShortName>WARRANT LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureWarrantLiability</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31001 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31201 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantsTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureWarrantLiability</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31301 - Disclosure - STOCK OPTION PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansTables</Role>
      <ShortName>STOCK OPTION PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureStockOptionPlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31701 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31801 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails</Role>
      <ShortName>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40501 - Disclosure - OTHER RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivableDetails</Role>
      <ShortName>OTHER RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureOtherReceivable</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails</Role>
      <ShortName>LEASES - Quantitative Information About Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40702 - Disclosure - LEASES - Maturities of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails</Role>
      <ShortName>LEASES - Maturities of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40703 - Disclosure - LEASES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>LEASES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40901 - Disclosure - WARRANT LIABILITY - Valuation Methodology (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails</Role>
      <ShortName>WARRANT LIABILITY - Valuation Methodology (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40902 - Disclosure - WARRANT LIABILITY - Changes in Level 3 Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>WARRANT LIABILITY - Changes in Level 3 Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41001 - Disclosure - FAIR VALUE MEASUREMENTS - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41101 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41201 - Disclosure - WARRANTS - Summary of Share Purchase Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails</Role>
      <ShortName>WARRANTS - Summary of Share Purchase Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41202 - Disclosure - WARRANTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>WARRANTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41301 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails</Role>
      <ShortName>STOCK OPTION PLANS - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41302 - Disclosure - STOCK OPTION PLANS - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails</Role>
      <ShortName>STOCK OPTION PLANS - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41303 - Disclosure - STOCK OPTION PLANS- Stock-based compensation expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails</Role>
      <ShortName>STOCK OPTION PLANS- Stock-based compensation expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41304 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails</Role>
      <ShortName>STOCK OPTION PLANS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41401 - Disclosure - GRANT INCOME - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails</Role>
      <ShortName>GRANT INCOME - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41701 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41801 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41802 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails</Role>
      <ShortName>INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrkr-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41803 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mrkr-20201231x10k.htm">mrkr-20201231x10k.htm</File>
    <File>mrkr-20201231.xsd</File>
    <File>mrkr-20201231_cal.xml</File>
    <File>mrkr-20201231_def.xml</File>
    <File>mrkr-20201231_lab.xml</File>
    <File>mrkr-20201231_pre.xml</File>
    <File>mrkr-20201231xex21d1.htm</File>
    <File>mrkr-20201231xex23d1.htm</File>
    <File>mrkr-20201231xex31d1.htm</File>
    <File>mrkr-20201231xex31d2.htm</File>
    <File>mrkr-20201231xex32d1.htm</File>
    <File>mrkr-20201231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrkr-20201231x10k001.jpg</File>
    <File>mrkr-20201231x10k002.jpg</File>
    <File>mrkr-20201231x10k003.jpg</File>
    <File>mrkr-20201231x10k004.jpg</File>
    <File>mrkr-20201231x10k005.jpg</File>
    <File>mrkr-20201231x10k006.jpg</File>
    <File>mrkr-20201231x10k007.jpg</File>
    <File>mrkr-20201231x10k008.jpg</File>
    <File>mrkr-20201231x10k009.jpg</File>
    <File>mrkr-20201231x10k010.jpg</File>
    <File>mrkr-20201231x10k011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrkr-20201231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 92,
   "dts": {
    "calculationLink": {
     "local": [
      "mrkr-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrkr-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mrkr-20201231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrkr-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrkr-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrkr-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 412,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 9,
    "http://www.tapimmune.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 15
   },
   "keyCustom": 66,
   "keyStandard": 282,
   "memberCustom": 14,
   "memberStandard": 20,
   "nsprefix": "mrkr",
   "nsuri": "http://www.tapimmune.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS",
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - OTHER RECEIVABLE",
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivable",
     "shortName": "OTHER RECEIVABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://www.tapimmune.com/role/DisclosurePropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - LEASES",
     "role": "http://www.tapimmune.com/role/DisclosureLeases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:WarrantLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - WARRANT LIABILITY",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantLiability",
     "shortName": "WARRANT LIABILITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:WarrantLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.tapimmune.com/role/DisclosureFairValueMeasurements",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - WARRANTS",
     "role": "http://www.tapimmune.com/role/DisclosureWarrants",
     "shortName": "WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - STOCK OPTION PLANS",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlans",
     "shortName": "STOCK OPTION PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:GrantIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - GRANT INCOME",
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncome",
     "shortName": "GRANT INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:GrantIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - LEGAL PROCEEDINGS",
     "role": "http://www.tapimmune.com/role/DisclosureLegalProceedings",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11801 - Disclosure - INCOME TAXES",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30601 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30701 - Disclosure - LEASES (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureLeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "mrkr:WarrantLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_3B73NaasBEmFQYB4WCOXUQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:ValuationMethodology",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30901 - Disclosure - WARRANT LIABILITY (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables",
     "shortName": "WARRANT LIABILITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "mrkr:WarrantLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_3B73NaasBEmFQYB4WCOXUQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:ValuationMethodology",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31001 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_e3jl9ISh90CJS6uJdshXmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31201 - Disclosure - WARRANTS (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantsTables",
     "shortName": "WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_e3jl9ISh90CJS6uJdshXmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31301 - Disclosure - STOCK OPTION PLANS (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables",
     "shortName": "STOCK OPTION PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31701 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31801 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
     "shortName": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:NetLossPerShareTableTextBlockTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:NetLossPerShareTableTextBlockTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TenantImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - OTHER RECEIVABLE (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
     "shortName": "OTHER RECEIVABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TenantImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "role": "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)",
     "role": "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails",
     "shortName": "LEASES - Quantitative Information About Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - LEASES - Maturities of Operating Leases (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails",
     "shortName": "LEASES - Maturities of Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - LEASES - Additional Information (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "LEASES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_6_30_2020_0mRnfJauaUCmbcC5hv3mMg",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:ValuationMethodology",
       "mrkr:WarrantLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember__pIPPDpQCU-WKKP23kwqnw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "mrkr:FairValuesAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - WARRANT LIABILITY - Valuation Methodology (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails",
     "shortName": "WARRANT LIABILITY - Valuation Methodology (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:ValuationMethodology",
       "mrkr:WarrantLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mrkr_SharePurchaseWarrantsMember__pIPPDpQCU-WKKP23kwqnw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "mrkr:FairValuesAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:MeasuredAtFairValue",
       "mrkr:WarrantLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - WARRANT LIABILITY - Changes in Level 3 Liabilities Measured at Fair Value (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
     "shortName": "WARRANT LIABILITY - Changes in Level 3 Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:MeasuredAtFairValue",
       "mrkr:WarrantLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2018_x-NKWUUwYEq1BpTxoCKPiw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "mrkr:FairValueTransfersAmount",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "mrkr:FairValueTransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - FAIR VALUE MEASUREMENTS - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "mrkr:FairValueTransfersAmount",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "mrkr:FairValueTransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_82up_zfWNUmUUgXpcdgRMQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_82up_zfWNUmUUgXpcdgRMQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_mrkr_ConsultingArrangementsMember_2YOLfsHrJUiQ-nXn-u702g",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock",
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_DHJbubAeRUWa-j3SvASgDw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - WARRANTS - Summary of Share Purchase Warrants (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails",
     "shortName": "WARRANTS - Summary of Share Purchase Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock",
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_rUIKy6Cl1UeZB8Oav-23pQ",
      "decimals": "0",
      "lang": null,
      "name": "mrkr:NumberOfWarrantsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - WARRANTS - Additional Information (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails",
     "shortName": "WARRANTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_T7yGVpdE50Svfs_HvS-JUg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
     "shortName": "STOCK OPTION PLANS - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_y0SmO4QIJ0mKeBFTUK18kg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_iR2ThMvN30malanztgioBw",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - STOCK OPTION PLANS - Weighted Average Assumptions (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails",
     "shortName": "STOCK OPTION PLANS - Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_hDNMG3aD_k6xEE_W5DfXHQ",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41303 - Disclosure - STOCK OPTION PLANS- Stock-based compensation expenses (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails",
     "shortName": "STOCK OPTION PLANS- Stock-based compensation expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:StockBasedCompensationExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wi8B3dNGskeO0KIAZp0PNA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41304 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
     "shortName": "STOCK OPTION PLANS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - GRANT INCOME - Additional Information (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails",
     "shortName": "GRANT INCOME - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "mrkr:GrantIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_9yHzLxI9J0KiGOFm8vPRig",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41801 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails",
     "shortName": "INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_edEmQ1NAc02dGKm0ZjYJHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41802 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails",
     "shortName": "INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_hI1jQO9qdkK6McFEKv90Mg",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:Taxcreditcarryforwardexpirationyearrangestart",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41803 - Disclosure - INCOME TAXES - Additional Information (Details)",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "INCOME TAXES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:Taxcreditcarryforwardexpirationyearrangestart",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - NATURE OF OPERATIONS",
     "role": "http://www.tapimmune.com/role/DisclosureNatureOfOperations",
     "shortName": "NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS",
     "role": "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans",
     "shortName": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_NdBee03Cc02OapgLSABNHw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrkr_AccruedTechnologyLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Consulting agreements payable.",
        "label": "Accrued Technology License Fees",
        "terseLabel": "Technology license fees"
       }
      }
     },
     "localname": "AccruedTechnologyLicenseFees",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_AgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement",
        "label": "Agreement Term"
       }
      }
     },
     "localname": "AgreementTerm",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrkr_AmortizationOfOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings for the periodic recognition of operating lease right of use asset.",
        "label": "Amortization Of Operating Lease Right Of Use Assets",
        "verboseLabel": "Amortization on right-of-use assets"
       }
      }
     },
     "localname": "AmortizationOfOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_AspireCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aspire Capital [Member]",
        "label": "Aspire Capital [Member]",
        "terseLabel": "Aspire Capital"
       }
      }
     },
     "localname": "AspireCapitalMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_BoardCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board Compensation [Member]",
        "label": "Board Compensation [Member]",
        "terseLabel": "Board Compensation"
       }
      }
     },
     "localname": "BoardCompensationMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ClassOfWarrantOrRightOutstandingIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding class of warrant or right.",
        "label": "Class Of Warrant Or Right, Outstanding, Intrinsic Value",
        "verboseLabel": "Total Intrinsic Value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingIntrinsicValue",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercise Price Cashless Exercised",
        "label": "Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercise Price Cashless Exercised",
        "terseLabel": "Weighted Average Exercise Price, Cashless exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights outstanding exercised weighted average exercise price.",
        "label": "Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercised For Cash",
        "verboseLabel": "Weighted Average Exercise Price, Exercised for cash"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.",
        "label": "Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Expired or cancelled"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.",
        "label": "Class Of Warrant Or Rights Outstanding Warrants Granted Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price.",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right outstanding issued weighted average remaining life.",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life",
        "verboseLabel": "Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.",
        "label": "Clinical Trial Agreement With Baylor College Of Medicine [Member]",
        "terseLabel": "Baylor College of Medicine"
       }
      }
     },
     "localname": "ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Capital Shares Reserved For Future Issuance [Line Items]",
        "label": "Common Stock Capital Shares Reserved For Future Issuance [Line Items]",
        "terseLabel": "Common Stock Capital Shares Reserved For Future Issuance [Line Items]"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceLineItems",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Capital Shares Reserved For Future Issuance [Table]",
        "label": "Common Stock Capital Shares Reserved For Future Issuance [Table]",
        "terseLabel": "Common Stock Capital Shares Reserved For Future Issuance [Table]"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceTable",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_CommonStockWarrantsEquityTreatment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants - equity treatment.",
        "label": "Common Stock Warrants Equity Treatment",
        "verboseLabel": "Common stock purchase warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsEquityTreatment",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_CommonStockWarrantsLiabilityTreatmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants Liability Treatment",
        "label": "Common Stock Warrants Liability Treatment [Member]",
        "terseLabel": "Common stock warrants - liability treatment"
       }
      }
     },
     "localname": "CommonStockWarrantsLiabilityTreatmentMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computers, equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ConsultingAgreementWithDr.JuanVeraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Consulting Agreement with Dr. Juan Vera.",
        "label": "Consulting Agreement With Dr. Juan Vera [Member]",
        "terseLabel": "Dr Juan Vera"
       }
      }
     },
     "localname": "ConsultingAgreementWithDr.JuanVeraMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ConsultingArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Consulting Arrangements [Member]",
        "terseLabel": "Consulting Arrangement"
       }
      }
     },
     "localname": "ConsultingArrangementsMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_CorporateHeadquartersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense/Income in Corporate headquarters.",
        "label": "Corporate Headquarters [Member]",
        "terseLabel": "Corporate headquarters (Member)"
       }
      }
     },
     "localname": "CorporateHeadquartersMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_DecreasedDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the amount of decreased deferred tax assets.",
        "label": "Decreased Deferred Tax Assets"
       }
      }
     },
     "localname": "DecreasedDeferredTaxAssets",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Deferred tax assets, operating lease liability.",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Operating Lease Liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_DeferredTaxLiabilitiesFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax liability, Fixed Assets",
        "label": "Deferred Tax Liabilities, Fixed Assets",
        "negatedLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax liability, Right-of-Use Assets",
        "label": "Deferred Tax Liabilities Right of Use Assets",
        "negatedLabel": "Right-of-Use Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_Deferredtaxassetslicenseagreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets license agreement.",
        "label": "Deferred tax assets license agreement",
        "verboseLabel": "License Agreements"
       }
      }
     },
     "localname": "Deferredtaxassetslicenseagreement",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_Deferredtaxstockbasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax stock based compensation.",
        "label": "Deferred tax stock based compensation",
        "verboseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "Deferredtaxstockbasedcompensation",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the effective tax rate reconciliation due to change in fair value of derivative liability.",
        "label": "Effective Income Tax Rate Reconciliation Change in Fair Value Of Derivative Liability",
        "verboseLabel": "Permanent differences- Change in fair value of derivative liabilities, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the effective tax rate reconciliation due to other permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Other Permanent Differences",
        "verboseLabel": "Permanent differences- Other permanent differences, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_ExerciseOfStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Of Stock Warrants [Member]",
        "terseLabel": "Exercise of Stock Warrants"
       }
      }
     },
     "localname": "ExerciseOfStockWarrantsMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ExerciseOfWarrantsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants amount.",
        "label": "Exercise Of Warrants Amount",
        "verboseLabel": "Warrants exercised for cash"
       }
      }
     },
     "localname": "ExerciseOfWarrantsAmount",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ExerciseOfWarrantsShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants share.",
        "label": "Exercise Of Warrants share",
        "terseLabel": "Warrants exercised for cash, shares"
       }
      }
     },
     "localname": "ExerciseOfWarrantsShare",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_FairValueTransfersAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers between levels 1, 2 or 3 of the fair value hierarchy.",
        "label": "Fair Value Transfers Amount",
        "terseLabel": "Transfers between levels 1, 2 or 3 of the fair value hierarchy"
       }
      }
     },
     "localname": "FairValueTransfersAmount",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_FairValuesAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed upon price for the exchange of the underlying asset.",
        "label": "Fair Values Assumptions Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "FairValuesAssumptionsExercisePrice",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrkr_FairValuesAssumptionsExpectedDividendRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected dividends to be paid to holders of the underlying shares or financial instruments.",
        "label": "Fair Values Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield (per share)"
       }
      }
     },
     "localname": "FairValuesAssumptionsExpectedDividendRate",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_FairValuesAssumptionsExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the instrument, asset or liability is expected to be outstanding.",
        "label": "Fair Values Assumptions Expected Term",
        "terseLabel": "Contractual term (years)"
       }
      }
     },
     "localname": "FairValuesAssumptionsExpectedTerm",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrkr_FairValuesAssumptionsExpectedVolatilityRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.",
        "label": "Fair Values Assumptions Expected Volatility Rate",
        "terseLabel": "Volatility (annual)"
       }
      }
     },
     "localname": "FairValuesAssumptionsExpectedVolatilityRate",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_FairValuesAssumptionsRiskFreeInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk-free interest rate assumption used in valuing an instrument.",
        "label": "Fair Values Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "FairValuesAssumptionsRiskFreeInterestRate",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets and liabilities measured at fair value on recurring basis.",
        "label": "Financial Assets And Liabilities Measured At Fair Value On Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_FixedLeaseRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents amount of fixed lease rent payments under the initial term.",
        "label": "Fixed Lease Rent Payment",
        "verboseLabel": "Fixed lease rent payment"
       }
      }
     },
     "localname": "FixedLeaseRentPayment",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_GrantIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Grant Income",
        "label": "GRANT INCOME"
       }
      }
     },
     "localname": "GrantIncomeAbstract",
     "nsuri": "http://www.tapimmune.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mrkr_GrantIncomePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Income [Policy Text Block]",
        "label": "Grant Income [Policy Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "localname": "GrantIncomePolicyTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_GrantIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Grant Income",
        "label": "Grant Income [Text Block]",
        "terseLabel": "GRANT INCOME"
       }
      }
     },
     "localname": "GrantIncomeTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_Incometaxreconciliationchangeinfairvalueofderivativeliability": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation change in fair value of derivative liability.",
        "label": "Income tax reconciliation change in fair value of derivative liability",
        "verboseLabel": "Permanent differences- Change in fair value of derivative liabilities"
       }
      }
     },
     "localname": "Incometaxreconciliationchangeinfairvalueofderivativeliability",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in operating lease liability.",
        "label": "Lease liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of common stock issued as commitment fee for future financing.",
        "label": "Issuance Of Common Stock, Shares, As Commitment Fee For Future Financing",
        "verboseLabel": "Issuance of common stock as commitment fee for future financing (Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockSharesAsCommitmentFeeForFutureFinancing",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents value of common stock as commitment fee for future financing.",
        "label": "Issuance Of Common Stock , Value, As Commitment Fee For Future Financing",
        "verboseLabel": "Issuance of common stock as commitment fee for future financing"
       }
      }
     },
     "localname": "IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_LiquidityFinancialConditionAndGoingConcernAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS"
       }
      }
     },
     "localname": "LiquidityFinancialConditionAndGoingConcernAbstract",
     "nsuri": "http://www.tapimmune.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity Financial Condition And Going Concern Text Block",
        "label": "Liquidity Financial Condition And Going Concern [Text Block]",
        "terseLabel": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS"
       }
      }
     },
     "localname": "LiquidityFinancialConditionAndGoingConcernTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_LossContingencyDamagesSoughtNumberOfTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of transactions of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Number of Transactions"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtNumberOfTransactions",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrkr_ManufacturingFacilityInHoustonTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Manufacturing Facility In Houston Texas [Member]",
        "terseLabel": "Manufacturing Facility in Houston, Texas [Member]"
       }
      }
     },
     "localname": "ManufacturingFacilityInHoustonTexasMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_MaximumCommonStockCommittedToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents maximum number of common stock to be purchased.",
        "label": "Maximum Common Stock Committed to Purchase",
        "terseLabel": "Aggregate shares of common stock"
       }
      }
     },
     "localname": "MaximumCommonStockCommittedToPurchase",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_MeasuredAtFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value.",
        "label": "Measured At Fair Value",
        "terseLabel": "Schedule of Changes in Level 3 Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "MeasuredAtFairValue",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_NetLossPerShareTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Loss Per Share",
        "label": "Net Loss Per Share [Table Text Block]",
        "verboseLabel": "Schedule of anti-dilutive securities"
       }
      }
     },
     "localname": "NetLossPerShareTableTextBlockTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_NonCashExerciseOfWarrantsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of warrant exercised of non cash amount transaction.",
        "label": "Non Cash Exercise Of Warrants Amount",
        "terseLabel": "Stock warrants cashless exercised"
       }
      }
     },
     "localname": "NonCashExerciseOfWarrantsAmount",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of Issuance of common stock as commitment fee for future financing.",
        "label": "Non Cash Issuance Of Common Stock As Commitment Fee For Future Financing",
        "verboseLabel": "Issuance of common stock as commitment fee for future financing"
       }
      }
     },
     "localname": "NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of renewal options.",
        "label": "Number of Renewal Options",
        "verboseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrkr_NumberOfWarrantCashlessExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants cashless exercised.",
        "label": "Number Of Warrant Cashless Exercised",
        "negatedLabel": "Number of Warrants, Cashless exercised"
       }
      }
     },
     "localname": "NumberOfWarrantCashlessExercised",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_NumberOfWarrantExercisedForCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrant Exercised For Cash",
        "negatedLabel": "Number of Warrants, Exercised for cash"
       }
      }
     },
     "localname": "NumberOfWarrantExercisedForCash",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_NumberOfWarrantExpiredOrCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants expired or cancelled.",
        "label": "Number of Warrants, Expired or cancelled",
        "negatedTerseLabel": "Number of Warrants, Expired or cancelled"
       }
      }
     },
     "localname": "NumberOfWarrantExpiredOrCancelled",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_NumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants, Granted.",
        "label": "Number Of Warrants, Granted",
        "terseLabel": "Number Of Warrants, Warrants granted"
       }
      }
     },
     "localname": "NumberOfWarrantsGranted",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense/income at Office Space.",
        "label": "Office Space [Member]",
        "terseLabel": "Office space (Member)"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_OperatingLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense summary:"
       }
      }
     },
     "localname": "OperatingLeaseExpenseAbstract",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_OperatingLossCarryforwardsLimitationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of limitation for operating loss carryforwards",
        "label": "Operating Loss Carryforwards Limitation Percentage"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationPercentage",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_OtherLeaseInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Other information",
        "terseLabel": "Other information:"
       }
      }
     },
     "localname": "OtherLeaseInformationAbstract",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; excluding cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment Excluding Construction In Progress",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_Permanentdifferencesotherpermanentdifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Permanent differences other permanent differences.",
        "label": "Permanent differences other permanent differences",
        "negatedLabel": "Permanent differences- Other permanent differences"
       }
      }
     },
     "localname": "Permanentdifferencesotherpermanentdifferences",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_PropertyAndEquipmentConstructionInProgressPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for property and equipment, construction in progress.",
        "label": "Property and equipment - Construction in Progress",
        "terseLabel": "Property and equipment - Construction in Progress"
       }
      }
     },
     "localname": "PropertyAndEquipmentConstructionInProgressPolicyTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Excludes construction in progress.",
        "label": "Property, Plant and Equipment Other Than Construction in Progress",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherThanConstructionInProgress",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_PurchasesFromBioTechneCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about the purchases from bio techne corporation.",
        "label": "Purchases From Bio Techne Corporation [Member]",
        "terseLabel": "Bio-Techne Corporation"
       }
      }
     },
     "localname": "PurchasesFromBioTechneCorporationMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_RelatedPartyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Disclosure",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyDisclosureAbstract",
     "nsuri": "http://www.tapimmune.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mrkr_ResearchFacilityInHoustonTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Research Facility In Houston Texas [Member]",
        "terseLabel": "Research Facility in Houston, Texas [Member]"
       }
      }
     },
     "localname": "ResearchFacilityInHoustonTexasMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_RetainExistingPolicy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Defined.",
        "label": "Property and Equipment",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "RetainExistingPolicy",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lease cost and other information related to operating leases.",
        "label": "Schedule Of Lease Cost And Other Information Related to Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of quantitative information about operating leases"
       }
      }
     },
     "localname": "ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement number of share options available for issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Options Available for Issued",
        "terseLabel": "Number of shares options available to be issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_SharePurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Warrants [Member]",
        "label": "Share Purchase Warrants [Member]",
        "terseLabel": "Share Purchase Warrants"
       }
      }
     },
     "localname": "SharePurchaseWarrantsMember",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share purchase warrants.",
        "label": "Share Purchase Warrants [Table Text Block]",
        "terseLabel": "Schedule of share purchase warrants"
       }
      }
     },
     "localname": "SharePurchaseWarrantsTableTextBlockTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options granted in period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrkr_StockBasedCompensationExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of stock based compensation expenses recorded.",
        "label": "Stock based Compensation Expenses [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expenses"
       }
      }
     },
     "localname": "StockBasedCompensationExpensesTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected tax expense benefit based on federal statutory rate is reconciled with actual tax provision benefit.",
        "label": "Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rate is Reconciled With Actual Tax Provision Benefit [Table Text Block]",
        "terseLabel": "Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit"
       }
      }
     },
     "localname": "SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_Taxcreditcarryforwardexpirationyearrangeend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year range end.",
        "label": "Tax credit carry forward expiration year range end",
        "verboseLabel": "Tax credit carryforwards expiration year end"
       }
      }
     },
     "localname": "Taxcreditcarryforwardexpirationyearrangeend",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mrkr_Taxcreditcarryforwardexpirationyearrangestart": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year range start.",
        "label": "Tax credit carry forward expiration year range start",
        "verboseLabel": "Tax credit carryforwards expiration period"
       }
      }
     },
     "localname": "Taxcreditcarryforwardexpirationyearrangestart",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mrkr_ValuationMethodology": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation methodology.",
        "label": "Schedule of valuation methodology",
        "verboseLabel": "Schedule of valuation methodology"
       }
      }
     },
     "localname": "ValuationMethodology",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_WarrantLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANT LIABILITY"
       }
      }
     },
     "localname": "WarrantLiabilityAbstract",
     "nsuri": "http://www.tapimmune.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mrkr_WarrantLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for warrant liability, including all tables.",
        "label": "Warrant Liability [Text Block]",
        "terseLabel": "WARRANT LIABILITY"
       }
      }
     },
     "localname": "WarrantLiabilityTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_WarrantOfCashLessExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Of Cash Less Exercised.",
        "label": "Warrant Of Cash Less Exercised",
        "terseLabel": "Stock warrants cashless exercised"
       }
      }
     },
     "localname": "WarrantOfCashLessExercised",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_WarrantOfCashLessExercisedSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The warrant exercised of non cash transaction shares issued.",
        "label": "Warrant Of Cash Less Exercised Shares Issued",
        "terseLabel": "Stock warrants cashless exercised, Shares"
       }
      }
     },
     "localname": "WarrantOfCashLessExercisedSharesIssued",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_WarrantsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS"
       }
      }
     },
     "localname": "WarrantsDisclosureAbstract",
     "nsuri": "http://www.tapimmune.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mrkr_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about warrants.",
        "label": "Warrants Disclosure [Text Block]",
        "verboseLabel": "WARRANTS"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://www.tapimmune.com/20201231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r48",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r170",
      "r171",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r170",
      "r171",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r121",
      "r157",
      "r158",
      "r315",
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r121",
      "r157",
      "r158",
      "r315",
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r160",
      "r170",
      "r171",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r160",
      "r170",
      "r171",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update201409 [Member]",
        "terseLabel": "Accounting Standards Update 2014-09 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r40"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r139"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r28",
      "r204"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r201",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid- in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r81",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r228",
      "r229",
      "r230",
      "r231",
      "r317",
      "r318",
      "r319",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r173",
      "r193",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r69",
      "r110",
      "r113",
      "r119",
      "r126",
      "r242",
      "r247",
      "r270",
      "r336",
      "r343"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r45",
      "r69",
      "r126",
      "r242",
      "r247",
      "r270"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r69",
      "r126",
      "r242",
      "r247",
      "r270"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "verboseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r33",
      "r367",
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r33",
      "r65"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash, Cash Equivalents and Credit Risk"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r271"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash, FDIC Insured Amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash, Uninsured Amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r154",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Number of Warrants, Ending balance",
        "periodStartLabel": "Number of Warrants, Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r42",
      "r146",
      "r339",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 15)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock shares par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 150 million shares authorized, 50.7 million and 45.7 million shares issued and outstanding as of December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      },
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r24",
      "r25",
      "r218",
      "r337",
      "r342"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Taxes and Other Assets [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "terseLabel": "Charitable Contributions"
       }
      }
     },
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net Deferred Tax Assets/(Liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net Operating Loss Carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r224",
      "r225",
      "r226"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r63",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r63",
      "r108"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r46",
      "r49",
      "r259",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r255",
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "verboseLabel": "Warrant liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r73",
      "r252",
      "r253",
      "r255",
      "r256",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "STOCK OPTION PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK OPTION PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted",
        "verboseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "Net loss per share data:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Income tax provision (benefit), Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r213",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "U. S. federal statutory rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r213",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r213",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax rate change, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r213",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Deferred true-up, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r213",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes, net of federal benefit, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r79",
      "r86",
      "r88",
      "r95",
      "r130",
      "r151",
      "r153",
      "r201",
      "r202",
      "r203",
      "r230",
      "r231",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r266",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair value hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r161",
      "r162",
      "r167",
      "r169",
      "r266",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r161",
      "r162",
      "r167",
      "r169",
      "r266",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r266",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "verboseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityChangesInLevel3LiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Country [Member]",
        "terseLabel": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r214",
      "r216",
      "r223",
      "r232",
      "r235",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r70",
      "r87",
      "r88",
      "r109",
      "r212",
      "r233",
      "r236",
      "r350"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax provision/ (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "verboseLabel": "Permanent Differences"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r67",
      "r210",
      "r211",
      "r216",
      "r217",
      "r222",
      "r227",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r209",
      "r213"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "verboseLabel": "Tax rate change"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U. S. federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "verboseLabel": "Deferred true-up"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "verboseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Changes in fair value of warrant liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r67",
      "r135",
      "r312",
      "r313",
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "verboseLabel": "Patents and Patent Application Costs"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "verboseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r56",
      "r107"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r289",
      "r291"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r6",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Lease hold improvements",
        "terseLabel": "Lease hold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "verboseLabel": "Year ended December 31, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "Year ended December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "Year ended December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "Year ended December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "Year ended December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "verboseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "verboseLabel": "Initial lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r69",
      "r114",
      "r126",
      "r243",
      "r247",
      "r248",
      "r270"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r69",
      "r126",
      "r270",
      "r338",
      "r345"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r69",
      "r126",
      "r243",
      "r247",
      "r248",
      "r270"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r22",
      "r23",
      "r69",
      "r126",
      "r243",
      "r247",
      "r248",
      "r270"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "verboseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "OTHER RECEIVABLE"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r146",
      "r147",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r96",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r53",
      "r64",
      "r69",
      "r78",
      "r82",
      "r83",
      "r84",
      "r85",
      "r87",
      "r88",
      "r90",
      "r110",
      "r112",
      "r115",
      "r118",
      "r120",
      "r126",
      "r270",
      "r340",
      "r349"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToParentDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r110",
      "r112",
      "r115",
      "r118",
      "r120"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r282",
      "r291"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease, liability",
        "terseLabel": "Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December 31, 2020",
        "verboseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r280",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows - operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease, right-of-use asset",
        "terseLabel": "Operating lease, right-of-use asset",
        "verboseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r288",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate as of adoption date - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r287",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r150",
      "r262",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed To Issuers Equity Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r40"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivable",
        "verboseLabel": "Receivables of reimbursement for out of pocket buildout costs"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForConstructionInProcess": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.",
        "label": "Payments for Construction in Process",
        "negatedLabel": "Purchase of construction in progress"
       }
      }
     },
     "localname": "PaymentsForConstructionInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "terseLabel": "Cost to acquire necessary lab equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value",
        "verboseLabel": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized",
        "verboseLabel": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r133",
      "r134"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from Issuance of Warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r58",
      "r196"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r59",
      "r69",
      "r78",
      "r87",
      "r88",
      "r110",
      "r112",
      "r115",
      "r118",
      "r120",
      "r126",
      "r241",
      "r245",
      "r246",
      "r249",
      "r250",
      "r270",
      "r341"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Member]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r67",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r138"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r140",
      "r346"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of property and equipment",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER RECEIVABLE"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r168",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party transaction expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r168",
      "r295",
      "r298",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r293",
      "r294",
      "r296",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r208",
      "r373"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r67",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r153",
      "r204",
      "r344",
      "r361",
      "r366"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r79",
      "r86",
      "r88",
      "r130",
      "r201",
      "r202",
      "r203",
      "r230",
      "r231",
      "r357",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r105",
      "r106",
      "r111",
      "r116",
      "r117",
      "r121",
      "r122",
      "r123",
      "r156",
      "r157",
      "r315"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Grant received recorded as revenue",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r286",
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of right-of-use assets and lease liability from new operating lease agreements"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of computation of loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r71",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party transaction expenses recorded during the respective periods"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock awards granted to nonemployee directors that were outstanding at the beginning and end of the year, and the number of awards that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule or Description of Weighted Average Discount Rate [Table Text Block]",
        "terseLabel": "Schedule or Description of Weighted Average Discount Rate"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock compensation expenses"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate of interest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Number of Shares, Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options, grants in period, gross",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Total Intrinsic Value Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r179",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy": {
     "auth_ref": [
      "r67",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans, Director Policy [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r188",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r283",
      "r291"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r75",
      "r76",
      "r77",
      "r79",
      "r86",
      "r88",
      "r95",
      "r130",
      "r151",
      "r153",
      "r201",
      "r202",
      "r203",
      "r230",
      "r231",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityValuationMethodologyDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "WARRANTS",
        "verboseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables",
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r95",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables",
      "http://www.tapimmune.com/role/DisclosureWarrantLiabilityTables",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Common shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r151",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance common stock for cash, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross",
        "verboseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r151",
      "r153",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Stock options exercised for cash, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r151",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance common stock for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r153",
      "r174",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r151",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Stock options exercised for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r30",
      "r31",
      "r69",
      "r124",
      "r126",
      "r270"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r153",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Reimbursements",
        "terseLabel": "Reimbursements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r81",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r228",
      "r229",
      "r230",
      "r231",
      "r317",
      "r318",
      "r319",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r284",
      "r291"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock purchase warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r89",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r375": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r376": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r377": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r378": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r379": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r381": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001104659-21-033855-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-033855-xbrl.zip
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M5(CF:O"I%']5'F-5@HQF'%4#BT;03%%@3 D$BM"FIMLKN#O+7)HE,&A%J32
MZ/DD%7['$AA*?(L-  H A#F%>G)!!C6WZTJ+&7'RC&NJK&J <G;TPL(R7 31
MV$(/[DZD;:T_;@QKI3O(%;9A_VX2(AX?R-E+IM+5V.1LZT?]3\9(;.Z[_7X/
M0&GPJ.-ZU_6YE^!3R=G> *7G8E>XT4O@*+F*L &@KBNGEDM'R[5S7>L.BZCJ
M)K3A:%Z>_'MFZE2A@OOF:!=2--?2U/0VY .MR*G&L\)M\0UBNBZ(?(P.TM2H
M%%_JWJ!P)+]$/D852JH1?-7]W0W&-8WC^:"JLBI1K'+LN0&MVC8A'ZIL!C5
M9;>7-ZB\0?!?T:T$-:M1(?SNB*& 341UG7BC K +<JFQU(@^:D!ZK6FY #"-
M$DKP*AN:_U\A*?X1)R9G9(GDBYYWXE7&CQ><;K8B9B_XMF9D^?%"O&7:BIZ
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MH'=9?\C9.-R$W@M9&N49AP8!DYTS-'5 )S:1[S/L,_2.R>M(N'_)@QH9A<&
M(O\G(YPWPY;164W4#<[G,&;^:=A3'$&94EU]J%0G*TAP=JBZ$M_E>&(0R^N_
MX]MF:-EB$*L.S2/R0C<B6U1 ?.,(&%PQ..:+'=5<@P6+0:$B+H^_2]WXZX@1
MYFO=G2<LXEMC=(5B\)D2G\?K51RO$TX83 ?G;O/-+P)Z@NA7(0A:%]L$7 7
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M[(Q=_>Z=L&\N7\I2([D8^.O_ 5!+ P04    " #JA6E2Q^V,ZVD;  !+I $
M%0   &UR:W(M,C R,#$R,S%?9&5F+GAM;.U=7W/B.K)_OU7W._CF/NSN0R8A
MR4R2J3.[Y0"989< %Y@SYSR=\M@B>,?8',E.PG[Z*PE#;)!DV=BXR5 U54-
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M=O)FO'DX-G]KCXY;B&6DF5&PXL<WE#Z]K# @_UTS17.;!P KYS9I&ME^HN)
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MYD6T^;_Q3GL>D@,#*XN4=:FJM"#A%$7"AE%-. XB2'[/-]25S3,<*=2B_6>
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M_#&$ 1;&;+2,BV8B!?1N%AHN.FI2PJ(2>*9Z^>!GX].'<\R!<Z;L*[RCH2!
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M<=IR&;,U'/)-P#-.]C@W;-:Z8%#Y_G)VV]G];1B 7'X9 Y+,?0X&_N#8D5_
MI\4E"Q=$)V@= <KLKW'Q=+HGAZ$MSLB&>+.G9R#:^X+\W^H^>M'+[$8)5.?[
M""TQ"Q<R4);CSJ-*61&=2E310E\),511FZ&:'JH((D(1U A'$)TO++QU.Y&(
M_)!FM"%HE).?V2!0P8[Q9.2IRZ4XH 5R<K8?/7_9X20W+J-J<*@PH)[]=@A0
M#@L0_M,Q(@F7Y649F0H!?,%UE* I.(A+!- E.,=$PYX(^V?$_#8IZS!;2J*T
M>RT.U+)J(4A[ =4@ "R51FXDBR+'8=8@8%66 ;7R#91DU6 !'NMQ0JQT0UM:
MK+9Q$E.+I@4.])9AQ (Z_ML)TPH)Z%'\APEL^.GNG3@6;P_3PH.UD>'21"V\
M *HA5XN?0F()''"UXT.&I=6-*R"X:L9M#C2;B0H0YLVB+;]\IY]VMD !:#"_
M?[M2M[&70@)K<9=IJ1XW8'":?,B#1I<Y*'I#@2>J=6&MT$:VZ9]X8*)4ZS0!
M5.?K-$G;K)<6:3C+6N#!J+JU0*+B&Y&\FX$E1[(&"&G'+DK4;P-HZM!7KD7Q
MA+/RO@2]*9>!;P%/PDWSH8]1G%"C7B3-[ZZQN9N5$@^ZI95!('E?*P428',K
M+4>:#E<S1#'+U02E"1+_1 C G 'ZRG7Z1/Z%:?VT=127.?2T0-_7@TY8H)7&
M+Y-GG+.2S]PG7"9D/LAO%'.A!H?*'M.SWTX?D\,"Y(_I&.GH40->+BOT H5C
M0*TESA+P/X/?NA-C-1X>#F" ]E(R1EO[)A' _QZI.WIW/X2+]O' 9]4PHU.W
ME6!#_@QSKAG"H3^+JBH,5@_+/D1YO*01Y7BS+Y0O4HQ8,%9G*8QHAP84[Y9I
MQ4^W+%Y5P[)^NSA##)/?6'!<&$/M)U##_&I"YBU6RG[L5W:-R(&-/S68H0>3
M2/Z,_E<</SX1#N9D J)'?+VGZ7:+-1-0>$=AYPOZ$H-Q$<-$%SU'/TK>'<H0
M-KM-@$MBJ*2&.#EZ*NK65_#E@BRL>)I)B,I)2.I)6)9/C )Z7%0_<R'BNG?>
ML<*%*M7K(%B[>J\%(D!!7VNN7)XHW=TO3O_R\^+J[/SV[@_H_-\^7][_%;TY
M.[^X/+V\A^P"97[V',);9],#9]!7S19/@3T\7K8K\&QFM5W:N7IL"EKBV<QT
MI[BSBF_/5=<YTV?[C+!VPZ1EY4.N\5?V%U7LQ!(7L#:[K6"=<NTF1)@*[G9<
MR8NZET:-.#;BZ'6K'4*" P!U+QPB'OTC-:9Z/\7$7:<96D;Y4W"FQ2V^IVUU
MD(,R+H5H%M9U@!F*>4G9<K*O:DD-U,#L!-1;6-B+&/O;8L?2/\Y?<+:,<_4>
MTIU.4/9G%MAVH9,2"<4J31SV60 Y2$D/U02A0A#C2IZ68N$*.O35<02CU1(*
MRFHM1+9>08.V6R.+\@/IR4-$5?8TW=)D));(A^8TJ>*114#0PRL2X6ZB5_;K
M^=<H(_9=CC2K;3JG.1J<H0"7XC&->\C"O,U^RYCIOGM?&B[]S=\JEA;K7WE>
M2S[?IOOD,"1H@/5K?E:,4PO3 DYB1*MTN:?*RI3:90Y549$27$@\RE'$,+Z;
M1-EE7F 0XXLUJA 0Q_"]!/=AOV9YG!76VOAD59/UH$&87J<NL@XN%,/35=*5
MVAV[UP$W.RNV1:O+_==I[L&ZQN)FY8W:B)97'8 7Z\.^T/.<_B9FV7$7&%^D
MV<6^V&?X(DX(0K=<Y7!R !8\@OBUE0^@!>,)!C/<#:?0NA$[PBRF"EQG"K>"
M*U'._LV)HS7&3+W7C#Y:5P-X]BX33$4562(>2*P>BNJ#^3Q'#6E$:"-"'''J
MJ"8/LDF8<#KZJ</4'J^LHSV:R[.F%XK/<YP O=.S)!:0UW/BV.#VNFDP0C^?
M(W)_ ^=$X?^:BX-C\W\CS4<_!XC>\.%[I:HH/&&YTR1"DKWE%<Z5 4DC-( 7
M,S-?^R@U*(P',O&C.A(P4R(HB.(TD7S/OF)D[@'.8\X2\(U;??RE1[$-%0*K
MA)C$*#6I8DZ801FK*K', 2TT([9(E[I_PO7SR>:83U:&A"P+5+U00?Z61TMV
M)=!J71&,M5N(J;=\R"Z-PV4S^H3 DP?*1QQX)=X^];FS51 *ZB+20F3K_ $I
ME5 N(HTL]LH@4-Q5LK?LU&N13? :QW3#&E8.4,_9*$5="N#!&7%YIRJ5[6.F
M?A7<GUQ0!FTMOGU^@9I6*,9MR6BO+#ZUC3/*@64+#9H)B7FC-W&US8)\"](\
M?:$[DHM-^M54$%B/ OX@22F&XAU2!Q[R^9&"&9=71Z?SNY_1Q=7BU_$:(_6I
M%4$EN<G2YWB%5Q]>/Q/MOTSJ<F-S<LAX9M5;3 6[>A "JSK14^2#TA2.5"#J
M5_1B4?I0FQW1*E(T]^P-I8;BY%O4%,IK*()7P1Y->"8XLW1>54\F+6"=,"+@
M.BXTE5Y$ !B#Z[(H&E+S5^\&<CBTN;J+V-7A)LUX3N9!P9=K,B.T_T"ZV? B
M>1-6,3*:@96(L,55YJO_V/,R2_E]>HNI0L4;W"H,<Y^.LTA-,Q2,54TY;:)]
M3C&.=TN?3HB.00E#46]0#X:ZI:+(GX]M6?4XD17UF!_":/R[*AA#)H[^S&+A
M>SY?0A'G*(1U^8Q>^2\Y[^3G#:8_T KK6[IL_$,74+5#A:KB:2]6NY"G&0^@
MEJ<M4Y)RG@WJ#-7(O+2_@ X5&AE)-%[<7R./U_[/&8YR?(;Y?R^%\J1739%1
MQ7Q88X/UAW81[J!?M TJ1/]H>[XDQ30Y%GI3X7]+G7Q# EVI"\OZ60J'"<CK
MYN:!%\YUNP@,Z[+/_D(OD$L[IZLH140>Z(9MBELT;[<(+LSSAB$\-Z]U1S"D
M<X@BV4=<JQ?K>@-]19W-+:VNMEB3O35M9U@<+GL]\ $2?_H(6*?_N"##) &Y
M<RA-!2HU"RV)GC[2'.''*$[R N&JG"G-""T(("_8%"]94\[')*Z.3<W):,.6
MU(R.3?] CDXHHL-[3AL:86)$$C2#J#DL,RJ(D:%_((00IP22*SRVJ.3_V.<[
M2=<G]><#K:Q_N FJ93R-=C%QEH:0G N!4/;F)A'UVW,5=@ [=#UKMIOTQA9+
M,N!1J\&2"KMU(<[$;(\=D87-.F#,J2OF389W4;S2MXDTHX5B>')Q].;6Q@G
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MT+Y+RFIK0]6"\+]3D@S?W0*=S^\@ W17.,\Q;N< &R/?)B0HA; 1I:T@.@P
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M13F>/V88T]#3H0Q2?^N(ZU]=G 6K=,@:T:MB.7(E>_9:XJ.: )*H((BS'4-
M>UD&!+U/TVR7TD?"/^-H]?<]&8N()#T)FL$!PMX6[-=Q;PTL3.#;R)#T/@CS
M,C-ORZQI&DFHZ* G@9#G8+>[, W;(@K067>P#.+4HS<<:<QR/HLU.4OCNUVT
MQ&KSE !!W.ZJ6&TN< \A@.YHY6QHS2[F9A<5B&,CAN[9V&P9%UF$-"Q'?G/&
M[Q C&NGBBX=HXW_@U6F:%_EB_3FA3ZCPZB:C-^^T4LSYRW*S7^'5!='_^38E
MO_L'T[</KR7,ZR(C/_T'7A:::-,D(P%=ODTW::WKN_&'\7\!.)4,W0(@' (\
M$E;RH;UJ.("!T6(IHZ+^M0"\:XYD=/4W![T\<.)T_//-+<XQ^>Q/%]&2%0V[
M3'Y.]WF1)O?X)=(<=.SP #97+@+5^RT;))@MF#UG':U)WD9^=UT#>*U0485+
M[[-+;,30(;=GHPH6UX+-#)(-,.M/4;)?1\MBG\7)HZMM.R #&+BS:+656V/"
MF+HC>_#V/I3A%GZ8EC^1B./Z@)$.<YLH)SOL7]F;P&*1W<:/3]HCF1H>Z&!E
M$J!U/%(!^S_DZ#GIAM0H/$WE+3%0FB&& WYXD4JBO;O78@2D1>I;>@UX&)JD
MOT)ANK1H=&E1ZQ+H'7Q?2:16,?ZAZ?P%9\LXQXLU2^ MA]3LJ P($)6&;41H
M*@GKH+WIN2TKW5I6)0[5=)XE7J%![BT&29(>2@+G]FE"RV(]YZ4$Z Y7LVE0
MP,*X>BWCHI.7 GIW[QHNNC<R-,F(Z(@ S1[T7J?)223\[I[\F)/]*2V/!KY_
M$)C-Y\F*\"JP*G*J?Z#@2@7HR4(_85N/&-Q(^'_6T(>_;L*T0 7-N0ZK51CV
MZ</X IN-=HJ<ER3?;^@S4Y$57=*+#AXDZ\4L@)#VH@:&RGLQ<=2-_7@._?1@
ML4%!+0T'S6<928H1C6^>[^(,ZU[BJ<$ 3$W#;FUA$A@8PU(RTO7!#-+/BSJE
MD87)KMZD^O(\H@5]2*-L=9IN:3X24P6U%2E! 2S)P'9M30HX&(O2,M/YY P:
MB>! EA4VVWH+&\H[Y'/SN@C^19I=XZ_SY9+F<)/%]"9+$_+CLMP[JP,(CC2@
MGJ/W$+3]/-V! ,!S=6?N9,]@2Q1:;BQ9L0HVGW<KFBH,'8<H RVK=*=</?2@
MH.$L*=N2:%8+#BJ8)6%"'LM:K%$%#'S(=^4\%3D?^]F?NP^N[:XV.VYU9!?U
MQ^]_U$?6['"!?*Z+8"U?:X/HW\?:<^7B6SDV=)AL&MD013_12.>S= @K\'!#
MGZ:)T;H/K^)?--L<%P)0)49<16R7';'%!BA%XL::).6/5_=@<.";&9%I;2Z&
M#!!>M=29%UTH4%4QO,5MJ01H;L7(3 ^Y9R @\3+:W&=QM*G? /\:%T\?HM=-
MFIVFFPU^))NM3W@5+^-$\["O-RF(VXEA8C<7%_WH -UI#&%6U](Y3M9IMJW[
MF-!*3'1S4*2H&A*Q,85'\%_)J(@/B\IQZ2Z]&MGWP^!19T8I]*\2H1>-T*#7
M,*/.@/K#CNBZ;LK*!3E]=O8A3N_Q\BG!U6MG;<S9&A7 -3F*5;LB2SP8U^/$
MG*VKB1[2?<%JZU9%+')$)Q(]Q"DJV AHV0SAV:<,$[G&1A0=$7S$"2"! J3#
M&"8>03CIRC--_H3HS,ZR[_YU'R6_X"RRRJ4PX,+F55@))LNQT"*"YUM8<">I
M?A#G:,L@:*^X9)6STO-BID![ZT$((TH94=+>RY ,DE4JU*\=H0))ZN@CX5G6
MB %W:J][@\[WQ5.:Q=I@D0H8YO2N9UT\P<LAO9_B=6SH>K'6X. QGJX$VDB/
M&CP4C5%'?52P 6B--I@BUQO00-"4$OC3_;)'&RL&E[UJ[Z_DH# ZKV-;U'<9
MG'==5S/1T9(2%)6PP#=-/1@_T&_PJZ16C[=_W6=QOHJ7QKP$(Q:,UEL*(QJ
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M#2W/\-Y'UMIV=D'O/RFH_>?Y*"6&I[T8NYUO@5]T>_<%E?A"U]B7JGU>>)!
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MVN<HV13.YLX<Z,!X1=\KT?=,"QQ[-W-L.-2\=[3PPZGM!?&R1!?SF^'8SS&
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M^VS!5@%/*1XAJ4"SAOU1KFMW CSRV,=7:!4/&,4D9#:H?G9[*8'Q2&,TMHH
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M7 G$1M:+[S$LDTQM2#.@2\.472JK*Z"I,2+XU_D*1GM.B-AB.1W\+3H7^O?
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M<G6PXNCAICE 1V7Q'Y$-U*7B2W$S;6=220W4\K2:<)<A437(D8-2/\XU#\R
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MQH^%>"JY-UZ-%=Q;GGIM2'[W8RR<3JV<XB]E2,>!>SV*V872*W:A1(DY/@>
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MH54O)#6*X\'P3[R'58'(QTU]L)6;UCC=CY*5DGD(,!$QKX$/^E745>R)[M3
MNE,%0G-X$_:VTRO(A<?W3=B/(.(:'YJ]AM2^E&0:*'WT22$@WV=HA?J\5-_;
M!E=M"&]%Y!>6#GH*X A>JV+9I'K<(=MOXA,/N.+2@<B !PV8!"E;$DS_8#O
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MQ'^DB(\$\N96D#?72Y^?]2Z7]M2K9+0$N1F6XFZ]%(6,M!7(Y9X/N=S;Y%\
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M,@+QS.>3?LW4,(672/VEI(X(X#R\.Y9TMCFA@BS=D11I3@PC-C:M.8Q'% <
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M"/H.IE!.X*?(7H+9O'DV%ST@-2D'!Z0JTLA&I?)?G6;I)1ZPIS[)?N) @.S
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MZ!(%LS)Q?F[QMNS(<4>.#.=1?()*/]&92@M7!CJ@])#:%D@IGL$P6)D"4LT
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MMV" DDY=AH"YQ4VP[A]=DSGT= =T)>-'/&?%O1OX?WSK?XL_C1UIXW W$/=
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M\*\0@PVXOQ^[H[LVH+I]F*N#7D<;'XB8C("\6 M*!M8H2T@6JE'CRE!,T.9
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MU,V[50)1ZS"$N\EH\V]FV<;3S^P*0?\JS A@?Z.&_3ZM>@C \3L!.#[NTRM
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MX'&4-Z$(\IP8A7UW&!PZOW/TRC=H#1^(J L'/)-JB63*4IX;S>8/=QZX%)=
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M0N&\P;OS*/44U*W<O(L+.F64,NG/>V,UF'?O69]:V6V H;5X(NF> 'D?)/U
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M E_R_%=X2;2,8RL75&IL3"I_*44!][8*40%2GI<*+-\VJ06_3$XA!P9:[ 2
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MY',E#91J[&9&Z("H2RNNRL6JP%Y>TT&+)F*\_80=MRVAV(P7&P7-? .N-H,
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MX39K\V)0C4"0.H^:D[_^-V'LSA@0>>V=UD^[]<\")OW6Y]3C&QGLD9:H?/%
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M:H1$/PWM?^G_PN'>L&_&!._$.K_4.$Q*[W!?,KPY?_"M<*BAWPY/* KTE0$
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M06;PGFXS>-L,WA\Q@Q?@7X?@IC8BC1B)PTVQH?,TB!-CH]B08\G*#M*A]6[
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MV\TDK.D!TM2457-)DBX=C]9ME+-&D[NVXD'W6,D.Z#Z/!1HE3\[BY(N)XJ0
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MU8R9>AQ7-A,]-R9B&UO )@J\&S9^Y!3? LWN%T(ZR6"T6YI;<@V*+Z8._.X
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M&)YGB;[;R<->+=EY6>%%1^]RTO%00!.B+$<5(_?]Y>6Q%AMJX'$XS\P]#**
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MRR2%'\F/'KRQR;3'>RE/@&&USF=Y3C$5-*,S=8;R10!1S XOC,(;=^9O7(U
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M08X6&'5JP$@ _'/M('VCB(B=]Q:P-E@3<RU,9PJ"(.(OB)Y397L9WXS%M/O
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MH$FE6-(T*AML,<($,M'CU2:DFBU39J=KC]9X"J/7+O?YI YX8IE_:L#=K\_
MW3-P]]Z!N^?#X7PX9 Z'E*0$#;/+&_4APFFT,7P)&1_/SLEY_=UQ_2F&CFB#
M2(^,.S81O>0CO,I!UHP!U_Y? &3MW2AZ#(&J+*#NW_F(<:!6]>7R<2CX(=I(
M+L?H?E)U$!PCM-LUC2-&'> Z<Q@U=OVX[9JZ.Z_\\\J_V\JW:QWK>C4F14Y)
M"40HI%.UO>=1"20N\&W^_%PK?-B1RGA0U28)Z3TJGE30(7%>W^?U_4M9=IMV
MVP#)"3"O8[Q8^<5..-IZOP:Z#*U\2SJ/U_N*:<,0! ]^2XD8Z8MN>W'H-M!;
MRAT]Y7IPG&O$R/,][O<8_O81+?<'Y]7^\:]VN[Y+RZAJM)TQLP+=1HU?@NQS
M1WD6I+5L-#&NL'KO833=3<0)_\F)=X1V',"\&R  'WB#T-9RU0G5W)2I54@T
MD6]"*ZEM"^2W0OE7D#@ -*V=;J?!I)6_E(E[HF:+N._ S$0^%(K9"TQS.C3E
M1.TZTI3$P']!&F1+PDN9M?C&"X)CS,YHJ(;ODPCK&X<D#,K-,F>^926!DE ?
M 7U';PAB%MMN0P20&7&'Q;8?R2FR@CI+"OB%AF*P)C,YEUA V7>_!*^Z()>.
M#)XU 5DC[L[88\IT0&R5KBM-A]+R7GIVX.G":Q+=*H[>%?*]1H@7[1\EDA49
M/N$:KG'8-O6 =T7.6)P/)J46*2OB?,#VME9(E.U-8M4*8>5E*H=H0.@Q!A&R
M -I.]DX-[\M=)G)IWG3U'VO74+XY1P6M_4+Q_@.&+6C;P7;QLIE$Q3XWLM@[
M"^RJ*N&Z55I9H/ H,U.O"ZD'1ASOQ@\[)*4@C =%E]AZ6HZ9?<X",''MO6#.
M;1Q6I8#KCF4#9XD%3D'5OARHMX 9]T8V44R0Y%HRLEH#@+8$DB\GAACL<A[\
M:37K;Y\W#(77R2?X/Z&>TS<,=<^U33&:#)F'D43NJ'QT%RJE%S6XW=K9B2ON
M/8@$;E?5N^_VSR=0[C$"2K4QP3 4V@W+3H!P-W>D2FCV+9>KJ,, CO?&E7 (
MP&F)#7'>8+='0SREL09,''=RTN8(>.W,6)YH_$?4BW3]0_LE,!///RKG]')3
M!5@\_S9,>21G/C$QZ&.8C5FVH2C,S>$MJQSD;Z$I@&"L,MK41*6;=.]K'WZV
MD7^YF9VZ )%E@O,3E9$-TI7*K%T\)\C?B4QE>7P;;*JI96X+G/SUY#W"XX$X
MF+SY?8O$T7ZT<0T8MUBMMNDUR?'?13H\[>3'"&W>K(5P)AP!Y-J] J^)*#+W
M#A^!SM1HJ>?\.WA?:R0"K)JDEP?1;;!M.Y@:^N9O3Y0, 8GBX-AE-M+0$5\W
M2%7+C1%I)Y 9B]43N"+Y;S2TSNB3)KW7Q@:68\D->NA4P'S4+<A.T5$#*J<#
M+! X3[/>N>Z(N)AMV$1@VZ((2>4&7+W!J:"UK0].S)'\]-:"VT<*I.RX$G=N
M#\@D9!>SB;B2-4N1HE/$2_CI8]$1F$C@.6E+4J!:ABQW(@"P)1I[8(YLX&RB
MHS]8QHSY \Y X!XHH:N@T+T*M&GBHYOCB[EFU+(D8B ;US0)-& #&<T^H41)
M-X\>K>6XNRE/INN5Q8X9, INB'A7L(Y*?<V,TG0V,PI![F!")1H6@(H)&PTW
MM]UFH_ <JX<2)<J5*A%6T57+M"U$IASU46=ZW:!CR'L';77HZO8>6]E_<H&5
MQ$QV\$^DYP1*,@NM>^0*7Y<@_W(D@FT@YH\L*E\P< ]3F_9"MN(+FZWXWYI@
M_OR/YY3;+XAK@H67$].A@VJO\+NHG4^6]*^V5^^\"'_6(@2U'438XXE 9V%K
ML[XH3$(GA7C;<$JI"55^=,O_0I6ZIZ]>#+GN?R1@96 S75YISUGB/2L(W[JK
M3EAP2];HN8; *!:M(H4%H"9UF+*!I^#2N][[O$_.^^2#JX$F.L0T/ 5EI,GG
M/SY.'-]"%..?;-UYUYKH"%Y]4T R !WWS);XWX,9_>+!&3-ZQHR>,:-G6_XQ
MVG+FCB>J.RX#*7D\@C%Z58:G@BV8Z+//<%YG=UMGN_(ZDN[0P*T4)0"H=8Y3
MWUHE#E<2^2%EAR^F4ZTDYX5W7GB9A9<+MR#=69=&H2 2[D"00-\=#@0>QH3H
MV>Z=E]^'M4CCXV%]+[<2'_O%]A&MJ?\9>.)Y2?U,>&),4,PD:"-0Y[<C*Q"C
M]%!3;T%^697*F$H*4>-23B',^+AS>VH#DG33.B@YKLNA%C1)3-+-DEV?'( Q
ME8G&ZE\;E+4Q3Z:EE+4+ DU!OVJ15CZJE+ &&"D=^!$,\@9&1S(GJ02AX*L7
M*Y5F(BV)C#23%5\B/%<J?Y55O0IB5S\)TI+J1BU")5RO9:,MZZ#698OU=2C:
MP24;:#IVXPY70CT,H-I1#BC9H'(6>=&V60EML23J/]S4;F(F5Z3'QQ:'=_6
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M)<A@2P-&/_%T NYAO@E2(($4XL.^E1=<6/3+M>PW?&*S^0D&/KU$INY"B**
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M< X;O"9SL]J* 7WP7Z'(O/"P,K#ZJIONH  @;9.U8:"A//-G5U9GGI<W<_9
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MWBXN&RB[M,C\%:OU5$,3N.Y&<L>)%FG..8UY/-88$_TD?J[Z_IO:0+. 6(S
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MF'(LHP4BNDEPV\"7Q=<&$1XXG?&RWAIAX7 +=00*^Y^7C;_:?O77R]4WWI-
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M1TO";N[,<I [#1M@[2U"[#G(=>"3GTB?#/8Y+.7+7O(8/]4Q_H5;9=XCMOV
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M>/10Y9WE) +WUD^B52J2-T?R0>O-6V#,[!-YN[ ,%]XHTD)6JK[D9&0A(R/
MC*$*\OK$"I;X *I;$"[^OTV'\L7[VH'A+; +6\UIT% !(#"^7Y>PM%'H\,X;
MTT%26=L2(P8V7D%/=,#J "WV<'627B*RRLC(P17*5LYN= P,B6Y:'ME'9'$$
MI8HRR@CEF#WY%>3Z7"1!@(] &@2[:5^V9I,929T=>O:JY*VY.PM/X4&6E#.-
M,_PK<UR2AP[^5(,^>ST4% >',X#5&,!;936&X ;/R1 7;\Z8JW#PL[S"%8P+
M_7U/9VW*QQ?3'_K%C<*V4#Y24F& <]"D,S^MMQZT'<*XBRML@6,SKQ@K5527
MK_O-M*=4]:* ""OK,3?JK3I'A?FR1 4$EP.G,=+;-6Q)[Z4S2@8A>WEOYGJ,
M[V.A,9 VOC_#$#"(# YLCBHN;?>8AJO@L*7TM:D>U(*&"Y<P!3SAK"8*>8!D
MN-4>I\^ //'O-J@%S1>ZF.5.J@Z_W^$24KD6]0L-DC- :(^VF1<M3R]9]93]
MVS1&T&KT0^RW1=W0^9HR+!?&GS*FI.W:"[4T,X<7%9PBNMF\L\O*9HE,35[H
M+[C<&@=GV:"CN;0/5FC5UI#+4X%I_G2WXH0361(%RN3AAQI,K/5H\8\KS.OV
ML*#*2;R4 TDT\<<VS<46*EM5GLA:396_;0V2Z[!LB/NV92PT%_&CQ=EIH8Q$
M1;>2/%I18&WF*W=;_T2;TR))&"-$8%*AQJ7YGYV1.BJ?9JWFT;E6<Z[5_!IK
M-7?/_4!@.<\1Q)E@DR* DP&J&MY!="3IX$] 0-%;1?A$89'L58EQ N-=" "M
MCKYZPUG#1<:ZZV,>=$>,XO5P_QK4^3'TOUE.M?QWC6.$=,$4#C5E$""!5!U2
MB3$!+N/1V:V'#D5/U@#A=IP_[:8#.4#^?(JT9 E&O>@VI[T*=-X!6RC(ST-2
M.01[G,-:'+8CQ)-4E(@#-! TC$/^> B9,U<T&?B?JC^3 ^<?RC&&9OO!&]TF
MN+-)2DWK:DE"(<90W#*SR7<9PQB3^MLBSN@&]1--:TOD'!!$Q&XDQ!MSW6<^
MUMO:AXH+D*SO)I!OH+B]&=P-E'\B,&H)1&!8GPR$Q=P($=\E<;JX*:TYPE?C
MC:0*M-:W>@Y+<?[LX:KHNVV[#2)LZ/MV57)?GV9-,5BG_8#7PNU9VA0B%<CX
MSOOR'["=3MX\B+!"U+WA_+5Z@DG"8N;$5U'GT]R?U[3'TE/(8M=?Q!.U\7?8
M^\TB8@GD/<9+S3O<6@ 19*1N]!1C"IGZ:)E- Q$9H&C'/)<PRQV;';R8U)U)
MNV==6S- 85*DC2E=[:ZIYOT["-)$*!P =N$T$FLK+7F4%(2W2KMZO$D=*=TU
MW5]H;L4VR<"2P2-L0>A.1, :3H?;^QA5+-,>[U/R]/=F%2F6^2_^!($EIEOF
MLZ>N@1#MLV_\D>PO=?'\")I@K_W*7Z\+_Y*;G?OLS_X#+2Q\4)'H-V^+U8_>
MFODCQ2^AOWI;LWJ)\_/9GVM0'BU63_;^DL7JY=8/ V?4_]R4[[K7>S_'?VWJ
M5J%R9>-?I>*H+6@H1V],BA[&$/CU%"^3@-5^2J*A\&#?-)-;0S#V3=W1,SRI
MRL.(IVBX?Q\,3M=BL#HRG!EA(0Y!D=+B8;6<P<+!-+"-*:C[@BM?9OH4:0N>
M4)&9DF=^*/T5BM6S/?1^;ORC_^C>/>/'_,F?HL^?_2V:LP+L69G\ZHW?2/'O
M\)U?.5!.[0#?2I>DJ@6D]/#E>5A94N_"#L"^JVB/1QTN]M'':8^3LZV;D9.)
MS7%_V'6;XQC"77^V+'\F7!2/%*PX6WNTD%5?/:$'2DPEYHV'H"U"RT2$MI#_
M/+?#N!%7G53_\I(G7I:PM\8?T1TAHVS+7B&1E!SX4<J($S-TI!DQ=$ZV,TD[
M9:&QSY3/-%6W3U_&8=^2/1V3?F9*^?'V6T.WD9Y]1<B385756NG(,ZHH.=UK
M(5-PU?!8"A%>TGR@ S[[A(L:>'P2"^#W$CX"F>0P#8=IW; [.3O][+&I]P!4
M'#KHF%G W]UT/> Q1.PMNVB\A[:K&VF1GC[X,?Q?_3JH-7,ETFS@_&/?D;^P
M%<*0!B4("_RJ0(F@V##![(H"-.V H,]'?I75*/8?1BEO)\ZS<9FMW"\DK34E
MG$F,1\]@G.N/I1:&(S)OKP!8BK:XJ4W']E-HT0-[Z*?QA]=/WX0N1#1,3Y[_
MS<=!DG8L&%6%I9G)[Y!N&G+NLC&W_@"MX5-"%&5IHG"@\0Y/-IL.NU,:8F+
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M_);R94%"QC(?W[7?:V%3(Q=J:[EFDSJ<O&::,5IJ8X_%IQ@6?KI*W367^95
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MQ]A46HA$)!T0O"?Z._OK:AM%E)$6":*+W,F$2'MM5 <QX6:GRC>H!21R$7=
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M83:\H1C)>Z'+M&"N;F?:"]ZJG]439XC>W<;)S$;F5?0ZKB_JY;QG<=XI<:>
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M[HLW[52#2$<.=#F;(:(B7@_;"0LDB1;]W)6GW5=E#P(<'3;A[<>[?:F2R$U
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M_<9EM)LQT?.1@"*Y:\UD%_0);<]?4>%Z;^+?BHGWSC=.NE%91NE;N("85%_
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MYKQ7YX/X"BS5U4:L,G#/7)LZ+G*CDH6[] B>'N;UP^A+'GZ/LN!2KP8[4K]
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MODDCV%>S)G$V[O(X;Q+%-_C2HF8=_\CBPEB9^7)9*,4\=5@&![O;3A 7U%<
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M\;_0^I+$()4#(IB@(Y]IG7(:8("BQ3+9)_]$9^]D4;;D]THTP%ORR=&#HTP
MA"+XL2F(B)4E*8TG&(<VCF9VT]UQ3;F#!^(J3^8,BP"<\=V_OWYQ</QL0DF
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MZ7<X1'GLZAC2MWV< ']-?"BY\:#/T6-:85W@\%B))HZH"G++;29N#T )K%4
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MU.E'O3#SR9,'^<F#A\6G9XO\\:>'CQ\\_#1]\NS)I^.CI_/YTV</\Z?%XU[
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MW2\O0G0@W_GP\NS7-Q_Q%:JWG-(']Y:2_(B#6C6^^C*!@_S(#CL\^#G1! Y
MZP;1&L%GCGC:?"Y2<W_=5DYK[KOR>Y$FF*/%D4C:@I,[!^AB"&,%#,0 < ;#
MZ#8$/L-?ORO#31!S2*L447< D2W1QT]2RY$(1+'4RFA#2+6JVEIW/D<3;D(%
M4M=JO^'!LJX_,W^Z#5M49%A=1JC9#!7":!, / S!PFV1HN>F\TL K7D)QCS7
M'R  ZAJ(5Z7U5CH>+D&,#:O3LK1B1BN0V]Z3 _U<G)=WEP3^+J[NW;]21LRP
M[U*_64F$I/5!7<V\&.0N4@TZ9I.N4%=?'R7,>56'+TT^3F;%<GG :"J^!Q5$
M0_A<J"!G^"(CP-9%,)%Y(5^^S&<S4'XH27N"<KPH@J$8P^H*3Y\S7PL0O[38
M)IOM"HP8<V7!9/4L'GW!XEY+6L(#O)0F7/<VV%#Y\?3TP-2.^)DBR>O.55-Y
M[)(L:$'J6G)_7EZU-C/5 <BCB@*T81AF]_*RM"B:.:^H=8D?QF&W:$V<%T+M
M&09H\#-ZO_QME@:,'0S5Y#.!XOE#ODL862/45+S4Y#>*S-31Y.#!I[X-U1S2
M@:UH@M;+SCW%QP;KZ12ZE>A-:+8K#/Q 'H>FIR3E"[7+^:6(7&VNP@7*-4D;
M<0 W\))R)IK4K7_T50FO[+\P G +PR&TJS[<H(DM=ZOU15B 67S"U2Y8#OTE
M?/_MVTSU*Y@JU-E<:RTC82.KJ3_5O=?!F^6S[4:N7Q+[X_9SL2KY1J=OWPA,
M#M_A84V7>5CIL\XWW[PYG/PD'?11$X'N#QEA]#:PW6$$XZ:M2S1C/M0E.NV,
M_V?H3334OMF6PCT([4YN5R#S!^V143V+H"QUOQ*Z^TO8V7%2H'U6Y7CB @F'
M=]C^&N(%8HL'J?5Z0RW4W%]R\)$G2$:O'\M&DNXW=-1H[!?.DS)*;8EF$'$]
M&UOP-$S=HMRDS'BR@?"&.+)[^:VNV-*;NGX_6Q6;G,ZO\$5O1_>IUPA.!&(T
M9#79=G.P:<(F1J[2AHP20AA<U9^[399Y$N"(-:U)GAY09WM;T^N\:96B]\?C
M+.@FKUZ<LM(6$G)KLA1ACZ8MB6\<K.SMQX.'1\?#4XPA@]R #"1L.Z"B\RL4
M)'&\ .Q)V2NZ8:7LH/Z*M"$@[T2N:R0+Y%D*(?5[J#8==TFLPY<P.#)/V@'F
M.[HWUG>[J^8-]T"'+>?%60:O=:O<Q S$5L$Y(=V=_)3OEK0R@I=<G"- >DM=
M(."1"G__Z?E;9*,-T8T>0V:*%UHEGM!P@S?;Y3*?D-SP\C";'!]KCN7X25P]
MQ@SZU^TEB+?*EGN(BPVCSJ&O:!K,-\[E]2^)3_YU71:;D5>&A_S3V?./U C
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M/[O7?NJ6 H.*EXIN? +B]N;T5+O1'*#6UZ3)J;(./GK_3CT7*$SH]IF]@$>
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M#KP@ I-Y%3Y @?6J@_C2.00M_C]V@J<(X@/:,GYA:'TCX_7$6F4KWDZ34'[
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M]D(0A>$\/ZAHDGH^-76RD['H/*13&\[T@I[0W]C*8PI5+EO;IVNZ?$2V;T]
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M(5*%E%]=6H-P/VP21!H8)1NBEK%2!L9*8:Q4&V.EUIQ+4$S]6 EVA^@JGH/
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MP2#52'@$A*V\3LEL$#<!"4!%L=0 V5:;"Q7WF=,_(*$: D<B(D+_Z-IEKMX
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M75QA)&Q28B*MK.!BSM.@F"X!!P#O'MO7-(B6YMJ5MPH6KU?T^HIL)*K_Z8/
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M")(D$[[X5+#F5&JUTSOX*6B$[21#?'1-VT*;>8IT ](-#3&+% (X2#?4DF[
M0DGUH1N,8\,\-OIU66 ((&H,()!N0+H!Z0:D&]#T1KI!'9-"O>E6PHQ'N@'I
MAKHO[<K7,:*%RNF&'N($I!N.1HVB&\Z0;D"ZH2%FD4( !^F&6M(-NRB\TW#L
MH0S00+H! 032#8V"$4@W-+Z32IC32#<@W=  GZ1ZTZV$&8]T ](-=5_:E:]C
M1 N5TPT6X@2D&X[&C:(;WB/=@'1#0\PBA0 .T@VUI!MV,5T-QQ[*  VD&Q!
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M5Y-I"Y)60"H!J82&6#P*81>D$FI))9@(*VK#)(R.#>/8V$6Z"6(#M3JI'C9
M)@&9!&02D$E TQN9!'5,"O6F6PDS'ID$9!+JOK0K7\>(%BIG$L:($Y!)( ]6
M3VTFX0R9!&02&F;Q*(1=D$FH)9/00UB!3$*M]RS$!C6#LX@0D$EHH.V,3$*K
M3&]D$EIELR.3T":3'YD$1 OJ=E(]M+ C)F&I0@("A;92"9;:5,)[I!*02FB8
MR:,0>$$JH994@H6X JF$6N]930,'F0%M;C*@BT#A$%OU3H#"JEG(7C"F7[Z6
MBM@X0$^+?[]2/_UW=5])O+'GWJENA.^QR^J8Y-5/\H&-^2H'02'+7H%Y;\T8
MJ ,-JI[U0X.*RF==!811]:2W::E7BUL4'P2]:]34AE46RHUW2/D8",@4!V15
M$$#]'1) XYWS/^?-Y']J#SW'SW!\UI,,JMRDW#]^?,;DU9D8JGP&]PX%GS&!
M5G<7)RH@GJM ;]:+,%)D]A"8(3 [.,=VB-2=VL(S3-UI!DV&J3MM8L<P<Z=-
MGG),W&D1%X9Y.[BP&XZM6H&F7HR?CA-[XA/ZK^M]^^4=_2&?Y/C$CJ"_,_&Z
M(][WDQZ\5HBVKO]T@,DTK46BZ?E_X @19[6S5K.?__D?Q=9/;.?K712F@7M$
MT5(8G?RHL_^]+71KQFD'D\W2'3F:1,3^>F1/Z9M/;/_>?HQ%-T>CKFG]]'82
M1B[]2I?-@H'0Z 8V^DG+?X7A6!G+N?UP5!BQ$FG'[Y(?1:Q)XK,P]A(O#$XB
MXMN)]XW LTM/9=-"8="):70'(!?T3]$KP^I:>YJG7/K8A/3R67EG"QKJQYO+
M,P42AVY MH$Y.J-74Y&*5YBBK5)?GK1UL\$63R9S3#Y WGQ[$9,3^4NQ,S!+
M8H;@^0YOEUQA3"#L- GE!UP<V"<EH2EH%G$-6T#0FB/??@Q3<5-Y^IFO9%::
MD.TCN,T;JEX!E/S6T4L\23,V*&NR'%\_0)4E0HY6-H?)NMY,0M]EPV$,]+>K
M/]\=3\J#LQN).9!+YF BLT<QV;-79T5,-DO"NB4RW.,2L<QNSY![K30YC,6#
M%H>^YVIR&]_SX#PE0]M6U47@A-$BC.R$N'P4)X_\WRLR)1$)'++[!;85?&P:
MS"2R WI/E.] ZP9T[VWD4&$'C<P)@=UN<C46QG,>'P0"I[V;1-KQ]LN#=#XA
MT8IX'G!S_#XQ.!Q9-9)6:7$ #[V!%+?5^@LI5Y(NB9W(6X"I?4@U"3LNRMY+
M98]3,T^)GO@>@&JMY!+B#@^Z58\KE\&E(5N?F*T0IA!L46,ET/,)'[\@[-;*
M:FR=)'(FJZF"6+ C#R."C"%#$7R1" ZWC5G=)9"J0MH<&#DQAD^C&9="\/8I
M367%<SO.KX<($O=%$C@C$;GWDEEY1/?LISCXTMY339%6>O!WQ>_NS\-0C7BI
M,R2UC\7<FP.@&LG82PS(0;#^ 4=FAQ76]@??47Y4C2E35'Q*F!NE1]7H4T6E
MIPB747B44CWJ#T,)S-;9)%8VBVZ7Y4W,AN7/E4<)RYN\KKS)0.GR)J='!A8X
MP0(GJ@9,8H$3=<PEE690C0(GNRB1H5R2WKZG#@N<U'3VZI.$5\$@5)V2]_HN
M*PO-#COM"-<VS;:RQ4\J6.8-1C7U*8Q2R;RW""/5J&A*-:+0^C%0KZ!*!8/0
M)N16FV(KJ! 0 R(&; P&W"4]UT.\A_3<"CTW5)J>>X_T'-)S+8*>2,\U8@;5
MH.>&"/*0GFO-["$T0VB&]%S[X!K2<ZU -4C/(49">@Y-/J3G$+DA/8<* 3$@
M8L#*,> NZ3D+\1[2<ROTW%@M>D[0<A^0E$-2KC4;*I)RC9A!-4BY74Q=FZ =
MDG)UGCT$9 C(D)1K'TA#4JX5J 9).<1(2,JAR8>D'"(W).50(2 &1 Q8.0;<
M)2G71[R'I-P**6?H:K)RF"R'O%R+,"?R<HV8035X.4-'>(?$7&MF#T$9@C(D
MYMH'U)"8:P6L06(.01(2<VCR(3&'R V).50(B $1 U:. 7=)S T0[R$QMTK,
MJ<7+G:9W:9QHIFX,M"^1]\U.B/;%I[(WIY*-5!U2=:W999&J:\0,*D+5(=Y#
MIJXULX<H#5$:,G7M0V[(U+4"U2!3AQ@)F3HT^9"I0^2&3!TJ!,2 B $KQX"[
M9.J&B/>0J5MEZA2CZC9P=*=WR-0A4]<F%(I,72-F4!&F#JDZI.K:L_(0IB%,
M0ZJN?= -J;I6P!JDZA D(56')A]2=8C<D*I#A8 8$#%@Y1APEU3="/%>>ZDZ
MRS)URQCJO5Y?-X^_68-QSS)NR8-UI!A5]X\T(,#7#3&G#IFZ%H-0E9@ZXZ@W
M'"-35V.F#N%>+8FZP;%I'B_%6.'"0Y"&($TED(9$7>46+Q)U[4$U2-0A1D*B
M#DT^).H0N2%1APH!,2!BP,HQX"Z)NC'B/23J5HDZ4RVB;@-'ASEUR-2U"X4B
M4]>(&52#J3,1[R%3UYK90Y2&* V9NO8A-V3J6H%JD*E#C(1,'9I\R-0A<D.F
M#A4"8D#$@)5CP!TR=::.>*^]3-VFZI>&WE.+J1-DG'8Z)X$K2+J("+INVR%V
M2-\A?=?XK5<E^@Y+8M::OC/T;@]18"WY.RR)B=@-L9OJV WYN\I-7N3OV@-K
MD+]#D(3\'9I\R-\A<D/^#A4"8D#$@)5CP%WR=P;BO?;R=YLR[0S]2%$"[_R!
M1(X7DYR_0X8.&;K&;ZXJ,7288(<,7;MPGBH,'6;8(3I#=*8Z.D.&KG*3%QFZ
M]L :9.@0)"%#AR8?,G2(W)"A0X6 &! Q8.48<)<,G8EXK^T,W4CO]7I#ZSCY
M9HT'QLA4\=0Z/*L.";KV8D\DZ!HQ@RH0='A677WYN='QTAG#N.X0FB$T4PF:
M(3U7N<&+]%Q[0 W2<PB1D)Y#DP_I.01N2,^A0D ,B!BP<@RX2WJNAW@/Z;DU
M])QB9]4A/8?T7'NQIVKT7&^\BQRL-IF("M%S>$ =TG.MF3R$9@C-D)YK'UQ#
M>JX5H ;I.81(2,^AR8?T' (WI.=0(2 &1 Q8.0;<)3UG(=Y#>LX<]88ZH^<L
M70=ZSE0M>^Z3'7TE$7)RR,FU9D-5C9/#E+G:<G(FILS5E)/K'QM]).40D"$@
M4QF0(2E7N<6+I%Q[4 V2<HB1D)1#DP]).41N2,JA0D ,B!BP<@RX2U*NCWBO
MO:2<;@WZ8U/7>Z8UZ!TG<U/O6X.A:_"LN;X:O-Q[$CN1MTB\, !Z[BR<S^EO
MUTGH?"W0=3<S$MD+DM*)BSO:1>!TD;FK&W-GZ$C=U0>6(IO7/(3YO*2[/N+$
M6N#$9\QF[]@PCTT=UR<"/@1\R@(^)/TJ-Y:1]&L/($+2#]%5U>BJ%J. )A^2
M?@CFD/1#A8 8$#%@34@_0U\*T4>\UR;2SS*MT<@R^O1WO6\=BT<:NFII>%<D
M3J+42=*(#K5V>A<17BN3=HBXVB?[43-''<W4C3X2?74C^C!%K]8I>OJ1.321
MU*MKBMZ* 8"@KRXY>H/CWK&Q"_JU30L/D1HB-63KVH?>D*UK!:I!M@XQ$K)U
M:/(A6X? #=DZ5 B( 1$#5HX!=\G6F8CWD*T#MFZH'EMW.B=4=EW-#ES&V#%R
M;@-UUQ'<G1T#O_>/-"":B0P>,G@MV7V1P6O$#"*#5]^Y4X+!ZR.#A^@-T9O*
MZ T9O,HM7F3PVH-JD,%#C(0,'II\R. A<$,&#Q4"8D#$@)5CP%TR>#W$>ZUE
M\+*3[WJ]WM!B)]\-C!&<?*<.BR=S[JZ)DT9>XM%7?DEIO^R8%#+O?O8"QT]A
M)K2(W'DQ'2-6E#."A\=OD,1#$J_Q&[!*)![6UD02KUU84!T2;X0GY2& 0P"G
M,H!#$J]RBQ=)O/:@&B3Q$",AB8<F'Y)X"-R0Q$.%@!@0,6#E&'"7))Z%> ])
M/'/4&^J,Q+-T'4@\4Q4.[ZI(R5TQ2B[G[I";0VZN\?LJ<G.-F$$5N#D3J;F:
M4G.078?<'.(RQ&4JXS+DYBJW>)&;:P^J06X.,1)R<VCR(3>'R VY.50(B $1
M U:. 7?)S?41[[66FRN4R#1,!0^T^^A1.8X)*Y%Y&L?T&Y9-MU(6\Q^I_ZB9
M!J^(V='NO62FW<P(''47:A_"-' YMS<-(^T3<6%JM7,W=?BGH@ GL>EH_?=_
M(]]7-[Z/RNO_()BM+^&'%35K3?AA,EYM&;_1L6%A24U$>XCV5$9[R/A5;O,B
MX]<>7(.,'X(D9/S0Y$/&#Y$;,GZH$! #(@:L' /NDO$;(-YK+>-GC'N&V3<&
M SH@?>O8-?I#7>^Y4%%S6 _.C[-[+V?V!%5(;]2,,6,*!TCV(=G7AGT:R;Y&
MS""2??6=.S7(OOZQ,<"5AT /@9ZR0 _)OLIM7B3[VH-KD.Q#D(1D'YI\2/8A
M<D.R#Q4"8D#$@)5CP%V2?4/$>^TE^WCIS;%N6+T^E-[LTT_T 3\_SU0DQ^_\
MP?'3F'9#D\Q?3O5-2')/2*#]:C_Z8:2=A;Y/[@@<M\>X/B_@-.$G._I*(LCX
MB^P%2>G<QAWM(G"Z&><'_)\Q8*S?Z+^1]JLE[8=%/6M,^V%1S[K3?B;R?O7D
M_7J,]\.EAY@/,=]ZS-=[#N8[A.]O5Z!O-S5\K4JM6H1VKX=VY@ZA'>O6*['=
M]2(,XC BA2C,,WH?C,*NL-WG\!N93^@5C85W-01TS]G#&HOHZHCAGM/)1H.X
M&L*VYRVRKFDV$;?5#ZD]IXL-AFHM!6>M@&/- 6#*36US4)BR 96M"*%L:=!D
M2\,DVQH8V<[(IY8&/[8SW+&= 8ZXL!$S(692$S/MBK3:C=NC*7"IB:25.&Y
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M&U@(>';IJ6Q:* PZ,8WN .2"_BEZ95A=:T_SE$L?FY!>/BOO;$$,_7AS>:8
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M&;V:BE2\0L1LE?KRI*W,1G&TC6Z?CP!;3ID4,HD!"?3M14Q.Y"_%[L&\B:?
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M*X94E+96<6S]Q<PU69W5DCK/ KFYKKFETE!7NM,ZND,[JM-&H6I-+#[\@XD
M'_ZY78/G'410);O%6DH?F')Q3*:77N8QV4 ;X@RR<02>BO/$W1=EV1H_SR 0
MM?QQ$S:^5^%J/*6[B-#?46[158L' P<#YUKWO$XGGEL*-6Q?\=JE7E$88A=Z
MZ-^AUW$PZ(NY(32TN TGZ$_ =?@AK^G%/T^E#,=B$!<0Q,<VQ%^3S$U&*(ZX
M(_5!?F)/E=[&*E8FLP)5S02Y!'1'PD*N#!OG2"8ND,=.WF*6P"QQ8I8X%J#
M+/'9X8MCA8O28K/FJ3W/2@A6;K%QUS)HARR!-F:X.,V*<>KH+1/]>XM=7)]=
M?5T4BCVNJQ'&?5PMAW&"<7(7D0D<B'C;8"KEI62^E&_EY69,JJ1CS58U5<Q5
M2VFYT?R_?]#B7S&YKN1;W?MT/[Y(OOT]W??RPN!.-T2LH3>MH5<8]#ZNH7?D
MG.TNXYZ86JBK)CA>,PE;EG=I67Z)^A(?7G>PLF-EOV;OZ#Q+V-6N5-&1/$G7
MX03Y7FRFK5')Z+ PDJ;K;@",_>4+&Y(W:D@>O7OW]E:;FT_0WN*L%L%,L@TI
M EGI!\9>KCIJVN-Q=3V6+2LUEY@^\&LC?KB$_8SJ 1 D#?_AU&T,VNM:-6\^
MF?JW0%M:E9(YL2 7+6VA!FR_(=&E3!V!-KS^DF?Y./?14L&WYQ!'9D9X_.[)
MGEAC]^#+N =7) QLQISXP/Z.!M<ODV"U%T"A66U+ 75U.>13Y()L2RH555\4
MA#@OOG;8!-,#IH<[VX2](GHX\W'[=] #O7 U>VJ!%)$JI>1><F88;'6(Z ':
M2!3!Q$GZ@V?1KMP0:FNNJ^WM#!PUA;XBI=W=\=I3[S%?>JP?RTG=5XB$!_2$
MN4I$VO ]%_Y'':VHFFG+W8)BZM*@U&]FU4*[_O/?;AE].\;?&D#T(WHLE"\D
MM,E?^^D?VX\.1KD_+3,7),*)@<3\ZO\23XI^LJ/3&.-WC7%\,O[<MDD:CG@!
MC9,%>%?TAM2)W(*;N D9M$LS<]XK+[+CI4J%51MI\HU[<N\B='/T=LPW]H2P
MF_8EJZKA*S+O(+CS+EY,U>@LX28VG%6=S\OSC=306CSTV.AH*XHAR+CP:OT0
MS!68*_ ]F;=N3;V+*\!C-C,59=XCN!S1G>M.Q;*G$N**< =,%*FX0-Y+?"=Z
MQ?YEF6]E?WY%FON* >K;VZ8ZD *^,1.K^_W>1'$Z*=R%WW\T92.\J"'F#)X"
M 3/'1:LU-NRQ87]]PL+1@DNE@KQ:>C27:DMURLMUY?FPS ZF4VDDMH<JQ8;W
M-Y!Q@1/B#/.^1%9,,IADKB)AY-+2NB*2^:R$DE=)1E@O,B33]8<RM6A7Q, 5
M[9$C(9)!.24"$:<8_DYB#B_>X8!/[MS_YC.^R.'RA'?./9A724[*C-,.,RGT
MK%1!H-/#=$%H!I#DN%^PI# ;8#; .2O7:/Z\EPT8OL0E%A.M:35KDL$,.T91
M3@T1&_RJR7-[42M\I<--.4]W$>J^HY-)9]GRP<C!R+G[0SMGW3VZVN66V(L\
MX&C#_?L77_HXR^T&$8XX"V4^2W(C;6D03<IB FU*5N9K2:6$,'0@Q"D>^0OO
M2^'$T,;0QA&!RT0$CD!;F>6SPV7*:5G-0KH?/!J=!!,,$;11'  BFXX3K'CO
MD8#K,U+O@?:P^W*[CO^M2 /C!.,$7Y!P\:4SY4RGIC\%J"XHJ@>*[!O8 6#K
MT.R(_>$!$*LX/HB1[)_8*;C11.][N@+A5\I/S+Q4O30?3E6%ZGJ+-,%K_C@K
M_?RW%R\_ 1T4I'PD]4/Y\ $+C+OKB'S_"NYLF5PF3#I7E[.)/$<LZ7*:ZEU?
MV9=(]UZ!'?:4L0> /0#L*6.<7%P8&"?84[[04)N^HULC9V( UXMN!P3S (T5
MV^=?WCZ_O%]\!1.*E?BVE?CR3N8+@[O+VP.CD_<U%PR ZP(T$+B\Q!*Q?[Z^
M29TV%Z8!PBUJ;Z2YP%-'Z4HY2VMIU>)6LJRVV?2@DZO_]DXU_8&=ZJ=1A&MD
M37.K;M/7?& \:I, U(#;1%W]>1.[HKFNVJ.3Z^G22RL6*(NKSBRP);HO0=F?
M70KO2L7Y)"GDQVG+ENJ3AMP<]UE@REPW*4(I0%TAR"-[^#]]$)MI;FR!WA)_
M;X[#5FQF@VJ-RHL*3< !:?;&'YI.<OG;RI/@?EENH9 \*?!'C@LA9#S)B]N3
MU[)'\B0USCG*FNI-5&I.$GSI3:WY_<&_2V?./?AASW,#$?9.H?R2J4IJ)U"+
MRV]_L^]0%,A@$R282 (Q[>E-X>;/?>A.WO."%T17ZL^&&WM1;EN@F[=3JW)E
M/7ZLWXO>O#+PR6(=#*NIE$JL;4'-]!8U=:,@@GF'SFQUQ0R?'NJ)$_@>D@E<
M*F.:'TL#'4S[P(W6:9J,1]^@88?-T<3'8_ 9,Z"CHKP3?"D0CI?<;USQU-LH
MO70F,TZW$VN+$V<SNUN>#*W&\ JW4=Z_?8FQCK%^%['14V-]/>0T9C4KCZSI
MQ %%MI8F*YOE#6+]EN*[W%,F%+*,D3T5OTDW/!K!Q[W/#,5I0W_H] C0KE1!
M46;K;O<V??!?%4%16,T?1;&I*%RYN^%JE=&B.5U^$0=\3VCO<D!ILLP$^86;
M5U+UMJ06$I,*L&_2B_KHR$TU*/JES69"%/N/ JAH>78=0*20['L<J1>=[_,K
MS?M$Q_Z.Z%[Q/MGU+&>Q0C\KIYA<D;47@$@!%+$@'@YK53R)Z7HB$K\EE^H/
M9_FH<&QKL<@U1OF!DAKD'N<+><U5RU X#/N:<+8Z] Z3HJ8F9SVUOTXK7'&1
MR*DRGU]=U>5;J&0'[$X47WAN3T0Z\/88V?6@DU+4+D>LV<QL6MIDVG/EFERD
M[1CW B<_#]1#!7=/$TGYBD[45_25[B#\<6.GK??(/;0ICYS+;-*41X]% QK!
MY08Q[*<-JE"25)I!1ZY9(L[3Q^Q)#&(,XMN-:]S4L>IW8-BOS-:%MC+KR\ I
M;4RERXQRFR7",(?LLCA/"?=^L#J*B4CP?6ATV@1ZN*:1,.V8KLU,7YO@J.Z7
MB>I^VH5_5T5J-V:9_$!J#0(U;Z<BF!XA-RY9"L1NMO9(%&VZ3NDZT74KT$ )
M"_/3 AUG:3I.4QRNS(\A_[7V9VZL/LS[(:^;@T1F6)ZTK01=FG>M8;J6K0\1
MY-$%QSP99WDZ+A(?K!9S[;:+K@?38(+B_U#  U,W?>QG_8:?=>E23[ABW4O5
M6_^X+5.E 7S-M.$S-=>&DO/V@)J.< HI# []O]\21[C,6^:&UJ1!V@1@&;[2
MH3(S#T#S):R&3[-<G*+%.",P!UR&ZU=@]-]^4;O/1O_)K9;?0_]$J,MK(ZA1
M1#,I5%N)C&V.^D.$?F3)4'SHO##DJ^B_B_A,](JH)J_WPLE$[+!=\"HU&M*&
MX03]";ARCCSK/8P7D,(5N7PG-YWVSR#+(<:/<*2=G,K)I)9PB.JF-Y3DI9%*
M6Y C>60A08JD&08Y?#B^@^GB\@&@BTOABNCBY+;6N^A"$VOE=(-W67E>80MV
M_Y'-!8,ZH@NTV<7$"0'Z5-1K='%+L:%+>5%W08 W%\?^DDDVARXB5G>L[G>;
MCG(Z*=Q18. __6>OV.:E]J$I\->1FWS"W-*7HPC]K^0:',@+^PJ_HVO_/+OZ
MW&+8X561W5A,8N^:$LDVWN5R^+-92Y8$=VZUDUJME,LR=(\9JK2((A0,&^=(
M)BZ0Q^I98"K"5'2]5'2+(8T+4M$Y;TQZ+Q4Q[J ^S_H)GC"=(*BP.3[/S>J(
MBE#T@XO3K!BGA&,WI/5_MAS_[6MPEL\PB>/ \\W!>E]O?F**Z#=/.Y;H>N1W
M<L7).ZL#.-WN\[ZV1B"FZ;HSA:]=HZ(QMN,CJ].%']LQ$_[!T U3C%T?G8+R
M1\ #2&_";=<P@6=@VIJMF^%F%_P@O*_BX80#>%FT[Y2C%BJ42HA]8\ "H%*"
MQJ@,J=-J7Z"!RHL\( W2$ <Z7.+^\V\-_C/,Q=__@5^>CJ=-@.8BDAG]]7P^
M:=2M'<40_SH+43R?-HK9L>L33V02=*3O8;?#K__[/_O=/V31+=WMC6L4L0L5
M,M\0)/HNT*R$-H"O_JY-EMK:VXY3$!XH9D>EWY\H$TDBQCX(PK]B/[Y%\C@0
MYE1;)?9$MN79Z'KPZ*]V'X44N?O,\<*4NN\NF&CH@!UZ]K.GAO/B.[/O%/F
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MK!2'G=++.J67M*^?0,'\,BCX!T&\:"7O$X,F%98*B BDZ3NZ=:H:G??LNIZ
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M!+(^/AJEQ-R!N>-NLAIO,^#Y4>RONBXC C.[D9O)8<VU!'TUEU#, @4UD=W
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M4J(O2W-5F58=0+D]3J@6(Y9 Y499(DX0KV5]W7*.IS-XGN:I>>'/IH\X/C8
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M44*<IO!)',Q'UR ,',^]EGCN23GH<:CYG86\](CY4A!DB9/6TV1H#.&LUBM
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M[]IDJ:V][3@%X8%B=NSY_8DED21B[(,@_"OVXULDCP-A3K558D]D6VI-3,#
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M\&$07/!0V^^"Y(4S3!@9UX8,X6#$;Q_ .OQZD,SRA 'J5S% 4@\$>=,8>.W
M'E:#+Z0&I/@F[_W2F=:+$.)K0TUIWBB6@:Z/%QNXSC16G0%T,-D>QB0=^CO0
MHP'>]W,GOEW:F+AP)= W8@EW/OHW'/C['CW6_"\\^AO2_&NW^Y\R#[FWE[Q=
MM=M;,?3.HL37C]1_GJ;4S&7+_)_C!,_GEHZIN<[ ]-^J&Z,T@V2OGTB.Y&(W
M(2Y2[6IQ,4898?39RTIA_&'\71)_I+B//_B3J^2+:RXU(1702PI5;9&@Z-DO
MGX5['_YX?2Y.\FIS0'"U0<"OTP6F.$%YEAS$'QEG*#XN<D</P-V\A_N1I;\!
MX$3J$*S1W:;.(&;O2M_[3OB]COSA -V":L+?/SG#&G:&[]8E./\=L%=!@U<T
MR5C%L8J?0<6?Q[5OSG4-#ZZ@?;B9"TV!:(6"IDE,FSJPNYOP VPO7RW&+E)(
M]1HNL;N3ZZ/V<0>_GP#TC60;TA[\CE7.,09-<R&6"]::=6R*8AE>RDHJCSQ?
M1F#C''.LVA=&,4;QUT3QF=WE7T3Q)#MISYFE[BM!BR-[BZ*9"AI+B&+H/Y,$
M&R>I8_4<[L=WWMH>J9%F#^&SH.\[T$PWMD!WYR$W>:FYKF9#5]G40D! 1Q@[
M"-A!N"6:N_U0?-[67:!Y( VB_^8AP[GF(LQ++_T YFMQ0K4_5JFN8S $J(QU
MFFG7^YW.4A60M8(J*!/OC-%CH&.@?V&@G]F(.0'0>R5G4[?5RES.-F?S;G)>
M9!_G$@0Z,FB$MX!^:S&3L'!7HH_N]XWI>Q?\8D?K!HGHUOCFKJ(@[[\HFTWV
M!GVNZA+48RDSZDWK<\*15!%9$N^Y)AL#$@/R+@!Y9EO@W8"D@32OTJ5RWM*X
MI&@4I861:2) <@B0J RN>/1^E+L+8NR'>F+P_Z%Z))Q!(O! 3/,\X./8!79I
M,*-]MHDQ=2WW^SXXJX.GTR8EY.8TT*BK \4#4HC2(R37Y>IIL??(S^3BD!S-
M:GHC9<["ZFO([!").$&_S^C :,=HQV@_H_UR"K2;J;73'138OI*=C&>-LBCX
M0W6(T!Y&,<@XP[Z&]EN+8KQ^4._'ULQ>6F(HN3!+9&]GYL44Q2_!;;=,8;?&
M5"\F76&=PSIW!8E^M^; "N$+:BZ8::81 ROD[X.(WPT0%IC"KBLV9F\-KG>W
M[;X%J!SA\XCA6LQR\\%PT=2(:JN^*&\"DK#X9=A%Z*;2T' 5#D-Q>*,=0QM#
M^\(;[6]">Z8"JIH9+(I6,:\IE4XP2<C>$'41^:1Q6F#B/,7>Q^9Z9([D4?4<
MX/DQ%^C 7* *[-C0OT'>N35ZN8N@]\M,(^FZ&P!CAZ[&$[@JP'\ML\<N<5TZ
MZS0X*U'/:+*HD]GY?(GN_T"V!1OGZ,/4'HQ7C-<[P^NG6P:_BM?4<AYTE4VK
MIH!R4_94.RET\^%]/6ACGHR+@G#?N_*1%0'%![OL>[&9M@XO<0F/-D8R?8IT
M8 \(>T"8\J[)1 DQ6XL@BXY118!]GH3\,^.US,I@;N=6!#'MS K$JE6N*QT)
M73N&SD3&*8J*,T>* 6'P8_#?$OCO,?SQ3L2_:.PTDQ.W'C2:(T7K2"O!3#0V
MQ60(?6CLB!P=%SG^GF(C82;#T][[&OM9'R&D"U:(O@HAA 1V:2'<Y=9-F'QT
MR&[/$Y!VE+9^C=#2A4>E[X!62TZ-@RK?8V?5RE!"]Z)"6X;DZ3C%';ION*PA
MY@', U=@Z)R.!U1[K=8*2^91";)VMLW[+7<>W8\<IB*R<9(_3$6\J_**%!.^
MH/*>(HG8E3NO*W=ILKB(JW?I0=^EI;1S!2&LT54@-==9F 8PDFO%0['N)Z;\
M<1O(:RS97U)DB2"6CJ61126?&E )*9#0U?!T>.Q<8,4X1Q\6Q,*I+Y@P,&'<
MA$EU6L)(,Y5^OPDV R61G,PV,YV5!K60,*(Z%93 Q"GQL/;6#86,WCS8\=,-
M3'E[ ;SWWL#T):CPEJ/=MQC4_OPIPWJ)]?)-O;S74Q_1O06UP-5':#/!&<1F
M+G*J_768(P'F@3F; MO'-C+>'[TQR-ZH4QR&#6O:&J'.:SF2#B'H@MH6E;6)
M9ON2;<@[8,HK?1(@T:8<V_/=(!PI2B5WAB[PCF5(E/C)B!HN9$"L15!J.?U9
MQD=)Y%$=1N@B0U>9>36>B"D 4P"F@#/O')R3 @PJ8):U[&1II4PQG\X-.<&>
MUQ$%0,^7YIFX*-RTV_N*>:/OR0CM(,RV4L*.Q,V&]/"NZ1V9/T]7SVWI+^.X
M![2F'V>UC6D^#KIP6$1J/393>68Q\J2E2H9E(;DX+XAQ0L0)$QCZ=PW]6SL)
MLP&N8VC>Z 0$D$VL2X_#5"]+I,1U56R ?C[MUA$!<)$FD-1?]WW<A3J>)F$^
MA?5QF@3>]<2[GK=I$KVPZ_FT9_>^74\I:_0-E3)*<K57Y+O69D+5BDO8WS!-
M@HBNZV5>393'A($) Q/&55A/GT 8VL L5K0JV52:[+CF46NI:*TE1!CW$2SZ
M:(Y$QK0U6\<Y$G@O^JKVHK'.89W#^0^_N$& 0@K V!*\Z7D!9/CM=L%TZB!5
M=70+&\!X _268'M7!2)V$,U A.:W *T.4B$\PQO8CEBN WJ5;3N@6E. W%Q,
M^RTE*Z2@JTM%&P*DP,4)\GTW9&.<8YQCG)\YXO\+$&?K);TY2:9K5GM1G_=J
MHCVCZ1#BOQKROQT[!:R JYM16D-HH,2<&1H?SF6X13K"K'->Z^(]K!.R3#4"
MD;Q%EW&$=4"OET^+/ITA4G0N76^WJ#%%#54J+(/Y-NM@5&)4W@4JSQR__A5H
M:LU"Y9&O%CM$<]G,-S>;3H.@ZPB:J.(E'^<9YJY3 -XR%)::ZVHVOLH#.SF8
MV*XBF-&. +GCM&-Y3=6.Q0>]24ZPUH4A7ZE7$BS%0TYCHJK;1)P@<$5+#' ,
M\*NT7-X!<'&\S%57@F]:T](2=!=SS53L$.#0:.%9(<[3AUOL-QC%^#D_<;;-
M3(CUU['!T[;ZZSF*7X*J[CF!Z-[RA.[*,GDA9>@IY^59RM#/-$98TR5EC^MY
MN3C,^%Z#X7*^(JD4NSV 0;]_OP6C'*/\"Z/\,HF![T-Y(T5NVL3:GA)!IU40
MJ(+32V:&".706!%(+L[PA]G#)PVQO*1$ET@=1+:,L2WNB8Y:(+L&NU[8];HE
MU^OVCT8@-D/_T)GX!>0K&UH?P/-=4_>!@7XAV<;S#_9:UJ"\'./G2KU/I^KA
M-R/-'H*&Y@-Y, #ZJS<ND:!+CH!>]10P[*ACONMJV1)DQ[ *)47%69:,LZ_?
M0X!) Y,&)HWS6T'70QJ%1,\>SZE>16Y[B_S:2_;5R3(D#52)DH\+#!7GQ8_6
M^+ZJ&-!%/*;;Y+WKI[=+';O_U$'B4I187V])7W]YD#>;]+ [G(<J58;[">#'
M^AS3_%@?P(8VVE)P!C%_!&*S<-'&EC8^R'QR2_S2@[Y<Z%+RU.I@WTI/YPK]
MH"^!AM+6$F.ZN9":P_1ON?;'\KQH6755I;61BTVM;S']E=D/ZBH55K%DZ+A(
MP']'REAB\&/P8_"?"_S_S]Z7-2>N+.N^WXC['Q1]SKZQ=H3Q$C/TVKLCF,%F
M!AGC%T)(!0B$A#4P^-??S"I)B,E3&X/=G#B[EXT+J2HKAR^S,K,2O66@>ML1
MA$4W]QA,S]I+/7-;5SY:^#/E3'\XN>E/^<?1K3U=RL7*Z&Z!P@_^<BQX%8_$
MX']OO-K\W*#-RTT)#N$> I]O(9Y+=X+?46-AD&A9M_'F^)/HL?\]T@GK"=9U
M+JHJQ/>(G)LV@M64Q(?DPNV4?QAW;XJI#U95L:16+A=K\3HO5I78O?EPEZY.
M *?0II2AX%4X&KH*)T*7I(B+N%[$]?1N1<)>=>1,3B_G[%[=X*5@YD:-#U%<
M8Z]T*RBR^-O"&\S/1L3.9!HBI7(O(05)))0,]?AXG/0B<3':2_"PR\E@.!@-
M]B.)8"0*+_A;=+\!^U*-\Y-Y+6$U)K7;2+FI6.ULO=K 4Z+MD?%E9_Z0C+17
MPK2O%<0'(1N?QE*]T.Y(\_8N7QF&^=*D]9!+Y%,YH_E %KWP[D@YURVFY%J_
M)1"#'S[52X+6OQW"R)UYQL,3.9O.!6YRA7*V'VV7[\/M6*,7Z?';(\.5^2JM
M*OG1Y#&>KLSNN[61^;#H17='WMW<)21;2G:$@O78B<[O&FWE!D?NS+-NR?-5
MLS8-YTCW+J,,FV:B41S"R)UY"JGN_''<2M7X6['46"S:N7GH<=&+[;Z]%UUF
M!]VDEN<#M:9IIIZ4W.-- T;NO/W!'#^DVZUH?5(3\@_SHCTLM%=#&+GS]D"A
M4UN.4T59*/0>VX' L+"H=H>]^.[;]7PVEBD^+BN34+O<+\:24KJ\7,#(G;=K
MPXDA13KAL)"!)Q>L5D"]-_"9[MNI2'K^'U.LX/NIXLPD/]T?_#R/I50CAKJG
MXC) E9/FZ=F 2@:67_$&J(*DG[@JG/\72HIEN&]UGA9D$O1!KH>LS/<\7X=G
M#E1]X0JD^WL ;<S/OD'$26 !1/AGIIL*JK"?!E%%2YF3K6<ZMH>^V!TJ]L&_
MM2VRM=!CJQG?0/CC:^$%K,7[]ZAXZK(1G[01+YT@73;BLS;BA5.NRT9<5-.?
MM1$7U70N&W%131^Z$:\/F)\X.]\7L9  KA/C5:1)O($TYQV42^P_!-O]=V,Q
MX/_@"O_[(_KCO0N+78>21U_92[O[W)E)7C?8RJT183]TB6B8[,><)I.M<Y*O
M<$9TF)MW"/ ]V/M--'CCDC],"$YX'OR[0I(E$IGVB2,IX>"5JRPNDG'FDO&;
MBC_T7IX/AJ[YTR9^_"[/XVG@5SDBO^SR^W<YF'Q1C7V9Q-=GE]JR9S.5X/5I
MHLJ9THC(MDJ[?VFZ%J 9(_NZ;1R\Q.*2'_=%R]#.:?6?7:_VHO-W6GI<9.$/
M7OV7EH5S!_];K3"YTH'K/#C1I+\K%AI*;D (9H]P ]NR#>(SD%\!%9Y/)M87
M3;3ZOGE4G].(86I,C)]57<.TJKV]^U-FQI.U/"%YW<A30?-ZSNQ)QJHG:M7J
M7)L($R597D[C@2=;O6_T:#NI<"1ZR9F\2.HWEM2/OVCC*$):U":51+^9B_/B
M@%]H:7V9?ERBD/XA=VX[**-))'VHT8,^!!J4=0+Z(&";!("&2; R0Y,YE?:)
M4A61"3GKSZW!^_49P=T'O,&&B$.#4 _>W M +F[(%W5#]BK"+^M8?$LLXZ:(
M-W%QM8%@DA0*<*UOB8J&??+<YBZ@'VNNV)91:LNN7._K\4ONB_',;=F>Q)*3
M!SZ5';2>AIAQB]=N!Z^"P<A5^-+&^R+\%^$_]3UD'ROWK5YL>&=HE?O)BMBA
M@M8*F>4H9L5_QPO*. HCO4M&:'6J2DS3NX)$OH13OIAZNFBAS[V7S.^DN7<&
MU ;.)0)F:@J&PMI7$E_/M07A3LX(A=NF(L;Z8DMI-WKQRXUD%U'\,T3Q2-TB
MWRF/G7;03,YFN>ZD%;]5N]-T)U@24R"/8/;_S/+1%\ZCVB/"B9*D3^&U*XR#
M:+H%SQ<-^%CC%/C"T!!5;B8:EM/<PB3(#C3_1+0 63A'-ICR8,$'-'AR?8;U
MKZ(<'X0'X6A/%L5(+Q*-#GK]OM3OD7!0Y,-2-!R5@T[-(DO ]N652RH1#93\
MD3,=KS8<IW6,Q/*#VQ:*^. ?(TH^$-O.'O^__V<C+7['UW'RAGSK<M+Q0U1A
M#4F 9=V+ WCU3U%=B"O366<B<1V*N"E)/[W<(Z0$%[U.)/[%K7]$>NP0$ZLZ
M?23;*.QDW]HL[70^>R'UW]D72Y_]# 6O$1=/X5>WR"!R'3G21FV!\O!Z6X#Q
M1@9JS/]IUS+[4B/?^TKV*SX(M!GH474CM]+YR,= 2%D4=5J)"T*<T6E)K>D)
MB>BO/CC$]IN;MF\W/H:@.XE5+VBP2JIYFVMR[6*NF:KGA'8ITW*R9TO5S+5/
M U1K[5P+MJ)6;=7*I6RJG<OF2]54-5-*E5MM^+62J[9;7N'R:59#)\FFWZYQ
M_KERWF2Y]6P_4,^^::;>O5*N"JK1'8 YMC(PP6XNU6QQV5PF5TGGFEY2,X=8
MG4M5LQS+"H2Y,XM<M:<P)^E#(/_6G1LBGJ34!D[D  R7@Q7ZO?DP%ZI7\S.-
M5VZCM]%X=\D'&@!V"*"*&3S",FQR/*X^3$MD 4:RX,]#::;55%MHYKA:GJO5
M@>_;)6"4XX"&L6U:RF"U)7.B,2$&!^ !<"^Q 1Z;5UQ)DZZO.)'+@DI8(("0
M=&.F,ZIS?V%;+#3.(?Z?#$,;]+?@/YQNN']8$.>S?U]Q"H 03E(5C4)O@!9#
MPBG3J:WI 5U#*S9<<0YLX<P900"B/"& 433:@DLF<Z+J,YID0CMVZ=,IPD@<
M)KKG19H.@[@V)Q%5#?1%#)2P=UAT90IAQT>*!@.IFN-F9&8I,G$&SP$Z*1J,
MPA06?*L%5I,EML#31P0P+LX4E\!-*3T1*CE/92F\ECV%[RJ:#(,H?UXC63D?
MC8+Q?TRN8JN6TDZE G2M Y 5-FO.(M)(8^0 DK%IZ8P$)E&)1&=-EO PTUNT
M%B :;"8A!I&OV RVGVO"$T2+,]CYVA-QYBF:I@XT1-P'.%P9$@TV'EPA:40A
M(QMD :L0"_Z JYPH.$GZ.7LNS,4@IHE;98UT0)/.<+IN^-5]/SY/)MB]'5YF
MZ;ZI3)$6,W7K=3AF!DZ]+1&N;^BB3-D"A'A*IQIP%L#R;E<;5.86H@E;X/(K
M<H$&TC(791%_"B:3(;H6@VP/\G@=?JY)EMX'J<"&?,SN_+VAW<X&$!]+YU*?
MK:P\VHH,4\B[?@' #9F"A90F%W38=_A (H;6AK>F55V:>!HY*"B5G#3HJH)R
MDQ]W 5\.%GR*N9^*9A,Y93TSKH?#@N>DOT,']??:EH.)SY90?U]QA5JI6L /
M,KEFE9K)2JJ:*E!+S]7+J0]5\3X0J5B@FJ1G <"N%=A>]9[*GQ<0ZH]?*1/U
MD5O[Q+D(X8IJ+U<V1Z+3;G%OWT7XOC@#L5\JH&N)NN)<1G_'=/[W]*WO M$W
M-M,"F=JZ(B-E943#0%_^3E1! MP@28R)617^V"L/[V;J7:GTF"/I05%NMN9/
MI<@0.^-=[[NG_=T4Y8 W57C&?INVKH'@P!Q(J$0E0N^:ATV?LS"#8J*FG1GP
M)V4FJK#!N.,2+-= "\(4/K/P/DM('4<P0(:H4$,#"@&9G%DD0()(8OP<#!%X
M.!+C+1]BN.9:MB2!E1K8*D49*G$A@[5G(7ZL 3,:&N*4FO@K#BT58TS&U**%
MIUHN0("Q X4U2-(]?.H8OAG19#I,<W-CX24:+@I(P6X[@>5,=6RSCF@%'@\?
MX9\QY\7)<P&3*-)U<#,=73Z%XA# ;I;Y#\ #:2/E%C[Q%@UTI@O!K^(#73I+
ML"H:]T%\8.CV$&^3)2Y,8R+J_N*C"H \>IP'!!_:X##JQHJ)+? L$D+7",)
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M89M)'7#4 @HUV4PI.*:21A^9%-*VVZ[)6E.>VN)-X?74"CJXBI,N<:"K]WZ
MRD2%:-1R^Q]MZ529TZ>N4TNIK)BNT#O\Z!.@3=X$>\96 P;=D-$4&<!A. ]X
M-4P Y@2R-')D90#BH(.<(M+9E%!L68L._! @JR-;ZWT()__90 F>?A4Q[#+4
M*6AB;MJF@%&C1;<6I@?.O,FD'#=:!!&:SMC&4-JB&J \CF\ ); P= I:$*OY
M'LEDW+9@,D],\XIS45$I<=?2:^JV@>)IZ@ 64,WC\10(E6T80#;5VU9/BR*8
MV*])USN#'$:GR3*,KAQFHQ]1]8X'$;@BF )N[.;K\=L:BP/0PQ!/[WA@3F16
M8G/G-W8; T>N@G@Q9'7-I8DD8FZS T0U].%U&[9?,2?L+;;FF"&FKM;QFH5B
MC5X?&7NE!7+W$K0)/@X(P()!_OU%8M+X,6-M'TDWT9([0^1Z/&]4F&6A/R+X
MMXBC>!7CY35LBCQPJNU(J[[F60K(Z4DRTQC.K8+KG=)MBQHI?,.6.+NF;YO
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M<$#IPJ/F!'MFE/&_\(>9;;FM\@9X3Q0[?Z>;]O-;=[\()2_U ;]1'\#X)\B
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MPN[G-$Q=&/=N@_U!<5+(5T+=R+AH)1N?J&&R":DF&XEV65@1V>";I6 PN&J
MAL'(?OA/".S'=H7++Q S@]#673"FK5NBRG'<)SCMIX?RWS'VOZ,_#JSZ^&O_
M%A;V8R-4I[8S7X18%]C_KAN(CFI$P^E4L3N)ADJY4%=I-F./4:/WA'>0 $R/
M7 5CK[\=]:)?+OKEY/KE]+0Z(_4"F#];O.G;_11I"ATQ, ZWYJG6,/N) ?)N
M=-CFZS>+A# -IY;C^KVMU$HI4"^ T:/O >EGB\77$=6?>(.C/;55&D&5"<!P
M2:&I%]\B4/Z%"QM^'T3_B;;LVYFL#]O>\P>T.VOG_OIBB#:UUJ59GRJ%G]G]
MMV"%4E,=MNV)?G[00NTQ3KVG>*M>*N93DT!;#:[N^&KQ?C#L)1'[1I/[4T/_
M?=$*%ZWPQ6'H9RN%C\>A1U0*L\1J.0L^3L2<&&S>S0N#L&G=+T I8$H'O[^J
MY-_?+*[,7I'9O/2<<R\I_][!XS/R9\\1()\1>;Z%&;T$BBZ!Z--'BCX>MON-
M1PD-,#4=A\)$LV1O9286_%"PXW=Q)3%[FF2$!=Y:C6G85_$WY(M<M,M%NYQ<
MNYR>5F>D7-X%_Y^(H<NB.?H]O:*HXX#]5"@:@ECN2W=#]4:SDU2O)!A'!$/_
M?*OX,\OS&"A+(G.B:1++O.(TLK=KYY=#YI? \Q]FO3[ 2(5!\<JZC1?5GX.5
MVMO^[0/ ZPF6>48&YA/3**ID7\SHMIB:)Z72DYJ;1@>=8#W7S)KC5"\81/@:
MY-_4^/$BZ!=!/X@C_VPY_\1\AOURGLIF#(G/]UH"D>[[XVRW,^K=-E#. 4Y&
M@J^J]_O;$F'[?NVT)/CPW1K;IJ4,5GX&V1)6]A?/1PG-7MWB_A,F2V4*Y^2P
MEC_.SY'EC&@FP8WFK!'AL-V<R1%-!MCKWBK(A8-7'!H'VEL2N8=;B"8GSF:&
MOJ3E;>J*^]\/9MB7FFQ4Y30A?#@#=JHFSH;E5BI=+6[R;_0-_.LGBL>O,5\7
MO<?@))'+=&>:<-L?==-WRWDK5&W\^ 4(>(=1.=A%%6F ]#HR84"4?82!WPRA
M=+N*9=2@0![2B9HX#X3"L\;Q"-,.=J.!Z /LB;C0=?$I4+QK24,D3/ @8:XX
M\#5G1,(;K]75-1/L[<XB])9HWUW8D@J\B;I^],^FO(61KX]Q&?;!&M!0Q#55
MGE3E \'0]AW7__?_;-SEO1,5<0R/;V'.'>(A:H.&),"N"A<'\.Z?HKH05Z:S
MT$3B.A1QC=I/SW@A*;CH=2+Q+V[](Q)DAYI3<1GPT<RQ> &5#*R?[%ON1]18
MN9^]<%^YLS&6/OL9"EYC5<44?G5O1H]<1XZT4UO:+KS>E_^(W,A N?F?=BVS
M[U*2][Z2_8H/ K8%85(W+JYU/O)Q$%(6XPIHM+!0.(,R36N^'6L@_O+QSR&^
MW]RT?;L!8H3J0M%LIN&IQ>WW%JT6WTG-\TV^EKUMBF*D7R^210^'!H\A,"_;
MH9+&W=@:H9;EBAH?;((F:BN.RAH8($6S=$YT2JK10HD<S,(>@#:Q#6!-#GZB
M)A8/58LZO!%52YLL1?.:@\?#XC3"E.Y"L4;T'?L?L/G^$5@W19-L R<AZ:9E
M<C/;,&V -AS."!3[T""TA(L]6.3F8#+1A.J@9TU8_Q4L M9-B''%]6U%E:DM
M(##,LD55Q1F;%OS 37795D6#PUW6#%V?XJL/+O2:8X&-CS8J[W$#WV)%7A-L
M]!N5V8*?W@_S]1!/C*:>X1\>M'@I]>-7[#IQV-HJ)I@5"34BLLY&[(ZC(<K@
M/[CHO4?Q'/R*+- 7 <!*A#-'A%CP9934'1QTS7%M&"L!N[ L"1R%WW:WB;XM
M_H^Y^3I=<EA*9IOJ/=?#5GXFA*40$&E8"DQ?0H=G "Z/174'/@D&293Q;X!3
M1&.%3X'YX6-@VJ8MC2A*FZG@#CFB!$([Q\YU6U^"Y639C+8>!>S)N!^(J",&
M@ =Y@D2Y6K=1 F!<GZQI#V\E, H6MLG$&SW*_P9I4?<VP6!+8$DG\#3XF$'3
MO;T47,K3;=Y]+OWI^E1(^X * GX#C0[[XZDO:R1:&YL/SI2V9A3\BPG4!;H\
MPOY8K-/$KM[T=-8G0?.(#YK'>F'^ ^\G"HF*.4K>"I-I.Q!LJU4[/1+>KW[J
MXHJR5EM/2? F@U1$:03:V5CMS6'R:Z)JU99ZXVI3$E8].=U(%5O-ASC@_M!U
MZ+ F@MUQ!(>^#O<0N #4# J7ZK\%#"V&!.^!+0=10E%'C\Q0Z'2OJ9JY;-]O
M;)^EB@]BV0B,!3*4(M-$>QB>W2U>V#Z%FG_5=@S)QK5M5(RWK0MJ+/A2G^!.
M>W4*KO+Z<^[ZHB3/"M%9?F).JL)M_28<RA3J(:,%)!^ -6/QA6U?ST4U*7 X
MD!H(D YHMN, GS7W\].F-K@1;5'(3/M2)CJ:AZ>5X;LY=V_5_V'8$YTL^$[V
M0<M,"MU\*5T-ZXFG"0TRA)_A5NV0(65N 1H0?;_A67O>?I?A=WJ?'@K+;),%
MY(;4@*GH_"B53,#M5EK5I<D/UV=1R]WV?;'2D<%S&=Y&5I5,<&([&PB3)7+*
M>F:<X]L ;I#$&;P<<!CY,$_'[^O1F[\/HX!JK9WCXC^Y<B[5RK5.A47:A_TK
M#=ZX=FC0SZ*04S=FNH& <T1$V<$=YJZG=<4M1@KP%*!A^#[#FES*'L(8%Z6X
M\DW-F0)RJHBJOU$6J,YG6(Z):,)AL6!/O:]V ZU'29K8@U:C'NR%*[UJZBWZ
M;!_[M6$BM0$ZY2A@/IDL-R6C/;(&M<DJTD_?A*3.H]  =0;.^WYMQH#>*_54
M;89_-7OWB]+B?G)7OIW$.O5^/#1N/^2PT^]>V4OX9"_AB5XR.M7Z9JN7$D2S
M8H[+8V56:&T$_OA=(H'VVB(2MB/_"6L!TU$;- &&+D35F>5V()_29]4=WS16
M+?M.4/I\/?>D+>-F!>FST'=UUJNW&=3QPHY$IZ,9X3M6?#PJ1^]KM=9O;[.S
M(-QMWQJ6MVJPW2X$FSG;;':G-_>%^]S8,5D!W.2=/3;8<P"H4\I<<WF*!PR4
MH)D#5V#/9<=W<9F>LKMHD",C]-?2\HU6C;(&7:A+2\N!9GNM64R-#O*UDAZ;
MM!X>ENE!7NH/57#BH]>Q@];L%5  X)9JZC2"#)17,)SFZBQSA+1%!]G==/>
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MZ"E65VK 2)?R!^J G\V5_ZSF&6UZ_(JA><3ZICV%O\*733R,A2E;U!@ \&(
MD4+;/M9'[?.SMD-F/ZD5.E8% SU$:TDC(MLJJ0TH'L6X;TJ3Z0%,:3WG)@MC
MM/7M.@>TH+O%#D]2MS@7[<3MI-88APIZL1(:M19'*E_XI.XFM$.+AQ]9 Q[
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M@M$>B_[&D)<JP3\GO^6/2&L[9Q8X,[3QI\O#.1'C]/E>!]3%I1KP6T4WUM6
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MNDRV47J#O_MDXV<2>;N4T.)%@NY)F5&<G_* @./7C2-.]N(#S-Z^ !L#VP5
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M(1L%:)+EOP:L%_YPH&O/MX_?20"-&9J  B,(R?]:#,L]#1JVM:!@+,N9+[Q
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MH.1#+-3U0E"\K7&B+]CMPQBO.T>2C1>F,A6DG9U)D>$<,QP8$WA_.FXP#^H
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M.MZL%7 ^UV/I1U#J+'ES*F48A!AH@3%&?8R1Y7[0(CI@=;^Z#=5,<&UA_(2
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MP!AG-:%$JS)R1.JN,/ +C$'GQL!>7^V4=(VHL: ^JZW,4D<6:AX&'I*7/L?
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M,45GCFJG2)F6 ZT=#EL(!F,M-,5&)Q1M006>1/T'!K4ZU"]DHPNH521'X;G
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M-T(;]JIEMC:-K/W0=L^/ORK;>$@+ X-A:3F?4%WN8>)D RXEZC>=(#X<?D6
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M )&.:RIWG[LK=+,#3TA,M,H-T!2:[@P@9R;*WCQF.'2DRL6=?KEFVA9INC,
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MTQRHM939RQ?N!I.81;P6$FHQB0/=U#KMD.K,]O3\5SSLZ.&<%.$)2M T<RD
M%UQV]BC<P+N\Z&Q]5/-VS<S<FI?S"%2;14YD<K:-G'6>R0=B?<FPRU4M$KE)
M*D)A;MTV\J90R_=Y,.P,CM$25W0BO.9RD3MW%Q/7?>3\\E-QL7<EZN6[+_R\
MWN8:A4YA/C59.;\0/+ZUQ$(#P1Z3BB9WT['A[9?0F)Q4?'@(8W*=+]M5I^YV
M"UX\GDX,IH5>1"7&A&SB)=-,:$PN<1_O8D++8QB34K$M+F--84)WJ]+D9A!C
MU5JL@X7&!ZE+OS'@##?WCA]PKGF!<BP71=S91:3 CK6?=\2BJR?G!!P'*8$D
MT#9?&>.*@W1[C]W79O'Y<)09Y7FAOKB;W49:O=%HB8<+020;>WL(>7:R\;D;
M?:?,\=\R8"0"P$E3UW9T9#@O)XZ+O)(TT\U5N^!>IS/WGC2B:;:#)T"V -/A
M%N"E:/^/R\)IQH#O5/_/QG_"H-K@Q5IA5F@ID;N^,>^Q$B)V .(_-O6.8YS?
MV1"D3YOY+^70YA_:@1WUSR)MR#NC <=[CB27FG-AF1L3YH<XCHFRZ1  [TRV
M#7U&P&#CU,PR<<1C&O_Y&:",7_BI\Y/;-WRL"F.@"B73'6GH1'4A)@_#'C3=
M=WPF^:+]L3-;^DL,AW(P'L5P@;*M&?*'L]?X7:_D^VFAD*W1$;%U+UW3"95-
M0>P3"ZZWA;6;0B49*LE#[/N<V=)?8JSP5B79266FR?'4XO@>76HUET[1FZ[&
M6$FFCZ D3R]T^(\C ./^7E.AZ>K0I7@ /L5QG")[VY-_XOGZOVP"<!9:O-$9
M_IK!<MT<E8K3$)\@6[24$70N4/A*[AC$",N5,X%?)J8F42!1\)N.!!MD"D>O
ME. X\(CK(,SXT!+^KQ@"1+M!55^_U79ON(_M'DS9CXY,F_QNPR<5&13TAE8S
MA+$!*<>D1BCX7H$>R ,6<ES+B%)%\E[31NO:37;0/GCI/9*N@D?6[Z!TH -N
MHIL6BFB*BC0OXDP$(V*83O"T#4T$Q8"WNS-X JV ^H9_['/DX=Z O2G!A3=;
M!,,E2G$VGDL>B4@?(<M7V3'FBL(.UA69-M8B5YA(%J*6^!_#!*7U,$XRR/4L
MHM0-4#-GZL .WL-D8'%$T7*AL8+K:R.8".YZA@Q!P^.@!!M^V02=R*\.&*6:
M)B600Q>V_^IU+^MEFPG>>CF>Z]AY9G*;N3T>LF)3HFM9T*GF49BPPE*P" J.
M_ZOM0J>@>I %LULHP,^P! YH9!<X#=[O:@Y>;9PB5&101C"X8)#VE3]\T+F8
M3T#? N,#PTG0C;]$LF7J%&:%S9(K!IFF <+@C]Y#@A7]0C$[*YW0,JB&8(D3
MBDVM&1A3+\==%[H4)SK4$M@,. -T+&9$O%P@)2"#(#RYUFTE'V$RL%JPN+HB
M1BF>K'*@:/RN$#%_1&3\"_\V6:*@7H!->$H3EO"'M2W*ZW4$XZB8$@46"0;I
M+^R2TM!8L36? Q0R/JP^ J[<#%T7)$0M!'C>M<D+X35;8Q U5R*RK9OP+[GA
M B^ ;VSJI_(W;F"!]L(M\&LU15<<(7 _\"2[R'=&F&3LY_1OHMV@606+% @2
M=8T6R'"QD$A$%)A,.GF%919\ WA>HG[BYGC=6?J?RG6._,7\\S>14RQC@;"!
MU &I\=4;!00+C"U^*?3ORSL>W98@7\'(8>B$'F1JE(/$B8$-/(@;B*@_9-OT
M)7 .@@42AXFMXZ25KZ?A+WB=XU$@B5A!*KJ.)! WT)UK+2,%-(!Q;]$A_5/]
M^PH& "/0!16_7S<E(M&!OC=]NQ%4X",%^7S?!YIJIFU3EJL]6AI_VN3WYY_R
MGW#)$0I@&J!=^FJ7@C 14; L/%GL#&T&@Q&ZP""*B+P0N 2S.H5U!N%3XBCC
MQF/0UJ3 !3:9,DP?TWV&]1EP%U!F)BC2ECX.&/NGLL#+,<&&,F DS.+@=077
M]HF6U C/$+ PL#V*[NJ$78'_)&(?2O"++PV!RB6Q4.H?FY)=3=MW3V&C#I^*
MLP2CQ"IZ(L#+8'UAX8%7*--XSJ3;ONK$[I7HNZR"[V5^MJOWP3SB10WC16U-
M?&%L0:A8<G><6SUMYA/1D.R02;TU*2LIB]__A7_6O8H:" *."B;_/+9D,=QK
M$!/0]%\'B0Q%A-7:F@)L?!T.;&*!8H1EML9-_OWWO[;'OQOW! 'NUL0F"$>@
MO]@G9$M$TYMD0(0$J8^_<LR93X69,$:1$=@*-2+(,.!?PL)4I( XZ724C:\#
M[E\TIE,PV)$I>?"_B:-KO_\?4$L#!!0    ( .N%:5(-8ED\!!\  !H@   8
M    ;7)K<BTR,#(P,3(S,7@Q,&LP,#$N:G!GG7AW.-Q-&^[J(40B"((EB+)*
M=-$V$6Q$$%WT\B)ZM.A6"9(E1&_)BA*"[*[>:_1-]+):B-ZB6Q9K]\C[GN_[
MSG>N\\<YYYE_YKIFKIG[?GXS]]S/CSA)_ 6X_D1=0QU 0@H D%PV '$&\ AP
MA9*2BI+B"A45%37U%1I:1CK:JU=I61ENTC-RL $Y.=C8V;EX1?FY[@CSL+,+
MR H*WQ.7DI("\M]7DI-0%)64DOBS" DU-37M55H6.CH6"6YV;HG_YR"V 6Y<
M 5B1%)"1W &0WB ANT%"[ 0 +W%2D/P=@/\9)*1DY!245%>H::Y>3JB^#B E
M(2,C)2>CH" GOQP-N1P'D-^@8. 6?TAY4]>&ZHXGHT1X8NX5'I7R=B:]X3U>
M25NO"&H:YELLK&Q\=_D%!(6DI&5DY>[+/U)54X<\UGBB;V!H9&SRW-3N+WL'
MQQ=.SMX^OJ_\_ ,"(U]'1<>\>0M+2DY)34O/R,S*RR_X7%CTI;BDHK*JNJ:V
MKK[A6T=G5W=/;Q]Z9'1L? (S.36]L+BTO+*ZMKZQN7]P>(0]/L&=GOWA10(@
M(_E7_!]YW;CD14I.3D9.]8<7":G?GPDWR"FXQ2D9'NI2V7C>O",1?H51)3&W
MO)V:1U)OC\G6:YB&F5=J@6__#[6_F?W?$8OX_V+V;V+_X34-H"4CN?QX9#<
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M\[5:$)F4H=_C_MKWF0GK3<:,WU4#Y6&!@P<Q8^U[#<9A'Y=OO[NK=R1IAI*
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M&G>"Y>5WZMYWOUOUZM:YYWMSU_AK[;UKC=I+QIAK[C_S?WX"7J@JJB@"T)X
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M<&Y:^%A"/1U$Y2'04"UHO3[HMQL7S^*B<4,J+549\,9/X_LX\Q=MINW[WN0
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M4^H'1RH;S+<WT7+]&8^YAMI=,SS%.)5%4Q;(;;\7+U]DW&'%O*SO+XU\'U_
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MFF:<NC"-\L^/Y"7BWGL&R"FI(.]<99J^)'BAY.A5YU_$+$Y"S_V.3:^2<N;
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M[=[UZ\CU_1B=#6-<98468RDLK+C9)HG=V*&.'0D_>L8*C[W5C W1<E=)7))
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MFM.Z#)&&X2$FI_\8U\( ^GFI?[ED\C+TL[LHZL.6P1<AWZHEN73?'#J[U&V
MSVWZ90SZ.R"K<NAT\$^!-9-3!^$T2>$-TS3&D%H!UQB5H^ 0U2L97.1!.HV@
M>=OO0NJX>N&^;X,:.&O8>]MZR6)J&<8^(@[Y!=D;U [1B<K%'VU21"L9YZ2&
MYA/2N";DPF%0;24==7?QZ^XA)T.G8 %!R<;> W?.I#-)X,;>:YGT*K[CL\I]
MX/0)L5-ZP3;('L/L/?%V46,.]-=M3FRMNE"R4S+T]%JG4>(X2FPYQ<!>*DH;
M_IYUL&QMY?W*C!.\]B8HUR1^S>Z<PN^#D]L5!W!K.&2I] HB>1822?4P:B"$
MG9VAH"?-?&IVV,B<DZ-0:1?Q9A+13CC?V? '8%?!4D[XT _]$!I7J177H8*+
M(MT^G;'_\ERI5Z*:;E?F")(2-$:A[L+L1[@L^>X'WTOO2J_%'ROTR0(.G^.5
MO]$+0&^U'PJH_P">$]R)J(009N.NCU&AI.F^*0Y/MA/P5^V!^G+]4X:Z#6"'
M&41HYPPH3FCM#9 D/;J>?,I.Q+-3^&+$S\0URK*PFVATA6GSZ:<!6&S9EY)R
M\A9)#!IUJ5</4T.NR8<MVB6F@QKG#!::'F8I,-JCU)(!<<7)+H8QT@,ZWI-$
M\#9O.852,/W6YO@<R5X(&M_JWI0K#5%9? C'8>>&I;@C:(3.X#6V24R 7G1
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MJ[#^_M_]1^7_;_Q9^'\ 4$L#!!0    ( .N%:5*^A^E6[3H  /T]   8
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MOELV'Z$IB"W"0=)?I@W*;ZQIC.47,1]Y+18JMPIB.CI"[U4_I6AVSAVN%56
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M=$]8I%S-XU?S=G\W\]"-M"JQ7\3P(U'8'A^65NLL+.S7'$?T" 568S57K-4
M72QK9=LT.TQ7-"("0X922MEZQ#A5U^MWCQ/OM>+>*(OIJ>9CM.D(U:._LMW>
M%&O3L'SS=67<C;3T,R!QI^).1X,AR9T\X* RZI8L6%\_W=R6_G,,,80G&NMV
M_L:.SW),/3NY+>F15S23>I[$\F!W2/"V<S<#GNE'YF,I;GW4WZ)$];LPHN3+
M)XD/OECYA=#0'9ZHLJVYN9^B*(:O^P5W#;W8R-0U-C<C?[MW>KA+CNAIIO&"
MCPL,X]6D"/>_JDD1 /XWD(;M M!K9]L^/99[L@H?S-,<",]B3P ^X8LV(*;[
M([$)#2@>N5E;*AT\#,W08@VY:-V-++3W9+;E-39T&)2'#\Y%0&7U+^%KF'CL
MBV&V'W#F[C0<K;BY)+J%L6KY1I/8SH=;Z1,&:4JKJV/4'(^;0KY@M<_7]8!P
M;:X#IX32VF$NX%)7[Z*;@"6':\9YY>UXW.G+PF[/I+W:D5*C0>!2FF?ZRL^
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M5S/E+N=.+QVNC>6M<:H=A$WNKN"37"QD2RWJL,H;SS(U6BB+M;^K-X472NF
M+.")G ZH/<NX94B2HL5+_Y$W,:$\N_8"=X\: T/-2VF9AQH <EF!+][S93M#
M'=6-+UOGS,?VG\D4OFYPRQQN8%V*D,5!98\580 I\56]@1<HRG=6*3[WMKY^
MJQC:VRM<W.$GYGCS_DYI?@AT7\X;B@'$XB%'Z-H9G;!.\D:YZUP?[L^P+SD2
M%I#M.TV)T.JANV[[9[PU#GM^T#IRH/'-%]J[LBL')UD8QG,[]^@[J[+^2_8:
M&12'3+=FL8RJ"+N-SN?QI3O:ME,RLT=%'_W:=\B=^&<'AHMBFV^S]A53,?4R
M"PN\/8"'=SGS%^7O[RD5]TW((_B>^5QEVFMZB0.#?(G]8&><E5H;H19T*WR0
MG;7-Q/U4<G%O[B[AUZ'1)GN_R=>#-P@FR#];^O+'-E;>*K!V>\1IQSEEOY!Q
MV=Y2]$+2?KC^?&;\81R] %5IO3PO0N;4A_G-:Z^L[X@[9 U+L+\E\[C+M)%+
M^F)XK#E\:JLT5\,Z8*NO9:,?&O")>F%/YSJE3J7(7.]B=97TJ/GF=W_"S&UI
MNH05N&19Y=.U"_S56=>E4E/-:.+Y9W6DD^J3SJ<@C"LB=,_D7Q2 N@FBM?-3
M)3;3.[*FEU>I5QFE5T,I)$PCZY8/$.QVR;VA/?R$-:4"T$?;D9W-Z]QN[7 ]
MS4M9[M.'$TT?%I2TFJY=X<K7"F AP(7XVR=2]+O4SWQ]&:E@^=WQZ_7'LP?6
MB=+O5&ST%*R0(A,N7%,&'CDH\1JXYNU'_FGQ1YG[T3+-@IU4>:3G]F>.-#C*
M2^1XC3VL(Z^:"];M0)]DV9M^ES)/= AZ,/"Z;9-#NZ:\(O+>QD%UD=_4>Q.I
MK3Q!-&.3RY1NC<KXJ$]VK^_6N'BH(U3!\DB(@.=.=??WZH1/;-;P]):LIJFY
M6UZE;6RFQ0R3:F5)9"57+&*1MR]$*@(>D;+2#6ZXD!#HPRM.J;W;G;("GIKG
MLKWOEY8@KJ_EYK4WS0VCETXY=-:6G<ZVA)Q?3]((;3#LEG@FURBA*R2Z4_,V
ML -^?TS2NL.E]D7<\]O+BSK7(LJZ[U>$?33=RBL@V*]4O$CTKN+CK=@PG_V#
MEOG];OL(31(SEZ=!8G$&?;0I_BE!;'Y_U*9(E7 OH\>UBR#<6S;.QJN)!A:P
M,JO^L$&H^6Z'$%2V8!J*LY]F<5%D_L5%Y!F)\9@CPL6Z)L].I&@"<J+T.(BT
M!-9I],QM7B/-GSDX-?.A\'E)L3QU79VQLZ-<WALN'LSHAKXU)AYQ,_SJ-$<Q
MO+=)':7H*^Y5LIO$BYN+N=W9,C&1EH#S3+A!^2>&[HOC<BX]G/=YZ"H) ZB.
M@@(4SUFT/48TI0UY9A]P!/<=66SK7W&\PV!L?\9;%>'P]L ! RR<2D7LYB@2
M>TOUF_6]NAM)=YI=<:;);@%-NGGVDZ"\N0X%HH'@\-T9W#!!Y2<]0>O<?/0<
M2J_E/3)&%"]3C5TU#B%)0>$E=S)WE4B7)+U:]2 N]$\UB@\0(-7SZB.E!/VF
MX/S2+0HO_]+,)%9Z1X>D_II\>LH'916Z+QYSSKRAM&HM\JOS?)3DE*YET$XV
M<,O^ZU5#AS$<CIWTU6AD5\&CCDM:NK6$*+X 6CQ&%[&:/D>Q3IUM$5=]J!+B
M78V-RKI2WR#W6VIIZ98,A=$!1/>(A+ \65%.8P.^EMD%[<6I&@K!<;[N57+(
M.LYYG$\E-[+#!!FDIFTB&J8,Q-F"8;<71:\#?/3<N&D-D+#\S1U.=HF7AHJE
MQJ2'A:80EI[NC*J>QP4S:E4E0<[BT=ID-T['Y[C9*Q7-^-YB[$-Q>W#=9WVA
M7=1#:SW@;*,PH-%]N>9#[+>RAW6/+T0(BECNZ8@F>9T2<WJ(AY#:NRA=?V:'
M7"0OH22ZL*STJ:"QP8M7?E#B-[W?94AN6FS67FCQFC%\$="B6*Z%'S;\(4P:
MSRGN6;/HI<U;\0\9"C*7Y3+CS6G5V/ ]E@V^VJ19]KN1BI1$G?\"[G@0 ,N2
ME?4K::XI"UM&&1/;S)G+?5[6.E_%!!GH'V:VY'O?1=@^(?!,$>@%SJF7==O"
M0Z4""YO[.3[R%#R>R?-RJ0W8L9;I]O+AZ693FJ-G!+*0_$:6KHP[XV>D?;L]
MOQ;:HI82G)'WD.8Q[@[W4'+]X7<!HIN'_>9/A.72]KUT^D94*K;N1PJJ%B?.
M=]?$B%S[3)M1&=J!7QZY_N7\:;NL[) I?9RQA&(OQF^.,OZ.BG,R??)6SX9*
MBG2E-_.?Y8_YQ"K6;#]BNN)Z VV2O+F6[(P!B,8^O.5+_0+9X.(PZ!3K+CZH
M'A&YW4]T,P312(:.-EGZW']XDWZL6C7YLG^X&#5Y2+<G95[NPWTY173[1DWT
MIQO>A?-+'NB2)YN&T(T7;>@-M$E5NH0$<3(^+D#R.;FJL*3V>8.;'1T" [A*
MX*E+:D37M\@Q7"K0^6HZ)7))LX39[":5F=UC /HFU: '^M&;-O7@U<OWL>U.
MRQ'2:)<U'HOAQZ5RYLQ1I(_+1RY)$@=[J8PNTOC,*K> ,]U&A4/>=;Y\)\^W
M4.ICUQ:,;ES,=$:>^/L4LHF^\B-#.5W_^@M?9@O5A=A;AX]7W5QXJ+J90YX(
MS0@'K:[M<'(HN5C7B Z[*I<\" ^X[*FFM&\N7A;],%#FHPS9G+:QDE@6,MRU
MLH\T_*UB0!X_["Q*-'%K',]KX-LGN2S1FEJ:^0*7=4+K2KJM):2,73YY@X=#
MH0TZM;NFP&A=V]'=_'Z,$^^BALT5(2YC%9G#WNSL/0LZ[:\HME T] P&2%\G
M-!/5\BU_CU+I6N,_1W-GF9^;.=6._;3"^'X^4C""-4:PEY&U3IT*4"T--NI6
M%UDST^2*,4_41JDB5"45BZN:?.C<;_#018ALJG%Y*WI-&^)8J8X-\I?C'=@%
M$Q@:ZZ\D4G5]CTZ+E/GH9AK13'ZUK[^PV$O,HG\SWK[JOH3DJ*=)$I]&UID8
M?<73O0 &\+=.P0 ##72PNA [ZP7:EG&ZLSB01P:UJ@;OATDBD%F/AUVRGO)&
M!S?>RD*27XT33>!O=&I[B"MWOM%6Z2%!LDCV<5E830)<<#^; )D1V'DL((P!
M)O@EA^2\=1_2RQ>;8@!ZG5WK/*[F@QGK*BUSBPZEUB>E28^[N2(STM='*#HN
M./D)CSUS):AAUD$4.C+(3(ZY?JV/B\DQSZ<L"W_[(>:>^':7D<9X^DQ%">2L
M%66<:+PP(\^I#C7C)VL$)6YEE0RQ6;+,-86EY>&2N#)4)@0SJBT9.N(6-B9E
M+SDWI**R3\TLRG1P:Q"?@]Q9^JAEI8.G&6E5%CM<#JU^X/WB4T;HJ,;\BS'#
M>QOA*H2CT'C-0JFI/ HR9[A<L428C7T13KE7+SS9DD>*S"Y#YX,X.N^!.-%.
MMDMT[O.LH=$22PS @)@_2DGI@\[2.J"G<JR>2!*0"5LSDAN'>08UHW?;.=_-
M&1+Z?L\)A7E.=,=/1D,V/O)/2S%JHDL677740Q-J5V+"ZJOGJHO/).6S&77G
MVMB:53SMIIH/FYM5PWE]%(?HTS3;6O$(#"819;5((Q$G_<Y!J]K?D3Y-+]EB
MT,?U.)> Z*RTF.];9_Z5;4L*2@&',7GSL[$7CMNH<1X>,O31=SQ)&^M@*>_)
M2W\-HVTF0BVE:ELFOR6EW+@1Q+:[/SWQ<67]8SN5R8TQZX_[]Z60YZ96YV&J
M^I4+PU8/MCF#3\E06I<'/PQ\EV7#MRPBRDN?4*S$)L3(=R9R7R5!_6J7)(60
MW8LX\HZ2J2T;R<6\SM<YH]-%U0*;W-*E"*.2OH15KF1Y?X9;!T43&>2+9AH/
M.P/YK-N&O1)XNBUU<ZKO1BI3-X]^$'=PJ_A>*52QF=1(M5N>E\@IVH5>'?59
M,3V8SM*VZD=3[K_):L^.><JF^*5)IK7N>TW$</<9:0U:BPBJV)3+=>0Z>^+=
MN]0:NF.BX],25.>N&[] +?6IPZX(WO(X%YI#4K:INUHZ4AUS+U-;^KK0?.)H
M;]SI=,L4;ZE>_*/7U>U+:5FSD4V>O3K78O$6A75\*A^\*M$W!9XLL+%T%5?%
M%[F()MEPUBTR29[Q=1Y[6%),^=$\>J&RI.P9RBE;/I<@B/;=485K!.'D_$Y^
M2+4R03 G_QUZKL^&U^\?V;XVUIM$+NNG?P_)L+HB,1=U:67*N[7!=%%%>[$_
MSEM4'33F-:=2/F*H;*R*0$T)S:N1=[.)Q)NNL5,)),L/^MQ&QB3G"1%OVP8R
MR-\\-'=$4VU29&\*N^XQ7<@Y:_Y=-0YIG42Z2-GS9JUX1#L=VKQY"G;[PZ%/
M6DR26<3XM;)FX9146]%H@SY.B5:D< ;@3:>',X!B(WZRH;;9V7YLW0?] ,:
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MSY><S;*RX8\>*P?ADY<$/R,S <.$WTU)UO1V"IR;DFQ.DA:%1$$WY<!HX?=
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MVI$R#+#=7UH[1?X,[<D/V0@"5UV1<Q#-)C<2G5>F("D,@/94_DD+WP;VF8,
MM<-WTOD8DH\*L5/5CL1.;/?#5[^N'RSK&OZB\)>49 -8D'-[J)W4G^3Z)U",
MX/HM#OI=&*Q3,G70Q"N06?S2D2,6V!NV'-O.@\NMJH,!?M*@B1;F/'6[[/4H
M37E7(^?@P36[1KG[:;N7U:(:]5^0N9(M[<:T2!>K*#_ GDLQXB2+4OIU-N4?
MN7CD1Q'T !$'Z+"Q8H_9Q/P\<\-6LR"8;D\O<0LN:W0[2$P.7*Z'=; G<"R
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M](VA;4^0]);A>MF\5#SWWLAV/@8XXNE!N[/,R1V_,0=YJVZE+I%#7XN\6O/
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MJH!:[D .YK]HB7N7!RXO>H;;39D@3C[WP70?=ON/? ?NB%KFP6WY<"!J&Y+
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M\L< ^]+<&. 3UGN>8H"CF:T\PWT)1NA6'S9ZJW ?+%EW(@7SUDR_*GTY0<$
MZ9"-,$,8; =$O3\-SD,>./'@[D C=<C$*Y!3G -]\<SZ.CH*]EG,YQ@#=)?
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M%27:J?-)CIH&7K&%CDK>O6]2'TA-+;( ;D'B-O//*D6?NW*T6K=XEWXJE6Z
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MU?KOQ=?#,^K@@B!4"Z?I$2\2=?."NZ!D[/"'?NK(/21QMYTEMWYFCT;ARMH
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M93, A,2)@?+]!?CEA8**AHZ!B74-&P<7*5!Z X"*@H:&BHZ&@8&.CN1Z(OD
M=$(,(CJN>YC$D,=8]'9 [I<1[ZXQW"_\1*+:M\7(8VSO@XU#2D9.0<ETBYF%
ME8V7CU] 4$A8\H&4M(RLG+R:NH:FEK:.KLD34S-S"TLK!T<G9Q=7-W=?/_^
MP%=!L,BHU]$QL7'Q":EIZ1F96=GO/Q05EY26E5=45C4V-;>TMK5W="+Z!P:'
MAD>^CL[,SLTO+"Y]6U[9WMG=VS\X/#H^N8H+!8"&\NOK3^,B1,:%BHZ.AHYU
M%1<*JLN5 "$Z!AT7)M$]"-9C.V)Z[I?7@/<CWA5^PF;@4=TB,;;OPR%EY)UA
MVKX*[7MD_UQ@/O^ER'X&]K>X1@%X:"C(R4,C!( !AR<LJ=XX_[^F-%X 1$X*
MP %\K8IBD9X:ARO%! 24J$(D?GO :0%(A;$@2011@0%454-*(O5^E?+6967)
M1.V3.^J3^%-MBA2,U"A>,V]2&(\4 /A]#/@:R32# 719TI%,&.L5!A'O$N3?
M!J2QU&DD'!6D104)#"#DWT"J*B@)BDW C@5MF_GHNA56DSW4&C2-X=+5TW,9
MW>+Z2@4JN8&G<K)XN'8M^G1?%*+A*;MR"6V]I:^<0 2Z*Y@:.,:8TB;>UX46
M/\X?I<U8;.(7&W0^P?\80<C^=BY/F;W6-UYWR3J!Q]!EFZ!U.>,;*VV\/<9$
M+P:%%H.Y0U);A#K'F89USADX'&JM/Z:,B3Z,2T6*[ML_]%[-N<(A;6"'I>OY
M*#AX+Y%!"I&WR4<5'%N%];G"56_IN+#;7>M>GFN4XM9YB$N"7VZA["?U#Z1"
MHF$8"L$T?<72U@20;<VHC&7(BH +IB"C02?.6;.G\* -;ALEV:M\Q5K_/NZ7
MB46W&J<>[K^3VF!F=*P$/E$#!XOE='DQ6Y<7=IFF6T9UX ]T588\O??IQ).U
M5;2[R8:A7P!' &?W3L!)UXZ5>YCOA_$.OI9J:MX0[:AQA[U\GI:JC5*;.;WT
ML@%.3?+T]E#3FX]HX_)(,!<Z)1/3'+[A]555B$%;.&RW5CCN8VOK*U.RA=M_
M%04MZ0<V*6II5@R;!9R<+)KNZ/ATL#Y[#F63][6L7A/@]3!;ZTO820X4SCO?
MA#E9/+-E3N"-;DPKI)-@SG#//OO C(5E'%51F4:?X [5G78\7<U3GC4=MW1@
M*2J%4Y&$(<9IDQ.9J'S=DUXF/#S1H-$9%>.<&805O;OIV^4JXU^CEJMWE(K]
M;'/#K'2WDULT/9]M1JZ3(XKU:_)]WU5I!T.];37#NC(]*GS^65GSV$._UF:B
M"K$6LR.HYD#ZD5;NA)SG\T-63E+-\!BCZM[^ \Z.P!*MPK5 X!.M$%?SQDFZ
M;=JP!)^C_!V:2T"#3AA8%]'+MV[>9,AV"?!ST:L4N"M"#%SC;G86.A-66=8S
MPW$9V-?OE269OQ ?=J(XT\!\:9M-(XX*6W2RR6(6VQ%CXQ"K49BQ)=9K&(X5
MKO5OU^\J393V\.T6+ZF-6E L=)A(JHYHH0 F%EE_J3&85513W29RM;X/Y6@_
MWTO+QJH0'R0,?OI>A#8Q0EHFSPTS:R:9_,CJ6BFNHO.2BN/C.*6Y$_.$V+:J
MNE+;F2Y^RXS([IW[>#Y8#,=0MGKS_!#]+_NY,&[V+C[<9EKFWB%%]Q5L6EZP
MF;J9CA*6ZG7VM*KM@Y>/L[NRQL>+E $8GT+F4KYY[+]_;J(JHY; _AHA?O/(
M0Z_^E"2Q/QXNL1V-]4W19%G+3J!9[#YX?35>1^_-+>F1M]=1NEGF319EWBW"
M%IR27XG3]A9(94R,4<AVTTG>I&T.B\Y)/_)5'%H3'S,5=/7NF/@$@HQ&A<2\
M<[1:C&(8JLB!PPS)RBH]G*M?5_$C5.D;SJ^MJHO368<R^\[6(PIH>2->!]';
M9&5/S[Y7LWDGQ.A^RT$A0MN+*$GNC.OQ;81H)*^\ E>'J(81R1%49=@DZ"F?
MF^,<K0*OVW$]/9N;Y\R40B*G%$N+*V'A-NI1TP7A)>!([H[ (Y"(A\M!EXLS
M6>^9.+3H*-"@HC9F;?&6Q8@_6H'#"KL<8N'K>+3(ACL9\(EQS:'Z]E!0_K)
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MDA/9U.@R>J/>1:]\TI1KND#IZ\&':/5)OYV[1X8R9W0?43TN ?(++[385L#
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M"? KE[T$)&>D71!-,%QXQ=18H_5"7GYC0?L*G>% @)>6+7Z*%% V[ $?N>,
M#M1FNV[N5>D2-Y]8MQ,^([M58R<Q+DCBWB4S1C=WY.]646.2QD0RL+?ERC+L
M&WT@5DDN'$#MP\VZCY%UYMYT,7VA(;AL&&(PV,.7(X(!A#R\)P5$-A+_:809
MZ7UC4&],3R&[S("^Z(1/9U.[[B:C'AX72'ZQ95:\0&Z \ZW00N>=@UM!EP#Q
MK8O[^5^_?M5ME2JQR/8ZX-)_=LQU.+:;0Z;VF2"@@,;T"9W7EBAL>TNH9\AJ
M1[=-0Y^Y&,[7G<].16[*+8F.2[?2Z7LKW9I*:Z)JE)YJTU2&;[[*J8_T0(!2
M8WV]ZW3W]K,OGX_-JN)K;-RLLV]KD8:_PK499SHNOMA@_Z:9/:N[XC2G7(Q;
MHMM(1MYP3PG6C2#Y2E(CFY7X(46+(,<U2[]"861OE;SLWI!,K"TT@T=Q^_H[
MH(KH%E;E7<R&*#;7<];TUH@)*G8CP8<VL[M::=$49RM:4A&RIGA9A=24TX'!
M!7RX(F_<9F&X?E0O PPN =G+>E&K/,C"]-EC3N9OF0GCB9#_HLD_][$D\%RC
M1"ZIXIZDMJX<??M!(4_!A+%WA+[_5.B=O-27E(B)9QD0YIA=?RJ[I(KTJ#;$
M9VN*XM*@3([ J5N#6*LPP)IA)\)24XYCUL4PI!T;%$HT,MJYLJ,GQ7 =Q10=
M-O^LQB GL,RG1R%,(<C=EQ/H)9ARA#A0O;V^9N*IYMR/*^</"F,AZ2XL614"
M['(8/ZIWL4>#.<9H%OOMVLQZ)B,_P3/L>5R']CEP.'Q*=\I:@Z$4)[,)%WSU
MI:5QAMJ,+D'M4B\*9D=2",>RKU7HHXR@(!(39@E"\V_VBZ[F6) Z"TH4HP9>
M8, 06\-!8<6\0\.$K;%<>!'4;X9!NK=YLH J?]UMH.>NF\M3MB8=V+"&@@)N
MFL,0*;V8&)< _]P"#IN94%5,;Y\B&7+T<'9A6]3<(OG@;&&=+Y\RR@E#N%J%
M%ZMQ6"H()7$^$4DG.TECN#*W:8\:$7UKKW>+0SE..'Q3G7U[?71V5BJ,<2$^
M#%  ."K_H+UBR-F;T+DHY-/.#2D>[\52JL,=[&0EO.Y;>^>,3K?M; >4Z#[
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M-91C&40LWVJ?*UC6(CP.A4D*?'%C@N'"LVW1 JUMAZ6]X!&R% 6N;L3:'2>
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M"X\(:K2DTLWG^[I1+1DB(YVY-],*K6<RTSSM9L5BR2([,^1&6VL+W8?]7W
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M5;M3*2?.1GX: 8E^W"4;<<G?M"5/H^Y%5Y%9N!^Q<Y]%=TL9#D@F7$:C8 K
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M SY3U,/ZC9LD&,!19Z)D89TJL7#B>CPJ0'RS-6]%3\$/<[%_CC827XUAC2=
M])F)=[?W^CW$<8V3UYO:BK74G>K#T=+![(IUO$K3LO*:4K7=YZ;<Z58!5[T5
MFUU23#A1%54!J197JNDYU$A7C,X^+ RG;)OE41[?5$=2M01 49"%%+D,EQWF
MQ.?DV&&+AI;'#/ZL N+K3"])>R626*7*9C?@E E0 SE[Q)A]-&$^:G)^=5-J
M%EJ"=98V5UO91;Y+'#%E_( !7/$C%L\V6<H_H+:4BA,>E\@S7]=HPT!V1M^
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M'DTZPODI@/GZPN+JVUCL8N8%53RB3N:HU/-?*\9?:\)SWW*4 0P52$#3\PU
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MB&.X,MNQ\."0+":9UO_N<#?%00)BPV6VXY$ 3JA]UH$&/,H6"3#.O-#$JMU
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MC%$O:EP5W!G^$]U*+/O.L*I=BS3@;1,?ERPSQ1Z"MGY:5X6$>S'.;9(K9'U
M]-FI$B>'@BQC!5=>LO??C!>C+*3$2E-_ _4/Z6L?_5056=[<X>$TGC.Y2.81
M[)/ _.[0!P%81T3TM8 L?>ZH["*ZR+[9@1A]PM("C<1*W_VAI_C_JL=RBQ/T
M'TG4N>(@_RU"SOYSA/Q6N!?^ 5[>J&%;K)"=5%?[=F5>U+0.7O3EJ:I*/.=/
M%YL-22XD@"DC&=5"8!T+EQG0DZ/:"PW4EKP4_2)E]%,Z8^R*^A%G7'&:HW3B
M1MJCC5)Y'FN3B@FA&745\,+NGAPD6G%#CXT@8P5N7_89G\X+(7^I,88$Y)I*
MV<4TH IZ -M-02^CKVX)/Q_8$?E.IJ7@EHZF0-Y"1+)U)G*F1G>:GO-SL)S;
MD8Q+N=&M-K/,SDZ$M8>Y*:LN%4@>#UXP,)GN(?/\RE+2XM:#$;L_$@'2.DS
MR35K*E(C6&N4=LTY3)RMHPWT/<WO;DNG>T[>V[.";3FT%C?W*N;TI0&Y%<C&
M^:F X$23@31/14T0FMMZ8R=&DAN97](#15>7D2;:*..-#9L2!E)[4GUO4W6E
MI^X"#VZ+,#.G#&3J3+CC@%G&V(*V!E83^&C-\:VIL;[Y:69-BN5XG.B),42
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M-X& Q?Q<1AA9G]GOK@4Z;&<>K_R1(%H*Z)>-Z+];!-IM<D/X._P9B.R?I<L
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M63]X%99!%]B;,OLR)SE2ZI;V>C1CXX5YS$;37+?6G'=W=W7[:YHR3W6!9S/
M$+?G<<\J)0X&9RD0L_.V9Q2]\I\T"]AJ[&JBLV=L=2F^1GI+GEM@#Q<!5-!+
M[8"5]@O'O8.(*Z>#[)WI,_A1Y:\':[AD;.G7+TW7V0_:FR>=7O$"THQ3WV?2
MWN[I!(I_*=[PBF>YK"GD=8S5>FGD/O>5"ST.RW#K37\9<)!+YFJWN154:9__
MCB"6/F3FU^WE:A&BQ7Y22NW3N2?'JK@)[W'\FXI4H8RZ V5+GTJK14_QM##B
MWF/PQK,S0YAE5&<H4I:C>)HB0 HO97+YIJKW+]:L?STJ='/#NRI7X0]C;\63
MF39\=9LE30X7*L7HRC%U\;/6E.!=$G"[1C7QFV%%5GGQM%/AX>M44R0@XP]6
M&*PFFJ&)F=>PA26E*I#+47N[-&5L5;_J5"E:TEKL<C)M-N>*, :"R"+/MN=N
M%^M:*H4%8V^O<LO@D@GE[S; '/P0/@9(P((#@LQ/^0SO\9<<FV%]6XAFWVH)
M1**"2?,6]/,*V-+HW,^,1@,F":G9?&D $6><UZEQ&:_7^,]LWW!$H4C[C>J3
M]#3/J[!7+?)*G+>I,&AILE%[M^<_DJ+7U:D2K4@ZL/0GL%A\W4ST_@>#"/73
M&KQ5KS\HLT!4\%OFL4<YQ=]&D<XG,6 OR#FX?P'3#HHE]]AT_GB![^>^;2+S
M/VOZ>F#2#8%\Z*>%/.C>^=ISS*C+O,:0Z&0C;ISR/"U<)'&]]VKR\5M9V K8
MZ.IA$Q(@B>JY;YY@PY7^+19LZ1?CC"B*__ZY3??;/R<KQT>,XCO8LR3DV#X
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M@5$EDTPD#Z+FJ_K-#Z2ZF<P6DD=<^9(4X@/Q5B(12D)3^M0+UTTZCOK[$S6
M1QG,&M\Y*A-D44@P9"J.#/%LJC$J<'D2K%?13'1V>JV)?36(^V9//A^/V97:
M+W:6ZR7A>T?6,14%_<LOG<X,NX_^&@4_SM"/BXQYOGJ0"&5HCY;I6V&KA4O<
M_F76&V)XWTS@\.,R<L+J(XOJ_; %51KP=1;K$3 MA$6ZD^Y1:Q-8W_T[S[(!
MVBE(85IK:."E'%1Q:D6HO5;.-"I6?0A16X1D^3B"9DHD80ISU,A_33:W8G'O
MLEY;N4@X\EH@V8OWS-F@A@$$4SB%V_6!@%*_[M=B3A>,KQ2]+71L,"_6:HP-
M#>TL<4?%%\@XA=.T?,NRL2")4-OS5ZZ2(J)]]7"CBX%O9;/R:Z2ZFNVC)I!Q
ML;*(AZXK*1Q\ZYQ"_1J M>^B A>%\NA<A$%I4+?YUUC1F(2/Y_:+8>FJ]KGS
MJ$(Y[G)%:K6/2#98<AX%1J92B<P\JFW27(&#BTW1\.72"YH5<CD16 Y9G,3(
M(N2,5TS*D"V5[;MR(.?\!T$Y%CH)B<,$.^42^6'K$C+FMN7](DG7M"2]7IYW
MLKHE9]0J^7_(Y5_GZL(#BH2Y/$Q+K&]K7K'4%-'N"-/&S/)@63X-\VPQZ(>+
MT)&Z1WW5?N$G8PQ@!'M)SF_P3G:Q=K]T"I7J3 6OA#_Q=9A.E'2=U]*([!/X
MT";[@,37P,0CQ<KXP#IX$9*T+++P)6I.^S: O,9K+"9?NIO'H/UQ<=FK[ZDA
MMR^-!&"MV&FBWC<KURIMJ<DH&(%W\( -,8XCCWL;B(M=Y7A >"MH<:@N$J(T
MQ9^_)IB<$L25-G%\U\O%1M3VD-!ANZUX\\"R3F@+=SB&Z+D)&\ZI7*^LUM;-
M:$H7>%EGN+;/OO%G%[7#-R: ].K8.^);ZP:?,T<(*P$"D>4*N/!=?4.>,MV:
MM]J6<ICAP#(Y3,RS5.R'*\DFNK+6V,NNT=VI!YG1>@X>/LL6]#C,RS[D+>J+
M@:O[!OJHIIUE+>%IQP/Z<R*<7>C;@Q2UI8N0SS[6I*DQ;)\>-\93183YUZH(
M=W*/,]YT PX+AM86SR?&Y(E,2]?HFT^,#-N\S9\,OQ@"(*;6B58IJ2SP/10N
M(;+W+.?C&-;WUJ-N%%ER^GXFF @%NPRQX_X@XPP3Y[I<P<Q/+$KR.3>.DE[&
MT=ZR_'( 2P*;\<Q:M3U.&)D7GJ,W"H$+O\L6XKL90TL=>./I6]^Q4AOL/4<)
MW>\>))%$914*UZMNOK@+&2(:)ZMV?/6!]'G;//I.6+J75>;.2O1.($_3,'WJ
MV4C #CVK)%?,VEFM>^-6_?EO!&[9\G2IS>8S'8?8QCU.9%X>MF%)+/XQ'85=
M]*[?N$+;,&\5OSD=V 67U,HIVDJWSS06E6B_<) 7G7#)L+K!6U#L)38=;E96
M'=T.D5MS6AXH=5 RR1H>?& IU"P_51N9_N%![1MND<@;V,WG2T+ZLATZG8YI
M2O?YK5C,0S_"U<E_\*^JM%#@%ANCNELSCCX@&K6*2G21C'<KT7D9Q1FMGC;3
MU;+QU"(['+V27.]AC_I>\J%V&$7*?*8VP-1,)FWJ-XA8RX55%==FE[3*G,MI
M=V6GR!JXY(E(WWQ;&1^7^IC[9EN1,^7#R3T*CF-"!(_S/#XIE>=7N<H ;?D*
M74SIU7T+FUP&FZRA$Y.,JVT>G]>0I>08*ZDKNX+SM .MOL4)ITZJXP$TB3&]
M1_++*];@3W>BC,^\A:L:Z5L]B6-"[K01MH)0S-$:J!FV_.ZX,*[K< (::EBX
MKA*9->X5-F9L)G9!1X!X8F(BO-,&,[^OUE&//)>U>$$XE+\S89"L[DN8NP>J
M</VL&!X DZ@[?E9[ #K#E[;U^Q15;4Y78QU4O9JBMO,2;$_^YG$![<DLX-J'
M1WB E MTE_#3SC" S<+F),Z-=56&$S+GLZ!-C LA(Z%<3\<#WOGQ[6_6$$(>
MDCU4^:RVX!Y2OKS:DG[F!:QP5OM32GF&?9"U_H?$N"(DEHT?VI7PF\N>O/'Q
MJT[(&/@=H#S\RX-,W=0>%85]VQ(R,-0='&IWD<CRNQG-&N_]_.N#? ?8OWM:
M/Q$W//8]W]1^AO-L 88^VRA1;"+(U&SHCM^3]0^6O06>'>/_X-5TS"MIMX7
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M1NE(5Y67^G)7W&O?;S(5?E[K F _</K&8(YF;&)^-OT*PJS<#S6$$J1YX]G
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M>$/M^[?=(J#U(*.C.)ZW#U^$MR>Z75)Q (E_=IP,2.E=D2DZ^K*@=Z:WL!6
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MX6:\$YH(8EBTS&Q[@Q_Z+U!+ P04    " #KA6E2I-JECD0S  !06   &
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M@WO4$<=B;A[UIFNZG8X$9C+=;%TSH'OSHS$@U0U\RTEGW2,IL\>].:7"4I%
M;/9>UV]0K:\BU<%S+D>#3CP>G-UTG%D<PADEX2=VR_+&-@*2O'PTZ("CL0U$
M_91PBOQGZ#+Q>U/\.M(^%J*GZ78Z@3W_]-?9[8%_5]?X5%.[[ED'6;; :?J9
MJGNS IE#:?W3]GD]71IQ3W82EV*WXNAXIR5BB".W.YQ%OZ] Z/ >F_ZLVWQV
M8UI\#5&)!"H458UA>PN009'92?VO 4*L/*A:UX*10 G*IIZ$@J.&?T^5W_I[
MIOV>6N;9SX>7;/;KOR.:RF%U5-X8I4C 6\WABGEH5DA%3OO+@WZE"+:W+C'*
M:2[W%=-B&].ZQ(DA K^R;4K7D(#:;I0K-V@+ZA./V76&"50V.+3>5PXC10+:
M;F_1&,XT<6<3I5R@K91=E4M-IZ<3);8-CS1?XEN3QK=6#GB1PDI\'1<T8(ZW
MM -'EZ*\>K<#+P^W&+M^D>6?6=!I(T+S&2,JD<.>ZQK\7I7 QI)]L7[JS6?]
M3WHV4>G;C'Z-V&RJ4Q;U\3HMU1S/''.B? '6ADI7),!@#D$"N2CJ]')A=V+T
M>Q* !!IDR(%!J4(WZ(\[&7C=,J$,CH6:">66N_>24"MV/.BTK*@JO/7^4XM.
MH)'O7/4882C"Q1=\4H@4WO+.CS"(_*]M@BSPQA:3OTV;Y$0C")C!,Z6)I\7@
MW5(79GO!*-84)/#ROMS>,M//<KMSF?J/"8D:(0H6.]R=_$W*[#]#RC]R*')_
MU5=:3O!S1CK<O?$8)(#U-FYC2&'IPY#(VPK*-N(>: T#(WR'Z+1P,7' -^1H
MY!&W'5WUD4+M^WK0:4D-HZK]+IWWM;_J)4+G(S'T1*M,><<GC:2J;RF56[+(
MAZQ3Z;\B@:*#KNUJYSZ4=L^A;D&[D,:=!5%'DE8ZUB6W3=?<D2+H& @TBAK5
MVN&^X _*?.Y/ RL0V.&"VC$'?%P9B_8;O! )?)18KS@P.M)]%W%(N8JG0:9G
MCMKV;EN9)RS0:E#02E<',!4<AA(L.K"B67W,^5<V("4/:U\2LNM0YO->'43<
M'0 M0S67..""TYJ5C\0NXAJE[^I]Z38A?QG!:46/5_HYY_Y"5)*VG-Q%Q1NU
MO2]CLQ90 8,QS;_50OQ&3H%%J/U;*X[:OS>/]J_#_E=G_RCEYF0I2H<DMZ4D
M,N"0M3'+ BZ#V2!#]?RNG:4P$C!^E$($XU\F6S9!'SHKOF$..40M"D>EN9/R
M=X*D)7&J-+1@UYXMWOW'>K:',J)GAGUTH(6.@R(&"?! W([9_3-#J\?5MJZF
MA^DAAUU;J=OQYWR9?DV1^/O5=3US;Y! )EP&$#T+E@A:".I.2FO<G]B,Q_Z;
MH[PCR@IPJ(.IO>H>+I)^]5I;4-*CH5W]1<B-^-@PO)@)*GR5DO+8_L7%(IGU
MO6!>0[4!7 QG>8PEHJ8IJ8<:P2\"W@I8RDO8J*O&\G=RVMU.^>*L.>:C\E66
M^/7FHQM0(6"6]:M=[AX'.>>A4S7B)6M/9E.E@1-#4 ,[N<EG-G90[D%-E)K]
MG:<M,SE=VL9P!H?JC7;.)M12QM99@6_XK?.5]$T;+R78VZJ1_<;CA=:HN2 !
MX7%X $CMG8M)3 QQPY^Q5L-&4#Y>H)H.TC=-#6,T%K>.^Q/K-PE;3M[%/M]_
M*9/755?_OQ7)K5=>O8(S@03&6*M0ULW:32+)LZ[$9JB>(DE?X[, 1L3'(Y@K
ML=H2]+[HP&96F49REYEOYG9U,LA\7Z&E9K9(7.5 KSNHZ)!I2M]6,R'C,'<.
M D.\??:QG%U!Q6U@,Q'54%!=YVI:1C6J :H=91:'G[+]GSWYC!^DSIMNS41Y
M!Q1=!%\^]& :XR(#FC&%HS:QWE5*-F8R\1&$6"19*KZ<2YKJ=2524'Y$I" .
M_#6=+E=_:"YXN??M&8<>(J#9;7:_YT")X2!Q06[I[/UZ;!E2>T[L!.!Z%@PE
M%)0LI1"TU3@G1GCV6>M,0ONRBZ"Z R78E1#AGF?5*G 0;3;T^ZIRV-6N1B>L
M B;8-5"D)EJ[@"C*8!B>^:8ML?UQ#P!2/;AMHC;57C'3!T)\R";H$[D]E&,%
M1-(?!S $) 83=[TB4W],L,R$CE_SJ)\3PW1$I4?[,_O;PA"IZA(ZT2%_-6:#
MK-E8NMYLMB>YO LR+"UWI^[DIX4HS6;V.<U4.=.K=MX&/$@- J]U\\J3K!.K
MBER1>J7 IJD3(HEW-[O\')A2_L+^6BX(VJR)6FL+*-J\IMNJ>VOB-4/I;E5B
MDJ3.IR8X_HZ7#MCG"M@KBE=E=#'@+L*5 9Z&:.H%SW3KM53AF>P(E.D]"B-V
M.*"31P)Q4E 6<#X?_MYFQ'IBE$AMV#:S@AKT)^,WB&#BD. _OI%R<:I%+Z3+
M2_VG=C%7PYX77#/7 (8$:4/?6I3VZAF8GWC-#XBO%:@](K>G<!CI@-I%<>M9
M(B/3(VLW88>S!WI5=W]R$P^X5Q!.X"E(Q9#(N.6)Y_;^R=LV'(6O0UN"'$I=
MZD9/_"'^3]YB:_7>)!((HUZQVO$Y\>#SH)],T/<(Z$8S$F 1&1E;N8)2)ZCH
MH!?\DPDNX$#%^Z$(99>JVI'K*&U YCMIT)],J)$.RG PPM-V7+PKK80R+=><
M;V;YP1=@-$@@R+%Z"-12&;XCUO=XC?9!. _O'?'6%XV:6Z6WU>G./_0"$"HS
M/:IO@PS(Z.=Z"F91!CQ;3OA7!OADYQUY2UWH<#H3D.#[2T([<1@ITCN0_CC8
MV;F'Q^!Y)'!%+N4N(G>-]^PTA3\T!WP_Y-A[N-.?(?(/42Y7?_5DJ4GUUC02
MV+^<@P0T8O<'I:-TA(;D;!,G_8O1P)IK"^P0O4^[S8F?BE(9DFJ&W56LONO4
M1@$[9PXB\-B\AD1R#NOM>)WM_#R[?6_)G[=&*UP;24H1WY'K[9D]2\]S7"='
M,E1LXH0$[)/.=+P8)Q.,$@W2A)J=Z3:93QRSZ+&;[CPS?&#A0I0>LMP_GFT@
MY*QQ_!&J;-1$ B%C"4A@X&>J)+H^HOH[$B"S-=U>KD]<0P+GB+HK\J_8]VY%
ML4:@0MY2:$<9?/;G'PMR!J)U+NH[0KZ_J)S=YEFD[A=I3_"=0ODT#M#&,E0(
M?%J*^!]@%@79I"6407>EO>$'<>U!/TL#T2]+!D/S3#EZ",(Q)" ZLY'XVQ_?
M.C[^M]).7K"-WFH$_MX..(8/KDZ*OVGSI8VZP=43UEC6IZ!=#6>H1;AVS$!^
MEGEQ#[?SENV(U#A1[MD*99ML]KK^]->B\3>1+)<8<>)6)%"C#9X90MA"3TL7
MLFU\<^H9!?%G2.!4'NBT/!77^S\61Y5Y]B##.<O=4N*T\W<_,C5^[]#4^T?-
MW9^]J?Z>(L-/[BU*E@+US(IO56#DZ20)O&EIHMV%KLEF;"WEC GQ!_>[ML,2
MOG+XS)ZP30HN?I@XV0H9(\Y[7E5YLBB($<F]3660J28*HN'5)4*,"5,-*LR^
MJF\K)WY[.RQQB57\G<Z5+GE4\]\#2YWLG:R-3%RE3W]73W\./@TJ@I989:3Z
MU(A00"-?SR56"$S5[\89(TQP9@U9(PE0N_,I<'2Q06>6@N9@0%K?;GM8=&26
M8Y3_QNYF4_JTS+<&4E\[1A9KY^Q65$#$8W5D,8X#ZO3CW<MT[OY_DW?^%0D?
MC!LE]*O%4OHL;TF[2"T;:C2\TVJSHJ,'B B=LFS[^"C8+^I]ZF+H3RU\U?6.
M/T?GL02.F^$(IIS9IHC<W2"EOLV VZF/+?C5@N4Y[B[?*16-,6O(2TG)2QB9
MRQ<,X/A@HO&Y6;Z6+!Y+6,3.Q76L@L+OVST2Q<]9K=50>JMG(LX#9-'#%/7[
MSPG-]M_N\%3P]<B4:E[X\OG!*IZ+444,HUR$;%?\Q]BEG"@F>+5 _!UE*P%J
MCX\TJRHU.EKL[176-BF#@B9/)GV>B?!<=Z!V-4'/R25?VX&'98,052 D<(=X
ML6A"5^0\7*OK,RI,O@<]Q%+IV>WBV=5(%[_5"EV.$BY!S.7>&Z/XTU,\1I?L
M^NA!2A [$B@W02M4JD0Q$X]J 0NBE6/F4;7[_]XF6K '")44GI&/<!0@^Y9
M,O\$CAFCD=\K_V\G@4,6$KANB>HTLKK<G%K9]&L;_DD0T[%NA.JQ.?H@)5"9
M\FOG?P&;3-W^#=N^;K3)^^G!Z##OL_AI(^^3$,EXCP=JVS79=M@#8<$S,CD)
M8OJAH3=W9*C_-5 G%+3[&-_B&1D%.@G XH[;'N$ITP0C/YQD(S001VV=_G50
MJ<FVV>,9!/WML_V7V FX'6-TIAAT[AW"J$I.# D$N]4B2AG7<YG6;+EC[G.^
M"?UHO\.W0([%&J]^[L8];'BFQVA5\/0/SBW8U\X$7]:[@__@T.I&_V?+0'(F
M&H+MFPN(U=R[O5NW=$!RX?MK+;<OMU[F\5T7J%1+VHV8$ VR3GFP+E'<1L;F
MY<1V"7"Y&0':(5E/; TZ\-M32HO'V+-& M90%N%2)%!:'2;D"UC^@P!I4P'\
MN4W5CO;IZ:>9E'/_-%G_!2#'(>Q:#T_?M(_'2@C@CPMVWE>"G[2A/\G44$PU
M'M;#T]8G$.,(Y7DFM$_:T"&]EB .\#+GE&S"S^IOG@FY1X]7'B$!6S?E)WK+
M02WAOH",WV'7GD(>M!S,HLF$QL^Y YF2J$?,PM--XK$\<F/=%'9<68XQ2IC[
M&X@E*3'L8^PQ4%H<N'Z$3?M6/0P*8R<"HDD.$M<33P04RI\[EA%PU%BQZ_?:
MH1%E5$!:A/:5MH]J3_WJ[VEV_K@AQ9&TY+]E1"?M((2Y$3L0)5CRZ>EAZ8\*
M(NVL:V0GO[*<$ N@ P\5Q-$>_ES#?[<C_4EDO%S:]QY%T8?PS^?$>^Z2K[=)
M-'1W3-C[AA=_%$OI:B:0(#*VFO'=,MN@>O)BK5:<$?%\%.6HB-#F>I4<<K,I
M!OK=J<1O.N]W5;F:H/U!5K,;ZBQ5R8RJX)90Q,"W%B/LDAGY5&BIIPG8$0TO
M+$AL;<5C*OPQ%BP:U26*#9SD$GWYY5,9J\#.^YWH:2DK>IHW<[,!(=^G6UN)
M?YP%.5YW"AAZ N_7BN/^AG']5]9)7D=E.8?V%48X!,>G%71;)8MOF$<I+*&@
M0NJQ0@@@K/",2O)ZPDA6%^JULOT[CT1X/(U1VZE)VK/AY?:)!JF'Y4YTX=/;
M(DTOE*R6;QWT"^WVJ';S'NJ:#]]IU+S:CWBB--<Y1O!1E@)W-,9VA'YUP3QJ
MU'N9FL(IF\TX7/KU#-J+2V0*[A+X? 8:JTN5")(^VS:.[OY^Z0KCUT[6K[_0
M7^9YL2)V=9-*@Z\*IT=1.82+][9ODQ>6P(PGK&QB_" SCD+3--PJO4=CA)F#
MU'4'1Y9D,%6$%7J[I,JOMC^\_+T"Q(:2EE%=._\'[CD\3'UM7SA[3];SNREZ
MIAV.'V_3";<R;'JG"<"PM^+Q[^0RK_'L0<EMC9! ZG&^V[G("=__76X#%6G0
MWN91E"6NXZM%[7WB%-5C7;IFJFP/>/!L+$]2+7G".XD=SB+O;**A)Q[29Z:*
MVJ5KL?;]X*D?E!.9W1@),J*<'CWQ[(^<5B"QFRXW9O@1)U<?5SJ<49U\]Q8L
M^7,AU%\%VZI/?&8=JKW([+9^N\7A2<3 &+N)ZJ3@_Y3X.Y28&GXT8Q]L6S;_
MJ@S_U>@Z-<J-V>SWMW_@H1*U@I::4XR5P+USP$.(HOK7 1GWUJUE=^<9LQ3$
MB2&5O\KI$C5!^Q#7XQYX'^J-FZ!M_@J!(N+C"YHPAN-D+"!U]G<D_SWI:HUC
M*4(#HE@$6@X#CC.;"5_3N.N 6Z&Z^IFME'$4FXJ!6:(-AWC0U_*8'Y" H282
M>!:TF*FWK )C*4L>TDY+/@PS/VP!YV=#R]1,$J-T:L.(JH\>(-LJN3LL2T0V
MTJ7/$B*.'I@0+46(*9V$0%,'/&7%XP?0=]7JH<Q"A3:.L19?O:.'Q .6@8,P
M>U_!Y"%!!>FCA[?-O!6&Z-A#.)TITCMJAV,0W@IO%I:_5(5I.L)J2ISSZ$'A
M6)\*<<KN9<I_M'))QWS=Q*+CSCMD.'K36QQ23U7)/LEC_6LT^8MIBN6ML.3-
M:>>*@AYWUG2:D/PW:!)IDPB3NBC1!<_^DF:;BSL'$ZF5,[TZH.]AKJE7+EJ(
MZ.-4L[^;*-,LE2VO($Y$_N^\B?CM1@*BWCW1;UN691BN'J+@L<:E"KK#VI@%
M9[ 8"_(O%ZFJ&NZ=[U^Z/C=E+(B+(7B]ZE-EK;:=7, ^LQ'@&K '7L$!-O=9
M. N_( $1I8W$I1O0#F7XW'>O9I.T3SV8\"VY]J#3NH2O'-+BXMOOP#,9;K:N
M*?A[\W$Q5_6?:?YUX]F"BR%="J< D*DGPCEU1OR==KBOWVG]P0/01A]8B*UF
MLO TSJD^03T(&;\*.Y\F.S;B=Z/LD>^#($UN$5.@4/&Q<U?P@MA%\>N0;#+J
MPM]A0,R.VYB@Y1V'.H'<_''98+I^]ZN^IWR3I*:MQ)\,7^FT:P_S'[R6,WHB
M?[U[*,I7_.$\F23-)FWX"Z_3MT00M#5S"#LZ4AU=L/[2F!T1]_'BZ#VYJCK;
M6!V;1=/-8QMY]N=SQTM"\?@J6_[\VS,D_A[9C#"L,31XVZ1H:LQ9I.F8$59:
M-S"JN\,J?.C];3,8&PG5Z]WLANGG\F%BQEA/515H@/?G,- FDN].Q.%5ORZ*
MPZWI&HZ6S#$T][%(,H%Q3;VG:FUJ'H_.<"2OE5NU+S-/J;5SL+$QFX\SBTQ]
M-BA[+IP^L!"M7]WLZGYXY*7#0M_55M(WQ \A= )-.092:[U1#:7;5V%/J.\T
M*;4+^6NU8]A,N<Y_6QW2?\YHB*/>;*0X1'>;WDT#%P,?/47.>6S1UGV W"(L
M]15'X=*=D4<;(^^:@T8)MZP@E/N=F.EJ 8X'B/O]02@3@:(/.-N:?W6SI28W
M<:]CS"B92$'7I^:7SD<D>- 5;=,:/H\3@EX\SC-;X_VQ?\;BU--"37E=DP88
M"X0$VSI.?&WM@53BTO4C=SUSXJ[U#Y.ZMD./G*W-B;/]B.@V08%0_KKLSWLY
M\K9#I]X67!@EVFV"<MA/3Y,=()@,R)07Y?-OBI[X?'R4C,*H(X\==^*QO5$R
M8#)'3O]7BBRTB])(39MM-QX&+>CHP62L=;F@/ K%X$4DH%E[Y:)2V;31^B>R
M_<2^0OP]0 ,ZP*6I$AT/;3K7BBCS[4X+;,R$[%IOWA8G4N+[#_Z X)18F^$J
MC\N]&RS(,9[%P\!TAV.Z>;H&V=!FJR[H0MO1HI"Y=>L#GRM>)H( "SPS+=>D
M@ 2P7H(V-A@G69,2"K=[EN4*O VBD<#+._A[>Z'K1-"::YAP>/,>SAQ3XJ!<
MJ8N O6#U[CT:)! 7";X&@=->AG9\C7N3$^(K4GC@_:]I*K::12 D4/IFS!N3
MN%N)X2 3L9J\E#HD\MZ%+.[;#:AK&N*+Y\&29J_B=LBRJ&0D^,]Y"DL,0X*T
MCY' PR^'VXD'&/@K1>8*D,((JTF?T$-/S!U8T"(I^%-?MCAUMTYMR'6Y;5S0
MJ!GXXT/$@6H1D8N4 ]X?Z0\69,HQUGR%BE> U-C%+A5Z5)<M\&EN/\KU?])M
MEJO69_ORK+66G6>-'Q]>0(>SYB2DR#1K2MA9;<XWAIO-YAJ8%?/+#[)>)<CI
ME'/.$R<*4)32.++9-:C%A=5X<D(],=]G'^U/\AHGZSKMS'3825)B_^2"4PS_
M+-@_+./ 9,ZO1OXJ@J\H>U#SZ\1%;O\P.&OC8B&[G,1N:V)]FCFA&2&%O=5R
MM-5-/*&!DH%W"WKKVKQZ^QNH8YH\9NI9L<+)HDGM.2[._H9* >9[2QZ=]N@3
MC\VFX]=WIJ/YC_R" U"\E66B\XTEK9G^!YKV3&"17QM^3<&HNF3PD,^C (W>
M&Q0QRN]!!MH./KF5=Z)<$:&B193YPJ8L<E3E.7TT(4EX\2@_E(%QX>XYG. W
MMR>(-4>5/E;$_"C^5!RE?-#5R%+ V8M>_VB$HE4/X&&;UDHNU);,+&%$_YC#
M>:][F3?N\NZS;6D_C?[=)O[!FCSN,>R]2*?0M3DQZCS=VQ-:Z1:B-TS6:[Y9
MF\"1P&<OYT/'@:#JR6P3)+ U>W3+G9F22_\ <=4.O!IL!MZ !>U*%H'VEC24
MU: %009!L3IM>B<<")Q>,PB^G97!M&V]2+F^;(8$:L33D$"'&7B,MA<Z4V2H
M "D(>C@3\:P_=3Q <:1&RB .E\MSM[_:?:MBV&AD*O?QB'Q =;;U?@?<(P4.
MCK$%740"$]T[\]7]E8L28=TZ0<:7B%:YHS5'X4%B";[,E"^. YR(Y=R#FKB3
MXNP(!V+&M"2&Z[<<EY[:<[+0S@QN3S].8#F]1#\SMD(_65THR4'9X**SPZ-_
MT?D4 ]._$%M89JS9MC3F<C/; ^D9"I5:@L:/O,4(W$[V;([L1Q_/47SP\93\
MJNXJU;0 *TF+Q]DNYN^WES(^[V+199]!* <*,)H;(>SBC=[YE)]/, 16X^8Q
MF,6F<2,N0BDX@> K#E^9P @B8BUK.[Z )UXDGA8:@$=<(D%4'J<?QQ>7K^=D
MH59.C<C1BT>'P.E@0?!5OI$NK<-'$KHUC!=03G [$0D(7P*M!J%6T^<!%W&0
M^AL7K/<D)U!>Z&E3G24BUT>W%VF=/J6.!2B.UT@FEC $W@"3?UNE]G-)'!S*
M7I3@GK3HF-#Q(NY0&HV[)3379Y4PFQW[ 343CX\G]33.WSPIF<Z<>2+[A,!>
MX,3L<!]?7Y]I+_XC0_.?)-^?R\EFF[[,QH;X_LSOK;?]35"VHT3R>#5Q\QI8
MIBJBQNC6[M)W@Z(-K1GM0)N2?;7./B^;,7/I7&(MQQ>3T,+!.H-[$Z2,X&YW
M@=%=6;@KZH5?1AF,<"0P?O1!]$KCZ.8U?#BV)8*V2M07V,#__P##\BIO[6Z#
M$-^+JEYAPH^#F8#V4(G>P725<QY<9FS0DLBD(T6G(DGVBX]LI3SF1?PZ?*H.
M7!O(CQN*XKBI2^Q-='2[S$A@-6;W /$2Y6)>L".!.K5DS<_%Q6\&/S \"I"_
M,HO!HOF_?QK^"(:9HO&3B#+;<PP G?&0H7K7=POGR6OZ@#>;#\4!)[S0-;GZ
M_4H;OB /54-?B8"FLJ>DU)#A;-!?=<):N#KZRD*8[\)7U?Q;?CY11ISSC7PE
M8M3Z2 ![-*AZ]@YHEW 4+@[ZJRE-[?J/@XAPUNN1W,ZI3Y;ZD4S2 ZFB/9!^
MG"M\.&J@J?=7:,.C/1AW==#19]+:QI+D;9KH'"42"'C:B?D.6N,PL;)_V1MQ
MO@0)$$#@C&ZBJ/,I%O2'-'2->&Y3_C\(\<8<1"1LD*@>78$$SF?=8)X*:(6N
M\=ESOJ:^%444#D;S\.?&AVD%(X'G:G;CEGB#CHF2KOSS$,EW'O?MLF\Y7H7!
M!*XL)W@1H4U7_^7\*?SENW!V14% _]$0U:<!:VKUL*\\_'$_DB/UWS1,:I?@
MXM,M#WSL)WGUG-UTS(1CO#!X2/MK#S_<2HH1%3E2_"]:^/\4B,Q8QVOGD0\3
M)K:7C&LS4RH[>3_ QQNGJ+T@V<XR^M)CYE*5>IBO89"#!S<*6>)J/;@.F=#M
M_Z[O$UO,AQ4M6 [JYS)'X@LCB[]AUK%E#&*Q!AXZ#Z0,4($]GCZN#*'O:S$I
MD)Z6UI]$K^BU;)>0$V%"S_'9J0ETSO>42U+!^0 1N\%L\LMC78YY_54E6<5I
M5[<)Z9YQI8K%W'R(0>?C&? #-6GM5%]AYK2%_;"8ON+\XF#89!:AID_PNXEI
MFO>$7(W)@,[J\_*7(R"?+1(GAJ$ONG*5S:5+C*.DV?/)R5JZL&_T0E[S(]J<
M&JH$ET7CF.;4?JU AE!#ID7"G,WHL(!D I749_I5S!FUC(L5M\P/C(HK2WS'
M,0^Z6EZ\/;P=C\?XV?EP.3?;K-4U[8NHJN##5\SH6&'Y]JNRDA/7*V"?N^!T
M*;-1?<N)AI:6^#!B(@@12S37^PGJLNQ?_W]?YGS^IACOAS)"P>Z&+,X$GF+4
M8K$T \F5)0-D6Z1/'I=BM3]%*]9^;]#2,#&0XS+P48U\!*O4_(7E80XT[UZ"
M@OXD[B3EBVK!!C$1UORS;U71&S7?;I</)STS4]MVMBYYU"C+D,SS=.^V//:@
M_^0$]5:/H^ST^DK-]A4S0KH17FC5XX>U@B*-Q2RQ16/1K<,Z?#*<REH7<^EK
M%OO'Y9MD);_04;%*BW4E=MHZ\NZ^;Z*C+",=<K6&N?.>=2\\L770]FRT;O]9
MO;#57!"-JIBH@R#51L]J5M4=&36E.)W>A_T<2QCOYXL[[WT+*"7;P%RSB7V7
MTZK4C9%L;<K\+O7[)+Z_L0,=G!5?:=6B;WAKX_O")5/C-.*;]@C)1[O \^RX
MT%0S8(YW,+RRQV*95#\&C<\LL>0%>_;$*ZZ7XI]__>4U^I5Z;K.NV=#B('HN
M63I[[I8*#X"GDZ C^5'])43>V*6KTZ[.%J+H9ODZ<A2+8=_2Z' =J3;J[790
MKML\O[28O5"& E)!Q<T5-5FD=WYD9+9<-M(XVS7J%E:-@(L^;9L[T!(:."PR
M>V[%PZ@R6BJBH[2TO$3C_N"0]DQ;\+-G6@(K/8%A/:I/_0S3U+\["05^H%KT
M]+(MN>Q%_0ZC\.Q,R;^8T%M3UG0+3->>:F$_C2RT8;,?ITK$^OJBX+UQ?Y /
M@KV?MTKK05[74T2[HGIRQ;7;[!2E8H+417=U/H;LZ*Y%WPZV.U?/=MX.EP":
M8DZX/&\!K271I8NQ/TQ4\&!"HWQ=]QJR$ 5L7Y*KAV$$.;+S79)E8J2A>GEE
M[X>U7.]SI0]SV%?TYF_4,,AQ"T\NZRF\T(6FRA@8(7B]M4WZQ]7>>+US?_QZ
M&48BXKB9U4;=A@2*GU^.Z"*<97"L\PS3F;&<\P56^.1>:[)1DU7V\P[.<GB5
M#7J07AJR<NQPGLYR8V#H\.&-C@X0I^G.8=.4ZF1FR5_"I.+YPB>M\+JX:.)U
MHJRP^Z#82FSAZ$7V[-$ 89;6J0?IB<%A-.Y?2, !@+.V*$OG3%=2/VWO!PM1
MSNH;[22K#:8PL$^AY66GN.\.:T/O$*ORMT'OB"?78.H=)'Y+RT]'ZM647G\1
MNL9Z9<^IU2!^08?3:^MBX5JMEBX5HV*(EG@](BK:'I!K00)<2."ZN\CUO\=L
M_R\GK MA&6UL-;!K;$.28QAZ\RZ]=)(]X@FPBQ?UGV:1/5I_U7F[26"_#\9T
MSFO:.]F,Y*+(<K2I-;?K=P8O#>_.8*6B@,0VHC:+*])8=4_E#3'SEE29XG%&
MO_?K/NYV#:':",@O_A)![=W_H;"+-UND:W%S0<M>[,Z[!!4:ZM+/F9OR%_B[
M;:=]IZ_GE7 -0W.52.NJ5YP1O,-@B>[-A!FYGB6+BZLC]V[S;-7K_L_3C/\R
M8D[ND[T(N!5B7WZ/<?[0!*U7A4I.H\?61-5"=G^DFU_@$H_7>02?ELR:K&>6
M=K3K3;6"BG>7&@0,<:T77HB1'^<*5* E,-=*]<,$<!$1M].M3Q:)_A,]47DG
MV0#BZ Q'3\DN?JB9F6J_"V(ECD;[D$=E\;G>6)OLG,43NPH*G\'E1J*6KU <
M '9L.CZ45Y3D%;M$IX>0&I Y4?Y@VN&C*DXV=.*IM; CRJ?!;?''!OP]=SV8
MSO6=I!N"3R5ICLH75,0ZLB\_"E>G>)SFCRVQ*1IF]*>ALE0-;V6_-&<8KK.B
MNR'?S8_&&)]P<4$K<NK5Q=>3X=3TXD_>[G=>\/T-SF.-\YZ,")1]D5=V4%6<
ML9/\@NU1ONG&B8'+L<P6G\V_2> 7KE/#/LI%71I_\4]9!/EAG<%O-4;E,==>
M4UK:?VX#9,1I\\M9TR^H/R884NQ$$U?SV.^?=GKH,2[(X.U#H,4@6O0()75.
MP34!='0UB_9(DSF=5A);XE+07=E_ZU[#XZSK%IIW5'O(]:U/YZH&A:H[&:5_
M+/9V3H1BIYI"V89_LF,#"ROGI>08F.QU^ERS!95KS08Q/1$B[<;C+Q/("IDO
MA8XL52AM._9R0=]9H8U_4']:E$MH&J$Z0E+>.?;1QIJWIR%X+QY]_?G+&<$.
MT; ^1[_:[@6'J,=K[<$7!?M5<;&'T##1U[.WY6>5-^DPRO \6TCTUAA&_#C]
M?O3Y?O=[<T5V?4#?_Z.N%D5!\\H#4<;>Y:W4FZ(,%M0_6JJ->@Q?DD[[Q[T-
MATD.B2SH($#S8PS=#_NR)U;A$><LZ5HM!<5HEB[UD%&'B<QX/K]MI2>GH]NU
M:4K?K#%F%',%;*=."6#*,J%3J\\4[C92'4Y_7/M"'=YS_P-1O'P+S@S9%^&9
M;(M=O_$+WG"Z%?X7+E3U7T.2L,8DL33<&8,'^>PM<73%)T1N:N95O+"(+^2/
MN-SN%=E# T^RPD?/-G6,KGVSZRGA0G./<%F#-@PR9$?CN><+;"RYZ*YQ>D:M
MR)3UZR),%^E+/<8FQ$TB2>@?XA(TP3.V<G+'V:FA>/-"X1D#X>4%281:;^7S
M>#@<F-$94Z&:Z>-!6.:6"691#24NQ(=P5<X+^1IU+0#+7:MG4L*J<=["#%FC
MD ]#"R6KTH;ZY#*6YZVYF^@;*9H7W"67Q*B*\XS-'5*TB^H+>8B]6B+I+@6]
MW6RS >$NL@W4K+47O\%^V7[>@ZLB-X<UO^QEARDOC?OC@#>@!_ZJ:EZ%4L+@
MA.R7!6Q?Z8V'$M&C@-8UW?0TZ).Y<KR89T^FJEI%NM.,Q"FM\,]O+FB(TO07
MC6(ZVM_KY6-*#9=^04G27GH-CUL=+: VUI.*]<,:H_?3HEL5(M(/RGQ'%0O!
M%4YO\PEFQ:8+<H2I,LRBA+OFRSMBTGAK3&+Y:)DD&W%28RJ==^+Q1?O@:FS[
MJD6)EYR*!DV?4-\K,RDF_<;<) "H1)L?WI4KZT_N\6N\5E2$+\1D@+/'' &L
MFN>4KUJ^W@K@42CI*XJ^LW.9])&T^OU[9>>O/GPF-3<2#D8WZ[<9T5$W6ZNU
M8;/*,M8??.O/V'[+TW_<G<T1I!"[/3X'\3'H7R)&(^0^'P82]CCWPM\AI[],
M[]*NI<+'_J=; 8^6^\V_CZESF9))UJ '?V%\'ZJC JA51C07&V]F!2V!MS.-
MYH>T/W==<3?G.3@'WILUEQ085*1/=KVXIIWQC>)5LXIB0V7IKG==4'SKA&%?
MY)-KI9:[X5@#!A)9\O!OPR$2S@,9MY\$:^YA3FL_G*ER@L?A\]G[;"KW+0W4
M*LH:ND#9*Y>2P@U1JUQP3GZ'^8E-.9M0'Q+P$3:$)L^WI39>:I7+(U!ON<,,
M^XZ)/J?*(6R8/L]LS+=<P>B=G52D&N@XIG'5U'H#_8T56N.,UMW/NC1Y?7SI
MA=F/VEEU%!4?^ZJ_>^OOCH<%=@DL>JJ'L0"SR[)WQLLV*_88UC>Q'.<&Q!JF
M&F[(.=]EW@VM+W$V"DW4;,W2@C4[6U]/) _'>0]OX1I()<TQ6FB$53KK)AJF
M+@0XK\J1A*;MB5V%V&D3N/,T+^GTC;Y((I>(IHYQSC.[BC\-86LM(PN4.H]G
M/QG+$H8Z\!:U&4M%H1Q7B4LZ!]T;K 16');\XG-;'9A5 'M.:J:C35UQ?WE[
M-M]6S'!E*%N(A"\="QJ=NX@Y<U&;:>$MEVRUNC63->VA,L(]_20L,H^,G&XL
M.DR^7L?!+_F.F9"20H^-Q8*Z">Z)#"@A@C;3G!JWE[ZJF]-6:U#]^L>2 ]'!
M=ZV)>-@"YVWJ :><],QY7=HNP]<+Z\-W#3/I%;1?OR6+8/:0P+@A8SL@RM+'
M&VGGPE!&J"-2=]5*UD"%I5W#X3V>W%VUY%W3=)'PA$25DIMJ:N;V^<+&)E;*
MZR*BFA6,M8.9I7;,G)SQ-TLX*5>;"2_G?8VD^;'='(^+?WG7L^[3I>)>-@Z^
MB.K2:-F;]@-RY*SWOH1)?B:E"]4DM\\<9^?165TP$ZH=&5Q >_F&URR!]G))
MB]CY32HSK5%OY_8*<^CULDS--BA[W+>E6-)( Q\I1:GS(;)J6]FM<5AR(C/>
MC"36+Y(*2"CD5KB]'#<7Q*@LZ%Q[-I.3Z&A\@=4 Y_DQN\'/!2W FU7*_ESW
M9<;0^AN9;727 KX\,D^OWK6YM+0Y<'TQ/;C$H#O;1/>"GW@?X=93Z3!%KJT<
M0UGM 5'=<!W?0 9E<^E1*+>W']\E"P2-*?GUF(PJKZ*VQ%96>K/&:Y^;FD0R
MH_J>6]API&>DK1EO&YB&.'%I[EW[U*N,T4J52M8ND"O6*\S#OA+(.^SZE.!1
M8;$C.6TJFS3Z&RA.2^6J6XE%IIY<O)F]?7&4YUX)MC6V@YHPX4LK ?0<\Z1]
MSZCBM9NOX4HYKE$]2J'2+PIG<V2;^B(I<R0I7OR(T_2MK8ME<J607<.%E9F(
MSY6$][3JY&>$*THUW-YS43,T^-$:+4<HDR'Z828KW-3BX$L$@W) W6:&_'/1
M<N\:^=F&_2OT#I96C[]9W382:(3CN#/MUNI%]2B6$NXVB(!:2S9HBCRNT4DZ
MT=DK3X@(\+F/\/>G](Q7D6!%@+X3/GBLWALRQE-![[R=4[SRA;RSGX]YD>^6
MP!(?,:UAU'53$CH0<SN0-;6KY5Q\??! %MV/F9W8WW@W H@"@F3ZX%+ZT#&_
MS$/#E6O]5(]"AA/E\T*2)B_S#&[E)#8*#4^'&1N:ITKFZ8RV7PM4Y"GXP+C@
MWZNXR^]$4DNCTP#.FY8"38$KT20_;RYHBK*N+CAZR_G0E!Z(3%5ZJ%^GNZ9.
M,/!M,QX/7W<-]+J2B4^$6T8E-T52U=PEG4Y%_PO]90P15KG[U6MX8>,ZA")W
M-4+EB_O8/7D5)3)H;3QPWJ )._?D?J(V@PT)>37D9@Q*I6LWT$J\XE=/E,<:
MDVIWVLK>@[/SEN=X.7(87$RIRRM?$GR.:STG1E3ID#$ZMV[:50_EB-1G_5C6
M2^<O^-H@$$M$%E-VJW77?W2^&D_W]CB7$_DP$*$@<5.2I^&'V!?JOM%=;YG^
M7/(1"Q(%#YAD\RA5"XE/PZT7GNH6/[3*GG.Z&+ O@F D2F0PY3NTE]ZO5EF'
MBA%7<F6:^8U+5[&,[RVS+V4I3 SYWK!G7A19('FP)EN=>S?15,',PL+.L;U'
M)X/94!Z;]+Q!T=-JS^?B>,G$AZ\R#2C7-0]C%YZSW34 B+Y,N OU\L?A%5'=
ME.H1K<T0*R_RY-(8X3:PDL#2'RB+Q[.4*NV'@\<'YY(KG<9)K+6&WOA%JKQS
M7VHDG7ROEKCKHEC>5R2C^J.=0DZ*F%T%<MYB+]"M+ <LW[D,%TPP#YUWL'!U
MS0"N77U3TLHIT*B-&\O376&)90KZYD:2E\_@EV'Y;-CA)B/8)_Z2>:T?<Q,2
MB+6 9W[.X5@6KXN;(SR<@!M]<H\"\Y/1M=],U_NJALE8R_0X.&XIH+G-0),P
M+,M9PXTVAL/2M!=:B_TX0K::6[+]7FM HTC&>Z&4"J<)SLO,?9/><MV>]]_0
MFSW_BE\N159OYT:V.N[X;,0Q1(DQ:BS?Y>&CC+D1(A<9%^WJV#%Z;Z4+SXL4
M<3R_-&>F1/D^F*J7Y<EFAABT+[E=TY&TX#.!WR\AE+/*@(EY3TE^V[8H:Z+>
MZM'0W?6K[QD=F8O*ZYDH#%:\J,=^O[5!=OTV7?7] H,?*Y?52;-H^BT2NFG?
M2<9JW].VP'PYW$,ZD2R)N#R0Q6%YY4X_^]*37&WA3T^>='_8DJ#$KR,O>&\4
MF6O6O3NCV?/4^+"^.*J 7@R7=9GF_=:2=E&USW.9S'EG_KBK!0PEL*DR#7KU
MSO?7M WHBF7LG+T][9+Z)WLW+33/AX]W:@Y%-WUO9:*?M&C YU.[MVOCE#RO
M*3Y4_E;)U2N5<YVR.K($U.+.-*>94\7YFF^@;,#(G)VJ9T=4T>U@\KR'=7"(
M3;W^(/QN1="B4"Z<WF-=R\>C-8D>S*8?V%54/#DA.#GP84Z4P)Q*3J^TM%1*
MOX]*G3;] B!?V6\4]V.40(.ORKU_J4>BY)$RA( $MTJ,LR>W"'@VH;.FO"]:
MD<-116]M&A'*HO7ZC0^!.CQI@NX%K)RHSZZ:>+Y-/]4L*-E/RV0R>") O6G9
M]]O>BXFH A+WIP:KGRJ2*&;]YI7:6*0^CJ&'NKM:1SV/Q>^W/4BJZ.2CD'::
M+)%\*E/W8,PW3:?5@^OSBAB9+OV:;&)R1[))>7C!U5#AX(CR3SXW]R<>T@36
MIF4'>7^BC]-ZA8"YY+EN2UE3_9#Y9$9H)?EY)N@^YW.J#.*>7'8^NU#50L5L
MOO$(J=L=N!CXSH.KRQ'IIOWKQ9EN)0Z*9093.=\Z[7'P:=WYT_Z.[]+^C_Z/
M_H_^]Q/R^_\#4$L#!!0    ( .N%:5*)9*IB!-\  +L* 0 8    ;7)K<BTR
M,#(P,3(S,7@Q,&LP,#DN:G!G[+L%6)3KU@8\2(N"()T2TMV-@+1T#R4@.0+2
M#2(".I2 @'1+#MU#2'>7='=WPP_NL[>><W2??;[_^\YU_=__C=?CA<^L9ZU[
MW6NM^WWGQ;G^>CT#>" M+B4.@+D# ,#<_ %<CP-$ 4@("(@(\$B(B(C(R$AW
M[V'>OX>"<@\/XR$:)A$^"3$1/B'A(PI&JD=D].2$A-1<-/3,+.SL["14/ +<
MK/R,;.RLMTY@D)&1[Z'<P[U_'Y>5E)"4]=]^77\!H"/=$8+=@84A ]Q!AX%%
MA[EN!)#<X(2'^?8"_.T%<P<6#AX!$0GY+LJ-0<D#P!T86-@[<+#P\'!P-^^Z
MW[P/@$.'QR!E$49XJ*B/2&:-R>H5DH1$+E)0AZ74MT/!9F#S!ODN-@XN'OYC
M2BIJ&EIV#DXN;AY>T:=BXA*24M+**JIJZAJ:0,,71L8FIF;FMG;V#HY.SB[>
M;WU\_=Z]!X>&?0R/B/P4%9V<DIKV.3TC,ZNPJ+BDM*R\HK*^H;&IN:6UK;U_
M8'!H>.3KZ-CLW/S"XM+RRNK:[M[^P>'1\<GIV6U>, !8F-]?/\T+_2:O.W!P
ML'"(MWG!W'&\-4"'@R=E0< 05D34MWY(QNJ%A"D2DE10ATS.IK2#96#3=Q>;
M@GWV\>YM:M\R^VN)O?DO9?9'8M_S&@/<@X6Y*1XL.D (D #;'X FW7/5Y[EU
M5ZA8[_Q-M:6:TT5K[Y>#%-C^HFO [5;P)L[53$JX'RL[LP#UEX.<:\"WC7.Q
M:T Y]:)^9^ ]-&EF 3JAWS:^N=+.X0E)\EH51TPSN0:8UA[#DXPQ7=;)_Y^/
M_Z2/=R7,_(MGJH3NM$1ZJB&6F"^);OSIRI\NT8GA&":CB6H1UP>XTU%]VZ(1
M*EFXFDEO;Z_("T[#/5.3.*I*F,#T!+5=UDG0H42?G"D&I[WX[9_?WK')_S_#
M_QG#:P!_$V$.X\MFQ$\)P)572"32<V1#J6Q46RW 5=_D$Y)'&1\UPZ7()?YQ
M<-/#HVS)1?]Q-TB-\"?#G-;>$(6/2_SQN8N:YY'_->"5XF7R-6 "\U3C_US\
M)UR$G<.J7P,2[:;#2;[BUU["?K[(7F%(Z?50L2#VWLN5AW04C!Y*'@NZ7WT9
MN@:L$'$M2APAY%T#GJQ> VC/4$P/2,())!(O,LXFH(A#Y!.GQW_F+F7=9H-$
M)=AV>7KCOMZ5U\"5BN=S\VO  6K,7EYB:;#PJ6*Q"UI[,*0CWUU)H"?!,Y_#
M\PQ1]E3QTBO[&M#+Z]E>\V9, '%1O&]%B%:PC+'NY\!J_P[7^/]%_%\1\1_Z
MZQKP5QK,XW=@"?\FL,N^4\7#"@>T+(F*?4;(+,1&:O!SU*L&HHB;69O%&JE=
M>6A[#7 ;&=+".<\^52SPK!2B!1$P-ONCAI;TA'M^M^B_!M33Y7GV4BY?G>9E
M.3 =J^^E&%P#[#UI!:&,3:[P$Z=:5^@ZKE=>7$+'75079)7'EW<L/;>CS]*?
M7\U=J4"_N3\<=4![#DV@\_S#5<KW0^[*-]%KPRGK+IMN6-J (N;K](37_D4$
M=1LXMHM6)V+VVV=P$]> :?:$'?#Z] %RQ36@!K0&\;\<NLCX6CNIUQZ<VY'_
M#VA)?C0-]+X!JK2AMY6W*#%B]%7@S9;;#:-(N=4WA8Q).%^*_!G@H?]NP''_
MC +R(XK@[P<Y#L5O 63^YG^]<(.XSE%0]1KP5EWWIKUD>R[W97X\69/YC8:P
MYU=K5RKN#CK>7QF7VZ\!WX.;"?VT+6K#270BGQ^A5.R5?2^N_ V,:\#O..3^
M&8?:CS@D?NR*WXB0]?['MKCIWEN^TGX\J*?RC0GQIA\Q3_\#Y)N1^QMF/L0;
M!&E_M=K^/ZMV[9]5^X?V_'&&^GY.\]Q?H?D&,LX_0#800EFO5[D&O%?M9A7R
MK11.-)]!.XF4'^BO\;ZQNQ638XE%T6:I [8(+)G,_>WO%S.A;V(@?ZK>JW5K
M\TV<]+3<WY^ENB8(7@-^%[B4/RYP[O"W8A)XJSWNECK>:R%;;N=_"$GPWP1(
M]0#[UA'GK?;\+BC;?PC<CS%O1.Y6>R2&%[\*9A(O]]3^3=XR_A!&/>%O&G>K
MB21:D<__#EC"7P-F]3NPJ[\"3/9/@*7_16#?&;N1[+^"[$\I^Z-.?P;M.V="
M?Q':_Q^*^3-@\QG)X 6^.P%SX#=;=B7%$;/=V.ST4D>8,!QX6/N3RTWR&$3B
M9HE18M'M#H$I6\NKNJO)YLA9*T=E!1^>9B"?'4-HE3YBO'S7)6,H FX<K-)*
M6GWHS%7YED5J4FI!-8Y/9X##]%DI5\@S_V-P?'@"G?01[4I_:PIXK]IJSE]B
MKMPNFXG& OM)D?;#9K[A;?]#G2=?-2=,74KB*B6=0PT; AQFABIMU&J5G >^
M;E%WV48[5%N9I *)#)5*<5@I9;P;SH/HU.95BDJ*<6PG6HB@=B'!",F=V<F;
M>#G3FUUL&PCGF_F7'ST[M'<UCVJX=Q8GO[PA4H(EY885D.7 /H/OZ^M7HD-0
M$&[E]];V; RTN08T7.%S1;MY44XA2/98/S58V/""TL4%F7:]2KCG)IIQ$BP>
M/Z_T48I,4N4!8*YR_5*IXYF8Z_BG&35N^&ZVI\ESI\)\V9&V8DJR<MTR3*5I
MG186 :>)N^"<&HJ^J<E<',777_SNS98CA'_2'D[.S[W02QP5)1PP?P47MA4W
M:38BR-"[^3(%&J/HHQ^YQ>DRL!CY?$E\$B_G7,=$OCJ?:_C8NCH?CQ7V2Y:M
M4YFP[VBNEDK9WL>9?,L#FYHZ.TOC@&'9TC+#+#/;R=4RQ>Y,@@<J!X_4HYWH
M6L["M]\SD0Y;&6I1BQ)^0& Y416/38W9H*+(<44U[7JQJDO1;U]J/[!M&!>V
M31LOQI@]QT E!GLN<D0MM8*[K]B^#4)=&4HN+*Y%7P7V"HT>%\A)J"IW">HX
MRKS9W@B=%@F[!O1P6IH65>?@L&?D4//K)4Y,$W"74.-;7_ DN>DGUJ0<P0\F
M<>&-%PE<TNQUY.L0%!MGFN-#(L*MEJ<F6N[I3=D.%S)<.,Y",]^RK'W ,7S-
M-MB;0I4E;&?WT3A$@]57"8G_#=W#)@]2OP9>S+&W*;;4]4S'T:&R4-+J^^UL
MNH@F<R0D3H52N7;-=)AN'[*8!2K5%6?0\-;+7* K9Y/% >J/9,MPR0L@:2**
MLM.&'(IL0ZS4>23];A:YVA?2O/Q%F47[X,TQMN#V,D9[(G<W4XL!C0(M-#82
M$ZKEEG3Y=:55CO+3OI6H%(X82FA:DY,%\1E6.<E>9QF'VG33&=94TA&N/:[N
M//=7-&7%]O9*+E9J./P9-\,,4$1E4Z5994E<#MS]ODYG_J.9$0U[.G<A&?#2
MU1+WR',&4OZ'08/<Q6%;..S[4M'+%OQ6L^/C7G#XJ?=O6Q1DL'8UW/QU0D<N
M1$0H,!B3NR1%V*Y#,[GBX^XUP)<BIET'>+]Q'J*R>U5KF^HD5L+ :#2E86'=
M2HXY2#&FAOK"@2=%(#O@Q")W^L2[P7=?X0/_E#X>+.%SM>" S\.)O5$'N!U3
M6[@ $S A?B0=#L=0-QA\>@U0WIT..I *)9)ZB\'=[BO<LZJ#YF??\XXK.C#V
M^$/"QLAIO*PW@;N+6AX:19Z==$9,2;!>%UZ.%+]FDAAA(9'<]$L]S_O]%7H/
MU\?"&TLCB4F&<_2+0YSWY:>6RQ *%2PB%D)61E.[7@2J3<OUS50,;LT]2YPD
MY6<YRGK@M-^@_A I9>@YHQRBP"IU62%*2EI:+LJ<WGNF"Z$D8<>TSJP];H)\
M)'*$$C?$;)UU#ZS2ZII7^^4+7N!TV;U].XS0ZJ $=G<Z-MUA_5X[YT/D4XW(
M1R[Q]54&))@G\\WJ142$G^8"EI$0,-VMY3!CA^J5)(]S^G2I9GO>54Z%S<'W
M\S^%?JRIEVP@S0-6CMA!:93HLE<,0K[0YC@_ZH_C$1Y]^R(J+9J.=U]KH'@7
MKZH*C,9LQ!5KB>4UST0P?@*2U(KQ9)QSEM@*$Y" /#.DX2,MC4C7%[.^NK.K
M?D'APMMFSZ]G22\CDAZ.E9;AU/%D@&J/\9!:27'(MM\/F0IT)]1\Z<BT-0O?
M(4\_6W190[N%UY':1=5"N0F?,Z".:7O.YQI0*<]N QVKLWNI&-TUP#')I1E0
MD^!(.&,_YJ*LUX@OK5U=9/X@9S6N52M$NN=Y)0=UE[[F2:W((&/\V+B2SZ)V
M:.*9TK@35*2J]OP>?@"3=>Q+Q,ST#L9;[0"G99A' +6)W0_KA4F.8X>-@@/Y
MA3(F4%PMY' ^Q,+W #&UU"49@][<VI4"56L37&T)T3V=>X#MA;NU?E9;3['/
M4AG("6'BBT.MM&YTM4\2U<P45U$,$_ _O<+K+M1&A JKJ'?$OT:O;!"7;^O,
MY@GNMKS.<]/+J&.NU;"8)117%QK.C63BM?D:I3M&+&21L8I^0CO_+(*+]VTH
MHGH+ '5HQ?->E1C-CD>*87F,_U,&W*-K "445Y#$E&55ROSH07&R@*^.-\4\
MY/F)UBQDQ(_CN!IG_7%QE+J?E2I5.G U#FCKSQKP&#L([0L^0["_FZC;V42-
M/JS#R$M+GMSUAGBT/G8]C,YAWBF9+5%S0CN!+"+E6>Q+.:TN J70CDZ*<*):
MX,!.9 .?%>H:E3*T' 2=ZG1!<XD.)W]LS_1A'KO8=*_:1*30>XZE'V$61#'O
M(,\?$+UZ16<6,2;D>P!"$7F&CH&Y/%8IC^W&;.&JS9L6=UH:7E!NR'\69#:V
MW1#39=)0:1E]%F%4?-Y?WN8YG#TN5EYZA$,^I+'L)IKH:>Y&.6"5K&1<'$#,
MN_FE9R_72GT7,_KX[8$L*K9Q@L<HIKLD29IK4'@B)-(GI2\75SJ9B2&&R*G)
MVH/H1([="B,WG6.L"]-2E[OT8'E=&DO?Q"/F?KT.*ML<5E4E0TU@8I)16=!C
M8\#.AE16M)]O>OF 16!$0*G-# E_=X)0+?!('M>)MJ=IN""GTZ#<_U([T2Z7
ME^0M3J$,OAZH2,H";Q9&0 "10R&/6+4/K.#(YWDG4-B-#D2<*M3_P*)[QH:M
MA2S?@\6S-=IS/?'* !K(V\[ 6T\GR;;8"!67DS5P&FE@=<H6Y43O)N7SMB3G
MZ$).4Y0Z9@=-%K1>X);[DJ!.O#<.1/ZXTXGHLEKEG"H\)W]71Q0E->PI=)YZ
MM.Z"SC=XICD%8X[!-%% ) !M60?5.TUL9UJ^LGSX4#P:^2N@T6Y^'3BX:+OL
M#Z7D6BR2B-4\2=JL(=!9\7E7OE]*O5T&'JWM0PC<,6==>SJ"01^X[MV::WY?
M<*31\T$GOH)Q4:@G&_=*2L*J[NS<- K)@Q,+.W_GMS#2FP9LK^F H0% G<,7
M8IQ1<\,>.*65)_:VN1WTOG,/WVKO(')0^?'36>2<<"D.;AF'=9:TOF?[LJH;
M8[9SY&IU9\+):8K&6>XIU,6C^!+VRT/3*<S:OK%-G5PITOIY(H'+3-ZU'MW:
MUT-L/B>N=+5>;A)XAOE/)?%6&]0<&_)0S3P>\8+7K/8:D<48@MQ!90,7#YF\
MW0AR*<I 0G'(=2@!STD\76;<X&<U^97*YJ:N9*22N>%YF8^7\J(9I#[+1IMI
MU.X,SVD)8:Q%/*@ &7O5X<V_=LZ91G!RF&Z<8H065(;T/] ):FC+T]@);H!Z
MWA.VV11*<+;&$R4EI";+=A*:G;C"V\4\BYG*R7ZDG\_(>\6!6FQ%&26-)A/O
M.:,1%+[+*L--5"JN*9C"@1UC0>+O\7A"&"+M5LM2H_;2CHBN]\#3[^%J/(>[
M<YYJ7VQ99-G(;NHN5_U7#@O5$@'.S8W<V$7P =5PL 4J:/KS;.N&\^%FL0?6
M28*%58KD4UV#^UFCN%0ALKO%".=SYE]T4O;!-(_V6).KT1J$4)+Z.50'#^E*
MJRN5PR>_GO6#2.XO#UX81Z]-99%5WD3J-1SV =)J':!*:>RC89^X3#=<T7O+
M%T8\";4X?;_P8F:PAFMGLM;GT)U;LX.4-0O*1NQHW>6B!_8@Z,D[";VORJ3&
M$6S5JLY3UP.1FF?R"SM)/NMVVL9&M_22I(L].$Y2U]V<SHCCRGR_>V=>.$RV
M7UDC8DDF@51:#,60WYY?'78ND)>.CH]G\R OG]Q]F/7.]M8KT+";ZLX0OQC6
MQY!)9RZU/J0.0]+7.?YYWOLZ9EEA((PN!S0T2DG%%00SY6RDM(Q%9+;R'?X]
M;2<AN5 U^BL%/"%A[;)FIS1/%)'54'_JR>"DW)X&%Y5H2A^+](Y'(4DZT-?-
MYLUY:<!UX(MAG/>5-.)H);;-YFQ+'.:[!0UNCZ#%>DCL'B] 9)(R;YX(P%NN
M3G'M7&Y!&2,MUQB'VG=JG;S7P3/&)\(036UI]CBM%VC-;-[!'J#T'8D&C2HV
M.WN449^N55Q$0@8S167'\&,R_O;V%MC$:T";L=79"?NDI&?3BH#G_/PPM%IH
MMOA(EYOWM$9-GKDVO.P:D"?6TV"VQ6]]#4 &5"O$6UX#F*RN ;HE1_G5V[WQ
M4AY4"4XU(YNU6/'CG::-_638RJUP0U:8*\Q.ZLT1G$>L@LCJ'<3"<]5T2B=6
MUN[S1B/#AZI80Q?5-7Z"Q=< K N>A$9=LM+!^6J-B$<P(A7=0OA8IBMY:5YU
MT%CUIEPWY;10>9:6Z<LL_SFCR<8QW^!T_IR(FJ<F>/,?6$'07;^&S O9K#%=
M":<")"R53.UE1,$2S\9IM(TJF<]:HNR^=-EV2$741ZE9=3:GL&]+>-PE9EM\
M1IX51'%@%7[("J.VCJ0PAIR,%J/H(9D=5:9=-G6:LSQ\VL!*HMRD'#RS.+C7
M'!U40C%<$$^^G%[&T7<2.=L45)8R.@ILM0C\U"@;L+NML$ALY*R=S<='WFK?
MQ3K,A-ID;Y9*8"I%8$GQ >>5N]=5>/]$#_TU $ZYRV;\Q:.'JUT6GO4)\18,
M,]#AQ]'ZC8^6#= ^@]2OL";;=DAWUG5S+\_?QGC47!W>8$[-*Z)DCJA$WK&Z
M>CI_#="1W\-:*>ET(F_ .%$6Y\3HIGQ\; F+-:#.H!8[+IZOIF;B<P&Z!H2\
M:;BJ(%G6S4XVO'H@XWFV;[4 BM\=:1B]T,O4FI1PRD<*L[R[S'\)RBL8 /8T
M[*ZF';.*&$P&FU?(<HN1J0##3'H\[N\LZ%+M6C3Y= :5GCJ\2H> +E3Z(<6@
M2;+Z7BQ?ZE9=S['<_;IIU/2=EG<F@PM5FFI/IA]I&PH%2LWG^>T[015+*H-V
MGS_(95;G65[7<C4]%\M]NR>HQQ:_6U6)>(00C UYW"&_"$O('&LRL:M-]?Y@
MQ8(=JKEYD)#?W+ 8D@J_<,S-L:Y+?6(>3UI<,&YG4%D2(%&+!X=V0X+AA!MQ
M]++,7OH-?1L/L*8?J[H#NC#7ZFETP(IA+%4Z[&$75'WQ:O2+!6$G(^X[15=/
MM832% :OB+77!.\7]@;.98]S;K-9Z587;>LPO2VFVIGR0HC>>P\4S$&@X^EF
M3*#=4C$8S-5W P9)\:.S!&!@BS$$2S><T-B;5SY>H'RJ>?%%D@HN0/WS]->Z
M3$T9,YN8V7#I_#P*Z(E0EN94525EAD'@^R_=_8CI0)IVQIBW<7X4@Q4AW1?B
MT01Y[\ ,TD6(8H]YVB;5!"DS@QO')#Y)TMUS+73WL;_".E%@[Y*U9S!8WE1.
MFLCB-1D\&ZX-\B 1FULUJ B:WSAF":QH%L9*+WT3JH-.&%K$S>0?R:Q-Z5OP
M+%=MT@:K*"A<*/@@VW9&@$#UM*8_!*F%W_ BNM9V1W.J&TM6,7I6OGN+E66%
M)[='?>>%2XOW3._2I^SZ1/I$1\SJ5/*.]B-4*;Z)67Z<-"VS&KBJ7:QLKB-_
M,;*=20"1M48MJAM?VLGG;84834^6P5"L<;P>EP,T)#?^BIV- 13(TTE@!YXH
M G-5,.3%U,6C$*;4\KY#308,$2G%>+9QB! (>R&O5D'1Q12X4^M[4'M_#6?
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MK%G.>-Q8H;S>*Z"2REW9]R7U4)GZ.3+!542>G"P>R@I9LV8&0>/G4K/5(MQ
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MGC]XI?KA=&:XBXU:^3!QLF-!]VK\X[+" 0A$Z@,<TQ+UBFV ZLBN>TB!9$I
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M*K*UB&R&S_ABH+9VF[#BN&7<Y+#V /MC8!.D)G3LG?L.?.OX5+*?=J'KUY=
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M@KZ[>&U3)T\U5JWU_Q#WE7%1?6V[(Z@H*4BW="/=)=+2/91TC(!T@XB M("
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M"\H2?T0&W+8<.(U#<ZAYKV!NSO_20%YR0QQ%=5U5BD7W8;/BNN@>!J7>['L
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MG".]]'OV]CIQ4O+#E8NNNZK('N.U>T(:2,PMY3ME(%JL8JU)UK42JZ$8&'(
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M>(A;]J2#^;M<2YCTE=Y:^C=TTHVV.7TOOX,BX+C32EW=!'V"O@C#>MQHW3T
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MIH:!/-]S:"3")4.6.EO_+W' U+E!W>F$G7V81L]V';@X6/J@Y(<C?Q(=GS9
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MYM5<DOW6'EL4O\I0[P_IWJKQ,= !=V 7&.58?!ZD\X;:@ZV"JOJW$W!3%SK
MDHK+"W7B('D<8DT]7FZ[BB\%)+ 3XJKD75^V5L![V[?A0Z^>-CY@S:N4M7:9
MN1YP_9(XY'-DK_N"/-?Z!*()4T)!KYV9N?=P:SK+,Z9 QJTK+R%JBA1+BHX
M %6SO,_U8<Q]G)>0XH_)Q'AOQ)(L[Y-XQM+O_[A_3LN[?Q[_F]-SWS%J].&8
M7#KW_?_<$L+W#SDV_"H/QQ31$:D\]Y^,NE+YVT/\B;7UMQ)G<2PY:6LL,QA
M*,(.9?#WM1VY1'&<O(Q$><6_64/_O/7/9\6QI/@9QI/([KM)>]RG$ GFT_N_
ME*('Y<_?O9/(@W;7XW]FL_[U=QG"/YM-\BPR*^@RO$)ZMS4751$.(JPOIPI6
MM?G=8EVZGT118!__F#<*D@(XDL4D.Q:=4_7%V8'F>E%O'\KU;"E/[K"=L$JW
M+\,1[UZ_#N+CPXMI;:CH&C-7JWB@/DF&1TC ',6X\1C@U$H7L:=24VMUW$=F
MWJ"UDZPIG W[9#QAQRM[_".>4Q:IE>P<]:P(XI*D@I[5LY2E1O+[2MB>(B/'
MRT[,W1[MJ%"QR%!O<UI]P)86@U4X1%KPB)8E*K:[A3*-UIIYQQ6;.Y,,4)(O
M>6!-%'8+ $DV7)>>O"(A*?B/!<DQ:)L"2;68Z#3C;U") SY,A9>3!I%F0AX]
MY]Q#3C>,LB\ZA12[>[C?Y!(9_,:.&)A0*@ N/VGG21APX2_#>002#KI00<\;
M$]^4 A :Z=>_BJ=)T9")6T*C(+K4C#BJ?(Y C8/RX+L*I'01@KHFC""LF*(<
M",#=<1&A(!C 1F.M7?ID58-S2\B[[IE='=-:R PT6^Z8<)U(S="Z<:[Q2PF-
M9(@E'F45Y<S)R,IXP23T;2&9P7X/ X+8=?CDYL!47"P@%U>>.,ZG:'O!QN-\
M'KF>Z;E<KIUY[DN^-4*HMZ6M==AYQAFGVH9,C_KMZ[K1_F\;]BI[=V'Z4PZ7
M3/..80^I:&!1I>A!=&&)<^GLT"E#.N*I>O\OK]W5;!^6MG?R#Z6?[FS><>=?
ML4WY4PKM;%!1IQ']_LG,:U,O:3':#!G*[I;GZ:O"CI76<#+SE$1F96$P%NG.
MGK;",JS"0GMIH8<W_UJF)=NMKHVS9PU;AA$-TP?U4J;'B&Z";?!%/DUCO6H(
M)3AB^6-=RN&222#7H>"2C,T&;]-76YXP'G='9W?2@8%;@/ M8 ;]^J1B6AY3
MOG=)TW)Y=]NET2_&E56OZYM_%V5^9BD'29PGKF>O?=C-JQ SBJK.\E#L IES
M;1&P]33Q=,!28E\,>]KZQG.-5II)R,E+"3T$QR.%JOR]UR\W-'*+@&AEHOIS
MN[O")B6+UBQ^>1=V9E2;S_%2C!UW=.!4+UQYFV-WQKKA%QT[%!$C^Y#,VK>P
MC))H6-+'?3]DU7'71Y2[*HHL?V)6G$:7G(5L/)J1;\46,UDWO\!'Z19@<.#6
M5/2HN<;JTT0AD@Y3U-A,TR4G[&QBCH?XQL!4(FP58**_4(S 6ZK$&4S/"#=O
M,IY'4+IY7?F=;"4$+N@WP$F>0V- :#"\ J)TX!I^&<^$\JH;(C6F6:%@_BN#
MC@>2@K$C5K7+:*+9O1A5RXI-SWA"B]3T[PP:]9KFA\R]MP!W@/NHYPV_S8W?
M D;$3B7*6ZB4ZMN:U;$NF$CGCM8?/*8<QN&W,H+;:#6,B77Z/7_/&6.UK/T^
M1"V7"JE/[,L[5>&"G.3)81U#WUMBQGI]<NE:P=V9GES[K9BI5B)LVCJU.10.
M.7="G^@ $JM]M7UN-B!V.#M+M0[!R?3P*,<LO\BTL_EUK3CU>,[R4  QERDZ
M%LBB<(_*1_S#H6\Y2JE?5S$%3GG74YU9YX^K.YY+T.!705Q3I+QYES9#"A<^
MIT:&E<]F9=],*F6J*[+'O2M'6+>EE7R[EFQL2H:X/HEAB#-E$B=!7RA%9?,?
M\,6#;'?5\.;)K3IP5;L<^=R<%^<+6LHM\IU_O"PK/*!#MM3&VX-Y G</V8S\
M=OUJ+D<W?RI:89;/D;=VKV6M0!0TJZU,K,"3B<G83V;0<\_*4\]CETD8K) Q
M="X"YLP/;C2'K<E\NOXL7^ B:8VYAS(?/2P_3U2MG61/W>['"'_',X^D:>&5
MIX!_;X%>V#M7-QS4EKD68?UA&7"5N#J7#^SU\4U.M3C@UR!VS.B,AO1U[*!1
M5WL+HNGL3NT6<"!DKM%O]+U,J^SI%9HN+$/P2.);=:;OIOZ99@AJ1,9Y]&2$
M>*L6(Q6N2'#ITIP?(#.P;<.*NTPW-;<#+.9QY G"DP>TYW@.5=-T^%)F7,E]
MB75I:ZJQ<[NZ<JV0AX_[O#OX6!L%3> 'N)5$,PI IP>=RGBF<GIW3HS)SS-D
MFH' I"_N,@B.E4E'/4_[:/L3""\89@6>,EN5_F$JL;-GL!Y6R;I]#/0ADB,Z
MO /0_F)])[UW_S35U<^[NHNI+N)%HT),@#AXIJM]1T<D?W([:VA&E.8\Y&DZ
M$SC<$(=4/NH6P/RK_J "XEZ$M<,PX!!TMA^'Q= VWD!%:%/;6%A(!N?%PM^V
M]NJ5\4SLJ-TSU]=J^/K3RC^ZZ!Z4S)*>9'E$8!F;G?X&4-?[CE"3ECLT0">'
M*YE7FCMFW>DG(0.1;B% 4H\8%7"LV9X!X4Z[D?&0,$<87(;.S&AA:K2]0V+4
M,N(ZW.)>QW)^WP* ]UF(DB4_=?,_V S-&Z_96?GAV544 6TE>_#^LNK9GN8=
M-J ,V6:@UY?0;-7V*($3"FU<:VN1DW[]V=<>%/OH]IXHX?<>CU-"GX320.97
MO9L7CT;^Q%FY+!>6AY0.=6BY_$4R2S"O]B^2- _"T6$F<@?DG7Q'4'4I_$8*
MKF3 '2SM^S>ISL7&;^)Z/][#&/6;L>1:LU3/QC..KYBODR_-J]?'2N/;B'D0
M8J@C?=W0<<56ZTB1&*&=TLUY=8[Q.'5Q$UY=?D./*G,)V:&QX@[%%"1,7NJE
M[(NI=&8*'!;MN='WJXGH;LUBVRM()_D"I+$P(UB1)[9I3]:=>9M5 5OQ>[XY
M6,>W1EI.OR;X+D8DMH5;^CS5SY4%L0!5E7O5J?;[(W^+>7[DTI\G.I6]Z?JP
M/_-E?NA7,N,-"@IRE;MJB'E^^9XHM\J,;B4-X.%$\EB'_@LM0NTWE;ZA]L7G
MMX N,HNQN@8=S<82!$?'I*,^F78,[)F](HAU@1&FT_WN.TF<ER^LYSQDEX1G
MP.=5X[SA^X$Y/_<_.=/'I924X[LP\F,0+8?,TT6Z;@<"S(XM0DTEC5WY3GBT
MD<:><YY?N!$-K(%S3@J_FN\EIK]?LOTB:$"K:3Q5?0S;B9K]4I).PEP4U@EJ
MTH).GM!=O;'1HOLU@5,=OU )4EM09..'[UERZ#+^N',<!NP_JP?;9.Y23!OV
M%X65[;P4!5;\B4SQ(SAQ;7KO%@]]M!3HCU&&&(EQO:*N<ZO$;O1N0]U;+]&3
M'S;$> LH;N5'#VGC#ZLJ;398JW*MN-ER):L-*W=W</?]H#Y"D^_Q5 LSH;N?
ME GU#,:<)AJ:P-<?6AN2(?;IC B)L((?=[H+*;Z6.!!-<X&?/<6LT[0%8XO(
M$';,Z@UYN-2>;NC)"#] -#[S1"TL*M2-DW9-30HWWP+F;P'F*E6$!N1.OXB8
MH26U2* O@Z;9RKRZ]H3>6ZUP7MF+PU_8LB(M6Q37B@?87,G)U'/1(>_NK+O!
M;G#1B >(/N;](X>L/=$[9-W#3M[Z**@=V9IBAC5AG<7%' M+:3]FF;DQ>:/Y
M25$A?>1(Y,E1MV?+:5)C2CA2*/<6(.OOKXL+,;5N(X#QMD2AGI+6,CR#.HEL
MO6UW&]]T;(5Y< 8.:020W@)2%GY5>*DT*,JHIUBQ7L.2^V13%TI!$25,QD9=
MDUU:JE$3-=N>1$TK8L\WH^K<AK 1WG-=C*H]5<4\?N&I9R]@L(L8[CL>^G.0
M+]3D6>R/A%C43<XI\R+6WKYS1E[=+Y=Q=77II\A7 5B]/?YO5=5:=/ITKP,+
MF:&6Y6<;[F2IL=>J!?,9'G# O&9@%,>V#"&XZ/Q,8^IX+6(F+U8]-B[J"2WE
MPDG_UK2#WB:'U?8R:I>F8?UF_8HW[=OF&?^TJ6S!(?67W03? "EV>TVEOCEC
MW3*RYE)M&5E?^O,0TD%G6HFXI:1B] OM]QXKBEI7\H8*DISU47[YXN)O0J<W
MX<WW!3V3:XM*+E(.@C4,"Y4.J?2F]K/*TS_:.AV:V9O[1X?>6[DLH1/!.7;7
M.9<J7H,YP0S#*S(A]RY657OUG<T[:'&A'R-&I[W-EI_Q0.;+.D2S^#GE"1RW
M@2,P\J1)7B;+.G_IZE8UWHK2)\;8($L=5[X70VYM35 [[S8_F]=&^8E*^JZ8
M.NG5:I$ID25EN=<RS2WQVWL+ H5QIJ0.'.2C4R(*/:V,X_:4"*0)MNCF7U4U
MD H.[BYP2SFM2HD?(;FA\MQL5B[6ERB8M4*F[.[BGJ12S9_^L9;!4].8M8-?
MR\4P0XOO&.BZZR+D%PM3-%:V@B 83Q@O?OU=072&#O@[50Q(D#&O>G_=+:>7
M+A7VDA.[[)62\7*K74\7CCX]D%)<5I2?5IW\DM+[L+L)NV65IH4AK*QOR$ML
M4)E8=V+=J>9Z>.&L1Z_S%*O86E2_$_RB4\,NZO(/"[_2>4$IZ[:?K2QB)H;<
MBI3R)';IE_$';3@[W2%$_*]V^WW6>CR9ASJ5>_WE57)U5:6]#4-X*81EZY=S
M%UR>2UE[]#C:J]OWU43$/(*'VWK\B.+;G7^;D>LMV]R2O,/[)(;4G"3DXY,'
M9^5>EL;/0'96)WPO%-S:&J%V;EXWL'Y=W9$2HWMG(VO67RRD A01GUZS^,VY
M$QXUH3A__-9'O<>7:=S>"+YI@BVH]1=;[>,]*IOTULS1V:_@R8FX\CL&!BTT
M[+U8U/]YAV\!?/<0M\WQSZ)-QYC+5<;5%"C_D"9RS>/(WU\MV3.^I+_ R8B^
MW.:PQ.@6$# NUCF"]U/PSG73NG?=_.1G6@Z&*UV+V,#Y'O9DL8OM&D3W((4?
ML!79EMA@VJX\,#,,43K$6X"<NZ%/:,(B&[PSI!YAC%S7GO:LR/.BG.N/#-T)
M.'D]Y@0KFM)/J0A.5-U"3FB 9AV$JO%[VKRQ%*!()8MLHD @4T.$"OA0]&3]
MS)D5>>? 841;.&G1[61/C96Q!2Q=V%9^5109'73K7.\_NP6(0K^%%4\H&7.$
MT$.3$E/FE7(ZJ/#7&MJ($-V=NCCX4K_1]HRRR,,)N#(#N3#VC+E_S<RAB$ML
M;4D3M 7(O;RF1XU()MA<LO#)%<I"TC4IJG9V#.O)IICI"\ZR+NRH(1J3)T=\
MQ7D1Q[@:_V/;6(0Q7X3Q(?3LM':XA&>3O$[*+-"Z"N6F-D<.VLVS#M5X-N0L
MJS71>1EDH]+TIM,G*ZRW)[<<2$[>Z]I;41!^TV]/V[W8G/^]VZ<8K35#%1:X
MJC_ J(N9^G-;Q(HL*[Z._^$:#68F\?R/"B?M&#'B19&>5_K>:<<K8A#G$NPM
MAR-A+CE3MIE55PH!9L"/RU'T AG71]\]-IFA.L/[H,+9A=GY$J!'@J9ZH,HZ
M8??,;!J49?8II8)K0XKN:['Y#P>79*GM\#IKKV(#O$B?@.<5#IV,I.N;XB\K
M?*))5PH\\HD:RR+=O2*;>V/&<83\9?^(%\'@Y4N*'7-TO1%B-<P!(9^=<\;]
MWU[I;["3:0:*=],C5D:G2I'" @;G01K'G5X'$[X_<[8,#?]CI4Z>O,2$!Y=C
MWS\)D)X4#)%>CCX<DR( J.&EZ]GMV0 BO'3L5/+'RDI0&%MJ&%/B:/Y/ $5$
M/X:9T,H^H0MLQ4P"'@/6LF1QK*W^70 $HS<7&Y-[1USPGWN&[W\JBI-RYF]]
M/ ;#JFMHD*--'I9CO07 *[X>B\*Z;19$%<DN(&S;=%I4+D<AA"KJ]O/<);VI
MS=8Z(&Z9"<E"!+UVG"U[MOAIZ:>E8?_.1((OB0D*.'[R=K$K ZPF^2&,B+=Q
M7/%UY'^"30V]=0.[UQ2 T5Q6R/<A6D/,R88,>TTO23X05'FJQ/+&Y)_SR]X,
MW8SHS+ >I6 ZZ&]I$B]-ATX&K0KVF,J<:RYBGY=V=,*S;6MLDWVO98HK L,F
M;0VYF)?FF024^*Q^3'J_+K )QW;':TO&:)<N F@0B3X>W68;7V-Q,E?2=G^E
MK2Q%<8A8\QU^^PNYY_T4;$.L[.Q4+0R93+D%;&G44F*-'2]RS$KV'[*-7ZSB
MVFQL%(VPZ"UMKWC]6B6_&]J@[K>X!"<YDY%-;;^E9^/2:7^RX[G$E728D*VP
MT?&Q$8:FQTHLWWHK.W)PRY@.*7ZODU(M:55>D^;;T',*VU?S(L**_%G >3$>
M[KB?L/1Z.,U^*^*T;[)1U]%+(MV=F.R]L< H?F5GE[\242T9\A(X]Y_5,SO*
MPSEX;@$8UD(&3I!R*3+5$+]E-$0Q?P?DP=<:J=>F3G(T.>.-*#%,0:37W$L!
M7LL8%Q"WK"'W]M,7M(^0@=E_4>P)G8R=$T2KHKEFJ?A' LH>?K_?+32JAW#0
MHOE[&^K,!ZHS(-QW50T*89 ^%Z0[102*B7$]&>*P&FN6UKK/%UMB")L:[SVL
M4U.^!>@535Q3%5A;,R,Z>\>CB$<&T6$N!$D-2*"!(,T=6OI+\#NT\N*J!&F_
MKQ]#GNRGI+A4%99_3IGIPW1LVM(_5E]/O?]NG'$H)=4CWZ7AM^9^P0:M^T;Q
MQ1@I_XB3_=C%)<EYH-Y+H"*4\]-O5LSN>Z3H)I+GG!X4SH.PI)H;O,+'9>)C
M:;_? C!1Q>!L_3F13+ZJD<T%W'$76.IV%:'UD[_3F+N( R4E3<N+JZ%(D%T_
MKF@C2'+N SJ<.B*ZL4 R\C<#9$[2??:9W]4#%_5&J'"\14FH7I\+HL3:&U&,
MZ@DH!B7V;\.+(';922+:;/[#9</B"(?'[ZWO).I'LM'<211?OZJM+B<C7%O_
M)]/X?4+3N5>>T;S(4+O\84.?:<<U,Y#]D17"Q:D ^@;"B!C)%J_(CNCX-='&
M"Z-!'5?Z:CI'BF%?B\K1,SUEH%WU"[:B>F+-($_FX@AUNQAX+,!Z4I$004@&
M-,?"E;,E<"S9G^BHJJZ+6T<7H/4+-IQL)LQ'M:HTR,P\;[]'#&H:_"Y=ZWL*
M98*6J@R=]?Z9>$V#W$H=76)\$TG>WM)IN(_+&?]3FMZ>!-D[T+8<I=A-E.!(
MB1,;K3IFP4@J-"N$TP?6/ MK::SU.)'2G&L6,5Q\N9!WRFKWW;<WP+_480TJ
MPKSTD/X8BVM<L&AF[4-Z!0>G=YEVHB=RHF3G'A3\,W-_>6^81>!%YA.P5"*R
M'&.OMF\97X81W&E?_?J+E,##;]_W*8,+%U@G^59[V]S=!2I*(^RBR%M@Y-\4
MF^K!"<WG?GFH>\U,$*ZXT[8;0M[0 *BA(!W1:#44#!3U0$,T>C*>\NQYH4]M
M&ET7K^!VW$L9\4Z9-D&LO:(ND,=R0BJP<Q,@^%J)WP=8V$7R3:6P\6''N+X4
MA>DU[SY*Z+_@,YYL)LZW*<,WD+XQ>/^4+).Q(I% 7<.Z /BP8T*^GQ'YV1OM
MF_6T@O.S!BZ&^?EAIKI6P)@K5M&=A:2464WPNYR"JZIO,R'@Q%.;>G.E/8(F
MOX=H/M2EO]5)P^[ OKBHTEU?R@E-"^>4E1.DC1_9O(-$B  !BUN@3)03@.!\
M/">7OADBPGJ1#U@-%I@_*8V\F]O2'Q<X#LY1L?L5_1$O,>U!WX1%&)I5!Q;/
MR64FL[D=R9.CW?(><J C/U3MXP05S;,.:B'SC3*^.QH:DA1M,RV<4MU#4KK.
MX/'[&;%*DU=94C+2-_]>0:I,?L_3? BQ@KPVY\;F7E_K@;GD!!-XD1B=3A)B
M6B^FJD>)/1,6U;DSWMGY=[)J*P?RV&^/%94KQ7UZ0[#B#F^T8=1@@L2]$:&#
MJG:S=RCC@.\LG/^]I&7N-^AC,+[8D>C3;KX\M!]_6(K!!,F8P.UPDQ(Z.PVG
M%&-<* M607W$$R[V^3<275SK2_!@=X>CP83FF+_3.^V6EU-5!-01A<C#D=(X
MD4LB#!+QJ]5!^/Q:=HIV 0K2S"L87;HTLN\XM"*^0U6E5/]W 6\T7337A]'0
M!C#/ ]URVX43.P3')RD$.:+\,\ ,C3*IP)^4X6&<@$F<$ZZC^-/O[@^3&-$
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ML&=^VM+/Q8&MTW.M\.B8PN**&0/]EU[;DU5W6.;!QQ_D1,QYQ4$;]:Z%2@M
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M2?^FU@]/VBX:5'Y ^<[AMX*??K2D7D<F!V)*>[U.^GJ=SOLQZ2I+Q., B6O
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M4%<<CJ7\7\7#]P\QT/LI@0BE#(OYC^[^O_I=BG@Y_N=E^K>\58CAJ3T<QU,
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MO%VK0+?F;H^3-:N!9^L?K*DE(PVPKC\K@K4]P/:W87Q$M1-T7G[8Z^0"'[/
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M%A!C,3M16< MX#<3+#D7%?6*P I'06$O\-6E'8/B:L-@R&Y25W=,YDH/A"3
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M51>5[2@+FCW*UYP6\TN#A+0_$UF<V;5:.-/QE]QKFO%@D!RB_+QJC3!88*
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M3^EA75L%NVW8S=P9O^LFGY2_86FOM8-G7=/#8>BG[<X%<[._[V5 $Y'AX[Q
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M9LN0,DI")--L+4KPBAB6KK\5 )Q5NZS+9VI4KG/E=37M%I0I#E*;R#Q^\+>
M\#5(=^!S?U"D'=& :LEGQM%.9U?/(P]OQ*2HV5:ZF5-5@GF'!4JT[=KR>V1
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M0?6U.\#31)K]B"F&D_Z*^]!>'(*+O-]!/U92I!7D$^SWLO?UCY9"5&P,"^\
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MIE?TW0-.AP+KPM"Q,8W#/Z,;%,H1B\2+H-8CECL U@]9'>_>]Z!.&ZY5XXU
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MVN/B&Z!2[;#+4T3"C[<7,?%I<N9&3].S5#/U2O)<S.G/8O%F)# P=\$DBUW
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M60V#S7%^LL3>8&$W9YJ.K;N&LOR24E>=8CM2RUD]S'#D7WZ;U@FVOMU.A,.
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M1_NIK#4D\LK#<\\E']AS'U5#6"AKCXF=OL[*_*GB<,C?+)$IU1V*-AG:Z0\
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M1%4!0N5WQE>GNQB<]-\V8W&3"$KX<T!%Q29SVW4;B/7P;N%8WG"5SQ9UFS^
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M$7<$\SM2M:NI!:[.BR:MHO."Z2S&GEYG[ :TH!T@3&)%Y.@"./X7X MJNF>
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M.98CV=87UW(\XY*X!@ 2I!A#MI6< "%8V(OS#BQ,^3]/O"2(#7^TQUL\V]#
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MG!D-5V4\<\8@\RK\RI*;D%DBV$FBLYX% VM? >=_^-CD]V6=%YAC%;2XG=?
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M);.W5QZ\#T>HBFL:;R1 H:^5##1Z6[ZLR/E*^+Z&6MR(]M'Q3JE<:GM\JZ!
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MX+=@B/]R(%FJ:[#3)'%^UJ+HL+P/XGE#>@TVWQ8N!WU<[PRC]6<(;GI3$?0
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M<_: $;OZF?)X@G8I"[W>(QPT%E+:B_S;[^=O'2]U_:D=K[R=H^=0D603Z9!
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MB%^49?9VC@$]:[#<L[+K:.M";=AN=>\"S05%0/VB<"D$<3S!]>@_)Y,D;)Y
MYL]V#TELR.V<14_J4Y@'FTIH[^FRZY$'WUR%WZ<$B*0_UOQFK)*]$\%L1'S-
MZVSS%IYND6<VK^U16Y!!HQ$_UE]!DF2Q@WXYSNYVI8F $-:RII<ZZU//^:S:
M4R@U GU*9AEH]BAI<HJV[]^,0X$Q=/!='C-:O,B9I&WE3%:HL-9.@CLF<<@:
MSCNJGS.\86Z[)^M#83F^Z%+S:NQN4P7VI"H\Z?9L/N47;#'4UA[UN$\FFN1"
MGQ!*K.C8^6H4[ C 1H$2/ZM?U'P[\=?:,/X@SC^VT>+931Z5>WO\(!#X!VU
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M8#&BSO=5*_@+L/@+L,[O532=S&:(*2Y%0W"%*DO TG:K9F(O XS2I!MHN3*
M7$/LV/VFIV6+[&,<D(FG=WGV=<T4WY6ZF%94=FN=-F.4.C;X&54R,6P:=^O]
M.6'L8$1#LHMIHH619MSEE&Z+W\K5NF[\7HC95X4X8]GLG44-;,[C!V#F/,P8
M,0Z@)B;CO1$ET*9^*E+'C^Z <[Y,8=\6I$)GLIE:%UR:C7HJ8%6,1K'AF+/0
MW,[\97Z@6!2QN, X/\6W)R0F+?2T;^CYUT$<G9[ACW)MGX_L_,/\N?]D*6Q:
MU2<H3S+\4!#MIWG\0:R'H$]>7_%3IH4:(U_KM,_W1?$Q\*;GZPS8!R%6U;^
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M+&A!Z%Y_R]3Y,Z-QM-D]@UPJC.\_F:N7FAGZ"]C54NV5GSQWQ^I:W=AIT@I
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M%I'.E K/"+4S4U8B%G!5R/.O?>:7!%]V1!/,S]C0=+?C#M!EQ_6N1B:A=$J
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M']5^F1QZ_!GAGC7I+A;2,7B'(=Z37:&5WP, 8F%.M>2\:$DW2CSQ5W]&]^R
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M^P&]O5KMOB3\F1,O=8WS.<X ]ERJ)7LX[&)^083B.'?\7<R"G5_)CY??#K^
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M7H.VP[HE+B/V-='D.Y4;T(?750*FZ$-3IR?"ZY0K9=2'+M9(J\K/C4Q32<<
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MVDY))=MSX=;ERAVZ,3SZ9'OG%)GT*)N:1C+P\X;:>C%3_(9AB-(BM^"<"FJ
M[#"",&;*M\"7:L?!C[1X'6%ZQ>F6K/7#/-\QGL#^]WT][+VH!)_A B=+O87:
M>OFD1W*;!/\<]T^-BIE;MO43/:#+<RHL3V+TWLDZ.-SZ!\[<;PW9\1/[4)E-
MX-S!KPADFI#A1'=HI[/#6'Q_B&K#E!0<%^]KS!'W_ZO(_.]EZ97DFQ9(8*IB
MER6BO<)86.:CH-&G^YGAY-EG8=S3H(G[0AINW-A4&K30F?)*Y466O5.$15WH
MF'J<<CR<@'\%LV=MV;,<+<$_Q+#Y[77)S4(L'M%&TK?/C%^>C<7WR+ZC*<AP
MY3A_=M,Y=-331&K11SO#D5D<11!:C:YS_L4@8Z 2^L33?+8Q^6>=KUW9-4PG
M>>^SZ+B1*CYR$HU-B3FK.%EZ WE'DSLP:=V MY"\8^>QGH/K=[!\TK.D<;YZ
M:Q0UY38&Q]=CL=%F&9\_P9J8;*PLF.2Z]?HBWG%M4""9:/4ZQ-?V#Q9C),:J
MXPFXT0G'3@OTOEVI+\=;GY6RF,\KS* F,=,NR4HE^3/#>S*,>:K=5#29G$($
M#GR&8E[+_SY&#[7%ZMSVMM[1Z(AVS1SEOQSZ+N\1RQP#O"RE"51>%W_%!3VW
M'NF%RLR_G$MM%(P#,[WLH0&_?/_&!/BZU #4 __;94=^69]LFXT+^/_1Y#[]
MS(H:*X$>%%E6$;>O6,O 7YO %'R6FC'<33_:."XTCHF/??E3_D0?896LV!QI
M\RCU%5.0;/T:#<E9^07^.NHR>N3)PR1D]LR/CQ]]>+[^')Z9V./58BN'KAU1
M94#!W \3S2@PEJ&2*=GXC0.J4Y[E>^^/5-]V,AT.1-)33JH+=#:JYF]MN+J^
M:51:5FP#><NHF[0D)BZ^E(2#"S?)CGIQQ>^+78J@9_?%+MN3L:A'J"\G</S$
M%?+4F=-"KE>@E9#J"TW'2*B0",.'VX_-(/4^@C(,[O\.+R'G8<U4[9&)]!G[
MNK=>N[WYT$4*V6HE?&R]Y1=9AAC'GPY /K.EJ0(IC5!*9FD40R]ID:8J55]T
M;$YB*#8@/Z.:11\L&TI/6JWU[&/:X1W&EE[,7!Q@2H6B@I0I:5;Z;"P#/C*1
MYG4&'*O.L(RBU.?W&\2^?0*:I6I"J(S"2UE6)Y<B7HE'^USI)YX@BO."X\BW
M3O)TD8GE/I9F)-5*5G+L'(["T\ GQR6&69UX0LH9%JF4(&,K2U/=L G2I<N5
MF)K0,H&:_'8#Z?E+7[V>T&5_0[0)_XW0W]PD<JQ;@ZR*BPUEX;YR-?P)DK<X
M0VII-<,*8[>,ZY,QBU,LYS,M&P'!*/U XN-&3GA=YJQ;/#XV8\6&J0 _EQ _
ME]:NKFNM=#=D%A&B6>[EJ%+VWEO+Z(6LBT__SIX<I(8I=3/D17?UF(GFAJ%Z
M;'6SN179[Z:_W7O<]=S'I1N2;.L'R@=-+TN*?FOA S=,)9S<!=(/IJ5?Q5J*
MZ)%.;*%_SIU[X%GOD(UI. I:T-F>]"S<?Y,5RV%48X #53 Y0Q=%$%.]5?;J
MA-H-JJO>2G6S<OW0R=\2$7VA'6!V8W\X0Z[=-"9 L?SKZ;\A=!0E/L%'3OUN
M4:N,Q&ERLO-([PF_VKFC@53)1LV.#+=IJ6J.ON3JF.KIXZD*NHVD23?]+1KH
M;U8]-8\LGSSR+@E\$!$ELTD/=?A\0.)J &T+(O0<U$4^R5 O9OGY$/ODM%!<
MVAP,WT1.32HS155<P9'?NU'+:W+]?"5_"DI];N$'3U21,/DD=D.A1U#Y%<.\
MG^??<^=F8(CDF*R<@)0*D7T4U/Y;;_XL<-6@..DH[=XQQG<8F8E#QIW?9OKB
ME9HU_^C3WFST4VLR,U?1'%$5L9>E;-<%$E<WXC[XQ=U-HL<,3NJJ=+":6)I"
M/.>52.ZL,%^';$+_Q?/L@ X6?V2IH0A=O\.@OY(\Z?\-X:[>$">F6)%--)>K
MK'D]YOLFTT*/6'V[ZN_J>5[^5-^!$N;ZNK/.UYX-0[T6P;$*0!'O3OPRT<UY
MSRS=>84H>B<7U21$5AE(4=UZE>UV%%;.F3IZ0MW\5D.IC-\D=HQB^9XS%!OT
MMGOXDG+Y&[J+6%5)Z-^2U4;-LK?RWM;83GL=O0]3C=.0@QK0!VE#LPR/I"CM
M:I,JG#S)&!KJ-9"3<?,L57X2OIX./MPYX=/R]_0,T_+-29%77V464_#!28XV
M% B'=TD0 W79.4*%AT0#$EVU#V[38*+>E<H'BCE0G155;_KP;6[ #FBA.D'<
M7_D.P_E2+RS4\KLF")!6V+3U&!8=<X?!Y7\T=8=1)@=)-$ZG6XPU!PW^GES+
M^^NG/.JTBYSVCJ]*?^:8DM]R_KW [LS)">(DBLA2(QB+/$@K1,[N&KSZ/B#G
M0MKCL\GU><)/BF\<*XF;_$S(IH1^]PH9*YA?0<O#X1UB-RMJ0A>7?WZD@H9Y
M.7AR+?R?WKX[K DERC> = '!@'24WI$2I1<10I&2T -("2 0>F\*J(A&FB"@
M2)/> M*1CO3>0T= BE0I$IK PWLM['W>M]_NVV__F#]F)F?.[Y0Y,YDYF;AD
M?7/ Y/D6(#5'IY3MG3/N1+YMN# 2V2@\8<3;KP2]+:8'VR@U83'<1*[X%!$;
M[I\Y K4P6;KHW(HZ?T\WY<7[L'<>'M;K(N&,!JLWBJ6J^3"OGO@]D7R'R?.6
MYAUO9@&SOQ$7CQ>*:BO@*ZY,[-G@6J>)L62Q8= H]6#D*2NKZ+=W5RVAJLP+
M< @"?V1,@] ;&PQ6>EB_@N>JOXGTL/XB,WNS[,WMDZ&B<M^ NE5SK1V.6?W4
MN84P602A; ]AK\I.+ZGM%0QMGKR&/(N21XF4?+@SC%%D<(W7702A2RSRR*U/
MX!H)V17(X%*X6LO6;KK&N,+X1&)XEI]L>5'ADT,Z97X^"Z;[9%/23XK7'_#:
ME%\1;.;+>\%"?X4CT.A*$+]#]]XHR_-UJBAG$;4];4_I87GCDN+BX<4G+1#>
MJR?@@9>%T=[:Z*9.)L,7VAKJK;DKIP!RY@'^VR[Z2ENB72[9=/I0&QD*MW7H
MZEHW\:TU:;76)]+1C?LV'W4&,P=WV:8RFM)C/$X!,>#1$0Y.I7S62VT&D+#6
MY:\BF2'9=,IVK9+W]<<1]_IV.S\B+XT:2Y4<VK4S)RYE[5*FIGIA>@T?.C)3
M&;YJN<WKI.^KASWK[D]8.OU.\G4RG?V2E"5F+U\=O8A0S5HLMS)X^2W=)TJ'
MUUA)V<2*HG7X\:##\O%2CNJ6^3@AC,MM+%)!E%N#N2RJ!;,G3F>KJ_M%3&,W
M(OL@ID( :-C@.7MDKWN@.Z+CW 4_@9%!>>(W3U+]S7(^H(F,)V=3Z(._IQ+F
M1"3Q>-[)#,M5+V!-&)0"^AD5M4V9<>XNI=N:>!U.CV@$:SX<WN!+HR]BJKA/
M4""Y59MD=N\^,&8!7O'2(6[*F\ V,\CARV4(E68SYKE-1<SE/8\]Z:$8[CRK
M67:V4!1M6/SKZ8EO!H.+%6%B?*RAU#/OI;@W"K9(&9@MR>"L$15=KEQT^GHO
M5S%E-V#5?:.=B\VG@.3$N;)J_@%;#SU:]T/'03ATVM6_DV7-GUNS>=C%R1$B
MSV#0/NAX=\DU[=N=P5V)?KM-$=+&>7XOCH&WM?M)I D>F!%:NXX5KZ6'4@K>
MK*OTGD*L0E2AU&M1;UOAQA;P(_B'(HT\,BY4"U^^QK2_H_])*:?Y2KOH1VW@
MUG!&O&..Q/&55@QLTI7W>I%1BU"AL&G=0%'&/@JWI/?B^)DAZ86BNKT5JK<-
MU:,^K$6^/3#P&;&9X_$2J 8YYJQP\[DKSG"N<NXRYU!7%C]"N%UJU<U6*UGK
M7ZYEW +%/EWW6[4:__1%L?6%X?W<)08R2-U@J;[EH"?-,YQ.IM9]O3XT13<H
M1,@(O-#102SP-K^:G64";-PKCX/T>NH[D=)&O02$CR<H># T.LL!5[@ DY!R
MD16N@$D(TAT(F"HQ3U  W 3B9D)D29A#:,^:/I#PDX@C 68PS8KOC0VIP!5.
M+$'5'T?K_U8TU3GSPBDF)V%>#[81FGX+&B_#AK"R6&\I7<QD</*!++:&3IM_
M&G%WBGO\##Z[S_&NZL5\?$HWQRMUX+MV3,9^G.C:.B_S('ND,VOG^[]VQLFD
M9[&SQ45P%9+>!.7D8KXN12"%"!TLX&#$KGVS3L+ZF=XT46MQ.2[S01\X9?F&
M1W'E"C1(,"B*FJY(^9NP+..C:K<VH'#.)U>L)"WDSGUY[4KIZX-^8_DL2#')
MY(!+1?0!^H?H+\^7E-UB8\8U!ZX>&+!/E"?6?L5"#UB]YP,;5)=L3K\&Q0=T
M.G4$S9MHC5"^87I6ZNNM.BGITA)+AM=L1-50+X(U7?V<ELJ%$@RUT7GT5_8C
M<M8,G?]EC&^#+4S?D7R/F=2\H?4KZA1 H,%Z0EMB0\C*+^2[(TM7\J?_+E5?
M52NMCK9(O+16(V2[ ,12*,EEKS 8G[KX?+#O :7;12+8WS<[DLBWSFEC4T:H
MIDV>KE2LG3;*!TA 3Q2XV*5W/I"%R_B@1VJ9SPVA:GBAF#SX&?6[J15UUT-T
M-!!+R28&_H OM;,,\RE[]YC[,_7YKS-ZD0.$ELJ,0"&.*7,Q2G,D0*5]I"?U
M.'XY/>5-,#5N./$7V-=7W>SY>5P\N8P<,HU)%$9=@^I;U?DN7<JH@GVY4F,>
M%:K#>S$.&4RU"94%[PJ@]6G$1KFX:A*[HJFQ VJUF4B%S48C[VA+ZP^%!Q\Y
M1%&A&@VPUK'8.P-HT;PAO_6H2ODO=[.1=XA8'F:>[>XY%[Z:QQEKT \^N+*B
MYI-Q_,)^)!(8GV2;9+"I][14[+9SFJ!!<Y-FMBC.T$B^/5X (.V==N0[WDID
M.+=DJNR^O3M"XJXM=Z0(7/"6N.!>3F7=0TF-W&F:)4%3IZ>$'\([:H*Q0XC\
MH9F='<&[1$;Q"61" Y+$OBDV \;<8.F,1@*ZC=8O^GI,I-6JWDY[EZL=>>)C
M6$=*UH')FIMNXZK)J@+IG%E?P;'@&7L]Y8%JE*CB2#'9=,_'#U*XYN#-5N-(
MRYV[U].^=2EW^UKA\O>KZ'-#2YNV5_A'/GO?39]),/M^(A CNAYP//\XXOLI
M3.T5VU!OI@ECBDF7">5V3('EN!3G.%<U)?M&P\)7PRK)*/TSL=VYJ*CA2![.
M"B0;QX[(,?$L:JJFTWA%CJF3)HR\/[S&IX6SQ?HP0=K![!1P;V!QR:>X#>2/
MZY5D4"5\QYR@&DS-023#W=_OA^^=:M#N!0^[KQ2BB-K3FJZ1L$X;%^_?%?>;
MG +3D[!)/\A\/OE-:HMOO2OV"AE]E%@[:](FZJDD<8X-[=U.+#J3+D'6[F\X
M?7K9YE'V; \S$M!S828J?)W9<_#9F!K6F;;^V?"NID@$0G-3O0#WX7*ETNV
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M-(Q4Y-54BQV()P9C[G*LU,'**WT8*).R;?$:X-=PKH@NOJ8JM-O:L.*>&L*
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M8!GJT)^NK<MZ27VC$7C@KO^@F:V+PRL\*YF$EH>=Q&$J1??5@9TZ8'<O.ZS
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MMD6_3%H"WD5>.4'V"B/2_%@5-F5%8N)K(,SS/K(G?J/'+G?<F98I%<G++L^
M$$^VFM5'98E&#N.Y5@_^5RB#_B1'^4;XO);"Q8VQNY#V[-R%LBM"M0\K%RA!
M1C6KF>%:>CGYT6VOP]5__:BJ(,[CIXE3@J)J++P5^'B7P4C;$*9HR]!<:P]\
M)8.?Z^"*/VR2^_DN:%I[U C_]*AX-35)N#=C2(Q;P3G@T"BEZ.9>+N6CH;1T
M+):2*:Z0WWU,T44%&Q1-;1E4\F9[PMXE@^[T,\F[>7FKD:7\]SCZV8_*666V
M[]$7;;E>8O9O]D\S;S?M<'ZZ4UX^VD8WH.6-T5T^#HV5C/+)OW.JI>BZ*(8^
M: S0WXET5]5[#*S,9K)HJ%<=3@[8SGP5%'&#]6)8=3M^C,NY0.=0&PO[9'F!
M/^JAWB,V]Z>^J7.A:"4ZDCF_29EW<:H)O[JHD+3[G&DBB2DM"3]U< !<52.4
M^7UCEB5%T=F9NPR\&2T2XD(X$2M Z1YDT#-2=I506P4_D9 AI)TJ5>X^TC03
MD;,I)8?4-BPP4*(->8GEQ@>Y'%Q(X:VB26+JTYQ)WUR4SFF676OG>*:8J9[!
M'=F6J&_J<0WGRH%3XC"&R-LV"-K9J_7W#0Z^JG2L_WD)-N;F;Y@[)S]6=Q7H
M-[,/5@Z@7!8GR(<^ ^3B,?JU9"Q&-TSFFM))SM8[FM>L4B9K(9I#_MF#RV?#
MSP"7S-'F726#"'7K7B9%FK*@3@AYV1 +B0M'?R'3X"LINU=(5#M8K/IV1U*A
M<H$RJ:2YF"0#SX!@D#P.K>D"UE='^ULHA!$SUS)_3N?C:<=K](T:[P1-]2Z(
M#[BTS(RI_B1UA5+O=\Z7UXZ,5B.6"[80P[PEA>NKTX%'6"P\ \*'<#-P7A$%
MWZNH?G,!Y.(1J'7RK)@EY&Y)X&?C), *_A%OQM45LXR(0H)\%\P 9Y4W(GX-
M^^98?^C\.K49:& O%@+0R2DQLDGF)?6;=<<4:D9QY+J='"GZHS\7D6J?+8,M
MB_$%>UV<H*C$NN2WK)4][ S!7G"@U8XR2B?<HR!,'B_\-"YV$(QZ-XZ8.$NG
M$LLIOKNO,F\TM^1PS],-/N"WBWR%O:K%@!#<<&J4_PQ DYIIG?-9@_&,#L<D
M%(IMPZ!Z-Z5J30%'LPJ4%N:L;QR(J5S[1UR1!Q&XXV^9MV1X:T#QS"38Z'/6
MQRRP=N<J-9J0C5M"FLI#97&.B@>0.UNZ$V\J_!L\N8,#O_W7'@\<2J+LT[@\
M4E6Z%$3)\@F-3K&"SL?:+@ZHT@[9B[^7BD:F(X\K+U"RQNIM/(7Q"V5HAA:P
M2JOJ!V(X?$EA48C.73UG?6M15<=Q;+G&3+SWQ6.T,X6G/#W!LQD&6$Z,33J:
M1)%F\?S0/SYT!8K,_:9O4S]$4K8$Q86KKLH#YL<@(UME><E[OS94LVQ,AM:;
M[#Z_L_WQEGP#'-;:N@'F%!I_$DJM_>%=Q((6EY;WX^M@FBNT-!-UM\'6D4YZ
M4>@;!O*F#-%:LC':']F"_)AT<!7C /,[#%^K<2Q6MI/EWU)@M\U9>NNU\AD1
M+L6&R<_QDS-RW>EP/.#8SO_&;EO$_)SX+P2-QM_$3K=MQ.9Y%K613FF? ;ES
MV%=1MM+K0,UV9+ @Y]:LRE78BYM6]?!9-ZI^!I0'0G?DFX?4_B'4J&7C&>+:
MI2K?+HGK(9\XPKB6GDQ7-&X63=P[QY;Z*UG<+6)3GMT3TO$,*+" 4M0IJPNY
M#"4\ Q1&V$*DUZ0'N?S[=9\!^XU/KH5K,_-E,7=KF8/5&]N:8V7KM[#9*'6+
MQMRG[_1G%6\/QB;>/&X0QAT8HT;[$%+>;]]"CGL\CSNNQH+$+V)?Z)Q1,/-T
MWF.W#YO8XYY?S@RY?M0_V)Q",AV$-ZI7-1159%\R<HO:]4Q]BYSQ?O:^LZXW
MJC#FULUX>/(9 +)^!IP?_$S-PO3=$XNYS/6Z6-:G_#WG_W#_?LOJJ7?J&;#]
MQY]+G.C)]!G@H=JF?/I45_485?@,&*M^LH@Y,!1[\DTYYX:+:?-O93@GO']A
MI9_]37?_V6;N/:GR,R#3_&$$ #HV/D87[GDZ>=@'_4M*^;OYG_T@4'J]M*ZA
MK50P:?S=TL[^?WJMG6;/9T#*7TTH_RL/R(CS@4J3".$+(_'5.* /8:G&GFU)
M5[$M:Y'^E,^\8&%AP)FQOE[L>."/;>*I>R1K*X?%9^XSVG:G0(G196=-(@$A
M:H-$S3\.W1F,4P]OK?K+Z*<-'//.,[U.12QUVV<K2+:N+,#*:!F$)T7V1_3M
M3=X1Q22R:1M5/*_F+AG&(PE:TM1+MOKKQXM&.W#DN<@ 0K#HU#PC6\)O=N88
M,@>>5([,<SYT)W=]XE*-S1A.7D!9FI []5)#=:V]UP5;1XY+>#?&KL5XS3,-
M^O.N.,^ -]H5UEX\H5'V5-4-,M.OLL#^)*W\NY.!'4#] ",[N>H?TP?!>&[D
M"IX$'.=DWAH6TBEAO1./ZW*Q)6F9W^\@PU7" V:KA%:7W#D )<,(D@3NICQ
MUGL G#PL@5L%?BT^&NGM)\8O!Q.0R/Y<*/M"KV!U3&\$G&G-SRVA9\#G9T!O
M(5_EJ^JB!UMA(\G'>N-APW8CKDPHP$Y54W01;I?IR>74F=3%Z782O@>?*$[9
MRV]5'$/JG=4(@!$0^1H;EFWK2L\DEVF3PET+A[P+NA]J\Y62B\\+VA2^4R_A
M"Z',^#JM@I@VHRBI4#/#"L'HQ]4PB?ENB?_NENI^'?S7H ]V]&IL!2^++YSZ
M$_K0)4^+; 7W?B3[CJWZXJLAQ*Q;5@7 :"E^<Y/^BO*P<LF>)<"4CR*&#/ZG
M5H3-)&ECJ-M$3^,N#=KD7DP:5T""WA,FT-#]\%SZ;"7,W45T+>M4[.LE)=8(
M'?2 UBQ$%K :P%\AK?@*YH!D70^3%@S&^8J9&QG+B?; +#QJG\^F(S+:6OIG
MJCQ?&Y1^2IAY-07&A]"3K=>9822!":ATQ\217/>1'K2> ;OU:0'G=B^T32]Z
M$+M^;',7QDK;U$$%HC28'>97%.+V"Y'DRB5QB] "I@31-,;H5D9NCV[\K%QK
MBV_R1_<PV$6?U5:@.)(8%62X*,]H,^#A0[7QT;+^%DK=DLC+Q8/%H)Q*W;L^
M[34KQIO"8A85*1*V5N_Z_G6?+=B.-6&T$8%U[.6?SF@ZY?D5&U-7L.(?[,CL
M?[!MN,34EU&C^?5:O_'FHMKX48?^CZU]%]!44HXWZXE2KZ_Z-#9:4[Y_)O9T
MZ[T#U,U1+@%8#92DP0QDYDMIYKP>(3 MK7 T9F&R0X!OJB"P*BZSFM)?QPUH
M?D>N&>**DJ_>3,EF"Z)Y\VMN?9^",N90V' ^D\EDV;$\IW6_\_#QQRF&=B69
M-#C0G.+V95[3SK'X0A"N, $!Z#%RA>L!<DL'6 05%Y+7.<L4M/?#S^W>LO8%
M46K*,]0QUS0=#1^Y,Y+%"JZW>57!!:#$VOYH/6'[Y@D^)W4FCMV2 E*)O1@1
MB7'8M;6>M[ZU-A9>UY-N5*>H$ZR1U<J0]^<:WU=%^3Q$E+COH6%F8-&D X)D
M=IVY_+I:4_Y<(DWRDE8OUDCUQ>'*\ONJ;S'710BCP"9?!XJ8[-V&-T-XR9V2
MCN'D\P%]/*;GW1DT$P_"D/P]4QTZQ@W!+U,58A5R^VP/]-G00&E:>4Q'7#5Q
M1_73,FL>2E2=[_C;;^J:Z#C1.K)2E3@6?QB]FF:K,\3AP2B>!#8*!;Y_J*%(
M&K.=\ZTK[,8BV>)<^MS3D R65IU+'NIM)YT(+K5$#(OGO4(HL*4XUSWQ*R[&
MV%UIM.X8K#]NN2BTD&XH?.@MTX(U%T9=ULZPKQ%]B2([*0WHQQ^Y\0W9*LW7
M,182S:@6BR_OLWTH/"\/W5<_L:]B 1LD1VL:_KA%C)$T1+>F()MUZ;>S2Z8/
MQ;[TT^V0DP(ZI72.HN@$,O1]8[$;PH _#2SI0^]S<]K5JCVT\44 IG1N 6UW
MX2-8,G1U+,5";7^^\#<%$MO?K)7L+0X^EZ"]%YX@5*!8-&\\8!/E_/D'=>RE
MJH0E^<GH+VOWN9E8-P<VA^\U;\;P=V: 8[*U58V-&4M4\0:\NT3N/%[_X?32
M?W/7OJR\% "_R^=C36/&W)P,R%+#X8?5B#L>3-,I5*5K/'(&:%"^,2H\V/?=
M R3=\D-AVJ!SD#8R>($C(4CGCO>']V.+ ^6?/"3:VV_J 4;#14593"$47TP#
M\&SF@ZV(KA$@L_-#QESO3<A1WJ.CU G&JL&05U]ZA7<O\<I3%DUUQ@-MFU%I
M=LEXJ?"W:SMO>KA@:1GCL!;^+L1%ZP5_)1J#NACC<I/>V]D3AY3%?QPOV<3+
M$+^JR))JA7OHP/1^!K356I[G>U"G?*.6ICQDX!FYU/F3.^^YJ6Q+DM;"3";=
M&8'Q QLMI/E;KJ7O8!F[TXA[X/>BHD85 /F7PO E#E4MZ3BC&JB6)J6J54YX
M[EM&J_]X# P4  $ [7*JCXYH(<;5^IE+#4L.1^'Q=Z<Y\/R]NWFKTH5MSDLT
MLR8G&8F_/UV?OX+;S]0KZAGX@[L1W\+H\;/'T<.TZX" EN<B*%Y@_LBV=SM9
M/W7).JTU&CSL!8$<;=G.%[/9D[7&D\4K2H9?,DQJS*9N:[SXP/!S?0KRDYGC
ML.-@WGXM*C]/F17TS"XCXJ93BBSJ*+GYXL>-]"\5+I,N$8H$/:QV-.@E I_!
MO3EM?HH$6XE%YS97S#L4Y)4GA]]#)SFV0-L)+5IM=,"S^'D:8OOMR=:M>7=+
ML"SSJWA52H0M!PE%G!2A?(%G@&6=  W:F-:1]44HPWJA'"/#"("5N&A./#=!
MMP$R3/ K:O['N IRMB-3[>R).)HGGA_/T**M.Q\9?7]=VL$H>%A?M #RL=ZE
M@8(F! VG5*!LU_6^6'0%G?E=I'IEN5Z"6DM"V<B-!A8W]#H/=#-EW2&[@R5$
M19HL(LMMFD]P=A45LZI$</;"?]X]%#6^/A-\H\82_Y[I0(S$*5!U(.HGDV*>
M*_*7=]%W1V(M7'[OH#W0Q5X_'_:R _4JJ<"M!XJWP%])Z)#I(-5 D[-&L2BG
M;.NA) $UZ<F$,(,C2:@PR8;=I5 8ZL!"+JR>U=4C_Q>HK@U+,5P!-D)<%*_2
M!>4\NYM7KO4N;4HF>FV>'@,?.T3<7Z0@I;03/;7@QM/SVT<Z0ON4ISR]4(^X
MS)+6M^BTGW^MI000+=! 7L[;>*BF 096O_(0B>*AM9HW^QFD@D)^JC2ZM-]Q
M1FRJS4QM$K;I9V+0GEW,ENH *I@SY8]J;II_L"3?;S]MBVL_2;J0X^S@B^G*
MW#72=;!J/@HP9TB$=LO@\64#'*W9+RB:H_H_'Q$=<>BUD\ HAC1DLS]+TF88
ME/Z^?ZH+A!"4'%9M1JFW((R*,<U/NMS,J]15U2#+9#EP6F-#38SR&"5&O6@U
MU+UH?A-"M:;+VP<*#90#?6I9 S3\ZXAX422T"/:$&N>( 5WE6$[CHXYU!;G$
MKUSR<L8XJMNM:S&&0DQGG>,W8]0/[[1Y[(IZ7(FPJ60)0[7X>^R7_QC<:&M
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M@[V2"6XDLVF>1ORP73 9FKWN-?JVH;J0FVLGYF=BU0OI0F34UN+;YP^!8-<
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MA\BL:H\]Y[>("-C#H_.BDJ8MBE)!G9$5J>M8/S"F'==U$PT7OCU6D)WGW&*
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M7U+3]<'.)KG"<8^?8T8%L0.$O&V0<0_T=W]<ELPSF=CA$S]H?"4A.G@'#_@
MV% O+4K2P^5/SNL_T_PU W$GMFQJB[*(:JWXP$A$_L[+8<T\C8D9WHU/#<<)
M5%@0@7-/8@L-J3>?)BK%%*\&.,&S6U,W1Q6D2E"C8OA"Z]79;1\YT%\QT=!?
M@R\#U[FJT=H]+C^KTDFJ!B'8ID7+T4C:B),C_^R/-9#_.4@-1S00B&0=-SIF
M@J>S\]S0)(5&RS<3]OK1I2,G!8\5T;X0LY^?K@)']4M1BF;"/S:H].CR0#K8
MG,YO]W72@9%:BL^!MI/Q]X55H9J*233-VS\J,U0<FQN%"+ 8-D[.OJ3.QI&3
MTO7IM(3U.-.8N]$6]'D6CMC."S!]V)Z8P< >=@;J5IGU> K0>A%<]%"U K?+
MB&5OK(<O)+=9D$BA4+<#/2SC&T%U?5R7D@9+:\IR[<0S"6T&^G1&49R;J(!G
MM%EOW++&EGO+^G:Y]&+OJEC$1-CXUAZJ!,)Y^MU1D@_H0!A<'R^_A<@^RQ\,
M7^SX<&!X.2]L*;Q+0K](#MM*V08#<XG"V;LX-VPQ5M1[U-[938>J.H#1_BKZ
M="ZRH[^2_D?IF$QK+!2&UII)]:R0$_ \;?D]4Q$*N()FE665M97"],Z@J.$5
M8W\1!68 $QK8,H-P&E@;*&VMM9+$B&*21?'K%X(M,T+KM?$KC80[*C[+G^)6
MUGJ+<#CLOZP5@MV)[HHY8YD%K+7=9IXC/8UA9R"NK]BU+6G'IT<)(T0M6.D
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MTZ!L2XA7KN[-.9J5LA&-$T%_\T+S3O1!)JZ?HZ8=24S,5FJAMGAE?MD1XAC
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MXX,>RN"-Z%M*-2Y\3MT^NN8V=GEZ#@4@UG\UQ_9?\1^=F/;?!4Q>%;T]U@E
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M?8H^.G'74Q2#%:/[U)I;D#"JD$.[M9 6=J9\EEG\:<EC&$R\UB8.LS&K>W/
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M>?[*]%L-$N+Y?1Q@S-T),@[>R)$?0O*(@!?)98R/'E":RK',W*RJBEHF-$M
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M>^/VY?CC G*=!\"[AJF]J N21U%$_&([VFIE?^2?Q@T_ 9"\3!"8^OR&FLR
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M0ON%+8BVE8XQLV\,G7+A1G[,WK2SD_BUD.0SAV924C]@$M9CAR<CZN<UQ0C
M#H8+)UF4(43YL>";<W)2DY)=KCX'A\\*Y4GGQ:::NG-UG/95E)OJEK+O'@!V
MK^:$_WJ>PN8)3DLOZ9T? ,$3[P5FU"WW8Q'YYD*R6R!=P%0XGS+!697V7)&I
MD$57^40O@.^#]NP_^N:>BNI3*:Q?>+:1\3P%GY3GVF%::->7BU:,IW0<V"P&
M'J&XV8[5:_EOJ+*S]V%O+]059SL4SHN;V%DV@MG]4YB=WC/Y^Q3+%F[D9F%
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MYK3/+?[/@N__I_Q?F1DR#W_^#5!+ P04    " #KA6E239&E@VD"   %!P
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MW,+OQ=-OU+N5^.;.&/T 4$L#!!0    ( .N%:5)0Z@^_:P0   <2   8
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M[NTM/:,KZ]@7C-Q;2/:UIN/_ 5!+ P04    " #KA6E2+;%2#.((  !8-@
M&    &UR:W(M,C R,#$R,S%X97@S,60R+FAT;>U;;5/C.!+^*SJV]H:IBN.\
MP XX+%4AA#IJ!YAB,G6W'V5;CG7(EE>2$W*__KHE.SB!&3(WPQPPX0.)I9;4
MDI[N?EJ1C_[F>>,\I7G$8O*/R<5[$LNHS%AN2*08-5 ZYR8E$UD4-"<73"DN
M!#E1/)XR0@[;A^UN^]T[SSL^@IY&51.9!Z3O'_J]3J]+.H=!=R_H_D8^7)#=
M3Y/16RM\>C6:_/EA[,;\\.GD_?F(['B^_\_^R/=/)Z>N8J_=Z9*)HKGFALN<
M"M\?7^Z0G=28(O#]^7S>GO?;4DW]R;6?FDSL^4)*S=JQB7>.C[ $_C,:'Q]E
MS% 2I51I9G[?^30Y\PY PG CV/&17W\ZV5#&B^.CF,^(-@O!?M_)J)KRW#.R
M"/J=P@R@I0_5:S*WWIS')@VZG<ZO@X+&,<^GGF")"?;;!P=W18I/TV69=%,+
M%!/4\!G#OAN]1H)1%832I(/U 1YJ6=3M$ID;+Z$9%XO@S81G3)-+-B?7,J/Y
MFY8K@4_-%$_>#*RTYO]AT#5,S[!;XU'!I] YZCIP\P^JJ8<K@\R9G4XH10R5
MX]N4A]R0?K?=._)#6*?B";2* *!,K:F%XO5 ,ZY!#<'-(DAY'+,<!/[^RT&O
MTQ\<^2CX(Q7[TGJ-QM>3\[/ST7!R?G4)AG#]\=/P<D(F5^3C>&3+^IT>N3HC
M'X?7)\/+\4?OZE_OQW^2X6B"I;U.YZ=9YA4USEMDF)M4Y@OR!\]:)&+*\&1!
M3$I-\%2#/I.YKZ@1<UT(N@AX+GC.O%#(Z,;M(<]!*6/;.+?1_^U^\T@*J8)?
M.O9O\$TZND?L-LBERJ@8-/%>%370A9X1U.FVE\ME/\Y)2F>,*#;C; [!Q*1<
MPU[G)17DFA52&8@OY RZ(]V.]P>1";F@ZH8I,DF9H@4K#8]TBYSG47NP1<(+
M0D)O#0DG5%LR0;(%N<GE7# @'2T'".60$$M0+)? 5J !Y3FAX!#*W*B2P;R
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MHI6JVS+Z[@.%'(PNHN.CXT$_.AZ?(10O)I?]LPBB\;.5.-B'2W?B#ER8T-A
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M,C R,#$R,S$N>'-D4$L! A0#%     @ ZH5I4J%IG7UZ#@  3;P  !4
M         ( !810  &UR:W(M,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M .J%:5+'[8SK:1L  $ND 0 5              "  0XC  !M<FMR+3(P,C Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " #JA6E2F8])?41A  #?C04 %0
M        @ &J/@  ;7)K<BTR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @
MZH5I4EQ,$?9,0P  HGT$ !4              ( !(:   &UR:W(M,C R,#$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( .J%:5*V#L)%<VL# "F8(@ 5
M      "  :#C  !M<FMR+3(P,C Q,C,Q>#$P:RYH=&U02P$"% ,4    " #K
MA6E2#6)9/ 0?   :(   &               @ %&3P0 ;7)K<BTR,#(P,3(S
M,7@Q,&LP,#$N:G!G4$L! A0#%     @ ZX5I4@=/7)?6(0  CSX  !@
M         ( !@&X$ &UR:W(M,C R,#$R,S%X,3!K,# R+FIP9U!+ 0(4 Q0
M   ( .N%:5(@<XOWA3(  $XV   8              "  8R0! !M<FMR+3(P
M,C Q,C,Q>#$P:S P,RYJ<&=02P$"% ,4    " #KA6E2OH?I5NTZ  #]/0
M&               @ %'PP0 ;7)K<BTR,#(P,3(S,7@Q,&LP,#0N:G!G4$L!
M A0#%     @ ZX5I4MX,A#*M20  36P  !@              ( !:OX$ &UR
M:W(M,C R,#$R,S%X,3!K,# U+FIP9U!+ 0(4 Q0    ( .N%:5)_-5651E4
M !*!   8              "  4U(!0!M<FMR+3(P,C Q,C,Q>#$P:S P-BYJ
M<&=02P$"% ,4    " #KA6E2IP(RUC5E   1<P  &               @ ')
MG04 ;7)K<BTR,#(P,3(S,7@Q,&LP,#<N:G!G4$L! A0#%     @ ZX5I4J3:
MI8Y$,P  4%@  !@              ( !- ,& &UR:W(M,C R,#$R,S%X,3!K
M,# X+FIP9U!+ 0(4 Q0    ( .N%:5*)9*IB!-\  +L* 0 8
M  "  :XV!@!M<FMR+3(P,C Q,C,Q>#$P:S P.2YJ<&=02P$"% ,4    " #K
MA6E29;UE<)9F 0"AB $ &               @ 'H%0< ;7)K<BTR,#(P,3(S
M,7@Q,&LP,3 N:G!G4$L! A0#%     @ ZX5I4E-K!N__HP  #[   !@
M         ( !M'P( &UR:W(M,C R,#$R,S%X,3!K,#$Q+FIP9U!+ 0(4 Q0
M   ( .N%:5)-D:6#:0(   4'   8              "  >D@"0!M<FMR+3(P
M,C Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4    " #KA6E24.H/OVL$   '$@
M&               @ &((PD ;7)K<BTR,#(P,3(S,7AE>#(S9#$N:'1M4$L!
M A0#%     @ ZX5I4K-'5QOC"   J#4  !@              ( !*2@) &UR
M:W(M,C R,#$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( .N%:5(ML5(,X@@
M %@V   8              "  4(Q"0!M<FMR+3(P,C Q,C,Q>&5X,S%D,BYH
M=&U02P$"% ,4    " #KA6E2VTO3#KL%   %'0  &               @ %:
M.@D ;7)K<BTR,#(P,3(S,7AE>#,R9#$N:'1M4$L! A0#%     @ ZX5I4A)"
M4'; !0  1!P  !@              ( !2T ) &UR:W(M,C R,#$R,S%X97@S
=,F0R+FAT;5!+!08     %P 7 #0&  !!1@D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
